PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cohen, M; Demers, C; Gurfinkel, EP; Turpie, AGG; Fromell, GJ; Goodman, S; Langer, A; Califf, RM; Fox, KAA; Premmereur, J; Bigonzi, F				Cohen, M; Demers, C; Gurfinkel, EP; Turpie, AGG; Fromell, GJ; Goodman, S; Langer, A; Califf, RM; Fox, KAA; Premmereur, J; Bigonzi, F			A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; STANDARD HEPARIN; INTRAVENOUS HEPARIN; ASPIRIN; ANGINA; SURGERY; PREVENTION; ENOXAPARIN; EFFICACY; TRIAL	Background Antithrombotic therapy with heparin plus aspirin reduces the rate of ischemic events in patients with unstable coronary artery disease. Low-molecular-weight heparin has a more predictable anticoagulant effect than standard unfractionated heparin, is easier to administer, and does not require monitoring. Methods In a double-blind, placebo-controlled study, we randomly assigned 3171 patients with angina at rest or non-Q-wave myocardial infarction to receive either 1 mg of enoxaparin (low-molecular-weight heparin) per kilogram of body weight, administered subcutaneously twice daily, or continuous intravenous unfractionated heparin. Therapy was continued for a minimum of 48 hours to a maximum of 8 days, and we collected data on important coronary end points over a period of 30 days. Results At 14 days the risk of death, myocardial infarction, or recurrent angina was significantly lower in the patients assigned to enoxaparin than in those assigned to unfractionated heparin (16.6 percent vs. 19.8 percent, P=0.019). At 30 days, the risk of this composite end point remained significantly lower in the enoxaparin group (19.8 percent vs. 23.3 percent, P=0.016). The need for revascularization procedures at 30 days was also significantly less frequent in the patients assigned to enoxaparin (27.0 percent vs. 32.2 percent, P=0.001). The 30-day incidence of major bleeding complications was 6.5 percent in the enoxaparin group and 7.0 percent in the unfractionated-heparin group, but the incidence of bleeding overall was significantly higher in the enoxaparin group (18.4 percent vs. 14.2 percent, P=0.001), primarily because of ecchymoses at injection sites. Conclusions Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase. This benefit of enoxaparin was achieved with an increase in minor but not in major bleeding. (C) 1997, Massachusetts Medical Society.	HOP ST SACREMENT,QUEBEC CITY,PQ,CANADA; INST CARDIOL & CIRURG,BUENOS AIRES,DF,ARGENTINA; MCMASTER UNIV,HAMILTON,ON,CANADA; RHONE POULENC RORER,COLLEGEVILLE,PA; RHONE POULENC RORER,PARIS,FRANCE; ST MICHAELS HOSP,TORONTO,ON M5B 1W8,CANADA; DUKE UNIV,DURHAM,NC; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND	Laval University; McMaster University; Sanofi-Aventis; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Duke University; Royal Infirmary of Edinburgh	Cohen, M (corresponding author), ALLEGHENY UNIV HLTH SCI,MCP HAHNEMANN SCH MED,DIV CARDIOL,MAIL STOP 119,PHILADELPHIA,PA 19102, USA.		Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; EDMONDSON RA, 1994, LANCET, V344, P914, DOI 10.1016/S0140-6736(94)92269-1; EDMONDSON RA, 1994, LANCET, V344, P1307; *FRAGM INST COR AR, 1996, LANCET, V347, P561; *GLOB US STRAT OP, 1996, NEW ENGL J MED, V335, P775; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; HIRSH J, 1992, BLOOD, V79, P1; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Klein W, 1997, CIRCULATION, V96, P61; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LECLERC JR, 1992, THROMB HAEMOSTASIS, V67, P417; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MELANDRI G, 1993, AM J CARDIOL, V72, P450, DOI 10.1016/0002-9149(93)91139-9; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; *PARAGON INV, 1996, CIRCULATION, V94, P553; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; *RISC GROUP, 1990, LANCET, V336, P827; SAMAMA MM, 1994, HAEMOSTASIS, V24, P105; SERNERI GGN, 1995, LANCET, V345, P1201; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; *THROMB MYOC INF T, 1997, J AM COLL CARDIOL, V29, P1474; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	30	1159	1213	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					447	452		10.1056/NEJM199708143370702	http://dx.doi.org/10.1056/NEJM199708143370702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250846	Bronze			2022-12-28	WOS:A1997XQ49900002
J	Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM				Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM			An antagonist decoy receptor and a death domain-containing receptor for TRAIL	SCIENCE			English	Article							APOPTOSIS; FAS	TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell fines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baker SJ, 1996, ONCOGENE, V12, P1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROJATSH J, 1996, CELL, V87, P1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	1350	1527	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					815	818		10.1126/science.277.5327.815	http://dx.doi.org/10.1126/science.277.5327.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242610				2022-12-28	WOS:A1997XQ24700043
J	Shaffer, LG; Phillips, MD				Shaffer, LG; Phillips, MD			Successful treatment of acquired hemophilia with oral immunosuppressive therapy	ANNALS OF INTERNAL MEDICINE			English	Article							FACTOR-VIII; CYCLOPHOSPHAMIDE; INHIBITORS; COMBINATION; PREDNISONE	Background: Acquired autoantibodies to factor VIII in patients without hemophilia are rare, but they cause severe illness and death if not eradicated. Objective: To examine daily therapy with oral cyclophosphamide and prednisone for acquired hemophilia. Design: Case series. Setting: Academic medical center. Patients: Nine consecutive patients without hemophilia who had severe hemorrhage caused by high titers of factor VIII inhibitors. Interventions: Daily oral cyclophosphamide and prednisone. Coagulation factors were used only for bleeding. Measurements: Plasma titers of factor VIII inhibitor, factor VIII activity, and clinical evidence of bleeding. Results: All patients achieved complete remission, which was defined as loss of residual inhibitor activity and return to a normal titer of factor VIII. Therapy lasted a median of 12 weeks (range, 3 to 37 weeks), Bleeding resolved in a median of 3 weeks (range, 2 to 10 weeks). Median follow-up after discontinuation of therapy was 91 weeks (range, 61 to 164 weeks). Conclusion: Daily administration of oral cyclophosphamide and prednisone without empirical factor VIII therapy seems to be an effective and well-tolerated treatment for acquired hemophilia.	UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System; UTMD Anderson Cancer Center								GREEN D, 1993, THROMB HAEMOSTASIS, V70, P753; GREEN D, 1981, THROMB HAEMOSTASIS, V45, P200; GREEN D, 1971, BLOOD-J HEMATOL, V37, P381, DOI 10.1182/blood.V37.4.381.381; HERBST KD, 1981, ANN INTERN MED, V95, P575, DOI 10.7326/0003-4819-95-5-575; Hoyer LW, 1995, ADV EXP MED BIOL, V386, P35; HULTIN MB, 1991, AM J MED, V91, pS9, DOI 10.1016/S0002-9343(91)80141-8; LIAN ECY, 1989, ANN INTERN MED, V110, P774, DOI 10.7326/0003-4819-110-10-774; LOTTENBERG R, 1987, ARCH INTERN MED, V147, P1077, DOI 10.1001/archinte.147.6.1077; MORRISON AE, 1993, BLOOD, V81, P1513	9	73	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					206	209		10.7326/0003-4819-127-3-199708010-00005	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245226				2022-12-28	WOS:A1997XN12900005
J	Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S				Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S			Failure of parturition in mice lacking the prostaglandin F receptor	SCIENCE			English	Article							OXYTOCIN RECEPTOR; LUTEOLYTIC HORMONE; RAT MYOMETRIUM; EXPRESSION	Mice lacking the gene encoding the receptor for prostaglandin F-2 alpha (FP) developed normally but were unable to deliver normal fetuses at term. Although these FP-deficient mice showed no abnormality in the estrous cycle, ovulation, fertilization, or implantation, they did not respond to exogenous oxytocin because of the lack of induction of oxytocin receptor (a proposed triggering event in parturition), and they did not show the normal decline of serum progesterone concentrations that precedes parturition. Ovariectomy at day 19 of pregnancy restored induction of the oxytocin receptor and permitted successful delivery in the FP-deficient mice. These results indicate that parturition is initiated when prostaglandin F-2 alpha interacts with FP in ovarian luteal cells of the pregnant mice to induce luteolysis.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; ONO PHARMACEUT CO LTD,FUKUI RES INST,FUKUI 913,JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DIV MOL & CELLULAR IMMUNOL,OSAKA 59002,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Ono Pharmaceutical Co Ltd; Kyoto University			Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Segi-Nishida, Eri/0000-0002-0803-6513; Murata, Takahiko/0000-0003-0132-5424				ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P739, DOI 10.1210/endo-106-3-739; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; Hasumoto K, 1997, J REPROD FERTIL, V109, P45, DOI 10.1530/jrf.0.1090045; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LEFEBVRE DL, 1992, SCIENCE, V256, P1553, DOI 10.1126/science.1598587; LEWIS RB, 1973, LANCET, V2, P1159; MATSUMOTO K, 1981, FOLIA PHARMACOL JPN, V78, P231, DOI 10.1254/fpj.78.231; MCCRACKEN JA, 1972, NATURE-NEW BIOL, V238, P129, DOI 10.1038/newbio238129a0; MOELJONO MP, 1976, PROSTAGLANDINS, V14, P543; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; SOLOFF MS, 1988, ONSET LABOR CELLULAR, P87; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; THORBURN GD, 1979, PHYSIOL REV, V59, P863, DOI 10.1152/physrev.1979.59.4.863; Young WS, 1996, J NEUROENDOCRINOL, V8, P847, DOI 10.1046/j.1365-2826.1996.05266.x	19	484	497	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					681	683		10.1126/science.277.5326.681	http://dx.doi.org/10.1126/science.277.5326.681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235889				2022-12-28	WOS:A1997XN90700039
J	Ryan, TA; Reuter, H; Smith, SJ				Ryan, TA; Reuter, H; Smith, SJ			Optical detection of a quantal presynaptic membrane turnover	NATURE			English	Article							EXCITATORY SYNAPSES; NERVE-TERMINALS; RAT HIPPOCAMPUS; SINGLE; MICROSCOPY; MOLECULES; NEURONS	Exploration of the mechanisms and plasticity of synaptic transmission has been hindered by the lack of a method to measure single vesicle turnover directly in individual presynaptic boutons at isolated nerve terminals. Although postsynaptic electrical recordings have provided a wealth of invaluable basic information about quantal presynaptic processes(1), this approach has often proved difficult to apply at most central nervous system synapses(2-6). Here we describe the direct optical detection of single quantal events in individual presynaptic boutons of cultured hippocampal neurons. Using the fluorescent dye FM 1-43 as a tracer for presynaptic endocytosis(7-10), we have characterized both evoked and spontaneous components of presynaptic function at the level of individual quanta. Our results are consistent with quantal interpretations of previous electrophysiological analyses(1-6) and provide new information about the unitary membrane recycling event and its coupling to individual action potential stimuli, about spontaneous vesicle turnover at individual boutons, and about the numbers of vesicles recycling at individual boutons.	STANFORD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305; UNIV BERN,DEPT PHARMACOL,CH-3010 BERN,SWITZERLAND	Stanford University; University of Bern			Ryan, Timothy/AAO-8286-2020	Ryan, Timothy/0000-0003-2533-9548; Smith, Stephen/0000-0002-2290-8701				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; DEHANNE D, 1996, J PHYSL, V491, P163; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Katz B., 1969, RELEASE NEURAL TRANS; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, J NEUROSCI METH, V44, P47, DOI 10.1016/0165-0270(92)90113-R; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; Malgaroli Antonio, 1994, Seminars in Cell Biology, V5, P231, DOI 10.1006/scel.1994.1029; Mertz J, 1995, OPT LETT, V20, P2532, DOI 10.1364/OL.20.002532; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1993, NEURON S, V10, P55; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1	25	136	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					478	482		10.1038/41335	http://dx.doi.org/10.1038/41335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242407	Bronze			2022-12-28	WOS:A1997XN55300050
J	Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM				Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM			Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA	SCIENCE			English	Article							NON-B HEPATITIS; NON-A; VIRAL-HEPATITIS; HIGH-FIDELITY; CDNA CLONE; VIRUS; IDENTIFICATION; AMPLIFICATION; CHIMPANZEES; MARMOSETS	More than 1% of the world's population is chronically infected with hepatitis C virus (HCV). HCV infection can result in acute hepatitis, chronic hepatitis, and cirrhosis, which is strongly associated with development of hepatocellular carcinoma. Genetic studies of HCV replication have been hampered by lack of a bona fide infectious molecular clone. Full-length functional clones of HCV complementary DNA were constructed. RNA transcripts from the clones were found to be infectious and to cause disease in chimpanzees after direct intrahepatic inoculation. This work defines the structure of a functional HCV genome RNA and proves that HCV alone is sufficient to cause disease.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; US FDA,DIV VIROL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	Washington University (WUSTL); US Food & Drug Administration (FDA)					NCI NIH HHS [CA57973] Funding Source: Medline; NIAID NIH HHS [AI40034] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER HJ, 1978, LANCET, V1, P459; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EMERSON SU, 1992, J VIROL, V66, P6649, DOI 10.1128/JVI.66.11.6649-6654.1992; FALKOW S, 1988, REV INFECT DIS, V10, pS274; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; KOLYKHALOV AA, IN PRESS HEPATITIS C; KOLYKHALOV AA, UNPUB; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAJOR ME, 1997, HEPATOLOGY, V25, P527; Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; POPPER H, 1980, VIRCHOWS ARCH A, V387, P91, DOI 10.1007/BF00428432; REED KE, 1997, HEPATITIS C VIRUS, V61; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476	26	580	647	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					570	574		10.1126/science.277.5325.570	http://dx.doi.org/10.1126/science.277.5325.570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228008				2022-12-28	WOS:A1997XM86700053
J	Nishimura, N; Balch, WE				Nishimura, N; Balch, WE			A di-acidic signal required for selective export from the endoplasmic reticulum	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; G-PROTEIN; MDCK CELLS; CYTOPLASMIC TAIL; TRANSPORT; SEQUENCE; ER; GLYCOPROTEIN; DEGRADATION; ENDOCYTOSIS	Transport of membrane proteins between intracellular compartments requires specific sequences in the protein cytoplasmic domain to direct packaging into vesicle shuttles. A sequence that mediates export from the endoplasmic reticulum (ER) has proved elusive. A di-acidic signal (Asp-X-Glu, where X represents any amino acid) on the cytoplasmic tail of vesicular stomatitis virus glycoprotein (VSV-G) and other cargo molecules was required for efficient recruitment to vesicles mediating export from the ER in baby hamster kidney cells. The existence of such a signal provides evidence that export from the ER occurs through a selective mechanism.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRUAN M, 1989, EMBO J, V8, P3633; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; KLAUSNER R D, 1989, New Biologist, V1, P3; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NISHIMURA N, UNPUB; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SCHMID SL, IN PRESS ANN REV BIO; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749	35	394	399	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					556	558		10.1126/science.277.5325.556	http://dx.doi.org/10.1126/science.277.5325.556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228004				2022-12-28	WOS:A1997XM86700049
J	McFadden, ER; Warren, EL				McFadden, ER; Warren, EL			Observations on asthma mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NEAR-FATAL ASTHMA; NEW-ZEALAND; MECHANICAL VENTILATION; UNITED-STATES; BETA-AGONISTS; PRESCRIBED FENOTEROL; PRECIPITATING FACTOR; RESPIRATORY ARREST; DISTINCT ENTITY; SUDDEN-DEATH	The rate of death from asthma in the United States has been increasing over the last decade, but such deaths still remain uncommon. Mortality rates differ markedly by region and ethnicity, and case-fatality rates are highest in black men living in inner cities. In general, patients in greatest jeopardy are those with severe, unstable disease who are not being objectively monitored; however, death can occur in anyone ii the attack is intense enough. Sudden catastrophic episodes of asthma occur but are very rare. Failure to recognize the seriousness of the terminal episode or to treat the episode appropriately remains the chief contributing cause of poor outcome. Little compelling evidence shows that adverse effects of medications play much of a role in asthma-related death. The disease characteristics that place patients at risk remain inadequately defined. Of those suggested, only a history of recurrent hospitalization and the need for ventilatory assistance are specific enough to be helpful. These characteristics, however, are found in only 36% and 6% of cases, respectively; thus, their absence is of no Value in assessing risk. The prognosis after a near-fatal episode of asthma is poor, and approximately 10% of patients die in the year after the event. Given the current state of knowledge, it is wise to view all exacerbations of asthma that last longer than a few days as potentially fatal and to treat them accordingly. This is especially true in patients who have previously had a severe episode of asthma.	CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH USA	Case Western Reserve University	McFadden, ER (corresponding author), UNIV HOSP CLEVELAND, DIV PULM & CRIT CARE MED, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NCRR NIH HHS [MO-RR00808] Funding Source: Medline; NHLBI NIH HHS [HL 37117, R01 HL 33791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117, R01HL033791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, ANN ALLERGY, V60, P31; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BENATAR SR, 1982, S AFR MED J, V62, P308; BOULET LP, 1991, J ALLERGY CLIN IMMUN, V88, P838, DOI 10.1016/0091-6749(91)90239-K; BRAMAN SS, 1990, JAMA-J AM MED ASSOC, V264, P366, DOI 10.1001/jama.264.3.366; Bray GA, 1999, DIABETES CARE, V22, P623; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; BURNEY PGJ, 1986, LANCET, V2, P323; CANNY GJ, 1989, PEDIATRICS, V83, P507; *CDC, 1992, JAMA-J AM MED ASSOC, V268, P1999; *CDC, 1992, JAMA-J AM MED ASSOC, V268, P1995; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; CRANE J, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307; CROMPTON G, 1987, BRIT J DIS CHEST, V81, P321, DOI 10.1016/0007-0971(87)90179-3; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; FLETCHER HJ, 1990, ARCH DIS CHILD, V65, P163, DOI 10.1136/adc.65.2.163; FOUCARD T, 1994, ALLERGY, V49, P616, DOI 10.1111/j.1398-9995.1994.tb00128.x; GLAZEBROOK KN, 1985, NEW ZEAL MED J, V98, P590; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HUDGEL DW, 1974, ANN INTERN MED, V80, P622, DOI 10.7326/0003-4819-80-5-622; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KALLENBACH JM, 1993, AM J MED, V95, P265, DOI 10.1016/0002-9343(93)90278-W; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LOFDAHL CG, 1992, EUR RESPIR J, V5, P898; MACDONALD JB, 1976, BRIT MED J, V2, P721, DOI 10.1136/bmj.2.6038.721; MANNING P, 1987, IRISH MED J, V80, P406; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1991, NEW ENGL J MED, V324, P409, DOI 10.1056/NEJM199102073240609; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; MCFADDEN ER, 1995, LANCET, V345, P1215, DOI 10.1016/S0140-6736(95)91995-3; MCFADDEN ER, 1995, AM J MED, V99, P651, DOI 10.1016/S0002-9343(99)80253-8; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MIYAMOTO T, 1970, J ALLERGY, V45, P248, DOI 10.1016/0021-8707(70)90135-8; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MOLFINO NA, 1992, CHEST, V101, P621, DOI 10.1378/chest.101.3.621; MOUNTAIN RD, 1988, AM REV RESPIR DIS, V138, P535, DOI 10.1164/ajrccm/138.3.535; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; NEDER GA, 1963, DIS CHEST, V44, P263; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; OSMAN J, 1987, BRIT J DIS CHEST, V81, P232, DOI 10.1016/0007-0971(87)90155-0; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PICADO C, 1989, EUR RESPIR J, V2, P127; PICADO C, 1983, EUR J RESPIR DIS, V64, P102; POMA PA, 1988, J NATL MED ASSOC, V80, P1275; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; ROBERTSON CF, 1990, MED J AUSTRALIA, V152, P511, DOI 10.5694/j.1326-5377.1990.tb125350.x; ROE P F, 1965, Br J Dis Chest, V59, P158, DOI 10.1016/S0007-0971(65)80006-7; ROTHWELL RPG, 1987, NEW ZEAL MED J, V100, P199; RUBINFELD AR, 1976, LANCET, V1, P882; RYAN G, 1991, AUST NZ J MED, V21, P681, DOI 10.1111/j.1445-5994.1991.tb01370.x; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCOGGIN CH, 1977, JAMA-J AM MED ASSOC, V238, P1158, DOI 10.1001/jama.238.11.1158; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P319, DOI 10.1016/0091-6749(87)90038-8; SHY CM, 1978, HLTH EFFECTS AIR POL; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPEIZER FE, 1987, J ALLERGY CLIN IMMUN, V80, P368, DOI 10.1016/0091-6749(87)90051-0; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; TAI E, 1967, LANCET, V1, P644; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; *US BUR CENS, 1992, US BUR CENS SER P, V60; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; WEISS KB, 1990, AM J EPIDEMIOL, V132, pS107; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WENG TR, 1970, AM REV RESPIR DIS, V101, P274; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WHALLETT EJ, 1993, RESP MED, V87, P183, DOI 10.1016/0954-6111(93)90089-I; 1987, BR J DIS CHEST, V81, P30; 1992, CURRENT PROBLEMS, V33, P658	94	93	95	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					142	147		10.7326/0003-4819-127-2-199707150-00009	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230005				2022-12-28	WOS:A1997XK15800011
J	Proudfoot, J; Guest, D; Carson, J; Dunn, G; Gray, J				Proudfoot, J; Guest, D; Carson, J; Dunn, G; Gray, J			Effect of cognitive-behavioural training on job-finding among long-term unemployed people	LANCET			English	Article							ATTRIBUTIONAL STYLE QUESTIONNAIRE; EXPLANATORY STYLE; SOCIAL SUPPORT; MENTAL-HEALTH; DEPRESSION; REEMPLOYMENT; THERAPY; SEEKING	Background The principles of cognitive-behavioural therapy (CBT) have been applied successfully through individual psychotherapy to several psychiatric disorders. We adapted these principles to create a group-training programme for a non-psychiatric group-long-term (>12 months) unemployed people. The aim was to investigate the effects of the programme on measures of mental health, job-seeking, and job-finding. Methods 289 volunteers (of standard occupational classification professional groups) were randomly assigned to a CBT or control programme, matched for all variables other than specific content, that emphasised social support. 244 (134 CBT, 110 control) people started the programmes and 199 (109 CBT, 90 control) completed the whole 7 weeks of weekly 3 h sessions (including three CBT, seven control participants who withdrew because they obtained employment or full-time training). Questionnaires completed before training, on completion, and 3-4 months later (follow-up data available for 94 CBT, 89 control) assessed mental health, job-seeking activities, and success in job-finding. Analyses were based on those who completed the programmes. Participants were not aware that two interventions were being used. Investigators were aware of group allocation, but were accompanied in all programmes by co-trainers who were non-investigators. Findings Before training, 80 (59%) CBT-group participants and 59 (54%) controls scored 5 or more on the general health questionnaire (GHQ; taken to define psychiatric caseness). After training, 29 (21%) and 25 (23%), respectively, scored 5 or more (p<0.001 for both decreases). Improvements in mean scores with training on the GHQ (between-group difference 3.91, p=0.05) and in other measures of mental health were significantly greater in the CBT group than in the control group. There were no significant differences between the groups in job-seeking activity during or after training, but significantly more of the CBT group than of the control group had been successful in finding full-time work (38 [34%] vs 13 [13%], p<0.001), by 4 months after completion of training. Interpretation These results suggest that group CBT training can improve mental health and produce tangible benefits in job-finding. Application of CBT among the unemployed is likely to benefit both individuals and society in general.	UNIV LONDON,INST PSYCHIAT,DEPT BIOSTAT & COMP,LONDON SE5 8AF,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT ORG PSYCHOL,LONDON WC1E 7HX,ENGLAND	University of London; King's College London; University of London; Birkbeck University London	Proudfoot, J (corresponding author), UNIV LONDON,INST PSYCHIAT,DEPT PSYCHOL,DECRESPIGNY PK,LONDON SE5 8AF,ENGLAND.			Carson, Jerome/0000-0002-7596-116X				ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; BEEHR TA, 1976, J APPL PSYCHOL, V61, P35, DOI 10.1037/0021-9010.61.1.35; BRUGHA TS, 1991, COMMUNITY PSYCHIAT, P115; CAPLAN RD, 1989, J APPL PSYCHOL, V74, P759, DOI 10.1037/0021-9010.74.5.759; CORR P, 1955, PERS INDIV DIFF, V18, P241; CROWLEYBAINTON T, 1955, EVALUATION OPEN LEAR; EDEN D, 1993, J APPL PSYCHOL, V78, P352, DOI 10.1037/0021-9010.78.3.352; Feather N. T., 1990, PSYCHOL IMPACT UNEMP; FURNHAM A, 1992, J ORGAN BEHAV, V13, P27, DOI 10.1002/job.4030130104; Goldberg DP, 1972, DETECTION PSYCHIAT I; GOLDSTEIN IL, 1993, TRAININGORG; Hawton KE, 1989, COGNITIVE BEHAV THER; HOLLON SD, 1990, PSYCHIAT ANN, V20, P249, DOI 10.3928/0048-5713-19900501-07; KINICKI AJ, 1990, J VOCAT BEHAV, V36, P339, DOI 10.1016/0001-8791(90)90036-2; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS; PETERSON C, 1982, COGNITIVE THER RES, V6, P287, DOI 10.1007/BF01173577; PETERSON C, 1988, J PERS SOC PSYCHOL, V55, P23, DOI 10.1037/0022-3514.55.1.23; PROUDFOOT J, 1996, THESIS U LONDON LOND; ROETHLISBERGER FJ, 1939, IND JOBS WORKER; Seligman M.E.P., 1998, LEARNED OPTIMISM; SELIGMAN MEP, 1986, J PERS SOC PSYCHOL, V50, P832, DOI 10.1037/0022-3514.50.4.832; SELIGMAN MEP, 1988, J ABNORM PSYCHOL, V97, P13, DOI 10.1037/0021-843X.97.1.13; SPERA SP, 1994, ACAD MANAGE J, V37, P722, DOI 10.2307/256708; Stratton P., 1988, LEEDS ATTRIBUTIONAL; SWEENEY PD, 1986, J PERS SOC PSYCHOL, V50, P974, DOI 10.1037/0022-3514.50.5.974; TANNENBAUM SI, 1992, ANNU REV PSYCHOL, V43, P399, DOI 10.1146/annurev.ps.43.020192.002151; ULLAH P, 1985, PSYCHOL MED, V15, P283, DOI 10.1017/S0033291700023564; VINOKUR A, 1987, J APPL SOC PSYCHOL, V17, P1007, DOI 10.1111/j.1559-1816.1987.tb02345.x; WARR P, 1988, J SOC ISSUES, V44, P47, DOI 10.1111/j.1540-4560.1988.tb02091.x; WARR P, 1984, ROLE TRANSITION; WEINER B, 1985, PSYCHOL REV, V92, P548, DOI 10.1037/0033-295X.92.4.548; WONG PTP, 1981, J PERS SOC PSYCHOL, V40, P650, DOI 10.1037/0022-3514.40.4.650	32	89	91	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					96	100		10.1016/S0140-6736(96)09097-6	http://dx.doi.org/10.1016/S0140-6736(96)09097-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XK114	9228961				2022-12-28	WOS:A1997XK11400009
J	Petitti, N				Petitti, N			Sand as a foreign body	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Petitti, N (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,300 S HAWTHORNE RD,WINSTON SALEM,NC 27157, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					96	96		10.1056/NEJM199707103370205	http://dx.doi.org/10.1056/NEJM199707103370205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211679				2022-12-28	WOS:A1997XJ82200005
J	Beitel, A				Beitel, A			Neighbors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					88	88						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214511				2022-12-28	WOS:A1997XH66700001
J	Burnham, GM				Burnham, GM			Ivermectin where Loa loa is endemic	LANCET			English	Editorial Material											Burnham, GM (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205, USA.							CARME B, 1991, AM J TROP MED HYG, V44, P684, DOI 10.4269/ajtmh.1991.44.684; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; *MECT EXP COMM, 1996, CENTR NERV SYST COMP; PINDER M, 1988, PARASITOL TODAY, V4, P279, DOI 10.1016/0169-4758(88)90019-1; REMME JHF, 1995, PARASITOL TODAY, V11, P403, DOI 10.1016/0169-4758(95)80017-4; VANBOGAERT L, 1955, J NEUROL NEUROSUR PS, V18, P103, DOI 10.1136/jnnp.18.2.103; VANHOEGAERDEN M, 1987, T ROY SOC TROP MED H, V81, P441, DOI 10.1016/0035-9203(87)90163-5; *WHO, 1991, WHO DRUG INF, V5, P127	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					2	3		10.1016/S0140-6736(05)66233-2	http://dx.doi.org/10.1016/S0140-6736(05)66233-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217709				2022-12-28	WOS:A1997XH86900003
J	Engel, S; Zhang, XM; Wandell, B				Engel, S; Zhang, XM; Wandell, B			Colour tuning in human visual cortex measured with functional magnetic resonance imaging	NATURE			English	Article							STRIATE CORTEX; CHROMATIC MECHANISMS; EVOKED-POTENTIALS; RED GREEN; MACAQUE; PHOTORECEPTORS; LUMINANCE; SPACE; CONE	The primate retina contains three classes of cones, the L, M and S cones, which respond preferentially to long-, middle- and short-wavelength visible light, respectively. Colour appearance results from neural processing of these cone signals within the retina and the brain. Perceptual experiments have identified three types of neural pathways that represent colour: a red-green pathway that signals differences between L- and M-cone responses; a blue-yellow pathway that signals differences between S-cone responses and a sum of L- and M-cone responses; and a luminance pathway that signals a sum of L- and M-cone responses(1-3). It might be expected that there are neurons in the primary visual cortex with response properties that resemble these three perceptual pathways, but attempts to find them have led to inconsistent results(4-7). We have therefore used functional magnetic resonance imaging (fMRI) to examine responses in the human brain to a large number of colours. In visual cortical areas V1 and V2, the strongest response is to red-green stimuli, and much of this activity is from neurons receiving opposing inputs from L and M cones. A strong response is also seen with blue-yellow stimuli, and this response declines rapidly as the temporal frequency of the stimulus is increased. These responses resemble psychophysical measurements, suggesting that colour signals relevant for perception are encoded in a large population of neurons in areas V1 and V2.	STANFORD UNIV, DEPT PSYCHOL, STANFORD, CA 94305 USA	Stanford University								BOYNTON RM, 1964, VISION RES, V4, P87, DOI 10.1016/0042-6989(64)90035-5; Calkins DJ, 1996, NATURE, V381, P613, DOI 10.1038/381613a0; COLE GR, 1993, J OPT SOC AM A, V10, P38, DOI 10.1364/JOSAA.10.000038; Cottaris N. P., 1996, Society for Neuroscience Abstracts, V22, P951; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DEVALOIS RL, 1965, COLD SPRING HARB SYM, V30, P567, DOI 10.1101/SQB.1965.030.01.055; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Gur M, 1997, VISION RES, V37, P377, DOI 10.1016/S0042-6989(96)00183-6; HURVICH LM, 1957, PSYCHOL REV, V64, P384, DOI 10.1037/h0041403; KELLY DH, 1971, J OPT SOC AM, V61, P537, DOI 10.1364/JOSA.61.000537; Kleinschmidt A, 1996, EXP BRAIN RES, V110, P279; LENNIE P, 1990, J NEUROSCI, V10, P649; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; POIRSON AB, 1993, J OPT SOC AM A, V10, P2458, DOI 10.1364/JOSAA.10.002458; RABIN J, 1994, VISION RES, V34, P2657, DOI 10.1016/0042-6989(94)90222-4; REGAN D, 1973, VISION RES, V13, P2381, DOI 10.1016/0042-6989(73)90237-X; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; STOCKMAN A, 1991, VISION RES, V31, P189, DOI 10.1016/0042-6989(91)90111-H; THORELL LG, 1984, VISION RES, V24, P751, DOI 10.1016/0042-6989(84)90216-5; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; TSO DY, 1988, J NEUROSCI, V8, P1712; VAUTIN RG, 1985, J NEUROPHYSIOL, V54, P273, DOI 10.1152/jn.1985.54.2.273; WANDELL BA, 1985, J OPT SOC AM A, V2, P62, DOI 10.1364/JOSAA.2.000062; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	30	249	268	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					68	71		10.1038/40398	http://dx.doi.org/10.1038/40398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214503	Bronze			2022-12-28	WOS:A1997XJ14300051
J	Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL				Akashi, K; Kondo, M; vonFreedenJeffry, U; Murray, R; Weissman, IL			Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; GAMMA-CHAIN; IL-2 RECEPTOR; POSITIVE SELECTION; NEGATIVE SELECTION; CELL-DEATH; B-CELLS; BCL-2-DEFICIENT MICE; FUNCTIONAL COMPONENT; LYMPHOID DEVELOPMENT	Mice lacking functional IL-7 or lL-7R alpha genes are severely deficient in developing thymocytes, T cells, and B cells. IL-7 and IL-7 receptor functions are believed to result in lymphoid cell proliferation and cell maturation, implying signal transduction pathways directly involved in mitogenesis and elaboration of developmentally specific new gene programs. Here, we show that enforced expression of the bcl-2 gene in T-lymphoid cells (by crossing in the E mu-bcl-2 transgene) in IL-7R alpha-deficient mice results in a significant restoration of thymic positive selection and T cell numbers and function. We propose cell survival signals to be the principal function of IL-7R engagement in thymic and T cell development.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Akashi, K (corresponding author), STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; APPASAMY PM, 1993, J EXP MED, V178, P2201, DOI 10.1084/jem.178.6.2201; BHATIA SK, 1995, J EXP MED, V181, P1399, DOI 10.1084/jem.181.4.1399; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FRIEND SL, 1994, EXP HEMATOL, V22, P321; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; GRATIOTDEANS J, 1993, J IMMUNOL, V151, P83; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; He YW, 1996, J EXP MED, V184, P289, DOI 10.1084/jem.184.1.289; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONDO M, 1997, IN PRESS IMMUNITY; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; Maki K, 1996, J EXP MED, V184, P2423, DOI 10.1084/jem.184.6.2423; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA KI, 1995, J EXP MED, V182, P1101, DOI 10.1084/jem.182.4.1101; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RAY JR, 1996, EUR J IMMUNOL, V26, P10; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; STEPHAN YL, 1997, J CLIN INVEST, V99, P169; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDA T, 1991, J IMMUNOL, V146, P3068; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonBoehmer H, 1996, J EXP MED, V183, P713, DOI 10.1084/jem.183.3.713; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YOUNG E, 1997, IMMUNITY, V6, P23	66	517	525	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1033	1041		10.1016/S0092-8674(00)80291-3	http://dx.doi.org/10.1016/S0092-8674(00)80291-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215626	Bronze			2022-12-28	WOS:A1997XG83000008
J	Benaron, DA; Cheong, WF; Stevenson, DK				Benaron, DA; Cheong, WF; Stevenson, DK			Imaging - Tissue optics	SCIENCE			English	Editorial Material							COHERENCE TOMOGRAPHY		STANFORD UNIV,SCH MED,DEPT PEDIAT,NEONATAL & DEV MED LAB,STANFORD,CA 94034	Stanford University	Benaron, DA (corresponding author), STANFORD UNIV,HANSEN EXPT PHYS LAB,MED FREE ELECTRON LASER PROGRAM,BIOMED OPT GRP,STANFORD,CA 94034, USA.							BENARON DA, 1993, SCIENCE, V259, P1463, DOI 10.1126/science.8451643; Boppart SA, 1996, DEV BIOL, V177, P54, DOI 10.1006/dbio.1996.0144; Brezinski ME, 1996, AM J CARDIOL, V77, P92, DOI 10.1016/S0002-9149(97)89143-6; Brezinski ME, 1996, CIRCULATION, V93, P1206, DOI 10.1161/01.CIR.93.6.1206; CONTAG C, IN PRESS PHOTOCHEM P; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; DREXLER B, 1985, RADIOLOGY, V157, P41, DOI 10.1148/radiology.157.1.4034975; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1; HINTZ SR, IN PRESS PHOTOCHEM P; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; IZATT JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P1584, DOI 10.1001/archopht.1994.01090240090031; Millikan GA, 1942, REV SCI INSTRUM, V13, P434, DOI 10.1063/1.1769941; PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217; SCHMITT JM, 1994, PHYS MED BIOL, V39, P1705, DOI 10.1088/0031-9155/39/10/013; SCHMITT JM, 1995, DERMATOLOGY, V191, P93, DOI 10.1159/000246523; SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; vanHouten JP, 1996, PEDIATR RES, V39, P470, DOI 10.1203/00006450-199603000-00015	19	45	47	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2002	2003		10.1126/science.276.5321.2002	http://dx.doi.org/10.1126/science.276.5321.2002			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221510				2022-12-28	WOS:A1997XG74800051
J	Enright, SJ				Enright, SJ			Fortnightly review - Cognitive behaviour therapy - Clinical applications	BRITISH MEDICAL JOURNAL			English	Review							CHRONIC TINNITUS; PANIC DISORDER; INTERVENTIONS; RELAXATION; PREVENTION; PROGRAM; METAANALYSIS; DEPRESSION; MANAGEMENT; NERVOSA				Enright, SJ (corresponding author), FAIR MILE HOSP,DEPT CLIN PSYCHOL,WALLINGFORD OX10 9HH,ENGLAND.							Azrin NH, 1996, BEHAV RES THER, V34, P41, DOI 10.1016/0005-7967(95)00049-4; Baucom D.H., 1990, COGNITIVE BEHAV MARI; Baucom D. H., 1996, ADV COGNITIVE BEHAV, P210; Beck A.T., 1979, COGNITIVE THERAPY EM; Beck A.T., 2015, COGNITIVE THERAPY PE; Beck A.T., 1985, ANXIETY DISORDERS PH; BECK AT, 1979, COGNITIVE THERAPY DE; BECK JG, 1994, J CONSULT CLIN PSYCH, V62, P818, DOI 10.1037/0022-006X.62.4.818; BENNETT P, 1994, BEHAV COGN PSYCHOTH, V22, P125, DOI 10.1017/S1352465800011917; Birbaumer N., 1992, PERSPECTIVES PROMISE, P81; BLACKBURN IM, 1995, COGNITIVE THERAPY AN; Blackburn IM, 1996, COGNITIVE THERAPY AC; Blanchard EB, 1996, PROF PSYCHOL-RES PR, V27, P241; Blanchard EB, 1996, CURR OPIN PSYCHIATR, V9, P445, DOI 10.1097/00001504-199611000-00015; BRADLEY C, 1994, BR J CLIN PSYCHOL, V4, P561; BRAMBILLA F, 1995, NEUROPSYCHOBIOLOGY, V32, P59, DOI 10.1159/000119213; BROWNELL KD, 1995, BEHAV MED, V20, P155, DOI 10.1080/08964289.1995.9933732; BUTLER G, 1991, J CONSULT CLIN PSYCH, V59, P167, DOI 10.1037/0022-006X.59.1.167; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; CLARK DM, 1994, BRIT J PSYCHIAT, V164, P759, DOI 10.1192/bjp.164.6.759; Cole A., 1989, COGNITIVE THERAPY CL, P183; COLLAND VT, 1993, PATIENT EDUC COUNS, V22, P141, DOI 10.1016/0738-3991(93)90094-D; COTTRAUX J, 1993, PSYCHOL MED, V25, P1460; DAVIES S, 1995, PSYCHOL HEALTH, V10, P129, DOI 10.1080/08870449508401943; Devine E C, 1995, Oncol Nurs Forum, V22, P1369; Dobson K. S., 1996, ADV COGNITIVE BEHAV, V2, P31; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; ELLER S, 1995, ANN BEHAV MED, V17, P339; ESPIE CA, 1991, PSYCHOL TREATMENT IN; EVANS MD, 1992, ARCH GEN PSYCHIAT, V49, P802; Fairburn C. G., 1989, COGNITIVE BEHAV THER, P277; FALLOON IRH, 1994, BEHAV CHANGE, V11, P213, DOI 10.1017/S0813483900004484; Fava GA, 1996, AM J PSYCHIAT, V153, P945; FOA EB, 1995, J CONSULT CLIN PSYCH, V63, P948, DOI 10.1037/0022-006X.63.6.948; FOA EB, 1979, BEHAV RES THER, V17, P169, DOI 10.1016/0005-7967(79)90031-7; FONAGY P, 1989, PRACTICE BEHAVIOURAL, P161; Fowler D, 1995, COGNITIVE BEHAV THER; GAFFAN EA, 1995, J CONSULT CLIN PSYCH, V63, P966, DOI 10.1037/0022-006X.63.6.966; GARNER DM, 1985, HDB PSYCHOTHERAPY AN, P107; GOLDSTEIN LH, 1990, BRIT J CLIN PSYCHOL, V29, P257, DOI 10.1111/j.2044-8260.1990.tb00884.x; HACKERHUGHES JGH, 1994, CLIN PSYCHOL PSYCHOT, V1, P125; Halford K., 1992, BEHAV CHANGE, V9, P19; Hawton K., 1989, COGNITIVE BEHAV THER, P370; HEIM E, 1995, PATIENT EDUC COUNS, V26, P145, DOI 10.1016/0738-3991(95)00733-G; HEIMBERG RG, 1990, COMP HDB TREATMENTS, P203; JAMES IA, 1995, BRIT J PSYCHIAT, V166, P444, DOI 10.1192/bjp.166.4.444; Jarvis T, 1995, TREATMENT APPROACHES; JOHNS D, 1989, HPLC MACROMOLECULES, P1; JOHNSON M, 1990, STRESS MED PROCEDURE; Kemp R, 1996, BRIT MED J, V312, P345; KRAAIMAAT FW, 1995, BEHAV RES THER, V33, P487, DOI 10.1016/0005-7967(94)00094-Z; KRONERHERWIG B, 1995, J PSYCHOSOM RES, V39, P153, DOI 10.1016/0022-3999(94)00098-P; LANGOSCH W, 1989, PRACTICE BEHAV MED, P27; LEITENBERG H, 1995, BEHAV CHANGE, V12, P81, DOI 10.1017/S0813483900004265; Linden Wolfgang, 1994, Annals of Behavioral Medicine, V16, P35; Linehan M., 1993, COGNITIVE BEHAV TREA; MCCRACKEN L M, 1991, Annals of Behavioral Medicine, V13, P57; McGuire J., 1995, WHAT WORKS REDUCING; MCNALLY RJ, 1995, CURR OPIN PSYCHIATR, V8, P395, DOI 10.1097/00001504-199511000-00011; MEICHENBAUM DH, 1974, COGNITIVE BEHAVIOR M; MILLER IW, 1989, AM J PSYCHIAT, V146, P1274; Moorey S., 1989, PSYCHOL THERAPY PATI; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; Novaco R.W., 1975, ANGER CONTROL DEV EV; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; OEI T P S, 1991, Journal of Addictive Diseases, V10, P63, DOI 10.1300/J069v10n03_07; RAMANO JM, 1994, CURR OPIN PSYCHIATR, V7, P494; ROSEN RC, 1995, J CONSULT CLIN PSYCH, V63, P877, DOI 10.1037/0022-006X.63.6.877; Salkovskis Paul M., 1996, P103; SCHOLING A, 1995, BEHAV RES THER, V34, P447; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; Sommaruga M, 1995, Monaldi Arch Chest Dis, V50, P398; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; Taylor S, 1996, J BEHAV THER EXP PSY, V27, P1, DOI 10.1016/0005-7916(95)00058-5; Teasdale JD, 1988, COGNITION EMOTION, V2, P247, DOI 10.1080/02699938808410927; TURK DC, 1996, ADV COGNITIVE BEHAV, P83; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189; WARWICK HMC, 1990, BEHAV RES THER, V28, P105, DOI 10.1016/0005-7967(90)90023-C; WILLIAMS ACD, 1993, BRIT J GEN PRACT, V43, P513; WILSON GT, 1994, ADV BEHAV RES THER, V16, P31, DOI 10.1016/0146-6402(94)90002-7; Wilson GT, 1996, BEHAV RES THER, V34, P197, DOI 10.1016/0005-7967(95)00068-2; Wright F D, 1993, NIDA Res Monogr, V137, P123; YOUNG G, 1990, COGNITIVE THERAPY PE	84	46	47	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1811	1816		10.1136/bmj.314.7097.1811	http://dx.doi.org/10.1136/bmj.314.7097.1811			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG166	9224087	Green Published			2022-12-28	WOS:A1997XG16600028
J	Pusey, A; Williams, J; Goodall, J				Pusey, A; Williams, J; Goodall, J			The influence of dominance rank on the reproductive success of female chimpanzees	SCIENCE			English	Article							BABOONS	Female chimpanzees often forage alone and do not display obvious linear dominance hierarchies; consequently, it has been suggested that dominance is not of great importance to them. However, with the use of data from a 35-year field study of chimpanzees, high-ranking females were shown to have significantly higher infant survival, faster maturing daughters, and more rapid production of young, Given the foraging behavior of chimpanzees, high rank probably influences reproductive success by helping females establish and maintain access to good foraging areas rather than by sparing them stress from aggression.	JANE GOODALL INST,RIDGEFIELD,CT 06877		Pusey, A (corresponding author), UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,JANE GOODALL INST CTR PRIMATE STUDIES,ST PAUL,MN 55108, USA.		Klein, Richard G/B-5910-2009	Pusey, Anne/0000-0002-2280-8954				[Anonymous], 1993, DESIGN ANAL ECOLOGIC; Baker Kate C., 1994, P227; Bygott JD., 1979, GREAT APES, P405; Chapais Bernard, 1992, P29; CLUTTONBROCK TH, 1979, AFR J ECOL, V17, P131, DOI 10.1111/j.1365-2028.1979.tb00250.x; COLLINS DA, 1988, J HUM EVOL, V17, P553, DOI 10.1016/0047-2484(88)90084-X; DEWAAL F, 1982, CHIMPANZEE POLITICS; DEWAAL FBM, 1984, ETHOL SOCIOBIOL, V5, P239, DOI 10.1016/0162-3095(84)90004-9; ELLIS L, 1995, ETHOL SOCIOBIOL, V16, P357; Frank Laurence, 1995, SERENGETI, P364; GOODALL J, 1977, FOLIA PRIMATOL, V28, P259, DOI 10.1159/000155817; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HARCOURT AH, 1987, J ZOOL, V213, P471, DOI 10.1111/j.1469-7998.1987.tb03721.x; MOSES LE, 1992, AM J PRIMATOL, V28, P49, DOI 10.1002/ajp.1350280105; NISHIDA T, 1987, PRIMATE SOC, P318; NISHIDA T, 1990, UNDERSTANDING CHIMPA, P68; PACKER C, 1995, NATURE, V373, P60, DOI 10.1038/373060a0; Pusey A, 1979, GREAT APES, P465; Pusey A.E., 1987, P250; PUSEY AE, 1990, BEHAVIOUR, V115, P203, DOI 10.1163/156853990X00581; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; PUSEY AE, 1983, ANIM BEHAV, V31, P363, DOI 10.1016/S0003-3472(83)80055-4; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; van Schaik CP., 1989, COMP SOCIOECOLOGY BE, P195; Wallis J, 1997, J REPROD FERTIL, V109, P297; Walters J.R., 1987, P306; Wrangham R W, 1980, J Reprod Fertil Suppl, VSuppl 28, P13; WRANGHAM RW, 1980, BEHAVIOUR, V75, P262, DOI 10.1163/156853980X00447; WRANGHAM RW, 1974, ANIM BEHAV, V22, P83, DOI 10.1016/S0003-3472(74)80056-4; WRANGHAM RW, 1992, HUMAN ORIGINS, P81	31	360	367	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					828	831		10.1126/science.277.5327.828	http://dx.doi.org/10.1126/science.277.5327.828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242614				2022-12-28	WOS:A1997XQ24700047
J	Holloway, HC; Norwood, AE; Fullerton, CS; Engel, CC; Ursano, RJ				Holloway, HC; Norwood, AE; Fullerton, CS; Engel, CC; Ursano, RJ			The threat of biological weapons - Prophylaxis and mitigation of psychological and social consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-STRESS ENVIRONMENT; WARFARE; CARE	The microbial world is mysterious, threatening, and frightening to most people. The stressors associated with a biological terrorist attack could create high numbers of acute and potentially chronic psychiatric casualties who must be recognized, diagnosed, and treated to facilitate triage and medical care. Media communications, planning for quarantine and decontamination, and the role of community leaders are important to the mitigation of psychological consequences. Physicians will need to accurately diagnose anxiety, depression, bereavement, and organic brain syndromes to provide treatment, reassurance, and the relief of pain.			Holloway, HC (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PSYCHIAT,4301 JONES BRIDGE RD,BETHESDA,MD 20814, USA.		Ursano, Robert J/ABE-6533-2020	Ursano, Robert/0000-0002-1861-9173; Engel, Charles/0000-0002-9232-3389				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BAUM A, 1990, HEALTH PSYCHOL, V9, P653, DOI 10.1037/0278-6133.9.6.653; Blackwell B, 1996, ARCH FAM MED, V5, P457, DOI 10.1001/archfami.5.8.457; Flanagin A, 1996, JAMA-J AM MED ASSOC, V276, P419; FULLERTON CS, 1992, J APPL SOC PSYCHOL, V22, P1608, DOI 10.1111/j.1559-1816.1992.tb01759.x; FULLERTON CS, 1994, MIL MED, V159, P524, DOI 10.1093/milmed/159.7.524; FULLERTON CS, 1996, EMOTIONAL AFTERMATH, P111; FULLERTON CS, 1988, PUBLICATION DTIC, P113; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Kenardy JA, 1996, J TRAUMA STRESS, V9, P37, DOI 10.1007/BF02116832; *NAT RES COUNC, 1996, UND RISK INF DEC DEM; National Research Council, 1988, HLTH RISKS RADON OTH; National Research Council, 1989, IMPR RISK COMM; National Research Council, 1983, RISK ASS FED GOV MAN; Okumura T, 1996, ANN EMERG MED, V28, P129, DOI 10.1016/S0196-0644(96)70052-5; PECHURA CM, 1993, VETERANS RISK; Presidential advisory committee on Gulf War veterans' illnesses, 1996, PRES ADV COMM GULF W; RAPHAEL B, 1995, BRIT MED J, V310, P1479, DOI 10.1136/bmj.310.6993.1479; Raphael Beverley, 1996, P463; RUSSELL PK, 1997, EMERG INFECT DIS; Schwartz S P, 1985, J Public Health Policy, V6, P58, DOI 10.2307/3342018; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; URSANO RJ, 1995, HARVARD REV PSYCHIAT, V3, P196, DOI 10.3109/10673229509017186; URSANO RJ, 1988, PUBLICATION DTIC; URSANO RJ, 1988, PUBLICATION DTIC, P79; Ursano Robert J., 1994, P3, DOI 10.1017/CBO9780511570162.003; *US C OFF TECHN AS, 1991, PUBL US C; WEISAETH L, 1997, PROG PSYCH, P91	28	111	114	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					425	427		10.1001/jama.278.5.425	http://dx.doi.org/10.1001/jama.278.5.425			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XN518	9244335				2022-12-28	WOS:A1997XN51800035
J	Lentle, B; Aldrich, J				Lentle, B; Aldrich, J			Radiological sciences, past and present	LANCET			English	Article								Few observations can have been as rapidly and widely disseminated in medicine as the diagnostic X-ray (radiograph). The first few decades after Rontgen's discovery saw technical developments that made radiography more practical, quicker, safer for both imager and patient, and able to achieve greater contrast. This article reviews the history of imaging but it also looks to the future and begins to open up some of the issues that radiology faces In the 21st century-issues that the next six articles in this Lancef series will enlarge upon. The conventional radiograph remains the most common medical image but a host of new techniques have come along. Are they research tools, clinical methods, or both-and how, in an age of sensitivity about the costs of health care, do they stand up?	VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC V57 1M9,CANADA	University of British Columbia	Lentle, B (corresponding author), UNIV BRITISH COLUMBIA,DEPT RADIOL,855 W 12TH AVE,VANCOUVER,BC V57 1M9,CANADA.							ALDRICH J, 1995, NEW KIND RAY RADIOLO, P21; ALDRICH J, 1995, NEW KIND RAY RADIOLO, P77; ALDRICH J, 1995, NEW KIND RAY RADIOLO, P5; BARJON F, 1918, RADIODIAGNOSIS PLEUR; BELL AG, 1903, SCIENCE, V18, P1555; Blume S.S., 1992, INSIGHT IND DYNAMICS; BRUWER AJ, 1964, CLASSIC DESCRIPTIONS, V1; Cannon W. B., 1898, AM J PHYSIOL, V1, P359, DOI DOI 10.1152/AJPLEGACY.1898.1.3.359; COHEN M, 1995, NEW KIND RAY RADIOLO, P17; CONNOR JTH, 1995, NEW KIND RAY RADIOLO, P19; COX J, 1896, MONTREAL MED J, V24, P661; DONIZETTI P, 1967, SHADOW SUBSTANCE STO; DUTREIX J, 1995, MED PHYS, V22, P1869, DOI 10.1118/1.597442; Eisenberg RL, 1991, ENHJORNING; Gagliardi RA, 1996, HIST RADIOLOGICAL SC; GRIGG ERW, 1963, TRAIL INVISIBLE LIGH; Kevles B., 1997, NAKED BONE MED IMAGI; KLICKSTEIN HS, 1966, NEW KIND RAYS BIBLIO; KNUTSSON F, 1969, ACTA RADIOL DIAGN, V8, P449, DOI 10.1177/028418516900800601; LEE DL, 1995, P SOC PHOTO-OPT INS, V2432, P237, DOI 10.1117/12.208342; LENTLE BC, 1995, NEW KIND RAY RADIOLO, P287; LEVI H, 1976, EUR J NUCL MED, V1, P3; POSNER E, 1970, BMJ-BRIT MED J, V4, P357, DOI 10.1136/bmj.4.5731.357; ROGUES JD, 1981, REBELS GENIUSES, P310; SCHWIERTZ G, 1995, ELEKTROMEDICA, V63, P34; Schwierz G., 1995, Electromedica, V63, P2; TANNAHILL R, 1980, SEX HIST, P348; THOMAS AMK, 1995, INVISIBLE LIGHT 100; URICH K, 1995, SUCCESSES FAILURES D; WILLIAMS FH, 1896, MED REC NY, V49, P665; 1896, GLOBE TORONTO   0227	31	12	13	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					280	285		10.1016/S0140-6736(97)05306-3	http://dx.doi.org/10.1016/S0140-6736(97)05306-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242813				2022-12-28	WOS:A1997XM86600042
J	Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD				Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD			Microtubule interaction site of the kinesin motor	CELL			English	Article							MONOMERIC MOTOR; ATP HYDROLYSIS; PROTEIN; MYOSIN; DOMAIN; DROSOPHILA; ACTIN; MOLECULES; TRANSPORT; MOVEMENT	Kinesin and myosin are motor proteins that share a common structural core and bind to microtubules and actin filaments, respectively. While the actomyosin interface has been well studied, the location of the microtubule-binding site on kinesin has not been identified. Using alanine-scanning mutagenesis, we have found that microtubule-interacting kinesin residues are located in three loops that cluster in a patch on the motor surface. The critical residues are primarily positively charged, which is consistent with a primarily electrostatic interaction with the negatively charged tubulin molecule. The core of the microtubule-binding interface resides in a highly conserved loop and helix (L12/alpha 5) that corresponds topologically to the major actin-binding domain of myosin. Thus, kinesin and myosin have developed distinct polymer-binding domains in a similar region with respect to their common catalytic cores.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Woehlke, G (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.			Woehlke, Gunther/0000-0001-8462-9962	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42895] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOSREMEDIOS CG, 1995, BBA-BIOENERGETICS, V1228, P99, DOI 10.1016/0005-2728(94)00169-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1993, GENETICS, V135, P35; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Pearce KH, 1996, BIOCHEMISTRY-US, V35, P10300, DOI 10.1021/bi960513b; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Tucker C, 1997, J BIOL CHEM, V272, P9481; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1997, IN PRESS ANN REV CEL; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	56	306	312	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					207	216		10.1016/S0092-8674(00)80329-3	http://dx.doi.org/10.1016/S0092-8674(00)80329-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244295	Green Published, Bronze			2022-12-28	WOS:A1997XN24900005
J	Lauretta, DS; Lodders, K; Fegley, B				Lauretta, DS; Lodders, K; Fegley, B			Experimental simulations of sulfide formation in the solar nebula	SCIENCE			English	Article							IRON-NICKEL ALLOY; FE-NI; CHONDRITES; METEORITES; ORIGIN; SYSTEM; SULFUR	Sulfurization of meteoritic metal in H2S-H-2 gas produced three different sulfides: monosulfide solid solution [(Fe,Ni)(1-x)S], pentlandite [(Fe,Ni)(9-x)S-8], and a phosphorus-rich sulfide. The composition of the remnant metal was unchanged. These results are contrary ta theoretical predictions that sulfide formation in the solar nebula produced troilite (FeS) and enriched the remaining metal in nickel. The experimental sulfides are chemically and morphologically similar to sulfide grains in the matrix of the Alais (class Cl) carbonaceous chondrite, suggesting that these meteoritic sulfides may be condensates from the solar nebula.			Lauretta, DS (corresponding author), WASHINGTON UNIV,PLANETARY CHEM LAB,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,1 BROOKINGS DR,ST LOUIS,MO 63130, USA.			Lodders, Katharina/0000-0001-7531-626X				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BASTOW BD, 1985, CORROS SCI, V25, P253, DOI 10.1016/0010-938X(85)90080-0; CLARK JB, 1963, T METALL SOC AIME, V227, P1250; CONDIT RH, 1974, OXID MET, V8, P409, DOI 10.1007/BF00603390; DEAN DC, 1986, METALL TRANS A, V17, P1131, DOI 10.1007/BF02665311; DEVOUARD B, UNPUB METEORIT PLANE; DREIBUS G, 1995, METEORITICS, V30, P439, DOI 10.1111/j.1945-5100.1995.tb01150.x; Folinsbee R.E., 1967, GEOCHIM COSMOCHIM AC, V31, P1625; HANOWSKI NP, 1996, METEORIT PLANET SC S, V31, pA57; HUSS GR, 1981, GEOCHIM COSMOCHIM AC, V45, P33, DOI 10.1016/0016-7037(81)90262-3; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P359, DOI 10.1016/0012-821X(79)90091-8; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P1, DOI 10.1016/0012-821X(79)90149-3; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1215, DOI 10.1016/S0016-7037(67)80013-9; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P97; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P111; LAURETTA DS, 1995, LUNAR PLANET SCI, V26, P831; LAURETTA DS, UNPUB METEORIT PLANE; LEWIS JS, 1972, EARTH PLANET SC LETT, V15, P286, DOI 10.1016/0012-821X(72)90174-4; LEWIS RS, 1975, P NATL ACAD SCI USA, V72, P268, DOI 10.1073/pnas.72.1.268; MILLION B, 1981, MATER SCI ENG, V50, P43, DOI 10.1016/0025-5416(81)90084-7; NARITA T, 1975, DENKI KAGAKU, V43, P443; Nazarov M. F., 1996, LUNAR PLANET SCI, V27, P939; ORCHARD JP, 1989, OXID MET, V31, P105, DOI 10.1007/BF00665489; ORCHARD JP, 1989, J ELECTROCHEM SOC, V136, P545, DOI 10.1149/1.2096679; RAMDOHR P, 1963, J GEOPHYS RES, V68, P2011, DOI 10.1029/JZ068i007p02011; SHEWMAN RW, 1970, CAN J EARTH SCI, V7, P67, DOI 10.1139/e70-005; UREY HC, 1952, PLANETS	28	65	68	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					358	360		10.1126/science.277.5324.358	http://dx.doi.org/10.1126/science.277.5324.358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219690				2022-12-28	WOS:A1997XL35800042
J	Bosset, JF; Gignoux, M; Triboulet, JP; Tiret, E; Mantion, G; Elias, D; Lozach, P; Ollier, JC; Pavy, JJ; Mercier, M; Sahmoud, T				Bosset, JF; Gignoux, M; Triboulet, JP; Tiret, E; Mantion, G; Elias, D; Lozach, P; Ollier, JC; Pavy, JJ; Mercier, M; Sahmoud, T			Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	30th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 14-17, 1994	DALLAS, TX	Amer Soc Clin Oncol			RANDOMIZED CLINICAL-TRIAL; INDUCED LUNG DAMAGE; PREOPERATIVE RADIOTHERAPY; CURATIVE RESECTION; RADIATION-THERAPY; CARCINOMA; SURVIVAL; CHEMOTHERAPY; IRRADIATION; MULTICENTER	Background We conducted a multicenter, randomized trial to compare preoperative chemoradiotherapy followed by surgery with surgery alone in patients with stage I and II squamous-cell cancer of the esophagus. Methods The preoperative combined therapy consisted of two one-week courses; each involved radio therapy, in a dose of 18.5 Gy delivered in five fractions of 3.7 Gy each, and 80 mg of cisplatin per square meter of body-surface area, administered 0 to 2 days before the first day of radiotherapy. The surgical plan included one-stage en bloc esophagectomy and proximal gastrectomy by the abdominal and right thoracic routes, to be performed immediately after randomization in the group assigned to surgery alone and two to four weeks after the completion of preoperative chemoradiotherapy in the group assigned to combined therapy. Results A total of 297 patients entered the study; 11 were found to be ineligible, and 4 were lost to fol low-up. Of the remaining 282, 139 were assigned to surgery alone and 143 to combined therapy. After a median follow-up of 55.2 months, no significant difference in overall survival was observed; the median survival was 18.6 months for both groups. As compared with the group treated with surgery alone, the group treated preoperatively had longer disease-free survival (P=0.003), a longer interval free of local disease (P=0.01), a lower rate of cancer-related deaths (P=0.002), and a higher frequency of curative resection (P=0.017). However, there were more postoperative deaths (P=0.012) in the group treated preoperatively with chemoradiotherapy. Three prognostic factors were found to influence survival in a multivariate analysis: the disease stage, based on computed tomography; the location of the tumor; and whether the surgical resection was curative. Conclusions In patients with squamous-cell esophageal cancer, preoperative chemoradiotherapy did not improve overall survival, but it did prolong disease-free survival and survival free of local disease. (C)1997, Massachusetts Medical Society.	UNIV HOSP COTE NACRE, CAEN, FRANCE; UNIV HOSP C HURRIEZ, LILLE, FRANCE; UNIV HOSP ST ANTOINE, PARIS, FRANCE; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; UNIV HOSP A MORVAN, BREST, FRANCE; UNIV HOSP, SCHILTIGHEIM, FRANCE; EUROPEAN ORG RES TREATMENT CANC, CTR DATA, BRUSSELS, BELGIUM	CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; CHU Strasbourg; European Organisation for Research & Treatment of Cancer	Bosset, JF (corresponding author), UNIV HOSP J MINJOZ, DEPT RADIAT ONCOL, F-25030 BESANCON, FRANCE.							AISNER J, 1983, CANCER TREAT S, V2, P87; [Anonymous], 1978, 29 ICRU; ARNOTT SJ, 1992, RADIOTHER ONCOL, V24, P108, DOI 10.1016/0167-8140(92)90287-5; BEDENNE L, 1986, B CANCER, V73, P526; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; CALAMENT G, 1993, GASTROEN CLIN BIOL, V17, P9; CHERIECHALLINE L, 1988, GASTROEN CLIN BIOL, V12, P126; COX DR, 1972, J R STAT SOC B, V34, P187; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; FINK U, 1994, ANN ONCOL, V5, pS17, DOI 10.1093/annonc/5.suppl_3.S17; FOK M, 1993, SURGERY, V113, P138; FOK M, 1992, 5 WORLD C INT SOC DI, P149; FOWLER JF, 1992, INT J RADIAT ONCOL, V23, P457, DOI 10.1016/0360-3016(92)90768-D; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GIGNOUX M, 1987, WORLD J SURG, V11, P426, DOI 10.1007/BF01655805; GIGNOUX M, 1989, ANTICANCER RES, V9, P1023; GIRI PGS, 1985, INT J RADIAT ONCOL, V11, P527, DOI 10.1016/0360-3016(85)90184-1; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOK T, 1992, 5 WORLD C INT SOC DI, P38; LAUNOIS B, 1981, SURG GYNECOL OBSTET, V153, P690; Law SYK, 1996, BRIT J SURG, V83, P107, DOI 10.1002/bjs.1800830134; LEPRISE E, 1994, CANCER, V73, P1779; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MULLER JM, 1990, BRIT J SURG, V77, P845, DOI 10.1002/bjs.1800770804; NYGAARD K, 1992, WORLD J SURG, V16, P1104, DOI 10.1007/BF02067069; RODER JD, 1994, BRIT J SURG, V81, P410, DOI 10.1002/bjs.1800810330; ROTH JA, 1988, J THORAC CARDIOV SUR, V96, P242; Schlag P M, 1992, Arch Surg, V127, P1446; SIEWERT JR, 1994, ANN ONCOL, V5, pS1, DOI 10.1093/annonc/5.suppl_3.S1; SUGIMACHI K, 1983, SURG GYNECOL OBSTET, V157, P537; TAM PC, 1987, ANN SURG, V205, P189, DOI 10.1097/00000658-198702000-00014; TENIERE P, 1991, SURG GYNECOL OBSTET, V173, P123; URBA S, 1995, P AN M AM SOC CLIN, V14, P475; VANDYK J, 1989, RADIOTHER ONCOL, V14, P55, DOI 10.1016/0167-8140(89)90009-1; VANLANSCHOT JJB, 1994, BRIT J SURG, V81, P1320, DOI 10.1002/bjs.1800810921; VONDERMAASE H, 1986, RADIOTHER ONCOL, V5, P245, DOI 10.1016/S0167-8140(86)80054-8; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702; WANG M, 1989, INT J RADIAT ONCOL, V16, P325; WURTZ A, 1990, J CHIR-PARIS, V127, P63	41	1075	1104	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					161	167		10.1056/NEJM199707173370304	http://dx.doi.org/10.1056/NEJM199707173370304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XK818	9219702	Bronze			2022-12-28	WOS:A1997XK81800004
J	Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR				Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR			Expression cloning of new receptors used by simian and human immunodeficiency viruses	NATURE			English	Article							INFECTION; IDENTIFICATION; DETERMINANT; TYPE-1; STRAIN; HIV-1	Several members of the chemokine-receptor family serve, in conjunction with CD4, as receptors for the entry of human immunodeficiency virus type I (HIV-1) into cells(1-6). The principal receptor for entry of macrophage-tropic (M-tropic) HIV-1 strains is CCR5, whereas that for T-cell-line-tropic (T-tropic) strains is CXCR4. Unlike HlV-1, infection with either M-tropic or T-tropic strains of simian immunodeficiency virus (SIV) can be mediated by CCR5, but not CXCR4 (refs 7-10). SIV strains will also infect CD4(+) cells that lack CCR5, which suggests that these strains use as yet unidentified receptors(7,9,10). Here we use an expression-cloning strategy to identify SIV receptors and have isolated genes encoding two members of the seven-transmembrane G-protein-coupled receptor family that are used not only by SIVs, but also by strains of HIV-2 and M-tropic HIV-1. Both receptors are closely related to the chemokine-receptor family and are expressed in lymphoid tissues. One of the receptors is also expressed in colon and may therefore be important in viral transmission. Usage of these new receptors following experimental infection of non-human primates with SIV strains may provide important insight into viral transmission and the mechanisms of SIV- and HIV-induced acquired immune-deficiency syndrome.	NYU,MED CTR,HOWARD HUGHES MED INST,SKIRBALL INST BIOMOL MED,DIV MOL PATHOGENESIS,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University			KewalRamani, Vineet/V-5084-2019					Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUKASAWA M, 1988, NATURE, V333, P457, DOI 10.1038/333457a0; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; HILL CM, IN PRESS J VIROL; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LIAO S, 1997, J EXP MED, V185, P2015; MARCON J, 1997, J VIROL, V71, P2522; MARTHAS ML, 1989, J MED PRIMATOL, V18, P311; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; STEFANO KA, 1993, J VIROL, V67, P6707, DOI 10.1128/JVI.67.11.6707-6715.1993; THEODOROU J, 1997, LANCET, V349, P1219; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	31	590	615	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					296	300		10.1038/40894	http://dx.doi.org/10.1038/40894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230441	Bronze			2022-12-28	WOS:A1997XL12100056
J	Yemaneberhan, H; Bekele, Z; Venn, A; Lewis, S; Parry, E; Britton, J				Yemaneberhan, H; Bekele, Z; Venn, A; Lewis, S; Parry, E; Britton, J			Prevalence of wheeze and asthma and relation to atopy in urban and rural Ethiopia	LANCET			English	Article							SKIN-TEST REACTIVITY; BRONCHIAL-ASTHMA; IGE LEVELS; CHILDREN; ALLERGY; PARASITES; SCHOOLCHILDREN; ASSOCIATION; SYMPTOMS; SAMPLE	Background Asthma and allergy in developing countries may be associated with adoption of an urbanised ''western'' lifestyle. We compared the rates of asthma symptoms and atopy in urban populations in Jimma, southwest Ethiopia, at an early stage of economic development with those among the population of remote, rural, subsistence areas, and assessed the potential role of environmental aetiological factors leading to the differences, Methods Information on wheeze of 12 months' duration, diagnosed asthma, and cough for 3 months of the year was gathered by questionnaire in random household samples of 9844 people from urban Jimma and of 3032 from rural areas, Atopy was defined by allergen skin-test response to Dermatophagoides pteronyssinus and mixed threshings measured in a one-in-four subsample of those aged 5 years and older from both groups. Findings All respiratory symptoms were rare in children and were significantly less common overall in the rural than in urban group (wheeze odds ratio 0.31 [95% CI 0.22-0.43], p<0.0001). Asthma was reported by 351 (3.6%) of the urban group, with a median reported duration of 8.5 years (IQR 4-17 years) that was unrelated to age. Atopy was a strong risk factor for asthma in urban Jimma. In the rural areas, skin sensitivity to mixed threshings was only slightly less common than in urban Jimma (0.67 [0.40-1.12], p=0.13), whereas sensitivity to D pteronyssinus was significantly more common (3.24 [2.40-4.38], p<0.0001), and since none of the 119 atopic individuals in the rural area reported wheeze or asthma, atopy was possibly associated with a reduction in the risk of disease among this group. Wheeze or D pteronyssinus sensitivity were positively associated with housing style, bedding materials, and use of malathion insecticide, but no single factor accounted for the urban-rural differences. Interpretation Wheeze and asthma are especially rare in rural subsistence areas, and atopy may be associated with a reduced prevalence of these symptoms in this environment. In urban Jimma, self-reported asthma seemed to emerge as a clinical problem about 10 years before our study began, which is consistent with an effect of new environmental exposures. The factor or factors leading to the increase in asthma and allergy have not been identified, although exposures related to general changes in the domestic environment are likely to be involved.	CITY HOSP, DIV RESP MED, NOTTINGHAM NG5 1PB, ENGLAND; JIMMA INST HLTH SCI, JIMA, ETHIOPIA; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, LONDON WC1E 7HT, ENGLAND	University of Nottingham; Jimma University; University of London; London School of Hygiene & Tropical Medicine			Britton, John R/G-9705-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BRITTON J, 1994, LANCET, V344, P357, DOI 10.1016/S0140-6736(94)91399-4; BUCHANAN DJ, 1974, POSTGRAD MED J, V50, P680, DOI 10.1136/pgmj.50.589.680; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1987, J ALLERGY CLIN IMMUN, V80, P373, DOI 10.1016/0091-6749(87)90052-2; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; MOKOETLE KE, 1994, THORAX, V49, P340, DOI 10.1136/thx.49.4.340; MOQBEL R, 1990, CLIN EXP ALLERGY, V20, P611, DOI 10.1111/j.1365-2222.1990.tb02699.x; NEWMANTAYLOR A, 1995, LANCET, V345, P296, DOI 10.1016/S0140-6736(95)90280-5; ODHIAMBO J, 1994, AM J RESP CRIT CARE, V149, pA385; PRITCHARD DI, 1993, INT J PARASITOL, V23, P167, DOI 10.1016/0020-7519(93)90137-N; PRITCHARD DI, 1995, PARASITE IMMUNOL, V17, P71, DOI 10.1111/j.1365-3024.1995.tb00968.x; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEYOUM B, 1992, ETHIOPIAN MED J, V30, P225; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Starr SE, 1996, LANCET, V348, P1257, DOI 10.1016/S0140-6736(05)65753-4; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VANNIEKERK CH, 1977, LANCET, V1, P96; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARRELL DA, 1975, Q J MED, V44, P325; WOOLCOCK AJ, 1981, AM REV RESPIR DIS, V123, P564	30	284	291	2	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	1997	350	9071					85	90		10.1016/S0140-6736(97)01151-3	http://dx.doi.org/10.1016/S0140-6736(97)01151-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228959				2022-12-28	WOS:A1997XK11400007
J	Balas, EA; Jaffrey, F; Kuperman, GJ; Boren, SA; Brown, GD; Pinciroli, F; Mitchell, JA				Balas, EA; Jaffrey, F; Kuperman, GJ; Boren, SA; Brown, GD; Pinciroli, F; Mitchell, JA			Electronic communication with patients - Evaluation of distance medicine technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; FOLLOW-UP; COMPUTERIZED REMINDERS; APPOINTMENT REMINDERS; INFLUENZA VACCINATION; INCREASE COMPLIANCE; COST-EFFECTIVENESS; TELEPHONE PROGRAM; PRIMARY CARE	Objective.-To evaluate controlled evidence on the efficacy of distance medicin Data Sources.-Systematic electronic database and manual searches (1966-1996) were conducted to identify clinical trial reports on distance medicine applications. Study Selection.-Three eligibility criteria were applied: prospective, contemporaneously controlled clinical trial with random assignment of the intervention; electronic distance technology application in the intervention group and no similar intervention in the control group; and measurement of the intervention effect on process or outcome of care. Data Extraction.-Data were abstracted by independent reviewers using a standardized abstraction form and the quality of methodology was scored. Distance technology applications were described in 6 categories. computerized communication, telephone follow-up and counseling, telephone reminders, interactive telephone systems, after-hours telephone access, and telephone screening. Data Synthesis.-Of 80 eligible clinical trials, 61 (76%) analyzed provider-initiated communication with patients and 50 (63%) reported positive outcome, improved performance, or significant benefits, including studies of computerized communication (7 of 7), telephone follow-up and counseling (20 of 37), telephone reminders (14 of 23), interactive telephone systems (5 of 6), telephone access (3 of 4), and telephone screening (1 of 3). Significantly improved outcomes were demonstrated in studies of preventive care, management of osteoarthritis, cardiac rehabilitation, and diabetes care. Conclusions.-Distance medicine technology enables greater continuity of care by improving access and supporting the coordination of activities by a clinician, The benefits of distance technologies in facilitating communication between clinicians and patients indicate that application of telemedicine should not be limited to physician-to-physician communication.	UNIV MISSOURI, SCH MED, INTEGRATED TECHNOL SERV, COLUMBIA, MO 65211 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; POLITECN MILAN, I-20133 MILAN, ITALY	University of Missouri System; University of Missouri Columbia; Harvard University; Brigham & Women's Hospital; Polytechnic University of Milan	Balas, EA (corresponding author), UNIV MISSOURI, SCH MED, HLTH SERV MANAGEMENT PROGRAM, 324 CLARK HALL, COLUMBIA, MO 65211 USA.		Boren, Suzanne Austin/M-6589-2014	Boren, Suzanne Austin/0000-0003-4727-399X; Balas, Andrew/0000-0003-3535-8822; Kuperman, Gilad/0000-0002-4130-1577	NLM NIH HHS [LM05545] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM005545] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*AD LITTL INC, 1992, TEL CAN IT HELP SOLV; AHRING KK, 1992, DIABETES CARE, V15, P971, DOI 10.2337/diacare.15.8.971; ALEMI F, 1995, MED CARE, V33, P227, DOI 10.1097/00005650-199503000-00002; Alto W A, 1994, J Am Board Fam Pract, V7, P472; BALAS EA, 1995, MED CARE, V33, P687, DOI 10.1097/00005650-199507000-00005; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; BALAS EA, 1995, J AM MED INFORM ASSN, V2, P307, DOI 10.1136/jamia.1995.96073833; BALAS EA, 1994, P 17 ANN S COMP APPL, P586; BECKIE T, 1989, HEART LUNG, V18, P46; BIGBY J, 1983, JAMA-J AM MED ASSOC, V250, P1742, DOI 10.1001/jama.250.13.1742; BILLIARD A, 1991, DIABETES CARE, V14, P130, DOI 10.2337/diacare.14.2.130; Blake R L Jr, 1990, Fam Med, V22, P365; BRENNAN PF, 1995, NURS RES, V44, P166; BRIGG EH, 1968, FAM COORD, V17, P41, DOI 10.2307/581971; BRIMBERRY R, 1988, J FAM PRACTICE, V26, P397; BRYCE RL, 1991, BRIT J OBSTET GYNAEC, V98, P1001, DOI 10.1111/j.1471-0528.1991.tb15338.x; CALLE EE, 1994, AM J PREV MED, V10, P361, DOI 10.1016/S0749-3797(18)30566-X; CAPONE RJ, 1988, AM HEART J, V116, P1606, DOI 10.1016/0002-8703(88)90749-1; CHANDE VT, 1994, PEDIATRICS, V93, P513; CHERRY R, 1994, EAR HEARING, V15, P256, DOI 10.1097/00003446-199406000-00006; *COMM EV CLIN APPL, 1996, TEL GUID ASS TEL HLT; Cummings K M, 1985, Am J Prev Med, V1, P54; DARNELL JC, 1985, MED CARE, V23, P20, DOI 10.1097/00005650-198501000-00003; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; ELDER JP, 1993, AM J PUBLIC HEALTH, V83, P1239, DOI 10.2105/AJPH.83.9.1239; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; FITZGERALD JL, 1985, J STUD ALCOHOL, V46, P418, DOI 10.15288/jsa.1985.46.418; FLETCHER EC, 1991, AM REV RESPIR DIS, V143, P936, DOI 10.1164/ajrccm/143.5_Pt_1.936; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; Gerson L W, 1986, J Community Health, V11, P111, DOI 10.1007/BF01321512; GOODMAN C, 1990, SOC WORK, V35, P556, DOI 10.1093/sw/35.6.556; GOODMAN CC, 1990, GERONTOLOGIST, V30, P399, DOI 10.1093/geront/30.3.399; GORTNER SR, 1990, J ADV NURS, V15, P1132, DOI 10.1111/j.1365-2648.1990.tb01704.x; GROVER S, 1983, CAN MED ASSOC J, V129, P1101; HAGOPIAN GA, 1990, CANCER NURS, V13, P339; HARLOW BL, 1985, AM J EPIDEMIOL, V122, P335, DOI 10.1093/oxfordjournals.aje.a114105; HEATHER N, 1990, BRIT J ADDICT, V85, P1177; INFANTERIVARD C, 1988, J AM GERIATR SOC, V36, P306, DOI 10.1111/j.1532-5415.1988.tb02356.x; JONES PK, 1990, ANN EMERG MED, V19, P16, DOI 10.1016/S0196-0644(05)82133-X; JONES SL, 1988, MED CARE, V26, P1172, DOI 10.1097/00005650-198812000-00007; KING ES, 1994, AM J PUBLIC HEALTH, V84, P104, DOI 10.2105/AJPH.84.1.104; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KIRSCHT JP, 1981, HEALTH EDUC QUART, V8, P261, DOI 10.1177/109019818100800303; KLUGER MP, 1983, COMMUNITY MENT HLT J, V19, P137, DOI 10.1007/BF00877606; LANDO HA, 1992, AM J PUBLIC HEALTH, V82, P41, DOI 10.2105/AJPH.82.1.41; LEIRER VO, 1991, GERONTOLOGIST, V31, P514, DOI 10.1093/geront/31.4.514; LEIRER VO, 1989, J AM GERIATR SOC, V37, P1147, DOI 10.1111/j.1532-5415.1989.tb06679.x; LERMAN C, 1992, J CLIN ONCOL, V10, P330, DOI 10.1200/JCO.1992.10.2.330; LEVY R, 1977, MED CARE, V15, P435, DOI 10.1097/00005650-197705000-00010; LINDBERG DAB, 1995, JAMA-J AM MED ASSOC, V273, P1667, DOI 10.1001/jama.273.21.1667; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MAYER JA, 1986, J BEHAV MED, V9, P179, DOI 10.1007/BF00848476; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; Mohler P J, 1995, Fam Med, V27, P117; Munro A J, 1994, Clin Oncol (R Coll Radiol), V6, P242, DOI 10.1016/S0936-6555(05)80294-8; NELSON EW, 1991, AM J DIS CHILD, V145, P440, DOI 10.1001/archpedi.1991.02160040098016; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; ODA DS, 1986, AM J PUBLIC HEALTH, V76, P1348, DOI 10.2105/AJPH.76.11.1348; PARKERSON GR, 1989, MED CARE, V27, P680, DOI 10.1097/00005650-198907000-00003; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICHARDSON A, 1994, AUST J PUBLIC HEALTH, V18, P290; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; RUSH JP, 1991, BIRTH-ISS PERINAT C, V18, P193, DOI 10.1111/j.1523-536X.1991.tb00101.x; SANMARTI LS, 1993, TUBERCLE LUNG DIS, V74, P217; SANMARTI LS, 1993, TUBERCLE LUNG DIS, V74, P28, DOI 10.1016/0962-8479(93)90065-6; SCHECTMAN G, 1994, ANN PHARMACOTHER, V28, P29, DOI 10.1177/106002809402800104; Schneider S J, 1993, Proc Annu Symp Comput Appl Med Care, P37; Schroeder S A, 1973, Med Care, V11, P75, DOI 10.1097/00005650-197301000-00010; SERWINT JR, 1991, PEDIATRICS, V88, P444; SHEPARD DS, 1976, MED CARE, V14, P268, DOI 10.1097/00005650-197603000-00008; SHESSER R, 1986, ANN EMERG MED, V15, P911, DOI 10.1016/S0196-0644(86)80674-6; Shultz E K, 1991, Proc Annu Symp Comput Appl Med Care, P53; SHULTZ EK, 1992, ANN NY ACAD SCI, V670, P141, DOI 10.1111/j.1749-6632.1992.tb26084.x; SIMKINS CV, 1986, DRUG INTEL CLIN PHAR, V20, P799, DOI 10.1177/106002808602001017; SORUM PC, 1994, JAMA-J AM MED ASSOC, V272, P1949, DOI 10.1001/jama.272.24.1949; SPARKS KE, 1993, HEART LUNG, V22, P298; STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426; SWINSON RP, 1995, BEHAV RES THER, V33, P465, DOI 10.1016/0005-7967(94)00061-N; THOMPSON B, 1993, MONOGR NATL CANC I, V14, P105; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; TURNIN MCG, 1992, DIABETES CARE, V15, P204, DOI 10.2337/diacare.15.2.204; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; WEINBERGER M, 1994, J AM GERIATR SOC, V42, P1295, DOI 10.1111/j.1532-5415.1994.tb06515.x; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	93	186	190	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					152	159		10.1001/jama.278.2.152	http://dx.doi.org/10.1001/jama.278.2.152			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214532				2022-12-28	WOS:A1997XH66700037
J	Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J				Hata, A; Lo, RS; Wotton, D; Lagna, G; Massague, J			Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4	NATURE			English	Article							BETA	Smad2 and Smad4 are related tumour-suppressor proteins(1,2), which, when stimulated by the growth factor TGF-beta, form a complex to inhibit growth(3). The effector function of Smad2 and Smad4 is located in the conserved carboxy-terminal domain (C domain) of these proteins and is inhibited by the presence of their amino-terminal domains (N domain)(4,5). This inhibitory function of the N domain is shown here to involve an interaction with the C domain that prevents the association of Smad2 with Smad4. This inhibitory function is increased in tumour-derived forms of Smad2 and 4 that carry a missense mutation in a conserved N domain arginine residue. The mutant N domains have an increased affinity for their respective C domains, inhibit the Smad2-Smad4 interaction, and prevent TGF beta-induced Smad2-Smad4 association and signalling. Whereas mutations in the C domain disrupt the effector function of the Smad proteins, N-domain arginine mutations inhibit SMAD signalling through a g-ain of autoinhibitory function. Gain of autoinhibitory function isa new mechanism for inactivating tumour suppressors.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL EMBRYOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Rockefeller University				Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barrett MT, 1996, CANCER RES, V56, P4351; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim SK, 1996, CANCER RES, V56, P2519; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nagatake M, 1996, CANCER RES, V56, P2718; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Uchida K, 1996, CANCER RES, V56, P5583; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	24	295	308	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					82	87		10.1038/40424	http://dx.doi.org/10.1038/40424			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214507	Bronze			2022-12-28	WOS:A1997XJ14300055
J	Lappalainen, P; Drubin, DG				Lappalainen, P; Drubin, DG			Cofilin promotes rapid actin filament turnover in vivo	NATURE			English	Article							DEPOLYMERIZING FACTOR; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; GENE ENCODES; YEAST; CYTOSKELETON; ENDOCYTOSIS; POLYMERIZATION; ORGANIZATION; INHIBITION	The ability of actin filaments to function in cell morphogenesis and motility is coupled to their capacity for rapid assembly and disassembly. Because disassembly in vitro is much slower than in vivo, cellular factors that stimulate disassembly have long been assumed to exist. Although numerous proteins can affect actin dynamics in vitro, demonstration of in vivo relevance of these effects has not been achieved. We have used genetics and an actin-inhibitor in yeast to demonstrate that rapid cycles of actin assembly and disassembly depend on the small actin-binding protein cofilin, and that cofilin stimulates filament disassembly. These results may explain why cofilin is ubiquitous in eukaryotes and is essential for viability in every organism in which its function has been tested genetically. Magnitudes of disassembly defects in cofilin mutants in vivo were found to be correlated closely with the magnitudes of disassembly defects observed in vitro, supporting our conclusions. Furthermore, these cofilin mutants provided an opportunity to distinguish in living cells those actin functions that depend specifically on filament turnover (endocytosis) from those that do not (cortical actin patch motility).	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Lappalainen, Pekka/0000-0001-6227-0354				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; WELCH MD, 1997, OPIN CELL BIOL, V9, P54; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	30	367	370	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					78	82		10.1038/40418	http://dx.doi.org/10.1038/40418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214506	Bronze			2022-12-28	WOS:A1997XJ14300054
J	Lewis, RF; Abrahamowicz, M; Cote, R; Battista, RN				Lewis, RF; Abrahamowicz, M; Cote, R; Battista, RN			Predictive power of duplex ultrasonography in asymptomatic carotid disease	ANNALS OF INTERNAL MEDICINE			English	Article						ultrasonography, Doppler, duplex; carotid stenosis; cerebrovascular disorders; cerebral ischemia, transient; carotid arteries	5-YEAR FOLLOW-UP; NATURAL-HISTORY; ARTERY STENOSIS; STROKE RISK; SURGICAL-TREATMENT; ENDARTERECTOMY; PROGRESSION; MANAGEMENT; BRUITS; PLAQUE	Background: Duplex ultrasonography is considered a valid measure of stenosis of the carotid arteries, but the prognostic value of repeated ultrasonographic examinations is unknown. Objective: To determine the ability of serial ultrasonographic measurements to predict cerebrovascular events in patients with asymptomatic carotid disease. Design: Secondary analysis of data from a natural history study of asymptomatic carotid disease. Patients: Asymptomatic patients with cervical bruits. Measurements: Duplex ultrasonography of the carotid arteries was done at study enrollment and biannually thereafter. Multivariable Cox proportional hazards models with fixed and time-dependent covariates were used for analysis. Results: 61 transient ischemic attacks (TIAs) and 38 strokes occurred in 715 participants over a mean follow-up period of 3.2 years; 4 strokes were disabling, and no deaths from stroke occurred. Sixty percent of strokes occurred in persons who did not have severe stenosis. One fifth of; participants had stenosis progression. Baseline carotid stenosis was a significant predictor of the outcome ''TIA or stroke'' (relative risk, 1.5 [95% CI, 1.2 to 1.7]) and retained its predictive ability for more than 3 years. Progression of stenosis to 80% or more significantly increased the risk for cerebrovascular events and death. The sensitivity and positive predictive Value of progression as an independent predictor of TIA or stroke were low. Conclusion: Severe carotid stenosis is associated with a higher risk for cerebrovascular events, but the power of repeated ultrasonography to predict ischemic events is limited by low incidence rates and low rates of progression. The evidence does not support the routine use of serial ultrasonography to determine the risk for stroke in unselected patients with asymptomatic carotid disease.	MONTREAL GEN HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3G 1A4, CANADA; MCGILL UNIV, MONTREAL, PQ H3A 2T5, CANADA	McGill University; McGill University				Abrahamowicz, Michal/0000-0002-3172-3952				ABRAHAMOWICZ M, 1992, CAN J STAT, V20, P171, DOI 10.2307/3315466; ABRAHAMOWICZ M, 1996, JASA, V61, P1432; ALDOORI MI, 1987, BRIT J SURG, V74, P496, DOI 10.1002/bjs.1800740626; ALEXANDROV AV, 1993, STROKE, V24, P1292, DOI 10.1161/01.STR.24.9.1292; AUTRET A, 1987, LANCET, V1, P888; BARNETT HJM, 1995, ANN INTERN MED, V123, P723, DOI 10.7326/0003-4819-123-9-199511010-00012; BARNETT HJM, 1993, NEW ENGL J MED, V328, P276, DOI 10.1056/NEJM199301283280410; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BOCK RW, 1993, J VASC SURG, V17, P160, DOI 10.1016/0741-5214(93)90020-M; BROTT T, 1995, ANN INTERN MED, V123, P720, DOI 10.7326/0003-4819-123-9-199511010-00011; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COTE R, 1995, ANN INTERN MED, V123, P649, DOI 10.7326/0003-4819-123-9-199511010-00002; COX DR, 1972, J R STAT SOC B, V34, P187; DIENER HC, 1991, STROKE, V22, P1229; DYKEN ML, 1986, STROKE, V17, P355, DOI 10.1161/01.STR.17.3.355; ELLIS MR, 1992, EUR J VASCULAR SURG, V6, P172, DOI 10.1016/S0950-821X(05)80236-1; ESDAILE JM, 1994, ARTHRITIS RHEUM, V37, P359, DOI 10.1002/art.1780370309; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; Frey JL, 1996, ANN NEUROL, V39, P405, DOI 10.1002/ana.410390322; FUSTER V, 1995, AM J CARDIOL, V76, pC24, DOI 10.1016/S0002-9149(99)80467-6; GROTTA JC, 1989, NEUROLOGY, V39, P1325, DOI 10.1212/WNL.39.10.1325; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; Hankey GJ, 1996, MED J AUSTRALIA, V164, P53, DOI 10.5694/j.1326-5377.1996.tb94120.x; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JAVID H, 1970, SURGERY, V67, P80; JOHNSON BF, 1995, J VASC SURG, V21, P120, DOI 10.1016/S0741-5214(95)70250-4; JOHNSON JM, 1985, ARCH SURG-CHICAGO, V120, P1010; KARTCHNER MM, 1977, SURGERY, V82, P840; KERNAN WN, 1991, STROKE, V22, P1108, DOI 10.1161/01.STR.22.9.1108; LANGSFELD M, 1989, J VASC SURG, V9, P548, DOI 10.1067/mva.1989.vs0090548; LEWIS RF, 1996, THESIS MCGILL U MONT; MACKENZIE T, 1993, THESIS MCGILL U MONT; MACKEY AE, IN PRESS NEUROLOGY; MAHONEY F I, 1965, Md State Med J, V14, P61; MANSOUR MA, 1995, J VASC SURG, V21, P346, DOI 10.1016/S0741-5214(95)70275-X; MARKUS H, 1995, LANCET, V345, P721, DOI 10.1016/S0140-6736(95)90892-7; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCLAUGHLIN MA, 1995, MT SINAI J MED, V62, P265; MONETA GL, 1987, STROKE, V18, P1005, DOI 10.1161/01.STR.18.6.1005; MOORE DJ, 1985, J VASC SURG, V2, P654, DOI 10.1067/mva.1985.avs0020654; MOORE DJ, 1985, ANN SURG, V202, P491, DOI 10.1097/00000658-198510000-00009; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; NORRIS JW, 1990, J NEUROL NEUROSUR PS, V53, P235, DOI 10.1136/jnnp.53.3.235; OHOLLERAN LW, 1987, AM J SURG, V154, P659, DOI 10.1016/0002-9610(87)90238-8; RANKE C, 1995, LANCET, V345, P721; ROEDERER GO, 1984, STROKE, V15, P605, DOI 10.1161/01.STR.15.4.605; SHANIK GD, 1992, EUR J VASCULAR SURG, V6, P10, DOI 10.1016/S0950-821X(05)80087-8; SUTTONTYRRELL K, 1994, STROKE, V25, P44, DOI 10.1161/01.STR.25.1.44; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TAYLOR LM, 1988, J VASC SURG, V8, P255, DOI 10.1067/mva.1988.avs0080255; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WARLOW C, 1995, LANCET, V345, P1254, DOI 10.1016/S0140-6736(95)90920-6; WEINSTEIN R, 1992, HEMATOL ONCOL CLIN N, V6, P1131, DOI 10.1016/S0889-8588(18)30300-9; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WILTERDINK JL, 1992, ARCH NEUROL-CHICAGO, V49, P857, DOI 10.1001/archneur.1992.00530320089016; ZIERLER RE, 1990, J VASC SURG, V12, P447, DOI 10.1067/mva.1990.22603; ZIERLER RE, 1987, J VASC TECHNOL, V11, P196; ZWIEBEL WJ, 1992, AM J ROENTGENOL, V158, P29, DOI 10.2214/ajr.158.1.1727355; 1991, ARCH NEUROL-CHICAGO, V48, P683	62	49	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					13	+		10.7326/0003-4819-127-1-199707010-00003	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214247				2022-12-28	WOS:A1997XG91400002
J	White, K; Roy, D; Hamilton, I				White, K; Roy, D; Hamilton, I			ABC of mental health - Community mental health services	BRITISH MEDICAL JOURNAL			English	Review																		Hamilton I, 1995, Nurs Times, V91, P35; KINGDON D.G, 1994, PSYCHIATRIC B, V18, P68; MCCARTHY A, 1995, PSYCHIAT B, V19, P195; Stafford D.M., 1995, WHAKAREWAREWA BRIEF; Weller M, 1993, DIMENSIONS COMMUNITY	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1817	1820		10.1136/bmj.314.7097.1817	http://dx.doi.org/10.1136/bmj.314.7097.1817			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG166	9224088	Green Published			2022-12-28	WOS:A1997XG16600029
J	Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P				Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P			The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group a streptococci in Finland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROUP-A STREPTOCOCCI; JAPAN; PYOGENES; DECLINE	Background In the early 1990s there was an increase in erythromycin resistance among group A streptococci in Finland. In response, policies regarding outpatient antibiotic therapy were changed, and nationwide recommendations were issued that called for reductions in the use of macrolide antibiotics for respiratory and skin infections in outpatients. We studied the effect of this policy on the pattern of erythromycin resistance throughout Finland. Methods From 1991 through 1996, a total of 39,247 group A streptococcal isolates from throat swabs (82 percent of the isolates) and pus samples (18 percent) and 290 isolates from blood cultures were studied in regional microbiology laboratories. The susceptibility of the isolates to erythromycin was tested by the disk-diffusion or the screening-prate method. Results Consumption of macrolide antibiotics decreased from 2.40 defined daily doses per 1000 inhabitants per day in 1991 to 1.38 in 1992 (P=0.007) and remained near the lower level during the study period. The change in consumption was followed by a steady decrease in the frequency of erythromycin resistance among group A streptococcal isolates from throat swabs and pus samples, from 16.5 percent in 1992 to 8.6 percent in 1996 (odds ratio for 1996 as compared with 1992, 0.5; 95 percent confidence interval, 0.4 to 0.5). Conclusions in Finland, after nationwide reductions in the use of macrolide antibiotics for outpatient therapy, there was a significant decline in the frequency of erythromycin resistance among group A streptococci isolated from throat swabs and pus samples. (C) 1997, Massachusetts Medical Society.	NATL PUBL HLTH INST,DEPT BACTERIOL,TURKU 20521,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND; SOCIAL INSURANCE INST,HELSINKI,FINLAND; UNIV TURKU,DEPT BIOSTAT,TURKU,FINLAND; AURORA HOSP,SF-00250 HELSINKI,FINLAND; CENT HOSP KANTA HAME,HAMEENLINNA,FINLAND; JORVI HOSP,SF-02740 ESPOO,FINLAND; CENT HOSP PAIJAT HAME,LAHTI,FINLAND; DEACONESS INST HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI HOSP,HELSINKI,FINLAND; CENT HOSP VAASA,VAASA,FINLAND; CENT HOSP SATAKUNTA,PORI,FINLAND; UNIV TURKU,CENT HOSP,FIN-20520 TURKU,FINLAND; CENT HOSP ETELA POHJANMAA,SEINAJOKI,FINLAND; KUOPIO UNIV HOSP,SF-70210 KUOPIO,FINLAND; CENT HOSP MIKKELI,MIKKELI,FINLAND; TAMPERE UNIV HOSP,TAMPERE,FINLAND; CENT HOSP KESKI SUOMI,JYVASKYLA,FINLAND; CENT HOSP ETELA KARJALA,LAPPEENRANTA,FINLAND; CENT HOSP POHJOIS KARJALA,JOENSUU,FINLAND; CENT HOSP SAVONLINNA,SAVONLINNA,FINLAND; CENT HOSP KYMENLAAKSO,KOTKA,FINLAND; CENT HOSP KAINUU,KAJAANI,FINLAND; NATL PUBL HLTH INST,OULU,FINLAND; CENT HOSP LAPPI,ROVANIEMI,FINLAND; UNIV HOSP OULU,OULU,FINLAND; DEACONESS INST OULU,OULU,FINLAND; UNIV OULU,OULU,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Vaasa Central Hospital; Satakunta Central Hospital; University of Turku; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Central Finland Central Hospital; Finland National Institute for Health & Welfare; University of Oulu	Seppala, H (corresponding author), NATL PUBL HLTH INST,ANTIMICROBIAL RES LAB,POB 57,TURKU 20521,FINLAND.		Huovinen, Pentti/C-1917-2009; Vaara, Martti S/D-1698-2013					Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BASS JW, 1994, ARCH PEDIAT ADOL MED, V148, P67, DOI 10.1001/archpedi.1994.02170010069016; Bronze MS, 1996, AM J MED SCI, V311, P41, DOI 10.1097/00000441-199601000-00008; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; FUJITA K, 1994, PEDIATR INFECT DIS J, V13, P1075, DOI 10.1097/00006454-199412000-00001; GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HOUVINEN P, 1991, FINN MED J, V46, P3241; HUOVINEN P, 1992, FINN MED J, V47, P13; LEPPER MH, 1953, J LAB CLIN MED, V42, P832; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MITSUHASHI S, 1982, MICROBIOLOGY 1982, P151; MOLSTAD S, 1988, SCAND J INFECT DIS, V20, P329, DOI 10.3109/00365548809032459; Muotiala A, 1997, J INFECT DIS, V175, P392, DOI 10.1093/infdis/175.2.392; *NAT AG MED, 1995, FINN STAT MED 1994; *NAT COMM CLIN LAB, 1995, PERF STAND ANT SUSC, V15, pM100; National Agency for Medicines and Social Insurance Institution, 1996, FINN STAT MED 1995; NISSINEN A, 1995, SCAND J INFECT DIS, V27, P52, DOI 10.3109/00365549509018972; RIDLEY M, 1970, LANCET, V1, P230; SAS Institute, 1990, SAS STAT US GUID VER; SEPPALA H, 1993, J ANTIMICROB CHEMOTH, V32, P885, DOI 10.1093/jac/32.6.885; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003	27	915	948	0	74	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					441	446		10.1056/NEJM199708143370701	http://dx.doi.org/10.1056/NEJM199708143370701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250845				2022-12-28	WOS:A1997XQ49900001
J	Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ				Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ			A cytoplasmic inhibitor of the JNK signal transduction pathway	SCIENCE			English	Article							PROTEIN-KINASES; ACTIVATION DOMAIN; PHOSPHORYLATION; JUN; TRANSFORMATION; INTEGRATION; ASSOCIATION; MECHANISM; ONCOGENE; CONTAINS	The c-Jun amino-terminal kinase (JNK) is a member of the stress-activated group of mitogen-activated protein (MAP) kinases that are implicated in the control of cell growth. A murine cytoplasmic protein that binds specifically to JNK [the JNK interacting protein-1 (JIP-1)] was characterized and cloned. JIP-1 caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression. In addition, JIP-1 suppressed the effects of the JNK signaling pathway on cellular proliferation, including transformation by the Bcr-Abl oncogene. This analysis identifies JIP-1 as a specific inhibitor of the JNK signal transduction pathway and establishes protein targeting as a mechanism that regulates signaling by stress-activated MAP kinases.	UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; CHILDRENS HOSP, DEPT NEUROL, DIV NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Dickens, Martin/B-2001-2012; Sawyers, Charles/G-5327-2016		NATIONAL CANCER INSTITUTE [R01CA043855, R01CA065861] Funding Source: NIH RePORTER; NCI NIH HHS [CA65861, CA43855] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKENS M, UNPUB; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Rincon Mercedes, 1997, Genes and Function, V1, P51; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	616	647	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					693	696		10.1126/science.277.5326.693	http://dx.doi.org/10.1126/science.277.5326.693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235893				2022-12-28	WOS:A1997XN90700043
J	Kollas, CD				Kollas, CD			What the book says	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Kollas, CD (corresponding author), GEISINGER MED CTR, DEPT GEN INTERNAL MED, 100 N ACAD AVE, DANVILLE, PA 17822 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					238	239		10.7326/0003-4819-127-3-199708010-00012	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245233				2022-12-28	WOS:A1997XN12900012
J	Dattwyler, RJ; Luft, BJ; Kunkel, MJ; Finkel, MF; Wormser, GP; Rush, TJ; Grunwaldt, E; Agger, WA; Franklin, M; Oswald, D; Cockey, L; Maladorno, D				Dattwyler, RJ; Luft, BJ; Kunkel, MJ; Finkel, MF; Wormser, GP; Rush, TJ; Grunwaldt, E; Agger, WA; Franklin, M; Oswald, D; Cockey, L; Maladorno, D			Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BORRELIA-BURGDORFERI; MANIFESTATIONS	Background Localized Lyme disease, manifested by erythema migrans, is usually treated with oral doxycycline or amoxicillin. Whether acute disseminated Borrelia burgdorferi infection should be treated differently from localized infection is unknown. Methods We conducted a prospective, open-label, randomized, multicenter study comparing parenteral ceftriaxone (2 g once daily for 14 days) with oral doxycycline (100 mg twice daily for 21 days) in patients with acute disseminated B. burgdorferi infection but without meningitis. The erythema migrans skin lesion was required for study entry, and disseminated disease had to be indicated by either multiple erythema migrans lesions or objective evidence of organ involvement. Results Of 140 patients enrolled, 133 had multiple erythema migrans lesions. Both treatments were highly effective. Rates of clinical cure at the last evaluation were similar among the patients treated with ceftriaxone (85 percent) and those treated with doxycycline (88 percent); treatment was considered to have failed in only one patient in each group. Among patients whose infections were cured, 18 of 67 patients in the ceftriaxone group (27 percent) reported one or more residual symptoms at the last follow-up visit, as did 10 of 71 patients in the doxycycline group (14 percent, P greater than or equal to 0.05). Mild arthralgia was the most common persistent symptom. Both regimens were well tolerated; only four patients (6 percent) in each group withdrew because of adverse events. Conclusions In patients with acute disseminated Lyme disease but without meningitis, oral doxycycline and parenterally administered ceftriaxone were equally effective in preventing the late manifestations of disease. (C) 1997, Massachusetts Medical Society.	DANBURY HOSP,DEPT INFECT DIS,DANBURY,CT; MIDDELFORT CLIN,EAU CLAIRE,WI; NEW YORK MED COLL,VALHALLA,NY 10595; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	New York Medical College; Roche Holding	Dattwyler, RJ (corresponding author), SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794, USA.		DeHaas, Keith/I-4957-2017; Dattwyler, Raymond/ABH-2292-2021	Dattwyler, Raymond/0000-0002-1983-1301; Luft, Benjamin/0000-0001-9008-7004				ASCH ES, 1994, J RHEUMATOL, V21, P454; BLAAUW AA, 1989, ANN INTERN MED, V111, P261, DOI 10.7326/0003-4819-111-3-261_2; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; JOHNSON RC, 1990, ANTIMICROB AGENTS CH, V34, P1622, DOI 10.1128/AAC.34.8.1622-b; JOHNSON RC, 1987, ANTIMICROB AGENTS CH, V31, P164, DOI 10.1128/AAC.31.2.164; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P872; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MAYER W, 1990, 4 INT C LYM BORR STO; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; RAHN DW, 1991, SEMIN ARTHRITIS RHEU, V20, P201, DOI 10.1016/0049-0172(91)90017-T; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SIGAL LH, 1994, AM J MED, V96, P365, DOI 10.1016/0002-9343(94)90068-X; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STIERNSTEDT G, 1993, CLIN DERMATOL, V11, P423, DOI 10.1016/0738-081X(93)90099-X; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; 1995, MMWR-MORBID MORTAL W, V44, P590	22	126	130	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					289	294		10.1056/NEJM199707313370501	http://dx.doi.org/10.1056/NEJM199707313370501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233865	Bronze			2022-12-28	WOS:A1997XN11900001
J	Riechmann, L; Holliger, P				Riechmann, L; Holliger, P			The C-terminal domain of ToIA is the coreceptor for filamentous phage infection of E-coli	CELL			English	Article							GENE-III PROTEIN; ESCHERICHIA-COLI; ADSORPTION PROTEIN; FD; MEMBRANE; TOLA; BACTERIOPHAGES; TRANSLOCATION; ATTACHMENT; PRODUCTS	Filamentous bacteriophages infecting gram-negative bacteria display tropism for a variety of pilus structures. However, the obligatory coreceptor of phage infection, postulated from genetic studies, has remained elusive. Here we identify the C-terminal domain of the periplasmic protein TolA as the coreceptor for infection of Escherichia coli by phage fd and the N-terminal domain of the phage minor coat protein g3p as its cognate ligand. The neighboring g3p domain binds the primary receptor of phage infection, the F pilus, and blocks TolA binding in its absence. Contact with the pilus releases this blockage during infection. Our findings support a sequential two-way docking mechanism for phage infection, analogous to infection pathways proposed for a range of eukaryotic Viruses including herpes simplex, adenoviruses, and also lentiviruses like HIV-1.	MRC, CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	Riechmann, L (corresponding author), MRC, MOL BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ARMSTRONG GD, 1980, J BACTERIOL, V141, P333, DOI 10.1128/JB.141.1.333-341.1980; BAYER ME, 1975, MEMBRANE BIOGENESIS, P393; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOEKE JD, 1982, MOL GEN GENET, V186, P185, DOI 10.1007/BF00331849; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; Derouiche R, 1996, EMBO J, V15, P6408, DOI 10.1002/j.1460-2075.1996.tb01032.x; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUENAS M, 1994, BIO-TECHNOL, V12, P999, DOI 10.1038/nbt1094-999; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Gibson T., 1984, THESIS U CAMBRIDGE C; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Holliger P, 1997, STRUCTURE, V5, P265, DOI 10.1016/S0969-2126(97)00184-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JACOBSON A, 1972, J VIROL, V10, P835, DOI 10.1128/JVI.10.4.835-843.1972; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KREBBER K, 1995, FEBS LETT, V377, P227; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Model P., 1988, BACTERIOPHAGES, P375; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; RAMPF B, 1991, FEBS LETT, V280, P27, DOI 10.1016/0014-5793(91)80196-A; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; RUSSEL M, 1988, J BACTERIOL, V170, P5312, DOI 10.1128/jb.170.11.5312-5316.1988; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1992, CLONING FUSE VECTORS; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; ZACHER AN, 1980, GENE, V9, P127, DOI 10.1016/0378-1119(80)90171-7	46	151	178	5	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					351	360		10.1016/S0092-8674(00)80342-6	http://dx.doi.org/10.1016/S0092-8674(00)80342-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244308	Bronze			2022-12-28	WOS:A1997XN24900018
J	Bosl, GJ; Motzer, RJ				Bosl, GJ; Motzer, RJ			Testicular germ-cell cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LYMPH-NODE DISSECTION; POORLY DIFFERENTIATED ADENOCARCINOMA; HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-DOSE CHEMOTHERAPY; UNKNOWN PRIMARY SITE; STAGE-I; CLINICAL STAGE; ADJUVANT CHEMOTHERAPY; TESTIS CANCER; PROGNOSTIC FACTORS		MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV SOLID TUMOR ONCOL, GENITOURINARY ONCOL SERV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, ITHACA, NY 14853 USA	Memorial Sloan Kettering Cancer Center; Cornell University								AHMED T, 1985, CANCER, V56, P860, DOI 10.1002/1097-0142(19850815)56:4<860::AID-CNCR2820560426>3.0.CO;2-3; BAJORIN DF, 1993, J NATL CANCER I, V85, P60, DOI 10.1093/jnci/85.1.60; BAJORIN DF, 1993, J CLIN ONCOL, V11, P598, DOI 10.1200/JCO.1993.11.4.598; BATTIFORA H, 1984, CANCER, V54, P843, DOI 10.1002/1097-0142(19840901)54:5<843::AID-CNCR2820540514>3.0.CO;2-G; BERNARDI D, 1995, J CLIN ONCOL, V13, P2705, DOI 10.1200/JCO.1995.13.11.2705; BIRCH R, 1986, J CLIN ONCOL, V4, P400, DOI 10.1200/JCO.1986.4.3.400; Bokemeyer C, 1996, ANN ONCOL, V7, P31; Bosl George J., 1997, P1397; BOSL GJ, 1983, CANCER RES, V43, P3403; BOSL GJ, 1986, J CLIN ONCOL, V4, P1493, DOI 10.1200/JCO.1986.4.10.1493; BOSL GJ, 1994, J NATL CANCER I, V86, P349, DOI 10.1093/jnci/86.5.349; BOSL GJ, 1988, J CLIN ONCOL, V6, P1231, DOI 10.1200/JCO.1988.6.8.1231; BOSL GJ, 1981, LANCET, V2, P970; BOSL GJ, 1996, TESTICULAR CANC INVE, P251; BROUN ER, 1992, ANN INTERN MED, V117, P124, DOI 10.7326/0003-4819-117-2-124; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAGANTI RSK, 1993, UROL CLIN N AM, V20, P55; COCKBURN AG, 1984, CANCER, V53, P1991, DOI 10.1002/1097-0142(19840501)53:9<1991::AID-CNCR2820530931>3.0.CO;2-6; COSGROVE MD, 1977, J UROLOGY, V117, P220, DOI 10.1016/S0022-5347(17)58407-4; CULLEN MH, 1995, P AN M AM SOC CLIN, V14, P244; DANIELS JL, 1981, J UROLOGY, V125, P341, DOI 10.1016/S0022-5347(17)55030-2; DAUGAARD G, 1987, LANCET, V2, P528; DAVIS BE, 1994, J UROLOGY, V152, P111, DOI 10.1016/S0022-5347(17)32830-6; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; deWit R, 1997, J CLIN ONCOL, V15, P1837, DOI 10.1200/JCO.1997.15.5.1837; DONOHUE JP, 1982, J UROLOGY, V128, P315, DOI 10.1016/S0022-5347(17)52904-3; DONOHUE JP, 1993, J UROLOGY, V149, P237, DOI 10.1016/S0022-5347(17)36046-9; DONOHUE JP, 1987, J UROLOGY, V137, P1176, DOI 10.1016/S0022-5347(17)44439-9; DONOHUE JP, 1993, BRIT J UROL, V71, P326, DOI 10.1111/j.1464-410X.1993.tb15952.x; DUNPHY CH, 1988, CANCER, V62, P1202, DOI 10.1002/1097-0142(19880915)62:6<1202::AID-CNCR2820620627>3.0.CO;2-S; EINHORN LH, 1989, J CLIN ONCOL, V7, P387, DOI 10.1200/JCO.1989.7.3.387; EINHORN LH, 1981, CANCER RES, V41, P3275; EINHORN LH, 1981, NEW ENGL J MED, V305, P727, DOI 10.1056/NEJM198109243051303; ELLERBROEK NA, 1988, AM J CLIN ONCOL-CANC, V11, P93, DOI 10.1097/00000421-198804000-00001; FEUER EJ, 1994, J CLIN ONCOL, V12, P368, DOI 10.1200/JCO.1994.12.2.368; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; FOSSA SD, 1989, INT J RADIAT ONCOL, V16, P383, DOI 10.1016/0360-3016(89)90334-9; FOSSA SD, 1992, J CLIN ONCOL, V10, P569, DOI 10.1200/JCO.1992.10.4.569; FOX EP, 1993, J CLIN ONCOL, V11, P1294, DOI 10.1200/JCO.1993.11.7.1294; GELS ME, 1995, J CLIN ONCOL, V13, P1188, DOI 10.1200/JCO.1995.13.5.1188; GIWERCMAN A, 1991, J UROLOGY, V145, P77, DOI 10.1016/S0022-5347(17)38252-6; GREGORY C, 1986, RADIOTHER ONCOL, V6, P285, DOI 10.1016/S0167-8140(86)80195-5; HAINSWORTH JD, 1993, SEMIN ONCOL, V20, P279; HAINSWORTH JD, 1992, J CLIN ONCOL, V10, P912, DOI 10.1200/JCO.1992.10.6.912; HAMILTON C, 1986, RADIOTHER ONCOL, V6, P115, DOI 10.1016/S0167-8140(86)80017-2; HANKS GE, 1981, INT J RADIAT ONCOL, V7, P1413, DOI 10.1016/0360-3016(81)90038-9; HORWICH A, 1994, P AN M AM SOC CLIN, V13, P230; HORWICH A, 1991, TESTICULAR CANCER IN, P109; HOSKIN P, 1986, J CLIN ONCOL, V4, P1031, DOI 10.1200/JCO.1986.4.7.1031; JACOBSEN GK, 1981, CANCER, V47, P2660, DOI 10.1002/1097-0142(19810601)47:11<2660::AID-CNCR2820471123>3.0.CO;2-6; JACOBSEN GK, 1993, EUR J CANCER, V29A, P664, DOI 10.1016/S0959-8049(05)80342-9; KLEPP O, 1990, J CLIN ONCOL, V8, P509, DOI 10.1200/JCO.1990.8.3.509; Lange P H, 1984, Semin Urol, V2, P264; LIEN HH, 1986, ACTA RADIOL, V27, P199, DOI 10.1177/028418518602700212; Linkesch W, 1993, P AN M AM SOC CLIN, V12, P232; LITTLE JS, 1994, J UROLOGY, V152, P1144, DOI 10.1016/S0022-5347(17)32524-7; LOCHRER PJ, 1995, J CLIN ONCOL, V13, P470; LORIGAN JG, 1988, AM J ROENTGENOL, V151, P325, DOI 10.2214/ajr.151.2.325; MANIVEL JC, 1987, AM J SURG PATHOL, V11, P21, DOI 10.1097/00000478-198701000-00003; MATTINGLY RF, 1976, AM J OBSTET GYNECOL, V126, P543, DOI 10.1016/0002-9378(76)90745-6; MEAD GM, 1995, P AN M AM SOC CLIN, V14, P235; MENCEL PJ, 1994, J CLIN ONCOL, V12, P120, DOI 10.1200/JCO.1994.12.1.120; MILLER KD, 1996, P AN M AM SOC CLIN, V15, P240; MOSTOFI FK, 1994, ADV BIOSCI, V91, P153; MOTZER RJ, 1991, CANCER-AM CANCER SOC, V67, P1305, DOI 10.1002/1097-0142(19910301)67:5<1305::AID-CNCR2820670506>3.0.CO;2-J; MOTZER RJ, 1990, CANCER, V66, P2476, DOI 10.1002/1097-0142(19901215)66:12<2476::AID-CNCR2820661206>3.0.CO;2-D; MOTZER RJ, 1994, J CLIN ONCOL, V12, P2277, DOI 10.1200/JCO.1994.12.11.2277; Motzer RJ, 1996, J CLIN ONCOL, V14, P1098, DOI 10.1200/JCO.1996.14.4.1098; MOTZER RJ, 1992, JNCI-J NATL CANCER I, V84, P1703, DOI 10.1093/jnci/84.22.1703; MOTZER RJ, 1995, J CLIN ONCOL, V13, P274, DOI 10.1200/JCO.1995.13.1.274; MOTZER RJ, 1995, J CLIN ONCOL, V13, P2700, DOI 10.1200/JCO.1995.13.11.2700; MOTZER RJ, 1992, SEMIN ONCOL, V19, P8; MOTZER RJ, IN PRESS J CLIN ONCO; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; NARAYAN P, 1982, J UROLOGY, V127, P685, DOI 10.1016/S0022-5347(17)53996-8; NICHOLS CR, 1991, J CLIN ONCOL, V9, P1163, DOI 10.1200/JCO.1991.9.7.1163; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932, DOI 10.1200/JCO.1989.7.7.932; NICHOLS CR, 1993, J NATL CANCER I, V85, P36, DOI 10.1093/jnci/85.1.36; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; NICHOLS CR, 1987, J CLIN ONCOL, V5, P1290, DOI 10.1200/JCO.1987.5.8.1290; NICHOLS CR, 1995, P AN M AM SOC CLIN, V14, P239; NICOLAI N, 1995, J UROLOGY, V154, P1045, DOI 10.1016/S0022-5347(01)66972-6; OLIVER RTD, 1992, J UROLOGY, V148, P1453, DOI 10.1016/S0022-5347(17)36937-9; PANICEK DM, 1990, RADIOLOGY, V175, P499, DOI 10.1148/radiology.175.2.2158120; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PIZZOCARO G, 1984, EUR UROL, V10, P151; Pont J, 1996, J CLIN ONCOL, V14, P441, DOI 10.1200/JCO.1996.14.2.441; RAY B, 1974, CANCER, V33, P340, DOI 10.1002/1097-0142(197402)33:2<340::AID-CNCR2820330207>3.0.CO;2-Y; READ G, 1992, J CLIN ONCOL, V10, P1762, DOI 10.1200/JCO.1992.10.11.1762; RICHIE JP, 1991, J CLIN ONCOL, V9, P1393, DOI 10.1200/JCO.1991.9.8.1393; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; ROILA F, 1995, NEW ENGL J MED, V332, P1; Saxman SB, 1996, J UROLOGY, V155, P587, DOI 10.1016/S0022-5347(01)66457-7; SCHER H, 1983, UROLOGY, V21, P559, DOI 10.1016/0090-4295(83)90190-5; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SKAKKEBAEK NE, 1982, UROL CLIN N AM, V9, P377; SKINNER DG, 1980, J UROLOGY, V123, P378, DOI 10.1016/S0022-5347(17)55944-3; SOGANI PC, 1991, UROL CLIN N AM, V18, P561; Stephens AW, 1996, J CLIN ONCOL, V14, P1637, DOI 10.1200/JCO.1996.14.5.1637; STEPHENSON WT, 1995, J CLIN ONCOL, V13, P2278, DOI 10.1200/JCO.1995.13.9.2278; STOMPER PC, 1985, AM J ROENTGENOL, V145, P743, DOI 10.2214/ajr.145.4.743; THOMAS GM, 1982, INT J RADIAT ONCOL, V8, P165, DOI 10.1016/0360-3016(82)90509-0; TIMMERMAN JM, 1995, J CLIN ONCOL, V13, P1391, DOI 10.1200/JCO.1995.13.6.1391; TONER GC, 1990, CANCER RES, V50, P5904; TONER GC, 1990, J CLIN ONCOL, V8, P1683, DOI 10.1200/JCO.1990.8.10.1683; TONER GC, 1990, AM J MED, V89, P651, DOI 10.1016/0002-9343(90)90185-G; VANLEEUWEN FE, 1993, J CLIN ONCOL, V11, P415, DOI 10.1200/JCO.1993.11.3.415; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1985, CANCER, V56, P2765, DOI 10.1002/1097-0142(19851215)56:12<2765::AID-CNCR2820561208>3.0.CO;2-2; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; VUGRIN D, 1983, CANCER, V51, P5, DOI 10.1002/1097-0142(19830101)51:1<5::AID-CNCR2820510103>3.0.CO;2-J; VUGRIN D, 1981, CANCER, V48, P233, DOI 10.1002/1097-0142(19810715)48:2<233::AID-CNCR2820480204>3.0.CO;2-U; WARDE P, 1995, J CLIN ONCOL, V13, P2255, DOI 10.1200/JCO.1995.13.9.2255; WEISSBACH L, 1991, J UROLOGY, V146, P1295, DOI 10.1016/S0022-5347(17)38072-2; WILLAN BD, 1985, INT J RADIAT ONCOL, V11, P1769, DOI 10.1016/0360-3016(85)90030-6; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; WILLIAMS SD, 1987, NEW ENGL J MED, V317, P1433, DOI 10.1056/NEJM198712033172303; ZAGARS GK, 1987, INT J RADIAT ONCOL, V13, P163, DOI 10.1016/0360-3016(87)90123-4	122	659	679	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					242	253		10.1056/NEJM199707243370406	http://dx.doi.org/10.1056/NEJM199707243370406			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227931				2022-12-28	WOS:A1997XL99400006
J	Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA				Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA			Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove	SCIENCE			English	Article							CLASS-I MOLECULES; T-CELL RECEPTOR; NEONATAL FC RECEPTOR; 3-DIMENSIONAL STRUCTURE; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE ANTIGENS; VIRAL PEPTIDES; ALPHA-3 DOMAIN; COMPLEX; RECOGNITION	CD1 represents a third lineage of antigen-presenting molecules that are distantly related to major histocompatibility complex (MHC) molecules in the immune system. The crystal structure of mouse CD1d1, corresponding to human CD1d, at 2.8 Angstrom resolution shows that CD1 adopts an MHC fold that is more closely related to that of MHC class I than to that of MHC class II. The binding groove, although significantly narrower, is substantially larger because of increased depth and it has only two major pockets that are almost completely hydrophobic. The extreme hydrophobicity and shape of the binding site are consistent with observations that human CD1b and CD1c can present mycobacterial cell wall antigens, such as mycolic acid and lipoarabinomannans. However, mouse CD1d1 can present very hydrophobic peptides, but must do so in a very different way from MHC class Ia and class II molecules.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Castaño, A. Raul/A-5905-2012; Stura, Enrico A./A-2793-2010	Castaño, A. Raul/0000-0003-2107-8862; Stura, Enrico A./0000-0001-6718-2118; Segelke, Brent/0000-0003-3358-5028	NCI NIH HHS [CA-58896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; CASTANO AM, UNPUB; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLLINS EJ, 1995, P NATL ACAD SCI USA, V92, P1218, DOI 10.1073/pnas.92.4.1218; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; ERNST W, COMMUNICATION; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gulden PH, 1996, IMMUNITY, V5, P73, DOI 10.1016/S1074-7613(00)80311-8; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; Lenz LL, 1996, IMMUNITY, V5, P63, DOI 10.1016/S1074-7613(00)80310-6; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nataraj C, 1996, INT IMMUNOL, V8, P367, DOI 10.1093/intimm/8.3.367; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SEGELKE BW, UNPUB; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; SMITH KJ, 1996, P NATL ACAD SCI USA, V4, P203; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; Teitell M, 1997, J IMMUNOL, V158, P2143; *UCSF MGL, 1995, UCSF MID US MAN; VILLIEUX FMD, 1993, DEMON PROGRAM SUITE; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1983, P NATL ACAD SCI-BIOL, V80, P1792, DOI 10.1073/pnas.80.7.1792; Wang C., COMMUNICATION; WANG CR, 1995, CELL, V82, P655, DOI 10.1016/0092-8674(95)90037-3; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	77	537	563	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					339	345		10.1126/science.277.5324.339	http://dx.doi.org/10.1126/science.277.5324.339			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219685				2022-12-28	WOS:A1997XL35800037
J	Song, HJ; Ming, GL; Poo, MM				Song, HJ; Ming, GL; Poo, MM			CAMP-induced switching in turning direction of nerve growth cones	NATURE			English	Article							ADENYLYL-CYCLASE; PROTEIN-KINASE; AXONS; GUIDANCE; RECEPTORS; NEURONS; SYSTEM; CA2+	Development of the nervous system depends on the correct pathfinding and target recognition by the growing tip of an axon, the growth cone(1-3). Diffusible or substrate-bound molecules present in the environment may serve as either attractants or repellents to influence the direction of growth-cone extension(4-11). Here we report that differences in cyclic-AMP-dependent activity in a neuron may result in opposite turning of the growth cone in response to the same guidance cue. A gradient of brain-derived neurotrophic factor normally triggers an attractive turning response of the growth cone of Xenopus spinal neurons in culture, but the same gradient induces repulsive turning of these growth cones in the presence of a competitive analogue of cAMP or of a specific inhibitor of protein kinase A. This cAMP-dependent switch of the turning response was also found for turning induced by acetylcholine, but not for the turning induced by neurotrophin-3 (NT-3). Thus, in the presence of other factors that modulate neuronal cAMP-dependent activity, the same guidance cue may trigger opposite turning behaviours of the growth cone during its pathfinding in the nervous system.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Ming, Guo-li/J-7880-2013	Ming, Guo-li/0000-0002-2517-6075				BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BONHOEFFER F, 1980, NATURE, V288, P162, DOI 10.1038/288162a0; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kim YT, 1996, J NEUROSCI, V16, P5593; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Stoop R, 1996, J NEUROSCI, V16, P3256; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; YOVELL Y, 1992, J NEUROCHEM, V59, P1736, DOI 10.1111/j.1471-4159.1992.tb11005.x; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	508	521	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					275	279		10.1038/40864	http://dx.doi.org/10.1038/40864			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230436				2022-12-28	WOS:A1997XL12100051
J	Maron, BJ				Maron, BJ			Hypertrophic cardiomyopathy	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; SUDDEN CARDIAC DEATH; OBSTRUCTIVE CARDIOMYOPATHY; QUANTITATIVE-ANALYSIS; DIASTOLIC FUNCTION; CLINICAL-COURSE; HYPERTENSIVE HEARTS; NATURAL-HISTORY; FOLLOW-UP; PROGNOSIS				Maron, BJ (corresponding author), MINNEAPOLIS HEART INST, CARDIOVASC RES DIV, 920 E 28TH ST, SUITE 40, MINNEAPOLIS, MN 55407 USA.							CANNAN CR, 1995, CIRCULATION, V92, P2488, DOI 10.1161/01.CIR.92.9.2488; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FAY WP, 1990, J AM COLL CARDIOL, V16, P821, DOI 10.1016/S0735-1097(10)80328-6; FERRANS VJ, 1972, CIRCULATION, V45, P769, DOI 10.1161/01.CIR.45.4.769; FOX PR, 1995, CIRCULATION, V92, P2645, DOI 10.1161/01.CIR.92.9.2645; FRENNEAUX MP, 1990, CIRCULATION, V82, P1995, DOI 10.1161/01.CIR.82.6.1995; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; GRIGG LE, 1992, J AM COLL CARDIOL, V20, P42, DOI 10.1016/0735-1097(92)90135-A; Hecht GM, 1993, J AM COLL CARDIOL, V22, P489, DOI 10.1016/0735-1097(93)90054-5; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; KLUES HG, 1991, CIRCULATION, V84, P1188, DOI 10.1161/01.CIR.84.3.1188; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; KLUES HG, 1992, CIRCULATION, V85, P1651, DOI 10.1161/01.CIR.85.5.1651; KOFFLARD MJ, 1993, AM J CARDIOL, V72, P939, DOI 10.1016/0002-9149(93)91111-T; KRAJCER Z, 1988, CIRCULATION, V78, P35; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; LEVER HM, 1989, CIRCULATION, V79, P580, DOI 10.1161/01.CIR.79.3.580; LEWIS JF, 1989, J AM COLL CARDIOL, V13, P36, DOI 10.1016/0735-1097(89)90545-7; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; MARIAN AJ, 1995, CIRCULATION, V92, P1336, DOI 10.1161/01.CIR.92.5.1336; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1994, AM J CARDIOL, V73, P577, DOI 10.1016/0002-9149(94)90337-9; MARON BJ, 1993, AM J CARDIOL, V72, P970, DOI 10.1016/0002-9149(93)91117-Z; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; Maron BJ, 1996, J AM COLL CARDIOL, V27, P431, DOI 10.1016/0735-1097(95)00463-7; MARON BJ, 1979, CIRCULATION, V59, P689, DOI 10.1161/01.CIR.59.4.689; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MARON BJ, 1994, J AM COLL CARDIOL, V23, P1405, DOI 10.1016/0735-1097(94)90384-0; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; McCully RB, 1996, CIRCULATION, V94, P467, DOI 10.1161/01.CIR.94.3.467; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1985, BRIT HEART J, V53, P412; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; NIHOYANNOPOULOS P, 1992, J AM COLL CARDIOL, V19, P536, DOI 10.1016/S0735-1097(10)80268-2; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; Robbins RC, 1996, J THORAC CARDIOV SUR, V111, P586, DOI 10.1016/S0022-5223(96)70310-0; ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SCHOENDUBE FA, 1995, CIRCULATION, V92, P122, DOI 10.1161/01.CIR.92.9.122; SCHULTE HD, 1993, J THORAC CARDIOV SUR, V106, P709, DOI 10.1016/S0022-5223(19)33715-8; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SHAH PM, 1974, CIRC RES, V35, P179; SHAPIRO LM, 1983, BRIT HEART J, V50, P530; SHIRANI J, 1993, AM J CARDIOL, V72, P434, DOI 10.1016/0002-9149(93)91136-6; Solomon SD, 1993, J AM COLL CARDIOL, V22, P498, DOI 10.1016/0735-1097(93)90055-6; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPIRITO P, 1989, J AM COLL CARDIOL, V13, P820, DOI 10.1016/0735-1097(89)90222-2; SPIRITO P, 1987, J AM COLL CARDIOL, V9, P1013, DOI 10.1016/S0735-1097(87)80301-7; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; TANAKA M, 1987, CIRCULATION, V75, P1130, DOI 10.1161/01.CIR.75.6.1130; TANAKA M, 1986, BRIT HEART J, V55, P575; TEARE D, 1958, BRIT HEART J, V20, P1; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; WILLIAMS WG, 1987, CIRCULATION, V76, P104	68	307	326	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	1997	350	9071					127	133		10.1016/S0140-6736(97)01282-8	http://dx.doi.org/10.1016/S0140-6736(97)01282-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228976				2022-12-28	WOS:A1997XK11400044
J	Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V				Sainz, J; VanTornout, JM; Loro, ML; Sayre, J; Roe, TF; Gilsanz, V			Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMENOPAUSAL WOMEN; OSTEOPOROSIS; ALLELES; MASS; PUBERTY; VIEW	Background Bone mass is under strong genetic control, and recent studies in adults have suggested that allelic differences in the gene for the vitamin D receptor may account for inherited variability in bone mass. We studied the relations of the vitamin D-receptor genotype to skeletal development and variation in the size, volume, and density of bone in children. Methods We identified three allelic variants of the vitamin D-receptor gene using the polymerase chain reaction and three restriction enzymes (Apal, Bsml, and Taql) in 100 normal prepubertal American girls of Mexican descent. We then determined the relations of the different vitamin D-receptor genotypes (AA, Aa, aa, BE, Bb, bb, TT, Tt, and tt) to the cross-sectional area, cortical area, and cortical bone density of the femoral shaft and the cross-sectional area and density of the lumbar vertebrae. Results The vitamin D-receptor genotype was associated with femoral and vertebral bone density. Girls with aa and bb genotypes had 2 to 3 percent higher femoral bone density (P=0.008 and P=0.04, respectively) and 8 to 10 percent higher vertebral bone density (P=0.01 and P=0.03, respectively) than girls with AA and BE genotypes. There was no association between the cross-sectional area of the vertebrae or the cross-sectional or cortical area of the femur and the vitamin D-receptor genotype. The chronologic age, bone age, height, weight, body-surface area, and body-mass index did not differ significantly among girls with different vitamin D-receptor genotypes. Conclusions Vitamin D-receptor gene alleles predict the density of femoral and vertebral bone in prepubertal American girls of Mexican descent. (C) 1997, Massachusetts Medical Society.	CHILDRENS HOSP LOS ANGELES, DEPT RADIOL, LOS ANGELES, CA 90027 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90027 USA; UNIV CALIF LOS ANGELES, DEPT BIOSTAT, SCH MED, LOS ANGELES, CA USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [1K11 CA61870 02] Funding Source: Medline; NIAMS NIH HHS [R01-AR4-1853-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA061870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARGERLUX MJ, 1995, CALCIFIED TISSUE INT, V57, P161, DOI 10.1007/BF00298438; BEHRMAN RE, 1987, NELSON TXB PEDIAT, P24; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; CANN CE, 1991, EXPANDING ROLE MED P, P250; CARTER DR, 1992, J BONE MINER RES, V7, P137; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; Cooper GS, 1996, J BONE MINER RES, V11, P1841; Dawson-Hughes Bess, 1995, P335; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DYSON ED, 1970, NATURE, V225, P957, DOI 10.1038/225957a0; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Genant HK, 1996, J BONE MINER RES, V11, P707; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1994, RADIOLOGY, V190, P673, DOI 10.1148/radiology.190.3.8115609; GONG JK, 1964, ANAT REC, V149, P325, DOI 10.1002/ar.1091490303; Greulich WW, 1950, RADIOGRAPHIC ATLAS S; Hangartner TN, 1996, J BONE MINER RES, V11, P1518, DOI 10.1002/jbmr.5650111019; HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; KALENDER WA, 1992, OSTEOPOROSIS INT, V2, P82, DOI 10.1007/BF01623841; Matkovic V, 1996, J CLIN ENDOCR METAB, V81, P2013, DOI 10.1210/jc.81.6.2013; MELHUS H, 1994, LANCET, V344, P949, DOI 10.1016/S0140-6736(94)92297-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Need AG, 1996, EUR J CLIN INVEST, V26, P793, DOI 10.1046/j.1365-2362.1996.2080554.x; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SAMBROOK PN, 1994, BRIT J RHEUMATOL, V33, P1007; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SHOHAT T, 1995, HUM HERED, V45, P150, DOI 10.1159/000154276; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Viitanen AM, 1996, CALCIFIED TISSUE INT, V59, P231, DOI 10.1007/s002239900113; [No title captured]	35	238	251	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					77	82		10.1056/NEJM199707103370202	http://dx.doi.org/10.1056/NEJM199707103370202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211676				2022-12-28	WOS:A1997XJ82200002
J	Horton, R				Horton, R			The signature of responsibility	LANCET			English	Editorial Material																		Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; CARBONE PP, 1992, NEW ENGL J MED, V326, P1084; Eastwood Susan, 1996, Sci Eng Ethics, V2, P89, DOI 10.1007/BF02639320; Horton R, 1996, LANCET, V347, P780, DOI 10.1016/S0140-6736(96)90865-X; *INT COMM MED J ED, 1997, ANN INTERN MED, V126, P36; Medawar P, 1996, STRANGE CASE SPOTTED, P33; Parmley WW, 1997, J AM COLL CARDIOL, V29, P702; RENNIE D, 1997, IN PRESS JAMA; Smith R, 1997, BRIT MED J, V314, P992, DOI 10.1136/bmj.314.7086.992; 1997, NATURE, V387, P831	10	43	44	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					5	6		10.1016/S0140-6736(05)66236-8	http://dx.doi.org/10.1016/S0140-6736(05)66236-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9229669				2022-12-28	WOS:A1997XH86900006
J	Metcalfe, MA; Sloggett, A; McPherson, K				Metcalfe, MA; Sloggett, A; McPherson, K			Mortality among appropriately referred patients refused admission to intensive-care units	LANCET			English	Article							APACHE-II; HOSPITALS	Background The provision of intensive care is a perplexing issue for clinicians and the public. Concerns about the apparent lack of beds and the appropriateness of the patients admitted are tempered by the high cost of providing this service. As part of a study commissioned by the UK Department of Health, we tested the hypothesis that there is excess mortality among patients who are refused admission to intensive-care units. Methods All referrals to six intensive-care units with different numbers of beds were monitored during a 3-month period. Data on mortality 90 days after first referral were obtained from family physicians for all patients known to be alive at hospital discharge. We adjusted, where possible, for confounding, including for age, sex, appropriateness of referral, disease severity, surgery and emergency categories, and bed provision. We did multivariate analysis by multiple logistic regression to compare the adjusted 90-day mortality rates for patients who were refused admission and for those admitted. Findings 480 patients were admitted and 165 were refused admission. 90 days after referral there had been 178 (37%) deaths among the admitted group and 75 (46%) among the refused group. After multivariate adjustment, 113 patients appropriately referred for intensive care but refused admission to their first-choice intensive-care unit had a relative risk of death of 1.6 (95% CI 10-2.5), compared with the group of appropriately admitted cases with medium APACHE II scores for disease severity. Age, the assessed need for treatment or monitoring interventions, and emergency status also contributed to differences in mortality among all referrals. Bed provision did not contribute significantly to excess mortality. Interpretation Although this study is observational and case-mix adjustment is incomplete, we found a higher rate of attributable mortality in patients who were refused intensive care, particularly for emergency cases. We question whether the provision of more beds alone would be a solution and conclude that there is an urgent need for more appropriate admission and discharge criteria.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Metcalfe, MA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1 7HT,ENGLAND.							Campling EA, REPORT NATL CONFIDEN; CROSBY DL, 1994, ANN ROY COLL SURG, V76, P14; KILPATRICK A, 1994, ANAESTHESIA, V49, P666, DOI 10.1111/j.1365-2044.1994.tb04393.x; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; METCALFE MA, 1995, STUDY INTENSIVE CARE; *OFF POP CENS SURV, 1995, MORT STAT DH2; *OPCS, 1993, PP1933 OPCS GOV STAT; PETO R, 1994, MORTALITY SMOKING; ROWAN K, 1992, THESIS OXFORD U; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; SINGER M, 1994, INTENS CARE MED, V20, P542, DOI 10.1007/BF01705718; *WORK GROUP, 1996, GUID ADM DISCH INT C; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003	15	145	150	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					7	11		10.1016/S0140-6736(96)10018-0	http://dx.doi.org/10.1016/S0140-6736(96)10018-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217712				2022-12-28	WOS:A1997XH86900008
J	Wald, NJ; Watt, HC				Wald, NJ; Watt, HC			Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TOBACCO-SMOKE; EXPOSURE	Objective: To estimate the extent to which cigarette smokers who switch to cigars or pipes alter their risk of dying of three smoking related diseases-lung cancer, ischaemic heart disease, and chronic obstructive lung disease. Design: A prospective study of 21 520 men aged 35-64 years when recruited in 1975-82 with detailed history of smoking and measurement of carboxyhaemoglobin. Main outcome measures: Notification of deaths (to 1993) classified by cause. Results: Pipe and cigar smokers who had switched from cigarettes over 20 years before entry to the study smoked less tobacco than cigarette smokers (8.1 g/day v 20 g/day), but they had the same consumption as pipe and cigar smokers who had never smoked cigarettes (8.1 g) and had higher carboxyhaemoglobin saturations (1.2% v 1.0%, P < 0.001), indicating that they inhaled tobacco smoke to a greater extent They had a 51% higher risk of dying of the three smoking related diseases than pipe or cigar smokers who had never smoked cigarettes (relative risk 1.51; 95% confidence interval 0.96 to 2.38), a 68% higher risk than lifelong non-smokers (1.68; 1.16 to 2.45), a 57% higher risk than former cigarette smokers who gave up smoking over 20 years before entry (1.57; 1.04 to 2.38), and a 46% lower risk than continuing cigarette smokers (0.54; 0.38 to 0.77). Conclusion: Cigarette smokers who have difficulty in giving up smoking altogether are better off changing to cigars or pipes than continuing to smoke cigarettes. Much of the effect is due to the reduction in the quantity of tobacco smoked, and some is due to inhaling less. Men who switch do not, however, achieve the lower risk of pipe and cigar smokers who have never smoked cigarettes. All pipe and cigar smokers have a greater risk of lung cancer than lifelong non-smokers or former smokers.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, BUPA EPIDEMIOL RES GRP, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BENSHLOMO Y, 1994, AM J PUBLIC HEALTH, V84, P1235, DOI 10.2105/AJPH.84.8.1235; CASTLEDEN CM, 1973, LANCET, V2, P21; COWIE J, 1973, LANCET, V1, P1033; GOLDMAN AL, 1977, CHEST, V72, P33, DOI 10.1378/chest.72.1.33; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P1412, DOI 10.2105/AJPH.77.11.1412; PECHACEK TF, 1985, JAMA-J AM MED ASSOC, V254, P3330, DOI 10.1001/jama.254.23.3330; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V132, P628; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; WALD N, 1978, THORAX, V33, P201, DOI 10.1136/thx.33.2.201; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	12	66	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1860	1863		10.1136/bmj.314.7098.1860	http://dx.doi.org/10.1136/bmj.314.7098.1860			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224127	Green Published			2022-12-28	WOS:A1997XH73800020
J	Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A				Maraskovsky, E; OReilly, LA; Teepe, M; Corcoran, LM; Peschon, JJ; Strasser, A			Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1(-/-) mice	CELL			English	Article							NEGATIVE SELECTION; TRANSGENIC MICE; B-CELLS; THYMOCYTE DEVELOPMENT; RAG-1-DEFICIENT MICE; V(D)J REARRANGEMENT; POSITIVE SELECTION; CONTROL POINTS; GROWTH-FACTOR; GAMMA-CHAIN	Signals from cytokine and antigen receptors play crucial roles during lymphocyte development. Mice lacking interleukin-7 receptor are lymphopenic, due to a defect in cell expansion at an early stage of differentiation, and the few mature T cells that develop in IL-7R(-/-) animals are functionally impaired. Both defects were rescued completely by overexpression of the anti-apoptosis protein Bcl-2. T cell progenitors lacking antigen receptor molecules are also blocked in differentiation and die, presumably because they fail to receive a positive signal via their pre-T cell receptor. Surprisingly, Bcl-2 did not promote survival or differentiation of T cells in rag-1(-/-) mice. These results provide evidence that blocking apoptosis is the essential function of IL-7R during differentiation and activation of T lymphocytes and that pre-TCR signaling blocks a pathway to apoptosis that is insensitive to Bcl-2.	IMMUNEX RES & DEV CORP,DEPT MOL IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101		Maraskovsky, E (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Corcoran, Lynn M/C-9316-2013; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891				CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MEMON SA, 1995, J IMMUNOL, V155, P4644; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOLLINA TJ, 1992, NATURE, V357, P161; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORRISSEY PJ, 1991, J IMMUNOL, V147, P561; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUEGGE K, 1993, SCIENCE, V261, P93, DOI 10.1126/science.7686307; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PENIT C, 1995, J IMMUNOL, V154, P5103; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; RODEWALD HR, 1995, IMMUNITY, V3, P313, DOI 10.1016/1074-7613(95)90116-7; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	59	426	427	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1011	1019		10.1016/S0092-8674(00)80289-5	http://dx.doi.org/10.1016/S0092-8674(00)80289-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215624	Bronze			2022-12-28	WOS:A1997XG83000006
J	Diaz, MN; Frei, B; Vita, JA; Keaney, JF				Diaz, MN; Frei, B; Vita, JA; Keaney, JF			Mechanisms of disease - Antioxidants and atherosclerotic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED RABBITS; SWEDISH TRIAL PQRST; ENDOTHELIUM-DEPENDENT RELAXATION; HERITABLE HYPERLIPIDEMIC RABBIT; VITAMIN-E CONSUMPTION; BETA-CAROTENE; OXIDIZED LDL; IN-VITRO; FEMORAL ATHEROSCLEROSIS		BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, EVANS MEM DEPT MED, BOSTON, MA 02118 USA	Boston University; Boston University				Keaney, John/0000-0002-0866-1837; Vita, Joseph/0000-0001-5607-1797	NHLBI NIH HHS [HL 49954, HL 56170, HL 55854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056170, R29HL049954, P01HL055854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Anderson TJ, 1996, CIRCULATION, V93, P1647, DOI 10.1161/01.CIR.93.9.1647; ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; ANDERSSON TLG, 1994, ATHEROSCLEROSIS, V111, P39, DOI 10.1016/0021-9150(94)90189-9; BELCHER JD, 1993, ARTERIOSCLER THROMB, V13, P1779, DOI 10.1161/01.ATV.13.12.1779; BOSCOBOINIK D, 1991, ARCH BIOCHEM BIOPHYS, V286, P264, DOI 10.1016/0003-9861(91)90039-L; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; COLLINS T, 1993, LAB INVEST, V68, P499; Devaraj S, 1996, J CLIN INVEST, V98, P756, DOI 10.1172/JCI118848; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FALK E, 1992, CIRCULATION, V86, P30; FARUQI R, 1994, J CLIN INVEST, V94, P592, DOI 10.1172/JCI117374; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; FROSTEGARD J, 1991, ATHEROSCLEROSIS, V90, P119, DOI 10.1016/0021-9150(91)90106-D; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GAZIANO JM, 1995, ATHEROSCLEROSIS, V112, P187, DOI 10.1016/0021-9150(94)05414-E; GAZIANO JM, 1994, NATURAL ANTIOXIDANTS, P387; GEY KF, 1989, ANN NY ACAD SCI, V570, P268; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; JOHANSSON J, 1995, ARTERIOSCL THROM VAS, V15, P1049, DOI 10.1161/01.ATV.15.8.1049; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; KEANEY JF, 1994, NATURAL ANTIOXIDANTS, P303; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KLEINVELD HA, 1995, ARTERIOSCL THROM VAS, V15, P290, DOI 10.1161/01.ATV.15.2.290; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUGIYAMA K, 1993, CIRC RES, V72, P723; KUZUYA M, 1991, J LIPID RES, V32, P197; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; MOREL DW, 1983, J LIPID RES, V24, P1070; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OKeefe JH, 1996, AM J CARDIOL, V77, P649, DOI 10.1016/S0002-9149(97)89325-3; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PARKER RA, 1995, ARTERIOSCL THROM VAS, V15, P349, DOI 10.1161/01.ATV.15.3.349; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; REAVEN PD, 1992, ARTERIOSCLER THROMB, V12, P318, DOI 10.1161/01.ATV.12.3.318; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; RIEMERSMA RA, 1989, ANN NY ACAD SCI, V570, P291; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P1, DOI 10.1002/clc.4960141302; SHAISH A, 1995, J CLIN INVEST, V96, P2075, DOI 10.1172/JCI118256; SIMON BC, 1993, J CARDIOVASC PHARM, V21, P893, DOI 10.1097/00005344-199306000-00007; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STARY HC, 1983, ARTERIOSCLEROSIS, V3, pA471; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STEWARTLEE AL, 1994, ARTERIOSCLER THROMB, V14, P494, DOI 10.1161/01.ATV.14.3.494; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WALLDIUS G, 1993, AM J CARDIOL, V71, pB15, DOI 10.1016/0002-9149(93)90140-8; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	77	1105	1152	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					408	416		10.1056/NEJM199708073370607	http://dx.doi.org/10.1056/NEJM199708073370607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241131				2022-12-28	WOS:A1997XP40700007
J	Pearson, GS				Pearson, GS			The complementary role of environmental and security biological control regimes in the 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								As we approach the 21st century, there is increased worldwide concern about disease, whether natural or deliberate, in humans, animals, and plants. There are 2 driving forces for multilateral biological control regimes: international/national security and environmental protection. With respect to deliberately caused disease, these seemingly disparate forces are mutually reinforcing as demonstrated by simultaneous moves to strengthen the Biological and Toxin Weapons Convention and the entry into force of the Convention on Biological Diversity. Future multilateral biological control regimes based on these developments will aid the security, prosperity, and health of the world community.			Pearson, GS (corresponding author), UNIV BRADFORD,DEPT PEACE STUDIES,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND.							*FORS FORSKN, 1995, BRIEF BOOK BIOL WEAP; Garrett L., 1994, COMING PLAGUE NEWLY; HOLM JD, 1996, BIOL WEAP CONV 4 REV; Kaplan David E, 1996, CULT END WORLD INCRE; LOWE K, 1996, POTENTIAL VALUES SIM; NASSERI S, 1996, BIOL TOX WEAP CONV 4; Pearson GS, 1996, STRENGTH BIOL WEAP C; *UN, 1995, UN PUBL; *UN, 1992, UN C ENV DEV EARTH S; *UN, 1992, UN PUBL, P123; *UN, 1996, 4 REV C PART CONV PR; *UN ENV PROGR, 1996, 1 M OP END AD HOC WO; *UN ENV PROGR FAO, 1996, REG DES NAT AUTH IMP; *UN GEN ASS, 1989, UN GEN ASS PUBL; *UN SEC COUNC, 1995, UN SEC COUNC PUBL; *US ARMS CONTR DIS, 1996, THREAT CONTR ARMS CO; *US C OFF TECHN AS, 1993, US C OFF TECHN ASS P; *US C OFF TECHN AS, 1993, US C OFF TECHN PUBL; WHO, 1996, WORLD HLTH REP 1996; 1996, 51 GEN ASS UN SEP 24	20	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					369	372		10.1001/jama.278.5.369	http://dx.doi.org/10.1001/jama.278.5.369			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244314				2022-12-28	WOS:A1997XN51800004
J	Gewirtz, JC; Davis, M				Gewirtz, JC; Davis, M			Second-order fear conditioning prevented by blocking NMDA receptors in amygdala	NATURE			English	Article							LONG-TERM POTENTIATION; LATERAL NUCLEUS; INTRAAMYGDALA INFUSION; BASOLATERAL AMYGDALA; IMPAIRS ACQUISITION; STARTLE; ANTAGONIST; EXPRESSION; MEMORY; BLOCKADE	Antagonists of NMDA (N-methyl-D-aspartate)-type glutamate receptors disrupt several forms of learning(1-8). Although this might indicate that NMDA-receptor-mediated processes are critical for synaptic plasticity, there may be other mechanisms by which NMDA-receptor antagonism could interfere with learning(1,9-12). For instance, fear conditioning would be blocked by microinfusion of the NMDA-receptor antagonist AP5 (D,L-2-amino-5-phosphonovalerate) into the basolateral amygdala(6,13,14) if AP5 inhibited routine synaptic transmission, thereby reducing the ability of stimuli to activate amygdala neurons(15,16). In second-order fear conditioning(17,18), the reinforcer is a fear-eliciting conditioned stimulus rather than an unconditioned stimulus. Expression of conditioned fear is amygdala-dependent(19,20) and so provides a behavioural assessment of the ability of the reinforcer to activate amygdala neurons in the presence of AP5. We report here that intra-amygdala AP5 actually enhances expression of conditioned fear to the conditioned stimulus that provides the reinforcement signal for second-order conditioning. Nevertheless, acquisition of second-order fear conditioning is completely blocked. Our findings strongly support the view that NMDA receptors are critically involved in synaptic plasticity.	YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHIAT,NEW HAVEN,CT 06508	Yale University	Gewirtz, JC (corresponding author), YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHOL,34 PK ST,NEW HAVEN,CT 06508, USA.							BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BURNS LH, 1994, BEHAV NEURAL BIOL, V61, P242, DOI 10.1016/S0163-1047(05)80007-X; CAMPEAU S, 1995, J NEUROSCI, V15, P2312, DOI 10.1523/JNEUROSCI.15-03-02312.1995; CAMPEAU S, 1995, J NEUROSCI, V15, P2301, DOI 10.1523/JNEUROSCI.15-03-02301.1995; CAMPEAU S, 1991, BRAIN RES, V565, P349, DOI 10.1016/0006-8993(91)91669-R; CAMPEAU S, 1992, BEHAV NEUROSCI, V106, P569, DOI 10.1037/0735-7044.106.3.569; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; EVERITT B J, 1992, P401; FALLS WA, 1992, J NEUROSCI, V12, P854; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210; HATFIELD T, 1995, BEHAV NEUROSCI, V109, P663, DOI 10.1037/0735-7044.109.4.663; Hatfield T, 1996, J NEUROSCI, V16, P5256; IZQUIERDO I, 1995, NEUROBIOL LEARN MEM, V63, P19, DOI 10.1006/nlme.1995.1002; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KIM JJ, 1991, BEHAV NEUROSCI, V105, P125; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KIM M, 1992, BRAIN RES, V585, P35, DOI 10.1016/0006-8993(92)91188-K; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Pavlov I.P., 1927, CONDITIONED REFLEXES; Rescorla R. A, 1980, PAVLOVIAN 2 ORDER CO; ROMANSKI LM, 1992, J NEUROSCI, V12, P4501; ROMANSKI LM, 1993, BEHAV NEUROSCI, V107, P444, DOI 10.1037/0735-7044.107.3.444; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; Servatius RJ, 1996, BEHAV NEUROSCI, V110, P1040; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; WILLICK ML, 1995, BEHAV NEUROSCI, V109, P929, DOI 10.1037/0735-7044.109.5.929	30	168	170	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					471	474		10.1038/41325	http://dx.doi.org/10.1038/41325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242405	Bronze			2022-12-28	WOS:A1997XN55300048
J	Schwartz, DH; Laeyendecker, OB; ArangoJaramillo, S; Castillo, RC; Reynolds, MJ				Schwartz, DH; Laeyendecker, OB; ArangoJaramillo, S; Castillo, RC; Reynolds, MJ			Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR	LANCET			English	Article							VIRUS; INFECTION	Background In the USA, more than 2000 volunteers have received one or more experimental HIV-1 vaccines in phase I and II clinical trials, and there have been breakthrough HIV-1 infections among participants receiving vaccine and placebo. Serological diagnosis of new HIV-1 infections in vaccine-trial participants will become increasingly complicated as more viral components are used in vaccines. Recognition of this problem has led to a reliance on viral-genome measurement to distinguish vaccine-induced immunity from HIV-1 infection. Currently, quantitative RNA measurement is expensive, prone to contamination, and reliable only in laboratories certified by manufacturers or that have quality-control programmes. Methods A high-risk vaccinee presented after an acute febrile episode and was tested for HIV-1 infection by reverse transcriptase (RT) PCR of viral RNA. Further extensive tests were required to clarify the HIV-1 infection and immune status of the vaccinee, including repeat RT-PCR, nested DNA PCR, western blot, lymphoproliferation assay, cytotoxic-T-cell lysis, CD8-depleted co-culture, and HIV-1 challenge culture. Findings Initial testing of plasma by RNA RT-PCR was reported as positive. This result was not confirmed by viral cultures, nested DNA PCR, western blot, or EIA. Additional RNA RT-PCR assays gave positive results from earlier occasions in the vaccine trial. Eventually, testing of all previously reactive samples by RNA RT-PCR was repeated in a quality-controlled laboratory, and confirmed the negative HIV-1 status of the individual. Interpretation This case report exemplifies the difficulties with use of viral-genome measurement as a screening test to diagnose HIV-1 infection, particularly in individuals who have ever participated in HIV-1 vaccine trials. Monitoring of large numbers of phase III vaccinees by RNA RT-PCR will not be feasible. The design of efficacy trials for new vaccines should be in parallel with development of antibody-based diagnostic tests that are capable of differentiating between immunisation and true HIV-1 infection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR IMMUNIZAT RES,BALTIMORE,MD 21205	Johns Hopkins University	Schwartz, DH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,615 N WOLFE ST,ROOM 5309,BALTIMORE,MD 21205, USA.		Laeyendecker, Oliver B/B-9331-2009	Laeyendecker, Oliver/0000-0002-6429-4760				ALLAN JD, 1993, INT C AIDS, V9, P491; Coligan J, 1995, CURRENT PROTOCOLS IM; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; HO DD, 1995, NATURE, V373, P117; LUBAKI MN, 1994, AIDS RES HUM RETROV, V11, P1423; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; SCHWARTZ DH, 1995, CLIN DIAGN LAB IMMUN, V2, P268, DOI 10.1128/CDLI.2.3.268-271.1995; Volberding PA, 1996, LANCET, V347, P71, DOI 10.1016/S0140-6736(96)90205-6	12	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					256	259		10.1016/S0140-6736(97)01500-6	http://dx.doi.org/10.1016/S0140-6736(97)01500-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242803				2022-12-28	WOS:A1997XM86600013
J	Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR				Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR			Prevention of vascular and neural dysfunction in diabetic rats by C-peptide	SCIENCE			English	Article							ELEVATED GLUCOSE-LEVELS; RENAL-FUNCTION; PROTEIN; POLYPEPTIDE; SORBITOL; CONFORMATION; TYPE-1	C-peptide, a cleavage product from the processing of proinsulin to insulin, has been considered to possess little if any biological activity other than its participation in insulin synthesis, Injection of human C-peptide prevented or attenuated vascular and neural (electrophysiological) dysfunction and impaired Na+- and K+-dependent adenosine triphosphate activity in tissues of diabetic rats. Nonpolar amino acids in the midportion of the peptide were required for these biological effects. Synthetic reverse sequence (retro) and all-D-amino acid (enantio) C-peptides were equipotent to native C-peptide, which indicates that the effects of C-peptide on diabetic vascular and neural dysfunction were mediated by nonchiral interactions instead of stereospecific receptors or binding sites.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, DIV ENDOCRINE, INDIANAPOLIS, IN 46285 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, RES TECHNOL & PROT, INDIANAPOLIS, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Eli Lilly; Eli Lilly				Ido, Yasuo/0000-0002-3036-9971	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R01HL039934] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06600] Funding Source: Medline; NHLBI NIH HHS [HL 39934, HL 58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, DIABETES, V44, P968; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; CHANCE RE, 1971, DIABETES, P292; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DRYBURGH JR, 1980, DIABETOLOGIA, V19, P397, DOI 10.1007/BF00280527; EADES DM, 1989, J CHROMATOGR-BIOMED, V490, P1, DOI 10.1016/S0378-4347(00)82755-3; FRANK BH, 1983, MUNCH MED WSCHR S1, V125, pS14; Frank BH, 1981, PEPTIDES SYNTHESIS S, P729; GORKA J, 1989, Peptide Research, V2, P376; IDO Y, 1994, DIABETES, V43, P1469, DOI 10.2337/diabetes.43.12.1469; IDO Y, UNPUB; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543; JOHANSSON BL, 1993, J CLIN ENDOCR METAB, V77, P976, DOI 10.1210/jc.77.4.976; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KITABCHI AE, 1977, METABOLISM, V26, P547, DOI 10.1016/0026-0495(77)90099-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEHMANN EL, 1975, NONPARAMETRICS; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MARKUSSEN J, 1973, INT J PEPT PROT RES, V5, P69; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PUGLIESE G, 1990, DIABETES, V39, P323, DOI 10.2337/diabetes.39.3.323; ROGERS D, 1988, DIABETES, V37, P1689, DOI 10.2337/diabetes.37.12.1689; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scheffe H, 1959, ANAL VARIANCE; SNELL CR, 1975, J BIOL CHEM, V250, P6291; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; STEINER DF, 1978, DIABETES, V27, P145, DOI 10.2337/diab.27.1.S145; STEINER DF, 1995, ENDOCRINOLOGY, V2, P1296; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; TOYOTA T, 1975, TOHOKU J EXP MED, V117, P79, DOI 10.1620/tjem.117.79; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; WOJCIKOWSKI C, 1983, DIABETOLOGIA, V25, P288, DOI 10.1007/BF00279945; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; Zierath JR, 1996, DIABETOLOGIA, V39, P306	42	299	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					563	566		10.1126/science.277.5325.563	http://dx.doi.org/10.1126/science.277.5325.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228006				2022-12-28	WOS:A1997XM86700051
J	Neubuser, A; Peters, H; Balling, R; Martin, GR				Neubuser, A; Peters, H; Balling, R; Martin, GR			Antagonistic interactions between FGF and BMP signaling pathways: A mechanism for positioning the sites of tooth formation	CELL			English	Article							APICAL ECTODERMAL RIDGE; LIMB DEVELOPMENT; MOUSE; EXPRESSION; GROWTH; OUTGROWTH; INDUCTION; CHICK; GENE; DIFFERENTIATION	Vertebrate organogenesis is initiated at sites that are often morphologically indistinguishable from the surrounding region. Here we have identified Pax9 as a marker for prospective tooth mesenchyme prior to the first morphological manifestation of odontogenesis. We provide evidence that the sites of Pax9 expression in the mandibular arch are positioned by the combined activity of two signals, one (FGF8) that induces Pax9 expression and the other (BMP2 and BMP4) that prevents this induction. Thus it appears that the position of the teeth is determined by a combination of two different types of signaling molecules produced in wide but overlapping domains rather than by a single localized inducer. We suggest that a similar mechanism may be used for specifying the sites of development of other organs.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST SAUGETIERGENET,D-85764 NEUHERBERG,GERMANY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD34380] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Chen YP, 1996, DEVELOPMENT, V122, P3035; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GAUNT WA, 1964, ACTA ANAT, V57, P115; Grobstein C, 1967, Natl Cancer Inst Monogr, V26, P279; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; JONES CM, 1991, DEVELOPMENT, V111, P531; Kaufman MH, 1994, ATLAS MOUSE DEV; KOLLAR EJ, 1970, J EMBRYOL EXP MORPH, V24, P173; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LUMSDEN AGS, 1986, ARCH ORAL BIOL, V31, P301, DOI 10.1016/0003-9969(86)90044-0; LYONS KM, 1990, DEVELOPMENT, V109, P833; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Means AL, 1996, CELL GROWTH DIFFER, V7, P989; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUCH JV, 1984, DENTIN DENTINOGENESI, P47; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Thesleff I, 1996, ANAT REC, V245, P151; Thesleff I, 1996, SEMIN CELL DEV BIOL, V7, P185, DOI 10.1006/scdb.1996.0025; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; THESLEFF I, 1977, DEV BIOL, V58, P197, DOI 10.1016/0012-1606(77)90085-9; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; Wehr R, 1996, INT J DEV BIOL, V40, P369; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	43	483	498	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					247	255		10.1016/S0092-8674(00)80333-5	http://dx.doi.org/10.1016/S0092-8674(00)80333-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244299	Bronze			2022-12-28	WOS:A1997XN24900009
J	Guilhot, F; Chastang, C; Michallet, M; Guerci, A; Harousseau, JL; Maloisel, F; Bouabdallah, R; Guyotat, D; Cheron, N; Nicolini, F; Abgrall, JF; Tanzer, J				Guilhot, F; Chastang, C; Michallet, M; Guerci, A; Harousseau, JL; Maloisel, F; Bouabdallah, R; Guyotat, D; Cheron, N; Nicolini, F; Abgrall, JF; Tanzer, J			Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC GRANULOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; LOW-DOSE CYTARABINE; CHRONIC-PHASE; PROGNOSTIC DISCRIMINATION; CYTOGENETIC IMPROVEMENT; HEMATOLOGIC REMISSION; CYTOSINE-ARABINOSIDE; ALPHA; SURVIVAL	Background Treatment with interferon prolongs survival in chronic myelogenous leukemia. We conducted a clinical trial to assess the efficacy of treatment with a combination of interferon and cytarabine. Methods Previously untreated patients with chronic myelogenous leukemia were randomly assigned to receive either hydroxyurea (50 mg per kilogram of body weight per day) and interferon alfa-2b (5 million units per square meter of body-surface area per day), or hydroxyurea and interferon in the same dosages plus monthly courses of cytarabine (20 mg per square meter per day, for 10 days). The end points were overall survival, complete hematologic remission at 6 months, and major cytogenetic response (less than 35 percent Philadelphia chromosome-positive cells in the bone marrow) at 12 months. Results The trial was stopped when a sequential analysis showed a benefit of interferon and cytarabine. A significant improvement in survival was observed in the interferon-cytarabine group (360 patients) as compared with the interferon group (361 patients) (P=0.02; relative risk of death, 0.64; 95 percent confidence interval, 0.44 to 0.93). After three years, the survival rate was 85.7 percent with interferon and cytarabine and 79.1 percent with interferon alone. The rate of hematologic response was higher in the interferon-cytarabine group th an in the interferon group (P=0.003). Major cytogenetic responses were observed 12 months after randomization in 126 of 311 patients treated with interferon and cytarabine (41 percent) and in 75 of 314 patients treated with interferon only (24 percent, P<0.001). Conclusions The combination of interferon and cytarabine, as compared with interferon alone, increases the rate of major cytogenetic response and prolongs survival in patients in the chronic phase of chronic myelogenous leukemia. (C)1997, Massachusetts Medical Society.	HOP EDOUARD HERRIOT, LYON, FRANCE; HOP ST LOUIS, PARIS, FRANCE; HOP BRABOIS, VANDOEUVRE LES NANCY, FRANCE; HOP HOTEL DIEU, NANTES, FRANCE; HOP HAUTE PIERRE, STRASBOURG, FRANCE; INST J PAOLI I CALMETTES, F-13009 MARSEILLE, FRANCE; HOP NORD ST ETIENNE, ST ETIENNE, FRANCE; HOP ST ANTOINE, F-75571 PARIS, FRANCE; HOP MICHALON, GRENOBLE, FRANCE; HOP MORVAN, BREST, BELARUS; HOP LAPEYRONIE, LIMOGES, FRANCE; HOP LA BAUCHEE, ST BRIEUC, FRANCE; HOP REG, ANGERS, FRANCE; HOP HENRI MONDOR, F-94010 CRETEIL, FRANCE; HOP ROBERT DEBRE, REIMS, FRANCE; HOP BRETONNEAU, TOURS, FRANCE; HOP CLAUDE HURIEZ, LILLE, FRANCE; HOP JEAN BERNARD, POITIERS, FRANCE	CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; Nantes Universite; CHU de Nantes; CHU Strasbourg; UNICANCER; Institut Paoli-Calmette (IPC); CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU de Reims; CHU Tours; Universite de Lille - ISITE; CHU Lille; CHU Poitiers; Universite de Poitiers	Guilhot, F (corresponding author), HOP JEAN BERNARD, DEPT HAEMATOL & MED ONCOL, F-86021 POITIERS, FRANCE.			Guilhot, Francois/0000-0001-7222-487X				ALIMENA G, 1988, BLOOD, V72, P642; ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; [Anonymous], 1992, DESIGN ANAL SEQUENTI; COX DR, 1972, J R STAT SOC B, V34, P187; GOLDMAN JM, 1993, BLOOD, V82, P2235; GUILHOT F, 1991, LEUKEMIA LYMPHOMA, V4, P49, DOI 10.3109/10428199109107057; GUILHOT F, 1996, P AN M AM SOC CLIN, V15, P149; HEHLMANN R, 1995, BLOOD, V85, P3000, DOI 10.1182/blood.V85.10.3000.bloodjournal85103000; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; Imamishi J, 1984, Gan To Kagaku Ryoho, V11, P53; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KANTARJIAN HM, 1992, J CLIN ONCOL, V10, P772, DOI 10.1200/JCO.1992.10.5.772; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTSON MJ, 1993, AM J HEMATOL, V43, P95, DOI 10.1002/ajh.2830430205; SILVER RT, 1990, P ASCO, V9, P209; SOKAL JE, 1987, CANCER, V59, P197, DOI 10.1002/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SOKAL JE, 1988, LEUKEMIA RES, V12, P453, DOI 10.1016/0145-2126(88)90110-5; SOKAL JE, 1985, BLOOD, V66, P1352; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TURA S, 1994, NEW ENGL J MED, V330, P820	28	455	472	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					223	229		10.1056/NEJM199707243370402	http://dx.doi.org/10.1056/NEJM199707243370402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227927				2022-12-28	WOS:A1997XL99400002
J	Schnitzer, MJ; Block, SM				Schnitzer, MJ; Block, SM			Kinesin hydrolyses one ATP per 8-nm step	NATURE			English	Article							HEAD DOMAINS; MICROTUBULE; MOVEMENT; MOLECULES; MOTILITY; KINETICS; PROTEIN; FORCE; ASSAY; SIZE	Kinesin is a two-headed, ATP-dependent motor protein(1,2) that moves along microtubules in discrete steps(3) of 8 nm. In vitro, single molecules produce processive movement(4,5); motors typically take similar to 100 steps before releasing from a microtubule(5-7). A central question relates to mechanochemical coupling in this enzyme: how many molecules of ATP are consumed per step? For the actomyosin system, experimental approaches to this issue have generated considerable controversy(8,9). Here we take advantage of the processivity of kinesin to determine the coupling ratio without recourse to direct measurements of ATPase activity, which are subject to large experimental uncertainties(8,10-12). Beads carrying single molecules of kinesin moving on microtubules were tracked with high spatial and temporal resolution by interferometry(3,13). Statistical analysis of the intervals between steps at limiting ATP, and studies of fluctuations in motor speed as a function of ATP concentration(14,15), allow the coupling ratio to be determined. At near-zero load, kinesin molecules hydrolyse a single ATP molecule per 8-nm advance. This finding excludes various one-to-many and many-to-one coupling schemes, analogous to those advanced for myosin, and places severe constraints on models for movement.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,PRINCETON MAT INST,PRINCETON,NJ 08544	Princeton University; Princeton University	Schnitzer, MJ (corresponding author), PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOCK SM, 1995, BIOPHYS J, V68, pS230; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; GELLES J, 1995, BIOPHYS J, V68, pS276; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Kreis T., 1993, GUIDEBOOK CYTOSKELET; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	30	603	617	2	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					386	390		10.1038/41111	http://dx.doi.org/10.1038/41111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237757				2022-12-28	WOS:A1997XM52800053
J	Weiss, BD; Coyne, C				Weiss, BD; Coyne, C			Communicating with patients who cannot read	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LITERACY; COUNTRIES		AMC CANC RES CTR,DENVER,CO 80212	AMC Cancer Research Center	Weiss, BD (corresponding author), UNIV TEXAS,HLTH SCI CTR,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Weiss, Barry/AIB-2395-2022					ADLER DN, 1992, J ORAL MAXILLOFAC SU, V50, P27; BAKER D, IN PRESS AM J PUBLIC; Davis T C, 1993, Fam Med, V25, P391; DAVIS TC, 1994, PEDIATRICS, V93, P460; Doak CC, 1996, TEACHING PATIENTS LO; ESREY SA, 1988, AM J EPIDEMIOL, V127, P1079, DOI 10.1093/oxfordjournals.aje.a114884; FLEGG AT, 1982, POP STUD-J DEMOG, V36, P441, DOI 10.2307/2174055; GROSSE RN, 1989, ANNU REV PUBL HEALTH, V10, P281; Jastak S, 1993, WIDE RANGE ACHIEVEME; Joint Commission on Accreditation of Healthcare Organizations, 1996, ACCR MAN HOSP; Kirsch I, 1993, ADULT LITERACY AM 1; Kumar N B, 1993, J Cancer Educ, V8, P203; LLEWELLYNTHOMAS HA, 1995, PATIENT EDUC COUNS, V25, P97, DOI 10.1016/0738-3991(94)00705-Q; Meade C D, 1992, Oncol Nurs Forum, V19, P51; Meade C D, 1992, Oncol Nurs Forum, V19, P1523; Michielutte R, 1990, J Cancer Educ, V5, P55; *NAT COMM QUAL ASS, 1995, NCQA REV GUID ACCR M; PRIESTLEY KA, 1992, BRIT MED J, V305, P1263, DOI 10.1136/bmj.305.6864.1263; RANDALL T, 1993, JAMA-J AM MED ASSOC, V270, P160, DOI 10.1001/jama.270.2.160; Tourangeau R, 1996, PUBLIC OPIN QUART, V60, P275, DOI 10.1086/297751; Weiss B D, 1991, J Health Care Poor Underserved, V1, P351; Weiss B D, 1992, J Am Board Fam Pract, V5, P257; Weiss B D, 1994, J Health Care Poor Underserved, V5, P99; WEISS BD, 1995, J AM GERIATR SOC, V43, P807, DOI 10.1111/j.1532-5415.1995.tb07057.x; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677	25	140	146	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					272	274		10.1056/NEJM199707243370411	http://dx.doi.org/10.1056/NEJM199707243370411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227936				2022-12-28	WOS:A1997XL99400011
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 61-year-old man with psoriasis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		BAUGHMAN RD, 1996, JAMA-J AM MED ASSOC, V276, P1421; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228440				2022-12-28	WOS:A1997XL05900035
J	Kerr, EA; Hays, RD; Mittman, BS; Siu, AL; Leake, B; Brook, RH				Kerr, EA; Hays, RD; Mittman, BS; Siu, AL; Leake, B; Brook, RH			Primary care physicians' satisfaction with quality of care in California capitated medical groups	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; MANAGED CARE; FINANCIAL INCENTIVES; OUTCOMES	Context.-Managed care and capitation have placed new responsibilities on primary care physicians, including formally acting as ''gatekeepers'' for specialty services and tests. Previous studies have not examined whether primary care physicians who provide services to patients under many coverage arrangements feel differently about caring for patients covered under capitation vs those covered through more traditional forms of insurance. An understanding of whether California primary care physicians feel that they deliver a different level of quality to capitated patients could help signal whether variations in care for patients with different coverage forms are evolving. Objective.-To evaluate whether primary care physicians in California capitated groups report different satisfaction levels with quality of care for patients in their overall practice than for patients covered by capitated contracts and to examine whether physicians' satisfaction with capitated care quality is influenced by the characteristics of the practice setting. Design.-Cross-sectional questionnaire. Setting.-A total of 89 California physician groups with capitated contracts. Participants.-A total of 910 primary care physicians (80% response rate). Main Outcome Measure.-Satisfaction with 4 aspects of quality of care provided to patients covered by capitated contracts vs patients overall. Results.-Physicians reported lower satisfaction with all 4 aspects of care for patients covered by capitated contracts than for patients in their overall practice: 71% were very or somewhat satisfied with relationships with capitated patients (compared with 88% far overall practice), 64% were very or somewhat satisfied with the quality of care they provided to capitated patients (compared with 88% for overall practice), 51% were very or somewhat satisfied with their ability to treat capitated patients according to their own best judgment (compared with 79% for overall practice), and 50% were very or somewhat satisfied with their ability to obtain specialty referrals (compared with 59% for overall practice) (P less than or equal to.001 for all comparisons). Being in a medical group practice (vs an independent practice association) and having a larger percentage of capitated patients were independently associated by multivariate analysis with higher levels of satisfaction with capitated quality of care (P less than or equal to.005). Conclusion.-These California primary care physicians were less satisfied with the quality of care they deliver to patients covered by capitated contracts than with the quality of care they deliver to patients covered by other payment sources. However, those in medical group practices and with a higher percentage of capitated patients were more satisfied with capitated care. National expansion of capitation should be accompanied by efforts to ensure that the satisfaction of practicing physicians with the care they deliver does not decline.	VET AFFAIRS MED CTR,CTR PRACTICE MANAGEMENT & OUTCOMES RES,ANN ARBOR,MI; UNIV MICHIGAN,DEPT MED,ANN ARBOR,MI 48109; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; RAND CORP,SANTA MONICA,CA; VET AFFAIRS MED CTR,CTR STUDY HEALTHCARE PROVIDER BEHAV,SEPULVEDA,CA; MT SINAI MED CTR,NEW YORK,NY 10029	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Icahn School of Medicine at Mount Sinai			Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BAKER LC, 1993, HEALTH AFFAIR, V12, P258, DOI 10.1377/hlthaff.12.suppl_1.258; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; CHUCK JM, 1993, WESTERN J MED, V159, P665; *COUNC ETH JUD AFF, 1995, JAMA-J AM MED ASSOC, V273, P330; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Freeborn D K, 1985, Group Health J, V6, P3; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; KRAVITZ R, 1993, MIL MED, V158, P41, DOI 10.1093/milmed/158.1.41; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LICHTENSTEIN R, 1984, MED CARE, V22, P56, DOI 10.1097/00005650-198401000-00005; LINN LS, 1985, MED CARE, V23, P1171, DOI 10.1097/00005650-198510000-00006; MCGLYNN EA, 1988, PUBLICATION RAND; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; Pagano R A, 1993, Physician Exec, V19, P52; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SCHULZ R, 1990, HEALTH SERV RES, V25, P43; SCHULZ R, 1992, J FAM PRACTICE, V34, P298; STAMPS PL, 1994, ISSUES PHYSICIAN SAT; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; TERRY K, 1996, MEE EC           OCT, P196; Ubel PA, 1997, ANN INTERN MED, V126, P74, DOI 10.7326/0003-4819-126-1-199701010-00010; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WELCH WP, 1987, J HEALTH POLIT POLIC, V12, P723, DOI 10.1215/03616878-12-4-723; WELLS KB, 1994, AM J PSYCHIAT, V151, P694; 1995, INT COMP EDG VERS 6	33	71	71	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					308	312		10.1001/jama.278.4.308	http://dx.doi.org/10.1001/jama.278.4.308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228437				2022-12-28	WOS:A1997XL05900032
J	Thorpe, KE				Thorpe, KE			Incremental strategies for providing health insurance for the uninsured - Projected federal costs and number of newly insured	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To present several incremental strategies for extending health insurance coverage for segments of an estimated 40.6 million uninsured persons in the United States. Along with these strategies, the federal costs and estimates of the number of newly insured are presented. Design.-Using data from the Congressional Budget Office and the federal government, the number of newly insured persons in the United States under options designed to increase coverage among uninsured children, their parents, and workers between jobs are simulated. The federal costs and coverage implications of these options are estimated for federal fiscal years 1998 through 2002. Methods.-Three distinct incremental approaches for covering the uninsured are explored. The first approach would expand coverage through the current Medicaid program. The second approach would provide financial incentives for parents of children eligible for Medicaid to purchase coverage, and the final approach provides time-limited subsidies allowing workers and their families to purchase insurance when they are between jobs. Main Results.-The federal costs of these approaches range from $2 billion to $3 billion per year (enrollment outreach approach) to $5 billion to $7 billion per year (enrolling parents of Medicaid-eligible children approach). If pursued simultaneously, the incremental strategies under investigation could extend health insurance to more than 7 million uninsured persons in the United States. The cost of these options could be financed through Medicaid savings, restructuring the current disproportionate share payments made through Medicare and Medicaid, increasing excise taxes on tobacco, or all of the above. Conclusions.-The incremental strategies would build on the current US health care delivery system by providing targeted financial assistance to specific populations. By their nature, such reforms could provide a political means for compromise and agreement between Congress and the president. Though the reforms do not, by design, provide a comprehensive solution to the problems facing the uninsured, they would address the severe problems facing many low- and middle-income families unable to purchase health insurance today.			Thorpe, KE (corresponding author), TULANE UNIV,SCH PUBL HLTH & TROP MED,DEPT HLTH SYST MANAGEMENT,SL-29,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							*AM HOSP ASS, 1995, HOSP STAT 1995 96, P36; *C BUDG OFF, 1997, EC BUDG OUTL FISC YE, P133; *C BUDG OFF, 1994, PREL AN SEN MITCH HL, P3; *C BUDG OFF, 1996, RED DEF SPEND REV OP, P86; Davis K, 1996, JAMA-J AM MED ASSOC, V276, P831, DOI 10.1001/jama.276.10.831; Donelan K, 1996, JAMA-J AM MED ASSOC, V276, P1346, DOI 10.1001/jama.276.16.1346; EHRENBERG RG, 1979, AM ECON REV, V66, P754; *KPMG, 1996, HLTH BEN 1996; MARQUIS MS, 1994, INQUIRY-J HEALTH CAR, V31, P405; THORPE KE, 1997, HLTH INSURANCE COVER; THORPE KE, 1997, HLTH AFF MILLWOO JUL, P1; *US BUR CENS, 1996, CURR POP SURV; *US HOUS REPR, 1996, 1996 GREEN BOOK, P328	13	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					329	333		10.1001/jama.278.4.329	http://dx.doi.org/10.1001/jama.278.4.329			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228441				2022-12-28	WOS:A1997XL05900036
J	Kony, SJ; deVathaire, F; Chompret, A; Shamsaldim, A; Grimaud, E; Raquin, MA; Oberlin, O; Brugieres, L; Feunteun, J; Eschwege, F; Chavaudra, J; Lemerle, J; BonaitiPellie, C				Kony, SJ; deVathaire, F; Chompret, A; Shamsaldim, A; Grimaud, E; Raquin, MA; Oberlin, O; Brugieres, L; Feunteun, J; Eschwege, F; Chavaudra, J; Lemerle, J; BonaitiPellie, C			Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood	LANCET			English	Article							FAMILY HISTORY; BREAST-CANCER; RETINOBLASTOMA; SURVIVORS; CHILDREN; RADIOSENSITIVITY; RADIOTHERAPY; CHEMOTHERAPY; MUTATIONS; MORTALITY	Background Radiotherapy and chemotherapy are associated with an increased risk of second malignant neoplasm (SMN). An association between SMN and familial aggregation has also been shown. The aim of this study was to investigate the role of familial factors in the risk of SMM and their potential interaction with the effect of treatment. Methods We devised a case-control study of 25 children with SMN (cases) and 96 children with no SMN after a cancer treatment (controls), taken from a cohort of 649 children treated at our institution between 1953 and 1985. A complete family history was obtained for patients and controls and a familial index defined to evaluate the degree of familial aggregation. The radiation dose given at 151 sites in the body was estimated for each radiotherapy course for each child. Findings Among family members of the 25 SMN cases, there were ten with early-onset (less than or equal to 45 years) cancer, compared with eight among relatives of the 96 controls. Compared with patients who had no family history of early-onset cancer, those with one or more affected family members had an odds ratio of SMN of 4.7 (95% Cl 1.3-17.1; p=0.02). Adjustment for local radiation dose and exclusion of patients known to be predisposed to SMN (carriers of p53 mutation and those with Recklinghausen's disease) did not affect this risk substantially. Interpretation Both genetic factors and exposure to ionising radiation have independent effects on the risk of SMN. Follow-up of children treated for cancer should be especially vigilant when there is a family history of early-onset cancer.	INST GUSTAVE ROUSSY,INSERM,U351,RES UNIT CANC EPIDEMIOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PAEDIAT,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PHYS,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,LAB ONCOL GENET,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT RADIOTHERAPY,F-94805 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy			de Vathaire, Florent/L-2983-2016; Feunteun, Jean/AAZ-1267-2020	de Vathaire, Florent/0000-0002-8374-9281; Feunteun, Jean/0000-0003-1212-9189				BRESLOW NE, 1980, STATISTICAL METHODS; CHAKRABORTY R, 1995, RADIAT RES, V143, P293, DOI 10.2307/3579216; DARROUDI F, 1995, MUTAT RES-FUND MOL M, V328, P83, DOI 10.1016/0027-5107(95)00002-Z; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; Diallo I, 1996, RADIOTHER ONCOL, V38, P269, DOI 10.1016/0167-8140(96)01713-6; DORMAN JS, 1988, GENET EPIDEMIOL, V5, P305, DOI 10.1002/gepi.1370050502; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KERBER RA, 1995, GENET EPIDEMIOL, V12, P291, DOI 10.1002/gepi.1370120306; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; MALECOT E, 1948, MATH HEREDITE; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; PARKINS DM, 1992, CANC INCIDENCE 5 CON, V6; SCHWARTZ AG, 1988, AM J EPIDEMIOL, V128, P524, DOI 10.1093/oxfordjournals.aje.a115000; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBER W, 1993, ANTICANCER RES, V13, P1197; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	28	105	106	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					91	95		10.1016/S0140-6736(97)01116-1	http://dx.doi.org/10.1016/S0140-6736(97)01116-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228960				2022-12-28	WOS:A1997XK11400008
J	Anderson, DG; Kowalczykowski, SC				Anderson, DG; Kowalczykowski, SC			The translocating RecBCD enzyme stimulates recombination by directing RecA protein onto ssDNA in a chi-regulated manner	CELL			English	Article							SINGLE-STRANDED-DNA; HOT SPOT ACTIVITY; COLI SSB PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; BINDING-PROTEIN; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BACTERIOPHAGE-LAMBDA; SERRATIA-MARCESCENS	Double-stranded DNA break repair and homologous recombination in E. coli are initiated by the RecBCD enzyme, which unwinds and simultaneously degrades DNA from a double-stranded DNA end. This process is stimulated by cis-acting DNA elements, known as chi sites. Using both in vitro pairing and nuclease protection assays, we demonstrate that the translocating RecBCD enzyme, which has been activated by chi, coordinates the preferential loading of the homologous pairing protein, RecA, onto the resultant single-stranded DNA downstream of chi. This facilitated loading of RecA protein results in a substantial increase in both the efficiency and rate of in vitro recombination reactions and offers an explanation for stimulation of recombination and repair in vivo by chi.	UNIV CALIF DAVIS,GENET GRAD GRP,DAVIS,CA 95616; UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BIANCO PR, 1997, IN PRESS P NATL ACAD; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DEVRIES J, 1992, J GEN MICROBIOL, V138, P31, DOI 10.1099/00221287-138-1-31; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EMMERSON PT, 1968, GENETICS, V60, P19; ENNIS DG, 1987, GENETICS, V115, P11; FRIEDBERG EC, 1995, DNA REPAIR; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KOWALCZYKOWSKI SC, 1994, J MOL BIOL, V63, P991; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; KUZMINOV A, 1996, MOL BIOL INTELLIGENC, P135; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MYERS RS, 1995, GENETICS, V141, P805; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RINKEN R, 1991, BIOCHIMIE, V73, P375, DOI 10.1016/0300-9084(91)90104-9; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1990, P NATL ACAD SCI USA, V88, P3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J., 2002, MOL CLONING LAB MANU; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1980, GENETICS, V94, P235; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNSHINE MG, 1971, J BACTERIOL, V108, P695, DOI 10.1128/JB.108.2.695-704.1971; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Telander-Muskavitch K.M, 1981, ENZYMES, P233; TELANDERMUSKAVI.KM, 1980, MECHANISTIC STUDIES, P901; TRACY KRB, 1996, GENE DEV, V10, P1890; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005	61	245	253	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					77	86		10.1016/S0092-8674(00)80315-3	http://dx.doi.org/10.1016/S0092-8674(00)80315-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230304	Bronze			2022-12-28	WOS:A1997XL36200010
J	Nicoll, RA				Nicoll, RA			John C. Eccles (1903-1997) - Retrospective	SCIENCE			English	Item About an Individual									UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Nicoll, RA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143, USA.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					194	194		10.1126/science.277.5323.194	http://dx.doi.org/10.1126/science.277.5323.194			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235634				2022-12-28	WOS:A1997XK41800031
J	Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F				Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F			The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation	CELL			English	Article							PRIMITIVE STREAK FORMATION; BETA-CATENIN; SPEMANN ORGANIZER; XENOPUS-EMBRYOS; INDUCTION; PROTEIN; GENE; DROSOPHILA; LOCALIZATION; GASTRULATION	Mutations at the mouse Fused locus have pleiotropic developmental effects, including the formation of axial duplications in homozygous embryos. The product of the Fused locus, Axin, displays similarities to RGS (Regulators of G-Protein Signaling) and Dishevelled proteins. Mutant Fused alleles that cause axial duplications disrupt the major mRNA, suggesting that Axin negatively regulates the response to an axis-inducing signal. Injection of Axin mRNA into Xenopus embryos inhibits dorsal axis formation by interfering with signaling through the Wnt pathway. Furthermore, ventral injection of an Axin mRNA lacking the RGS domain induces an ectopic axis, apparently through a dominant-negative mechanism. Thus, Axin is a novel inhibitor of Wnt signaling and regulates an early step in embryonic axis formation in mammals and amphibians.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Princeton University; Princeton University			Fagotto, Francois/AAA-9983-2021; Hsu, Wei/ABG-6856-2021	Fagotto, Francois/0000-0002-1495-2112; Hsu, Wei/0000-0001-6738-6030	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037432, R37GM037432] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08784] Funding Source: Medline; NIDDK NIH HHS [DK-46934] Funding Source: Medline; NIGMS NIH HHS [GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1996, ADV DEV BIO, V4, P147; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P27; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FAGOTTO F, 1994, DEVELOPMENT, V120, P3667; Fagotto F, 1997, DEVELOPMENT, V124, P453; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GARDNER RL, 1992, J EXP ZOOL, V264, P437, DOI 10.1002/jez.1402640409; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GREENSPAN RJ, 1986, P NATL ACAD SCI USA, V83, P4413, DOI 10.1073/pnas.83.12.4413; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HUME CR, 1993, DEVELOPMENT, V119, P1147; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KHANER O, 1989, DEV BIOL, V134, P206, DOI 10.1016/0012-1606(89)90090-0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LYON MF, 1996, GENETIC VARIANTS STR; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TLIGHMAN SM, 1996, GENOME RES, V6, P773; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wylie C, 1996, DEVELOPMENT, V122, P2987; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZIV T, 1992, DEVELOPMENT, V115, P689	56	750	783	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					181	192		10.1016/S0092-8674(00)80324-4	http://dx.doi.org/10.1016/S0092-8674(00)80324-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230313	hybrid			2022-12-28	WOS:A1997XL36200019
J	Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J				Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J			Inhibition of death receptor signals by cellular FLIP	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROTEIN; FAS; CYTOTOXICITY; INTERACTS; DOMAIN; SITE; P35	The widely expressed protein Fas is a member of the tumour necrosis factor receptor family which fan trigger apoptosis(1). However, Fas surface expression does not necessarily render cells susceptible to Fas ligand-induced death signals(1,2), indicating that inhibitors of the apoptosis-signalling pathway must exist. Here we report the characterization of an inhibitor of apoptosis, designated FLIP (for FLICE-inhibitory protein), which is predominantly expressed in muscle and lymphoid tissues. The short form, FLIPS, contains two death effector domains and is structurally related to the viral FLIP inhibitors of apoptosis(3), whereas the long form, FLIPL, contains in addition a caspase-like domain in which the active-centre cysteine residue is substituted by a tyrosine residue. FLIPS and FLIPL interact with the adaptor protein FADD(4,5) and the protease FLICE6,7, and potently inhibit apoptosis induced by all known human death receptors(1). FLIPL is expressed during the early stage of T-cell activation, but disappears when T cells become susceptible to Fas ligand-mediated apoptosis. High levels of FLIPL protein are also detectable in melanoma cell lines and malignant melanoma tumours. Thus FLIP may be implicated in tissue homeostasis as an important regulator of apoptosis.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute Experimental Cancer Research; University of Geneva			Irmler, Martin/B-3317-2013; Hofmann, Kay/D-6714-2011; French, Lars/AAL-5977-2020; Thome, Margot/F-8167-2011	Irmler, Martin/0000-0003-3169-479X; Hofmann, Kay/0000-0002-2289-9083; French, Lars/0000-0002-4629-1486; Thome, Margot/0000-0002-5656-2139; Schneider, Pascal/0000-0003-0677-9409				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BODNER JL, 1997, IMMUNITY, V6, P79; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YU GL, 1996, SCIENCE, V274, P990	30	2073	2173	1	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					190	195		10.1038/40657	http://dx.doi.org/10.1038/40657			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217161	Bronze, Green Submitted			2022-12-28	WOS:A1997XK10900054
J	Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S				Jordan, BD; Relkin, NR; Ravdin, LD; Jacobs, AR; Bennett, A; Gandy, S			Apolipoprotein E epsilon 4 associated with chronic traumatic brain injury in boxing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID PROTEIN DEPOSITION; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA; PRECURSOR PROTEIN; TYPE-4 ALLELE; BETA-PROTEIN; BOXERS; AFTERMATH; DAMAGE	Context.-Given the similarities between Alzheimer disease and dementia pugilistica, we evaluated the relationship between apolipoprotein E (APOE) genotype and chronic traumatic brain injury (CTBI) in boxers to determine whether there is a genetic susceptibility to the effects of head trauma. Objective.-To assess the relationship between CTBI and APOE genotype in boxers. Design and Setting.-Clinical characterization of 24 volunteer and 6 referred boxers in an outpatient setting. Participants.-Thirty professional boxers aged 23 to 76 years underwent neurologic and behavioral assessment in conjunction with APOE genotyping. Main Outcome Measures.-Apolipoprotein E genotype was examined in relationship to measures of CTBI. A 10-point clinical rating scale (0-9), the Chronic Brain Injury (CBI) scale, was devised to assess the severity of traumatic encephalopathy associated with boxing, Boxers with abnormal CTBI scores were further classified on the basis of whether their impairments were possibly or probably related to boxing. Scores were analyzed in relation to boxing exposure (number of bouts) and APOE genotype. Results.-Among the 30 boxers, 11 were found to be normal (CBI score=0), 12 showed mild deficits (CBI score=1-2), 4 were moderately impaired (CBI score=3-4), and 3 showed signs of severe impairment (CBI score >4). High-exposure boxers tie, those with greater than or equal to 12 professional bouts) had significantly higher CBI scores (mean [SD], 2.6 [1.9]) than low-exposure boxers (mean [SD], 0.3 [0.7]) (P<.001), indicating that neurologic impairment as measured by the CBI scale seems related to boxing exposure. The APOE genotype frequencies of the study population were approximately the same as those found in the general population. Boxers with low exposure had mean CBI scores of 0.33, irrespective of APOE genotype. However, high-exposure boxers with an APOE epsilon 4 allele had significantly greater CBI scores (mean [SD], 3.9 [2.3]) than high-exposure boxers without APOE epsilon 4 (mean [SD], 1.8 [1.2]) (P=.04), All boxers with severe impairment possessed at least 1 APOE epsilon 4 allele. The tendency for greater CTBI among those with both high exposure and an epsilon 4 allele was statistically significant at the P<.001 level. ConcIusions.-These preliminary findings suggest that possession or an APOE epsilon 4 allele may be associated with increased severity of chronic neurologic deficits in high-exposure boxers.	CORNELL UNIV MED COLL,NEW YORK HOSP,DEPT NEUROL & NEUROSCI,NEW YORK,NY; CORNELL UNIV MED COLL,HOSP SPECIAL SURG,SPORTS NEUROL PROGRAM,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Cornell University								BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING, P147; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Katzman R, 1996, NEUROLOGY, V46, P889; LEHMANN EL, 1975, NONPARAMETRICS; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; UHL GR, 1982, ANN NEUROL, V12, P99; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	493	505	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					136	140		10.1001/jama.278.2.136	http://dx.doi.org/10.1001/jama.278.2.136			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214529				2022-12-28	WOS:A1997XH66700034
J	Summerfield, D				Summerfield, D			Medical ethics: The Israeli Medical Association	LANCET			English	Editorial Material											Summerfield, D (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON NW5 3EJ,ENGLAND.							*AMN INT, 1996, CONSTANT MED SUPERVI; *HUM RIGHTS WATCH, 1994, TORT ILL TREATM ISR; *PHYS HUM RIGHTS U, 1995, ISR OCC TERR SHAK FO; *PHYS HUM RIGHTS U, 1993, HUM RIGHTS HOLD; SiegelItzkovich J, 1997, BRIT MED J, V314, P539; SUMMERFIELD D, 1995, BRIT MED J, V311, P755, DOI 10.1136/bmj.311.7007.755c	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					63	64		10.1016/S0140-6736(05)66265-4	http://dx.doi.org/10.1016/S0140-6736(05)66265-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217730				2022-12-28	WOS:A1997XH86900054
J	Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ				Noll, KS; Roush, TL; Cruikshank, DP; Johnson, RE; Pendleton, YJ			Detection of ozone on Saturn's satellites Rhea and Dione	NATURE			English	Article							CHARGED-PARTICLE IRRADIATION; EUROPA; GANYMEDE; OXYGEN; CALLISTO; SPECTRA; ALBEDO; SEARCH; ICES; LIFE	The satellites Rhea and Dione orbit within the magnetosphere of Saturn, where they are exposed to particle irradiation from trapped ions. A similar situation applies to the galilean moons Europa, Ganymede and Callisto, which reside within Jupiter's radiation belts. All of these satellites have surfaces rich in water ice(1,2). Laboratory studies of the interaction of charged-particle radiation with water ice predicted(3) the tenuous oxygen atmospheres recently found on Europa(4) and Ganymede(5). However, theoretical investigations did not anticipate the trapping of significantly larger quantities of O-2 within the surface ice(6). The accumulation of detectable abundances of O-3, produced by the action of ultraviolet or charged-particle radiation on O-2, was also not predicted before being observed on Ganymede(7). Here we report the identification of O-3 in spectra of the saturnian satellites Rhea and Dione. The presence of trapped O-3 is thus no longer unique to Ganymede, suggesting that special circumstances may not be required for its production.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; SAN FRANCISCO STATE UNIV, DEPT GEOSCI, SAN FRANCISCO, CA 94132 USA; UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California State University System; San Francisco State University; University of Virginia	Noll, KS (corresponding author), SPACE TELESCOPE SCI INST, 3700 SAN MARTIN DR, BALTIMORE, MD 21218 USA.		Noll, Keith/C-8447-2012					BARTH CA, IN PRESS GEOPHYS RES; BURATTI B, 1984, ICARUS, V58, P254, DOI 10.1016/0019-1035(84)90042-3; BURATTI BJ, 1990, ICARUS, V87, P339, DOI 10.1016/0019-1035(90)90138-Y; BURATTI BJ, 1991, ICARUS, V92, P312, DOI 10.1016/0019-1035(91)90054-W; BURKE BF, 1986, NATURE, V322, P340, DOI 10.1038/322340a0; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CLARK RN, 1984, ICARUS, V58, P265, DOI 10.1016/0019-1035(84)90043-5; ELSILA J, IN PRESS ASTROPHYS J; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; KHARE BN, 1993, ICARUS, V103, P290, DOI 10.1006/icar.1993.1071; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEGER A, 1994, ADV SPACE RES, V14, P117, DOI 10.1016/0273-1177(94)90016-7; MATICH AJ, 1993, J PHYS CHEM-US, V97, P10539, DOI 10.1021/j100143a007; MORRISON D, 1975, ICARUS, V24, P157, DOI 10.1016/0019-1035(75)90093-7; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OWEN T, 1992, NATURE, V358, P43, DOI 10.1038/358043a0; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; ROUSH TL, 1995, VOLATILES EARTH SOLA, V341, P143; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUBE H, 1957, T FARADAY SOC, V53, P656, DOI 10.1039/tf9575300656; THOMPSON WR, 1987, J GEOPHYS RES, V92, P14933, DOI 10.1029/JA092iA13p14933; TIELENS AGGM, 1982, ASTRON ASTROPHYS, V114, P245; VAIDA V, 1989, J PHYS CHEM-US, V93, P506, DOI 10.1021/j100339a003; Vilas F, 1996, ICARUS, V124, P262, DOI 10.1006/icar.1996.0202; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	29	128	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					45	47		10.1038/40348	http://dx.doi.org/10.1038/40348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214500				2022-12-28	WOS:A1997XJ14300043
J	Eisenberg, DM				Eisenberg, DM			Advising patients who seek alternative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EOSINOPHILIA-MYALGIA-SYNDROME; HERBAL MEDICINES; CHIROPRACTIC MANIPULATION; SPINAL MANIPULATION; ADVERSE REACTIONS; CLINICAL-TRIALS; UNITED-STATES; CHINESE HERBS; CHRONIC PAIN; HEPATITIS-B	Alternative medical therapies, such as chiropractic, acupuncture, homeopathy, and herbal remedies, are in great public demand. Some managed care organizations now offer these therapies as an ''expanded benefit.'' Because the safety and efficacy of these practices remain largely unknown, advising patients who use or seek alternative treatments presents a professional challenge. A step-by-step strategy is proposed whereby conventionally trained medical providers and their patients can preactively discuss the use or avoidance of alternative therapies. This strategy involves a formal discussion of patients' preferences and expectations, the maintenance of symptom diaries, and follow-up visits to monitor for potentially harmful situations. In the absence of professional medical and legal guidelines, the proposed management plan emphasizes patient safety, the need for documentation in the patient record, and the importance of shared decision making.			Eisenberg, DM (corresponding author), BETH ISRAEL DEACONESS MED CTR, CTR ALTERNAT MED RES, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson IB, 1996, ANN INTERN MED, V124, P726, DOI 10.7326/0003-4819-124-8-199604150-00004; ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1988, HERBAL MED; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BARRETT S, 1990, HLTH SCHEMES SCAMS F; BELLAVITE P, 1995, HOMEOPATHY FRONTIER; Bigos S, 1994, CLIN PRACTICE GUIDEL; BLUMENTHAL M, 1996, COMMISSION E MONOGRA; *BURT GOLDB GROUP, 1993, ALT MED DEF GUID; BUTLER K, 1992, CONSUMERS GUIDE ALTE; CARRON H, 1974, JAMA-J AM MED ASSOC, V228, P1552; Carton Barbara, 1995, WALL ST J       0116, pB1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; CHENG TO, 1989, AM J MED, V87, P489, DOI 10.1016/S0002-9343(89)80853-8; COLLINGE W, 1996, COMPLETE GUIDE ALTER; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Coulter ID, 1995, APPROPRIATENESS SPIN; COWLEY G, 1996, NEWSWEEK        0603, P60; DANDEKAR UP, 1992, J ETHNOPHARMACOL, V35, P285, DOI 10.1016/0378-8741(92)90026-N; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P. A. G. M., 1992, P1209; De Smet P. A. G. M., 1993, ADVERSE EFFECTS HERB; De Smet PAGM, 1992, TOXICOLOGICAL OUTLOO, P1; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; DESMET PAGM, 1991, J ETHNOPHARMACOL, V32, P43, DOI 10.1016/0378-8741(91)90102-J; DUNKIN A, 1995, BUSINESS WEEK   1127, P134; Egan Timothy, 1996, NY TIMES, pA6; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EISENBERG DM, 1996, HARVARD MED ALUMNI B, V70, P20; EPSTEIN WL, 1987, ANN EMERG MED, V16, P950, DOI 10.1016/S0196-0644(87)80739-4; FAST A, 1987, SPINE, V12, P840, DOI 10.1097/00007632-198711000-00003; FRIEDMAN RA, 1996, NY TIMES        0419, pA29; Fugh-Berman A., 1996, ALTERNATIVE MED WHAT; FUSHIMI R, 1989, LANCET, V1, P339, DOI 10.1016/S0140-6736(89)91361-5; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLOCK M, 1995, NIH PUBLICATION; GOLDMAN JA, 1991, ARTHRITIS RHEUM, V34, P1207, DOI 10.1002/art.1780340922; GOLEMAN D, 1993, MIND BODY MED HOW US; GORDON DW, 1995, JAMA-J AM MED ASSOC, V273, P489, DOI 10.1001/jama.273.6.489; HALDEMAN S, 1992, SPINE, V17, P1469, DOI 10.1097/00007632-199212000-00005; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HEWALL CA, 1996, HERBAL MED GUIDE HLT; HILTS PJ, 1995, NY TIMES        1227, pB10; HOGAN RP, 1983, JAMA-J AM MED ASSOC, V249, P2679, DOI 10.1001/jama.249.19.2679; Hurwitz EL, 1996, SPINE, V21, P1746, DOI 10.1097/00007632-199608010-00007; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; JACKSON C, 1996, TAMPA TRIBUNE   0108, P8; James, 1995, ACUPUNCT MED, V13, P26, DOI [10.1136/aim.13.1.26, DOI 10.1136/AIM.13.1.26]; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Kaptchuk T.J., 1983, WEB HAS NO WEAVER; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUSS C, 1996, NY TIMES        0524, pB1; LAGNADO L, 1996, WALL STREET J   1007, pB9; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; LERNER M, 1994, CHOICES HEALING INTE; Marti J, 1995, ALTERNATIVE HLTH MED; MICOZZI MS, 1996, FUNDAMENTALS COMPLEN; MOORE JS, 1993, CHIROPRACTIC AM HIST; NEFF R, 1995, BUSINESS WEEK   0130, P60; *NIH OFF ALT MED, 1994, ALT MED EXP MED HOR; OConnor BB, 1995, STUDIES HLTH ILLNESS, Vxxiv; OLIVER LD, 1984, TEX MED, V80, P40; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; PHALON R, 1993, FORBES          1220, P254; PIZZORNO JE, 1993, TXB NATURAL MED; POWELL FC, 1993, NEUROSURGERY, V33, P73; RASO J, 1993, MYSTICAL DIETS PARAN; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; ROBERTS IF, 1979, BRIT MED J, V1, P296, DOI 10.1136/bmj.1.6159.296; RUSSELL FE, 1975, JAMA-J AM MED ASSOC, V233, P341, DOI 10.1001/jama.233.4.341; RUSSELL S, 1996, SAN FRANCISCO C 0925, pA1; SALE JD, 1994, OVERVIEW LEGISLATIVE; SCHECK A, 1995, INVESTORS BUSIN 0620; SEGELMAN AB, 1976, JAMA-J AM MED ASSOC, V236, P477, DOI 10.1001/jama.236.5.477; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHERLOCK P, 1967, J AMER MED ASSOC, V199, P794, DOI 10.1001/jama.199.11.794; SLATER PE, 1988, EUR J EPIDEMIOL, V4, P322, DOI 10.1007/BF00148918; SMITH GW, 1993, BRIT J RHEUMATOL, V32, P87; STALKER D, 1989, EXAMINING HOLISTIC M; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAYLOR GD, 1985, CAN MED ASSOC J, V133, P767; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; TRESOLINI CP, 1994, HLTH ED RELATIONSHIP; Tyler V. E., 1994, HERBS CHOICE THERAPE; Tyler VE, 1993, HONEST HERBAL SENSIB, V3rd; *US C, 1990, OTAH405; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vithoulkas G., 1980, SCI HOMEOPATHY; VITTECOQ D, 1989, NEW ENGL J MED, V320, P250; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WEINER M, 1982, COMPLETE BOOK HOMEOP; Werbach MR, 1994, BOT INFLUENCES ILLNE; *WHO, 1992, HERB MED CONT GERM W; WILKINSON JA, 1995, BRIT J PHYTOTHERAPY, V4, P34; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001; Zwicky JF, 1993, READERS GUIDE ALTERN; 1996, NY TIMES        1009, pA11; 1997, J MIND BODY HLTH, V13, P79; 1990, CAN MED ASSOC J, V143, P1009; 1995, MMWR-MORBID MORTAL W, V44, P41; 1997, INNOVIOSN COMMUNICAT, V3, P125; 1997, UPC C TRAIN SEM ALT, V3, P72; 1993, MMWR-MORBID MORTAL W, V42, P521	116	299	303	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					61	69		10.7326/0003-4819-127-1-199707010-00010	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214254				2022-12-28	WOS:A1997XG91400009
J	Alderson, P; Roberts, I				Alderson, P; Roberts, I			Corticosteroids in acute traumatic brain injury: Systematic review of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; CLINICAL-TRIAL; DEXAMETHASONE THERAPY; MANAGEMENT; STEROIDS	Objective: To quantify the effectiveness and safety of corticosteroids in the treatment of acute traumatic brain injury. Design: Systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury. Summary odds ratios were estimated as an inverse variance weighted average of the odds ratios for each study. Setting: Randomised trials available by March 1996. Subjects: The included trials with outcome data comprised 2073 randomised participants. Results: The effect of corticosteroids on the risk of death was reported in 13 included trials. The pooled odds ratio for the 13 trials was 0.91 (95% confidence interval 0.74 to 1.12). Pooled absolute risk reduction was 1.8% (-2.5% to 5.7%). For the 10 trials that reported death or disability the pooled odds ratio was 0.90 (0.72 to 1.11). For infections of any type the pooled odds ratio was 0.92 (0.69 to 1.23) and for the seven trials reporting gastrointestinal bleeding it was 1.05 (0.44 to 2.52). With only those trials with the best quality of concealment of allocation, the pooled odds ratio estimates for death and death or disability became closer to unity. Conclusions: This systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury shows that there remains considerable uncertainty over their effects. Neither moderate benefits nor moderate harmful effects can be excluded. The widely practicable nature of the drugs and the importance of the health problem suggest that large simple trials are feasible and worth while to establish whether there are any benefits from use of corticosteroids in this setting.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Alderson, P (corresponding author), UK COCHRANE CTR,NHS RES & DEV PROGRAMME,OXFORD OX2 7LG,ENGLAND.							ALEXANDER E, 1972, CLIN NEUROSURG, V19, P210; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; *CDCP, 1996, EP INF  VERS 6 03; *COCHR COLL, 1996, COCHR LIB DAT DISK C; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FANCONI S, 1988, INTENS CARE MED, V14, P163; Faupel G, 1976, DYNAMICS BRAIN EDEMA, P337; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hernesniemi J, 1979, Acta Neurochir Suppl (Wien), V28, P499; HOYT HJ, 1972, PHARMACOL THERAPEUT, V13, P141; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kraus JF, 1993, HEAD INJURY, P1; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; Murray C.J, 1994, GLOBAL COMP ASSESSME; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P638; Ransohoff J, 1972, STEROIDS BRAIN EDEMA, P211; ROBERTS I, 1995, BRIT MED J, V310, P1311, DOI 10.1136/bmj.310.6990.1311; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TAHARA I, 1972, NEUROL MED CHIR TOKY, V12, P111; *TASK FORC AM ASS, 1995, GUID MAN SEV HEAD IN; *UPD SOFTW, 1996, REVM VERS 3 0 WIND; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Zagara G, 1987, J Neurosurg Sci, V31, P207	35	111	117	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1855	1859		10.1136/bmj.314.7098.1855	http://dx.doi.org/10.1136/bmj.314.7098.1855			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224126	Green Published			2022-12-28	WOS:A1997XH73800018
J	Ferguson, JD; Banning, AP; Bashir, Y				Ferguson, JD; Banning, AP; Bashir, Y			Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters	LANCET			English	Article									JOHN RADCLIFFE HOSP,DEPT CARDIOL,OXFORD OX3 9DU,ENGLAND	University of Oxford			banning, adrian p/AAF-7229-2021	Banning, Adrian/0000-0002-2842-7861				BARTECCHI CE, 1990, TEMPORARY CARDIAC PA; FITZPATRICK A, 1992, BRIT MED J, V304, P365, DOI 10.1136/bmj.304.6823.365; LAN R, 1981, PAE, V4, P491; Murphy JJ, 1996, BRIT MED J, V312, P1134; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161	5	24	25	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1883	1883		10.1016/S0140-6736(97)24026-2	http://dx.doi.org/10.1016/S0140-6736(97)24026-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217762				2022-12-28	WOS:A1997XG41700013
J	Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR				Chao, QM; Rothenberg, M; Solano, R; Roman, G; Terzaghi, W; Ecker, JR			Activation of the ethylene gas response pathway in Arabidopsis by the nuclear protein ETHYLENE-INSENSITIVE3 and related proteins	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; MAP KINASE CASCADE; 2-COMPONENT REGULATORS; MUTANT ARABIDOPSIS; WILD-TYPE; YEAST; THALIANA; GENE; PLANTS	Mutations in the Arabidopsis ETHYLENE-INSENSITIVE3 (EIN3) gene severely limit a plant's response to the gaseous hormone ethylene. ein3 mutants show a loss of ethylene-mediated effects including gene expression, the triple response, cell growth inhibition, and accelerated senescence. EIN3 acts downstream of the histidine kinase ethylene receptor, ETR1, and the Raf-like kinase, CTR1. The EIN3 gene encodes a novel nuclear-localized protein that shares sequence similarity, structural features, and genetic function with three EIN3-LIKE (EIL) proteins. In addition to EIN3, EIL1 or EIL2 were able to complement ein3, suggesting their participation in the ethylene signaling pathway. Overexpression of EIN3 or EIL2 in wild-type or ethylene-insensitive2 plants conferred constitutive ethylene phenotypes, indicating their sufficiency for activation of the pathway in the absence of ethylene.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Ecker, Joseph R/B-9144-2008; Roman, Gregg/W-1586-2019; Solano, Roberto/O-5908-2017	Ecker, Joseph R/0000-0001-5799-5895; Roman, Gregg/0000-0003-1519-4699; Solano, Roberto/0000-0001-5459-2417; Terzaghi, William/0000-0002-7536-6432	NIGMS NIH HHS [1F32GM18003-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Abeles F, 1992, ETHYLENE PLANT BIOL; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; Chang C, 1996, TRENDS BIOCHEM SCI, V21, P129, DOI 10.1016/0968-0004(96)10019-0; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Darwin CR., 1881, POWER MOVEMENT PLANT; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GOESCHL JD, 1966, PLANT PHYSIOL, V41, P877, DOI 10.1104/pp.41.5.877; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIEBER JJ, 1993, TRENDS GENET, V9, P356, DOI 10.1016/0168-9525(93)90041-F; KNIGHT LI, 1910, SCIENCE, V31, P635; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAWTON KA, 1994, PLANT CELL, V6, P581, DOI 10.1105/tpc.6.5.581; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN R, 1982, PLANT PHYSIOL, V69, P1376, DOI 10.1104/pp.69.6.1376; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Orzaez D, 1997, PLANT J, V11, P137, DOI 10.1046/j.1365-313X.1997.11010137.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Penmetsa RV, 1997, SCIENCE, V275, P527, DOI 10.1126/science.275.5299.527; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROMAN G, 1995, GENETICS, V139, P1393; Rothenberg M, 1993, SEMIN DEV BIOL, V4, P3, DOI [10.1006/sedb.1993.1002, DOI 10.1006/SEDB.1993.1002]; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; Terzaghi WB, 1997, PLANT J, V11, P967, DOI 10.1046/j.1365-313X.1997.11050967.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WEIGEL D, 1995, PLANT CELL, V7, P338; ZHOU JM, 1993, PLANT MOL BIOL, V22, P517, DOI 10.1007/BF00015980	55	719	809	6	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1133	1144		10.1016/S0092-8674(00)80300-1	http://dx.doi.org/10.1016/S0092-8674(00)80300-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215635	hybrid			2022-12-28	WOS:A1997XG83000017
J	Dennis, PP				Dennis, PP			Ancient ciphers: Translation in Archaea	CELL			English	Review									UNIV BRITISH COLUMBIA,CANADIAN INST ADV RES,PROGRAM EVOLUTIONARY BIOL,VANCOUVER,BC V6T 1Z3,CANADA	Canadian Institute for Advanced Research (CIFAR); University of British Columbia	Dennis, PP (corresponding author), UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA.							Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; HANNER M, 1994, J BACTERIOL, V176, P409, DOI 10.1128/JB.176.2.409-418.1994; POTTER S, 1995, SCIENCE, V268, P1056, DOI 10.1126/science.7538698; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; Wilting R., 1997, Journal of Molecular Biology, V266, P637, DOI 10.1006/jmbi.1996.0812	6	139	143	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1007	1010		10.1016/S0092-8674(00)80288-3	http://dx.doi.org/10.1016/S0092-8674(00)80288-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215623	Bronze			2022-12-28	WOS:A1997XG83000005
J	Wang, J; Sattar, AKMA; Wang, CC; Karam, JD; Konigsberg, WH; Steitz, TA				Wang, J; Sattar, AKMA; Wang, CC; Karam, JD; Konigsberg, WH; Steitz, TA			Crystal structure of a pol alpha family replication DNA polymerase from bacteriophage RB69	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COMPLETE NUCLEOTIDE-SEQUENCE; AMINO-ACID MOTIF; REVERSE-TRANSCRIPTASE; CONSERVED REGION; ACTIVE-SITE; EXONUCLEASE ACTIVITY; DEOXYNUCLEOSIDE TRIPHOSPHATE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION	The 2.8 Angstrom resolution crystal structure of the bacteriophage RB69 gp43, a member of the eukaryotic pol alpha family of replicative DNA polymerases, shares some similarities with other polymerases but shows many differences. Although its palm domain has the same topology as other polymerases, except rat DNA polymerase beta, one of the three carboxylates required for nucleotidyl transfer is located on a different beta strand. The structures of the fingers and thumb domains are unrelated to all other known polymerase structures. The editing 3'-5' exonuclease domain of gp43 is homologous to that of E. coli DNA polymerase I but lies on the opposite side of the polymerase active site. An extended structure-based alignment of eukaryotic DNA polymerase sequences provides structural insights that should be applicable to most eukaryotic DNA polymerases.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA	Yale University; Howard Hughes Medical Institute; Yale University; Tulane University	Wang, J (corresponding author), YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06520 USA.		Steitz, Thomas A./C-6559-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12607, GM18842, GM54627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VISION 3 1 SYS; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONG Q, 1995, J BIOL CHEM, V270, P21563, DOI 10.1074/jbc.270.37.21563; DONG Q, 1993, J BIOL CHEM, V268, P24163; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; GIBBS JS, 1985, P NATL ACAD SCI USA, V82, P7969, DOI 10.1073/pnas.82.23.7969; GOODRICH LD, 1997, IN PRESS BIOCHEMISTR; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; HUANG WM, 1972, J BIOL CHEM, V247, P3139; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; JUNG G, 1987, P NATL ACAD SCI USA, V84, P8287, DOI 10.1073/pnas.84.23.8287; JUNG GH, 1990, BIOCHEM BIOPH RES CO, V170, P1294, DOI 10.1016/0006-291X(90)90534-T; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; LI QH, 1993, P NATL ACAD SCI USA, V90, P4299, DOI 10.1073/pnas.90.9.4299; LIN TC, 1994, J BIOL CHEM, V269, P19286; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRIESTLE JP, 1991, J APPL CRYSTALLOGR, V24, P946; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; ROBISON MM, 1991, CURR GENET, V19, P495, DOI 10.1007/BF00312742; SANKAR S, 1992, J BIOL CHEM, V267, P10168; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; SAVILAHTI H, 1987, GENE, V57, P121, DOI 10.1016/0378-1119(87)90183-1; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; Yue DX, 1996, RNA, V2, P895; ZHU WG, 1994, BBA-GENE STRUCT EXPR, V1219, P260, DOI 10.1016/0167-4781(94)90047-7	75	400	419	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1087	1099		10.1016/S0092-8674(00)80296-2	http://dx.doi.org/10.1016/S0092-8674(00)80296-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215631	hybrid			2022-12-28	WOS:A1997XG83000013
J	Adachi, JD; Bensen, WG; Brown, J; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; SteMarie, LG; Tenenhouse, A; Chines, AA				Adachi, JD; Bensen, WG; Brown, J; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; SteMarie, LG; Tenenhouse, A; Chines, AA			Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCED BONE LOSS; CYCLICAL ETIDRONATE; CALCIUM; WOMEN	Background and Methods Osteoporosis is a recognized complication of corticosteroid therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, placebo-controlled study of intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles, in 141 men and women (age, 19 to 87 years) who had recently begun high-dose corticosteroid therapy. The primary outcome measure was the difference in the change in the bone density of the lumbar spine between the groups from base line to week 52. Secondary measures included changes in the bone density of the femoral neck, trochanter, and radius and the rate of new vertebral fractures. Results The mean (+/-SE) bone density of the lumbar spine and trochanter in the etidronate group increased 0.61+/-0.54 and 1.46+/-0.67 percent, respectively, as compared with decreases of 3.23+/-0.60 and 2.74+/-0.66 percent, respectively, in the placebo group. The mean differences between the groups after one year were 3.72+/-0.88 percentage points for the lumbar spine (P = 0.02) and 4.14+/-0.94 percentage points for the trochanter (P = 0.02). The changes in the femoral neck and the radius were not significantly different between the groups. There was an 85 percent reduction in the proportion of postmenopausal women with new vertebral fractures in the etidronate group as compared with the placebo group (1 of 31 patients vs. 7 of 32 patients, P = 0.05), and the etidronate-treated postmenopausal women also had significantly fewer vertebral fractures per patient (P = 0.04). Conclusions Intermittent etidronate therapy prevents the loss of vertebral and trochanteric bone in corticosteroid-treated patients. (C) 1997, Massachusetts Medical Society.	MCMASTER UNIV, ST JOSEPHS HOSP, DEPT MED, HAMILTON, ON, CANADA; CHU LAVAL, Ste Foy, PQ, CANADA; UNIV CALGARY, FOOTHILLS HOSP, CALGARY, AB T2N 1N4, CANADA; UNIV WESTERN ONTARIO, ST JOSEPHS HOSP, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, VICTORIA GEN HOSP, LONDON, ON, CANADA; UNIV TORONTO, TORONTO GEN HOSP, TORONTO, ON M5G 1L7, CANADA; UNIV TORONTO, ST MICHAELS HOSP, TORONTO, ON M5B 1W8, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER GEN HOSP, VANCOUVER, BC V5Z 1M9, CANADA; UNIV SASKATCHEWAN, ST PAULS HOSP, SASKATOON, SK, CANADA; UNIV MONTREAL, HOP ST LUC, MONTREAL, PQ, CANADA; MCGILL UNIV, MONTREAL GEN HOSP, MONTREAL, PQ H3G 1A4, CANADA; PROCTER & GAMBLE CO, CINCINNATI, OH USA; UNIV OTTAWA, OTTAWA GEN HOSP, OTTAWA, ON K1N 6N5, CANADA; UNIV TORONTO, ST MICHAELS HOSP, TORONTO, ON M5B 1W8, CANADA; UNIV TORONTO, TORONTO GEN HOSP, TORONTO, ON M5G 1L7, CANADA; QUEENS UNIV, ST MARYS LAKE HOSP, KINGSTON, ON, CANADA; DALHOUSIE UNIV, VICTORIA GEN HOSP, HALIFAX, NS B3H 3J5, CANADA; UNIV WESTERN ONTARIO, VICTORIA GEN HOSP, LONDON, ON N6A 3K7, CANADA	McGill University; McMaster University; Laval University; University of Calgary; McGill University; Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; Universite de Montreal; McGill University; Procter & Gamble; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Queens University - Canada; Dalhousie University; University of Victoria; University of Victoria; Western University (University of Western Ontario)			Pope, Janet/G-3342-2011; Hodsman, Anthony/G-3303-2011	Pope, Janet/0000-0003-1479-5302; Brown, Jacques/0000-0003-1910-788X				ADACHI JD, 1994, J RHEUMATOL, V21, P1922; Chesnut CH, 1997, AM J MED, V102, P29, DOI 10.1016/S0002-9343(96)00387-7; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; FOGELMAN I, 1986, CLIN ENDOCRINOL, V24, P57, DOI 10.1111/j.1365-2265.1986.tb03254.x; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GENNARI C, 1990, OSTEOPOROSIS 1990, P1529; Healey JH, 1996, CALCIFIED TISSUE INT, V58, P73, DOI 10.1007/s002239900014; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MILLER PD, 1993, J BONE MINER RES, V8, pS338; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; MULDER H, 1992, BONE MINER S1, V7, pS331; RITCHIE DM, 1968, Q J MED, V37, P393; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; Sebaldt RJ, 1996, SCAND J RHEUMATOL, P91; SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026-0495(83)90221-4; Van Kuijk Cornelis, 1995, P249	18	588	597	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					382	387		10.1056/NEJM199708073370603	http://dx.doi.org/10.1056/NEJM199708073370603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241127				2022-12-28	WOS:A1997XP40700003
J	Nightingale, SL				Nightingale, SL			Public health advisory on protease inhibitors for HIV treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-28	WOS:A1997XN51800009
J	Simon, JD				Simon, JD			Biological terrorism - Preparing to meet the threat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The threat of terrorists using biological warfare agents has received increased attention in recent years. Despite the hope that, with the right mix oi policies, security measures, and intelligence gathering, a major biological warfare terrorist attack can be prevented, the history of conventional terrorism indicates otherwise. The greatest payoff in combating biological terrorism lies in focusing on how best to respond to a terrorist attack. The medical and emergency service communities will play the most important role in that process. Ensuring that they are trained to recognize the symptoms of diseases caused by biological warfare agents and have Critical Incident Stress Debriefing teams available to help them cope with the emotional aspects of treating exposed survivors should be part of contingency planning. By improving our readiness to respond to biological terrorism, many lives can be saved and terrorists denied their goal of creating panic and crisis throughout the country.			Simon, JD (corresponding author), POLIT RISK ASSESSMENT CO INC,OFF PRESIDENT,POB 82,SANTA MONICA,CA 90406, USA.		Telch, Michael J/E-7027-2010					ANDREW C, 1990, KGB INSIDE STORY, P644; Bailey Kathleen C., 1991, DOOMSDAY WEAPONS HAN; Burns C, 1993, J Emerg Nurs, V19, P431; Flanagin A, 1996, JAMA-J AM MED ASSOC, V276, P419; *G7, 1996, DECL TERR; Kahn H., 1962, THINKING UNTHINKABLE; KUPPERMAN RH, 1993, BIOL WEAPONS WEAPONS, P35; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Mitchell J. T., 1996, CRITICAL INCIDENT ST; SIMON JD, 1996, BOSTON GLOBE    0419, P19; Simon Jeffrey D, 1994, TERRORIST TRAP AM EX; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V274, P11; SOPKO JF, 1996, FOREIGN POLICY, V105, P3; Stephenson J, 1996, JAMA-J AM MED ASSOC, V276, P349, DOI 10.1001/jama.1996.03540050009003; *US ARM MED RES I, 1993, MED MAN BIOL CAS HDB, P92; *US C OFF TECHN AS, 1993, 559 OTA ISC US C; *US C OFF TECHN AS, 1993, 115 OTA BP ISC US C	17	61	61	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					428	430		10.1001/jama.278.5.428	http://dx.doi.org/10.1001/jama.278.5.428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244336				2022-12-28	WOS:A1997XN51800036
J	Cook, DJ; Greengold, NL; Ellrodt, AG; Weingarten, SR				Cook, DJ; Greengold, NL; Ellrodt, AG; Weingarten, SR			The relation between systematic reviews and practice guidelines	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; UPPER GASTROINTESTINAL HEMORRHAGE; MEDICAL LITERATURE; USERS GUIDES; ESOPHAGEAL-VARICES; RANDOMIZED TRIALS; RECOMMENDATIONS; METAANALYSIS; SCLEROTHERAPY; PREVENTION	Clinical practice guidelines have been developed to improve the process and outcomes of health care and to optimize resource utilization. By addressing such issues as prevention, diagnosis, and treatment, they can aid in health care decision making at many levels. Several other decision aids are cast in the guideline lexicon, regardless of their focus, formulation, or format; this can foster misunderstanding of the term ''guideline.'' Whether created or adapted locally or nationally, most guidelines are an amalgam of clinical experience, expert opinion, and research evidence. Approaches to practice guideline development vary widely. Given the resources required to identify all relevant primary studies, many guidelines rely on systematic reviews that were either previously published or created de novo by guideline developers. Systematic reviews can aid in guideline development because they involve searching for, selecting, critically appraising, and summarizing the results of primary research. The more rigorous the review methods used and the higher the quality of the primary research that is synthesized, the more evidence-based the practice guideline is likely to be. Summaries of relevant research incorporated into guideline documents can help to keep practitioners up to date with the literature. Systematic reviews have also been published on the dissemination and implementation strategies most likely to change clinician behavior and improve patient outcomes. These can be useful in more effectively translating research evidence into practice.	CEDARS SINAI MED CTR, DEPT MED, LOS ANGELES, CA 90048 USA; CEDARS SINAI MED CTR, DEPT APPL HLTH SERV RES, LOS ANGELES, CA 90048 USA; CEDARS SINAI MED CTR, DEPT MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90048 USA; MCMASTER UNIV, FAC HLTH SCI, HAMILTON, ON, CANADA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; McMaster University								AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; Cello JP, 1997, ANN INTERN MED, V126, P858, DOI 10.7326/0003-4819-126-11-199706010-00002; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; CRAWFORD MH, 1997, CLIN PRACTICE GUIDEL, V10; Dalkey NC, 1969, PUBLICATION RAND COR; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DEIGNAN M, 1995, PATIENT FOCUSED CARE; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; FARDY JM, 1994, AM J GASTROENTEROL, V89, P1938; Field MJ, 1990, CLIN PRACTICE GUIDEL; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; George JN, 1997, ANN INTERN MED, V126, P319; George JN, 1997, ANN INTERN MED, V126, P317, DOI 10.7326/0003-4819-126-4-199702150-00009; GOTZSCHE PC, 1995, BRIT MED J, V310, P1495, DOI 10.1136/bmj.310.6993.1495; Greengold NL, 1996, JOINT COMM J QUAL IM, V22, P391, DOI 10.1016/S1070-3241(16)30242-5; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HANDLEY MR, 1994, HMO PRACTICE, P10; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; HAY JA, 1995, AM J GASTROENTEROL, V90, P1661; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; JASTREMSKI MS, 1993, CRIT CARE MED, V21, P931; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KENT DL, 1994, ANN INTERN MED, V120, P872; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; LAINE L, 1995, ANN INTERN MED, V123, P280, DOI 10.7326/0003-4819-123-4-199508150-00007; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Lomas J, 1993, Int J Technol Assess Health Care, V9, P11; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; SCHOENBAUM SC, 1995, AHCPR PUBLICATION; STEIN PD, 1995, CHEST, V108, pS371, DOI 10.1378/chest.108.4_Supplement.371S; Sung JJY, 1995, LANCET, V346, P1666, DOI 10.1016/S0140-6736(95)92840-5; Thijs LG, 1996, INTENS CARE MED, V22, P166; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; VANRUISWYK J, 1992, GASTROENTEROLOGY, V102, P587, DOI 10.1016/0016-5085(92)90107-A; Villanueva C, 1996, NEW ENGL J MED, V334, P1624, DOI 10.1056/NEJM199606203342502; WALT RP, 1992, LANCET, V340, P1058, DOI 10.1016/0140-6736(92)93078-2; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811	58	266	278	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					210	216		10.7326/0003-4819-127-3-199708010-00006	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245227				2022-12-28	WOS:A1997XN12900006
J	Eckman, MH; Steere, AC; Kalish, RA; Pauker, SG				Eckman, MH; Steere, AC; Kalish, RA; Pauker, SG			Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROLOGIC MANIFESTATIONS; CEFTRIAXONE THERAPY; PERSONAL-COMPUTER; DECISION-ANALYSIS; BORRELIOSIS; NEUROBORRELIOSIS; DOXYCYCLINE; NEUROPATHY; PENICILLIN; TRIAL		TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,DIV RHEUMATOL,BOSTON,MA 02111	Tufts Medical Center	Eckman, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,DIV CLIN DECIS MAKING,BOX 302,750 WASHINGTON ST,BOSTON,MA 02111, USA.			Eckman, Mark/0000-0001-8253-269X; Steere, Allen/0000-0002-5268-9853	PHS HHS [CCU110291] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAPERTON EM, 1990, ARCH INTERN MED, V150, P1677, DOI 10.1001/archinte.150.8.1677; CHUA C T, 1979, SMJ Singapore Medical Journal, V20, P406; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1987, ARTHRITIS RHEUM, V30, P448, DOI 10.1002/art.1780300414; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; GELMAN CR, 1992, DOXYCYCLINE DRUG EVA, V72; GORBACH SL, 1974, NEW ENGL J MED, V290, P1289, DOI 10.1056/NEJM197406062902305; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; LOGIGIAN EL, 1996, 7 INT C LYM BORR SAN; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MOSKOVITZ BL, 1984, AM J MED, V77, P84; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSENBERG JM, 1984, AM J SURG, V147, P486, DOI 10.1016/0002-9610(84)90010-2; SCHEIFE RT, 1976, DRUG EFFECTS HOSPITA, P263; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SMILACK JD, 1991, MAYO CLIN PROC, V66, P1270, DOI 10.1016/S0025-6196(12)62479-3; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STRICKLAND GT, 1994, PUBLIC HEALTH REP, V109, P745; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; 1993, MMWR-MORBID MORTAL W, V42, P39	35	39	40	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					357	363		10.1056/NEJM199707313370525	http://dx.doi.org/10.1056/NEJM199707313370525			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233874				2022-12-28	WOS:A1997XN11900032
J	Schievink, WI				Schievink, WI			A surgeon with a nasty taste in his mouth	LANCET			English	Article									MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,ROCHESTER,MN 55905	Mayo Clinic								Deems DA, 1996, ARCH OTOLARYNGOL, V122, P961; Lawrence C, 1996, LANCET, V348, P1102, DOI 10.1016/S0140-6736(05)64449-2; Leys D, 1997, EUR NEUROL, V37, P3, DOI 10.1159/000117396; Mokri B, 1996, NEUROLOGY, V46, P356, DOI 10.1212/WNL.46.2.356; SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889	5	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					260	260		10.1016/S0140-6736(97)03403-X	http://dx.doi.org/10.1016/S0140-6736(97)03403-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242804				2022-12-28	WOS:A1997XM86600014
J	Bronowicki, JP; Venard, V; Botte, C; Monhoven, N; Gastin, I; Chone, L; Hudziak, H; Rhin, B; Delanoe, C; LeFaou, A; Bigard, MA; Gaucher, P				Bronowicki, JP; Venard, V; Botte, C; Monhoven, N; Gastin, I; Chone, L; Hudziak, H; Rhin, B; Delanoe, C; LeFaou, A; Bigard, MA; Gaucher, P			Patient-to-patient transmission of hepatitis C virus during colonoscopy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFECTION; ENDOSCOPY; GENOME; AREA		FAC MED,SERV HEPATOGASTROENTEROL,VANDOEUVRE NANCY,FRANCE; FAC MED,MICROBIOL LAB,VANDOEUVRE NANCY,FRANCE; FAC MED,ESTAB TRANSFUS SANGUINE,VANDOEUVRE NANCY,FRANCE; FAC MED,LAB COMMUN BIOL MOL,VANDOEUVRE NANCY,FRANCE; FAC MED,LAB PATHOL CELLULAIRE & MOL NUTR,VANDOEUVRE NANCY,FRANCE	Universite de Lorraine; Universite de Lorraine; Universite de Lorraine; Universite de Lorraine; Universite de Lorraine	Bronowicki, JP (corresponding author), CHU NANCY,SERV HEPATOGASTROENTEROL,F-54500 VANDOEUVRE NANCY,FRANCE.							ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; ANDRIEU J, 1995, GASTROEN CLIN BIOL, V19, P340; AXON ATR, 1991, J GASTROEN HEPATOL, V6, P23, DOI 10.1111/j.1440-1746.1991.tb01138.x; BIRNIE GG, 1983, GUT, V24, P171, DOI 10.1136/gut.24.2.171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KEMPEN PM, 1990, CAN J ANESTH, V37, P730; KIYOSAWA K, 1994, GASTROENTEROLOGY, V106, P1596, DOI 10.1016/0016-5085(94)90416-2; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; PARLOW JL, 1989, CAN J ANAESTH, V36, pS61; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; REY JF, 1995, GASTROEN CLIN BIOL, V19, P346; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1002/hep.1840210243; SPACH DH, 1993, ANN INTERN MED, V118, P117, DOI 10.7326/0003-4819-118-2-199301150-00008; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TENNENBAUM R, 1993, GASTROEN CLIN BIOL, V17, P763; TREPANIER CA, 1990, CAN J ANAESTH, V37, P156, DOI 10.1007/BF03005462; *WORK PART BRIT SO, 1988, GUT, V29, P1134; 1988, GASTROINTEST ENDOS S, V34, pS37	23	308	327	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					237	240		10.1056/NEJM199707243370404	http://dx.doi.org/10.1056/NEJM199707243370404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227929	Bronze			2022-12-28	WOS:A1997XL99400004
J	Simmons, D				Simmons, D			NIDDM and breastfeeding	LANCET			English	Editorial Material							1ST YEAR; LIFE				Simmons, D (corresponding author), MIDDLEMORE HOSP,S AUCKLAND ACAD DIV,AUCKLAND 6,NEW ZEALAND.			Simmons, David/0000-0003-0560-0761				FORMAN MR, 1984, AM J EPIDEMIOL, V119, P335, DOI 10.1093/oxfordjournals.aje.a113752; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; FORMAN MR, 1982, AM J CLIN NUTR, V35, P1477, DOI 10.1093/ajcn/35.6.1477; Gohdes D., 1995, DIABETES AM, V2nd; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; STARBIRD EH, 1991, SOC SCI MED, V33, P627, DOI 10.1016/0277-9536(91)90221-W; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	7	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					157	158		10.1016/S0140-6736(05)62345-8	http://dx.doi.org/10.1016/S0140-6736(05)62345-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250178				2022-12-28	WOS:A1997XL72200004
J	Wilson, SJ; Lillywhite, AR; Potokar, JP; Bell, CJ; Nutt, DJ				Wilson, SJ; Lillywhite, AR; Potokar, JP; Bell, CJ; Nutt, DJ			Adult night terrors and paroxetine	LANCET			English	Article									UNIV BRISTOL,SCH MED SCI,PSYCHOPHARMACOL UNIT,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								COOPER AJ, 1987, J CLIN PSYCHIAT, V48, P209; JENCK F, 1995, PSYCHIAT RES, V57, P181, DOI 10.1016/0165-1781(95)02673-K; KALES JD, 1982, AM J PSYCHOTHER, V36, P399, DOI 10.1176/appi.psychotherapy.1982.36.3.399; NAHOLD BS, 1969, J NEUROSURG, V30, P14; Schenck CH, 1996, AM J MED, V100, P333, DOI 10.1016/S0002-9343(97)89493-4	5	22	22	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					185	185		10.1016/S0140-6736(05)62351-3	http://dx.doi.org/10.1016/S0140-6736(05)62351-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL722	9250190				2022-12-28	WOS:A1997XL72200017
J	Annas, GJ				Annas, GJ			Patients' rights in managed care - Exit, voice, and choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1974, VANDERBILT LAW REV, V27, P243; [Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; *BNA, 1996, BNAS HLTH LAW R 1107, P1631; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; CHASE M, 1997, WALL ST J       0929, pB1; GAYNOR P, 1997, PITTSBURGH POST 0202, pC21; *HCFA, 1996, BNAS MANAGED CA 1211, P1159; HILTZIK MA, 1995, LOS ANGELES TIM 0827, pA1; Kinney ED, 1996, AM J LAW MED, V22, P301; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1319; 1997, CHASREG, V62, P23368	13	38	39	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					210	215		10.1056/NEJM199707173370323	http://dx.doi.org/10.1056/NEJM199707173370323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219710	Green Published			2022-12-28	WOS:A1997XK81800030
J	Benn, CS; Aaby, PA; Bale, C; Olsen, J; Michaelsen, KF; George, N; Whittle, H				Benn, CS; Aaby, PA; Bale, C; Olsen, J; Michaelsen, KF; George, N; Whittle, H			Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa	LANCET			English	Article							CHILDREN; TETANUS; AGE	Background WHO has recommended vitamin A supplementation for children aged 6 months or older in developing countries at the same time as immunisation. One study has reported significantly lower seroconversion ratios among children who have received vitamin A supplements with measles vaccine at age 6 months. The aim of our study was to assess the effect of Vitamin A supplementation on antibody response to measles vaccination at age 9 months, which is the more common age for immunisation in developing countries. Methods In an urban community in Guinea-Bissau, we did a randomised, double-blind, placebo-controlled study of the effect of simultaneous Vaccination and vitamin A supplementation in 462 children who received either a two-dose schedule of measles vaccine at the ages of 6 months and 9 months (150 infants) or one dose of measles vaccine at age 9 months (312 infants). Children were followed up to the age of 18 months and a blood sample was then collected to assess the antibody response. Findings 397 (86%) of the children took part in the follow-up (52 [11%] had moved and 13 [3%] had died). Among children who received a two-dose vaccine schedule, seroconversion was 98%. There was no difference in seroconversion or geometric mean titre (GMT) for children receiving vitamin A compared with children receiving no supplement. Among children receiving only one dose of measles vaccine at age 9 months, seroconversion was 95%. The GMT was significantly higher in children receiving vitamin A than in those receiving no supplement (3704 vs 2439 mIU; GMT ratio 1.52 [1.22-1.88]). The effect on plasma antibody concentration in the blood was stronger for boys (3902 vs 1916 mIU; GMT ratio 2.04 [1.53-2.72]) than for girls (3502 vs 3017 mIU; GMT ratio 1.16 [0.85-1.58]) who had received Vitamin A with measles vaccine, In a multivariate analysis of variance adjusted for sex, vitamin A supplementation was associated with higher antibody titres (p<0.001). There was a significant interaction between vitamin A supplementation and sex (p=0.02). Interpretation There is no indication that simultaneous administration of measles vaccine and vitamin A supplements has a negative effect on measles immunity. Among the children who had received two doses of measles vaccine at the ages of 6 months and 9 months, supplements of vitamin A had no significant effect. Among children only receiving one dose of measles Vaccine at age 9 months, 100 000 IU vitamin A increased antibody concentrations, especially for boys.	PROJECTO SAUDE DE BANDIM,BISSAU,GUINEA BISSAU; STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN S,DENMARK; ROYAL VET & AGR UNIV,RES DEPT HUMAN NUTR,COPENHAGEN,DENMARK; MRC LABS,FAJARA,GAMBIA	Aarhus University; Statens Serum Institut; University of Copenhagen; MRC Laboratory Molecular Biology				Aaby, Peter/0000-0001-8331-1389; Michaelsen, Kim F/0000-0003-0449-0839				AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1995, CROWDING HLTH LOW IN; BENN CS, 1995, LANCET, V346, P503; BROWN KH, 1980, AM J CLIN NUTR, V33, P212, DOI 10.1093/ajcn/33.2.212; FRIIS H, IN PRESS AM J CLIN N; JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9; KUTTY P M, 1981, Acta Vitaminologica et Enzymologica, V3, P231; MOLBAK K, 1994, BMJ-BRIT MED J, V308, P1403, DOI 10.1136/bmj.308.6941.1403; Molbak K, 1997, AM J CLIN NUTR, V65, P149, DOI 10.1093/ajcn/65.1.149; ROSS D, 1995, LANCET, V345, P1317, DOI 10.1016/S0140-6736(95)92531-7; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SEMBA RD, 1995, LANCET, V345, P1330; UZOECHINA ON, 1994, ANN TROP PAEDIATR, V14, P157, DOI 10.1080/02724936.1994.11747710; WHITTLE H, 1988, LANCET, V2, P811; WHO & INRUD, 1993, WHODAP931; YASSAI MB, 1989, J TROP PEDIATRICS, V35, P247, DOI 10.1093/tropej/35.5.247	17	106	107	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					101	105		10.1016/S0140-6736(96)12019-5	http://dx.doi.org/10.1016/S0140-6736(96)12019-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228962				2022-12-28	WOS:A1997XK11400010
J	Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G				Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G			Autoimmune enteropathy and villous atrophy in adults	LANCET			English	Article							EPITHELIAL-CELL AUTOANTIBODIES; SMALL-INTESTINE; CELIAC-DISEASE; PROTRACTED DIARRHEA; SPRUE; ANTIBODY; PATHOGENESIS; JEJUNUM; INFANCY	Background Autoimmune enteropathy is a condition described in children and characterised by villous atrophy, which is unresponsive to any dietary restrictions, and by the presence of enterocyte autoantibodies. We report two adult patients who fulfilled all the criteria for the diagnosis of this disorder. Methods Over the past 5 years we have seen four adult patients (all women, median age 51.5 [range 38-64] years) with subtotal villous atrophy, which was unresponsive to a gluten-free diet. The patients were HLA-DQ2 positive. IgA antigliadin and antiendomysial antibodies were not found in any of the patients. We did an indirect immunofluorescence search for enterocyte autoantibodies on monkey jejunum and for other autoantibodies for all four patients. Findings Of the four patients, two were positive for enterocyte autoantibodies and one of these two patients was positive for antiactin, antiparietal cell, and antithyroid microsomal autoantibodies. Interpretation To the best of our knowledge the two patients affected by severe enteropathy, who had never responded to any exclusion diet, and who were positive for enterocyte autoantibodies are the first cases of autoimmune enteropathy described in adults. We propose that adult patients whose disorders are unresponsive to a gluten-free diet should be tested for enterocyte autoantibodies.	UNIV BOLOGNA, DEPT INTERNAL MED, BOLOGNA, ITALY; CATHOLIC UNIV ROME, DEPT INTERNAL MED, ROME, ITALY	University of Bologna; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Corazza, GR (corresponding author), UNIV AQUILA, DEPT INTERNAL MED, VIA S SISTO 22E, I-67100 LAQUILA, ITALY.		Corazza, Gino Roberto/K-8500-2016; Biagi, Federico/G-2812-2011	Corazza, Gino Roberto/0000-0001-9532-0573; Biagi, Federico/0000-0002-2227-4622; De Franceschi, Lucia/0000-0003-1257-8101; Volta, Umberto/0000-0003-3405-3808				BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; CATASSI C, 1988, J PEDIATR GASTR NUTR, V7, P608, DOI 10.1097/00005176-198807000-00022; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; CORAZZA GR, 1985, J CLIN PATHOL, V38, P765, DOI 10.1136/jcp.38.7.765; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FERGUSON A, 1977, GUT, V18, P921, DOI 10.1136/gut.18.11.921; KATZ AJ, 1979, GASTROENTEROLOGY, V76, P375; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MARTINVILLA JM, 1991, GASTROENTEROLOGY, V101, P390, DOI 10.1016/0016-5085(91)90016-E; MARTINVILLA JM, 1993, LANCET, V342, P380, DOI 10.1016/0140-6736(93)91531-P; MCCARTHY DM, 1978, J IMMUNOL, V120, P932; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; MIRAKIAN R, 1988, J AUTOIMMUN, V1, P263, DOI 10.1016/0896-8411(88)90032-7; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; RUBIN CE, 1970, GASTROENTEROLOGY, V58, P409; SAVILAHTI E, 1985, ACTA PAEDIATR SCAND, V74, P472, DOI 10.1111/j.1651-2227.1985.tb11011.x; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; UNSWORTH DJ, 1985, J PEDIATR GASTR NUTR, V4, P375, DOI 10.1097/00005176-198506000-00009; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; WALKERSMITH JA, 1982, LANCET, V1, P566; WALKERSMITH JA, 1991, DEV GASTRO, V13, P131; WALL AJ, 1970, GUT, V11, P7, DOI 10.1136/gut.11.1.7	24	105	111	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					106	109		10.1016/S0140-6736(97)01042-8	http://dx.doi.org/10.1016/S0140-6736(97)01042-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228963				2022-12-28	WOS:A1997XK11400011
J	Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA				Carstea, ED; Morris, JA; Coleman, KG; Loftus, SK; Zhang, D; Cummings, C; Gu, J; Rosenfeld, MA; Pavan, WJ; Krizman, DB; Nagle, J; Polymeropoulos, MH; Sturley, SL; Ioannou, YA; Higgins, ME; Comly, M; Cooney, A; Brown, A; Kaneski, CR; BlanchetteMackie, EJ; Dwyer, NK; Neufeld, EB; Chang, TY; Liscum, L; Strauss, JF; Ohno, K; Zeigler, M; Carmi, R; Sokol, J; Markie, D; ONeill, RR; vanDiggelen, OP; Elleder, M; Patterson, MC; Brady, RO; Vanier, MT; Pentchev, PG; Tagle, DA			Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis	SCIENCE			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; DI-LEUCINE MOTIF; CULTURED FIBROBLASTS; STORAGE; ENDOCYTOSIS; LYSOSOMES; SITES	Niemann-Pick type C (NP-C) disease, a fatal neurovisceral disorder, is characterized by lysosomal accumulation of low density lipoprotein (LDL)-derived cholesterol. BY positional cloning methods, a gene (NPC1) with insertion, deletion, and missense mutations has been identified in NP-C patients. Transfection of NP-C fibroblasts with wild-type NPC1 cDNA resulted in correction of their excessive lysosomal storage of LDL cholesterol, thereby defining the critical role of NPC1 in regulation of intracellular cholesterol trafficking. The 1278-amino acid NPC1 protein has sequence similarity to the morphogen receptor PATCHED and the putative sterol-sensing regions of SREBP cleavage-activating protein (SCAP) and 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase.	NINCDS,NIH,BETHESDA,MD 20892; NIH,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; NIDDKD,NIH,BETHESDA,MD 20892; DARTMOUTH COLL,SCH MED,HANOVER,NH 03755; TUFTS UNIV,SCH MED,BOSTON,MA 02111; UNIV PENN,PHILADELPHIA,PA 19104; HADASSAH UNIV HOSP,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,IL-84105 BEER SHEVA,ISRAEL; HILLEL YAFFE MED CTR,HADERA,ISRAEL; DUNEDIN SCH MED,DUNEDIN,NEW ZEALAND; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS; FAC MED,PRAGUE,CZECH REPUBLIC; UNIV HOSP,PRAGUE,CZECH REPUBLIC; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; INSERM,U189,OULLINS,FRANCE; TOTTORI UNIV,FAC MED,YONAGO,TOTTORI 683,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Dartmouth College; Tufts University; University of Pennsylvania; Hebrew University of Jerusalem; Ben Gurion University; University of Otago; Erasmus University Rotterdam; General University Hospital Prague; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Tottori University			Patterson, Marc C./H-5331-2019; Markie, David/I-7893-2019; Patterson, Marc/AAI-5056-2020; Neufeld, Edward/R-3819-2019	Chang, Ta-Yuan/0000-0002-3249-0468; Markie, David/0000-0001-5452-9194; Pavan, William/0000-0001-8281-5120; Loftus, Stacie/0000-0002-1958-4689; Patterson, Marc/0000-0002-1116-126X; Kaneski, Christine/0000-0003-1453-2502				BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; CARSTEA ED, UNPUB; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GU JZ, IN PRESS P NATL ACAD; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Krizman D B, 1997, Methods Mol Biol, V68, P167; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; ORTGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Vanier MT, 1996, AM J HUM GENET, V58, P118; WANG X, 1994, CELL, V77, P52	30	1131	1174	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					228	231		10.1126/science.277.5323.228	http://dx.doi.org/10.1126/science.277.5323.228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211849	Green Submitted			2022-12-28	WOS:A1997XK41800042
J	Hales, KG; Fuller, MT				Hales, KG; Fuller, MT			Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase	CELL			English	Article							DROSOPHILA-MELANOGASTER; NUCLEOTIDE BINDING; ENCODED PROTEINS; LIVING CELLS; ORGANIZATION; ALIGNMENT; RETICULUM; DYNAMICS; MUSCLE; GENE	The Drosophila melanogaster fuzzy onions (fzo) gene encodes the first known protein mediator of mitochondrial fusion. During Drosophila spermatogenesis, mitochondria in early postmeiotic spermatids aggregate, fuse, and elongate beside the growing flagellar axoneme. fro mutant males are defective in this developmentally regulated mitochondrial fusion and are sterile. fro encodes a large, novel, predicted transmembrane GTPase that becomes detectable on spermatid mitochondria late in meiosis II, just prior to fusion, and disappears soon after fusion is complete. Missense mutations that alter conserved residues required for GTP binding in other GTPases inhibit the fusogenic activity of Fzo in vivo but do not affect its localization. Fzo has homologs of unknown function in mammals, nematodes, and yeast.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University				Fuller, Margaret T/0000-0002-3804-4987; Hales, Karen/0000-0001-8932-245X	NHGRI NIH HHS [HG00044] Funding Source: Medline; NICHD NIH HHS [1RO1-HD29194] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029194] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKEEVA LE, 1981, EUR J CELL BIOL, V25, P175; BAKEEVA LE, 1983, J MOL CELL CARDIOL, V15, P413, DOI 10.1016/0022-2828(83)90261-4; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANDT JT, 1974, BIOCHEM BIOPH RES CO, V59, P1097, DOI 10.1016/S0006-291X(74)80091-4; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; DER CJ, 1988, ONCOGENE, V3, P105; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Fuller Margaret T., 1993, P71; GAVEL Y, 1992, EUR J BIOCHEM, V205, P1207, DOI 10.1111/j.1432-1033.1992.tb16892.x; Gelbart WM, 1996, NUCLEIC ACIDS RES, V24, P53, DOI 10.1093/nar/24.1.53; GLICK B, 1991, ANNU REV GENET, V25, P21; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; HAYASHIDA Y, 1973, CYTOBIOLOGIE, V7, P289; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hime GR, 1996, J CELL SCI, V109, P2779; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kawano S, 1995, INT REV CYTOL, V161, P49; KIRKWOOD SP, 1986, AM J PHYSIOL, V251, pC395, DOI 10.1152/ajpcell.1986.251.3.C395; KRUGER JCD, 1991, J MORPHOL, V210, P163, DOI 10.1002/jmor.1052100206; LIN TY, 1996, KDEVELOPMENT, V122, P1331; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOHLER J, 1995, DEVELOPMENT, V121, P237; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OLSON GE, 1992, MOL REPROD DEV, V33, P89, DOI 10.1002/mrd.1080330113; PAL EF, 1990, EMBO J, V9, P2351; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; RANCOURT MW, 1975, J ULTRA MOL STRUCT R, V51, P418, DOI 10.1016/S0022-5320(75)80105-5; REUTER G, 1986, MOL GEN GENET, V202, P481, DOI 10.1007/BF00333281; ROBERTSON HM, 1988, GENETICS, V118, P461; Rothman JE, 1996, PROTEIN SCI, V5, P185; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer M, 1995, DEV BIOL, V172, P344, DOI 10.1006/dbio.1995.8049; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SKULACHEV VP, 1990, J MEMBRANE BIOL, V114, P97, DOI 10.1007/BF01869092; Smith DM, 1931, J MORPHOL, V52, P485, DOI 10.1002/jmor.1050520206; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; TAKANO H, 1994, CURR GENET, V26, P506, DOI 10.1007/BF00309941; Tates A.D., 1971, CYTODIFFERENTIATION; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thummel CS, 1992, DROS INF SERV, V71, P150; TOKUYASU KT, 1974, EXP CELL RES, V84, P239, DOI 10.1016/0014-4827(74)90402-9; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WARNOCK KDE, 1996, BIOESSAYS, V18, P885; ZOROV DB, 1990, BIOL MEMBRANY, V7, P243	56	452	482	3	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	1997	90	1					121	129		10.1016/S0092-8674(00)80319-0	http://dx.doi.org/10.1016/S0092-8674(00)80319-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230308	Bronze, Green Submitted			2022-12-28	WOS:A1997XL36200014
J	Vignes, M; Collingridge, GL				Vignes, M; Collingridge, GL			The synaptic activation of kainate receptors	NATURE			English	Article							LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; EXPRESSION; SUBUNIT; CLONING; CELLS; AMPA; CYCLOTHIAZIDE	L-Glutamate, the principal excitatory neurotransmitter in the vertebrate central nervous system, acts on three classes of ionotropic glutamate receptors, named after the agonists AMPA, NMDA and kainate(1). AMPA receptors are known to mediate fast synaptic responses and NMDA receptors to mediate slow synaptic responses at most excitatory synapses in the brain(2). Kainate receptors are formed from a separate set of genes (GluR5-7, KA-1 and KA-2) and are widely distributed throughout the brain(3-8). They are implicated in epileptogenesis and cell death(9). However, the physiological functions of kainate receptors are not known. The development of 2,3-benzodiazepine antagonists that are selective for AMPA receptors(10) enables kainate receptors to be specifically activated by exogenous ligands, such as kainate(11-16). Here we demonstrate that high-frequency stimulation of messy fibres in rat hippocampal slices, in the presence of the highly selective AMPA receptor antagonist GYKI 53655 (refs 13-15) plus NMDA- and GABA-receptor antagonists, activates an inward current in CA3 neurons that has a pharmacology typical of kainate receptors. The finding that kainate receptors can be activated synaptically adds to the diversity of information transfer at glutamatergic synapses.	UNIV BRISTOL, SCH MED SCI, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol			Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020; Vignes, Michel/AAA-7693-2019	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966				BAHN S, 1994, J NEUROSCI, V14, P5525; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Miller LDP, 1995, J NEUROSCI, V15, P8320; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Rammes G, 1996, BRIT J PHARMACOL, V117, P1209, DOI 10.1111/j.1476-5381.1996.tb16718.x; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; ROCHE KW, 1995, NEUROSCIENCE, V69, P383, DOI 10.1016/0306-4522(95)00253-F; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; TARNAWA I, 1990, AMINO ACIDS CHEM BIO, P538; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	30	353	358	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	1997	388	6638					179	182		10.1038/40639	http://dx.doi.org/10.1038/40639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217158	Bronze			2022-12-28	WOS:A1997XK10900051
J	Robinson, TD; Celermajer, DS; Bye, PTP				Robinson, TD; Celermajer, DS; Bye, PTP			How to stop ACE-inhibitor-induced cough	LANCET			English	Editorial Material							BRADYKININ		ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, SYDNEY, NSW 2030, AUSTRALIA	University of Sydney	Robinson, TD (corresponding author), ROYAL PRINCE ALFRED HOSP, DEPT RESP MED, SYDNEY, NSW 2030, AUSTRALIA.							Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; HARGREAVES M, 1992, CLIN SCI, V83, P399, DOI 10.1042/cs0830399; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; SESOKO S, 1985, ARCH INTERN MED, V145, P1524, DOI 10.1001/archinte.145.8.1524; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193	6	5	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	1997	350	9070					3	4		10.1016/S0140-6736(05)66234-4	http://dx.doi.org/10.1016/S0140-6736(05)66234-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217710				2022-12-28	WOS:A1997XH86900004
J	Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR				Bangsberg, D; Tulsky, JP; Hecht, FM; Moss, AR			Protease inhibitors in the homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; TUBERCULOSIS; COMMUNITY; RISK; RESISTANT; ADULTS; HIV; PREVALENCE; MANAGEMENT		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,AIDS RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hecht, Frederick/0000-0002-5782-1171	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55729] Funding Source: Medline; NIMH NIH HHS [MH54907, R01 MH054907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHE J, 1996, SAN FRANCISCO DEATH; *BHIVA GUID COORD, 1997, LANCET, V349, P1086; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUSH CT, 1990, HOSP COMMUNITY PSYCH, V41, P647; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; Fournier AM, 1996, AM J MED, V100, P582, DOI 10.1016/S0002-9343(95)00019-4; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P329; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; HANZLICK R, 1993, PUBLIC HEALTH REP, V108, P488; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LELAND J, 1996, NEWSWEEK        1202, P65; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Sontag Deborah, 1997, N Y Times Web, pB6; Stansell JD, 1997, AM J RESP CRIT CARE, V155, P60, DOI 10.1164/ajrccm.155.1.9001290; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Susser E, 1997, AM J PUBLIC HEALTH, V87, P256, DOI 10.2105/AJPH.87.2.256; THOMAS SB, 1991, AM J PUBLIC HEALTH, V81, P1498, DOI 10.2105/AJPH.81.11.1498; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WALDMAN A, 1997, WASHINGTON POST 0427, pCO1; Wilfert CM, 1996, CLIN INFECT DIS, V23, P438, DOI 10.1093/clinids/23.3.438; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	37	117	122	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					63	65		10.1001/jama.278.1.63	http://dx.doi.org/10.1001/jama.278.1.63			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG387	9207341				2022-12-28	WOS:A1997XG38700039
J	Xu, XZS; Li, HS; Guggino, WB; Montell, C				Xu, XZS; Li, HS; Guggino, WB; Montell, C			Coassembly of TRP and TRPL produces a distinct store-operated conductance	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; LIGHT-SENSITIVE CHANNELS; DROSOPHILA TRP; PLASMA-MEMBRANE; HUMAN HOMOLOG; K+ CHANNEL; T-CELLS; GENE; PHOTOTRANSDUCTION; PHOTORECEPTORS	The Drosophila retinal-specific protein, TRP (transient receptor potential), is the founding member of a family of store-operated channels (SOCs) conserved from C. elegans to humans. In vitro studies indicate that TRP is a SOC, but that the related retinal protein, TRPL, is constitutively active. In the current work, we report that coexpression of TRP and TRPL leads to a store-operated, outwardly rectifying current distinct from that owing to either TRP or TRPL alone. TRP and TRPL interact directly, indicating that the TRP-TRPL-dependent current is mediated by heteromultimeric association between the two subunits. We propose that the light-activated current in photoreceptor cells is produced by a combination of TRP homo- and TRP-TRPL heteromultimers.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	Xu, XZS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardie RC, 1995, J NEUROPHYSIOL, V74, P2590, DOI 10.1152/jn.1995.74.6.2590; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NEHER E, 1992, ION CHANNELS, P123; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sinkins W. G., 1997, Biophysical Journal, V72, pA271; SUSSTOBY E, 1991, J GEN PHYSIOL, V98, P848; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	50	263	280	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1155	1164		10.1016/S0092-8674(00)80302-5	http://dx.doi.org/10.1016/S0092-8674(00)80302-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215637	hybrid			2022-12-28	WOS:A1997XG83000019
J	Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S				Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S			Intracellular cleavage of notch leads to a heterodimeric receptor on the plasma membrane	CELL			English	Article							DROSOPHILA-NOTCH; GENE-PRODUCT; MAMMALIAN NOTCH; HUMAN HOMOLOG; CELL-FATE; PROTEIN; LOCUS; EXPRESSION; NEUROGENESIS; MELANOGASTER	Previous models for signal transduction via the Notch pathway have depicted the full-length Notch receptor expressed at the cell surface. We present evidence demonstrating that the Notch receptor on the plasma membrane is cleaved. This cleavage is an evolutionarily conserved, general property of Notch and occurs in the trans-Golgi network as the receptor traffics toward the plasma membrane. Although full-length Notch is detectable in the cell, it does not reach the surface. Cleavage results in a C-terminal fragment, N(TM), that appears to be cleaved N-terminal to the transmembrane domain, and an N-terminal fragment, N-EC, that contains most of the extracellular region. We provide evidence that these fragments are tethered together on the plasma membrane by a link that is sensitive to reducing conditions, forming a heterodimeric receptor.	YALE UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL & BIOL, BOYER CTR MOL MED, NEW HAVEN, CT 06536 USA	Howard Hughes Medical Institute; Yale University				Blaumueller, Christine/0000-0002-1236-9353	NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Baker R, 1996, DEVELOPMENT, V122, P617; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FOSTER GG, 1975, GENETICS, V81, P99; GEHRING WJ, 1973, GENETIC MECHANISMS D, P103; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARKOPOULOU K, 1990, J EXP ZOOL, V27, P23; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, THESIS YALE U NEW HA; STERN C, 1968, P NATL ACAD SCI USA, V60, P1252, DOI 10.1073/pnas.60.4.1252; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Sun X, 1996, DEVELOPMENT, V122, P2465; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	49	475	496	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					281	291		10.1016/S0092-8674(00)80336-0	http://dx.doi.org/10.1016/S0092-8674(00)80336-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244302	hybrid			2022-12-28	WOS:A1997XN24900012
J	Morgan, RO; Virnig, BA; DeVito, CA; Persily, NA				Morgan, RO; Virnig, BA; DeVito, CA; Persily, NA			The Medicare-HMO revolving door - The healthy go in and the sick go out	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OUTCOMES; DEMONSTRATIONS; DISENROLLEES; ISSUES; CARE	Background Enrollment in Medicare health maintenance organizations (HMOs) is encouraged because of the expectation that HMOs can help slow the growth of Medicare costs. However, Medicare HMOs, which are paid 95 percent of average yearly fee-for-service Medicare expenditures, are increasingly believed to benefit from the selective enrollment of healthier Medicare recipients. Furthermore, whether sicker patients are more likely to disenroll from Medicare HMOs, thus raising average fee-for service costs, is not clear. Methods We used Medicare enrollment and inpatient billing records for southern Florida from 1990 through 1993 to examine differences in the use of inpatient medical services by 375,406 beneficiaries in the Medicare fee-for-service system, 48,380 HMO enrollees before enrollment, and 23,870 HMO enrollees after disenrollment. We also determined whether these differences were related to demographic characteristics and whether the pattern of use after disenrollment persisted over time. Results The rate of use of inpatient services in the HMO-enrollment group during the year before enrollment was 66 percent of the rate in the fee-for-service group, whereas the rate in the HMO-disenrollment group after disenrollment was 180 percent of that in the fee-for-service group. Beneficiaries who disenrolled from HMOs re-enrolled at about the time that their level of use dropped to that in the fee-for-service group. Conclusions These data show marked selection biases with respect to HMO enrollment and disenrollment. These biases undermine the effectiveness of the Medicare managed-care system and highlight the need for longitudinal and population-based studies. (C)1997, Massachusetts Medical Society.	UNIV MIAMI,SCH MED,MIAMI,FL; VET AFFAIRS MED CTR,MIAMI,FL 33125; UNIV MIAMI,MICHAEL I ABRAMS HLTH POLICY RES CTR,PUBL HLTH TRUST,MIAMI,FL 33152; GEORGE WASHINGTON UNIV,SCH PUBL HLTH & HLTH SERV,WASHINGTON,DC	University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; George Washington University			Morgan, Robert/A-8577-2009					BROWN R, 1986, ENROLLMENT DISENROLL; BROWN RS, 1994, HMOS AND THE ELDERLY, P13; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; DOWD B, 1992, MILBANK Q, V70, P423, DOI 10.2307/3350130; Eggers P W, 1982, Health Care Financ Rev, V4, P55; Fleiss JL, 1981, STAT METHODS RATES P; *GAO, 1986, PUBL GAO; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Hill JW, 1990, BIASED SELECTION TEF; *HLTH CAR FIN ADM, 1997, MAN CAR MED MED FACT; KOCH GG, 1986, ENCY STAT SCI, P7; MECHANIC D, 1983, MED CARE, V21, P338, DOI 10.1097/00005650-198303000-00006; *PHYS PAYM REV COM, 1996, 1996 ANN REP C, P255; PRELL FW, 1992, FACTORS ASS DISENROL; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RILEY G, 1989, MED CARE, V27, P337, DOI 10.1097/00005650-198904000-00002; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906	19	186	186	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					169	175		10.1056/NEJM199707173370306	http://dx.doi.org/10.1056/NEJM199707173370306			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219704				2022-12-28	WOS:A1997XK81800006
J	Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B				Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B			Molecular assessment of the potential transmissibilities of BSE and scrapie to humans	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; PRION PROTEIN; SHEEP; GENOTYPE; FIBRILS; DISEASE; CATTLE; MICE; PRP	More than a million cattle infected with bovine spongiform encephalopathy (BSE) may have entered the human food chain(1). Fears that BSE might transmit to man were raised when atypical cases of Creutzfeldt-Jakob disease (CJD), a human transmissible spongiform encephalopathy (TSE), emerged in the UK2,3. I, BSE and other TSE diseases, the conversion of the protease-sensitive host prion protein (PrP-sen) to a protease-resistant isoform (PrP-res) is an important event in pathogenesis(4-7). Biological aspects of TSE diseases are reflected in the specificities of in vitro PrP conversion reactions(8-12). Here we show that there is a correlation between in vitro conversion efficiencies and known transmissibilities of BSE, sheep scrapie and CJD. On this basis, we used an in vitro system to gauge the potential transmissibility of scrapie and BSE to humans. We found Limited conversion of human PrP-sen to PrP-res driven by PrP-res associated with both scrapie (PrPSc) and BSE (prp(BSE)). The efficiencies of these heterologous conversion reactions were similar but much lower than those of relevant homologous conversions. Thus the inherent ability of these infectious agents of BSE and scrapie to affect humans following equivalent exposure may be finite but similarly low.	BBSRC,INST ANIM HLTH,COMPTON LAB,NEWBURY RG20 7NN,BERKS,ENGLAND; NIAID,ROCKY MT LABS,NIH,HAMILTON,MT 59840; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; DLO,INST ANIM SCI & HLTH,DEPT BACTERIOL,NL-8200 AB LELYSTAD,NETHERLANDS; WESTERN GEN HOSP,CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; NEW YORK STATE INST BASIC RES DEV DISABIL,NEW YORK,NY 10314; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Massachusetts Institute of Technology (MIT); University of Edinburgh; Case Western Reserve University; Institute for Basic Research in Developmental Disabilities; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Petersen, Robert/B-5075-2011; Bossers, Alex/AAA-6025-2021; smits, mari/J-4892-2013; Chen, Shu/Z-2943-2019; Bossers, Alex/F-7757-2019; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021; Hope, James/C-4966-2011	Petersen, Robert/0000-0002-3154-0072; Bossers, Alex/0000-0002-6586-717X; smits, mari/0000-0002-3493-291X; Bossers, Alex/0000-0002-6586-717X; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; Ironside, James/0000-0001-5869-2108				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY B, 1996, PRION DIS, P285; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; DAWSON M, 1990, VET REC, V126, P112; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; RICK R, 1996, NATURE, V382, P180; VANKEULEN LJM, 1995, VET PATHOL, V32, P299, DOI 10.1177/030098589503200312; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	26	221	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					285	288		10.1038/40876	http://dx.doi.org/10.1038/40876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230438				2022-12-28	WOS:A1997XL12100053
J	Levine, RJ; Hauth, JC; Curet, LB; Sibai, BM; Catalano, PM; Morris, CD; DerSimonian, R; Esterlitz, JR; Raymond, EG; Bild, DE; Clemens, JD; Cutler, JA				Levine, RJ; Hauth, JC; Curet, LB; Sibai, BM; Catalano, PM; Morris, CD; DerSimonian, R; Esterlitz, JR; Raymond, EG; Bild, DE; Clemens, JD; Cutler, JA			Trial of calcium to prevent preeclampsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY-INDUCED HYPERTENSION; SUPPLEMENTATION; RISK	Background Previous trials have suggested that calcium supplementation during pregnancy may reduce the risk of preeclampsia. However, differences in study design and a low dietary calcium intake in the populations studied limit acceptance of the data. Methods We randomly assigned 4589 healthy nulliparous women who were 13 to 21 weeks pregnant to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of unscheduled outpatient visits and all hospitalizations. Results Calcium supplementation did not significantly reduce the incidence or severity of preeclampsia or delay its onset. Preeclampsia occurred in 158 of the 2295 women in the calcium group (6.9 percent) and 168 of the 2294 women in the placebo group (7.3 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.16). There were no significant differences between the two groups in the prevalence of pregnancy-associated hypertension without preeclampsia (15.3 percent vs. 17.3 percent) or of all hypertensive disorders (22.2 percent vs. 24.6 percent). The mean systolic and diastolic blood pressures during pregnancy were similar in both groups. Calcium did not reduce the numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths; nor did it increase urolithiasis during pregnancy. Conclusions Calcium supplementation during pregnancy did not prevent preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes in healthy nulliparous women. (C) 1997, Massachusetts Medical Society.	UNIV ALABAMA,DEPT OBSTET & GYNECOL,BIRMINGHAM,AL 35294; UNIV NEW MEXICO,HLTH SCI CTR,DEPT OBSTET & GYNECOL,ALBUQUERQUE,NM 87131; UNIV TENNESSEE,COLL MED,DEPT OBSTET & GYNECOL,MEMPHIS,TN; CASE WESTERN RESERVE UNIV,METROHLTH MED CTR,DEPT OBSTET & GYNECOL,CLEVELAND,OH; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; EMMES CORP,POTOMAC,MD; FAMILY HLTH INT,RES TRIANGLE PK,NC 27709; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892	University of Alabama System; University of Alabama Birmingham; University of New Mexico; University of New Mexico's Health Sciences Center; University of Tennessee System; University of Tennessee Health Science Center; Case Western Reserve University; MetroHealth System; Oregon Health & Science University; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, RJ (corresponding author), NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,BLDG 6100,RM 7B03,BETHESDA,MD 20892, USA.		Catalano, Patrick/GVR-9069-2022		NICHD NIH HHS [N01-HD-5-3122, N01-HD-5-3121, N01-HD-5-3123] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baxter GF, 1996, LANCET, V348, P1424, DOI 10.1016/S0140-6736(96)07281-9; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; CARROLI G, 1994, BRIT J OBSTET GYNAEC, V101, P753, DOI 10.1111/j.1471-0528.1994.tb11940.x; CHAUDHURI SK, 1969, J OBSTET GYN INDIA, V19, P313; Cong K J, 1993, Zhonghua Fu Chan Ke Za Zhi, V28, P657; Cunningham FG, 1989, WILLIAMS OBSTET, V18th, P653; DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DULEY L, 1991, PREVENTION TREATMENT, P2; HEANEY RP, 1971, J CLIN ENDOCR METAB, V33, P661, DOI 10.1210/jcem-33-4-661; HOFFMAN RJ, 1988, CLIN CHEM, V34, P1313; ITO M, 1994, INT J GYNECOL OBSTET, V47, P115, DOI 10.1016/0020-7292(94)90350-6; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLAUS MH, 1986, CARE HIGH RISK NEONA, P227; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P340; Levine R, 1996, JAMA-J AM MED ASSOC, V276, P1387, DOI 10.1001/jama.276.17.1387; Levine RJ, 1996, CONTROL CLIN TRIALS, V17, P442, DOI 10.1016/S0197-2456(96)00106-7; LEVINE RL, 1992, CLIN APPL NUTR, V2, P30; LOPEZJARAMILLO P, 1989, BRIT J OBSTET GYNAEC, V96, P648, DOI 10.1111/j.1471-0528.1989.tb03278.x; LOPEZJARAMILLO P, 1990, LANCET, V335, P293, DOI 10.1016/0140-6736(90)90112-I; MAIKRANZ P, 1989, KIDNEY INT, V36, P108, DOI 10.1038/ki.1989.168; MARYA RK, 1987, GYNECOL OBSTET INVES, V24, P38, DOI 10.1159/000298772; MONTANARO D, 1986, MINER METAB RES ITAL, V7, P121; SANCHEZRAMOS L, 1994, OBSTET GYNECOL, V84, P349; SUZUKI Y, 1996, 10 WORLD C INT SOC S, P152; Swanson AF, 1993, ADV CLIN DIAGNOSTICS, P3; THEOBALD G. W., 1937, Lancet, P1397; TRUDEAU DL, 1967, CLIN CHEM, V13, P101; VILLAR J, 1987, OBSTET GYNECOL, V70, P317; VILLAR J, 1990, AM J OBSTET GYNECOL, V163, P1124, DOI 10.1016/0002-9378(90)90669-X; WACHTER KW, 1988, SCIENCE, V241, P1407, DOI 10.1126/science.3420397; 1990, AM J OBSTET GYNECOL, V163, P1689; 1942, LANCET, V2, P10	36	417	436	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					69	76		10.1056/NEJM199707103370201	http://dx.doi.org/10.1056/NEJM199707103370201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211675				2022-12-28	WOS:A1997XJ82200001
J	Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM				Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM			Evolution of genetic redundancy	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DUPLICATE LOCI; MICE; TENASCIN; DEVELOP	Genetic redundancy means that two or more genes are performing the same function and that inactivation of one of these genes has little or no effect on the biological phenotype. Redundancy seems to be widespread in genomes of higher organisms(1-9). Examples of apparently redundant genes come from numerous studies of developmental biology(10-15), immunology(16,17), neurobiology(18,19) and the cell cycle(20,21). Yet there is a problem: genes encoding functional proteins must be under selection pressure, If a gene was truly redundant then it would not be protected against the accumulation of deleterious mutations. A widespread view is therefore that such redundancy cannot be evolutionarily stable. Here we develop a simple genetic model to analyse selection pressures acting on redundant genes. We present four cases that can explain why genetic redundancy is common, In three cases, redundancy is even evolutionarily stable. Our theory provides a framework for exploring the evolution of genetic organization.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex	Nowak, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLENDORF FW, 1978, NATURE, V272, P76, DOI 10.1038/272076a0; BAILEY GS, 1978, P NATL ACAD SCI USA, V75, P5575, DOI 10.1073/pnas.75.11.5575; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brookfield JFY, 1997, ADV GENET, V36, P137, DOI 10.1016/S0065-2660(08)60308-9; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CHRISTIANSEN FB, 1977, AM J HUM GENET, V29, P195; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Fisher RA, 1935, AM NAT, V69, P446, DOI 10.1086/280618; GOLDSTEIN DB, 1992, EVOLUTION, V46, P412, DOI [10.2307/2409861, 10.1111/j.1558-5646.1992.tb02048.x]; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA M, 1979, P NATL ACAD SCI USA, V76, P2858, DOI 10.1073/pnas.76.6.2858; Krakauer DC, 1996, PHILOS T ROY SOC B, V351, P647, DOI 10.1098/rstb.1996.0062; Laney JD, 1996, DEVELOPMENT, V122, P2303; LI WH, 1980, GENETICS, V95, P237; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; OBRIEN SJ, 1973, NATURE-NEW BIOL, V242, P52, DOI 10.1038/newbio242052a0; OHTA T, 1989, GENETICS, V123, P579; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STEINDLER DA, 1995, J NEUROSCI, V15, P1971, DOI 10.1523/JNEUROSCI.15-03-01971.1995; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; YANG Y, 1996, NATURE, V379, P823	30	497	510	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					167	171		10.1038/40618	http://dx.doi.org/10.1038/40618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217155	Bronze			2022-12-28	WOS:A1997XK10900048
J	Helbing, D; Keltsch, J; Molnar, P				Helbing, D; Keltsch, J; Molnar, P			Modelling the evolution of human trail systems	NATURE			English	Article							ACTIVE WALKER MODELS; GROWTH-PATTERNS	Many human social phenomena, such as cooperation(1-3), the growth of settlements(4), traffic dynamics(5-7) and pedestrian movement(7-10), appear to be accessible to mathematical descriptions that invoke self-organization(11,12). Here we develop a model of pedestrian motion to explore the evolution of trails in urban green spaces such as parks. Our aim is to address such questions as what the topological structures of these trail systems are(13), and whether optimal path systems can be predicted for urban planning. We use an 'active walker' model(14-19) that takes into account pedestrian motion and orientation and the concomitant feedbacks with the surrounding environment. Such models have previously been applied to the study of complex structure formation in physical(14-16), chemical(17) and biological(18,19) systems. We find that our model is able to reproduce many of the observed large-scale spatial features of trail systems.	SCI COMP,D-72070 TUBINGEN,GERMANY; CLARK ATLANTA UNIV,CTR THEORET STUDIES PHYS SYST,ATLANTA,GA 30314	Clark Atlanta University	Helbing, D (corresponding author), UNIV STUTTGART,INST THEORET PHYS,PFAFFENWALDRING 57-3,D-70550 STUTTGART,GERMANY.		Helbing, Dirk/C-6114-2008					AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BENJACOB E, 1994, NATURE, V368, P46, DOI 10.1038/368046a0; CLEARWATER SH, 1991, SCIENCE, V254, P1181, DOI 10.1126/science.254.5035.1181; Eigen M, 1979, HYPERCYCLE; Feistel R, 1989, EVOLUTION COMPLEX SY; HAKEN H, 1987, ADV SYNERGETICS; HELBING D, 1995, PHYS REV E, V51, P4282, DOI 10.1103/PhysRevE.51.4282; Helbing D., 1995, QUANTITATIVE SOCIODY; Helbing D., 1997, VERKEHRSDYNAMIK NEUE; HENDERSON LF, 1971, NATURE, V229, P381, DOI 10.1038/229381a0; HENDERSON LF, 1972, NATURE, V240, P353, DOI 10.1038/240353a0; HERMAN R, 1979, SCIENCE, V204, P148, DOI 10.1126/science.204.4389.148; HERMAN R, 1973, SCIENCE, V179, P918, DOI 10.1126/science.179.4076.918; Hillier B., 1996, SPACE MACHINE CONFIG; KAYSER DR, 1992, PHYSICA A, V191, P17, DOI 10.1016/0378-4371(92)90499-G; LAM L, 1995, CHAOS SOLITON FRACT, V6, P267, DOI 10.1016/0960-0779(95)80033-D; MAKSE HA, 1995, NATURE, V377, P608, DOI 10.1038/377608a0; Nicolis G, 1977, SELF ORG NONEQUILIBR; SCHENK M, 1995, THESIS U STUTTGART; SCHIMANSKYGEIER L, 1995, PHYS LETT A, V207, P140, DOI 10.1016/0375-9601(95)00700-D; SCHWEITZER F, 1994, PHYSICA A, V206, P359, DOI 10.1016/0378-4371(94)90312-3; Stevens A, 1997, MATH BIOSCI INTERAC, P183; TIMMERMANS H, 1992, TRANSPORT RES B-METH, V26, P45, DOI 10.1016/0191-2615(92)90019-S	23	237	252	6	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					47	50		10.1038/40353	http://dx.doi.org/10.1038/40353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214501	Green Submitted, Bronze			2022-12-28	WOS:A1997XJ14300044
J	Webster, MWI; Scott, RS				Webster, MWI; Scott, RS			What cardiologists need to know about diabetes	LANCET			English	Article							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; INSULIN-TREATMENT; MICROVASCULAR COMPLICATIONS; ANTIHYPERTENSIVE THERAPY; AUTONOMIC DYSFUNCTION; BETA-BLOCKERS; MELLITUS; TRIAL; NEPHROPATHY		CHRISTCHURCH HOSP, CHRISTCHURCH, NEW ZEALAND; GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 1030, NEW ZEALAND	Christchurch Hospital New Zealand				Scott, Russell/0000-0002-2107-6480				ACCOLA KD, 1993, ANN THORAC SURG, V56, P872, DOI 10.1016/0003-4975(93)90347-K; Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; BARBOSA J, 1994, JAMA-J AM MED ASSOC, V272, P600, DOI 10.1001/jama.272.8.600; BARZILAY JI, 1994, AM J CARDIOL, V74, P334, DOI 10.1016/0002-9149(94)90399-9; Braun S, 1996, J AM COLL CARDIOL, V28, P7, DOI 10.1016/0735-1097(96)00109-X; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; EWING DJ, 1991, DIABETOLOGIA, V34, P182, DOI 10.1007/BF00418273; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; Garratt K. N., 1997, Journal of the American College of Cardiology, V29, p493A; Grossman E, 1996, ANN INTERN MED, V125, P304, DOI 10.7326/0003-4819-125-4-199608150-00009; JensenUrstad KJ, 1996, DIABETES, V45, P1253, DOI 10.2337/diabetes.45.9.1253; Jonas M, 1996, AM J CARDIOL, V77, P1273, DOI 10.1016/S0002-9149(96)00191-9; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KASISKE BL, 1995, ANN INTERN MED, V122, P133, DOI 10.7326/0003-4819-122-2-199501150-00010; KENDALL MJ, 1995, ANN INTERN MED, V123, P358, DOI 10.7326/0003-4819-123-5-199509010-00007; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; Kornowski R, 1997, CIRCULATION, V95, P1366; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAGER I, 1979, LANCET, V1, P458; LAM KSL, 1995, DIABETOLOGIA, V38, P604, DOI 10.1007/s001250050326; LANGER A, 1995, J AM COLL CARDIOL, V25, P610, DOI 10.1016/0735-1097(94)00459-4; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MARCHANT B, 1993, J AM COLL CARDIOL, V22, P1433, DOI 10.1016/0735-1097(93)90554-E; MCVEIGH G, 1994, DIABETOLOGIA, V37, P115, DOI 10.1007/BF00428787; MILLER M, 1976, DIABETES, V25, P1129; MORRIS JJ, 1991, CIRCULATION, V84, P275; MOYE LA, 1994, EUR HEART J, V15, P2, DOI 10.1093/eurheartj/15.suppl_B.2; Nattrass M, 1997, BRIT MED J, V314, P1497, DOI 10.1136/bmj.314.7093.1497; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SANDRONE G, 1994, AM J CARDIOL, V74, P340, DOI 10.1016/0002-9149(94)90400-6; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shindler DM, 1996, AM J CARDIOL, V77, P1017, DOI 10.1016/S0002-9149(97)89163-1; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEIN B, 1995, CIRCULATION, V91, P979, DOI 10.1161/01.CIR.91.4.979; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WEI K, 1995, J AM COLL CARDIOL, V26, P859, DOI 10.1016/0735-1097(95)00279-8; Woodfield SL, 1996, J AM COLL CARDIOL, V28, P1661, DOI 10.1016/S0735-1097(96)00397-X; ZARICH S, 1994, J AM COLL CARDIOL, V24, P956, DOI 10.1016/0735-1097(94)90855-9	53	38	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1997	350			1			SI23	SI28						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250280				2022-12-28	WOS:A1997XM26500007
J	Michel, M; Gutmann, L				Michel, M; Gutmann, L			Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Therapeutic realities and possibilities	LANCET			English	Review							BETA-LACTAM RESISTANCE; GRAM-POSITIVE BACTERIA; EXPERIMENTAL ENDOCARDITIS; ANTIBIOTIC-RESISTANCE; INVITRO ACTIVITY; IN-VITRO; FAECIUM; INFECTION; COMBINATION; GENTAMICIN	During the past decade much effort has been devoted worldwide to limiting the spread of methicillin-resistant Staphylococcus aureus. However, the recent emergence of almost untreatable vancomycin-resistant enterococci has led to a new and unexpected public health problem in hospitals and the community. Moreover, the threat of transfer of glycopeptide resistance to S aureus means that development of alternative antimicrobial strategies has become urgent. Whereas major advances have been made in our understanding of methicillin and vancomycin resistance mechanisms, we still need to identify the sources and reservoirs of the genetic determinants of resistance and to discover how they disseminate in the environment. The outcome of the battle between antimicrobials and bacteria is still uncertain, but the challenge is worth meeting.	HOP BROUSSAIS,MICROBIOL LAB,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								ACKERMAN BH, 1992, ANTIMICROB AGENTS CH, V36, P1766, DOI 10.1128/AAC.36.8.1766; Archer Gordon L., 1994, Trends in Microbiology, V2, P343, DOI 10.1016/0966-842X(94)90608-4; Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; BARBER M, 1961, J CLIN PATHOL, V14, P385, DOI 10.1136/jcp.14.4.385; BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507; BAYER AS, 1985, J INFECT DIS, V151, P157, DOI 10.1093/infdis/151.1.157; Berger-Bachi Brigitte, 1994, Trends in Microbiology, V2, P389, DOI 10.1016/0966-842X(94)90617-3; BillotKlein D, 1996, J BACTERIOL, V178, P4696, DOI 10.1128/jb.178.15.4696-4703.1996; BILLOTKLEIN D, 1994, J BACTERIOL, V176, P2398, DOI 10.1128/JB.176.8.2398-2405.1994; Brandt CM, 1996, J INFECT DIS, V173, P909, DOI 10.1093/infdis/173.4.909; BRUMFITT W, 1992, J ANTIMICROB CHEMOTH, V30, P29, DOI 10.1093/jac/30.suppl_A.29; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; CAGNI A, 1995, ANTIMICROB AGENTS CH, V39, P1655, DOI 10.1128/AAC.39.8.1655; CARON F, 1993, J INFECT DIS, V168, P681, DOI 10.1093/infdis/168.3.681; CARON F, 1995, J INFECT DIS, V171, P106, DOI 10.1093/infdis/171.1.106; CARON F, 1995, 35 INT C ANT AG CHEM; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P462, DOI 10.1128/AAC.39.2.462; COHEN MA, 1995, ANTIMICROB AGENTS CH, V39, P2123, DOI 10.1128/AAC.39.9.2123; COLLINS LA, 1993, ANTIMICROB AGENTS CH, V37, P598, DOI 10.1128/AAC.37.3.598; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; Dever LL, 1996, MICROB DRUG RESIST, V2, P407, DOI 10.1089/mdr.1996.2.407; ENTENZA JM, 1995, ANTIMICROB AGENTS CH, V39, P1419, DOI 10.1128/AAC.39.7.1419; FANTIN B, 1993, ANTIMICROB AGENTS CH, V37, P2466, DOI 10.1128/AAC.37.11.2466; FANTIN B, 1994, ANTIMICROB AGENTS SA, V30, P29; FINLAND M, 1979, REV INFECT DIS, V1, P4; Ford CW, 1996, ANTIMICROB AGENTS CH, V40, P1508, DOI 10.1128/AAC.40.6.1508; FRAISE AP, 1995, J ANTIMICROB CHEMOTH, V35, P877, DOI 10.1093/jac/35.6.877; FRANCIOLLI M, 1991, J INFECT DIS, V163, P514, DOI 10.1093/infdis/163.3.514; GUTMANN L, 1994, ANTIMICROB AGENTS CH, V38, P824, DOI 10.1128/AAC.38.4.824; HACKBARTH CJ, 1994, ANTIMICROB AGENTS CH, V38, P447; HENZE UU, 1995, ANTIMICROB AGENTS CH, V39, P2415, DOI 10.1128/AAC.39.11.2415; LECLERQ R, 1988, NEW ENGL J MED, V319, P1571; MAINARDI JL, 1995, J INFECT DIS, V171, P1646, DOI 10.1093/infdis/171.6.1646; MAPLE PAC, 1989, LANCET, V1, P537; MARKOWITZ N, 1992, ANN INTERN MED, V117, P390, DOI 10.7326/0003-4819-117-5-390; MCDOUGAL LK, 1986, J CLIN MICROBIOL, V23, P832, DOI 10.1128/JCM.23.5.832-839.1986; NICAS TI, 1995, ANTIMICROB AGENTS CH, V39, P2585, DOI 10.1128/AAC.39.11.2585; Nicolau DP, 1996, ANTIMICROB AGENTS CH, V40, P55, DOI 10.1128/AAC.40.1.55; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NORRIS AH, 1995, CLIN INFECT DIS, V20, P1137, DOI 10.1093/clinids/20.5.1137; ODONOVAN CA, 1994, DIAGN MICR INFEC DIS, V18, P105, DOI 10.1016/0732-8893(94)90074-4; PATTERSON JE, 1990, REV INFECT DIS, V12, P644; PORTIER H, 1984, J ANTIMICROB CHEMOTH, V14, P277, DOI 10.1093/jac/14.suppl_B.277; Ramsey MA, 1996, ANTIMICROB AGENTS CH, V40, P2820, DOI 10.1128/AAC.40.12.2820; Ristow TA, 1995, MICROB DRUG RESIST, V1, P335, DOI 10.1089/mdr.1995.1.335; RODRIGUEZ A, 1987, ANTIMICROB AGENTS CH, V31, P1444, DOI 10.1128/AAC.31.9.1444; Sahgal VS, 1995, MICROB DRUG RESIST, V1, P245, DOI 10.1089/mdr.1995.1.245; Shlaes David M., 1994, Trends in Microbiology, V2, P385; TOMASZ A, 1989, ANTIMICROB AGENTS CH, V33, P1869, DOI 10.1128/AAC.33.11.1869; TORRALBA MD, 1995, CLIN INFECT DIS, V21, P460, DOI 10.1093/clinids/21.2.460; UNAL S, 1993, J ANTIMICROB CHEMOTH, V31, P711, DOI 10.1093/jac/31.5.711; UTTLEY AHC, 1988, LANCET, V1, P57; VASQUEZ J, 1993, J ANTIMICROB CHEMOTH, V32, P356; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WADE HH, 1995, MICROB DRUG RESIST, V1, P241; WCHABERG DR, 1991, AM J MED S3B, V91, pS72; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; WHITMAN MS, 1993, ANTIMICROB AGENTS CH, V37, P2069, DOI 10.1128/AAC.37.10.2069; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259; WOODFORD N, 1995, CLIN MICROBIOL REV, V8, P585, DOI 10.1128/CMR.8.4.585; ZORZI W, 1996, J BACTERIOL, V178, P4968; [No title captured]	62	164	170	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1901	1906		10.1016/S0140-6736(96)11192-2	http://dx.doi.org/10.1016/S0140-6736(96)11192-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217771				2022-12-28	WOS:A1997XG41700042
J	Franz, DR; Jahrling, PB; Friedlander, AM; McClain, DJ; Hoover, DL; Bryne, WR; Pavlin, JA; Christopher, CW; Eitzen, EM				Franz, DR; Jahrling, PB; Friedlander, AM; McClain, DJ; Hoover, DL; Bryne, WR; Pavlin, JA; Christopher, CW; Eitzen, EM			Clinical recognition and management of patients exposed to biological warfare agents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ARGENTINE HEMORRHAGIC-FEVER; EQUINE ENCEPHALITIS-VIRUS; HUMAN BRUCELLOSIS; LASSA FEVER; VACCINE PROPHYLAXIS; INHALATION ANTHRAX; ENTEROTOXIN-A; OUTBREAK; IMMUNIZATION; MELITENSIS	Concern regarding the use of biological agents-bacteria, viruses, or toxins-as tools of warfare or terrorism has led to measures to deter their use or, failing that, to deal with the consequences. Unlike chemical agents, which typically lead to violent disease syndromes within minutes at the site of exposure, diseases resulting from biological agents have incubation periods of days. Therefore, rather than a paramedic, it will likely be a physician who is first faced with evidence of the results of a biological attack. We provide here a primer on 10 classic biological warfare agents to increase the likelihood of their being considered in a differential diagnosis. Although the resultant diseases are rarely seen in many countries today, accepted diagnostic and epidemiologic principles apply; if the cause is identified quickly, appropriate therapy can be initiated and the impact of a terrorist attack greatly reduced.	USA, MED RES INST INFECT DIS, FT DETRICK, MD 21702 USA; USA, WALTER REED ARMY INST RES, MED RES & MAT COMMAND, WASHINGTON, DC 20310 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; ACKLAND JR, 1994, MED J AUSTRALIA, V160, P704, DOI 10.5694/j.1326-5377.1994.tb125909.x; [Anonymous], 1980, REPORT INVESTIGATION; ARITA I, 1979, NATURE, V279, P293, DOI 10.1038/279293a0; ARIZA J, 1985, REV INFECT DIS, V7, P656; BAUER DJ, 1969, AM J EPIDEMIOL, V90, P130, DOI 10.1093/oxfordjournals.aje.a121057; BAUER DJ, 1963, LANCET, V2, P494; Bavari S, 1996, VACCINES, P135; BELL JF, 1964, MIL MED, V129, P591, DOI 10.1093/milmed/129.7.591; Benenson A.S., 1959, S Q FEVER, P47; BENESON AS, 1990, CONTROL COMMUNICABLE, P61; Brachman P, 1994, VACCINES, P729; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; BROUQUI P, 1993, ARCH INTERN MED, V153, P642, DOI 10.1001/archinte.153.5.642; BURKE DS, 1977, J INFECT DIS, V135, P55, DOI 10.1093/infdis/135.1.55; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; Butler T, 1983, PLAGUE OTHER YERSINI; Calisher C. H., 1988, The arboviruses: epidemiology and ecology. Volume I., P19; CALISHER CH, 1986, J CLIN MICROBIOL, V23, P155, DOI 10.1128/JCM.23.1.155-159.1986; CANONICO PG, 1984, J ANTIMICROB CHEMOTH, V14, P27, DOI 10.1093/jac/14.suppl_A.27; CAVANAUGH DC, 1974, J INFECT DIS, V129, pS37, DOI 10.1093/infdis/129.Supplement_1.S37; CAVANAUGH DC, 1982, INTERNAL MED VIETNAM; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P1; CHAN R, 1993, MED J AUSTRALIA, V158, P631, DOI 10.5694/j.1326-5377.1993.tb137636.x; CLARKE DH, 1961, AM J TROP MED HYG, V10, P67, DOI 10.4269/ajtmh.1961.10.67; COCHRANE RC, 1947, HIST CHEM WARFARE SE, V2; COIMBRA TLM, 1994, LANCET, V343, P391, DOI 10.1016/S0140-6736(94)91226-2; CROSBY E, 1984, J INFECT DIS, V150, P419, DOI 10.1093/infdis/150.3.419; DAVIS NL, 1991, VIROLOGY, V183, P20, DOI 10.1016/0042-6822(91)90114-Q; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; *DEPT ARM NAV AIR, 1996, NATO HDB MED ASP NBC; Deresiewicz RL, 1997, NEW ENGL J MED, V336, P1867, DOI 10.1056/NEJM199706263362604; DERRICK EH, 1973, MED J AUSTRALIA, V1, P1051, DOI 10.5694/j.1326-5377.1973.tb110910.x; DIXON C.W, 1962, SMALLPOX; DOVALLE LAR, 1965, LANCET, V2, P976; DOWNIE AW, 1965, B WORLD HEALTH ORGAN, V33, P615; DOWNIE AW, 1961, B WORLD HEALTH ORGAN, V25, P49; DUPUIS G, 1987, INT J EPIDEMIOL, V16, P282, DOI 10.1093/ije/16.2.282; Dutz W, 1971, Pathol Annu, V6, P209; Easterday B C, 1965, Adv Vet Sci, V10, P65; Eickhoff TC, 1996, AM J EPIDEMIOL, V144, pS39, DOI 10.1093/aje/144.Supplement_8.S39; ENRIA DA, 1984, LANCET, V2, P255, DOI 10.1016/S0140-6736(84)90299-X; ENRIA DA, 1994, ANTIVIR RES, V23, P23, DOI 10.1016/0166-3542(94)90030-2; Evans A.C., 1950, BRUCELLOSIS, P1; EVANS ME, 1985, MEDICINE, V64, P251, DOI 10.1097/00005792-198507000-00006; EVANS ME, 1997, TXB MILITARY MED MED, P503; FEEMSTER RF, 1958, NEW ENGL J MED, V259, P107, DOI 10.1056/NEJM195807172590302; FENNER F, 1988, SMALLPOX ITS ERADICA, P1341; FERRANTE MA, 1993, CLIN INFECT DIS, V16, P489, DOI 10.1093/clind/16.4.489; FRANCK PT, 1970, AM J TROP MED HYG, V19, P860, DOI 10.4269/ajtmh.1970.19.860; FRANZ DR, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P473; FRANZ DR, 1997, TXB MILITARY MED MED, P425; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; Gold H, 1942, ANN INTERN MED, V16, P556, DOI 10.7326/0003-4819-16-3-556; GOLDFIELD M, 1968, AM J EPIDEMIOL, V87, P32, DOI 10.1093/oxfordjournals.aje.a120807; GOTUZZO E, 1986, J INFECT DIS, V153, P122, DOI 10.1093/infdis/153.1.122; GOTUZZO E, 1982, SEMIN ARTHRITIS RHEU, V12, P245, DOI 10.1016/0049-0172(82)90064-6; GRIMONT F, 1992, RES MICROBIOL, V143, P55, DOI 10.1016/0923-2508(92)90034-L; HARPER GJ, 1961, J HYG-CAMBRIDGE, V59, P479, DOI 10.1017/S0022172400039176; HART KL, 1964, AM J TROP MED HYG, V13, P331, DOI 10.4269/ajtmh.1964.13.331; Hayes R. O., 1981, CRC handbook series in zoonoses. Section B: viral zoonoses. Volume I, P29; HENDERSON DA, 1973, PREVENTIVE MED PUBLI, P104; HINMAN AR, 1971, AM J EPIDEMIOL, V93, P130, DOI 10.1093/oxfordjournals.aje.a121233; Horgan ES, 1939, J HYG-CAMBRIDGE, V39, P615, DOI 10.1017/S0022172400059556; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; HUNT AR, 1985, VIROLOGY, V142, P334, DOI 10.1016/0042-6822(85)90342-3; HUXSOLL DL, 1987, J AM VET MED ASSOC, V190, P714; IBRAHIM AIA, 1988, BRIT J UROL, V61, P294, DOI 10.1111/j.1464-410X.1988.tb13960.x; Ibrahim MS, 1997, MOL CELL PROBE, V11, P143, DOI 10.1006/mcpr.1996.0093; JAHRLING PB, 1985, T ROY SOC TROP MED H, V79, P380, DOI 10.1016/0035-9203(85)90388-8; Jahrling PB, 1996, ARCH VIROL, P135; Jahrling Peter B., 1995, P1068; JEZEK Z, 1988, VIROL MONOGR, V17, P93; Johnson K M, 1974, Adv Vet Sci Comp Med, V18, P79; JOHNSON KM, 1964, P SOC EXP BIOL MED, V118, P113; Joint FAO/ WHO expert committee on brucellosis, 1986, WHO TECH REP SER, V740, P1; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Karabatsos N., 1985, INT CATALOGUE ARBOVI; KATO S, 1959, BIKEN J, V2, P353; LACKMAN DB, 1962, AM J PUBLIC HEALTH N, V52, P87, DOI 10.2105/AJPH.52.1.87; LAST JM, 1992, PUBLIC HLTH PREVENTI; LEE HW, 1989, REV INFECT DIS, V11, pS864; LEON CA, 1975, INT J EPIDEMIOL, V4, P131, DOI 10.1093/ije/4.2.131; LUZZI GA, 1993, T ROY SOC TROP MED H, V87, P138, DOI 10.1016/0035-9203(93)90460-8; MACCALLUM F O, 1957, Bull World Health Organ, V16, P247; MAIZTEGUI J, 1986, MED MICROBIOL IMMUN, V175, P149, DOI 10.1007/BF02122437; MARMION BP, 1990, EPIDEMIOL INFECT, V104, P275, DOI 10.1017/S0950268800059458; MARRIE TJ, 1989, EPIDEMIOL INFECT, V102, P119, DOI 10.1017/S0950268800029757; MARTIN DH, 1972, AM J EPIDEMIOL, V95, P565, DOI 10.1093/oxfordjournals.aje.a121426; Martini G.A., 1971, MARBURG VIRUS DIS; MATHEWS JH, 1982, J IMMUNOL, V129, P2763; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; MCCRUMB FR, 1961, BACTERIOL REV, V25, P262, DOI 10.1128/MMBR.25.3.262-267.1961; MCGOVERN TW, 1997, TXB MILITARY MED MED, P479; MCKINNEY RW, 1963, AM J TROP MED HYG, V12, P597, DOI 10.4269/ajtmh.1963.12.597; MEIKLEJOHN G, 1961, B WORLD HEALTH ORGAN, V25, P63; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; MIDDLEBROOK JL, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P515; MILLER RP, 1969, AM REV RESPIR DIS, V99, P31; MITRA AC, 1974, B WORLD HEALTH ORGAN, V51, P106; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; MONATH TP, 1991, AM J TROP MED HYG, V45, P1; MOUSA AM, 1987, T ROY SOC TROP MED H, V81, P1020, DOI 10.1016/0035-9203(87)90385-3; MOUSA ARM, 1987, REV INFECT DIS, V9, P531; MOUSA ARM, 1988, REV INFECT DIS, V10, P211; Moyer Nelson P., 1995, P549; OLLEGOIG JE, 1987, AM J PUBLIC HEALTH, V77, P335, DOI 10.2105/AJPH.77.3.335; PEERY TM, 1960, AM J PATHOL, V36, P673; PENN RL, 1995, PRINCIPLES PRACTICE, P2060; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; PETERS CJ, 1991, TXB HUMAN VIROLOGY, P699; RAO AR, 1966, LANCET, V1, P1072; RAOULT D, 1993, ANTIMICROB AGENTS CH, V37, P1733, DOI 10.1128/AAC.37.9.1733; RAOULT D, 1995, CLIN INFECT DIS, V20, P489, DOI 10.1093/clinids/20.3.489; RICHMOND JY, 1993, HHS PUBLICATION CDC; Rossi A L, 1967, Prog Med Virol, V9, P176; ROSSI ALB, 1964, GAC MED CARACAS, V72, P5; Russell P, 1996, J ANTIMICROB CHEMOTH, V37, P769, DOI 10.1093/jac/37.4.769; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; SALMON MM, 1982, LANCET, V1, P1002; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P523; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P517; SAWYER WD, 1966, BACTERIOL REV, V30, P542, DOI 10.1128/MMBR.30.3.542-550.1966; SHEPHERD AJ, 1989, REV INFECT DIS, V11, pS801; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SMITH DL, 1993, RESP MED, V87, P509, DOI 10.1016/0954-6111(93)90006-L; SPICER AJ, 1978, J ROY SOC MED, V71, P762, DOI 10.1177/014107687807101011; STILES BG, 1993, INFECT IMMUN, V61, P5333, DOI 10.1128/IAI.61.12.5333-5338.1993; TIGERTT WD, 1956, T ASSOC AM PHYSICIAN, V69, P98; TURNBULL PCB, 1996, SALISBURY MED B S, V87, P1; UHAA IJ, 1994, J CLIN MICROBIOL, V32, P1560, DOI 10.1128/JCM.32.6.1560-1565.1994; Ulrich RG, 1997, TXB MILITARY MED 1, P621; *US ARM, 1977, L3 US ARM, V2; VANEEDEN PJ, 1985, S AFR MED J, V68, P718; WAAG D, 1995, EUR J CLIN MICROBIOL, V14, P421, DOI 10.1007/BF02114898; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; *WHO, 1970, HLTH ASP CHEM BIOL W, P72; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283; YOUNG EJ, 1991, REV INFECT DIS, V13, P359; ZDENEK J, 1988, HUMAN MONKEYPOX; 1997, MMWR-MORBID MORTAL W, V46, P304	146	486	516	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					399	411		10.1001/jama.278.5.399	http://dx.doi.org/10.1001/jama.278.5.399			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244332				2022-12-28	WOS:A1997XN51800032
J	Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P				Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P			Chlorine-36 in fossil rat urine: An archive of cosmogenic nuclide deposition during the past 40,000 years	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; ENVIRONMENTAL TRACERS; ATMOSPHERIC C-14/C-12; YOUNGER DRYAS; ICE CORE; BE-10; ISOTOPES; C-14; CLIMATE; AGES	Knowledge of the production history of cosmogenic nuclides, which is needed for geological and archaeological dating, has been uncertain. Measurements of chlorine-36/chlorine (Cl-36/Cl) ratios in fossil packrat middens from Nevada that are radiocarbon-dated between about 38 thousand years ago (ka) and the present showed that Cl-36/Cl ratios were higher by a factor of about 2 before similar to 11 ka. This raises the possibility that cosmogenic production rates just before the close of the Pleistocene were up to 50% higher than is suggested by carbon-14 calibration data. The discrepancy could be explained by addition of low-carbon-14 carbon dioxide to the atmosphere during that period, which would have depressed atmospheric radiocarbon activity. Alternatively, climatic effects on Cl-36 deposition may have enhanced the Cl-36/Cl ratios.	LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; DESERT RES INST,RENO,NV 89512; PURDUE UNIV,DEPT PHYS,W LAFAYETTE,IN 47907	United States Department of Energy (DOE); Los Alamos National Laboratory; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Plummer, MA (corresponding author), NEW MEXICO INST MIN & TECHNOL,DEPT EARTH & ENVIRONM SCI,SOCORRO,NM 87801, USA.			Turin, H J/0000-0003-3861-692X				BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BARNOLA JM, 1991, TELLUS B, V43, P83, DOI 10.1034/j.1600-0889.1991.t01-1-00002.x; BAUMGARTNER S, 1995, SOLID STATE RES LARG; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; BENSON L, 1995, PALAEOGEOGR PALAEOCL, V117, P1, DOI 10.1016/0031-0182(94)00103-F; Bentley H.W., 1986, HDB ENV GEOCHEMISTRY, P422; BENTLEY HW, 1986, WATER RESOUR RES, V22, P1991, DOI 10.1029/WR022i013p01991; Betancourt J.L., 1990, PACKRAT MIDDENS LAST; Bierman P, 1995, QUATERNARY RES, V44, P378, DOI 10.1006/qres.1995.1082; BROWN ET, 1995, EARTH PLANET SC LETT, V129, P193, DOI 10.1016/0012-821X(94)00249-X; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FABRYKAMARTIN JT, 1993, DISTRIBUTION CHOLINE; FINKEL RC, IN PRESS J GEOPHYS R; FORESTER RM, 1997, 3GCA102M US GEOL SUR; FRIEDLINGSTEIN P, 1995, J GEOPHYS RES-ATMOS, V100, P7203, DOI 10.1029/94JD02948; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; HAJDAS I, 1995, RADIOCARBON, V37, P75, DOI 10.1017/S0033822200014818; HOERING TC, 1961, GEOCHIM COSMOCHIM AC, V23, P186, DOI 10.1016/0016-7037(61)90043-6; HOUTERMA.J, 1966, Z PHYS, V193, P1, DOI 10.1007/BF01326455; HOUTERMANS JC, 1973, J GEOPHYS RES, V78, P1897, DOI 10.1029/JC078i012p01897; Huggle D, 1996, PLANET SPACE SCI, V44, P147, DOI 10.1016/0032-0633(95)00085-2; KAUFMANN R, 1984, NATURE, V309, P338, DOI 10.1038/309338a0; KUTZBACH JE, 1985, QUATERNARY SCI REV, V4, P147, DOI 10.1016/0277-3791(85)90024-1; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; Laj C, 1996, GEOPHYS RES LETT, V23, P2045, DOI 10.1029/96GL02152; LAL D, 1987, GEOPHYS RES LETT, V14, P785, DOI 10.1029/GL014i008p00785; LAL D, 1988, SOLAR TERRESTRIAL RE, P216; LAL D, 1985, CARBON CYCLE ATMOSPH, P221; LAO Y, 1992, NATURE, V357, P576, DOI 10.1038/357576a0; LEHMANN BE, 1993, WATER RESOUR RES, V29, P2027, DOI 10.1029/93WR00543; Libby WF., 1952, RADIOCARBON DATING; MAZAUD A, 1991, GEOPHYS RES LETT, V18, P1885, DOI 10.1029/91GL02285; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; MIFFLIN MD, 1979, B NEVADA BUREAU MINE, V94; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; NEWELL RE, 1971, SCI AM, V224, P32, DOI 10.1038/scientificamerican0171-32; OBRIEN K, 1979, J GEOPHYS RES-SPACE, V84, P423, DOI 10.1029/JA084iA02p00423; PAPKE KG, 1976, B NEVADA BUREAU MINE, V87; PHILLIPS FM, 1994, SOIL SCI SOC AM J, V58, P15, DOI 10.2136/sssaj1994.03615995005800010003x; PHILLIPS FM, 1995, REV GEOPHYS, V33, P1029, DOI 10.1029/95RG00247; PLUMMER MA, 1996, THESIS NEW MEXICO I; REHEIS MC, 1995, J GEOPHYS RES-ATMOS, V100, P8893, DOI 10.1029/94JD03245; Richards J. H., 1986, MINERAL EXPLORATION, P82; Robinson C, 1995, EARTH PLANET SC LETT, V136, P551, DOI 10.1016/0012-821X(95)00202-N; SARNTHEIN M, 1996, EOS S, V77, pF14; Schmidt-Nielsen K., 1964, DESERT ANIMALS PHYSL; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOUVENY N, 1993, GLOBAL PLANET CHANGE, V7, P157, DOI 10.1016/0921-8181(93)90047-R; TYLER SW, 1994, SOIL SCI SOC AM J, V58, P25, DOI 10.2136/sssaj1994.03615995005800010004x; WELLS PV, 1976, QUATERNARY RES, V6, P223, DOI 10.1016/0033-5894(76)90052-1; Wood WW, 1995, WATER RESOUR RES, V31, P3121, DOI 10.1029/95WR02572; [No title captured]	55	49	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					538	541		10.1126/science.277.5325.538	http://dx.doi.org/10.1126/science.277.5325.538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9227999				2022-12-28	WOS:A1997XM86700044
J	DeShazo, RD; Chapin, K; Swain, RE				DeShazo, RD; Chapin, K; Swain, RE			Fungal sinusitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ALLERGIC ASPERGILLUS SINUSITIS; PARA-NASAL SINUSES; NEWLY RECOGNIZED FORM; INVASIVE ASPERGILLOSIS; MUCORMYCOSIS; INFECTIONS; DIAGNOSIS; NOSE; HISTOPATHOLOGY; ITRACONAZOLE		UNIV S ALABAMA, COLL MED, DEPT PEDIAT, DIV ALLERGY & IMMUNOL, MOBILE, AL 36617 USA; UNIV S ALABAMA, COLL MED, DEPT PATHOL, DIV ALLERGY & IMMUNOL, MOBILE, AL 36617 USA; UNIV S ALABAMA, COLL MED, DEPT SURG, DIV ALLERGY & IMMUNOL, MOBILE, AL 36617 USA	University of South Alabama; University of South Alabama; University of South Alabama	DeShazo, RD (corresponding author), UNIV S ALABAMA, COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL, 2451 FILLINGIM ST, MASTIN 400A, MOBILE, AL 36617 USA.		Amedee, Ronald/A-5480-2011					BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; BLITZER A, 1993, OTOLARYNG CLIN N AM, V26, P1007; BLITZER A, 1980, LARYNGOSCOPE, V90, P635, DOI 10.1288/00005537-198004000-00010; BRANDWEIN M, 1993, OTOLARYNG CLIN N AM, V26, P949; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; CHOI SS, 1995, ARCH OTOLARYNGOL, V121, P1188, DOI 10.1001/archotol.1995.01890100092016; CODY DT, 1994, LARYNGOSCOPE, V104, P1074, DOI 10.1288/00005537-199409000-00005; COREY JP, 1995, OTOLARYNG HEAD NECK, V113, P110, DOI 10.1016/S0194-5998(95)70153-2; DECARPENTIER JP, 1994, J LARYNGOL OTOL, V108, P314, DOI 10.1017/S0022215100126635; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; DENNING DW, 1994, AM J MED, V97, P497; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; deShazo RD, 1997, J ALLERGY CLIN IMMUN, V99, P475, DOI 10.1016/S0091-6749(97)70073-3; DOOLEY DP, 1992, J CLIN NEURO-OPHTHAL, V12, P245; Georgopapadakou NH, 1996, ANTIMICROB AGENTS CH, V40, P279, DOI 10.1128/AAC.40.2.279; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GONZALEZCRESPO MR, 1995, SEMIN ARTHRITIS RHEU, V24, P304, DOI 10.1016/S0049-0172(95)80002-6; GOWING NFC, 1960, J CLIN PATHOL, V13, P396, DOI 10.1136/jcp.13.5.396; Graybill JR, 1996, CLIN INFECT DIS, V22, pS166, DOI 10.1093/clinids/22.Supplement_2.S166; GREEN WR, 1969, ARCH OPHTHALMOL-CHIC, V82, P302, DOI 10.1001/archopht.1969.00990020304002; GUMAA SA, 1992, T ROY SOC TROP MED H, V86, P93, DOI 10.1016/0035-9203(92)90460-T; HARTWICK RW, 1991, ANN OTO RHINOL LARYN, V100, P427, DOI 10.1177/000348949110000515; Jahrsdoerfer R A, 1979, Am J Otolaryngol, V1, P6, DOI 10.1016/S0196-0709(79)80003-4; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; Klossek JM, 1997, LARYNGOSCOPE, V107, P112, DOI 10.1097/00005537-199701000-00021; LOFTUS BC, 1993, OTOLARYNG CLIN N AM, V26, P1115; Mabry RL, 1997, OTOLARYNG HEAD NECK, V116, P31, DOI 10.1016/S0194-5998(97)70348-6; MCGILL TJ, 1980, LARYNGOSCOPE, V90, P748; MEYER RD, 1994, MEDICINE, V73, P69, DOI 10.1097/00005792-199403000-00001; MILOSEV B, 1969, BRIT J SURG, V56, P132, DOI 10.1002/bjs.1800560213; MILROY CM, 1989, J CLIN PATHOL, V42, P123, DOI 10.1136/jcp.42.2.123; Morpeth JF, 1996, ANN ALLERG ASTHMA IM, V76, P128, DOI 10.1016/S1081-1206(10)63411-4; NUSSBAUM ES, 1994, SURG NEUROL, V41, P152, DOI 10.1016/0090-3019(94)90114-7; RADNER AB, 1995, CLIN INFECT DIS, V20, P163, DOI 10.1093/clinids/20.1.163; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SANDISON A. T., 1967, SABOURAUDIA J INT SOC HUM AN1M MYCOL, V6, P57; Soto-Aquilar M. C., 1997, Journal of Investigative Medicine, V45, p3A; STAMMBERGER H, 1984, ANN OTO RHINOL LARYN, V93, P251, DOI 10.1177/000348948409300313; STAMMBERGER H, 1991, FUNCTIONAL ENDOSCOPI, P398; Strasser MD, 1996, ARCH INTERN MED, V156, P337, DOI 10.1001/archinte.156.3.337; TALBOT GH, 1991, REV INFECT DIS, V13, P219; TEH W, 1995, CLIN INFECT DIS, V21, P529, DOI 10.1093/clinids/21.3.529; VERESS B, 1973, AM J TROP MED HYG, V22, P765, DOI 10.4269/ajtmh.1973.22.765; Walsh TJ, 1996, INFECT DIS CLIN N AM, V10, P365, DOI 10.1016/S0891-5520(05)70303-2; WALSH TJ, 1994, J MED VET MYCOL, V32, P33; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004; WEBER RS, 1987, LARYNGOSCOPE, V97, P937; YOUNG CN, 1978, J LARYNGOL OTOL, V92, P137, DOI 10.1017/S0022215100085145; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	51	316	326	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					254	259		10.1056/NEJM199707243370407	http://dx.doi.org/10.1056/NEJM199707243370407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227932				2022-12-28	WOS:A1997XL99400007
J	Nickerson, KG; Shea, S				Nickerson, KG; Shea, S			W H R Rivers: Portrait of a great physician in Pat Barker's Regeneration trilogy	LANCET			English	Editorial Material									COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University								Barker P, 1991, REGENERATION; BARKER P, 1984, BLOW YOUR HOUSE; BARKER P, 1983, UNION STREET; BARKER P, 1986, CENTURYS DAUGHTER; Barker Pat, 1993, EYE DOOR; Barker Pat, 1995, GHOST ROAD; OWEN W, 1965, COLLECTED POEMS W OW, P69; Rivers W. H., 1923, CONFLICT AND DREAM; RIVERS WHR, 1918, LANCET, V2, P173; SASSOON S, 1917, FINISHED WAR SOLDIER; SASSOON S, 1936, SHERSTONS PROGR, P80; SLOBODIN RWH, 1978, RIVERS; WINTER J, 1996, GREAT WAR SHAPING 20, P212	13	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					205	209		10.1016/S0140-6736(97)02033-3	http://dx.doi.org/10.1016/S0140-6736(97)02033-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250198	hybrid			2022-12-28	WOS:A1997XL72200045
J	Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE				Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE			Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease	SCIENCE			English	Article							DISEASE; NEURODEGENERATION; DEATH	Most cases of early-onset familiar Alzheimer's disease (FAD) are caused by mutations in the genes encoding the presenilin 1 (PS1) and PS2 proteins, both of which undergo regulated endoproteolytic processing. During apoptosis, PS1 and PS2 were shown to be cleaved at sites distal to their normal cleavage sites by a caspase-3 family protease. In cells expressing PS2 containing the asparagine-141 FAD mutant, the ratio of alternative to normal PS2 cleavage fragments was increased relative to wild-type PS2-expressing cells, suggesting a potential role for apoptosis-associated cleavage of presenilins in the pathogenesis of Alzheimer's disease.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02129; KWANGJU INST SCI & TECHNOL,DEPT LIFE SCI,KWANGJU,SOUTH KOREA	Harvard University; Massachusetts General Hospital; Gwangju Institute of Science & Technology (GIST)			Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Jung, Yong-Keun/0000-0002-9686-3120				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON EM, 1994, NEUROBIOL AGING, V15, P5187; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim T. J., UNPUB; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOVACS DG, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEBLANC A, 1996, MOL MECH DEMENTIA, P57; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NEAMATI N, 1994, J IMMUNOL, V154, P1693; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Paradis E, 1996, J NEUROSCI, V16, P7533; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; TANZI RE, 1997, TRENDS NEUROSCI, V20, P154; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; XIE W, 1997, J BIOL CHEM, V272, P7977	40	325	337	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					373	376		10.1126/science.277.5324.373	http://dx.doi.org/10.1126/science.277.5324.373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219695				2022-12-28	WOS:A1997XL35800047
J	Rowan, R; Knowlton, N; Baker, A; Jara, J				Rowan, R; Knowlton, N; Baker, A; Jara, J			Landscape ecology of algal symbionts creates variation in episodes of coral bleaching	NATURE			English	Article							ULTRAVIOLET-RADIATION; REEF CORALS; TEMPERATURE; ZOOXANTHELLAE	Reef-building corals are obligate, mutualistic symbioses of heterotrophic animals and phototrophic dinoflagellates (Symbiodinium spp.)(1). Contrary to the earlier, widely accepted belief that corals harbour only one symbiont, we found that the ecologically dominant Caribbean corals Montastraea annularis and M. faveolata can act as hosts to dynamic, multi-species communities of Symbiodinium. Composition of these communities follows gradients of environmental irradiance, implying that physiological acclimatization(2-4) is not the only mechanism by which corals cope with environmental heterogeneity. The importance of this diversity was underlined by analysis of a natural episode of coral bleaching. Patterns of bleaching could be explained by the preferential elimination of a symbiont associated with low irradiance from the brightest parts of its distribution. Comparative analyses of symbionts before and after bleaching from the same corals supported this interpretation, and suggested that some corals were protected from bleaching by hosting an additional symbiont that is more tolerant of high irradiance and temperature. This 'natural experiment' suggests that temporal and spatial variability can favour the coexistence of diverse symbionts within a host, despite the potential for destabilizing competition among them(5,6).	SMITHSONIAN TROP RES INST,BALBOA,PANAMA; UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,MIAMI,FL 33149	Smithsonian Institution; Smithsonian Tropical Research Institute; University of Miami	Rowan, R (corresponding author), UNIV GUAM,MARINE LAB,MANGILAO,GU 96923, USA.			Baker, Andrew/0000-0002-7866-2587				BROWN BE, IN PRESS CORAL REEFS; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; DCROZ L, 1997, P 8 INT COR REEF S, V2, P203; DUNBAR RB, 1993, 10 CLIM GLOB CHANG P; EDMUNDS PJ, 1994, MAR BIOL, V121, P127; Falkowski P.G., 1990, P89; Fitt WK, 1995, BIOL BULL, V189, P298, DOI 10.2307/1542147; GATES RD, 1990, CORAL REEFS, V8, P193, DOI 10.1007/BF00265010; GLEASON DF, 1993, NATURE, V365, P836, DOI 10.1038/365836a0; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; IGLESIASPRIETO R, 1994, MAR ECOL PROG SER, V113, P163, DOI 10.3354/meps113163; JEFFREY SW, 1968, BIOL BULL, V135, P149, DOI 10.2307/1539622; JOKIEL PL, 1990, CORAL REEFS, V8, P155, DOI 10.1007/BF00265006; LASKER HR, 1984, CORAL REEFS, V3, P183, DOI 10.1007/BF00288253; Leigh Egbert Giles Jr, 1995, Ecologie, V26, P131; LESSER MP, 1990, CORAL REEFS, V8, P225, DOI 10.1007/BF00265015; LESSIOS HA, 1997, P 8 INT COR REEF S, V1, P673; PORTER JW, 1989, P NATL ACAD SCI USA, V86, P9342, DOI 10.1073/pnas.86.23.9342; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; ROWAN R, 1991, MAR ECOL PROG SER, V71, P65, DOI 10.3354/meps071065; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; SANDEMAN IM, 1988, MASS BLEACHING CORAL, P46; Szathmary E, 1995, MAJOR TRANSITIONS EV; TRENCH RK, 1993, ENDOCYTOBIOSIS CELL, V9, P135; Ware JR, 1996, ECOL MODEL, V84, P199, DOI 10.1016/0304-3800(94)00132-4; WEIL E, 1994, B MAR SCI, V55, P151; Williams EH, 1990, ATOLL RES B, P330, DOI DOI 10.5479/SI.00775630.335.1; [No title captured]	30	580	599	2	258	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					265	269		10.1038/40843	http://dx.doi.org/10.1038/40843			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230434	Bronze			2022-12-28	WOS:A1997XL12100048
J	Eddy, DM				Eddy, DM			Investigational treatments - How strict should we be?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KAISER HLTH PLAN & PERMANENTE MED GRP SO CALIF,PASADENA,CA	Permanente Medical Groups								[Anonymous], 1992, MANUAL ASSESSING HLT; Eddy D.M., 1990, JAMA-J AM MED ASSOC, V263, P1269; Eddy David., 1990, JAMA-J AM MED ASSOC, V263, P1272; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; Eddy DM, 1996, JAMA-J AM MED ASSOC, V275, P650, DOI 10.1001/jama.275.8.650; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2505; EDDY DM, 1992, STAT SYNTHESIS EVIDE; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1275; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2498; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2501; Hasselblad V., 1992, FAST PRO; PETERS WP, 1995, BREAST CANC RES TR S, V37, P55	13	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					179	185		10.1001/jama.278.3.179	http://dx.doi.org/10.1001/jama.278.3.179			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218650				2022-12-28	WOS:A1997XK10800001
J	Sands, KE; Bates, DW; Lanken, PN; Graman, PS; Hibberd, PL; Kahn, KL; Parsonnet, J; Panzer, R; Orav, EJ; Snydman, DR; Black, E; Schwartz, JS; Moore, R; Johnson, BL; Platt, R				Sands, KE; Bates, DW; Lanken, PN; Graman, PS; Hibberd, PL; Kahn, KL; Parsonnet, J; Panzer, R; Orav, EJ; Snydman, DR; Black, E; Schwartz, JS; Moore, R; Johnson, BL; Platt, R			Epidemiology of sepsis syndrome in 8 academic medical centers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; SEPTIC SHOCK; DEFINITIONS; METHYLPREDNISOLONE; ANTIBODY; SURVIVAL; TRIAL	Context.-Sepsis syndrome is a leading cause of mortality in hospitalized patients, However, few studies have described the epidemiology of sepsis syndrome in a hospitalwide population. Objective.-To describe the epidemiology of sepsis syndrome in the tertiary care hospital setting. Design.-Prospective, multi-institutional, observational study including 5-month follow-up. Setting.-Eight academic tertiary care centers. Methods.-Each center monitored a weighted random sample of intensive care unit (ICU) patients, non-ICU patients who had blood cultures drawn, and all patients who received a novel therapeutic agent or who died in an emergency department or ICU. Sepsis syndrome was defined as the presence of either a positive blood culture or the combination of fever, tachypnea, tachycardia, clinically suspected infection, and any 1 of 7 confirmatory criteria. Estimates of total cases expected annually were extrapolated from the number of cases, the period of observation, and the sampling fraction. Results.-From January 4, 1993, to April 2, 1994, 12 759 patients were monitored and 1342 episodes of sepsis syndrome were documented. The extrapolated, weighted estimate of hospitalwide incidence (mean +/- 95% confidence limit) of sepsis syndrome was 2.0 +/- 0.16 cases per 100 admissions, or 2.8 +/- 0.17 per 1000 patient-days. The unadjusted attack rate for sepis syndrome between individual centers differed by as much as 3-fold, but after adjustment for institutional differences in organ transplant populations, variation from the expected number of cases was reduced to 2-fold and was not statistically significant overall. Patients in ICUs accounted for 59% of total extrapolated cases, non-ICU patients with positive blood cultures for 11%, and non-ICU patients with negative blood cultures for 30%. Septic shock was present at onset of sepsis syndrome in 25% of patients. Blood-stream infection was documented in 28%, with gram-positive organisms being the most frequent isolates. Mortality was 34% at 28 days and 45% at 5 months. Conclusions.-Sepsis syndrome is common in academic hospitals, although the overall rates vary considerably with the patient population. A substantial fraction of cases occur outside ICUs, An understanding of the hospitalwide epidemiology of sepsis syndrome is vital for rational planning and treatment of hospitalized patients with sepsis syndrome, especially as new and expensive therapeutic agents become available.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HOSP UNIV PENN,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; HOSP UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV ROCHESTER,SCH MED,DEPT MED,INFECT DIS UNIT,ROCHESTER,NY; UNIV ROCHESTER,SCH MED,DEPT MED,GEN MED GERIATR UNIT,ROCHESTER,NY; MASSACHUSETTS GEN HOSP,DEPT MED,DIV INFECT DIS,BOSTON,MA 02114; UNIV CALIF LOS ANGELES,MED CTR,DIV GEN INTERNAL MED & HLTH SERV RES,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MED CTR,DIV INFECT DIS,LOS ANGELES,CA 90024; DARTMOUTH HITCHCOCK MED CTR,INFECT DIS SECT,LEBANON,NH 03766; TUFTS UNIV NEW ENGLAND MED CTR,DEPT PATHOL & MED,DIV INFECT DIS,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111; JOHNS HOPKINS MED INST,PHARMACOEPIDEMIOL PROGRAM,BALTIMORE,MD 21205	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Rochester; University of Rochester; Harvard University; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Dartmouth College; Tufts Medical Center; Tufts University; Johns Hopkins University; Johns Hopkins Medicine			Kahn, Katherine/AAE-2857-2020; Snydman, David R/O-3889-2014	Kahn, Katherine/0000-0002-6605-1455; Snydman, David R/0000-0003-0119-3978; Hibberd, Patricia/0000-0002-7455-8117				American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, 1992, CRIT CARE MED, V6, P864; BANERJEE SN, 1991, AM J MED S3B, V0091, P00086; BATES DW, 1994, ARCH INTERN MED, V154, P1241, DOI 10.1001/archinte.154.11.1241; BONE RC, 1993, JAMA-J AM MED ASSOC, V269, P2266, DOI 10.1001/jama.269.17.2266; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; *CDCP, 1990, MONTHLY VITAL STAT R, V41, P5; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P31; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GEERDES HF, 1992, CLIN INFECT DIS, V15, P991, DOI 10.1093/clind/15.6.991; KIEFT H, 1993, ARCH INTERN MED, V153, P2241, DOI 10.1001/archinte.153.19.2241; KIEFT H, 1994, THESIS U UTRECHT; KISH L, 1965, SURVEY SAMPLING, P77; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; Knaus WA, 1996, CRIT CARE MED, V24, P46, DOI 10.1097/00003246-199601000-00010; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; KOLL BS, 1993, CLIN INFECT DIS, V17, pS322, DOI 10.1093/clinids/17.Supplement_2.S322; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; PARILLO J E, 1990, Annals of Internal Medicine, V113, P227; Parrillo J E, 1993, N Engl J Med, V328, P1471; Pittet D, 1996, AM J RESP CRIT CARE, V153, P684, DOI 10.1164/ajrccm.153.2.8564118; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; SASSE KC, 1995, CRIT CARE MED, V23, P1040, DOI 10.1097/00003246-199506000-00008; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	29	461	493	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					234	240						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218672				2022-12-28	WOS:A1997XK10800031
J	Epstein, Y				Epstein, Y			Predominance of type II fibres in exertional heat stroke	LANCET			English	Editorial Material							ENERGY				Epstein, Y (corresponding author), CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL.							ARMSTRONG RB, 1986, SPORTS MED, V3, P370, DOI 10.2165/00007256-198603050-00006; BALLBURNETT M, 1991, J PHYSIOL-LONDON, V437, P257, DOI 10.1113/jphysiol.1991.sp018594; EPSTEIN Y, 1983, J APPL PHYSIOL, V54, P831, DOI 10.1152/jappl.1983.54.3.831; Frank A, 1996, ENV ERGONOMICS RECEN, P194; Hsu YD, 1997, J NEUROL NEUROSUR PS, V62, P182, DOI 10.1136/jnnp.62.2.182; HUBBARD RW, 1990, MED SCI SPORT EXER, V22, P19; Siejo B K, 1985, BRIT J ANAESTH, V57, P47	7	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					83	84		10.1016/S0140-6736(05)61811-9	http://dx.doi.org/10.1016/S0140-6736(05)61811-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228957				2022-12-28	WOS:A1997XK11400005
J	Treasure, T				Treasure, T			Recent advances - Cardiac surgery	BRITISH MEDICAL JOURNAL			English	Review											Treasure, T (corresponding author), UNIV LONDON ST GEORGES HOSP,DEPT CARDIOTHORAC SURG,LONDON SW17 0QT,ENGLAND.							Acuff TE, 1996, ANN THORAC SURG, V61, P135, DOI 10.1016/0003-4975(95)00907-8; Angelini GD, 1996, LANCET, V347, P757, DOI 10.1016/S0140-6736(96)90107-5; Batista RJV, 1996, J CARDIAC SURG, V11, P96, DOI 10.1111/j.1540-8191.1996.tb00019.x; BENETTI FJ, 1995, J CARDIAC SURG, V10, P620, DOI 10.1111/j.1540-8191.1995.tb00651.x; Bryan AJ, 1997, HEART, V77, P307, DOI 10.1136/hrt.77.4.307; Calafiore AM, 1996, ANN THORAC SURG, V61, P1658, DOI 10.1016/0003-4975(96)00187-7; Calafiore AM, 1996, LANCET, V347, P263; CALFIORE AM, 1996, ANN THORAC SURG, V62, P1545; CONYBEARE J, 1949, TXB MED, P397; Cooley DA, 1996, TEX HEART I J, V23, P81; COOLEY DA, 1969, AM J CARDIOL, V24, P723, DOI 10.1016/0002-9149(69)90460-3; HARLAND J C, 1949, Br Med J, V1, P1019; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; Kumar P, 1996, BRIT J HOSP MED, V56, P33; LEWIS T, 1946, DIS HEART, P159; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Lytle BW, 1996, J THORAC CARDIOV SUR, V111, P554; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; McCarthy M, 1997, LANCET, V349, P855, DOI 10.1016/S0140-6736(97)23012-6; McCarthy PM, 1996, NAT MED, V2, P859, DOI 10.1038/nm0896-859; MCMICHAEL J, 1952, BRIT MED J, V1, P932; Pocock SJ, 1996, CIRCULATION, V94, P135, DOI 10.1161/01.CIR.94.2.135; PRICE FW, 1950, TXB PRACTICE MED, P1018; PRICE FW, 1946, TXB PRACTICE MED; ROBINSON MC, 1995, J CARDIAC SURG, V10, P529, DOI 10.1111/j.1540-8191.1995.tb00628.x; SHEPHERD R, 1996, SUNDAY TIMES MA 0512, P26; STANBRIDGE RD, 1995, LANCET, V346, P837, DOI 10.1016/S0140-6736(95)91650-4; Treasure T, 1997, HEART, V77, P304, DOI 10.1136/hrt.77.4.304; Treasure T, 1996, J ROY SOC MED, V89, P19, DOI 10.1177/014107689608900106; Ullyot DJ, 1996, ANN THORAC SURG, V61, P10, DOI 10.1016/0003-4975(95)00891-8; Westaby S, 1996, HEART, V76, P200, DOI 10.1136/hrt.76.3.200	31	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					104	107		10.1136/bmj.315.7100.104	http://dx.doi.org/10.1136/bmj.315.7100.104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240052	Green Published			2022-12-28	WOS:A1997XL25200028
J	Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT				Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT			ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor	CELL			English	Article							DNA-REPLICATION INVITRO; POLYMERASE-II TRANSCRIPTION; CELL-FREE SYSTEM; NUCLEOSOME; HISTONES; PURIFICATION; ACTIVATOR; BINDING; PROTEIN; GAL4-VP16	We describe the purification and characterization of ACF, an ATP-utilizing chromatin assembly and remodeling factor. ACF is a multisubunit factor that contains ISWI protein and is distinct from NURF, another ISWI-containing factor. In chromatin assembly, purified ACF and a core histone chaperone (such as NAP-1 or CAF-1) are sufficient for the ATP-dependent formation of periodic nucleosome arrays. In chromatin remodeling, ACF is able to modulate the internucleosomal spacing of chromatin by an ATP-dependent mechanism. Moreover, ACF can mediate promoter-specific nucleosome reconfiguration by Gal4-VP16 in an ATP-dependent manner. These results suggest that ACF acts catalytically both in chromatin assembly and in the remodeling of nucleosomes that occurs during transcriptional activation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of California System; University of California San Diego; Cold Spring Harbor Laboratory				Pazin, Michael/0000-0002-7561-3640	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GERMOND JE, 1976, NUCLEIC ACIDS RES, V3, P3173, DOI 10.1093/nar/3.11.3173; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUNSTEIN M, 1997, IN PRESS NATURE; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; STEIN A, 1985, BIOCHEMISTRY-US, V24, P1783, DOI 10.1021/bi00328a032; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe A., 1995, CHROMATIN STRUCTURE; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	51	513	523	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					145	155		10.1016/S0092-8674(00)80321-9	http://dx.doi.org/10.1016/S0092-8674(00)80321-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230310	Bronze			2022-12-28	WOS:A1997XL36200016
J	Woo, K; Fraser, SE				Woo, K; Fraser, SE			Specification of the zebrafish nervous system by nonaxial signals	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; RETINOIC ACID CAUSES; ANTEROPOSTERIOR AXIS; XENOPUS EMBRYOS; MUTANT EMBRYOS; MOUSE EMBRYO; EXPRESSION; GENE; HINDBRAIN; INDUCTION	The organizer of the amphibian gastrula provides the neurectoderm with both neuralizing and posteriorizing (transforming) signals. In zebrafish, transplantations show that a spatially distinct transformer signal emanates from tissues other than the organizer. Cells of the germring (nonaxial mesendoderm) posteriorized forebrain progenitors when grafted nearby, resulting in an ectopic hindbrain-like structure; in contrast, cells of the organizer (axial mesendoderm) caused no posterior transformation, Local application of basic fibroblast growth factor, a candidate transformer in Xenopus, caused malformation but not hindbrain transformation in the forebrain, Thus, the zebrafish gastrula may integrate spatially distinct signals from the organizer and the germring to pattern the neural axis.	CALTECH, BECKMAN INST, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, BECKMAN INST, BIOL IMAGING CTR, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology			Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Blader P, 1996, DEV GENES EVOL, V206, P3, DOI 10.1007/s004270050025; Blumberg B, 1997, DEVELOPMENT, V124, P373; Cox WG, 1995, DEVELOPMENT, V121, P4349; DAI ZS, 1995, J NEUROSCI, V15, P5466; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EYAL-GILADI H., 1954, ARCH BIOL [PARIS], V65, P179; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HOLDER N, 1991, DEVELOPMENT, V113, P1159; Hyatt GA, 1996, DEVELOPMENT, V122, P195; JOLY JS, 1993, DEVELOPMENT, V119, P1261; KELLY GM, 1995, DEVELOPMENT, V121, P1787; KELLY GM, 1995, DEV GENET, V17, P129, DOI 10.1002/dvg.1020170205; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRAUSS S, 1992, DEVELOPMENT, V116, P249; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LI Y, 1994, WEINBERG MECH DEV, V48, P229; Mason I, 1996, CURR BIOL, V6, P672, DOI 10.1016/S0960-9822(09)00446-1; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Sala M., 1955, Proceedings Akademie van Wetenschappen Amsterdam, V58C, P635; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SAXEN L, 1992, PRIMARY EMBRYONIC IN; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHIH J, 1995, DEVELOPMENT, V121, P2755; Shih J, 1996, DEVELOPMENT, V122, P1313; Sive H, 1996, DEV DYNAM, V205, P265, DOI 10.1002/(SICI)1097-0177(199603)205:3<265::AID-AJA7>3.0.CO;2-G; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THISSE C, 1993, DEVELOPMENT, V119, P1203; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WOO K, 1995, DEVELOPMENT, V121, P2595; WOO K, 1995, DEV BIOL, V170, P764; WOO K, UNPUB; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	52	118	119	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					254	257		10.1126/science.277.5323.254	http://dx.doi.org/10.1126/science.277.5323.254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211857				2022-12-28	WOS:A1997XK41800050
J	Sharp, VL; Shenson, D				Sharp, VL; Shenson, D			Humanitarianism under the gun	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Sharp, VL (corresponding author), BETH ISRAEL MED CTR,DEPT MED,317 E 17TH ST,FIERMAN HALL,1ST FLOOR,NEW YORK,NY 10003, USA.							BUCKLEY S, 1996, WASHINGTON POST 0123; GEDDA G, 1997, WASHINGTON TIME 0127; LYNCH C, 1996, BOSTON GLOBE    1229; *US COMM REF, 1994, WORLD REF SURV 1994, P2; Voelker R, 1997, JAMA-J AM MED ASSOC, V277, P446	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					160	160						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214533				2022-12-28	WOS:A1997XH66700038
J	FirthCozens, J				FirthCozens, J			Predicting stress in general practitioners: 10 year follow up postal survey	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION				FirthCozens, J (corresponding author), UNIV LEEDS,DEPT PSYCHOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							BLATT SJ, 1992, CLIN PSYCHOL REV, V12, P527, DOI 10.1016/0272-7358(92)90070-O; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; FIRTHCOZENS J, 1992, J OCCUP ORGAN PSYCH, V65, P61, DOI 10.1111/j.2044-8325.1992.tb00484.x; FIRTHCOZENS J, 1997, DEPRESSION PHYSICAL; JAYCOX LH, 1994, BEHAV RES THER, V32, P801, DOI 10.1016/0005-7967(94)90160-0	5	37	38	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					34	35		10.1136/bmj.315.7099.34	http://dx.doi.org/10.1136/bmj.315.7099.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233325	Green Published			2022-12-28	WOS:A1997XJ94700028
J	Sutton, M				Sutton, M			Personal paper: How to get the best health outcome for a given amount of money	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Sutton, M (corresponding author), UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND.			Sutton, Matt/0000-0002-6635-2127				BIRCH S, 1992, J HEALTH ECON, V11, P279, DOI 10.1016/0167-6296(92)90004-K; CHAPMAN PLH, 1988, BRIT J ADDICT, V83, P67; *EFF HLTH CAR, 1993, BRIEF INT ALC US BRI; MATTICK RP, 1995, DRUG ALCOHOL REV, V14, P134, DOI 10.1080/09595239400185211; TORGERSON DJ, 1994, BMJ-BRIT MED J, V308, P117, DOI 10.1136/bmj.308.6921.117; Torgerson DJ, 1996, BRIT MED J, V312, P35, DOI 10.1136/bmj.312.7022.35; Torrance GW, 1987, METHODS EC EVALUATIO; WILLIAMS A, 1994, OUTCOMES CLIN PRACTI, P99; Williams Alan, 1994, P829	9	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	1997	315	7099					47	49		10.1136/bmj.315.7099.47	http://dx.doi.org/10.1136/bmj.315.7099.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233329	Green Published			2022-12-28	WOS:A1997XJ94700036
J	Beinert, H; Holm, RH; Munck, E				Beinert, H; Holm, RH; Munck, E			Iron-sulfur clusters: Nature's modular, multipurpose structures	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; VINELANDII FERREDOXIN-I; ELEMENT BINDING-PROTEIN; COLI SULFITE REDUCTASE; MIXED-VALENCE SYSTEMS; FE-S CLUSTER; ELECTRONIC-STRUCTURE; DESULFOVIBRIO-GIGAS; CLOSTRIDIUM-PASTEURIANUM; CRYSTAL-STRUCTURE	Iron-sulfur proteins are found in all life forms. Most frequently, they contain Fe2S2, Fe3S4, and Fe4S4 clusters. These modular clusters undergo oxidation-reduction reactions, may be inserted or removed from proteins, can influence protein structure by preferential side chain ligation, and can be interconverted. In addition to their electron transfer function, iron-sulfur clusters act as catalytic centers and sensors of iron and oxygen. Their most common oxidation states are paramagnetic and present significant challenges for understanding the magnetic properties of mixed valence systems. Iron-sulfur clusters now rank with such biological prosthetic groups as hemes and flavins in pervasive occurrence and multiplicity of function.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53705 USA; HARVARD UNIV, DEPT CHEM & CHEM BIOL, CAMBRIDGE, MA 02138 USA; CARNEGIE MELLON UNIV, DEPT CHEM, PITTSBURGH, PA 15213 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Carnegie Mellon University	Beinert, H (corresponding author), UNIV WISCONSIN, INST ENZYME RES, MADISON, WI 53705 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034812] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-K06 GM 18442, GM 12394, GM 34812] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achim C, 1996, J AM CHEM SOC, V118, P8168, DOI 10.1021/ja9617698; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675; ANGOVE H, IN PRESS J AM CHEM S; ARNON DI, 1957, NATURE, V180, P182, DOI 10.1038/180182a0; BANCI L, 1993, BIOCHEMISTRY-US, V32, P9387, DOI 10.1021/bi00087a018; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1960, BIOCHEM BIOPH RES CO, V3, P41, DOI 10.1016/0006-291X(60)90100-5; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Belinskiy M, 1996, INORG CHIM ACTA, V243, P91, DOI 10.1016/0020-1693(95)04895-2; Berg J.M., 1982, IRON SULFUR PROTEINS, P1; BERTINI I, 1995, STRUCT BOND, V83, P1; BOMINAAR EL, 1995, J AM CHEM SOC, V117, P6976, DOI 10.1021/ja00131a021; BOMINAAR EL, IN PRESS INORG CHEM; BORSHCH SA, 1993, J AM CHEM SOC, V115, P5155, DOI 10.1021/ja00065a030; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CARNEY MJ, 1989, INORG CHEM, V28, P1497, DOI 10.1021/ic00307a015; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHRISTNER JA, 1984, J AM CHEM SOC, V106, P6786, DOI 10.1021/ja00334a054; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; CROUSE BR, 1995, J AM CHEM SOC, V117, P9612, DOI 10.1021/ja00142a049; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Demadis KD, 1996, INORG CHEM, V35, P4038, DOI 10.1021/ic960098b; Dickson D. P. E., 1974, J PHYS-PARIS, DOI 10.1051/jphyscol:1974659; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; DUIN EC, UNPUB; FINNEGAN MG, 1995, INORG CHEM, V34, P5358, DOI 10.1021/ic00125a040; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Gamelin DR, 1996, J AM CHEM SOC, V118, P8085, DOI 10.1021/ja9536633; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GILLUM WO, 1977, J AM CHEM SOC, V99, P584, DOI 10.1021/ja00444a044; GIRERD JJ, 1983, J CHEM PHYS, V79, P1766, DOI 10.1063/1.446021; GLOUX J, 1994, J AM CHEM SOC, V116, P1953, DOI 10.1021/ja00084a040; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Golinelli MP, 1996, BIOCHEMISTRY-US, V35, P8995, DOI 10.1021/bi9604284; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; Gutlich P., 1978, MOSSBAUER SPECTROSCO; HAGEN KS, 1983, J AM CHEM SOC, V105, P3905, DOI 10.1021/ja00350a028; HAGEN KS, 1981, J AM CHEM SOC, V103, P4054, DOI 10.1021/ja00404a013; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOLM RH, 1977, ACCOUNTS CHEM RES, V16, P2565; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; Iwasaki T, 1996, J BIOL CHEM, V271, P27659, DOI 10.1074/jbc.271.44.27659; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; JORDANOV J, 1990, INORG CHEM, V29, P4288, DOI 10.1021/ic00346a025; KAHN O, 1993, MOL MAGNETISM, pCH13; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1984, J BIOL CHEM, V259, P3145; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Lamotte B, 1997, CR ACAD SCI II B, V324, P117, DOI 10.1016/S1251-8069(99)80015-3; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Lovenberg W, 1973, IRON SULFUR PROTEINS, VI; Lovenberg W, 1973, IRON SULFUR PROTEINS, VII; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MORTENSON LE, 1962, BIOCHEM BIOPH RES CO, V7, P448, DOI 10.1016/0006-291X(62)90333-9; MOUESCA JM, 1993, J AM CHEM SOC, V115, P4714, DOI 10.1021/ja00064a036; MOURA I, 1986, J AM CHEM SOC, V108, P349, DOI 10.1021/ja00262a057; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; NOODLEMAN L, 1995, COORDIN CHEM REV, V144, P199, DOI 10.1016/0010-8545(95)07011-L; NOODLEMAN L, 1984, J AM CHEM SOC, V106, P2316, DOI 10.1021/ja00320a017; Orme-Johnson W H, 1978, Methods Enzymol, V53, P268; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; REYNOLDS JG, 1981, INORG CHEM, V20, P1873, DOI 10.1021/ic50220a052; Robinson M.B., 1967, ADV INORG CHEM, V10, P247, DOI [10.1016/S0065-2792(08)60179-X, DOI 10.1016/S0065-2792(08)60179-X]; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; SANDS RH, 1974, Q REV BIOPHYS, V7, P443, DOI 10.1017/S0033583500001517; SANPIETRO A, 1958, J BIOL CHEM, V231, P211; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; Spiro T. G., 1982, IRON SULFUR PROTEINS; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; THAUER RK, 1982, IRON SULFUR PROTEINS, P329; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843; Zhou J, 1997, J AM CHEM SOC, V119, P6242, DOI 10.1021/ja9704186; ZHOU J, 1992, J AM CHEM SOC, V114, P10843, DOI 10.1021/ja00053a021; 1996, J BIOL INORG CHEM, V1, P173	93	1448	1482	20	504	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					653	659		10.1126/science.277.5326.653	http://dx.doi.org/10.1126/science.277.5326.653			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235882				2022-12-28	WOS:A1997XN90700032
J	Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A				Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A			Analysis of a chemical plant defense mechanism in grasses	SCIENCE			English	Article							TRYPTOPHAN SYNTHASE-ALPHA; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; HYDROXAMIC ACIDS; MAIZE; EXPRESSION; GENE; BIOSYNTHESIS; SUBUNIT; MONOOXYGENASE	In the Gramineae, the cyclic hydroxamic acids 2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) and 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one (DIMBOA) form part of the defense against insects and microbial pathogens. Five genes, Bx1 through Bx5, are required for DIBOA biosynthesis in maize. The functions of these five genes, clustered on chromosome 4, were demonstrated in vitro. Bx1 encodes a tryptophan synthase a homolog that catalyzes the formation of indole for the production of secondary metabolites rather than tryptophan, thereby defining the branch point from primary to secondary metabolism. Bx2 through Bx5 encode cytochrome P450-dependent monooxygenases that catalyze four consecutive hydroxylations and one ring expansion to form the highly oxidized DIBOA.	TECH UNIV MUNICH, GENET INST, D-85747 GARCHING, GERMANY; DEKALB GENET CORP, MYSTIC, CT 06355 USA; TECH UNIV MUNICH, INST ORGAN CHEM & BIOCHEM, D-85747 GARCHING, GERMANY; PIONEER HI BRED INT INC, JOHNSTON, IA 50131 USA; OHIO STATE UNIV, DEPT HORT & CROP SCI, WOOSTER, OH 44691 USA	Technical University of Munich; Technical University of Munich; DuPont; Pioneer Hi-Bred International, Inc.; University System of Ohio; Ohio State University			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279; Glawischnig, Erich/0000-0001-9280-5065				BAILEY BA, 1991, PLANT PHYSIOL, V95, P792, DOI 10.1104/pp.95.3.792; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Chomet Paul S., 1994, P243; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; Desai SR, 1996, CHEM COMMUN, P1321, DOI 10.1039/cc9960001321; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; Glawischnig E, 1997, PHYTOCHEMISTRY, V45, P715, DOI 10.1016/S0031-9422(96)00832-1; HAMILTON R. H., 1964, WEEDS, V12, P27, DOI 10.2307/4040633; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KRAMER VC, 1995, PLANT MOL BIOL, V27, P1183, DOI 10.1007/BF00020891; KUMAR P, 1994, PHYTOCHEMISTRY, V36, P893, DOI 10.1016/S0031-9422(00)90458-8; KUTCHAN TM, 1995, PLANT CELL, V7, P1059, DOI 10.2307/3870057; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; Mena M, 1996, SCIENCE, V274, P1537, DOI 10.1126/science.274.5292.1537; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RADWANSKI ER, 1995, MOL GEN GENET, V248, P657, DOI 10.1007/BF02191705; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; TSUJI J, 1993, PHYSIOL MOL PLANT P, V43, P221, DOI 10.1006/pmpp.1993.1052; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; WOODWARD MD, 1979, PLANT PHYSIOL, V63, P9, DOI 10.1104/pp.63.1.9; WRIGHT AD, 1992, PLANT CELL, V4, P711, DOI 10.1105/tpc.4.6.711; Zhao JM, 1996, PLANT CELL, V8, P2235, DOI 10.1105/tpc.8.12.2235	28	498	547	6	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					696	699		10.1126/science.277.5326.696	http://dx.doi.org/10.1126/science.277.5326.696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235894				2022-12-28	WOS:A1997XN90700044
J	Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J				Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J			Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		outcome and process assessment (health care); dialysis; cost-benefit analysis; kidney failure, acute; decision making	ACUTE-RENAL-FAILURE; CONVENIENT APPROXIMATION; REQUIRING DIALYSIS; LIFE EXPECTANCY; RISK-FACTORS; APACHE-II; SURVIVAL; SYSTEM; PROGNOSIS; SUPPORT	Background: Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. Objective: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. Design: Prospective cohort study and cost-effectiveness analysis. Setting: Five geographically diverse teaching hospitals. Patients: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. Measurements: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of followup) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. Results: Median duration of survival was 32 days, and only 27% of patients were alive after 6 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as ''good'' or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128 200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274 100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61 900. Conclusions: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50 000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.	UNIV TENNESSEE, CHATTANOOGA UNIV, CHATTANOOGA, TN 37403 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; JOHNS HOPKINS UNIV, HLTH SERV RES CTR, BALTIMORE, MD 21205 USA; DUKE UNIV, SCH MED, DURHAM, NC 27710 USA; UNIV CINCINNATI, MED CTR, SECT OUTCOMES RES, CINCINNATI, OH 45267 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA	University of Tennessee System; University of Tennessee at Chattanooga; University of Virginia; Johns Hopkins University; Duke University; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Hamel, MB (corresponding author), BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY-330, BOSTON, MA 02215 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; GOLDMAN L, 1992, HEART DIS TXB CARDIO; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MAHER ER, 1989, Q J MED, V72, P857; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPURNEY RF, 1991, CRIT CARE MED, V19, P8, DOI 10.1097/00003246-199101000-00007; Torrance G W, 1972, Health Serv Res, V7, P118; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHEELER DC, 1986, Q J MED, V61, P977	29	165	166	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					195	+		10.7326/0003-4819-127-3-199708010-00003	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XN129	9245224				2022-12-28	WOS:A1997XN12900003
J	Bolla, M; Gonzalez, D; Warde, P; Dubois, JB; Mirimanoff, RO; Storme, G; Bernier, J; Kuten, A; Sternberg, C; Gil, T; Collette, L; Pierart, M				Bolla, M; Gonzalez, D; Warde, P; Dubois, JB; Mirimanoff, RO; Storme, G; Bernier, J; Kuten, A; Sternberg, C; Gil, T; Collette, L; Pierart, M			Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; CARCINOMA; TRIAL	Background We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced prostate cancer. Methods From 1987 to 1995, 415 patients with locally advanced prostate cancer were randomly assigned to receive radiotherapy alone or radiotherapy plus immediate treatment with goserelin. The patients had a median age of 71 years (range, 51 to 80). Patients in both groups received 50 Gy of radiation to the pelvis over a period of five weeks and an additional 20 Gy over an additional two weeks as a prostatic boost. Patients in the combined-treatment group received 3.6 mg of goserelin (Zoladex) subcutaneously every four weeks starting on the first day of irradiation and continuing for three years; those patients also received cyproterone acetate (150 mg orally per day) during the first month of treatment to inhibit the transient rise in testosterone associated with the administration of goserelin. Results Data were available for analysis on 401 patients. The median follow-up was 45 months. Kaplan-Meier estimates of overall survival at five years were 79 percent (95 percent confidence interval, 72 to 86 percent) in the combined-treatment group and 62 percent (95 percent confidence interval, 52 to 72 percent) in the radiotherapy group (P=0.001). The proportion of surviving patients who were free of disease at five years was 85 percent (95 percent confidence interval, 78 to 92 percent) in the combined-treatment group and 48 percent (95 percent confidence interval, 38 to 58 percent) in the radiotherapy group (P<0.001). Conclusions Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer. (C) 1997, Massachusetts Medical Society.	AKAD MED CENTRUM, AMSTERDAM, NETHERLANDS; PRINCESS MARGARET HOSP, TORONTO, ON M4X 1K9, CANADA; CTR REG LUTTE CANC VAL AURELLE, MONTPELLIER, FRANCE; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; ONCOL CENTRUM, BRUSSELS, BELGIUM; OSPED SAN GIOVANNI BELLINZONA, BELLINZONA, SWITZERLAND; RAMBAM MED CTR, HAIFA, ISRAEL; UFFICIO STERNBERG & PANSADORO, ROME, ITALY; EUROPEAN ORG RES TREATMENT CANC, CTR DATA, BRUSSELS, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Regional Hospital of Bellinzona & Valleys, San Giovanni; Rambam Health Care Campus; Technion Israel Institute of Technology; European Organisation for Research & Treatment of Cancer	Bolla, M (corresponding author), UNIV HOSP, DEPT RADIOTHERAPY, BP 217, F-38043 GRENOBLE 9, FRANCE.		Bernier, Jacques/AAE-7248-2020	Bernier, Jacques/0000-0002-0138-9906; Collette, Laurence/0000-0003-2518-7281; Warde, Padraig/0000-0002-4236-0026				Bagshaw M A, 1988, NCI Monogr, P47; DUSSERRE A, 1995, RADIOTHER ONCOL, V36, P229, DOI 10.1016/0167-8140(95)01612-K; FELLOWS GJ, 1992, BRIT J UROL, V70, P304, DOI 10.1111/j.1464-410X.1992.tb15736.x; HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO;2-P; International Commission of Radiation Units and Measurements, 1978, 29 ICRU; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEIBEL SA, 1994, INT J RADIAT ONCOL, V28, P7, DOI 10.1016/0360-3016(94)90135-X; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; National Institutes of Health Consensus Development, 1988, NATL CANCER I MONOGR, V7, P3; NEGLIA WJ, 1977, INT J RADIAT ONCOL, V2, P873, DOI 10.1016/0360-3016(77)90185-7; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; PILEPICH MV, 1995, P AN M AM SOC CLIN, V14, P239; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROZAN R, 1994, CONTR ONCOL, V47, P98; Scardino P T, 1988, NCI Monogr, P95; Schroder FH, 1990, EORTC GENITOURINARY, V7, P45; TAYLOR WJ, 1979, CANCER-AM CANCER SOC, V43, P1123, DOI 10.1002/1097-0142(197903)43:3<1123::AID-CNCR2820430351>3.0.CO;2-F; VANDERWERFMESSING B, 1976, INT J RADIAT ONCOL, V1, P1043, DOI 10.1016/0360-3016(76)90074-2; WHO, 1979, WHO HDB REP RES CANC	19	1237	1269	1	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					295	300		10.1056/NEJM199707313370502	http://dx.doi.org/10.1056/NEJM199707313370502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233866	Green Published, Bronze			2022-12-28	WOS:A1997XN11900002
J	Schekman, R; Mellman, I				Schekman, R; Mellman, I			Does COPI go both ways?	CELL			English	Review							ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; PROTEIN-TRANSPORT; MEMBRANE; SECRETION; COATOMER; STACK; CELL; ER		YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University	Schekman, R (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL CELL BIOL,BERKELEY,CA 94720, USA.		Mellman, Ira/ABG-5896-2020					ARIDOR M, 1995, J CELL BIOL, V131, P825; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; SABESIN SM, 1977, J LIPID RES, V18, P496; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHNEPF E, 1993, PROTOPLASMA, V172, P3, DOI 10.1007/BF01403716; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237	20	76	78	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					197	200		10.1016/S0092-8674(00)80326-8	http://dx.doi.org/10.1016/S0092-8674(00)80326-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244292	hybrid			2022-12-28	WOS:A1997XN24900002
J	Edmonson, MB; Stoddard, JJ; Owens, LM				Edmonson, MB; Stoddard, JJ; Owens, LM			Hospital readmission with feeding-related problems after early postpartum discharge of normal newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM NEWBORN	Context.-Increasingly short postpartum hospital stays in the United States precipitated a policy debate that culminated in passage of the Newborns' and Mothers' Health Protection Act of 1996. The debate occurred without population-based evidence for adverse health effects in newborns who are discharged early. Objective.-To determine whether early postpartum hospital discharge of normal newborns increases their risk for hospital readmission with feeding-related problems. Design and Setting.-Nested case-control analysis of 1991 to 1994 Wisconsin birth certificate and hospital discharge data. Subjects.-A total of 210 readmitted case patients and 630 control subjects selected from a cohort of 120 290 normal newborns who weighed at least 2500 g, were delivered vaginally of mothers with uncomplicated medical and obstetrical histories, and were discharged from the hospital either early (day of life 1 or 2) or conventionally (day 3). Outcome Measure.-Readmission at age 4 to 28 days with discharge diagnoses indicating a primary feeding problem, secondary dehydration, or inadequate weight gain. Results.-Early discharges increased 3-fold (reaching 521/1000 discharges) during the study period, but feeding-related readmissions (1.7/1000) remained stable. Most readmitted newborns (53.8%) were 4 to 7 days old, many (34.3%) had concurrent dehydration and jaundice, and 29% were admitted through emergency departments. Readmitted newborns were significantly (P<.05) more likely to have been breast-fed, firstborn, or preterm or to have mothers who were poorly educated (<12th grade), unmarried, or receiving Medicaid. Readmission was not associated with early discharge (adjusted odds ratio, 1.05; 95% confidence interval, 0.71-1.53), Conclusion.-Although several neonatal and maternal factors increase the risk that a normal newborn will be rehospitalized with a feeding-related problem, early discharge following an uncomplicated postpartum hospital stay appears to have little or no independent effect on this risk.	UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53792; WISCONSIN DEPT HLTH & SOCIAL SERV,CTR HLTH STAT,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	Edmonson, MB (corresponding author), UNIV WISCONSIN,CTR HLTH SCI,DEPT PEDIAT,H6-440 CLIN SCI CTR,600 HIGHLAND AVE,MADISON,WI 53792, USA.							*AM AC PED COMM FE, 1995, PEDIATRICS, V96, P788; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; Center for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P335; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P700; HOSMER DW, 1989, APPL LOGISTIC REGRES; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; Kini N, 1995, Wis Med J, V94, P143; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Margolis LH, 1995, CLIN PEDIATR, V34, P626, DOI 10.1177/000992289503401201; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; NEWMAN TB, 1992, PEDIATRICS, V89, P809; *OFF HLTH CAR INF, 1995, HLTH CAR DAT ANN REP; PARISI V, 1996, NEW ENGL J MED, V333, P1635; POSES RM, 1995, MED CARE, V33, pAS36; Public Health Service, 1988, INT CLASS DIS; *SAS I INC, 1990, SAS TECHN REP P 200, P175; SELBY JV, 1994, EPIDEMIOL REV, V16, P90, DOI 10.1093/oxfordjournals.epirev.a036148; Soskolne EI, 1996, ARCH PEDIAT ADOL MED, V150, P373, DOI 10.1001/archpedi.1996.02170290039006; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; *WI ASS PER CAR, 1993, INT C REP EARL DISCH, P1	22	93	98	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					299	303		10.1001/jama.278.4.299	http://dx.doi.org/10.1001/jama.278.4.299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228435				2022-12-28	WOS:A1997XL05900030
J	Super, M; Postlethwaite, RJ				Super, M; Postlethwaite, RJ			Genes, familial enuresis, and clinical management	LANCET			English	Editorial Material							NOCTURNAL ENURESIS; VASOPRESSIN		ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT NEPHROL,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Super, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT GENET,MANCHESTER M27 4HA,LANCS,ENGLAND.							Arnell H, 1997, J MED GENET, V34, P360, DOI 10.1136/jmg.34.5.360; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; EIBERG H, 1995, NAT GENET, V10, P354, DOI 10.1038/ng0795-354; FERGUSSON DM, 1986, PEDIATRICS, V78, P884; HOGG RJ, 1993, J UROLOGY, V150, P444, DOI 10.1016/S0022-5347(17)35506-4; Koff SA, 1996, PEDIATR NEPHROL, V10, P667, DOI 10.1007/s004670050186; RITTIG S, 1989, AM J PHYSIOL, V256, pF664, DOI 10.1152/ajprenal.1989.256.4.F664; Steers WD, 1997, LANCET, V349, P1604, DOI 10.1016/S0140-6736(05)61633-9; WILLE S, 1904, ACTA PAEDIAT, V93, P772	9	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					159	160		10.1016/S0140-6736(05)62347-1	http://dx.doi.org/10.1016/S0140-6736(05)62347-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250180				2022-12-28	WOS:A1997XL72200006
J	Engert, F; Bonhoeffer, T				Engert, F; Bonhoeffer, T			Synapse specificity of long-term potentiation breaks down at short distances	NATURE			English	Article							SLICE CULTURES; RAT HIPPOCAMPUS; ENHANCEMENT; PLASTICITY; TRANSMISSION; PROBABILITY; RELEASE; NEURONS	Long-term potentiation (LTP), the long-lasting increase in synaptic transmission, has been proposed to be a cellular mechanism essential for learning and memory, neuronal development, and circuit reorganization. In the original theoretical(1) and experimental(2) work it was assumed that only synapses that had experienced concurrent pre- and postsynaptic activity are subject to synaptic modification. It has since been shown, however, that LTP is also expressed in synapses on neighbouring neurons that have not undergone the induction procedure(3-5). Yet, it is still believed that this spread of LTP is limited to adjacent postsynaptic cells, and does not occur for synapses on neighbouring input fibres(2,6,7). However, for technical reasons, tests for 'input specificity' were always done for synapses relatively far apart. Here we have used a new local superfusion technique, which allowed us to assess the synaptic specificity of LTP with a spatial resolution of similar to 30 mu m. Our results indicate that there is no input specificity at a distance of less than 70 mu m. Synapses in close proximity to a site of potentiation are also potentiated regardless of their own history of activation, whereas synapses far away show no potentiation.	MAX PLANCK INST PSYCHIAT, D-82152 MUNICH, GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FROTSCHER M, 1990, PROG BRAIN RES, V83, P323; GAHWILER BH, 1981, PROC R SOC SER B-BIO, V211, P287, DOI 10.1098/rspb.1981.0007; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIPSKI J, 1981, J NEUROSCI METH, V4, P1, DOI 10.1016/0165-0270(81)90015-7; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Neveu D, 1996, J NEUROPHYSIOL, V75, P2157, DOI 10.1152/jn.1996.75.5.2157; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOLBURG H, 1991, J NEUROCYTOL, V20, P552, DOI 10.1007/BF01215263	25	192	195	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	1997	388	6639					279	284		10.1038/40870	http://dx.doi.org/10.1038/40870			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230437	Bronze			2022-12-28	WOS:A1997XL12100052
J	Rind, DM; Kohane, IS; Szolovits, P; Safran, C; Chueh, HC; Barnett, GO				Rind, DM; Kohane, IS; Szolovits, P; Safran, C; Chueh, HC; Barnett, GO			Maintaining the confidentiality of medical records shared over the Internet and the World Wide Web	ANNALS OF INTERNAL MEDICINE			English	Article							CONSENT; LEGAL	The Boston Electronic Medical Record Collaborative is working to develop a system that will use the World Wide Web to transfer computer-based patient information to clinicians in emergency departments. Maintaining adequate confidentiality of these records while still facilitating patient care is paramount to this effort. This paper describes an explicit protocol that would make it possible to electronically identify patients and providers, secure permission for release of records, and track information that is transmitted. It is hoped that other, similar efforts now underway will be able to use and build on this model. Comment on this proposal is invited from all parties with an interest in confidentiality. The system will be used only with ''scrubbed'' data-data from which all identifiers have been removed-until it is generally agreed that the confidentiality methods proposed here are appropriate and sufficient.	CHILDRENS HOSP, INFORMAT PROGRAM, BOSTON, MA 02115 USA; MIT, COMP SCI LAB, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rind, DM (corresponding author), BETH ISRAEL MED CTR, CTR CLIN COMP, 350 LONGWOOD AVE, BOSTON, MA 02115 USA.		Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160; Szolovits, Peter/0000-0001-8411-6403	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS008749] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [U01LM005877] Funding Source: NIH RePORTER; AHRQ HHS [HS08749] Funding Source: Medline; NLM NIH HHS [U01 LM 05877] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Anderson R, 1996, BRIT MED J, V312, P109; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; Cimino J J, 1995, Proc Annu Symp Comput Appl Med Care, P111; *COMP SCI TEL BOAR, 1997, REC PROT EL HLTH INF; DONALDSON MS, 1994, HLTH DATA INFORMATIO; GARFINKEL S, 1995, PRWACTICAL UNIX INTE; Jagannathan V, 1995, Proc Annu Symp Comput Appl Med Care, P12; Kittredge R L, 1996, Proc AMIA Annu Fall Symp, P628; Kohane I S, 1996, Proc AMIA Annu Fall Symp, P608; Kohane IS, 1996, J AM MED INFORM ASSN, V3, P191, DOI 10.1136/jamia.1996.96310633; KOHANE IS, 1995, PEDIATR RES, V37, pA139; Lowe HJ, 1996, J AM MED INFORM ASSN, V3, P1, DOI 10.1136/jamia.1996.96342645; MCDONALD CJ, 1995, P ANN S COMPUT APPL, P1029; SAFRAN C, 1995, M D COMPUT, V12, P187; Slack WV, 1997, M D COMPUT, V14, P83; Slack WV, 1997, M D COMPUT, V14, P8; SPRUNG CL, 1989, CRIT CARE MED, V17, P1346, DOI 10.1097/00003246-198912000-00022; van Wingerde F J, 1996, Proc AMIA Annu Fall Symp, P643; WALD JS, 1994, P AM MED INF ASS, P42; Willard K E, 1995, Proc Annu Symp Comput Appl Med Care, P771; WINSLADE WJ, 1982, J LEGAL MED, V3, P497, DOI 10.1080/01947648209513364; WOODWARD B, 1995, NEW ENGL J MED, V333, P1419, DOI 10.1056/NEJM199511233332112	23	66	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					138	141		10.7326/0003-4819-127-2-199707150-00008	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230004				2022-12-28	WOS:A1997XK15800010
J	Song, YH				Song, YH			Why tyrosinase for treatment of melanoma	LANCET			English	Editorial Material							VITILIGO				Song, YH (corresponding author), UNIV FLORIDA, DEPT PATHOL IMMUNOL & LAB MED, GAINESVILLE, FL 32610 USA.		Song, Yao-Hua/A-2516-2011					ALBADRI AMT, 1993, J PATHOL, V170, P149, DOI 10.1002/path.1711700209; Baharav E, 1996, CLIN EXP IMMUNOL, V105, P84, DOI 10.1046/j.1365-2249.1996.d01-727.x; Becker JC, 1996, J INVEST DERMATOL, V107, P627, DOI 10.1111/1523-1747.ep12584237; Berd D, 1996, CANCER IMMUNOL IMMUN, V42, P263, DOI 10.1007/s002620050280; BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; DUHRA P, 1991, CLIN EXP DERMATOL, V16, P303, DOI 10.1111/j.1365-2230.1991.tb00383.x; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; SALTER J, 1995, MELANOMA RES, V5, P267, DOI 10.1097/00008390-199508000-00010; SCHALLREUTER KU, 1991, DERMATOLOGICA, V183, P239, DOI 10.1159/000247693; SONG YH, 1994, LANCET, V344, P1049, DOI 10.1016/S0140-6736(94)91709-4; VISSEREN MJW, 1995, J IMMUNOL, V154, P3991	11	20	20	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	1997	350	9071					82	83		10.1016/S0140-6736(05)61810-7	http://dx.doi.org/10.1016/S0140-6736(05)61810-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228956				2022-12-28	WOS:A1997XK11400004
J	Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V				Giannelli, G; FalkMarzillier, J; Schiraldi, O; StetlerStevenson, WG; Quaranta, V			Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; IV COLLAGENASE; KERATINOCYTES; CARCINOMAS; ACTIVATION; ADHESION; COMPLEX	Structural changes in the extracellular matrix are necessary for cell migration during tissue remodeling and tumor invasion. Specific cleavage of laminin-5 (Ln-5) by matrix metalloprotease-2 (MMP2) was shown to induce migration of breast epithelial cells. MMP2 cleaved the Ln-5 gamma 2 subunit at residue 587, exposing a putative cryptic promigratory site on Ln-5 that triggers cell motility. This altered form of Ln-5 is found in tumors and in tissues undergoing remodeling, but not in quiescent tissues. Cleavage of Ln-5 by MMP2 and the resulting activation of the Ln-5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling.	SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV BARI, INST MED CLIN 2, I-70124 BARI, ITALY; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012; Quaranta, Vito/G-6512-2016; giannelli, gianluigi/A-8169-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Quaranta, Vito/0000-0001-7491-8672; 	NATIONAL CANCER INSTITUTE [R01CA047858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010063] Funding Source: NIH RePORTER; NCI NIH HHS [CA47858] Funding Source: Medline; NIDCR NIH HHS [DE10063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Baker SE, 1996, J CELL SCI, V109, P2509; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BURDSAL CA, 1991, DEV BIOL, V144, P327, DOI 10.1016/0012-1606(91)90425-3; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; CALOF AL, 1996, NATURE, V383, P441; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Giannelli G, 1996, LAB INVEST, V74, P1091; GIANNELLI G, UNPUB; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KARECLA PI, 1994, CELL ADHES COMMUN, V2, P309, DOI 10.3109/15419069409014206; KOHN EC, 1995, CANCER RES, V55, P1856; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURIE GW, 1982, J CELL BIOL, V95, P340, DOI 10.1083/jcb.95.1.340; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Plopper G, 1996, J CELL SCI, V109, P1965; PYKE C, 1995, CANCER RES, V55, P4132; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOULE HD, 1990, CANCER RES, V50, P6075; WANG X, 1994, CANCER RES, V54, P4726; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	32	997	1020	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					225	228		10.1126/science.277.5323.225	http://dx.doi.org/10.1126/science.277.5323.225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211848				2022-12-28	WOS:A1997XK41800041
J	Hall, JC				Hall, JC			Circadian pacemakers blowing hot and cold - But they're clocks, not thermometers	CELL			English	Review							DROSOPHILA-MELANOGASTER; TEMPERATURE; RHYTHMS; LOCUS				Hall, JC (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; Bunning E, 1973, PHYSL CLOCK; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; GIBBS FP, 1983, AM J PHYSIOL, V244, pR607, DOI 10.1152/ajpregu.1983.244.5.R607; HALL JC, 1997, IN PRESS J NEUROGENE; Iwasaki K, 1997, TRENDS GENET, V13, P111, DOI 10.1016/S0168-9525(97)01059-7; KONOPKA RJ, 1987, ANNU REV GENET, V21, P227, DOI 10.1146/annurev.genet.21.1.227; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; ROSBASH M, 1996, COLD SPRING HARB SYM, V61, P267; Ruby NF, 1996, J BIOL RHYTHM, V11, P126, DOI 10.1177/074873049601100205; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Sehgal A, 1996, MOL CELL NEUROSCI, V7, P165, DOI 10.1006/mcne.1996.0013; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	22	22	22	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					9	12		10.1016/S0092-8674(00)80308-6	http://dx.doi.org/10.1016/S0092-8674(00)80308-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230297	Bronze			2022-12-28	WOS:A1997XL36200003
J	Lindahl, T				Lindahl, T			Facts and artifacts of ancient DNA	CELL			English	Review											Lindahl, T (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Klein, Richard G/B-5910-2009					Austin JJ, 1997, P ROY SOC B-BIOL SCI, V264, P467, DOI 10.1098/rspb.1997.0067; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Schwartz JH, 1996, P NATL ACAD SCI USA, V93, P10852, DOI 10.1073/pnas.93.20.10852; SHREEVE J, 1995, NEANDERTAL ENIGMA; TORRONI A, 1994, AM J HUM GENET, V55, P760	7	54	64	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					1	3		10.1016/S0092-8674(00)80306-2	http://dx.doi.org/10.1016/S0092-8674(00)80306-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230295	Bronze			2022-12-28	WOS:A1997XL36200001
J	Wang, B; Kuspa, A				Wang, B; Kuspa, A			Dictyostelium development in the absence of cAMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; 3-DIMENSIONAL SCROLL WAVES; ADENYLATE-CYCLASE ACTIVITY; GENE-EXPRESSION; CELL-DIFFERENTIATION; PHOSPHODIESTERASE GENE; SIGNAL-TRANSDUCTION; EXTRACELLULAR CAMP; CATALYTIC SUBUNIT; DISCOIDEUM	Adenosine 3',5'-monophosphate (cAMP) and cAMP-dependent protein kinase (PKA) are regulators of development in many organisms. Dictyostelium uses cAMP as an extracellular chemoattractant and as an intracellular signal for differentiation. Cells that are mutant in adenylyl cyclase do not develop. Moderate expression of the catalytic subunit of PKA in adenylyl cyclase-null cells led to near-normal development without detectable accumulation of cAMP. These results suggest that all intracellular cAMP signaling is effected through PKA and that signals other than extracellular cAMP coordinate morphogenesis in Dictyostelium.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Kuspa, Adam/0000-0002-9156-149X	NIGMS NIH HHS [R01 GM052359] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052359] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; ABE K, 1983, J GEN MICROBIOL, V129, P1623; ANJARD C, 1992, DEVELOPMENT, V115, P785; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1959, P NATL ACAD SCI USA, V45, P379, DOI 10.1073/pnas.45.3.379; BRETSCHNEIDER T, 1995, P NATL ACAD SCI USA, V92, P4387, DOI 10.1073/pnas.92.10.4387; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Dormann D, 1996, DEVELOPMENT, V122, P761; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; GERISCH G, 1985, COLD SPRING HARB SYM, V50, P813, DOI 10.1101/SQB.1985.050.01.099; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, DEVELOPMENT, V119, P147; KENCHT DA, 1986, MOL CELL BIOL, V6, P3973; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; Levine H, 1996, P NATL ACAD SCI USA, V93, P6382, DOI 10.1073/pnas.93.13.6382; Loomis WF, 1996, MICROBIOL REV, V60, P135, DOI 10.1128/MMBR.60.1.135-150.1996; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANN SKO, 1992, P NATL ACAD SCI USA, V89, P10701, DOI 10.1073/pnas.89.22.10701; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETERS DJM, 1991, P NATL ACAD SCI USA, V88, P9219, DOI 10.1073/pnas.88.20.9219; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; Reymond CD, 1995, EXPERIENTIA, V51, P1166, DOI 10.1007/BF01944734; RICHARDSON DL, 1991, DEV BIOL, V144, P269, DOI 10.1016/0012-1606(91)90421-X; Rietdorf J, 1996, DEV BIOL, V177, P427, DOI 10.1006/dbio.1996.0175; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; SIEGERT F, 1995, CURR BIOL, V5, P937, DOI 10.1016/S0960-9822(95)00184-9; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Soede RDM, 1996, DEV BIOL, V177, P152, DOI 10.1006/dbio.1996.0152; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; WALLRAFF E, 1984, J GEN MICROBIOL, V130, P2103; Wang B., UNPUB; WEIJER CJ, 1987, METHOD CELL BIOL, V28, P449; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267	62	87	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					251	254		10.1126/science.277.5323.251	http://dx.doi.org/10.1126/science.277.5323.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211856				2022-12-28	WOS:A1997XK41800049
J	Nathan, DM; Meigs, J; Singer, DE				Nathan, DM; Meigs, J; Singer, DE			The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is ... or is it?	LANCET			English	Article							CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; RISK-FACTORS; FOLLOW-UP; MORTALITY; INSULIN; COMPLICATIONS; POPULATION; ONSET; PREVALENCE		MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Nathan, DM (corresponding author), MASSACHUSETTS GEN HOSP,DIABET UNIT,MED EVALUAT UNIT,BULFINCH 408,BOSTON,MA 02114, USA.		Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657				Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; [Anonymous], 1995, DIABETES AM; Aronson D, 1997, ANN INTERN MED, V126, P296, DOI 10.7326/0003-4819-126-4-199702150-00006; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COUTINHO M, 1996, CIRCULATION, V94, P214; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Diabetes Drafting Group, 1985, DIABETOLOGIA, V28, P615; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; FU CC, 1993, DIABETES CARE, V16, P137, DOI 10.2337/diacare.16.1.137; FULLER JH, 1980, LANCET, V1, P1373; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HAFFNER SM, 1991, DIABETES CARE, V14, P665, DOI 10.2337/diacare.14.7.665; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Howard BV, 1996, DIABETES, V45, pS6, DOI 10.2337/diab.45.3.S6; ITO S, 1996, DIABETES S3, V45, pS19; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Meigs JB, 1997, AM J MED, V102, P38, DOI 10.1016/S0002-9343(96)00383-X; MEIGS JB, 1995, DIABETES, V44, pA5; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Park S, 1996, DIABETES CARE, V19, P450, DOI 10.2337/diacare.19.5.450; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; PYORALA K, 1995, DIABETES, V44, pA35; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Siegel RD, 1996, METABOLISM, V45, P1267, DOI 10.1016/S0026-0495(96)90246-2; SINGER DE, 1989, DIABETES, V38, P350, DOI 10.2337/diabetes.38.3.350; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SMITH DA, 1986, DIABETES CARE, V9, P601, DOI 10.2337/diacare.9.6.601; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WILSON P, 1987, AM J CARDIOL, V59, P916; Wilson P W, 1985, Monogr Atheroscler, V13, P1; WILSON PWF, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90532-2; WINGARD DL, 1983, AM J EPIDEMIOL, V117, P19, DOI 10.1093/oxfordjournals.aje.a113510; WINGARD DL, 1987, AM J EPIDEMIOL, V125, P948, DOI 10.1093/oxfordjournals.aje.a114633; WINGARD DL, 1995, DIABETES AM, P429	58	28	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI4	SI9						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250276				2022-12-28	WOS:A1997XM26500003
J	Hall, W; Zador, D				Hall, W; Zador, D			The alcohol withdrawal syndrome	LANCET			English	Article							HOME DETOXIFICATION; CARE; INTOXICATION; MANAGEMENT; INPATIENT		CENT SYDNEY AREA HLTH SERV,DULWICH HILL,NSW 2203,AUSTRALIA		Hall, W (corresponding author), UNIV NEW S WALES,NATL DRUG & ALCOHOL RES CTR,SYDNEY,NSW 2052,AUSTRALIA.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				ADINOFF B, 1994, AM J ADDICTION, V3, P277; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BENZER DG, 1990, J SUBST ABUSE TREAT, V7, P117, DOI 10.1016/0740-5472(90)90007-D; Benzer DG, 1994, PRINCIPLES ADDICTION; BIRD RD, 1994, ANN PHARMACOTHER, V28, P67, DOI 10.1177/106002809402800114; CASTANEDA R, 1989, J CLIN PSYCHIAT, V50, P278; COOPER DB, 1994, ALCOHOL HOME DETOXIF; EARNEST MP, 1993, NEUROL CLIN, V11, P563, DOI 10.1016/S0733-8619(18)30139-7; Ferguson JA, 1996, J GEN INTERN MED, V11, P410, DOI 10.1007/BF02600188; Foy A, 1997, QJM-INT J MED, V90, P253, DOI 10.1093/qjmed/90.4.253; FOY A, 1995, DRUG ALCOHOL REV, V14, P49, DOI 10.1080/09595239500185051; FOY A, 1988, AUST PRESCRIBER, V11, P71; GLUE P, 1990, BRIT J PSYCHIAT, V157, P491, DOI 10.1192/bjp.157.4.491; GUTHRIE SK, 1989, PHARMACOTHERAPY, V9, P131; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; Heinz A, 1996, J STUD ALCOHOL, V57, P471, DOI 10.15288/jsa.1996.57.471; HELZER JE, 1991, PSYCHIAT DISORDERS A; ISBELL H, 1995, Q J STUD ALCOHOL, V16, P1; LISKOW BI, 1987, J STUD ALCOHOL, V48, P356, DOI 10.15288/jsa.1987.48.356; LOHR RH, 1995, MAYO CLIN PROC, V70, P777, DOI 10.4065/70.8.777; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MATTICK RP, 1993, OUTLINE MANAGEMENT A; McMicken David B., 1994, Emergency Medicine Clinics of North America, V12, P1057; O'Brien C.P., 1996, GOODMAN GILMANS PHAR, P557; PEDERSEN C, 1986, AUST DRUG ALCOHOL RE, V5, P133; ROMACH MK, 1991, ANNU REV MED, V42, P323, DOI 10.1146/annurev.me.42.020191.001543; ROSENBLATT SM, 1972, Q J STUD ALCOHOL, V33, P1060; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SELLERS EM, 1976, NEW ENGL J MED, V294, P757; SELLERS EM, 1983, CLIN PHARMACOL THER, V34, P822, DOI 10.1038/clpt.1983.256; SELLERS EM, 1978, PRINCIPLES PSYCHOPHA; Shaw GK, 1995, ALCOHOL ALCOHOLISM, V30, P765; SHAW JM, 1981, J CLIN PSYCHOPHARM, V1, P382, DOI 10.1097/00004714-198111000-00006; STOCKWELL T, 1990, BRIT J ADDICT, V85, P61; STOCKWELL T, 1991, ALCOHOL ALCOHOLISM, V26, P645, DOI 10.1093/oxfordjournals.alcalc.a045169; STOCKWELL T, 1994, ADDICTION, V89, P197; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; WARTENBERG AA, 1990, ALCOHOL CLIN EXP RES, V14, P71, DOI 10.1111/j.1530-0277.1990.tb00449.x; Wesson DR, 1995, TREATMENT IMPROVEMEN, V19; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409	41	133	134	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1897	1900		10.1016/S0140-6736(97)04572-8	http://dx.doi.org/10.1016/S0140-6736(97)04572-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG417	9217770				2022-12-28	WOS:A1997XG41700041
J	Chuang, HH; Jan, YN; Jan, LY				Chuang, HH; Jan, YN; Jan, LY			Regulation of IRK3 inward rectifier K+ channel by m1 acetylcholine receptor and intracellular magnesium	CELL			English	Article							BETA-GAMMA-SUBUNITS; NUCLEUS ACCUMBENS NEURONS; RAT SYMPATHETIC NEURONS; M-CURRENT INHIBITION; POTASSIUM CHANNEL; MUSCARINIC RECEPTOR; CALCIUM CURRENT; SUBSTANCE-P; CARDIAC MYOCYTES; ATRIAL MYOCYTES	Inward rectifier K+ channels control the cell's membrane potential and neuronal excitability. We report that the IRK3 but not the IRK1 inward rectifier K+ channel activity is inhibited by mi muscarinic acetylcholine receptor. This m1 modulation cannot be accounted for by protein kinase C, Ca2+, or channel phosphorylation, but can be mimicked by Mg2+. Based on quantitative analyses of IRK3 and two different IRK1 mutant channels bestowed with sensitivity to m1 modulation, we suggest that the resting Mg2+ level causes chronic inhibition of IRK3 channels, and m1 receptor stimulation may lead to an increase of cytoplasmic Mg2+ concentration and further channel inhibition, due to the ability of Mg2+ to lead these channels into a prolonged inactivated state.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.physiol.53.1.299; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; Collins A, 1996, J NEUROSCI, V16, P1; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CROWFROF.PJ, 1971, J PHYSIOL-LONDON, V219, P443, DOI 10.1113/jphysiol.1971.sp009671; DIFRANCESCO D, 1980, PFLUG ARCH EUR J PHY, V387, P83, DOI 10.1007/BF00584257; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; EGAN TM, 1986, NATURE, V319, P405, DOI 10.1038/319405a0; ELLIOTT DA, 1974, J BIOL CHEM, V249, P3985; ERDOS JJ, 1983, J PHYSIOL-LONDON, V337, P351, DOI 10.1113/jphysiol.1983.sp014628; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GRUBBS RD, 1986, J BIOL CHEM, V261, P2550; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MCLACHLAN EM, 1989, J PHYSIOL-LONDON, V415, P109, DOI 10.1113/jphysiol.1989.sp017714; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NOBLE D, 1984, J PHYSIOL-LONDON, V353, P1; NORTH RA, 1989, J PHYSIOL-LONDON, V417, P1; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OH U, 1995, J MEMBRANE BIOL, V147, P241; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; RIJKERS GT, 1993, BIOCHEM J, V289, P373, DOI 10.1042/bj2890373; ROBBINS J, 1993, J PHYSIOL-LONDON, V469, P153, DOI 10.1113/jphysiol.1993.sp019809; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SATO R, 1995, J MEMBRANE BIOL, V148, P185; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; SHEN KZ, 1992, J PHYSIOL-LONDON, V455, P471, DOI 10.1113/jphysiol.1992.sp019312; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STOREY KB, 1992, ANAL BIOCHEM, V201, P119; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; UCHIMURA N, 1990, J PHYSIOL-LONDON, V422, P369, DOI 10.1113/jphysiol.1990.sp017989; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; Wang HS, 1996, J PHYSIOL-LONDON, V492, P467, DOI 10.1113/jphysiol.1996.sp021322; WHITE RE, 1988, SCIENCE, V239, P778, DOI 10.1126/science.2448878; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	67	51	55	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1121	1132		10.1016/S0092-8674(00)80299-8	http://dx.doi.org/10.1016/S0092-8674(00)80299-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215634	Bronze			2022-12-28	WOS:A1997XG83000016
J	Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R				Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R			Neuroscience - Learning mechanisms: The case for CaM-KII	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; PROTEIN-KINASE; CALMODULIN; INDUCTION; LTP; AUTOPHOSPHORYLATION; TRANSMISSION; STORAGE; PKC		BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Brandeis University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Lisman, J (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BARRIA A, 1997, SCIENCE, V276, P2022; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; Lem J, 1996, CURR OPIN NEUROBIOL, V6, P453, DOI 10.1016/S0959-4388(96)80049-3; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OTMAKHOV N, IN PRESS J NEUROSCI; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9	19	108	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2001	2002		10.1126/science.276.5321.2001	http://dx.doi.org/10.1126/science.276.5321.2001			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221509				2022-12-28	WOS:A1997XG74800050
J	Reeve, JN; Sandman, K; Daniels, CJ				Reeve, JN; Sandman, K; Daniels, CJ			Archaeal histones, nucleosomes, and transcription initiation	CELL			English	Review							ARCHAEBACTERIUM; PROTEINS				Reeve, JN (corresponding author), OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210, USA.			Sandman, Kathleen/0000-0002-5222-5864				ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; DeDecker BS, 1996, J MOL BIOL, V264, P1072, DOI 10.1006/jmbi.1996.0697; Grayling RA, 1996, ADV PROTEIN CHEM, V48, P437; Grayling RA, 1997, EXTREMOPHILES, V1, P79, DOI 10.1007/s007920050018; Hamiche A, 1996, P NATL ACAD SCI USA, V93, P7588, DOI 10.1073/pnas.93.15.7588; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; STOLT P, 1993, MOL MICROBIOL, V7, P875, DOI 10.1111/j.1365-2958.1993.tb01178.x; TAKAYANAGI S, 1992, J BACTERIOL, V174, P7207, DOI 10.1128/jb.174.22.7207-7216.1992; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; vanHolde K, 1996, BIOESSAYS, V18, P697, DOI 10.1002/bies.950180903; Yang CF, 1996, J BACTERIOL, V178, P840, DOI 10.1128/jb.178.3.840-845.1996	19	131	132	2	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					999	1002		10.1016/S0092-8674(00)80286-X	http://dx.doi.org/10.1016/S0092-8674(00)80286-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215621	Bronze			2022-12-28	WOS:A1997XG83000003
J	Nightingale, SL				Nightingale, SL			National conference on implementation of the waiver of informed consent in emergency situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P1632	1	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-28	WOS:A1997XN51800010
J	Zilinskas, RA				Zilinskas, RA			Iraq's biological weapons - The past as future?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISSILE ATTACKS; GULF-WAR	Between 1985 and April 1991, Iraq developed anthrax, botulinum toxin, and aflatoxin for biological warfare; 200 bombs and 25 ballistic missiles laden with biological agents were deployed by the time Operation Desert Storm occurred. Although cause for concern, if used during the Persian Gulf Vilar, Iraq's biological warfare arsenal probably would have been militarily ineffective for 3 reasons: (1) it was small; (2) payload dispersal mechanisms were inefficient; and (3) coalition forces dominated the theater of war (ie, they had overwhelming air superiority and had crippled Iraq's command and control capability). Despite the Gulf War defeat, the Iraqi biological warfare threat has not been extinguished. Saddam Hussein remains in power, and his desire to acquire weapons of mass destruction continues unabated. In this context, the international community must be firm in its enforcement of United Nations resolutions designed to deter Iraq from reacquiring biological warfare capability and must take steps to develop a multidisciplinary approach to limiting future development of weapons of mass destruction.			Zilinskas, RA (corresponding author), UNIV MARYLAND,INST BIOTECHNOL,CTR PUBL ISSUES BIOTECHNOL,4321 HARTWICK RD,SUITE 500,COLLEGE PK,MD 20740, USA.							ALBRIGHT D, 1995, B ATOM SCI, V51, P53, DOI 10.1080/00963402.1995.11658103; ALBRIGHT D, 1995, TRACKING NUCL PROLIF, P125; ANWAR K, 1995, INT REV, V16, P1; Atkinson, 1993, CRUSADE UNTOLD STORY; BLEICH A, 1991, ISRAEL J MED SCI, V27, P673; Bryden John, 1989, DEADLY ALLIES CANADA; CARMELI A, 1991, ISRAEL J MED SCI, V27, P677; CARTER GB, 1992, BIOL WARFACE BIOL DE; CORDESMAN AH, 1990, LESSONS MODERN WAR 2; CORDESMAN AH, 1996, WEAPONS MASS DESTRUC; DANON YL, 1991, ISRAEL J MED SCI, V27, P601; DARWISH G, 1996, ALMAJALLAH      0128, P22; EISENSTADT M, 1995, JANES INTELLIGENCE R, P76; EITEL T, 1995, COMMUNICATION   1207; EMSLEY J, 1978, NEW SCI, V80, P92; FRANZ DR, 1994, DEFENSE TOXIN WEAPON; FULLERTON CS, 1996, EMOTIONAL AFTERMATH, P111; HUXSOLL DL, 1989, JAMA-J AM MED ASSOC, V262, P677, DOI 10.1001/jama.262.5.677; HUXSOLL DL, 1987, J AM VET MED ASSOC, V190, P714; *I MED COMM REV HL, 1996, HLTH CONS SERV PERS; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; KEENE J, 1958, 28 BWL PLANS EV OFF; LEITENBERG M, 1992, ARMS CONTROL TODAY, V22, P10; LINCOLN RE, 1959, 237 BWL PROC RES DIV; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; *OP RES GROUP, 1952, MIL UT AG 10; PATTEN RC, 1981, AM J TROP MED HYG, V80, P422; *STOCKH INT PEAC R, 1973, PROBL CHEM BIOL WARF; TAYLOR HL, 1991, P2438 I DEF AN; *UN, 1995, SC6137 UN; *UN SOV SOC REP, 1950, MAT TRIAL FORM SERV; *US ARM CHEM WARF, 1945, 9 US ARM CHEM WARF S; *US ARM MED UN, 1960, BIBL ANTHR; *US DEP STAT, 1982, 98 US DEP STAT; US Department of the Army, 1977, US ARM ACT US BIOL W; *US GEN ACC OFF, 1992, GAONSIAD92116; *US GEN ACC OFF, 1993, GAONSIAD932; WIENER SL, 1986, TRAUMA MANAGEMENT CI, P507; Williams P, 1989, UNIT 731 JAPANESE AR; ZILINSKAS RA, 1990, PERSPECT BIOL MED, V34, P44; ZILINSKAS RA, 1995, POLIT LIFE SCI, V14, P230, DOI 10.1017/S0730938400019134; ZILINSKAS RA, 1986, BIOL TOXIN WEAPONS T, P82; ZILINSKAS RA, 1996, ARMS CONTROL MULTIPO, P193	43	253	259	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					418	424		10.1001/jama.278.5.418	http://dx.doi.org/10.1001/jama.278.5.418			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244334				2022-12-28	WOS:A1997XN51800034
J	vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA				vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA			Medical end-of-life decisions made for neonates and infants in the Netherlands	LANCET			English	Article							INTENSIVE-CARE; EUTHANASIA	Background Advances in neonatal intensive care have lowered the neonatal death rate. There are still some severely ill neonates and infants, however, for whom the application of all possible life-prolonging treatment modalities may be questioned. Methods We did two studies in the Netherlands. In the first we sent questionnaires to physicians who had attended 338 consecutive deaths (August-November, 1995) within the first year of life (death-certificate study), and in the second we interviewed 31 neonatologists or paediatric intensive-care specialists and 35 general paediatricians. The response rates were 88% and 99%, respectively. Findings in the death-certificate study, 57% of all deaths had been preceded by a decision to forgo life-sustaining treatment; this decision was accompanied by the administration of potentially life-shortening drugs to alleviate pain or other symptoms in 23%, and by the administration of drugs with the explicit aim of hastening death in 8%. A drug was given explicitly to hasten death to neonates not dependent on life-sustaining treatment in 1% of all death cases. No chance of survival was the main motive in 76% of all end-of-life decisions, and a poor prognosis was the main motive in 18%. The interview study showed that parents had been involved in making 79% of decisions, The physicians consulted colleagues about 88% of decisions, Most paediatricians favoured formal review of medical decisions by colleagues together with ethical or legal experts. Interpretation Death among neonates and infants is commonly preceded by medical end-of-life decisions. Most Dutch paediatricians seem to find prospects for survival and prognostic factors relevant in such decisions. Public control by a committee of physicians, paediatricians, ethicists, and legal experts is widely endorsed by paediatricians.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	vanderHeide, A (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1986, NEW ENGL J MED, V314, P642, DOI 10.1056/NEJM198603063141010; BROUWERS HAA, 1995, OP GRENS LEVEN DOOD; CAMPBELL AGM, 1982, ARCH DIS CHILD, V57, P569, DOI 10.1136/adc.57.8.569; Cook L A, 1996, J Perinatol, V16, P133; de Kleine M J, 1993, Ned Tijdschr Geneeskd, V137, P496; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; EGANDERSEN G, 1989, ACTA PAEDIATR SCAND, P56; Frader JE, 1996, PEDIATRICS, V98, P149; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; LEENEN HJJ, 1994, HDB GEZONDHEIDSREC 1; LUCE JM, 1995, CRIT CARE MED, V23, P760, DOI 10.1097/00003246-199504000-00027; Nederlandse Vereniging voor Kindergeneeskunde, 1992, DOEN LAT GRENZ MED H; Rivers RPA, 1996, BRIT MED BULL, V52, P238; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WHITELAW A, 1986, LANCET, V2, P328	20	87	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 26	1997	350	9073					251	255		10.1016/S0140-6736(97)02315-5	http://dx.doi.org/10.1016/S0140-6736(97)02315-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242802	Green Submitted			2022-12-28	WOS:A1997XM86600012
J	Nagasaka, S; Iwamoto, Y; Ishikawa, S; Kuzuya, T; Saito, T				Nagasaka, S; Iwamoto, Y; Ishikawa, S; Kuzuya, T; Saito, T			Efficacy of troglitazone measured by insulin resistance index	LANCET			English	Article									TOKYO WOMENS MED COLL,CTR DIABET,TOKYO 162,JAPAN	Tokyo Women's Medical University	Nagasaka, S (corresponding author), JICHI MED SCH,DIV ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							Cleland SJ, 1996, LANCET, V347, P770, DOI 10.1016/S0140-6736(96)90126-9; DUNCAN MH, 1995, LANCET, V346, P120, DOI 10.1016/S0140-6736(95)92143-5; Iwamoto Y, 1996, DIABETES CARE, V19, P151, DOI 10.2337/diacare.19.2.151; Kumar S, 1996, DIABETOLOGIA, V39, P701; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883	5	25	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					184	184		10.1016/S0140-6736(05)62350-1	http://dx.doi.org/10.1016/S0140-6736(05)62350-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250189				2022-12-28	WOS:A1997XL72200016
J	Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A				Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A			Drosophila MAD binds to DNA and directly mediates activation of vestigial by decapentaplegic	NATURE			English	Article							HEDGEHOG; EXPRESSION; MELANOGASTER; ELEMENTS; PATTERN; PROTEIN; GENE; DPP	The TGF-beta (transforming growth factor-beta)-related signalling proteins, including Decapentaplegic (Dpp) in Drosophila and bone morphogenic proteins and activin in vertebrates, affect the growth and patterning of a great variety of structures. However, the mechanisms by which these ligands regulate gene expression are not understood. Activation of complexes of type I with type II receptors results in the phosphorylation and nuclear localization of members of the SMAD protein family(1-9), which are thought to act as co-activators of transcription, perhaps in conjunction with sequence-specific cofactors(10). Here we show that the aminoterminal domain of the Drosophila Mothers against dpp protein (Mad), a mediator of Dpp signalling(11-14), possesses a sequence-specific DNA-binding activity that becomes apparent when carboxy-terminal residues are removed. Mad binds to and is required for the activation of an enhancer within the vestigial wing-patterning gene in cells across the entire developing wing blade. Mad also binds to Dpp-response elements in other genes. These results suggest that Dpp signalling regulates gene expression by activating Mad binding to target gene enhancers.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AUSUBEL EM, 1994, CURRENT PROTOCOLS S, V28, P1661; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR S, 1995, BIOESSAYS, V17, P229; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIU F, 1996, NATURE, V381, P622; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1995, GENETICS, V139, P241; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; TREMML G, 1992, DEVELOPMENT, V116, P447; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	450	464	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					304	308		10.1038/40906	http://dx.doi.org/10.1038/40906			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230443	Bronze			2022-12-28	WOS:A1997XL12100058
J	Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J				Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J			Crystalluria and urinary tract abnormalities associated with indinavir	ANNALS OF INTERNAL MEDICINE			English	Article						crystalluria; urinary tract; indinavir; human immunodeficiency virus infections; kidney calculi	PROTEASE INHIBITOR; PATHOGENESIS; L-735,524	Background: Indinavir, a protease inhibitor widely used to treat patients with HIV infection, has been associated with nephrolithiasis. Distinctive urinary crystals and a spectrum of urologic disorders were noted in patients receiving indinavir. Objective: To determine the composition of urinary crystals and the frequency of asymptomatic crystalluria and urinary tract symptoms in patients receiving indinavir. Patients: Patients with HIV infection who were enrolled in studies conducted at the National Institutes of Health. Measurements: Microscopic urinalysis, high-performance liquid chromatography (HPLC) and mass spectrometry of urinary crystals and stones, and clinical evaluation of patients with urologic symptoms. Results: Of 240 patients receiving indinavir, 142 provided urine specimens for analysis. Twenty-nine (20%) had crystals consisting of plate-like rectangles and fan-shaped or starburst forms. Mass spectrometry and HPLC confirmed that these crystals were composed of indinavir. OF 40 patients who were not receiving indinavir, none had similar crystals (P < 0.001). Nineteen of the 240 patients receiving indinavir (8%) developed urologic symptoms. Of these, 7 (3%) had nephrolithiasis and the other 12 (5%) had previously undescribed syndromes: crystalluria associated with dysuria and crystalluria associated with back or flank pain. Four of the patients with the latter syndrome had radiographic evidence of intrarenal sludging. Conclusions: Indinavir forms characteristic crystals in the urine. This crystalluria may be associated with dysuria and urinary frequency, with flank or back pain associated with intrarenal sludging, and with the classic syndrome of renal colic.	NIAID, NIH, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kopp, JB (corresponding author), NIDDK, WARREN GRANT MAGNUSON CLIN CTR, NIH, BLDG 10, ROOM 3N116, BETHESDA, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X				BALANI SK, 1995, DRUG METAB DISPOS, V23, P266; Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BIRCH DF, 1994, COLOR ATLAS URINE MI; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Daudon M, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62506-8; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; Farina Luis A., 1995, Archivos Espanoles de Urologia, V48, P418; GULICK R, 1996, 3 C RETR OPP INF WAS, pLB7; Haber MB, 1981, URINARY SEDIMENT TXB; LIN JH, 1995, DRUG METAB DISPOS, V23, P730; MCEVOY GK, 1996, DRUG INFORMATION; *MERCK CO, 1996, CRIX IND SULF US PAC; PATZELT WJ, 1974, POLARIZED LIGHT MICR; Piscitelli SC, 1996, CLIN INFECT DIS, V23, P685, DOI 10.1093/clinids/23.4.685; PREMINGER GM, 1992, SEMIN NEPHROL, V12, P200; Rapado A, 1987, Contrib Nephrol, V58, P25; SAWYER MH, 1988, AM J MED, V84, P1067, DOI 10.1016/0002-9343(88)90313-0; TANOUYE E, 1996, WALL STREET J   1105, pA6; Tanouye E, 1996, WALL STREET J   1106, pA1; Tashima KT, 1997, NEW ENGL J MED, V336, P138, DOI 10.1056/NEJM199701093360215	22	247	251	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					119	+		10.7326/0003-4819-127-2-199707150-00004	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230000				2022-12-28	WOS:A1997XK15800006
J	Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD				Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD			Quadriceps weakness and osteoarthritis of the knee	ANNALS OF INTERNAL MEDICINE			English	Article						muscle weakness; osteoarthritis; knee joint; quadriceps; disabled	X-RAY ABSORPTIOMETRY; OSTEO-ARTHRITIS; MUSCLE; ASSOCIATION; OUTCOMES; PROGRAM; THERAPY; HEALTH	Background: The quadriceps weakness commonly associated with osteoarthritis of the knee is widely believed to result from disuse atrophy secondary to pain in the in volved joint. However, quadriceps weakness may be an etiologic factor in the development of osteoarthritis. Objective: To explore the relation between lower-extremity weakness and osteoarthritis of the knee. Design: Cross-sectional prevalence study. Setting: Population-based, with recruitment by random-digit dialing. Participants: 462 volunteers 65 years of age or older. Measurements: Radiographs of the knee were graded for the presence of osteoarthritis. Knee pain and function were assessed with the Western Ontario and McMaster Universities Arthritis Index, the strength of leg flexors and extensors was assessed with isokinetic dynamometry, and lower-extremity lean tissue mass was assessed with dual-energy x-ray absorptiometry. Results: Among participants with osteoarthritis, quadriceps weakness, but not hamstring weakness, was common. The ratio of extensor strength to body weight was approximately 20% lower in those with than in those without radiographic osteoarthritis. Notably, among women with tibiofemoral osteoarthritis, extensor weakness was present in the absence of knee pain and was seen in participants with normal lower-extremity lean mass (extensor strength, 30.1 Ib-ft for those with osteoarthritis and 34.8 Ib-ft for those without osteoarthritis; P < 0.001). After adjustment for body weight, age, and sex, lesser quadriceps strength remained predictive of both radiographic and symptomatic osteoarthritis of the knee (odds ratio for prevalence of osteoarthritis per 10 Ib-ft loss of strength, 0.8 [95% CI, 0.71 to 0.90] for radiographic osteoarthritis and 0.71 [CI, 0.51 to 0.87] for symptomatic osteoarthritis). Conclusion: Quadriceps weakness may be present in patients who have osteoarthritis but do not have knee pain or muscle atrophy; this suggests that the weakness may be due to muscle dysfunction. The data are consistent with the possibility that quadriceps weakness is a primary risk factor for knee pain, disability, and progression of joint damage in persons with osteoarthritis of the knee.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020582] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00750] Funding Source: Medline; NIAMS NIH HHS [2P60AR20582-20] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; FEINBERG J, 1992, ARTHRITIS RHEUM S5, V35, pR28; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, AM J PHYS MED REHAB, V73, P413, DOI 10.1097/00002060-199411000-00006; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P1319, DOI 10.1016/0003-9993(93)90087-Q; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; FULLER NJ, 1992, CLIN PHYSIOL, V12, P253, DOI 10.1111/j.1475-097X.1992.tb00831.x; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HAARBO J, 1990, J BONE MINER RES S2, V5, pS180; HADLER NM, 1992, ANN INTERN MED, V116, P598, DOI 10.7326/0003-4819-116-7-598; HURLEY MV, 1993, BRIT J RHEUMATOL, V32, P127; JEFFERSON RJ, 1990, ENG MED, V204, P21; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Mazzuca S. A., 1995, Arthritis and Rheumatism, V38, pS227; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; RUTHERFORD OM, 1986, J NEUROL NEUROSUR PS, V49, P1288, DOI 10.1136/jnnp.49.11.1288; Sharma L, 1996, J INVEST MED, V44, pA359; TATARANNI PA, 1995, AM J CLIN NUTR, V62, P730, DOI 10.1093/ajcn/62.4.730; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	27	640	674	2	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					97	+		10.7326/0003-4819-127-2-199707150-00001	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230035				2022-12-28	WOS:A1997XK15800003
J	Tanaka, Y; Miyazaki, M; Albert, ML				Tanaka, Y; Miyazaki, M; Albert, ML			Effects of increased cholinergic activity on naming in aphasia	LANCET			English	Article									YAMADA RED CROSS HOSP,DEPT NEUROL,MIE,JAPAN		Tanaka, Y (corresponding author), BOSTON UNIV,SCH MED,APHASIA RES CTR,DEPT NEUROL,BOSTON,MA 02130, USA.							AARSLAND D, 1994, BRAIN, V117, P1377, DOI 10.1093/brain/117.6.1377; ALBERT ML, 1988, NEUROLOGY, V38, P877, DOI 10.1212/WNL.38.6.877; AMADUCCI L, 1981, NEUROLOGY, V31, P7899; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; Jacobs DH, 1996, NEUROCASE, V2, P83	5	33	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					116	117		10.1016/S0140-6736(05)61820-X	http://dx.doi.org/10.1016/S0140-6736(05)61820-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228973	hybrid			2022-12-28	WOS:A1997XK11400021
J	Krings, M; Stone, A; Schmitz, RW; Krainitzki, H; Stoneking, M; Paabo, S				Krings, M; Stone, A; Schmitz, RW; Krainitzki, H; Stoneking, M; Paabo, S			Neandertal DNA sequences and the origin of modern humans	CELL			English	Article							HUMAN MITOCHONDRIAL-DNA; ANCIENT DNA; CONTROL REGION; ENZYMATIC AMPLIFICATION; AFRICAN ORIGIN; CHAIN-REACTION; EVOLUTION; HETEROPLASMY; POPULATIONS; CHIMPANZEES	DNA was extracted from the Neandertal-type specimen found in 1856 in western Germany. By sequencing clones from short overlapping PCR products, a hitherto unknown mitochondrial (mt) DNA sequence was determined. Multiple controls indicate that this sequence is endogenous to the fossil. Sequence comparisons with human mtDNA sequences, as well as phylogenetic analyses, show that the Neandertal sequence falls outside the variation of modern humans. Furthermore, the age of the common ancestor of the Neandertal and modern human mtDNAs is estimated to be four times greater than that of the common ancestor of human mtDNAs. This suggests that Neandertals went extinct without contributing mtDNA to modern humans.	PENN STATE UNIV,DEPT ANTHROPOL,STATE COLL,PA 16802; RHEIN AMT BODENDENKMALPFLEGE,D-53115 BONN,GERMANY; HOHERE BERUFSFACHSCH PRAPARAT TECH ASSISTENTEN,D-44799 BOCHUM,GERMANY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Krings, M (corresponding author), UNIV MUNICH,INST ZOOL,POB 202136,D-80021 MUNICH,GERMANY.		Stone, Anne C/B-5719-2009	Stone, Anne/0000-0001-8021-8314				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Armour JAL, 1996, NAT GENET, V13, P154, DOI 10.1038/ng0696-154; BENDALL KE, 1995, AM J HUM GENET, V57, P248; BRAUER G, 1997, IN PRESS CONCEPTUAL; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; COLLURA RV, 1995, NATURE, V378, P485, DOI 10.1038/378485a0; COMAS D, 1995, GENOME RES, V5, P89, DOI 10.1101/gr.5.1.89; FELSENSTEIN J, 1994, CAMBRIDGE ARCHAEOL J, V7, P3; FORSTER E, 1994, BIOTECHNIQUES, V16, P18; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Handt O, 1996, AM J HUM GENET, V59, P368; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; Hublin JJ, 1996, NATURE, V381, P224, DOI 10.1038/381224a0; Ivanov PL, 1996, NAT GENET, V12, P417, DOI 10.1038/ng0496-417; LINDAHL T, 1993, NATURE, V365, P700, DOI 10.1038/365700a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MADDISON DR, 1991, SYST ZOOL, V40, P355, DOI 10.2307/2992327; Moore DD, 1995, GLOB MOB SURV; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nei M., 1987, MOL EVOLUTIONARY GEN; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1991, Current Biology, V1, P45, DOI 10.1016/0960-9822(91)90125-G; PENNY D, 1995, MOL BIOL EVOL, V12, P863; Petri B, 1996, BIOL CHEM, V377, P661, DOI 10.1515/bchm3.1996.377.10.661; Poinar HN, 1996, SCIENCE, V272, P864, DOI 10.1126/science.272.5263.864; Rak Yoel, 1993, P523; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHMITZ RW, 1996, THESIS U COLOGNE COL; SCHMITZ RW, 1995, ADV FORENSIC SCI, V7, P42; Schwartz JH, 1996, P NATL ACAD SCI USA, V93, P10852, DOI 10.1073/pnas.93.20.10852; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; STRINGER C, 1997, NEANDERTHALS MODERN; Stringer Christopher, 1993, SEARCH NEANDERTHALS; TAKAHATA N, 1995, ANNU REV ECOL SYST, V26, P343, DOI 10.1146/annurev.es.26.110195.002015; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Trinkaus E., 1993, NEANDERTALS CHANGING; VANDERKUYL AC, 1995, J MOL EVOL, V40, P652, DOI 10.1007/BF00160513; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; vonHaeseler A, 1996, NAT GENET, V14, P135, DOI 10.1038/ng1096-135; WOLPOFF MH, 1989, HUMAN REVOLUTION; ZISCHLER H, 1995, NATURE, V378, P489, DOI 10.1038/378489a0; ZOLLIKOFER CPE, 1995, NATURE, V375, P283, DOI 10.1038/375283b0	53	841	893	37	255	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					19	30		10.1016/S0092-8674(00)80310-4	http://dx.doi.org/10.1016/S0092-8674(00)80310-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230299	Green Published, Bronze			2022-12-28	WOS:A1997XL36200005
J	Prodromou, C; Roe, SM; OBrien, R; Ladbury, JE; Piper, PW; Pearl, LH				Prodromou, C; Roe, SM; OBrien, R; Ladbury, JE; Piper, PW; Pearl, LH			Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone	CELL			English	Article							HEAT-SHOCK PROTEIN; GYRASE-B-PROTEIN; DNA GYRASE; STEROID-RECEPTORS; TYROSINE KINASE; PROGRAM; HETEROCOMPLEX; FRAGMENT; MODELS; CYCLE	Hsp90 molecular chaperones in eukaryotic cells play essential roles in the folding and activation of a range of client proteins involved in cell cycle regulation, steroid hormone responsiveness, and signal transduction. The biochemical mechanism of Hsp90 is poorly understood, and the involvement of ATP in particular is controversial. Crystal structures of complexes between the N-terminal domain of the yeast Hsp90 chaperone and ADP/ATP unambiguously identify a specific adenine nucleotide binding site homologous to the ATP-binding site of DNA gyrase B. This site is the same as that identified for the antitumor agent geldanamycin, suggesting that geldanamycin acts by blocking the binding of nucleotides to Hsp90 and not the binding of incompletely folded client polypeptides as previously suggested. These results finally resolve the question of the direct involvement of ATP in Hsp90 function.	UNIV LONDON UNIV COLL, JOINT UCL LICR XRAY CRYSTALLOG LAB, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Prodromou, C (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOL BIOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Prodromou, Chrisostomos/ABA-9133-2021	Prodromou, Chrisostomos/0000-0003-4320-1147; Pearl, Laurence/0000-0002-6910-1809; Roe, Mark/0000-0002-7371-9855; Ladbury, John/0000-0002-6328-7200	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chen CF, 1996, MOL CELL BIOL, V16, P4691; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DUNBRACK RL, 1997, 2 M CRIT ASS TECHN P, V1, pR27; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; HOHFELD J, 1995, CELL, V83, P589; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOODIE SL, 1993, NUCLEIC ACIDS RES, V21, P1369, DOI 10.1093/nar/21.6.1369; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Prodromou C, 1996, PROTEINS, V25, P517, DOI 10.1002/prot.13; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	59	1039	1110	1	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	1997	90	1					65	75		10.1016/S0092-8674(00)80314-1	http://dx.doi.org/10.1016/S0092-8674(00)80314-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230303	Bronze			2022-12-28	WOS:A1997XL36200009
J	Nicoll, M; Akerib, CC; Meyer, BJ				Nicoll, M; Akerib, CC; Meyer, BJ			X-chromosome-counting mechanisms that determine nematode sex	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; C-ELEGANS; GENE; IDENTIFICATION; XOL-1	Sex is determined in Caenorhabditis elegans by an X-chromosome-counting mechanism that reliably distinguishes the twofold difference in X-chromosome dose between males (1X) and hermaphrodites (2X)(1,2). This small quantitative difference is translated into the 'on/off' response of the target gene, xol-1, a switch that specifies the male fate when active and the hermaphrodite fate when inactive(3), Specific regions of X contain counted signal elements whose combined dose sets the activity of xol-1 (ref. 4). Here we ascribe the dose effects of one region to a discrete, protein-encoding gene, fox-1. We demonstrate that the dose-sensitive signal elements on chromosome X control xol-1 through two different molecular mechanisms. One involves the transcriptional repression of xol-1 in XX animals. The other uses the putative RNA-binding protein encoded by fox-1 to reduce the level of xol-1 protein, These two mechanisms of repression act together to ensure the fidelity of the X-chromosome counting process.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BIRD CG, 1994, SCIENCE, V265, P615; Bridges CB, 1916, GENETICS, V1, P1; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1979, GENETICS, V91, P67; MADL JE, 1979, GENETICS, V93, P393; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Nigon V., 1951, B BIOL FR BELG, V85, P187; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	15	68	72	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					200	204		10.1038/40669	http://dx.doi.org/10.1038/40669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217163	Bronze			2022-12-28	WOS:A1997XK10900056
J	Westfall, JM; McCabe, J; Nicholas, RA				Westfall, JM; McCabe, J; Nicholas, RA			Personal use of drug samples by physicians and office staff	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACEUTICAL-INDUSTRY; REPRESENTATIVES; COMPANIES; POLICIES	Context.-Pharmaceutical samples are commonly used in ambulatory care settings. There is limited research on their use or impact on health care providers and patients. Objective.-To determine the extent of personal use of drug samples over a 1-year period by physicians and medical office staff. Design, Subjects, and Setting.-An anonymous cross-sectional survey of all physicians, resident physicians, nursing staff, and office staff in a family practice residency. Main Outcome Measure.-Quantity of drug samples taken for personal or family use. Results.-Of 55 surveys issued, 53 (96%) were returned. A total of 230 separate drug samples were reported taken in amounts ranging from 1 dose to greater than 1 month's supply, Two respondents reported no use of drug samples, while 4 respondents reported taking more than 10 different samples. Conclusion.-Drug samples are commonly taken by physicians and office staff for personal and family use. The ethical implications of this practice warrant discussion.	COLUMBIA ROSE MED CTR,DENVER,CO		Westfall, JM (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT FAMILY MED,1180 CLERMONT ST,DENVER,CO 80220, USA.		Westfall, John/AAD-3570-2021					*ACCR COUNC CONT M, 1992, STAND COMM SUPP CONT; BROTZMAN GL, 1992, J FAM PRACTICE, V34, P54; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; *COUNC ETH JUD AFF, 1992, FOOD DRUG LAW J, V47, P445; *COUNC ETH JUD AFF, 1991, JAMA-J AM MED ASSOC, V265, P501; DRAKE D, 1993, MAKING MED MAKING MO, P27; LEXCHIN J, 1993, CAN MED ASSOC J, V149, P1401; Mainous A G 3rd, 1995, Arch Fam Med, V4, P335, DOI 10.1001/archfami.4.4.335; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; MORELLI D, 1992, J FAM PRACTICE, V34, P42; NEWTON W, 1992, J FAM PRACTICE, V34, P32; OSTERGAARD DJ, 1992, J FAM PRACTICE, V34, P29; SHAUGHNESSY AF, 1988, JAMA-J AM MED ASSOC, V260, P926, DOI 10.1001/jama.260.7.926; SQUIRES BP, 1993, CAN MED ASSOC J, V149, P1391; TONG KL, 1995, CAN FAM PHYSICIAN, V41, P1363; WILKES MS, 1989, NY TIMES MAGAZI 1105, P89	17	62	63	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					141	143		10.1001/jama.278.2.141	http://dx.doi.org/10.1001/jama.278.2.141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214530				2022-12-28	WOS:A1997XH66700035
J	Jewell, T				Jewell, T			United Kingdom - National health under new management	LANCET			English	Article																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					48	50		10.1016/S0140-6736(97)05437-8	http://dx.doi.org/10.1016/S0140-6736(97)05437-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217727				2022-12-28	WOS:A1997XH86900043
J	McAllister, C; Fee, JPH				McAllister, C; Fee, JPH			Research into intensive-care admissions	LANCET			English	Editorial Material									ROYAL VICTORIA HOSP,REG INTENS CARE UNIT,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND		McAllister, C (corresponding author), CRAIGAVON AREA HOSP GRP TRUST,INTENS CARE UNIT,CRAIGAVON,NORTH IRELAND.							BION J, 1995, BMJ-BRIT MED J, V310, P682, DOI 10.1136/bmj.310.6981.682; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; *INT CAR SOC, 1990, INT CAR SERV UK; METCALFE MA, 1995, STUDY INTENSIVE CARE; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727	5	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					2	2		10.1016/S0140-6736(97)22027-1	http://dx.doi.org/10.1016/S0140-6736(97)22027-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217708				2022-12-28	WOS:A1997XH86900002
J	Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK				Wah, DA; Hirsch, JA; Dorner, LF; Schildkraut, I; Aggarwal, AK			Structure of the multimodular endonuclease FokI bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; RESTRICTION-ENDONUCLEASE; ZINC FINGERS; RNA GENE; BINDING; RECOGNITION; COMPLEX; MUTANTS; DOMAINS; SITES	FokI is a member of an unusual class of bipartite restriction enzymes that recognize a specific DNA sequence and cleave DNA nonspecifically a short distance away from that sequence(1-3) Because of its unusual bipartite nature, FokI has been used to create artificial enzymes with new specificities(4-7). We have determined the crystal structure at 2.8 Angstrom resolution of the complete FokI enzyme bound to DNA. As anticipated, the enzyme contains amino- and carboxy-terminal domains corresponding to the DNA-recognition and cleavage functions, respectively. The recognition domain is made of three smaller subdomains (D1, D2 and D3) which are evolutionarily related to the helix-turn-helix-containing DNA-binding domain of the catabolite gene activator protein CAP(8). The CAP core has been extensively embellished in the first two subdomains, whereas in the third subdomain it has been co-opted for protein-protein interactions. Surprisingly, the cleavage domain contains only a single catalytic centre, raising the question of how monomeric FokI manages to cleave both DNA strands. Unexpectedly, the cleavage domain is sequestered in a 'piggyback' fashion by the recognition domain. The structure suggests a new mechanism for nuclease activation and provides a framework for the design of chimaeric enzymes with altered specificities.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University			Wilson, Matthew H/K-3193-2013; Hirsch, Joel/AAC-8000-2021	Hirsch, Joel/0000-0001-7544-8668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; FUREY W, 1993, PHASES PROGRAM PACKA; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; Hirsch JA, 1997, FEBS LETT, V403, P136, DOI 10.1016/S0014-5793(97)00039-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PODHAJSKA AJ, 1985, GENE, V40, P175, DOI 10.1016/0378-1119(85)90040-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SUGISAKI H, 1981, GENE, V16, P73; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WAUGH DS, 1994, J BIOL CHEM, V269, P12298; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; YONEZAWA A, 1994, BBA-GENE STRUCT EXPR, V1219, P369, DOI 10.1016/0167-4781(94)90061-2	29	212	277	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					97	100		10.1038/40446	http://dx.doi.org/10.1038/40446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214510				2022-12-28	WOS:A1997XJ14300058
J	Benbow, SJ; Walsh, A; Gill, GV				Benbow, SJ; Walsh, A; Gill, GV			Diabetes in institutionalised elderly people: A forgotten population?	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,CLIN DEPT AINTREE,FAZAKERLEY HOSP,DIABET & ENDOCRINOL CLIN RES GRP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	University of Liverpool	Benbow, SJ (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							SINCLAIR AJ, 1993, BRIT MED J, V306, P1142, DOI 10.1136/bmj.306.6886.1142; Sinclair AJ, 1996, POSTGRAD MED J, V72, P334, DOI 10.1136/pgmj.72.848.334; TATTERSALL RB, 1984, DIABETOLOGIA, V27, P167	3	59	59	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1868	1869		10.1136/bmj.314.7098.1868	http://dx.doi.org/10.1136/bmj.314.7098.1868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224129	Green Published			2022-12-28	WOS:A1997XH73800023
J	Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D				Hayashi, H; Abdollah, S; Qiu, YB; Cai, JX; Xu, YY; Grinnell, BW; Richardson, MA; Topper, JN; Gimbrone, MA; Wrana, JL; Falb, D			The MAD-related protein Smad7 associates with the TGF beta receptor and functions as an antagonist of TGF beta signaling	CELL			English	Article							COMPLEX	TGF beta signaling is initiated when the type I receptor phosphorylates the MAD-related protein, Smad2, on C-terminal serine residues. This leads to Smad2 association with Smad4, translocation to the nucleus, and regulation of transcriptional responses. Here we demonstrate that Smad7 is an inhibitor of TGF beta signaling. Smad7 prevents TGF beta-dependent formation of Smad2/Smad4 complexes and inhibits the nuclear accumulation of Smad2. Smad7 interacts stably with the activated TGF beta type I receptor, thereby blocking the association, phosphorylation, and activation of Smad2. Furthermore, mutations in Smad7 that interfere with receptor binding disrupt its inhibitory activity. These studies thus define a novel function for MAD-related proteins as intracellular antagonists of the type I kinase domain of TGF beta family receptors.	HOSP SICK CHILDREN,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139; LILLY RES LABS,DIV RES TECHNOL & PROT,INDIANAPOLIS,IN 46285; BRIGHAM & WOMENS HOSP,DEPT MED,DIV VASC RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Eli Lilly; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hayashi, H (corresponding author), HOSP SICK CHILDREN,PROGRAM DEV BIOL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Wrana, Jeffrey/F-8857-2013					Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOODLESS P, 1997, IN PRESS CURRENT TOP; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Sambrook J., 2002, MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; TOPPER JN, 1997, IN PRESS P NATL ACAD; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	1117	1185	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1165	1173		10.1016/S0092-8674(00)80303-7	http://dx.doi.org/10.1016/S0092-8674(00)80303-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215638	Bronze			2022-12-28	WOS:A1997XG83000020
J	Wilson, JA				Wilson, JA			Unsupervised surgical training: Questionnaire study	BRITISH MEDICAL JOURNAL			English	Article											Wilson, JA (corresponding author), UNIV NEWCASTLE,FREEMAN HOSP,DEPT OTOLARYNGOL HEAD & NECK SURG,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.			wilson, janet/0000-0002-6416-5870				Cobb R A, 1994, Ann R Coll Surg Engl, V76, P117; Potter M A, 1996, Ann R Coll Surg Engl, V78, P11	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1803	1804		10.1136/bmj.314.7097.1803	http://dx.doi.org/10.1136/bmj.314.7097.1803			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224083	Green Published			2022-12-28	WOS:A1997XG16600024
J	Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC				Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC			Clonality in nodular lymphocyte-predominant Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 1996	ORLANDO, FL	Amer Soc Hematol, US Dept Vet Affairs Merit Res Funds, NIH			REED-STERNBERG CELLS; POLYMERASE CHAIN-REACTION; V-H GENES; B-CELL; HISTOLOGICAL SECTIONS; GERMINAL CENTER; IMMUNOGLOBULIN; LINEAGE; REARRANGEMENTS; VARIANTS	Background There is general agreement that lymphocytic and histiocytic (L&H) cells, the variants of Reed-Sternberg cells in nodular lymphocyte-predominant Hodgkin's disease, belong to the B-cell lineage. However, the clonality of L&H cells remains controversial. Methods We used complementarity-determining region 3 (CDR3) of the immunoglobulin heavy-chain gene as a clonal marker to study individual L&H cells isolated by micromanipulation from tissue sections of five patients with nodular lymphocyte-predominant Hodgkin's disease. The heavy-chain CDR3 of each cell was amplified by the polymerase chain reaction, The products were analyzed by gel electrophoresis, and representative amplification products from each patient were sequenced. Results L&H cells whose heavy-chain CDR3 was related, indicating the presence of a clonal population, were detected in all five patients and were the dominant population in three. In four of the five patients, members of the clone were found in different nodules in the tissue section, different tissue blocks from the same tumor, or different lymph nodes from the same patient. The CDR3 sequences in each clone frequently contained nucleotide substitutions indicative of intraclonal mutation. Conclusions Clonal populations of L&H cells occur in nodular lymphocyte-predominant Hodgkin's disease. Intraclonal variation in nucleotide sequences suggests that hypermutation of the heavy-chain CDR3 continues to occur among the clonal progeny. (C) 1997, Massachusetts Medical Society.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [R01 CA61453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVAIKKO MJ, 1991, AM J CLIN PATHOL, V95, P194, DOI 10.1093/ajcp/95.2.194; ANGEL CA, 1987, J PATHOL, V153, P21, DOI 10.1002/path.1711530104; ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; BEREK C, 1992, IMMUNOL REV, V126, P5, DOI 10.1111/j.1600-065X.1992.tb00628.x; BORGGRECH A, 1989, J CLIN ONCOL, V71, P303; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; dAmore F, 1997, LAB INVEST, V76, P219; DELABIE J, 1994, BLOOD, V84, P3291; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HELL K, 1993, J PATHOL, V171, P137, DOI 10.1002/path.1711710211; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; KUZU I, 1993, HISTOPATHOLOGY, V22, P141, DOI 10.1111/j.1365-2559.1993.tb00092.x; LINDEN MD, 1988, HUM PATHOL, V19, P591, DOI 10.1016/S0046-8177(88)80210-7; LUKES RJ, 1966, CANCER RES, V26, P1063; MANZANAL A, 1995, HISTOPATHOLOGY, V27, P21, DOI 10.1111/j.1365-2559.1995.tb00286.x; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PINKUS GS, 1988, AM J PATHOL, V133, P211; POPPEMA S, 1989, AM J PATHOL, V135, P351; POPPEMA S, 1980, J HISTOCHEM CYTOCHEM, V28, P788, DOI 10.1177/28.8.6777426; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; SAID JW, 1991, AM J PATHOL, V138, P261; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; TAMARU J, 1994, BLOOD, V84, P708; TIMENS W, 1986, LAB INVEST, V54, P457; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312; WU G, IN PRESS DIAGN MOL P; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123	33	119	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					459	465		10.1056/NEJM199708143370704	http://dx.doi.org/10.1056/NEJM199708143370704			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250848				2022-12-28	WOS:A1997XQ49900004
J	Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE				Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE			Bidirectional transport by distinct populations of COPI-coated vesicles	CELL			English	Article							ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; BREFELDIN-A; BETA-COP; PROTEIN-TRANSPORT; MONOCLONAL-ANTIBODIES; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; MEDIATED RETRIEVAL	Electron microscope immunocytochemistry reveals that both anterograde-directed (proinsulin and VSV G protein) and retrograde-directed (the KDEL receptor) cargo are present in coPI-coated vesicles budding from every level of the Golgi stack in whole cells; however, they comprise two distinct populations that together can account for at least 80% of the vesicles budding from Golgi cisternae. Segregation of antero-grade- from retrograde-directed cargo into distinct sets of COPI-coated vesicles is faithfully reproduced in the cell-free Golgi transport system, in which VSV G protein and KDEL receptor are packaged into separable vesicles, even when budding is driven by highly purified coatomer and a recombinant ARF protein.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Orci, L (corresponding author), UNIV GENEVA,CTR MED,FAC MED,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.			Stamnes, Mark/0000-0002-5869-7985				ALLEN VJ, 1986, J CELL BIOL, V103, P2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GERICH B, 1995, P NATL ACAD SCI USA, V92, P8532; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MADSEN OD, 1983, ENDOCRINOLOGY, V113, P2135, DOI 10.1210/endo-113-6-2135; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; MORRE DJ, 1977, INT REV CYTOL      S, V5, P61; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORCI L, 1986, Diabetes Metabolism Reviews, V2, P71; ORCI L, 1974, DIABETOLOGIA, V10, P163, DOI 10.1007/BF00423031; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STORCH MJ, 1985, DIABETES, V34, P808, DOI 10.2337/diabetes.34.8.808; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	73	342	351	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					335	349		10.1016/S0092-8674(00)80341-4	http://dx.doi.org/10.1016/S0092-8674(00)80341-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244307	Bronze			2022-12-28	WOS:A1997XN24900017
J	Braveman, P; Kessel, W; Egerter, S; Richmond, J				Braveman, P; Kessel, W; Egerter, S; Richmond, J			Early discharge and evidence-based practice - Good science and good judgment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; MATERNAL CHILD & HLTH BUR,DIV SCI EDUC & ANAL,HLTH RESOURCES & SERV ADM,US DEPT DEF,WASHINGTON,DC; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	University of California System; University of California San Francisco; United States Department of Defense; United States Health Resources & Service Administration (HRSA); Harvard University; Harvard Medical School	Braveman, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,500 PARNASSUS AVE,BOX 0900,MU-3E,RM 306,SAN FRANCISCO,CA 94143, USA.							*AM AC PED AM COLL, 1992, GUID PER CAR, P91; Braveman P, 1996, J Am Board Fam Pract, V9, P254; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; EGERTER S, IN PRESS CLIN PERINA; Institute of Medicine Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; RICHMOND JB, 1970, YALE J BIOL MED, V43, P137	8	36	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					334	336						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228442				2022-12-28	WOS:A1997XL05900037
J	Hart, AL; Kamm, MA; Palmer, JG; Talbot, IC				Hart, AL; Kamm, MA; Palmer, JG; Talbot, IC			An extra-ordinary cause of megacolon	LANCET			English	Article									S MARKS HOSP,NORTHWICK PK HA1 3UJ,MIDDX,ENGLAND; CUMBERLAND INFIRM,CARLISLE,CUMBRIA,ENGLAND									GATTUSO JM, 1994, CONSTIPATION, P213; GATTUSO JM, 1997, IN PRESS GUT; KAMM MA, 1991, BRIT J SURG, V78, P899, DOI 10.1002/bjs.1800780803	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					110	110		10.1016/S0140-6736(97)04113-5	http://dx.doi.org/10.1016/S0140-6736(97)04113-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228964				2022-12-28	WOS:A1997XK11400012
J	McManus, C				McManus, C			Employing cognitive behaviour therapy to reduce unemployment	LANCET			English	Editorial Material							HEALTH; TRIAL				McManus, C (corresponding author), ST MARYS,IMPERIAL COLL SCH MED,ACAD DEPT PSYCHIAT,LONDON W12 1PG,ENGLAND.							[Anonymous], 1997, OX MED PUBL; BARTLEY M, 1994, J EPIDEMIOL COMMUN H, V48, P333, DOI 10.1136/jech.48.4.333; Clark D.M., 1997, SCI PRACTICE COGNITI; EZZY D, 1993, SOC SCI MED, V37, P41, DOI 10.1016/0277-9536(93)90316-V; Fowler D, 1995, COGNITIVE BEHAV THER; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; JIN RL, 1995, CAN MED ASSOC J, V153, P529; Owen K, 1995, J Psychiatr Ment Health Nurs, V2, P63, DOI 10.1111/j.1365-2850.1995.tb00145.x; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					80	81		10.1016/S0140-6736(97)22028-3	http://dx.doi.org/10.1016/S0140-6736(97)22028-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XK114	9228954				2022-12-28	WOS:A1997XK11400002
J	Schrot, RJ; Adelman, HM; Linden, CN; Wallach, PM				Schrot, RJ; Adelman, HM; Linden, CN; Wallach, PM			Cystic parotid gland enlargement in HIV disease - The diffuse infiltrative lymphocytosis syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; HLA-DR5; AIDS		JAMES A HALEY VET HOSP,SERV RADIOL,TAMPA,FL 33612; UNIV S FLORIDA,HLTH SCI CTR,DEPT FAMILY MED,TAMPA,FL; UNIV S FLORIDA,HLTH SCI CTR,DEPT INTERNAL MED,TAMPA,FL; UNIV S FLORIDA,HLTH SCI CTR,DEPT RADIOL,TAMPA,FL	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Schrot, RJ (corresponding author), JAMES A HALEY VET HOSP,MED SERV 11C,13000 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.							Albrecht H, 1996, SCAND J INFECT DIS, V28, P621, DOI 10.3109/00365549609037971; Beitler JJ, 1995, AIDS PATIENT CARE, V9, P271, DOI 10.1089/apc.1995.9.271; BEM C, 1992, BRIT J SURG, V79, P768, DOI 10.1002/bjs.1800790818; FOX RI, 1992, RHEUM DIS CLIN N AM, V18, P517; ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11472, DOI 10.1073/pnas.91.24.11472; ITESCU S, 1992, RHEUM DIS CLIN N AM, V18, P683; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; SHAHA A, 1988, AM J SURG, V156, P297, DOI 10.1016/S0002-9610(88)80297-6; SHAHA AR, 1993, AM J SURG, V166, P403, DOI 10.1016/S0002-9610(05)80342-3; SHUGAR JMA, 1988, LARYNGOSCOPE, V98, P772; SOBERMAN N, 1991, AM J ROENTGENOL, V157, P553, DOI 10.2214/ajr.157.3.1651645; SOM PM, 1990, HEAD NECK IMAGING, P277; TAMI TA, 1994, AIDS KNOWLEDGE BASE; Yeh S., 1991, DIS NOSE THROAT EAR, P299; ZELTLEN S, 1991, J SURG ONCOL, V47, P230	15	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					166	167		10.1001/jama.278.2.166	http://dx.doi.org/10.1001/jama.278.2.166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH667	9214536				2022-12-28	WOS:A1997XH66700041
J	Blomley, M; Cosgrove, D				Blomley, M; Cosgrove, D			Microbubble echo-enhancers: A new direction for ultrasound?	LANCET			English	Editorial Material											Blomley, M (corresponding author), HAMMERSMITH HOSP,DEPT IMAGING,LONDON W12 0HS,ENGLAND.							FLEISCHER AC, 1997, ULTRASOUND CONTRAST, P137; KEDAR PP, 1996, RADIOLOGY, V198, P679; Killam A, 1997, ULTRASOUND CONTRAST, P43; Nihoyannopoulos P, 1996, CLIN RADIOL, V51, P28; Schlief R., 1997, ULTRASOUND CONTRAST, P75	5	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1855	1856		10.1016/S0140-6736(05)63872-X	http://dx.doi.org/10.1016/S0140-6736(05)63872-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217754				2022-12-28	WOS:A1997XG41700005
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - Maternal and child health in China	BMJ-BRITISH MEDICAL JOURNAL			English	Article								China has made great progress in improving the health of women and children over the past two generations. The success has been attributed to improved living standards, public health measures, and good access to health services. Although overall infant and maternal mortality rates are relatively low there are large differences in patterns of mortality between urban and rural areas. The Chinese have developed a hierarchical network of maternal and child health services, with each level taking a supervisory and teaching role for the level below it Maternal and child health in China came to international attention in 1995 with the promulgation of the maternal and child health law. In China this was seen as a means of prioritising resources and improving the quality of services, but in the West it was widely described as a law on eugenics.	HLTH UNLIMITED, LONDON SE1 9NT, ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH, LONDON WC1N 1EH, ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				ANTON M, 1996, CHINA REV, V4, P29; HAWKES N, 1995, TIMES           0605; LIU X, 1991, Journal of Public Health Policy, V12, P104, DOI 10.2307/3342782; *MIN PUBL HLTH, 1995, CHIN HLTH STAT DIG; *UNICEF, 1989, CHILDR WOM CHIN UNIC; YOUNG ME, 1990, HEALTH POLICY, V14, P87, DOI 10.1016/0168-8510(90)90369-O; ZHANG LM, 1988, B WORLD HEALTH ORGAN, V66, P387; ZHENG Y, 1996, CHINA DAILY     1123; 1995, LANCET, V34, P131	9	29	30	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1898	1900		10.1136/bmj.314.7098.1898	http://dx.doi.org/10.1136/bmj.314.7098.1898			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224139	Green Published			2022-12-28	WOS:A1997XH73800036
J	Kadlec, RP; Zelicoff, AP; Vrtis, AM				Kadlec, RP; Zelicoff, AP; Vrtis, AM			Biological weapons control - Prospects and implications for the future	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								The Biological and Toxin Weapons Convention (BWC), which prohibits the acquisition of biological materials for hostile purposes and armed conflict, entered into force in 1975 and now has the participation of 140 nations (158 nations have signed the BWC, but only 140 of these have also ratified it). However, there is no monitoring mechanism associated with the BWC. Diplomatic efforts are now under way to create a supplemental, legally binding protocol to strengthen the convention. Measures to strengthen the BWC are analogous to the diagnostic processes familiar to physicians; the problem facing negotiators is to identify procedures with high positive and negative predictive value. Few proposed measures meet these criteria. However, the investigation of unusual disease outbreaks and allegations of use are highly diagnostic of illicit activities while avoiding false-positive accusations. At the same time, such information generated by the BWC can contribute to worldwide efforts to improve public health, control emergent disease, and establish an international norm against biological weapons proliferation.	OFF SECRETARY DEF,WASHINGTON,DC; SANDIA NATL LABS,ALBUQUERQUE,NM 87185; MALCOM GROW MED CTR,DEPT ANESTHESIOL,ANDREWS AFB,MD	United States Department of Energy (DOE); Sandia National Laboratories; United States Department of Defense; United States Air Force								*ADH GROUP GOV EXP, 1993, ID EX POT VER MEAS S; *BDM FED INC, 1996, UN OUTBR DIS EX; BLACKWILL RD, 1996, ARMS CONTROL US RUSS, P65; Brophy Leo, 1959, CHEM WARFARE SERVICE; BRYDEN J, 1989, DEADLY ALLIES CANADA, P256; *DEF NUCL AG DNA B, 1994, GLOB PROL DYN ACQ ST, P4; EKEUS R, 1996, BIOL WEAP CONV 4 REV; GERTZ B, 1992, WASHINGTON TIME 0704, pA4; HARRIS SH, 1994, FACTORIES DEATH JAPA, P59; HOLUM JD, 1996, 4 REV C BIOL WEAP CO; JANOFSKY M, 1995, NY TIMES        0524, pA12; KAPLAN DE, 1996, CULT END WORLD, P55; MERCK GW, 1946, US UN REPORT SERIES, V5, P65; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; MORGANTHAU T, 1996, NEWSWEEK        0506, P34; *NAT SEC STUD MEM, 1969, NAT SEC STUD MEM, V59, P1; *OFF PRES WHIT HOU, 1996, COMMUNICATION   0924; SCIOLINO E, 1992, NY TIMES INT    0116, pA9; SPERTZEL R, 1996, SAMPLING ANAL MONITO, P7; STARR B, 1995, JANES DEFENSE W 1111, P4; URBAN M, 1993, SPECTATOR MAGAZ 0123, P9; *US ARMS CONTR DIS, 1993, BIOL WEAP CONV WASH; *US ARMS CONTR DIS, 1996, ARMS CONTR DIS ARGR; US Army, 1977, US ARM ACT US BIOL W, VI; *US DEP ARM, 1991, LESS LEARN OP DES SH; Williams P., 1989, UNIT 731 JAPANS SECR, p[28, 214]; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	27	53	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					351	356		10.1001/jama.278.5.351	http://dx.doi.org/10.1001/jama.278.5.351			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244311				2022-12-28	WOS:A1997XN51800001
J	Daltroy, LH; Iversen, MD; Larson, MG; Lew, R; Wright, E; Ryan, J; Zwerling, C; Fossel, AH; Liang, MH				Daltroy, LH; Iversen, MD; Larson, MG; Lew, R; Wright, E; Ryan, J; Zwerling, C; Fossel, AH; Liang, MH			A controlled trial of an educational program to prevent low back injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECONDARY PREVENTION; CLINICAL-TRIAL; PAIN; INDUSTRY; COST; KNOWLEDGE; SURVIVAL; WORKERS; HEALTH	Background Low back injuries are common and costly, accounting for 15 to 25 percent of injuries covered by workers' compensation and 30 to 40 percent of the payments made under that program. The high costs of injury, the lack of effective treatment, and the evidence that there are behavioral risk factors have led to widespread use of employee education programs that teach safe lifting and handling. The effectiveness of those programs, however, has received little rigorous evaluation. Methods We evaluated an educational program designed to prevent low back injury in a randomized, controlled trial involving about 4000 postal workers. The program, similar to that in wide use in so-called back schools, was taught by experienced physical therapists. Work units of workers and supervisors were trained in a two-session back school (three hours of training), followed by three to four reinforcement sessions over the succeeding few years. Injured subjects (from both the intervention and the control groups) were randomized a second time to receive either training or no training after their return to work. Results Physical therapists trained 2534 postal workers and 134 supervisors. Over 5.5 years of follow-up, 360 workers reported low back injuries, for a rate of 21.2 injuries per 1000 worker-years of risk. The median time off from work per injury was 14 days (range, 0 to 1717); the median cost was $204 (range, zero to $190,380). After their return to work, 75 workers were injured again. Our comparison of the intervention and control groups found that the education program did not reduce the rate of low back injury, the median cost per injury, the time off from work per injury, the rate of related musculoskeletal injuries, or the rate of repeated injury after return to work; only the subjects' knowledge of safe behavior was increased by the training. Conclusions A large-scale, randomized, controlled trial of an educational program to prevent work-associated low back injury found no long-term benefits associated with training. (C) 1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,CAMBRIDGE,MA 02138; NORTHEASTERN UNIV,BOSTON BOUVE COLL PHARM & HLTH SCI,DEPT PHYS THERAPY,BOSTON,MA 02115; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; US POSTAL SERV,BOSTON,MA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA; UNIV IOWA,INJURY PREVENT RES CTR,IOWA CITY,IA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Northeastern University; Boston University; Framingham Heart Study; University of Iowa	Daltroy, LH (corresponding author), BRIGHAM & WOMENS HOSP,RBB MULTIPURPOSE ARTHRIT & MUSCULOSKELET DIS CTR,75 FRANCIS ST,BOSTON,MA 02115, USA.		Iversen, Maura/O-5388-2015	Iversen, Maura/0000-0003-4708-9914; Larson, Martin/0000-0002-9631-1254	NIAMS NIH HHS [AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYOUB MA, 1982, J OCCUP ENVIRON MED, V24, P751; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; BOMBARDIER C, 1985, ARTHRITIS SOC, P104; COX DR, 1972, J R STAT SOC B, V34, P187; DALTROY LH, 1993, HEALTH EDUC QUART, V20, P43, DOI 10.1177/109019819302000106; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DONCHIN M, 1990, SPINE, V15, P1317, DOI 10.1097/00007632-199012000-00015; FELDSTEIN A, 1993, J OCCUP ENVIRON MED, V35, P114, DOI 10.1097/00043764-199302000-00010; FIELDING JE, 1989, AM J PUBLIC HEALTH, V79, P16, DOI 10.2105/AJPH.79.1.16; Fitzler S L, 1983, Occup Health Saf, V52, P52; FORSSELL MZ, 1981, SPINE, V6, P104, DOI 10.1097/00007632-198101000-00022; Green LW., 1980, HLTH ED PLANNING DIA, V1; GUNDEWALL B, 1993, SPINE, V18, P587, DOI 10.1097/00007632-199304000-00011; KEIJSERS JFE, 1990, ARTHRIT CARE RES, V3, P204; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KLEIN BP, 1984, J OCCUP ENVIRON MED, V26, P443, DOI 10.1097/00043764-198406000-00017; LAHAD A, 1994, JAMA-J AM MED ASSOC, V272, P1286, DOI 10.1001/jama.272.16.1286; LAIRD N, 1981, J AM STAT ASSOC, V76, P231, DOI 10.2307/2287816; LINTON SJ, 1989, PAIN, V36, P197, DOI 10.1016/0304-3959(89)90024-9; Mattmiller A W, 1980, Physiotherapy, V66, P118; MCCAULEY M, 1990, AM J OCCUP THER, V44, P402, DOI 10.5014/ajot.44.5.402; PORTER RW, 1984, BACK SCH; SCHLAPBACH P, 1991, RHEUMATOLOGY, V14, P25; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; SHI LY, 1993, PUBLIC HEALTH REP, V108, P204; SNOOK SH, 1978, J OCCUP ENVIRON MED, V20, P478, DOI 10.1097/00043764-197807000-00009; SNOOK SH, 1988, OCCUP MED, V3, P45; SPENGLER DM, 1986, SPINE, V11, P241, DOI 10.1097/00007632-198604000-00010; VIDEMAN T, 1983, SOSIAALILAALCETIETEE, V20, P160; WALSH NE, 1990, AM J PHYS MED REHAB, V69, P245, DOI 10.1097/00002060-199010000-00004; Weber M, 1996, BRIT J RHEUMATOL, V35, P178; WOODRUFF SI, 1994, MIL MED, V159, P475, DOI 10.1093/milmed/159.7.475	32	157	158	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					322	328		10.1056/NEJM199707313370507	http://dx.doi.org/10.1056/NEJM199707313370507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XN119	9233870	Green Published			2022-12-28	WOS:A1997XN11900007
J	Devlin, B; Daniels, M; Roeder, K				Devlin, B; Daniels, M; Roeder, K			The heritability of IQ	NATURE			English	Article							BAYES FACTORS; INTELLIGENCE; PREGNANCY; APART	IQ heritability, the portion of a population's IQ variability attributable to the effects of genes', has been investigated for nearly a century, yet it remains controversial. Covariance between relatives may be due not only to genes, but also to shared environments, and most previous models have assumed different degrees of similarity induced by environments specific to twins, to non-twin siblings (henceforth siblings), and to parents and offspring. We now evaluate an alternative model that replaces these three environments by two maternal womb environments, one for twins and another for siblings, along with a common home environment. Meta-analysis of 212 previous studies shows that our 'maternal-effects' model fits the data better than the 'family-environments' model. Maternal effects, often assumed to be negligible, account for 20% of covariance between twins and 5% between siblings, and the effects of genes are correspondingly reduced, with two measures of heritability being less than 50%. The shared maternal environment may explain the striking correlation between the IQs of twins, especially those of adult twins that were reared apart. IQ heritability increases during early childhood, but whether it stabilizes thereafter remains unclear. A recent study of octogenarians(2), for instance, suggests that IQ heritability either remains constant through adolescence and adulthood(3), or continues to increase with age(2). Although the latter hypothesis has recently been endorsed(4), it gathers only modest statistical support in our analysis when compared to the maternal-effects hypothesis. Our analysis suggests that it will be important to understand the basis for these maternal effects if ways in which IQ might be increased are to be identified.	CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213	Carnegie Mellon University	Devlin, B (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA 15213, USA.			Roeder, Kathryn/0000-0002-8869-6254				BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; CHIPUER HM, 1990, INTELLIGENCE, V14, P11, DOI 10.1016/0160-2896(90)90011-H; CHURCHIL.JA, 1965, NEUROLOGY, V15, P341, DOI 10.1212/WNL.15.4.341; Daniels M., 1997, INTELLIGENCE GENES S; Falconer D. S., 1981, INTRO QUANTITATIVE G; GOTTESMAN II, 1997, SCIENCE, V276, P2522; HARRELL RF, 1955, EFFECTS MOTHERS DIET; Hernstein R.J., 1994, BELL CURVE INTELLIGE; HUSEN T, 1963, SCAND J PSYCHOL, V4, P108; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; LYNN R, 1990, BEHAV GENET, V20, P545, DOI 10.1007/BF01067719; MCCARTNEY K, 1990, PSYCHOL BULL, V107, P226, DOI 10.1037/0033-2909.107.2.226; McClearn GE, 1997, SCIENCE, V276, P1560, DOI 10.1126/science.276.5318.1560; McGue M, 1993, NATURE NURTURE PSYCH, P59, DOI DOI 10.1037/10131-003; *NAT RES COUNC, 1992, COMBINING INFORMATIO; OLDS DL, 1994, PEDIATRICS, V93, P221; PEDERSEN NL, 1992, PSYCHOL SCI, V3, P346, DOI 10.1111/j.1467-9280.1992.tb00045.x; PLOMIN R, 1989, BEHAV GENET, V19, P331, DOI 10.1007/BF01066162; Plomin R, 1990, BEHAV GENETICS PRIME; RAO DC, 1982, GENET RES, V39, P187, DOI 10.1017/S0016672300020875; REINISCH J, JAMA-J AM MED ASSOC, V274, P1518; ROSE RJ, 1980, NATURE, V283, P375, DOI 10.1038/283375a0; RUSH D, 1980, DIET PREGNANCY RANDO, P88; Singer B., 1997, INTELLIGENCE GENES S, P89; SMITH AFM, 1993, J ROY STAT SOC B MET, V55, P3; STREISSGUTH AP, 1989, DEV PSYCHOL, V25, P3, DOI 10.1037/0012-1649.25.1.3; *TASK FORC SCI AFF, 1995, KNOWNS UNKN; VERDINELLI I, 1995, J AM STAT ASSOC, V90, P614, DOI 10.2307/2291073	29	291	298	4	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					468	471		10.1038/41319	http://dx.doi.org/10.1038/41319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XN553	9242404	Bronze			2022-12-28	WOS:A1997XN55300047
J	Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP				Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP			Hedgehog elicits signal transduction by means of a large complex containing the kinesin-related protein costal2	CELL			English	Article							POLARITY GENE; DROSOPHILA-MELANOGASTER; SEGMENTAL POLARITY; SONIC-HEDGEHOG; FUSED GENE; PATTERN; FAMILY; TRANSCRIPTION; EXPRESSION; SUPPRESSOR	The hedgehog gene of Drosophila melanogaster encodes a secreted protein (HH) that plays a vital role in cell fate and patterning. Here we describe a protein complex that mediates signal transduction from HH. The complex includes the products of at least three genes:fused (a protein-serine/threonine kinase), cubitus interruptus (a transcription factor), and costal2 (a kinesin-like protein). The complex binds with great affinity to microtubules in the absence of HH, but binding is reversed by HH. Mutations in the extracatalytic domain of FU abolish both the biological function of the protein and its association with COS2. We conclude that the complex may facilitate signaling from HH by governing access of the cubitus interruptus protein to the nucleus.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Robbins, DJ (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Therond, pascal/AAE-4811-2019		NATIONAL CANCER INSTITUTE [P30CA045508, R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA44338, CA45508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUSSON D, 1988, ROUX ARCH DEV BIOL, V197, P221, DOI 10.1007/BF02439429; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLE DG, 1994, J BIOL CHEM, V269, P22913; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MOHLER J, 1988, GENETICS, V120, P1061; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Therond P, 1996, GENETICS, V142, P1181; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; ZECCA M, 1995, DEVELOPMENT, V121, P2265	56	307	316	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					225	234		10.1016/S0092-8674(00)80331-1	http://dx.doi.org/10.1016/S0092-8674(00)80331-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244297	Bronze			2022-12-28	WOS:A1997XN24900007
J	Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE				Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE			On/off blinking and switching behaviour of single molecules of green fluorescent protein	NATURE			English	Article							OPTICAL MICROSCOPY	Optical studies of individual molecules at low and room temperature can provide information about the dynamics of local environments in solids, liquids and biological systems unobscured by ensemble averaging(1-14). Here we present a study of the photophysical behaviour of single molecules of the green fluorescent protein (GFP) derived from the jellfish Aequorea victoria. Wild-type GFP and its mutant have attracted interest as fluorescent biological labels because the fluorophore may be formed in vivo(15,16). GFP mutants immobilized in aereated aqueous polymer gels and excited by 488-nm light undergo repeated cycles of fluorescent emission ('blinking') on a timescale of several seconds-behaviour that would be unobservable in bulk studies. Eventually the individual GFP molecules reach a long-lasting dark state, from which they can be switched back to the original emissive state by irradiation at 405 nm. This suggests the possibility of using these GFPs as fluorescent markers for time-dependent cell processes, and as molecular photonic switches or optical storage elements, addressable on the single-molecule level.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM 0340, LA JOLLA, CA 92093 USA; AURORA BIOSCI, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST 0647, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Moerner, William E/C-3260-2008; Wood, David W/B-2992-2012	Moerner, William E/0000-0002-2830-209X; 				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARBARA PF, 1996, ACC CHEM RES, V29; Basche T., 1997, SINGLE MOL OPTICAL D; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Fawcett J. S., 1966, SEP SCI, V1, P9; FOX GEP, 1970, TIME SERIES ANAL FOR; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; IRIE M, 1994, PHOTOREACTIVE MAT UL, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MOERNER WE, 1994, J PHYS CHEM-US, V98, P7382, DOI 10.1021/j100081a025; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; REILLY PD, 1993, PHYS REV LETT, V71, P4257, DOI 10.1103/PhysRevLett.71.4257; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; STUART JA, 1996, 6 BIENN IEEE INT NON, P35; Trautman JK, 1996, CHEM PHYS, V205, P221, DOI 10.1016/0301-0104(95)00391-6; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	30	1074	1114	16	432	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					355	358		10.1038/41048	http://dx.doi.org/10.1038/41048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237752	Bronze			2022-12-28	WOS:A1997XM52800043
J	Kaplan, SL				Kaplan, SL			Prevention of hearing loss from meningitis	LANCET			English	Editorial Material									TEXAS CHILDRENS HOSP,HOUSTON,TX 77030	Baylor College of Medicine	Kaplan, SL (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.							Dodds A, 1997, ARCH DIS CHILD, V76, P139, DOI 10.1136/adc.76.2.139; FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128; Kaplan S L, 1995, Adv Pediatr Infect Dis, V10, P167; Merchant SN, 1996, AM J OTOL, V17, P375; Richardson MP, 1997, ARCH DIS CHILD, V76, P134, DOI 10.1136/adc.76.2.134; Winter A, 1996, ACTA OTO-LARYNGOL, V116, P401, DOI 10.3109/00016489609137864; WOLFF AB, 1987, AM ANN DEAF, V131, P26	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					158	159		10.1016/S0140-6736(05)62346-X	http://dx.doi.org/10.1016/S0140-6736(05)62346-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250179				2022-12-28	WOS:A1997XL72200005
J	Vokes, FE				Vokes, FE			CHART for non-small-cell lung cancer - Promises and limitations	LANCET			English	Editorial Material									UNIV CHICAGO,MED CTR,DEPT RADIAT ONCOL,CHICAGO,IL 60637	University of Chicago; University of Chicago Medical Center	Vokes, FE (corresponding author), UNIV CHICAGO,MED CTR,DEPT MED,CHICAGO,IL 60637, USA.							Dillman RO, 1996, J NATL CANCER I, V88, P1210, DOI 10.1093/jnci/88.17.1210; FURUSE K, 1997, P AN M AM SOC CLIN, V16, pA1649; Ginsberg Robert J., 1997, P858; LECHEVALIER T, 1992, J NATL CANCER I, V84, P58; *NONSM CELL LUNG C, 1995, BRIT MED J, V311, P899; Sause William T., 1995, International Journal of Radiation Oncology Biology Physics, V32, P195, DOI 10.1016/0360-3016(95)97772-S; SAUSE WT, 1995, J NATL CANCER I, V87, P198, DOI 10.1093/jnci/87.3.198; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; TANNEHILL SP, 1997, P AM SOC CLIN ONCOL, V16, pA446; VOKES EE, 1997, P AN M AM SOC CLIN, V16, pA455	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					156	157		10.1016/S0140-6736(97)22029-5	http://dx.doi.org/10.1016/S0140-6736(97)22029-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250176				2022-12-28	WOS:A1997XL72200002
J	Laskin, CA; Bombardier, C; Hannah, ME; Mandel, FP; Ritchie, JWK; Farewell, V; Farine, D; Spitzer, K; Fielding, L; Soloninka, CA; Yeung, M				Laskin, CA; Bombardier, C; Hannah, ME; Mandel, FP; Ritchie, JWK; Farewell, V; Farine, D; Spitzer, K; Fielding, L; Soloninka, CA; Yeung, M			Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODY; ANTIPHOSPHOLIPID ANTIBODIES; ANTICOAGULANT; PREGNANCY; ABORTION; DEATH; MISCARRIAGE; PREVENTION; WASTAGE	Background Recurrent fetal loss has been well described in women with antiphospholipid antibodies. Such women also often have other autoantibodies commonly found in patients with systemic lupus erythematosus. Treating them with prednisone and aspirin may reduce the risk of fetal loss. Methods We screened 773 nonpregnant women who had the unexplained loss of at least two fetuses for antinuclear, anti-DNA, antilymphocyte, and anticardiolipin antibodies and for the lupus anticoagulant. Of 385 women with at least one autoantibody, 202 who later became pregnant were randomly assigned in equal numbers to receive either prednisone (0.5 to 0.8 mg per kilogram of body weight per day) and aspirin (100 mg per day) or placebo for the duration of the pregnancy. The women were stratified according to age (18 to 34 years or 35 to 39 years) and the week of gestation at which the previous fetal losses had occurred (less than or equal to 12 or >12 weeks). The primary outcome measure was a successful pregnancy. Results Live infants were born to 66 women in the treatment group (65 percent) and 57 women in the placebo group (56 percent, P=0.19). More infants were born prematurely in the treatment group than in the placebo group (62 percent vs. 12 percent, P<0.001). The major side effects of therapy in the mothers were hypertension (treatment group, 13 percent; placebo group, 5 percent; P=0.05) and diabetes mellitus (15 percent and 5 percent, P=0.02). Conclusions Treating women who have autoantibodies and recurrent fetal loss with prednisone and aspirin is not effective in promoting live birth, and it increases the risk of prematurity. (C)1997, Massachusetts Medical Society.	UNIV TORONTO,DEPT MED,DIV RHEUMATOL,TORONTO,ON,CANADA; UNIV TORONTO,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,TORONTO,ON,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON,CANADA; UNIV TORONTO,OBSTET MED PROGRAM,TORONTO,ON,CANADA; TORONTO HOSP,DEPT MED,DIV RHEUMATOL,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,WELLESLEY HOSP,DEPT MED,DIV RHEUMATOL,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,WELLESLEY HOSP,WELLESLEY RES INST,TORONTO,ON M4Y 1J3,CANADA; WOMENS COLL HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5S 1B2,CANADA; MT SINAI HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 1X5,CANADA; UNIV OXFORD,DEPT BIOSTAT,CAMBRIDGE,ENGLAND	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Oxford				Farewell, Vernon/0000-0001-6704-5295				[Anonymous], 1994, LANCET, P619; BRANCH DW, 1984, AM J REPROD IMMUNOL, V5, P100; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; CECERE FA, 1981, CLIN RHEUM DIS, V7, P747; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; COWCHOCK S, 1986, AM J OBSTET GYNECOL, V155, P1002, DOI 10.1016/0002-9378(86)90335-2; CRONIN ME, 1988, J RHEUMATOL, V15, P795; FOROUZAN I, 1993, J ULTRAS MED, V12, P135; FRAGA A, 1974, J RHEUMATOL, V1, P293; FRIEDMAN EA, 1956, OBSTET GYNECOL, V8, P601; GLEICHER N, 1989, AM J OBSTET GYNECOL, V160, P1376, DOI 10.1016/0002-9378(89)90858-2; GLEICHER N, 1986, ACTA HAEMATOL-BASEL, V76, P68, DOI 10.1159/000206024; GOLDMAN RR, 1988, RHEUM DIS CLIN N AM, V14, P169; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HAWKER GA, 1991, ARTHRITIS RHEUM, V34, pS95; LASKIN CA, 1990, AM J MED, V89, P129, DOI 10.1016/0002-9343(90)90288-O; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LUBBE WF, 1983, LANCET, V1, P1361; MERRILL JA, 1955, OBSTET GYNECOL, V6, P637, DOI 10.1097/00006250-195512000-00013; PARKE A, 1986, J RHEUMATOL, V13, P1178; PASSALEVA A, 1992, AUTOIMMUNITY, V14, P121, DOI 10.3109/08916939209083130; RAI RS, 1995, HUM REPROD, V10, P2001, DOI 10.1093/oxfordjournals.humrep.a136224; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; SILVER RK, 1993, AM J OBSTET GYNECOL, V169, P1411, DOI 10.1016/0002-9378(93)90410-K; SOLONINKA CA, 1991, J RHEUMATOL, V18, P1849; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; UNANDER AM, 1987, AM J OBSTET GYNECOL, V156, P114, DOI 10.1016/0002-9378(87)90218-3	29	293	303	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					148	153		10.1056/NEJM199707173370302	http://dx.doi.org/10.1056/NEJM199707173370302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219700				2022-12-28	WOS:A1997XK81800002
J	Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC				Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC			Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID-BINDING; ANNEXIN-V; LIPOCORTIN FAMILY; FETAL LOSS; LINES; CELLS; MICE	Background The mechanisms of vascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown. Levels of annexin V, a phospholipid-binding protein with potent anticoagulant activity, are markedly reduced on placental villi from women with this syndrome. Hypercoagulability in such women may therefore be due to the reduction of surface-bound annexin V by antiphospholipid antibodies. To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V on cultured trophoblasts and human umbilical vein endothelial cells and how they affect the procoagulant activity of these cells. Methods We isolated IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal controls. These antibodies were incubated with cultured BeWo cells (a placental-trophoblast cell line), primary cultured trophoblasts, and human umbilical-vein endothelial cells. Annexin V on the cell surfaces was measured by an enzyme-linked immunosorbent assay. The coagulation times of plasma overlaid on the cells were also determined. Results Trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control IgG had reduced levels of annexin V (trophoblasts, 0.37+/-0.02 vs. 0.85+/-0.12 ng per well, P=0.02; endothelial cells, 1.6+/-0.04 vs. 2.1+/-0.05 ng per well, P=0.001). Also, trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/-SE) plasma coagulation times than cells exposed to control IgG (trophoblasts, 8.7+/-2.0 vs. 21.3+/-2.9 minutes, P=0.02; endothelial cells, 9.8+/-0.8 vs. 14.2+/-1.2 minutes, P=0.04). Conclusions Antiphospholipid antibodies reduce the levels of annexin V and accelerate the coagulation of plasma on cultured trophoblasts and endothelial cells. The reduction of annexin V levels on vascular cells may be an important mechanism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome. (C)1997, Massachusetts Medical Society.	MT SINAI SCH MED,DEPT MED,DIV THROMBOSIS,NEW YORK,NY; MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY; NYU,SCH MED,DEPT OBSTET & GYNECOL,NEW YORK,NY	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; New York University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029019, R01HL032200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32200, HL-29019] Funding Source: Medline; NIAID NIH HHS [AI-24671] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; ANDREE HAM, 1992, PHOSPHOLIPID BINDING, P73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BLANK M, 1994, J AUTOIMMUN, V7, P441, DOI 10.1006/jaut.1994.1032; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; DOUGLAS GC, 1989, J IMMUNOL METHODS, V119, P259, DOI 10.1016/0022-1759(89)90405-5; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HASEGAWA I, 1994, THROMB RES, V74, P77, DOI 10.1016/0049-3848(94)90037-X; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; HUBER R, 1994, ANNEXINS, P105; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAUSE I, 1993, AM J REPROD IMMUNOL, V29, P155, DOI 10.1111/j.1600-0897.1993.tb00581.x; KRIKUN G, 1994, PLACENTA, V15, P601, DOI 10.1016/S0143-4004(05)80407-2; LOCKSHIN M D, 1991, Current Opinion in Rheumatology, V3, P797, DOI 10.1097/00002281-199110000-00008; Lockwood C J, 1994, Obstet Gynecol Surv, V49, P432, DOI 10.1097/00006254-199406000-00026; MESSMORE H, 1994, SEMIN THROMB HEMOST, V20, P79, DOI 10.1055/s-2007-1001892; ORNSTEIN MH, 1994, J RHEUMATOL, V21, P1360; Pierangeli SS, 1996, LUPUS, V5, P451, DOI 10.1177/096120339600500524; RAND JH, 1994, AM J OBSTET GYNECOL, V171, P1566, DOI 10.1016/0002-9378(94)90403-0; ROUBEY RAS, 1994, BLOOD, V84, P2854; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SAMMARITANO LR, 1992, J CLIN IMMUNOL, V12, P27, DOI 10.1007/BF00918270; Shapiro SS, 1996, ANNU REV MED, V47, P533; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TRIPLETT DA, 1995, THROMB HAEMOSTASIS, V74, P329	29	376	390	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					154	160		10.1056/NEJM199707173370303	http://dx.doi.org/10.1056/NEJM199707173370303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219701				2022-12-28	WOS:A1997XK81800003
J	Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH				Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH			P-falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1	NATURE			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; SWAIN-LANGLEY; MALARIA; EXPRESSION; PHENOTYPES; CYTOADHERENCE; ANTIGENS; SURFACE; DOMAINS	The factors determining disease severity in malaria are complex and include host polymorphisms, acquired immunity and parasite virulence(1). Studies in Africa have shown that severe malaria is associated with the ability of erythrocytes infected with the parasite Plasmodium falciparum to bind uninfected erythrocytes and form rosettes(2-5). The molecular basis of resetting is not well understood, although a group of low-molecular-mass proteins called rosettins have been described as potential parasite ligands(6). Infected erythrocytes also bind to endothelial cells, and this interaction is mediated by the parasite-derived variant erythrocyte membrane protein PfEMP1 (refs 7, 8), which is encoded by the var gene family(9-11). Here we report that the parasite ligand for resetting in a P. falciparum done is PfEMP1, encoded by a specific var gene, We also report that Complement-receptor 1 (CR1) on erythrocytes plays a role in the formation of rosettes and that erythrocytes with a common African CR1 polymorphism (Sl(a(-)))(12) have reduced adhesion to the domain of PfEMP1 that binds normal erythrocytes. Thus we describe a new adhesive function for PfEMP1 and raise the possibility that CR1 polymorphisms in Africans that influence the interaction between erythrocytes and PfEMP1 may protect against severe malaria.	JOHN RADCLIFFE HOSP,INST MOL MED,MOL PARASITOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV TEXAS,HOUSTON MED SCH,DIV RHEUMATOL & CLIN IMMUNOGENET,HOUSTON,TX 77030	University of Oxford; University of Texas System; University of Texas Health Science Center Houston	Rowe, JA (corresponding author), NIAID,PARASIT DIS LAB,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Newbold, Chris/0000-0002-9274-3789; Rowe, Alexandra/0000-0002-7702-1892	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold C, 1991, PCR Methods Appl, V1, P39; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; HELMBY H, 1993, INFECT IMMUN, V61, P284, DOI 10.1128/IAI.61.1.284-288.1993; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; MOULDS JM, 1992, VOX SANG, V62, P230, DOI 10.1111/j.1423-0410.1992.tb01204.x; MOULDS JM, 1991, J EXP MED, V173, P1159, DOI 10.1084/jem.173.5.1159; MOULDS MK, 1981, AM J MED TECHNOL, V47, P789; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; RINGWALD P, 1993, INFECT IMMUN, V61, P5198, DOI 10.1128/IAI.61.12.5198-5204.1993; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1994, EXP PARASITOL, V79, P506, DOI 10.1006/expr.1994.1111; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503; VENGELENTYLER V, 1996, AABB TECHNICAL MANUA; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595	29	451	460	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					292	295		10.1038/40888	http://dx.doi.org/10.1038/40888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230440	Bronze			2022-12-28	WOS:A1997XL12100055
J	Nowakowski, J; Schwartz, I; Nadelman, RB; Liveris, D; AgueroRosenfeld, M; Wormser, GP				Nowakowski, J; Schwartz, I; Nadelman, RB; Liveris, D; AgueroRosenfeld, M; Wormser, GP			Culture-confirmed infection and reinfection with Borrelia burgdorferi	ANNALS OF INTERNAL MEDICINE			English	Article							LYME-DISEASE		WESTCHESTER CTY MED CTR, LYME DIS DIAGNOST CTR, VALHALLA, NY 10595 USA	Westchester Medical Center	Nowakowski, J (corresponding author), NEW YORK MED COLL, DEPT MED, DIV INFECT DIS, MACY PAVIL 209SE, VALHALLA, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041508, R01AR041511] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41508, AR41511] Funding Source: Medline; PHS HHS [U50/CCU210280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; HASSLER D, 1994, DEUT MED WOCHENSCHR, V119, P338, DOI 10.1055/s-2008-1058700; HOLLSTROM E, 1958, ACTA DERM-VENEREOL, V338, P285; LIVERIS D, 1995, J CLIN MICROBIOL, V33, P589, DOI 10.1128/JCM.33.3.589-595.1995; Liveris D, 1996, J CLIN MICROBIOL, V34, P1306, DOI 10.1128/JCM.34.5.1306-1309.1996; PFISTER HW, 1986, LANCET, V2, P984; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; WEBER K, 1986, INFECTION, V14, P32, DOI 10.1007/BF01644807	9	23	24	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					130	132		10.7326/0003-4819-127-2-199707150-00006	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230002				2022-12-28	WOS:A1997XK15800008
J	Siegel, V				Siegel, V			Recognition of a transmembrane domain: Another role for the ribosome?	CELL			English	Review							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; SECRETORY PROTEINS						Siegel, Vivian/N-3672-2014; Siegel, Vivian/E-9604-2010	Siegel, Vivian/0000-0001-9537-9989; 				CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIARD V, 1997, J BIOL CHEM, V272, P1983; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519	19	13	13	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					5	8		10.1016/S0092-8674(00)80307-4	http://dx.doi.org/10.1016/S0092-8674(00)80307-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230296	Bronze			2022-12-28	WOS:A1997XL36200002
J	Hanahan, D				Hanahan, D			Signaling vascular morphogenesis and maintenance	SCIENCE			English	Editorial Material							RECEPTOR TYROSINE KINASE; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; MICE; VASCULOGENESIS		UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Hanahan, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOLKMAN J, 1995, MOL BASIS CANC, V9, P206; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9	22	970	1079	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					48	50		10.1126/science.277.5322.48	http://dx.doi.org/10.1126/science.277.5322.48			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9229772				2022-12-28	WOS:A1997XJ41800030
J	Fairfield, G; Hunter, DJ; Mechanic, D; Rosleff, F				Fairfield, G; Hunter, DJ; Mechanic, D; Rosleff, F			Managed care - Implications of managed care for health systems, clinicians, and patients	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIANS; HMOS	The rhetoric and realities of managed care are easily confused, The rapid growth of managed care in the United States has had many implications for patients, doctors, employers, state and federal programmes, the health insurance industry, major medical institutions, medical research, and vulnerable patient populations. It has restricted patients' choice of doctors and limited access to specialists, reduced the professional autonomy and earnings of doctors, shifted power from the non-profit to the for-profit sectors and from hospitals and doctors to private corporations. It has also raised issues about the future structuring and financing of medical education and research and about practice ethics. However, managed care has also accorded greater prominence to the assessment of patient satisfaction, profiling and monitoring of doctors' work, the use of clinical guidelines and quality assurance procedures and indicated the potential to improve the integration and outcome of care.	UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND; RUTGERS STATE UNIV,NEW BRUNSWICK,NJ 08903; BURE MANAGED CTR,SE-40229 GOTHENBURG,SWEDEN	University of Leeds; Rutgers State University New Brunswick								*AM MED ASS COUNC, 1995, JAMA-J AM MED ASSOC, V273, P330; BRADBURY RC, 1991, INQUIRY-J HEALTH CAR, V28, P87; CORAD D, 1996, HLTH SERVICES RES, V3, P235; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Fairfield G, 1997, BRIT MED J, V314, P1823, DOI 10.1136/bmj.314.7097.1823; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; HATCHER P, 1995, HLTH SERVICES MANAGE, V3, P1; Hellinger FJ, 1996, MED CARE RES REV, V53, P294, DOI 10.1177/107755879605300305; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Rodwin MA, 1996, HEALTH AFFAIR, V15, P110, DOI 10.1377/hlthaff.15.3.110; *SECR STAT HLTH, 1996, NAT HLTH SERV SERV A; *SECR STAT HLTH SC, 1996, CM3512; *SECR STAT HLTH SC, 1996, CM3390; Sisk JE, 1996, JAMA-J AM MED ASSOC, V276, P50, DOI 10.1001/jama.276.1.50; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WELCH WP, 1985, J HEALTH ECON, V4, P293, DOI 10.1016/0167-6296(85)90010-4; ZELMAN WA, 1996, CHANGING HEALTHCARE	20	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1895	1898		10.1136/bmj.314.7098.1895	http://dx.doi.org/10.1136/bmj.314.7098.1895			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224138	Green Published			2022-12-28	WOS:A1997XH73800035
J	Freeman, G; Hjortdahl, P				Freeman, G; Hjortdahl, P			What future for continuity of care in general practice?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; PRACTITIONERS KNOWLEDGE; PATIENT SATISFACTION; PERSONAL CONTINUITY; DOCTOR; CONSULTATIONS; QUALITY; VIEWS; KEY		UNIV OSLO,DEPT GEN PRACTICE & COMMUNITY MED,N-0317 OSLO,NORWAY	University of Oslo	Freeman, G (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DEPT PUBL HLTH & PRIMARY CARE,LONDON SW10 9NH,ENGLAND.							BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BRESLAU N, 1982, MED CARE, V20, P347, DOI 10.1097/00005650-198204000-00001; CHACKO MR, 1987, J ADOLESCENT HEALTH, V8, P261, DOI 10.1016/0197-0070(87)90429-3; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; FLYNN SP, 1985, J FAM PRACTICE, V21, P375; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; Freeman G., 1985, J ROYAL COLL GEN PRA, V5, P423; FREEMAN GK, 1994, BRIT J GEN PRACT, V44, P395; FREEMAN GK, 1989, J ROY COLL GEN PRACT, V39, P145; FREEMAN GK, 1993, BRIT J GEN PRACT, V43, P493; Freidson E., 1970, PROFESSION MED STUDY; *GEN MED SERV COMM, 1995, COR GEN MED SERV CLA; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; Haig-Smith C, 1989, BRIT MED J, V299, P494; Harris MF, 1996, MED J AUSTRALIA, V164, P456, DOI 10.5694/j.1326-5377.1996.tb122119.x; Heath I., 1995, MYSTERY GEN PRACTICE; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; LEWIS JR, 1994, SOC SCI MED, V39, P655, DOI 10.1016/0277-9536(94)90022-1; MCWHINNEY IR, 1989, TXB FAMILY MED, P12; MILLER MH, 1973, J HEALTH SOC BEHAV, V14, P176, DOI 10.2307/2137067; MOREHEAD MA, 1974, MED CARE, V12, P301, DOI 10.1097/00005650-197404000-00002; PENDLETON DA, 1996, OXFORD GEN PRACTICE, V37; PHILLIPS DM, 1984, J FAM PRACTICE, V19, P793; PRATT J, 1995, PRACTITIONERS PRACTI, P60; ROOS LL, 1980, MED CARE, V18, P174, DOI 10.1097/00005650-198002000-00004; *ROYAL COLL GEN PR, 1985, EV ROYAL COMM NAT HL, P1; Schon Donald A., 1988, ED REFLECTIVE PRACTI; SMITH WG, 1985, EVAL HEALTH PROF, V8, P339, DOI 10.1177/016327878500800305; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STARFIELD B, 1980, AM J PUBLIC HEALTH, V70, P117, DOI 10.2105/AJPH.70.2.117; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; WILSON M, 1996, MED WORKFORCE	44	105	107	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1870	1873		10.1136/bmj.314.7098.1870	http://dx.doi.org/10.1136/bmj.314.7098.1870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224130	Green Published			2022-12-28	WOS:A1997XH73800025
J	Gluckman, E; Rocha, V; BoyerChammard, A; Locatelli, F; Arcese, W; Pasquini, R; Ortega, J; Souillet, G; Ferreira, E; Laporte, JP; Fernandez, M; Chastang, C				Gluckman, E; Rocha, V; BoyerChammard, A; Locatelli, F; Arcese, W; Pasquini, R; Ortega, J; Souillet, G; Ferreira, E; Laporte, JP; Fernandez, M; Chastang, C			Outcome of cord-blood transplantation from related and unrelated donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW RECONSTITUTION; PROGENITOR CELLS; PLACENTAL BLOOD; HOST DISEASE; ANEMIA; GRAFT	Background Cord-blood banks have increased the use of cord-blood transplantation in patients with hematologic disorders. We have established a registry containing information on the outcome of cord-blood transplantation. Methods We sent questionnaires to 45 transplantation centers for information on patients receiving cord-blood transplants from 1988 to 1996. Reports on 143 transplantations, performed at 45 centers, were studied, and the responses were analyzed separately according to whether the donor was related or unrelated to the recipient. Results Among 78 recipients of cord blood from related donors, the Kaplan-Meier estimate of survival at one year was 63 percent. Younger age, lower weight, transplants from HLA-identical donors, and cytomegalovirus-negative serologic results in the recipient were favorable prognostic factors. Graft-versus-host disease of at least grade II occurred at estimated rates of 9 percent in 60 recipients of HLA-matched cord blood and 50 percent in 18 recipients of HLA-mismatched cord blood. Neutrophil engraftment was associated with an age of less than six years (P = 0.02) and a weight of less than 20 kg (P = 0.02), and it occurred in 85 percent of patients receiving 37 million or more nucleated cells per kilogram of body weight. Among 65 patients who received cord blood from unrelated donors, the Kaplan-Meier estimate of survival at one year was 29 percent. Cytomegalovirus-negative serologic status in these recipients was associated with improved survival (P = 0.03) and was the most important predictor of graft-versus-host disease (P = 0.04). Neutrophil recovery occurred in 94 percent of the patients who received 37 million or more nucleated cells per kilogram from unrelated donors. Conclusions Cord blood is a feasible alternative source of hematopoietic stem cells for pediatric and some adult patients with major hematologic disorders, particularly if the donor and the recipient are related. (C) 1997, Massachusetts Medical Society.	UNIV PAVIA,I-27100 PAVIA,ITALY; UNIV ROMA LA SAPIENZA,ROME,ITALY; HOSP CLIN,CURITIBA,PARANA,BRAZIL; HOSP VALLE DE HEBRON,BARCELONA,SPAIN; HOP DEBROUSSE,LYON,FRANCE; HOSP ALBERT EINSTEIN,SAO PAULO,BRAZIL; HOP ST ANTOINE,F-75571 PARIS,FRANCE; CLIN PUERTA HIERRO,MADRID,SPAIN	University of Pavia; Sapienza University Rome; Hospital Universitari Vall d'Hebron; CHU Lyon; Hospital Israelita Albert Einstein; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Gluckman, E (corresponding author), HOP ST LOUIS,HEMATOL BONE MARROW TRANSPLANT UNIT,1 AVE CLAUDE VELLEFAUX,F-75475 PARIS 10,FRANCE.		Rocha, Vanderson/AAO-1691-2020	ARCESE, WILLIAM/0000-0001-5697-366X				Brenner M, 1996, NAT MED, V2, P969, DOI 10.1038/nm0996-969; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; deLaSelle V, 1996, BLOOD, V87, P3977, DOI 10.1182/blood.V87.9.3977.bloodjournal8793977; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 1996, NATURE, V382, P108, DOI 10.1038/382108a0; GLUCKMAN E, 1995, ONTOGENY HAEMOTOPOIE, V235, P183; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Marshall E, 1996, SCIENCE, V271, P587, DOI 10.1126/science.271.5249.587; MAYANI H, 1994, BLOOD, V83, P2410, DOI 10.1182/blood.V83.9.2410.bloodjournal8392410; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; Petersdorf EW, 1996, P NATL ACAD SCI USA, V93, P15358, DOI 10.1073/pnas.93.26.15358; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; RUBINSTEIN P, 1993, BLOOD, V81, P1679; Silberstein LE, 1996, NEW ENGL J MED, V335, P199, DOI 10.1056/NEJM199607183350310; Speiser DE, 1996, BLOOD, V87, P4455, DOI 10.1182/blood.V87.10.4455.bloodjournal87104455; STORB R, 1983, ANN INTERN MED, V98, P461, DOI 10.7326/0003-4819-98-4-461; SUGARMAN J, 1995, JAMA-J AM MED ASSOC, V274, P1783, DOI 10.1001/jama.274.22.1783; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wagner JE, 1996, BLOOD, V88, P795	24	1068	1103	0	65	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					373	381		10.1056/NEJM199708073370602	http://dx.doi.org/10.1056/NEJM199708073370602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241126				2022-12-28	WOS:A1997XP40700002
J	Jaffer, A; Leifer, D				Jaffer, A; Leifer, D			Cerebral venous thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Jaffer, A (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06520, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					395	395		10.1056/NEJM199708073370605	http://dx.doi.org/10.1056/NEJM199708073370605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241129				2022-12-28	WOS:A1997XP40700005
J	Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F				Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F			Cross-language analysis of phonetic units in language addressed to infants	SCIENCE			English	Article							SPEECH; MOTHERESE; PATTERNS; PREFERENCE; PROTOTYPES; CATEGORIES; FEATURES; SUPPORT; WORDS	In the early months of life, infants acquire information about the phonetic properties of their native language simply by listening to adults speak. The acoustic properties of phonetic units in language input to young infants in the United States, Russia, and Sweden, were examined. In all three countries, mothers addressing their infants produced acoustically more extreme vowels than they did when addressing adults, resulting in a ''stretching'' of vowel space. The findings show that language input to infants provides exceptionally well-specified information about the linguistic units that form the building blocks for words.	EARLY INTERVENT INST, ST PETERSBURG 191194, RUSSIA; UNIV STOCKHOLM, INST LINGUIST, S-10691 STOCKHOLM, SWEDEN	Stockholm University	Kuhl, PK (corresponding author), UNIV WASHINGTON, DEPT SPEECH & HEARING SCI, BOX 357920, SEATTLE, WA 98195 USA.		Kozhevnikova, Elena/ABB-3431-2020	de Lacerda, Francisco/0000-0002-7980-3601	NIDCD NIH HHS [DC 00520] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC000520] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chomsky Noam, 1980, RULES REPRESENTATION; Fant G., 1973, SPEECH SOUNDS FEATUR; FERNALD A, 1987, INFANT BEHAV DEV, V10, P279, DOI 10.1016/0163-6383(87)90017-8; FERNALD A, 1985, INFANT BEHAV DEV, V8, P181, DOI 10.1016/S0163-6383(85)80005-9; FERNALD A, 1984, DEV PSYCHOL, V20, P104, DOI 10.1037/0012-1649.20.1.104; FROMKIN V, 1974, BRAIN LANG, V1, P81, DOI 10.1016/0093-934X(74)90027-3; GRIESER D, 1989, DEV PSYCHOL, V25, P577, DOI 10.1037/0012-1649.25.4.577; GRIESER DL, 1988, DEV PSYCHOL, V24, P14, DOI 10.1037/0012-1649.24.1.14; HILLENBRAND J, 1995, J ACOUST SOC AM, V97, P3099, DOI 10.1121/1.411872; IVERSON P, 1995, J ACOUST SOC AM, V97, P553, DOI 10.1121/1.412280; Jakobson R., 1969, PRELIMINARIES SPEECH; JOHNSON K, 1993, LANGUAGE, V69, P505, DOI 10.2307/416697; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1993, J MEM LANG, V32, P402, DOI 10.1006/jmla.1993.1022; KENT RD, 1982, J ACOUST SOC AM, V72, P353, DOI 10.1121/1.388089; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Kuhl PK, 1996, J ACOUST SOC AM, V100, P2425, DOI 10.1121/1.417951; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; Lane H., 1976, WILD BOY AVEYRON; LILJENCRANTS J, 1972, LANGUAGE, V48, P839, DOI 10.2307/411991; LINDBLOM B, 1963, J ACOUST SOC AM, V35, P1773, DOI 10.1121/1.1918816; LINDBLOM B, 1990, NATO ADV SCI I D-BEH, V55, P403; LIVELY SE, 1993, J ACOUST SOC AM, V94, P1242, DOI 10.1121/1.408177; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Perkell J.S., 1986, INVARIANCE VARIABILI; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; PETITTO LA, 1993, NATO ADV SCI INST SE, V69, P365; RATNER NB, 1984, J CHILD LANG, V11, P557, DOI 10.1017/S030500090000595X; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Snow C.E., 1977, TALKING CHILDREN, P31; Stevens KN, 1994, INTRO COMMUNICATION, P399; Stevens SS, 1937, J ACOUST SOC AM, V8, P185, DOI 10.1121/1.1915893; StuddertKennedy M, 1995, PSYCHON B REV, V2, P508, DOI 10.3758/BF03210986; SWOBODA PJ, 1978, CHILD DEV, V49, P332, DOI 10.1111/j.1467-8624.1978.tb02320.x; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81	36	533	539	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					684	686		10.1126/science.277.5326.684	http://dx.doi.org/10.1126/science.277.5326.684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XN907	9235890				2022-12-28	WOS:A1997XN90700040
J	Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR				Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR			Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells	NATURE			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MOLECULAR-CLONING; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; EXPRESSION; HAMSTER; GENE; DEFICIENCY; MUTATION	Mutation of the XRCC4 gene in mammalian cells(1,2) prevents the formation of the signal and coding joints in the V(D)J recombination reaction(3), which is necessary for production of a functional immunoglobulin gene, and renders the cells highly sensitive to ionizing radiation(4). However, XRCC4 shares no sequence homology with other proteins, nor does it have a biochemical activity to indicate what its function might be(2). Here we show that DNA ligase IV (ref. 5) co-immunoprecipitates with XRCC4 and that these two proteins specifically interact with one another in a yeast two-hybrid system. Ligation of DNA double-strand breaks in a cell-free system by DNA ligase IV is increased fivefold by purified XRCC4 and seven- to eightfold when XRCC4 is co-expressed with DNA ligase IV. We conclude that the biological consequences of mutating XRCC4 are primarily due to the loss of its stimulatory effect on DNA ligase IV: the function of the XRCC4-DNA ligase IV complex may be to carry out the final steps of V(D)J recombination and joining of DNA ends.	EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV MOL ONCOL,ST LOUIS,MO 63110	European Molecular Biology Laboratory (EMBL); Washington University (WUSTL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Lieber, Michael/0000-0003-3700-6345; Wilm, Matthias/0000-0002-5461-6834; Lieber, Michael/0000-0001-8809-0909				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GIACCIA AJ, 1989, SOMAT CELL MOLEC GEN, V15, P71, DOI 10.1007/BF01534671; Grawunder U, 1996, J EXP MED, V183, P1731, DOI 10.1084/jem.183.4.1731; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wu XT, 1996, MOL CELL BIOL, V16, P5186; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	518	530	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					492	495		10.1038/41358	http://dx.doi.org/10.1038/41358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242410	Bronze			2022-12-28	WOS:A1997XN55300053
J	Goldstein, FW; Garau, J				Goldstein, FW; Garau, J			30 years of penicillin-resistant S pneumoniae: Myth or reality?	LANCET			English	Editorial Material							PNEUMOCOCCI; MENINGITIS		UNIV BARCELONA,HOSP MUTUA TERRASSA,DEPT MED,BARCELONA,SPAIN	Hospital Universitario Mutua Terrassa; University of Barcelona	Goldstein, FW (corresponding author), FDN HOP ST JOSEPH,LAB MICROBIOL MED,F-75674 PARIS 14,FRANCE.							Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; Bradley JS, 1997, CLIN INFECT DIS, V24, pS213, DOI 10.1093/clinids/24.Supplement_2.S213; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; Jacobs RF, 1996, ANTIMICROB AGENTS CH, V40, P895, DOI 10.1128/AAC.40.4.895; Keefer CS, 1943, JAMA-J AM MED ASSOC, V122, P1217; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PARIS MM, 1995, ANTIMICROB AGENTS CH, V39, P2171, DOI 10.1128/AAC.39.10.2171	9	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					233	234		10.1016/S0140-6736(05)62222-2	http://dx.doi.org/10.1016/S0140-6736(05)62222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242797				2022-12-28	WOS:A1997XM86600006
J	Sisson, JC; Ho, KS; Suyama, K; Scott, MP				Sisson, JC; Ho, KS; Suyama, K; Scott, MP			Costal2, a novel kinesin-related protein in the Hedgehog signaling pathway	CELL			English	Article							POLARITY GENE COSTAL-2; DROSOPHILA-MELANOGASTER; KINASE-A; ENGRAILED LOCUS; HOMEOTIC GENES; IMAGINAL DISKS; SEGMENT; PATTERN; TRANSDUCTION; EXPRESSION	The Hedgehog (HH) signaling proteins control cell fates and patterning during animal development. In Drosophila, HH protein induces the transcription of target genes encoding secondary signals such as DPP and WG proteins by opposing a repressor system. The repressors include Costal2, protein kinase A, and the HH receptor Patched. Like HH, the kinase Fused and the transcription factor Cubitus interruptus (CI) act positively upon targets. Here we show that costal2 encodes a kinesin-related protein that accumulates preferentially in cells capable of responding to HH. COS2 is cytoplasmic and binds microtubules. We find that CI associates with COS2 in a large protein complex, suggesting that COS2 directly controls the activity of CI.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University								Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Ashburner M., 1989, DROSOPHILA LAB HDB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLE DG, 1994, J BIOL CHEM, V269, P22913; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Foe Victoria E., 1993, P149; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HEITZLER P, 1993, GENETICS, V135, P105; Hepker J, 1997, DEVELOPMENT, V124, P549; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MATHIES LD, 1994, DEVELOPMENT, V120, P2799; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARDUE ML, 1994, METHOD CELL BIOL, V44, P333, DOI 10.1016/S0091-679X(08)60922-X; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 2002, MOL CLONING LAB MANU; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; THEURKAUF WE, 1992, DEV BIOL, V154, P205, DOI 10.1016/0012-1606(92)90060-T; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; WHITTLE JRS, 1976, DEV BIOL, V51, P257, DOI 10.1016/0012-1606(76)90142-1; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; XU T, 1994, PRACTICAL USES CELL, V44, P655; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	68	287	302	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					235	245		10.1016/S0092-8674(00)80332-3	http://dx.doi.org/10.1016/S0092-8674(00)80332-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244298	Bronze			2022-12-28	WOS:A1997XN24900008
J	Straight, AF; Marshall, WF; Sedat, JW; Murray, AW				Straight, AF; Marshall, WF; Sedat, JW; Murray, AW			Mitosis in living budding yeast: Anaphase a but no metaphase plate	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; MITOTIC SPINDLE; SEGREGATION; KINETOCHORES; CHECKPOINT; DYNAMICS; FORCES; CELLS	Chromosome movements and spindle dynamics were visualized in living cells of the budding yeast Saccharomyces cerevisiae. Individual chromosomal loci were detected by expression of a protein fusion between green fluorescent protein (GFP) and the Lac repressor, which bound to an array of Lac operator binding sites integrated into the chromosome. Spindle microtubules were detected by expression of a protein fusion between GFP and Tub1, the major alpha tubulin. Spindle elongation and chromosome separation exhibited biphasic kinetics, and centromeres separated before telomeres. Budding yeast did not exhibit a conventional metaphase chromosome alignment but did show anaphase A, movement of the chromosomes to the poles.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Straight, AF (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Straight, Aaron/0000-0001-5885-7881				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; BAJER AS, 1986, J CELL BIOL, V102, P263, DOI 10.1083/jcb.102.1.263; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1992, J CELL SCI, V102, P681; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; PAGE BD, 1993, ANNU REV MICROBIOL, V47, P231, DOI 10.1146/annurev.micro.47.1.231; PETERSON JB, 1976, J CELL SCI, V22, P219; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687	23	313	318	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					574	578		10.1126/science.277.5325.574	http://dx.doi.org/10.1126/science.277.5325.574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228009				2022-12-28	WOS:A1997XM86700054
J	Thompson, JN; Moskowitz, J				Thompson, JN; Moskowitz, J			Preventing the extinction of the clinical research ecosystem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INVESTIGATOR; GENE		WAKE FOREST UNIV,BOWMAN GRAY SCH MED,OFF RES DEV,MED CTR,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,OFF DEAN,MED CTR,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center								AGNEW B, 1997, J NIH RES, V9, P30; Ahrens E.H., 1992, CRISIS CLIN RES OVER; ANGIER N, 1993, NY TIMES        0420, pB9; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Gallin JI, 1997, JAMA-J AM MED ASSOC, V277, P651; Genel M, 1996, PEDIATR RES, V39, P902, DOI 10.1203/00006450-199605000-00027; HEARN W, 1996, AM MED NEWS     0708, P31; *I MED, 1994, CARR CLIN RES OBST O; *NAT CTR HLTH STAT, 1985, US DEP HLTH HUM SERV, P48; *NIH, 1996, INT REP NIH DIR PAN; PARDES H, 1996, AMA MED SCH SECT M J; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Shorter E, 1987, HLTH CENTURY; Shulman LE, 1996, ACAD MED, V71, P362, DOI 10.1097/00001888-199604000-00013; SHULMAN LE, 1996, ACAD MED, V71, P398; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; TANOUYE E, 1997, WALL STREET J   0207, pB16; *US DEP ED, 1991, AM 2000 ED STRAT; Wyngaarden J B, 1979, Trans Assoc Am Physicians, V92, P1; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; WYNGAARDEN JB, 1981, B NEW YORK ACAD MED, V57, P415; 1996, RES AM ANN FOR AL VA; 1995, NEUROLOGY, V45, P839; 1996, GEN CLIN RES CTR JUL, P1; 1996, SCIENCE, V271, P585; 1995, RES AM ANN REPORT; 1996, WASHINGTON FAX INFOR	29	55	56	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					241	245		10.1001/jama.278.3.241	http://dx.doi.org/10.1001/jama.278.3.241			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218673				2022-12-28	WOS:A1997XK10800032
J	Turner, T				Turner, T			ABC of mental health - Schizophrenia	BRITISH MEDICAL JOURNAL			English	Review									HOMERTON HOSP,LONDON,ENGLAND		Turner, T (corresponding author), ST BARTHOLOMEWS HOSP,LONDON,ENGLAND.							[Anonymous], 1992, FAMILIES SCHIZOPHREN; BURNS T, 1996, PREVENTION MENTAL IL, P246; DAVIES T, 1994, BRIT MED J, V309, P353, DOI 10.1136/bmj.309.6951.353; PICKAR D, 1995, LANCET, V345, P557, DOI 10.1016/S0140-6736(95)90469-7; TYLEE A, 1994, PSYCHIAT SEM S, V23; WILKINSON G, 1996, CARERS GUIDE SCHIZOP; 1994, DRUG THER B, V32, P73	7	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					108	111		10.1136/bmj.315.7100.108	http://dx.doi.org/10.1136/bmj.315.7100.108			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240053	Green Published			2022-12-28	WOS:A1997XL25200030
J	Spencer, CP; Cooper, AJ; Whitehead, MI				Spencer, CP; Cooper, AJ; Whitehead, MI			Fortnightly review - Management of abnormal bleeding in women receiving hormone replacement therapy	BRITISH MEDICAL JOURNAL			English	Review							POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; MEDROXYPROGESTERONE ACETATE; PROGESTOGEN THERAPY; VABRA ASPIRATOR; BREAST-CANCER; TAMOXIFEN; ESTROGEN; SONOHYSTEROGRAPHY; PATTERNS				Spencer, CP (corresponding author), UNIV LONDON KINGS COLL HOSP,MENOPAUSE CLIN,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							AKKAD AA, 1995, OBSTET GYNECOL, V86, P330, DOI 10.1016/0029-7844(95)00172-N; ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; BORNSTEIN J, 1994, J REPROD MED, V39, P674; BROOKS PG, 1992, J REPROD MED, V37, P682; BRYCE FC, 1990, EUR J OBSTET GYN R B, V37, P55, DOI 10.1016/0028-2243(90)90095-I; COHEN JR, 1994, ULTRASOUND OBST GYN, V4, P227, DOI 10.1046/j.1469-0705.1994.04030227.x; DOWNES E, 1993, BRIT J OBSTET GYNAEC, V100, P1148, DOI 10.1111/j.1471-0528.1993.tb15187.x; EVANS MP, 1995, MAYO CLIN PROC, V70, P800, DOI 10.4065/70.8.800; FRIEDL A, 1994, BREAST CANCER RES TR, V31, P27, DOI 10.1007/BF00689674; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GAUCHERAND P, 1995, J CLIN ULTRASOUND, V23, P339, DOI 10.1002/jcu.1870230603; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GOLDSTEIN SR, 1994, AM J OBSTET GYNECOL, V170, P447, DOI 10.1016/S0002-9378(94)70209-8; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; HAHN RG, 1984, J FAM PRACTICE, V18, P411; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; HILLARD TC, 1992, AM J OBSTET GYNECOL, V167, P1; INDMAN PD, 1993, OBSTET GYNECOL, V81, P716; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; KAUNITZ AM, 1988, J REPROD MED, V33, P427; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; MAGOS AL, 1985, OBSTET GYNECOL, V65, P496; MARSH MS, 1993, BAILLIERE CLIN ENDOC, V7, P183, DOI 10.1016/S0950-351X(05)80275-7; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PARSONS AK, 1993, J CLIN ULTRASOUND, V21, P87, DOI 10.1002/jcu.1870210203; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P55, DOI 10.1016/S0002-9378(12)90884-4; ROSENFELD JA, 1994, AM J OBSTET GYNECOL, V50, P510; ROSS D, 1995, CURR OPIN OBSTET GYN, V7, P63; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; RYMER J, 1994, BRIT J OBSTET GYNAEC, V101, P53; SPAULDING LB, 1994, FERTIL STERIL, V62, P1181; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; THORNEYCROFT IH, 1995, PROG CARDIOVASC DIS, V38, P243, DOI 10.1016/S0033-0620(95)80015-8; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701	39	20	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					37	42		10.1136/bmj.315.7099.37	http://dx.doi.org/10.1136/bmj.315.7099.37			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233327	Green Published			2022-12-28	WOS:A1997XJ94700031
J	Feener, EP; King, GL				Feener, EP; King, GL			Vascular dysfunction in diabetes mellitus	LANCET			English	Article							GLYCATION; HEART; INHIBITION; COLLAGEN; DISEASE		HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AIELLO LP, 1996, CURR OPIN ENDOCRINOL, V3, P307; *BARI INV, 1996, NEW ENGL J MED, V335, P217; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CARROZZA JP, 1993, ANN INTERN MED, V118, P344, DOI 10.7326/0003-4819-118-5-199303010-00004; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Feener E, 1997, DIABETES, V46, P212; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; Hamdan AD, 1996, CIRCULATION, V93, P1073, DOI 10.1161/01.CIR.93.6.1073; Howard G, 1996, CIRCULATION, V93, P1809, DOI 10.1161/01.CIR.93.10.1809; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JIANG ZY, 1997, DIABETES S, V46, P210; Kornowski R, 1997, CIRCULATION, V95, P1366; KOYA D, IN PRESS J CLIN INVE; KOYA D, 1997, J AM SOC NEPHROL, V8, P526; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; Monnier VM, 1996, DIABETES, V45, pS67, DOI 10.2337/diab.45.3.S67; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; *SORB RET TRIAL RE, 1993, NEUROLOGY, V43, P1141; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; TILTON RG, 1993, DIABETES, V42, P221, DOI 10.2337/diabetes.42.2.221; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; Wu KK, 1996, ANNU REV MED, V47, P315; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; ZHU D, 1994, KIDNEY INT, V45, P425, DOI 10.1038/ki.1994.55	35	88	93	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI9	SI13						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250277				2022-12-28	WOS:A1997XM26500004
J	Ichas, F; Jouaville, LS; Mazat, JP				Ichas, F; Jouaville, LS; Mazat, JP			Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals	CELL			English	Article							RAT-LIVER MITOCHONDRIA; ASCITES TUMOR-CELLS; PERMEABILITY TRANSITION; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; CA2+ TRANSIENTS; INNER MEMBRANE; TRANSPORT; RELEASE	We report Ca2+-induced release of Ca2+ from mitochondria (mCICR) dependent on transitory opening of the permeability transition pore (PTP) operating in a low conductance mode. The Ca2+ fluxes taking place during mCICR are a direct consequence of the mitochondrial depolarization spike (mDPS) caused by PTP opening. Both mDPS and mCICR can propagate from one mitochondrion to another in vitro, generating traveling depolarization and Ca2+ waves. Mitochondria thus appear to be excitable organelles capable of generating and conveying electrical and Ca2+ signals. In living cells, mDPS/mCICR is triggered during IP3-induced Ca2+ mobilization and results in the amplification of the Ca2+ signals primarily emitted from the endoplasmic reticulum.			Ichas, F (corresponding author), UNIV BORDEAUX 2,DEPT MED BIOCHEM & MOL BIOL,INTEGRATED BIOL SYST STUDY GRP,F-33076 BORDEAUX,FRANCE.		Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248				ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; BABCOCK DF, 1979, J BIOL CHEM, V254, P8117; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1984, J BIOL CHEM, V261, P7223; BRARN RJ, 1994, NATURE, V371, P355; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CASWELL AH, 1972, J MEMBRANE BIOL, V7, P345, DOI 10.1007/BF01867925; CASWELL AH, 1971, BIOCHEM BIOPH RES CO, V43, P625, DOI 10.1016/0006-291X(71)90660-7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLL KE, 1982, J BIOL CHEM, V257, P8696; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DUBUY HG, 1961, SCIENCE, V133, P196, DOI 10.1126/science.133.3447.196; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; HOLMUHAMEDOV EL, 1986, EUR J BIOCHEM, V158, P543, DOI 10.1111/j.1432-1033.1986.tb09788.x; HOLMUHAMEDOV EL, 1995, BIOCHEM MOL BIOL INT, V36, P39; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; IKEDA K, 1993, HEARING RES, V66, P169, DOI 10.1016/0378-5955(93)90138-Q; JOUAVILLE LS, 1995, NATURE, V377, P348; KIM JV, 1984, CELL CALCIUM, V5, P29, DOI 10.1016/0143-4160(84)90152-0; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LUTHRA R, 1976, BIOCHIM BIOPHYS ACTA, V440, P744, DOI 10.1016/0005-2728(76)90056-6; LUVISETTO S, 1991, EUR J BIOCHEM, V202, P121, DOI 10.1111/j.1432-1033.1991.tb16352.x; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; Massari S, 1996, J BIOL CHEM, V271, P31942; MIYAZAKI S, 1995, CURR OPIN CELL BIOL, V7, P190, DOI 10.1016/0955-0674(95)80027-1; MOLLER IM, 1986, BIOCHEM J, V237, P765, DOI 10.1042/bj2370765; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Nicholls D.G., 1982, BIOENERGETICS INTRO; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PUSKIN JS, 1973, BIOCHEM BIOPH RES CO, V51, P797, DOI 10.1016/0006-291X(73)91385-5; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RUSTENBECK I, 1993, BIOCHEM BIOPH RES CO, V194, P1261, DOI 10.1006/bbrc.1993.1959; SCHONFELD P, 1992, FEBS LETT, V304, P273, DOI 10.1016/0014-5793(92)80636-U; SCHUSTER SM, 1974, J BIOL CHEM, V249, P7151; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; WISE D, 1984, CHROMOSOMA, V90, P156, DOI 10.1007/BF00292453; ZAMZAMI N, 1996, J EXP MED, V183, P1633; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	68	622	643	4	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1145	1153		10.1016/S0092-8674(00)80301-3	http://dx.doi.org/10.1016/S0092-8674(00)80301-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215636	Bronze			2022-12-28	WOS:A1997XG83000018
J	Tucker, JB				Tucker, JB			National health and medical services response to incidents of chemical and biological terrorism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								In response to the growing threat of terrorism with chemical and biological weapons, the US government has developed a national concept of operations for emergency health and medical services response. This capability was developed and tested for the first time during the Atlanta Olympic Games in the summer of 1996. In the event of a chemical or biological terrorist incident that exceeded local and state-level response capabilities, federal agencies would provide specialized teams and equipment to help manage the consequences of the attack and treat, decontaminate, and evacuate casualties. The US Congress has also established a Domestic Preparedness Program that provides for enhanced training of local first-responders and the formation of metropolitan medical strike teams in major cities around the country. While these national response capabilities are promising, their implementation to date has been problematic and their ultimate effectiveness is uncertain.			Tucker, JB (corresponding author), MONTEREY INST INT STUDIES,CTR NONPROLIFERAT STUDIES,425 VAN BUREN ST,MONTEREY,CA 93940, USA.							[Anonymous], PATT GLOB TERR; BACON LM, 1996, SURFACE WARFARE, V21, P18; BACON LM, 1997, CHEM BIOL INCIDENT R, P8; BACON LM, 1996, SURFACE WARFARE, V21, P21; Cheng, 1996, Mol Diagn, V1, P183, DOI 10.1016/S1084-8592(96)70004-8; EMBER L, 1996, CHEM ENG NEWS   0701, P22; EMBER LR, 1996, CHEM ENG NEWS   1104, P10; EVERS S, 1997, JANES DEFENCE W 0423, P6; GRANGE DL, 1997, NATL DEFENSE     MAY, P53; GREEN R, 1996, REUTERS         0327; KRULAC CC, 1996, JANES DEFENCE W 0828, P38; MAHONEY LE, 1987, ANN EMERG MED, V16, P354, DOI 10.1016/S0196-0644(87)80187-7; MILLER FC, 1997, COMMUNICATION   0305, P21; *NY CIT MAYORS OFF, 1995, ACT REP CHEM DIS MAN, P13; SHEETS G, 1997, WASHINGTON TIME 0425, pA1; SHEETS G, 1997, WASHINGTON TIME 0425, pA22; SMITH RJ, 1996, INT HERALD TRIB 0424, P3; STARR B, 1996, JANES DEFENCE W 0814, P16; *US DEP DEF, 1997, C DOM PREP PROGR DEF, P10; *US DEP DEF, 1996, HDB DOD ASS CAP RESP, P2; *US DEP HHS, 1996, HLTH MED SERV SUPP P, P1; *US FED EM MAN AG, 1997, FEMA229 US; *US MAR CORPS CHEM, 1997, CONS MAN EX WASH DC; *US PHS OFF EM PRE, 1995, P SEM RESP CONS CHEM, P3; 1997, BALTIMORE SUN   0417, P1; 1997, BALTIMORE SUN   0417, P8	26	67	67	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					362	368		10.1001/jama.278.5.362	http://dx.doi.org/10.1001/jama.278.5.362			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244313				2022-12-28	WOS:A1997XN51800003
J	Fitzsimonds, RM; Song, HJ; Poo, MM				Fitzsimonds, RM; Song, HJ; Poo, MM			Propagation of activity-dependent synaptic depression in simple neural networks	NATURE			English	Article							LONG-TERM DEPRESSION; NEUROMUSCULAR SYNAPSES; HIPPOCAMPAL-NEURONS; AREA CA1; POTENTIATION; INDUCTION; TRANSMISSION; STIMULATION; MECHANISMS; PLASTICITY	Triple whole-cell recordings from simple networks of cultured hippocampal neurons show that induction of long-term depression at glutamatergic synapses is accompanied by a back propagation of depression to input synapses on the dendrite of the presynaptic neuron. The depression also propagates laterally to divergent outputs of the presynaptic neuron and to convergent inputs on the postsynaptic neuron. There is no forward propagation of depression to the output of the postsynaptic neuron and no presynaptic propagation accompanying long-term depression at GABAergic synapses. Activity-induced synaptic modification is therefore not restricted to the activated synapse, but selectively propagates throughout the neural network.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Fitzsimonds, Reiko/0000-0002-0576-9885				ABRAHAM WC, 1983, NATURE, V305, P717, DOI 10.1038/305717a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; CHURCHLAND PS, 1972, COMPUTATIONAL BRAIN; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DAVIS GW, 1994, J NEUROBIOL, V25, P740, DOI 10.1002/neu.480250612; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; FITZSIMONDS RM, IN PRESS PHYSL REV; Goda Y, 1996, NEURON, V16, P103, DOI 10.1016/S0896-6273(00)80027-6; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MATHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91; MCMAHON LL, 1977, NEURON, V18, P737; MCMAHON LL, 1977, NEURON, V18, P266; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; PURVES D, 1985, PRINCIPLES NEURAL DE; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; RUMELHART DE, 1986, PARALLEL DISTRIBUTED, V1, P316; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; VINCENT P, 1993, NEURON, V11, P885, DOI 10.1016/0896-6273(93)90118-B; WILCOX KS, 1994, SYNAPSE, V18, P128, DOI 10.1002/syn.890180206; WOOD MR, 1986, J COMP NEUROL, V244, P43; XIAO MY, 1994, EUR J NEUROSCI, V6, P1055, DOI 10.1111/j.1460-9568.1994.tb00600.x; Zipser D., 1990, COMPUTATIONAL NEUROS, P192	51	141	143	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					439	448		10.1038/41267	http://dx.doi.org/10.1038/41267			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242402	Bronze			2022-12-28	WOS:A1997XN55300039
J	Ramsden, DA; Paull, TT; Gellert, M				Ramsden, DA; Paull, TT; Gellert, M			Cell-free V(D)J recombination	NATURE			English	Article							DNA-LIGASE-I; MOUSE THYMOCYTES; MAMMALIAN-CELLS; REARRANGEMENT; REPAIR	V(D)J recombination generates diversity in the immune system through the lymphoid-specific assembly of multiple gene segments into functional immunoglobulin and T-cell receptor genes (for reviews, see refs 1, 2). The first step in V(D)J recombination is cleavage of DNA at recombination signal sequences. Cleavage produces a blunt DNA end on each signal sequence and a hairpin end on adjacent coding gene segments(3,4), and can be reproduced in vitro by using purified RAG1 and RAG2 proteins(5,6). The later steps involve processing and joining of the cleaved DNA ends, and until now have been studied only in cells, Here we reconstitute the complete V(D)J recombination reaction in a cell-free system, We find that the RAG proteins are not only involved in cleavage, but are also needed in the later steps for efficient joining of coding ends. Joining is largely directed by short pieces of identical sequence in the coding flanks, but addition of human DNA ligase I results in greater diversity. Coding junctions contain short deletions as well as additions complementary to a coding flank (P nucleotides). Addition of non-templated nucleotides into coding junctions is mediated by terminal deoxyribonucleotidyl transferase. The cell-free reaction can therefore reproduce the complete set of processing events that occur in cells.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Paull, Tanya/0000-0002-2991-651X; Ramsden, Dale/0000-0003-1575-4748				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; GELLERT M, 1992, ANNU REV GENET, V22, P425; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROBBINS DJ, 1988, NUCLEIC ACIDS RES, V16, P2943, DOI 10.1093/nar/16.7.2943; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEI YF, 1995, MOL CELL BIOL, V15, P3206	22	111	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					488	491		10.1038/41351	http://dx.doi.org/10.1038/41351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242409	Bronze			2022-12-28	WOS:A1997XN55300052
J	Zeyl, C; Bell, G				Zeyl, C; Bell, G			The advantage of sex in evolving yeast populations	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; TY3	Sex is a general feature of the life cycle of eukaryotes. It is not universal, however, as many organisms seem to lack sex entirely(1). The widespread occurrence of sex is puzzling, both because meiotic recombination can disrupt co-adapted combinations of genes, and because it halves the potential rate of reproduction in organisms with strongly differentiated male and female gametes(2). Most attempts to explain the maintenance of sexuality invoke differences between parents and sexual offspring. These differences may be advantageous in novel or changing environments if new gene combinations are favoured from time to time(1). Sex would then serve to concentrate beneficial mutations that have arisen independently into the same line of descent. But in a stable environment sex might serve to concentrate deleterious mutations, so that they will be more effectively purged from the population by selection(3). We have studied the effect of sex on mean fitness in experimental populations of the budding yeast Saccharomyces cervisiae. Our results show that sex increases mean fitness in an environment to which the populations were well adapted, but not in an environment to which new adaptation occurred, supporting the hypothesis that the advantage of sexuality lay in the removal of deleterious mutations.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; MCGILL UNIV, REDPATH MUSEUM, MONTREAL, PQ H3A 1B1, CANADA	Michigan State University; McGill University; McGill University								Bell G., 1982, MASTERPIECE NATURE; BILANCHONE VW, 1993, GENETICS, V134, P685; Birdsell J, 1996, P NATL ACAD SCI USA, V93, P908, DOI 10.1073/pnas.93.2.908; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; Crow J. F., 1988, EVOLUTION SEX EXAMIN, P56; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KUNZ BA, 1981, MOL BIOL YEAST SACCH, V1, P371; MALMBERG RL, 1977, GENETICS, V86, P607; MAYNARD SMITH J., 1978, EVOLUTION SEX; MCPHEE CP, 1970, GENET RES, V16, P1, DOI 10.1017/S0016672300002238; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MORTIMER RK, 1981, MOL BIOL YEAST SACCH, V3, P341; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; PECK JR, 1994, GENETICS, V137, P597	17	112	118	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					465	468		10.1038/41312	http://dx.doi.org/10.1038/41312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242403	Bronze			2022-12-28	WOS:A1997XN55300046
J	Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA				Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA			Outbreak of toxoplasmosis associated with municipal drinking water	LANCET			English	Article							OOCYSTS; GONDII; OZONE; CATS	Background Outbreaks of toxoplasmosis are recognised infrequently. In March, 1995, a sudden increase of serologically diagnosed cases of acute toxoplasmosis was noted in the Greater Victoria area of British Columbia, Canada. Concurrently, but independently, seven cases of acute toxoplasma retinitis were diagnosed against a background of no cases in the previous 5 years. Methods Cases were defined by serological testing, clinical presentation, and residence in Greater Victoria. A screening programme for women who were or had been pregnant was started. Geographical mapping of cases, and case-control studies of symptomatic cases and of women enrolled in the screening programme were done. Findings 100 individuals aged 6 to 83 years met the definition for an acute, outbreak-related case. 94 resided in Greater Victoria and six had visited it; 19 had retinitis, 51 had lymphadenopathy, four others had symptoms consistent with toxoplasmosis, seven had other symptoms, 18 were symptom-free, and one would not provide information. 36 (0.9%) of 3812 screened pregnant and postnatal women were cases. Excess cases were not detected outside Greater Victoria and no conventional source of toxoplasmosis was implicated. Mapping studies of cases and of the screened women, and both case-control studies showed significant associations between acute infection and residence in the distribution system of one reservoir supplying water to Greater Victoria (ORs or RRs: 3.53, 3.05, 8.27, acid 5.42, respectively). The epidemic curve appeared bimodal, with peaks in December, 1994, and March, 1995, that were preceded by increased rainfall and turbidity in the implicated reservoir. Interpretation A municipal water system that uses unfiltered, chloraminated surface water was the likely source of this large community-wide outbreak of toxoplasmosis.	UNIV BRITISH COLUMBIA, DIV INFECT DIS, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER, BC V6T 1W5, CANADA; BC CTR DIS CONTROL, EPIDEMIOL SERV, VANCOUVER, BC, CANADA; BC CTR DIS CONTROL, PROV LAB, VANCOUVER, BC, CANADA; HLTH CANADA, LAB CTR DIS CONTROL, FIELD EPIDEMIOL TRAINING PROGRAM, OTTAWA, ON K1A 0L2, CANADA; CAPITAL REG DIST HLTH, VICTORIA, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; Health Canada								BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; BENENSON MW, 1982, NEW ENGL J MED, V307, P666, DOI 10.1056/NEJM198209093071107; DANNEMANN BR, 1990, J CLIN MICROBIOL, V28, P1928, DOI 10.1128/JCM.28.9.1928-1933.1990; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; Dubey JP, 1996, J PARASITOL, V82, P438, DOI 10.2307/3284082; DUBEY JP, 1970, J EXP MED, V132, P636, DOI 10.1084/jem.132.4.636; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P3674, DOI 10.1128/AEM.59.11.3674-3680.1993; FRENKEL JK, 1975, AM J TROP MED HYG, V24, P439, DOI 10.4269/ajtmh.1975.24.439; FRENKEL JK, 1972, J INFECT DIS, V126, P664, DOI 10.1093/infdis/126.6.664; KEAN BH, 1969, J AMER MED ASSOC, V208, P1002; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; Magaldi C., 1969, Revista Latinoamericana de Microbiologia y Parasitologia, V11, P5; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; *MAP CORP, 1992, MAP WIND 3 0 US GUID; MILLER NL, 1972, J PARASITOL, V58, P928, DOI 10.2307/3286588; MONTOYA JG, 1995, CLIN INFECT DIS, V20, P781, DOI 10.1093/clinids/20.4.781; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; SNOW J, 1965, SNOW CHOLERA; Stephen C, 1996, CAN VET J, V37, P241; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853; YILMAZ SM, 1972, J PARASITOL, V58, P938, DOI 10.2307/3286589	22	424	461	2	63	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					173	177		10.1016/S0140-6736(96)11105-3	http://dx.doi.org/10.1016/S0140-6736(96)11105-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250185				2022-12-28	WOS:A1997XL72200012
J	Carani, C; Qin, K; Simoni, M; FaustiniFustini, M; Serpente, S; Boyd, J; Korach, KS; Simpson, ER				Carani, C; Qin, K; Simoni, M; FaustiniFustini, M; Serpente, S; Boyd, J; Korach, KS; Simpson, ER			Effect of testosterone and estradiol in a man with aromatase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN-RECEPTOR GENE; SEX STEROID CONTROL; GONADOTROPIN-SECRETION; BONE MASS; FEMALE; MEN; RESISTANCE; MUTATION; OVARIES; CELLS		UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV MUNSTER, INST REPROD MED, MUNSTER, GERMANY; UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, PHILADELPHIA, PA 19104 USA; NIH, REPROD & DEV TOXICOL LAB, RES TRIANGLE PK, NC USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Munster; University of Pennsylvania; National Institutes of Health (NIH) - USA	Carani, C (corresponding author), UNIV MODENA, DEPT INTERNAL MED, DIV ENDOCRINOL, VIA POZZO 71, I-41100 MODENA, ITALY.		Simoni, Manuela/A-9600-2013; Faustini-Fustini, Marco/AAU-7933-2020	Simoni, Manuela/0000-0002-2133-4304; Korach, Kenneth/0000-0002-7765-418X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007190] Funding Source: NIH RePORTER; NICHD NIH HHS [5-T32-HD07190] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAGATELL CJ, 1994, J ANDROL, V15, P15; BHATNAGAR AS, 1992, J STEROID BIOCHEM, V41, P437, DOI 10.1016/0960-0760(92)90369-T; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; Bulun SE, 1996, J CLIN ENDOCR METAB, V81, P867, DOI 10.1210/jc.81.3.867; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; FINKELSTEIN JS, 1991, J CLIN ENDOCR METAB, V73, P621, DOI 10.1210/jcem-73-3-621; FINKELSTEIN JS, 1991, J CLIN ENDOCR METAB, V73, P609, DOI 10.1210/jcem-73-3-609; GRIFFIN JE, 1992, NEW ENGL J MED, V326, P611; INKSTER S, 1995, J CLIN ENDOCR METAB, V80, P1941, DOI 10.1210/jc.80.6.1941; ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; LEPHART ED, 1991, METHOD ENZYMOL, V206, P477; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; NITTA H, 1993, ENDOCRINOLOGY, V132, P1396, DOI 10.1210/en.132.3.1396; ROOT AW, 1993, ENDOCRIN METAB CLIN, V22, P573, DOI 10.1016/S0889-8529(18)30151-8; RUST J, 1985, BRIT J CLIN PSYCHOL, V24, P63, DOI 10.1111/j.2044-8260.1985.tb01314.x; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SOUTHARD RN, 1991, RADIOLOGY, V179, P735, DOI 10.1148/radiology.179.3.2027984; *WHO, 1987, WHO LAB MANUAL EXAMI; WINTERS SJ, 1979, J CLIN ENDOCR METAB, V48, P222, DOI 10.1210/jcem-48-2-222; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91	25	834	863	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					91	95		10.1056/NEJM199707103370204	http://dx.doi.org/10.1056/NEJM199707103370204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211678				2022-12-28	WOS:A1997XJ82200004
J	Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M				Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M			Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection	LANCET			English	Article							LOIASIS; DISEASE	Background In 1995, the World Bank launched an African Programme for Onchocerciasis Control to eliminate Onchocerca volvulus disease from 19 African countries by means of community-based ivermectin treatment (CBIT). Several cases of encephalopathy have been reported after ivermectin in people heavily infected with microfilariae of Loa loa (loiasis). We assessed the incidence of serious events in an area where onchocerciasis and loiasis are both endemic. Methods Ivermectin (at 150 mu g/kg) was given to 17 877 people living in the Lekie area of Cameroon. 50 mu L samples of capillary blood were taken during the daytime before treatment from all adults (aged greater than or equal to 15 years), and the numbers of L loa and Mansonella perstans microfilariae in them were counted. Patients were monitored for 7 days after treatment. Adverse reactions were classified as mild, marked, or serious. Serious reactions were defined as those associated with a functional impairment that required at least a week of full-time assistance to undertake normal activities. We calculated the relative risk of developing marked or serious reactions for increasing L loa microfilarial loads, Risk factors for serious reactions were identified and assessed with a logistic regression model. Findings 20 patients (0.11%) developed serious reactions without neurological signs but associated with a functional impairment lasting more than a week. Two other patients were in coma for 2-3 days, associated with L loa microfilariae in cerebrospinal fluid. Occurrence of serious reactions was related to the intensity of pretreatment L loa microfilaraemia. The relative risk of developing marked or serious reactions was significantly higher when the L loa load exceeded 8000 microfilariae/mL; for serious reactions, the risk is very high (odds ratio >1000) for loads above 50 000 microfilariae/mL. Interpretation Epidemiological surveys aimed at assessing the intensity of infection with L loa microfilariae should be done before ivermectin is distributed for onchocerciasis control in areas where loiasis is endemic, In communities at risk, monitoring procedures should be established and adhered to during CBIT so that people developing serious reactions may receive appropriate treatment.	SECT DEPT SANTE PUBL MBAM,BAFIA,CAMEROON		Gardon, J (corresponding author), CTR PASTEUR,ANTENNE ORSTOM,BP 1274,YAOUNDE,CAMEROON.		Gardon, Jacques/AAQ-8410-2020; Gardon, Jacques/J-8022-2016; Boussinesq, Michel/J-7256-2016	Gardon, Jacques/0000-0002-0570-634X; Gardon, Jacques/0000-0002-0570-634X; Boussinesq, Michel/0000-0001-6312-0681; Chippaux, Jean-Philippe/0000-0002-1976-8568				ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; *ASS RECH METH PHA, 1992, AN INC PHARM; AZIZ MA, 1982, LANCET, V2, P171; BERTRANDFONTAIN, 1948, B MEM SOC MED HOP P, V64, P1092; BONNET R., 1943, Medecine Tropicale, V3, P273; BOUSSINESQ M, 1995, AM J TROP MED HYG, V53, P63; BRUNETIERE M, 1913, GAZ HEBDOM SCI MED B, V30, P351; CARME B, 1991, AM J TROP MED HYG, V44, P684, DOI 10.4269/ajtmh.1991.44.684; CARME B, 1991, ANN SOC BELG MED TR, V71, P47; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; Ducorps M, 1995, B SOC PATHOL EXOT, V88, P105; FAIN A, 1978, B WORLD HEALTH ORGAN, V56, P155; HOSMER DW, 1989, APPL LOGISTIC REGRES; KULZ H, 1908, ARCH SCHIFFS TROP, V12, P547; MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186, DOI 10.4269/ajtmh.1993.48.186; PACQUE M, 1991, AM J MED, V90, P590, DOI 10.1016/S0002-9343(05)80010-5; REMME JHF, 1995, PARASITOL TODAY, V11, P403, DOI 10.1016/0169-4758(95)80017-4; RICHARDLENOBLE D, 1988, AM J TROP MED HYG, V39, P480, DOI 10.4269/ajtmh.1988.39.480; TAYLOR HR, 1989, AM J TROP MED HYG, V41, P460, DOI 10.4269/ajtmh.1989.41.460; *WHO EXP COMM ONCH, 1995, TECHN REP SER WHO, V852, P27; 1991, WHO DRUG INFORMATION, V5, P127	21	388	392	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					18	22		10.1016/S0140-6736(96)11094-1	http://dx.doi.org/10.1016/S0140-6736(96)11094-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217715				2022-12-28	WOS:A1997XH86900011
J	Collins, JJ; Brennan, FT				Collins, JJ; Brennan, FT			Euthanasia and the potential adverse effects for Northern Territory Aborigines	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; PAIN		AUSTRALIAN NATL UNIV,RES SCH SOCIAL SCI,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	Collins, JJ (corresponding author), MEM SLOAN KETTERING CANC CTR,PAIN & PALLIAT CARE SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.							ALCORN G, 1996, SYDNEY MORNING  0823; AUSTIN N, 1996, LETS MEET HALF WAY P; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; *CANC PAIN REL PAL, 1990, WHO TECHN REP SER, V804; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; CHASSIN MR, 1994, WHEN DEATH IS SOUGHT; CORDNER S, 1995, LANCET, V346, P692, DOI 10.1016/S0140-6736(95)92295-4; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1995, PAIN FORUM, V4, P163; HARRISON B, 1994, DEMOGRAPHY NO TERRIT; Hoy WE, 1996, MED J AUSTRALIA, V165, P126, DOI 10.5694/j.1326-5377.1996.tb124882.x; Maguire GP, 1996, MED J AUSTRALIA, V164, P721, DOI 10.5694/j.1326-5377.1996.tb122270.x; MCLENNON W, 1994, DEATHS AUSTR; MOBBS R, 1994, HLTH ABORIGINAL AUST, P292; PORTENOY RK, IN PRESS PSYCHOSOMAT; REID J, 1994, HLTH ABORIGINAL AUST, pR11; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; 1997, SYDNEY MORNING  0116	19	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1907	1908		10.1016/S0140-6736(96)12388-6	http://dx.doi.org/10.1016/S0140-6736(96)12388-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217772				2022-12-28	WOS:A1997XG41700043
J	Ruggenenti, P; Perna, A; Mosconi, L; Matalone, M; Garini, G; Salvadori, M; Zoccali, C; Scolari, F; Maggiore, Q; Tognoni, G; Remuzzi, G; Migone, L; Marubini, E; DelFavero, A; Ideo, G; Geraci, E; Loi, U; Bracchi, M; Costantino, E; Scolari, F; Maiorca, R; Cofano, F; Fellin, G; DAmico, G; Dissegna, D; Brendolan, A; LaGreca, G; Feriozzi, A; Ancarani, E; Gandini, E; dAmato, I; Giangrande, A; Garneri, G; Giacchino, F; Giannico, G; Giotta, N; Vitale, O; Manno, C; Mazzi, A; Garini, G; Borghetti, A; Pisoni, R; Bertani, T; Novelli, R; Scanferla, F; Bazzato, G; Oliva, E; Zoccali, C; Pieri, F; Sisca, S; Maggiore, Q; Pignone, E; Boero, R; Piccoli, G; Piperno, R; Rosati, A; Salvadori, M; Arnoldi, F; Gaspari, F; Signorini, O; Ferrari, S; Guerini, E				Ruggenenti, P; Perna, A; Mosconi, L; Matalone, M; Garini, G; Salvadori, M; Zoccali, C; Scolari, F; Maggiore, Q; Tognoni, G; Remuzzi, G; Migone, L; Marubini, E; DelFavero, A; Ideo, G; Geraci, E; Loi, U; Bracchi, M; Costantino, E; Scolari, F; Maiorca, R; Cofano, F; Fellin, G; DAmico, G; Dissegna, D; Brendolan, A; LaGreca, G; Feriozzi, A; Ancarani, E; Gandini, E; dAmato, I; Giangrande, A; Garneri, G; Giacchino, F; Giannico, G; Giotta, N; Vitale, O; Manno, C; Mazzi, A; Garini, G; Borghetti, A; Pisoni, R; Bertani, T; Novelli, R; Scanferla, F; Bazzato, G; Oliva, E; Zoccali, C; Pieri, F; Sisca, S; Maggiore, Q; Pignone, E; Boero, R; Piccoli, G; Piperno, R; Rosati, A; Salvadori, M; Arnoldi, F; Gaspari, F; Signorini, O; Ferrari, S; Guerini, E			Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; KIDNEY-FUNCTION; INHIBITION; PROGRESSION; ENALAPRIL; DISEASE; INJURY; MACROMOLECULES; HYPERTENSION; CAPTOPRIL	Background In diabetic nephropathy, angiotensin-converting-enzyme (ACE) inhibitors have a greater effect than other antihypertensive drugs on proteinuria and the progressive decline in glomerular filtration rate (GFR). Whether this difference applies to progression of nondiabetic proteinuric nephropathies is not clear. The Ramipril Efficacy In Nephropathy study of chronic nondiabetic nephropathies aimed to address whether glomerular protein traffic influences renal-disease progression, and whether an ACE inhibitor was superior to conventional treatment, with the same blood-pressure control, in reducing proteinuria, limiting GFR decline, and preventing endstage renal disease. Methods In this prospective double-blind trial, 352 patients were classified according to baseline proteinuria (stratum 1: 1-3 g/24 h; stratum 2: greater than or equal to 3 g/24 h), and randomly assigned ramipril or placebo plus conventional antihypertensive therapy targeted at achieving diastolic blood pressure under 90 mm Hg. The primary endpoint was the rate of GFR decline. Analysis was by intention to treat. Findings At the second planned interim analysis, the difference in decline in GFR between the ramipril and placebo groups in stratum 2 was highly significant (p=0.001). The Independent Adjudicating Panel therefore decided to open the randomisation code and do the final analysis in this stratum (stratum 1 continued in the trial). Data (at least three GFR measurements including baseline) were available for 56 ramipril-assigned patients and 61 placebo-assigned patients. The decline in GFR per month was significantly lower in the ramipril group than the placebo group (0.53 [0.08] vs 0.88 [0.13] mL/min, p=0.03). Among the ramipril-assigned patients, percentage reduction in proteinuria was inversely correlated with decline in GFR (p=0.035) and predicted the reduction in risk of doubling of baseline creatinine or endstage renal failure (18 ramipril vs 40 placebo, p=0.04). The risk of progression was still significantly reduced after adjustment for changes in systolic (p=0.04) and diastolic (p=0.04) blood pressure, but not after adjustment for changes in proteinuria. Blood-pressure control and the overall number of cardiovascular events were similar in the two treatment groups. Interpretation In chronic nephropathies with proteinuria of 3 g or more per 24 h, ramipril safely reduces proteinuria and the rate of GFR decline to an extent that seems to exceed the reduction expected for the degree of blood-pressure lowering.	OSPED RIUNITI BERGAMO,DEPT TRANSPLANT IMMUNOL & INNOVAT ANTIREJECT THER,I-24125 BERGAMO,ITALY; MARIO NEGRI INST PHARMACOL RES,I-24125 BERGAMO,ITALY; SPEDALI CIVIL BRESCIA,I-25125 BRESCIA,ITALY; OSPED PROV S CARLO BORROMEO,MILAN,ITALY; OSPED S BORTOLO,VICENZA,ITALY; OSPED GRANDE VITERBO,VITERBO,ITALY; OSPED PROV,BUSTO ARSIZIO,ITALY; OSPED CIVILE,IVREA,ITALY; POLICLIN BARI,BARI,ITALY; IST CLIN MED & NEFROL,PARMA,ITALY; CLIN CNR,REGGIO CALABRIA,ITALY; OSPED PROV UMBERTO 1,MESTRE,ITALY; USL ZONA 10H,BAGNO A RIPOLI,ITALY; OSPED ZONALE GIOVANNI BOSCO,TURIN,ITALY; OSPED REG CAREGGI MONNA TESSA,FLORENCE,ITALY	Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Hospital Spedali Civili Brescia; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; Universita degli Studi di Bari Aldo Moro; ULSS 3 Serenissima			Ferrari, Silvia/ABF-5648-2020; Perna, Annalisa/AAC-1323-2020; Zoccali, Carmine/AAR-4473-2020; Zoccali, Carmine/B-9445-2009; scolari, francesco/AAC-5957-2022; Remuzzi, Giuseppe/V-9766-2017	Ferrari, Silvia/0000-0003-0769-0414; Perna, Annalisa/0000-0002-9257-0283; Zoccali, Carmine/0000-0002-6616-1996; Manno, Carlo/0000-0002-7840-9426; Remuzzi, Giuseppe/0000-0002-6194-3446; Scolari, Francesco/0000-0003-0233-9705				ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; APPERLOO A J, 1992, Journal of the American Society of Nephrology, V3, P279; BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; CONOVER WJ, 1987, PRACTICAL NONPARAMET; EDDY AA, 1994, J AM SOC NEPHROL, V5, P1273; ERMAN A, 1991, J HYPERTENS, V9, P1057, DOI 10.1097/00004872-199111000-00012; GASPARI F, 1995, J AM SOC NEPHROL, V6, P1; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hirschberg R, 1996, J CLIN INVEST, V98, P116, DOI 10.1172/JCI118755; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; Ihle BU, 1996, AM J KIDNEY DIS, V27, P489, DOI 10.1016/S0272-6386(96)90158-4; KALBFEISH JD, 1980, STAT ANAL FAILURE TI; KAMPER AL, 1992, AM J HYPERTENS, V5, P423, DOI 10.1093/ajh/5.7.423; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MORELLI E, 1990, DIABETES, V39, P76, DOI 10.2337/diabetes.39.1.76; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PETTERSON JC, 1995, ANN INTERN MED, V123, P754; REMUZZI A, 1991, KIDNEY INT, V39, P1267, DOI 10.1038/ki.1991.160; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; REMUZZI A, 1993, J NEPHROL, V6, P36; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; Remuzzi G, 1995, Curr Opin Nephrol Hypertens, V4, P339, DOI 10.1097/00041552-199507000-00009; RICE EW, 1975, CLIN CHEM, V21, P398; ROSSING RP, 1994, KIDNEY INT S, V45, P145; WEIDMANN P, 1995, NEPHROL DIAL TRANSPL, V10, P39; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309	36	1475	1510	3	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1857	1863						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217756				2022-12-28	WOS:A1997XG41700007
J	Olsen, GJ; Woese, CR				Olsen, GJ; Woese, CR			Archaeal genomics: An overview	CELL			English	Review							EUCARYA				Olsen, GJ (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,URBANA,IL 61801, USA.							Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Olsen GJ, 1996, TRENDS GENET, V12, P377, DOI 10.1016/0168-9525(96)30092-9; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, J MOL EVOL, V10, P1, DOI 10.1007/BF01796132	12	188	199	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					991	994		10.1016/S0092-8674(00)80284-6	http://dx.doi.org/10.1016/S0092-8674(00)80284-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215619	Bronze			2022-12-28	WOS:A1997XG83000001
J	vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ				vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ			Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34	SCIENCE			English	Article							POLYCYSTIC KIDNEY-DISEASE; ABO BLOOD-GROUP; DIAGNOSTIC-CRITERIA; HETEROGENEITY; LINKAGE; LOCUS; LOCALIZATION; MUTATION; AUTISM; 16P13	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the widespread development of distinctive tumors termed hamartomas. TSC-determining loci have been mapped to chromosomes 9q34 (TSC1) and 16p13 (TSC2). The TSC1 gene was identified from a 900-kilobase region containing at least 30 genes. The 8.6-kilobase TSC1 transcript is widely expressed and encodes a protein of 130 kilodaltons (hamartin) that has homology to a putative yeast protein of unknown function. Thirty-two distinct mutations were identified in TSC1, 30 of which were truncating, and a single mutation (2105delAAAG) was seen in six apparently unrelated patients. In one of these six, a somatic mutation in the wild-type allele was found in a TSC-assaciated renal carcinoma, which suggests that hamartin acts as a tumor suppressor.	BRIGHAM & WOMENS HOSP, DIV EXPT MED & MED ONCOL, BOSTON, MA 02115 USA; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV ROTTERDAM HOSP, ROTTERDAM, NETHERLANDS; UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; UNIV LONDON UNIV COLL, GALTON LAB, LONDON NW1 2HE, ENGLAND; UNIV BATH, BATH BA2 7AY, AVON, ENGLAND; UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; MIT, WHITEHEAD INST BIOMED RES, CTR GENOME RES, CAMBRIDGE, MA 02139 USA; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT MED GENET, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CHICAGO, SCH MED, DEPT CHILD NEUROL, CHICAGO, IL 60637 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, BOSTON, MA 02129 USA; CHILDRENS HLTH CTR, DIV CHILD NEUROL, PL-04736 WARSAW, POLAND	Harvard University; Brigham & Women's Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; University of London; University College London; University of Bath; Cardiff University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Chicago; Harvard University; Massachusetts General Hospital; Children's Memorial Health Institute			Ravine, David/A-6797-2008; Hermans, Cedric/AAK-9433-2020; Lindhout, Dick/AAH-5765-2019; Jura, Jolanta/F-8889-2015; Green, Andrew/AAJ-7592-2020; Ali, Johari Mohd/B-5259-2010; Haines, Jonathan/C-3374-2012	Jura, Jolanta/0000-0002-0816-3475; Ali, Johari Mohd/0000-0002-6884-4280; Haines, Jonathan/0000-0002-4351-4728; Jozwiak, Sergiusz/0000-0003-3350-6326; Lindhout, Dick/0000-0001-9580-624X; Snell, Russell/0000-0002-8166-4014; Ekong, Rosemary/0000-0002-5984-7893; Green, Andrew/0000-0002-1077-7417				Au KS, 1996, J MED GENET, V33, P559, DOI 10.1136/jmg.33.7.559; Bjornsson J, 1996, AM J PATHOL, V149, P1201; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; BROOKES AJ, 1984, HUM MOL GENET, V3, P2011; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Cook JA, 1996, J MED GENET, V33, P480, DOI 10.1136/jmg.33.6.480; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FRYER AE, 1987, LANCET, V1, P659; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HAINES JL, 1991, AM J HUM GENET, V49, P764; Hawkins TL, 1997, SCIENCE, V276, P1887, DOI 10.1126/science.276.5320.1887; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KANDT RS, 1989, EXP NEUROL, V104, P223, DOI 10.1016/0014-4886(89)90033-2; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KUMAR A, 1995, HUM MOL GENET, V4, P2295, DOI 10.1093/hmg/4.12.2295; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KUMAR A, 1997, IN PRESS HUM MUTAT, V9, P64; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NELLIST M, 1993, J MED GENET, V30, P224, DOI 10.1136/jmg.30.3.224; NELLIST M, 1993, CELL, V75, P1305; NORTHRUP H, 1987, LANCET, V2, P804; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; ROACH ES, 1992, J CHILD NEUROL, V7, P221, DOI 10.1177/088307389200700219; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; SAMPSON JR, 1989, J MED GENET, V26, P511, DOI 10.1136/jmg.26.8.511; Sepp T, 1996, J MED GENET, V33, P962, DOI 10.1136/jmg.33.11.962; SMALLEY SL, 1992, J AUTISM DEV DISORD, V22, P339, DOI 10.1007/BF01048239; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Vrtel R, 1996, J MED GENET, V33, P47, DOI 10.1136/jmg.33.1.47; WANG Q, IN PRESS HUM MUTAT; WEBB DW, 1991, J MED GENET, V28, P417, DOI 10.1136/jmg.28.6.417; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Xu Y, 1994, Genet Eng (N Y), V16, P241; [No title captured]	54	1197	1215	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					805	808		10.1126/science.277.5327.805	http://dx.doi.org/10.1126/science.277.5327.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242607				2022-12-28	WOS:A1997XQ24700040
J	Tardif, JC; Cote, G; Lesperance, J; Bourassa, M; Lambert, J; Doucet, S; Bilodeau, L; Nattel, S; deGuise, P				Tardif, JC; Cote, G; Lesperance, J; Bourassa, M; Lambert, J; Doucet, S; Bilodeau, L; Nattel, S; deGuise, P			Probucol and multivitamins in the prevention of restenosis after coronary angioplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	69th Annual Scientific Session of the American-Heart-Association	NOV 09-16, 1996	NEW ORLEANS, LA	Amer Heart Assoc, Hoechst Marion Roussel Inc, Kansas City			LOW-DENSITY-LIPOPROTEIN; VITAMIN-E; BALLOON INJURY; HYPERCHOLESTEROLEMIC RABBITS; OXIDATIVE MODIFICATION; BETA-CAROTENE; CHOLESTEROL; ANTIOXIDANT; SUPPLEMENTATION; ATHEROSCLEROSIS	Background Oxidizing metabolites generated at the site of coronary angioplasty can induce chain reactions that may lead to restenosis. Antioxidants may counter oxidative stress and modify neointimal formation and vascular remodeling. Experimental data and small clinical studies have suggested that antioxidants may prevent restenosis after angioplasty. In a double-blind, randomized trial, we studied whether drugs with antioxidant properties decrease the incidence and severity of restenosis after angioplasty. Methods One month before angioplasty, 317 patients were randomly assigned to receive one of four treatments: placebo, probucol (500 mg), multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E), or both probucol and multivitamins - all given twice daily. Patients were treated for four weeks before and six months after angioplasty Patients received an extra 1000 mg of probucol, 2000 IU of vitamin E, both probucol and vitamin E, or placebo 12 hours before angioplasty, according to their treatment assignments. Base-line and follow-up angiograms were interpreted by blinded investigators using a quantitative approach. Results The mean (+/-SD) reduction in luminal diameter six months after angioplasty was 0.12+/-0.41 mm in the probucol group, 0.22+/-0.46 mm in the combined-treatment group, 0.33+/-0.51 mm in the multivitamin group, and 0.38+/-0.50 mm in the placebo group (P = 0.006 for those receiving vs. those not receiving probucol, and P = 0.70 for those receiving vs. those not receiving vitamins). Restenosis rates per segment were 20.7 percent in the probucol group, 28.9 percent in the combined-treatment group, 40.3 percent in the multivitamin group, and 38.9 percent in the placebo group (P = 0.003 for probucol vs. no probucol). The rates of repeated angioplasty were 11.2 percent, 16.2 percent, 24.4 percent, and 26.6 percent, respectively (P = 0.009 for probucol vs. no probucol). Conclusions The antioxidant probucol is effective in reducing the rate of restenosis after balloon coronary angioplasty. (C) 1997, Massachusetts Medical Society.	MONTREAL HEART INST, RES CTR, DEPT MED, MONTREAL, PQ H1T 1C8, CANADA; UNIV MONTREAL, MONTREAL, PQ, CANADA	Universite de Montreal; Universite de Montreal				Nattel, Stanley/0000-0002-5565-3311; Bourassa, Martial G./0000-0002-4439-8650				ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Beaudry M, 1996, J CAN DIET ASSOC, V57, P7; BRIN MF, 1989, ANN NY ACAD SCI, V570, P421; Burke Bertha S., 1947, JOUR AMER DIETETIC ASSOC, V23, P1041; BURTON GW, 1989, ANN NY ACAD SCI, V570, P7; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; CAVAROCCHI NC, 1986, J SURG RES, V40, P519, DOI 10.1016/0022-4804(86)90093-4; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; DEMAIO SJ, 1992, J AM COLL NUTR, V11, P68; ELINDER LS, 1992, J LIPID RES, V33, P131; FERNS GAA, 1992, P NATL ACAD SCI USA, V89, P11312, DOI 10.1073/pnas.89.23.11312; FREYSCHUSS A, 1993, J CLIN INVEST, V91, P1282, DOI 10.1172/JCI116326; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; *HLTH WELF CAN, 1991, CAN NUTR FIL; JIALAL I, 1992, J LIPID RES, V33, P899; KAGAN VE, 1992, J LIPID RES, V33, P385; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; KU G, 1988, AM J CARDIOL, V62, pB77, DOI 10.1016/S0002-9149(88)80057-2; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LEE YJ, 1991, CIRCULATION S2, V84, P299; LESPERANCE J, 1992, INT J CARDIAC IMAG, V8, P65; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; NUNES GL, 1995, ARTERIOSCL THROM VAS, V15, P156, DOI 10.1161/01.ATV.15.1.156; OKeefe JH, 1996, AM J CARDIOL, V77, P649, DOI 10.1016/S0002-9149(97)89325-3; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; REAVEN PD, 1992, ARTERIOSCLER THROMB, V12, P318, DOI 10.1161/01.ATV.12.3.318; REIBER JHC, 1993, DEV CARDIOVASC MED, V137, P75; SCHNEIDER JE, 1993, CIRCULATION, V88, P628, DOI 10.1161/01.CIR.88.2.628; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SETSUDA M, 1993, CLIN THER, V15, P374; SHAISH A, 1995, J CLIN INVEST, V96, P2075, DOI 10.1172/JCI118256; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P381, DOI 10.1016/S0025-6196(12)64861-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1986, AM J CARDIOL, V57, pH16, DOI 10.1016/0002-9149(86)90430-3; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; Watanabe K, 1996, AM HEART J, V132, P23, DOI 10.1016/S0002-8703(96)90386-5; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; Yokoi Hisashi, 1996, Journal of the American College of Cardiology, V27, p391A	42	453	528	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					365	372		10.1056/NEJM199708073370601	http://dx.doi.org/10.1056/NEJM199708073370601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XP407	9241125	Bronze			2022-12-28	WOS:A1997XP40700001
J	Danzig, R; Berkowsky, PB				Danzig, R; Berkowsky, PB			Why should we be concerned about biological warfare?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									USN,OFF UNDERSECRETARY NAVY,WASHINGTON,DC	United States Department of Defense; United States Navy								BEYERCHEN AD, 1996, MILITARY INNOVATION, P265; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; DANZIG R, 1996, STRATEGIC FORUM  JAN; HORROCK N, 1997, US NEWS WORLD R 0512, P36; MORGANTHAU T, 1996, NEWSWEEK        0506, P34; OLSON KB, 1997, TERRORISM, V1, P1; Tucker JB, 1997, JAMA-J AM MED ASSOC, V278, P362, DOI 10.1001/jama.278.5.362; VICK K, 1996, WASHINGTON POST 0403, pA8; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	9	42	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					431	432		10.1001/jama.278.5.431	http://dx.doi.org/10.1001/jama.278.5.431			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244337				2022-12-28	WOS:A1997XN51800037
J	Schreiner, CE; Langner, G				Schreiner, CE; Langner, G			Laminar fine structure of frequency organization in auditory midbrain	NATURE			English	Article							INFERIOR COLLICULUS; CENTRAL NUCLEUS; SPECTRAL INTEGRATION; COCHLEAR NUCLEUS; SINGLE UNITS; CAT; INHIBITION; NERVE; REPRESENTATION; RESOLUTION	The perception of sound is based on signal processing by a bank of frequency-selective auditory filters, the so-called critical bands(1-3). Here we investigate how the internal frequency organization of the main auditory midbrain station, the central nucleus of the inferior colliculus (ICC), might contribute to the generation of the critical-band behaviour of its neurons. We find a unique spatial arrangement of the frequency distribution in the ICC that correlates with psychophysical critical-band characteristics. Systematic frequency discontinuities along the main tonotopic axis, in combination with a smooth frequency gradient orthogonal to the main tonotopic organization of cat ICC, reflect a layering of the frequency organization paralleling its anatomical laminae. This layered frequency organization is characterized by constant frequency ratios of corresponding locations on neighboring laminae and may provide a spatial framework for the generation of critical bands and for signal processing within(4) and across' frequency bands for the analysis of sound.	TECH UNIV DARMSTADT,INST ZOOL,D-64287 DARMSTADT,GERMANY	Technical University of Darmstadt	Schreiner, CE (corresponding author), UNIV CALIF SAN FRANCISCO,SLOAN CTR THEORET NEUROSCI,WM KECK CTR INTEGRAT NEUROSCI,COLEMAN LAB,SAN FRANCISCO,CA 94143, USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		CHAN JL, 1982, SOC NEUR ABSTR, V8, P348; EHRET G, 1991, BRAIN RES, V567, P350, DOI 10.1016/0006-8993(91)90819-H; EHRET G, 1984, HEARING RES, V14, P45, DOI 10.1016/0378-5955(84)90068-6; EHRET G, 1976, BIOL CYBERN, V24, P35, DOI 10.1007/BF00365592; EHRET G, 1985, SCIENCE, V227, P1245, DOI 10.1126/science.3975613; EHRET G, 1988, BRAIN RES REV, V13, P139, DOI 10.1016/0165-0173(88)90018-5; Evans E. F., 1989, BRIT J AUDIOL, V23, P151; Fletcher H, 1940, REV MOD PHYS, V12, P0047, DOI 10.1103/RevModPhys.12.47; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; MALMIERCA MS, 1993, J COMP NEUROL, V333, P1, DOI 10.1002/cne.903330102; MERZENICH MM, 1974, BRAIN RES, V77, P397, DOI 10.1016/0006-8993(74)90630-1; NIENHUYS TGW, 1979, ACTA OTO-LARYNGOL, V88, P350, DOI 10.3109/00016487909137179; OLIVER DL, 1984, J COMP NEUROL, V224, P155, DOI 10.1002/cne.902240202; OLIVER DL, 1984, J COMP NEUROL, V222, P237, DOI 10.1002/cne.902220207; Palombi PS, 1996, J NEUROPHYSIOL, V75, P2211, DOI 10.1152/jn.1996.75.6.2211; PICKLES JO, 1976, J ACOUST SOC AM, V60, P1151, DOI 10.1121/1.381217; PICKLES JO, 1975, ACTA OTO-LARYNGOL, V80, P245, DOI 10.3109/00016487509121325; PICKLES JO, 1979, J ACOUST SOC AM, V66, P1725, DOI 10.1121/1.383645; POLLAK GD, 1993, HEARING RES, V65, P99, DOI 10.1016/0378-5955(93)90205-F; ROCKEL AJ, 1973, J COMP NEUROL, V147, P11, DOI 10.1002/cne.901470103; ROTH GL, 1978, J COMP NEUROL, V182, P661, DOI 10.1002/cne.901820407; SCHREINER CE, 1988, J NEUROPHYSIOL, V60, P1823, DOI 10.1152/jn.1988.60.6.1823; SEMPLE MN, 1979, J NEUROPHYSIOL, V42, P1626, DOI 10.1152/jn.1979.42.6.1626; SERVIERE J, 1981, NEUROSCI LETT, V27, P113, DOI 10.1016/0304-3940(81)90253-6; SHNEIDERMAN A, 1987, J COMP NEUROL, V266, P519, DOI 10.1002/cne.902660406; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; WATSON CS, 1963, J ACOUST SOC AM, V62, P167; YOST WA, 1989, J ACOUST SOC AM, V85, P848, DOI 10.1121/1.397556; ZWICKER E, 1957, J ACOUST SOC AM, V29, P548, DOI 10.1121/1.1908963	30	161	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					383	386		10.1038/41106	http://dx.doi.org/10.1038/41106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237756				2022-12-28	WOS:A1997XM52800052
J	Mullan, F				Mullan, F			The journey back - A physician retrains	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,WASHINGTON,DC 20052	George Washington University									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					281	283						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228424				2022-12-28	WOS:A1997XL05900014
J	Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG				Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG			Long-term risk of tuberculosis among foreign-born persons in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTIVE THERAPY; EPIDEMIOLOGY; INFECTION; TRANSMISSION; IMMIGRANTS; CANADA; ADULTS	Context.-Cases of tuberculosis (TB) in the United States have declined for 4 consecutive years, but cases among foreign-born persons account for an increasing percentage. Objective.-To describe the risk of tuberculosis among foreign-born persons with respect to their length of residence in the United States. Design.-Cross-sectional analysis of national surveillance data. Setting.-The United States. Patients.-All verified TB cases reported to the Centers for Disease Control and Prevention between 1986 and 1994. Main Outcome Measure.-Stratum-specific incidence rates of TB by age, place of birth, length of residence, age at arrival in the United States, or combinations of these variables. Results.-Several groups of persons from countries with a high prevalence of TB had incidence rates higher than 20 per 100 000 person-years more than 20 years after arrival. Among long-term residents, those who arrived in the United Stales after their fifth birthday had incidence rates of TB 2 to 6 times higher than those of similar age who arrived before their fifth birthday. A total of 45% of the TB cases were among persons younger than 35 years and an additional 18% were among persons who arrived in the United States before their 35th birthday. Conclusions.-Imported Mycobacterium tuberculosis infection (active or latent) is responsible for most TB cases among foreign-born persons in the United States. Detection of active cases among recent arrivals is the main priority in these populations, but many cases were in persons who arrived in the United States before the age of 35 years that could potentially have been avoided with preventive therapy. Elimination of TB in the United States may not be feasible using available diagnostic and treatment modalities without increased efforts to address the global burden of this disease.			Zuber, PLF (corresponding author), CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, 1600 CLIFTON RD, MAILSTOP E-10, ATLANTA, GA 30333 USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*1990 CENS POP HOU, 1992, PUBL US MICR SAMPL T; AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ASCH S, 1994, WESTERN J MED, V161, P373; BALLEW KA, 1995, SOUTHERN MED J, V88, P1025, DOI 10.1097/00007611-199510000-00005; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226, DOI 10.1093/clinids/23.6.1226; BISGARD K, 1994, AM J RESP CRIT CARE, V149, pA703; *BUR CENS, 1993, 1990 CENS POP FOR BO; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P40; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P703; *CDCP, 1996, MMWR; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P8; Centers for Disease control and prevention: Update: Trends in total alcohol syndrome-United States, 1995, MMWR-MORBID MORTAL W, V44, p[1979, 13]; DERIEMER K, 1995, 123 M AM PUBL HLTH A; ENARSON D, 1979, AM REV RESPIR DIS, V119, P11; ENARSON DA, 1994, MAYO CLIN PROC, V69, P85, DOI 10.1016/S0025-6196(12)61618-8; ENARSON DA, 1980, EUR J RESPIR DIS, V61, P139; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; GUERIN N, 1995, PEDIATR PULM, P18; HOPEWELL P, 1995, TUBER LUNG DIS S2, V76, P47; *IMM NAT SERV, 1996, STAT YB IMM NAT SERV; ISEMAN MD, 1995, NEW ENGL J MED, V332, P1094, DOI 10.1056/NEJM199504203321611; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIDZON R, IN PRESS J PEDIAT; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; Rothman K, 1986, MODERN EPIDEMIOLOGY; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SPRINGETT V H, 1958, Br J Prev Soc Med, V12, P135; SPRINGETT VH, 1964, LANCET, V1, P1091; STARKE JR, 1995, JAMA-J AM MED ASSOC, V274, P652, DOI 10.1001/jama.274.8.652; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; STEVENSON DK, 1962, BMJ-BRIT MED J, P1382, DOI 10.1136/bmj.1.5289.1382; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WELLS CD, 1996, 45 ANN EP INT SERV C; WILLERT PD, 1996, MID YEAR M N AM REG; *WORLD BANK, 1993, WORLD DEV REP; Zuber PLF, 1996, TUBERCLE LUNG DIS, V77, P524, DOI 10.1016/S0962-8479(96)90050-7; Zuber PLF, 1996, AM J RESP CRIT CARE, V154, P151, DOI 10.1164/ajrccm.154.1.8680671	46	175	176	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					304	307		10.1001/jama.278.4.304	http://dx.doi.org/10.1001/jama.278.4.304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228436				2022-12-28	WOS:A1997XL05900031
J	Grether, JK; Nelson, KB				Grether, JK; Nelson, KB			Maternal infection and cerebral palsy in infants of normal birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECONIUM ASPIRATION SYNDROME; PRETERM PREMATURE RUPTURE; PERINATAL RISK-FACTORS; INTRAAMNIOTIC INFECTION; COMPLICATIONS; PREDICTORS; ASPHYXIA; SEPSIS; POPULATION; PREVALENCE	Context.-Exposure to maternal or placental infection is related to risk of preterm birth and, in premature infants, of brain lesions predictive of cerebral palsy (CP). Few studies have investigated whether maternal infection is associated with risk of CP in children of normal birth weight. Objective.-To investigate maternal infection during the admission for delivery as a possible risk factor for CP in infants born weighing 2500 g or more. Design.-Population-based case-control study. Setting.-All hospitals in 4 northern California counties, 1983 through 1985. Participants.-A total of 46 children with disabling spastic CP who had no recognized prenatal brain lesions and 378 randomly selected control children weighing 2500 g or more at birth and surviving to age 3 years. Main Outcome Measures.-Disabling spastic CP and signs of neonatal morbidity. Results.-Maternal fever exceeding 38 degrees C in labor was associated with increased risk of unexplained CP (odds ratio [OR], 9.3; 95% confidence interval [CI], 2.7-31.0), as was a clinical diagnosis of chorioamnionitis. One or more indicators of maternal infection were present in 2.9% of control children, 22% of children with CP (OR, 9.3; 95% CI, 3.7-23.0), and 35% of those with the spastic quadriplegic subtype of CP (OR, 19.0; 95% CI, 6.5-56.0). Newborns exposed to maternal infection, both cases and controls, had 5-minute Apgar scores below 6 more often than those unexposed. Among children with CP, those born to infected women were more often hypotensive, needed intubation, had neonatal seizures, and received a clinical diagnosis of hypoxic-ischemic encephalopathy. Conclusion.-Intrauterine exposure to maternal infection was associated with a marked increase in risk of CP in infants of normal birth weight. Maternal infection was also linked with low Apgar scores, other evidence of hypertension and need for resuscitation, and neonatal seizures-signs commonly attributed to birth asphyxia.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grether, JK (corresponding author), CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.				PHS HHS [263-95-C0255] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Beebe LA, 1996, OBSTET GYNECOL, V87, P771, DOI 10.1016/0029-7844(95)00483-1; BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COUGHREY H, 1991, AUST N Z J OBSTET GY, V31, P92; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; EASTMAN NJ, 1955, AM J OBSTET GYNECOL, V69, P950, DOI 10.1016/0002-9378(55)90094-6; FAIX RG, 1985, PEDIATRICS, V76, P415; GERDES JS, 1991, CLIN PERINATOL, V18, P361, DOI 10.1016/S0095-5108(18)30528-1; GOLDSTEIN I, 1988, AM J OBSTET GYNECOL, V159, P363, DOI 10.1016/S0002-9378(88)80085-1; GRAU AJ, 1995, STROKE, V26, P373, DOI 10.1161/01.STR.26.3.373; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGEMAN JR, 1995, CLIN PERINATOL, V22, P251; HANKINS GDV, 1991, AM J OBSTET GYNECOL, V164, P1261, DOI 10.1016/0002-9378(91)90696-O; HERNANDEZ C, 1993, AM J OBSTET GYNECOL, V169, P61, DOI 10.1016/0002-9378(93)90132-3; KNUDSEN FU, 1976, ACTA PAEDIATR SCAND, V65, P725, DOI 10.1111/j.1651-2227.1976.tb04961.x; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; MABERRY MC, 1990, OBSTET GYNECOL, V76, P351; Magee JF, 1996, LAB INVEST, V74, P17; MANTEL N, 1959, J NATL CANCER I, V22, P719; Maseri A, 1996, BRIT MED J, V312, P1049; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NAEYE RL, 1979, BIOL NEONATE, V35, P150; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PEEVY KJ, 1983, AM J OBSTET GYNECOL, V146, P989, DOI 10.1016/0002-9378(83)90985-7; Perlman JM, 1996, PEDIATRICS, V97, P822; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROBERTS AB, 1991, ULTRASOUND OBST GYN, V1, P36, DOI 10.1046/j.1469-0705.1991.01010036.x; ROMERO R, 1993, J REPROD MED, V38, P543; *SAS I INC, 1989, SAS STAT US GUID VER, P2; Schlesselman J, 1982, CASE CONTROL STUDIES, P220; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; USTA IM, 1995, OBSTET GYNECOL, V86, P230, DOI 10.1016/0029-7844(95)00124-A; WAITZMAN NJ, 1995, MMWR-MORBID MORTAL W, V44, P695; WEGMAN ME, 1984, PEDIATRICS, V74, P981; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; YOUNG GB, 1995, NEUROL CLIN, V13, P645, DOI 10.1016/S0733-8619(18)30037-9; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	48	586	602	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					207	211		10.1001/jama.278.3.207	http://dx.doi.org/10.1001/jama.278.3.207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218666				2022-12-28	WOS:A1997XK10800025
J	Moser, RH				Moser, RH			On retirement	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					159	161		10.7326/0003-4819-127-2-199707150-00013	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230009				2022-12-28	WOS:A1997XK15800015
J	Carrell, RW; Lomas, DA				Carrell, RW; Lomas, DA			Conformational disease	LANCET			English	Review							AMYLOID PRECURSOR PROTEIN; INFANT-DEATH-SYNDROME; ANTITHROMBIN; AGGREGATION; MECHANISM; PYREXIA; DOMAIN	Several diverse disorders, including the prevalent dementias and encephalopathies, are now believed to arise from the same general disease mechanism. In each, there is abnormal unfolding and then aggregation of an underlying protein. The gradual accumulation of these aggregates and the acceleration of their formation by stress explain the characteristic late or episodic onset of the clinical disease. The understanding of these processes at the molecular level is opening prospects of more rational approaches to investigation and therapy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,MRC CTR,DEPT MED,CAMBRIDGE CB2 2QH,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; MRC Laboratory Molecular Biology; University of Cambridge	Carrell, RW (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,MRC CTR,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND.							ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; BAYREUTHER K, 1996, NATURE, V383, P476; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P453; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CARRELL RW, 1966, NATURE, V210, P915, DOI 10.1038/210915a0; CHINPRASERTSUK S, 1994, EUR J HAEMATOL, V52, P87; Collee JG, 1996, LANCET, V347, P917, DOI 10.1016/S0140-6736(96)91408-7; Collinge J, 1996, LANCET, V347, P916, DOI 10.1016/S0140-6736(96)91407-5; DARBY NJ, 1993, PROTEIN STRUCTURE, P16; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ELRADHI AS, 1996, BR J INTENSIVE CARE, V6, P305; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; *HUNT DIS COLL RES, 1993, CELL, V72, P971; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 1996, QJM-INT J MED, V89, P807, DOI 10.1093/qjmed/89.11.807; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; NELSON EAS, 1989, LANCET, V1, P199; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Perutz MF, 1997, NATURE, V385, P773, DOI 10.1038/385773a0; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28, P1; RICK R, 1996, NATURE, V382, P180; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; SVEGER T, 1978, PEDIATRICS, V62, P22; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WINTERBOURN CC, 1981, BRIT J HAEMATOL, V49, P111, DOI 10.1111/j.1365-2141.1981.tb07203.x	40	768	806	0	35	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					134	138		10.1016/S0140-6736(97)02073-4	http://dx.doi.org/10.1016/S0140-6736(97)02073-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228977				2022-12-28	WOS:A1997XK11400045
J	Jepson, A; SisayJoof, F; Banya, W; HassanKing, M; Frodsham, A; Bennett, S; Hill, AVS; Whittle, H				Jepson, A; SisayJoof, F; Banya, W; HassanKing, M; Frodsham, A; Bennett, S; Hill, AVS; Whittle, H			Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: Study of affected sibling pairs	BRITISH MEDICAL JOURNAL			English	Article							HLA		MRC LABS,FAJARA,GAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	Jepson, A (corresponding author), UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Talbot, Angela/0000-0002-0386-8070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT S, 1993, T ROY SOC TROP MED H, V87, P286, DOI 10.1016/0035-9203(93)90130-I; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; JEPSON AP, 1995, J INFECT DIS, V172, P316, DOI 10.1093/infdis/172.1.316; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0	5	59	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					96	97		10.1136/bmj.315.7100.96	http://dx.doi.org/10.1136/bmj.315.7100.96			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240049	Green Published			2022-12-28	WOS:A1997XL25200023
J	Stronks, K; Strijbis, AM; Wendte, JF; GunningSchepers, LJ				Stronks, K; Strijbis, AM; Wendte, JF; GunningSchepers, LJ			Who should decide? Qualitative analysis of panel data from public, patients, healthcare professionals, and insurers on priorities in health care	BRITISH MEDICAL JOURNAL			English	Article								Objective: To explore the arguments underlying the choices of patients, the public, general practitioners, specialists, and health insurers regarding priorities in health care. Design: A qualitative analysis of data gathered in a series of panels. Members were asked to economise on the publicly funded healthcare budget, exemplified by 10 services. Results: From a medical point of view, both panels of healthcare professionals thought most services were necessary. The general practitioners tried to achieve the budget cuts by limiting access to services to those most in need of them or those who cannot afford to pay for them. The specialists emphasised the possibilities of reducing costs by increasing the efficiency within services and preventing inappropriate utilisation. The patients mainly economised by limiting universal access to preventive and acute services. The ''public'' panels excluded services that are relatively inexpensive for individual patients. Moreover, they emphasised the individual's own responsibility for health behaviour and the costs of health care, resulting in the choice for copayments. The health insurers emphasised the importance of including services that relate to a risk only, as well as feasibility aspects. Conclusions: There were substantial differences in the way the different groups approached the issue of what should be included in the basic package. Healthcare professionals seem to be most aware of the importance of maintaining equal access for everyone in need of health care.			Stronks, K (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,INST SOCIAL MED,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.							Bowling A, 1996, BRIT MED J, V312, P670; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; DICKER A, 1995, BRIT MED J, V311, P1137, DOI 10.1136/bmj.311.7013.1137; FOWLER FJ, 1994, MED CARE, V32, P625, DOI 10.1097/00005650-199406000-00007; *GOV COMM CHOIC HL, 1992, CHOIC HLTH CAR; HOPTON JL, 1995, BRIT MED J, V310, P1237, DOI 10.1136/bmj.310.6989.1237; Lenaghan J, 1996, BRIT MED J, V312, P1591, DOI 10.1136/bmj.312.7046.1591; LOMAS J, 1996, FUNDAMENTAL QUESTION; McKee M, 1996, BRIT MED J, V312, P691; Smith R, 1996, BRIT MED J, V312, P391; TYMSTRA T, 1993, JAMA-J AM MED ASSOC, V270, P2995, DOI 10.1001/jama.270.24.2995	11	46	46	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					92	96		10.1136/bmj.315.7100.92	http://dx.doi.org/10.1136/bmj.315.7100.92			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240048	Green Published			2022-12-28	WOS:A1997XL25200022
J	Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N				Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N			Tom5 functionally links mitochondrial preprotein receptors to the general import pore	NATURE			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; INSERTION PORE; COMPLEX; TRANSLOCATION; SUBUNIT; MOM22; COMPONENT; ATP	Most mitochondrial proteins are synthesized as preproteins on cytosolic polysomes and are subsequently imported into the organelle(1-3). The mitochondrial outer membrane contains a multisubunit preprotein translocase (Tom) which has receptors on the cytosolic side and a general import pore (GIP) in the membrane. Tom20-Tom22 and Tom70-Tom37 function as import receptors(4-7) with a preference for preproteins that have amino-terminal presequences or internal targeting information, respectively. Tom40 is an essential constituent of the GIP(8,9), whereas Tom6 and Tom7 modulate the assembly and dissociation of the Tom machinery(10,11). Here we report the identification of Tom5, a small subunit that has a crucial role importing preproteins destined for all four mitochondrial subcompartments. Tom5 has a single membrane anchor and a cytosolic segment with a negative net charge, and accepts preproteins from the receptors and mediates their insertion into the GIP. We conclude that Tom5 represents a functional link between surface receptors and GIP, and is part of an 'acid chain'(5) that guides the stepwise transport of positively charged mitochondrial targeting sequences.	UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-92152 MARTINSRIED,GERMANY	University of Freiburg; Max Planck Society			Pfanner, Nikolaus/AAV-7878-2021	Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; Dekker PJT, 1996, BIOL CHEM, V377, P535; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	30	223	227	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					195	200		10.1038/40663	http://dx.doi.org/10.1038/40663			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217162	Bronze			2022-12-28	WOS:A1997XK10900055
J	MayoSmith, MF				MayoSmith, MF			Pharmacological management of alcohol withdrawal - A meta-analysis and evidence-based practice guideline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANALGESIC NITROUS-OXIDE; BLIND CONTROLLED TRIAL; RANDOMIZED CLINICAL-TRIAL; DELIRIUM-TREMENS; HOSPITALIZED-PATIENTS; ABSTINENCE SYNDROME; CARBAMAZEPINE TEGRETOL; CLONIDINE; DIAZEPAM; CHLORDIAZEPOXIDE	Objective.-To provide an evidence-based practice guideline on the pharmacologi Data Sources.-English-language articles published before July 1, 1995, identified through MEDLINE search on ''substance withdrawal-ethyl alcohol'' and review of references from identified articles. Study Selection.-Articles with original data on human subjects. Data Abstraction.-Structured review to determine study design, sample size, interventions used, and outcomes of withdrawal severity, delirium, seizures, completion of withdrawal, entry into rehabilitation, adverse effects, and costs. Data from prospective controlled trials with methodologically sound end points corresponding to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were abstracted by 2 independent reviewers and underwent meta-analysis. Data Synthesis.-Benzodiazepines reduce withdrawal severity, reduce incidence of delirium (-4.9 cases per 100 patients; 95% confidence interval, -9.0 to -0.7; P=.04), and reduce seizures (-7.7 seizures per 100 patients; 95% confidence interval, -12.0 to -3.5; P=.003). Individualizing therapy with withdrawal scales results in administration of significantly less medication and shorter treatment (P<.001). beta-Blockers, clonidine, and carbamazepine ameliorate withdrawal severity, but evidence is inadequate to determine their effect on delirium and seizures. Phenothiazines ameliorate withdrawal but are less effective than benzodiazepines in reducing delirium (P=.002) or seizures (P<.001). Conclusions.-Benzodiazepines are suitable agents for alcohol withdrawal, with choice among different agents guided by duration of action, rapidity of onset, and cost. Dosage should be individualized, based on withdrawal severity measured by withdrawal scales, comorbid illness, and history of withdrawal seizures. beta-Blockers, clonidine, carbamazepine, and neuroleptics may be used as adjunctive therapy but are not recommended as monotherapy.			MayoSmith, MF (corresponding author), CALIF SOC ADDICT MED, 3803 BROADWAY, OAKLAND, CA 94611 USA.							ADINOFF B, 1994, ALCOHOL CLIN EXP RES, V18, P873, DOI 10.1111/j.1530-0277.1994.tb00053.x; AGRICOLA R, 1982, J INT MED RES, V10, P160, DOI 10.1177/030006058201000305; Altamura A C, 1990, Eur Neuropsychopharmacol, V1, P37, DOI 10.1016/0924-977X(90)90008-X; *AM HOSP FORM SERV, 1995, AHFS DRUG INF 95, P1569; *AM PSYCH ASS, 1995, AM J PSYCHIAT, V152, pS11; AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P123; American Psychiatric Association Task Force on Benzodiazepine Dependency, 1990, BENZ DEP TOX AB; BALLDIN J, 1986, ACTA PSYCHIAT SCAND, V73, P131; BALLENGER JC, 1978, BRIT J PSYCHIAT, V133, P1, DOI 10.1192/bjp.133.1.1; BANGER M, 1992, J PSYCHIAT RES, V26, P117, DOI 10.1016/0022-3956(92)90003-7; Banki C M, 1983, Ther Hung, V31, P120; BAUMGARTNER GR, 1987, ARCH INTERN MED, V147, P1223, DOI 10.1001/archinte.147.7.1223; BAUMGARTNER GR, 1991, SOUTHERN MED J, V84, P312, DOI 10.1097/00007611-199103000-00006; BAUMGARTNER GR, 1988, SOUTHERN MED J, V81, P56, DOI 10.1097/00007611-198801000-00012; BECH P, 1989, NORDISK PSYKIATRISK, V43, P291; BENZER DG, 1990, J SUBST ABUSE TREAT, V7, P117, DOI 10.1016/0740-5472(90)90007-D; BJORKQVIST SE, 1975, ACTA PSYCHIAT SCAND, V52, P256, DOI 10.1111/j.1600-0447.1975.tb00041.x; BJORKQVIST SE, 1976, ACTA PSYCHIAT SCAND, V53, P333, DOI 10.1111/j.1600-0447.1976.tb00081.x; BONO G, 1991, INT J CLIN PHARM RES, V11, P35; BOWMAN EH, 1966, DIS NERV SYST, V27, P342; BROWER KJ, 1994, ALCOHOL CLIN EXP RES, V18, P196, DOI 10.1111/j.1530-0277.1994.tb00903.x; BRUNE F, 1971, Q J STUD ALCOHOL, V32, P334; BRUNNING J, 1986, ALCOHOL ALCOHOLISM, V21, P167; BURROUGHS AK, 1985, ALCOHOL ALCOHOLISM, V20, P263; Buschbaum DG, 1992, J GEN INTERN MED, V7, P517; CHAMBERS JF, 1965, Q J STUD ALCOHOL, V26, P10; CHU NS, 1979, NEUROLOGY, V29, P1397, DOI 10.1212/WNL.29.10.1397; CILIP M, 1986, RESUSCITATION, V13, P243, DOI 10.1016/0300-9572(86)90078-X; COOK DJ, 1992, CHEST, V102, pS305; CRAFT PP, 1994, SOUTHERN MED J, V87, P47, DOI 10.1097/00007611-199401000-00011; CUSHMAN P, 1985, ALCOHOL CLIN EXP RES, V9, P103, DOI 10.1111/j.1530-0277.1985.tb05527.x; CUSHMAN P, 1985, PSYCHOPHARMACOL BULL, V21, P651; CUSHMAN P, 1989, ALCOHOL CLIN EXP RES, V13, P361, DOI 10.1111/j.1530-0277.1989.tb00336.x; DAUS AT, 1985, INT J ADDICT, V20, P643, DOI 10.3109/10826088509044943; DAVIDO A, 1994, J CLIN GASTROENTEROL, V18, P178, DOI 10.1097/00004836-199403000-00030; DAYNES G, 1989, INT J NEUROSCI, V49, P83, DOI 10.3109/00207458909087042; DAYNES G, 1994, INT J NEUROSCI, V76, P13, DOI 10.3109/00207459408985987; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVENYI P, 1985, CAN MED ASSOC J, V132, P798; DICK P, 1984, EUR NEUROL, V23, P364, DOI 10.1159/000115715; DOUGHERTY RJ, 1990, J SUBST ABUSE TREAT, V7, P189, DOI 10.1016/0740-5472(90)90021-H; DRUMMOND LM, 1986, BRIT J ADDICT, V81, P247; FAULER J, 1993, EUR J CLIN PHARMACOL, V45, P165, DOI 10.1007/BF00315500; FLYGENRING J, 1984, ACTA PSYCHIAT SCAND, V69, P398, DOI 10.1111/j.1600-0447.1984.tb02511.x; FOY A, 1988, ALCOHOL CLIN EXP RES, V12, P360, DOI 10.1111/j.1530-0277.1988.tb00208.x; FRECKER RC, 1982, J CLIN PSYCHOPHARM, V2, P277; FUNDERBURK FR, 1978, J NERV MENT DIS, V166, P195, DOI 10.1097/00005053-197803000-00005; GALLIMBERTI L, 1989, LANCET, V2, P787; GILLMAN MA, 1986, BRIT J PSYCHIAT, V148, P604, DOI 10.1192/bjp.148.5.604; GILLMAN MA, 1990, POSTGRAD MED J, V66, P543, DOI 10.1136/pgmj.66.777.543; GLATT MM, 1965, BRIT MED J, V2, P401, DOI 10.1136/bmj.2.5458.401; Golbert T, 1967, JAMA-J AM MED ASSOC, V201, P113; GOWER WE, 1980, SURG GYNECOL OBSTET, V151, P382; GRAHAM AW, 1991, ARCH INTERN MED, V151, P958, DOI 10.1001/archinte.151.5.958; GRIFFITHS RR, 1990, J CLIN PSYCHOPHARM, V10, P237; GRIFFITHS RR, 1985, BENZODIAZEPINES CURR, P209; GRUENWALD F, 1960, DIS NERV SYST, V21, P32; GUSTAFSON TL, 1994, TRUE EPISTAT REFEREN; HANSBROUGH JF, 1984, AM J SURG, V148, P266, DOI 10.1016/0002-9610(84)90235-6; HART WT, 1961, AM J PSYCHIAT, V118, P323, DOI 10.1176/ajp.118.4.323; HEINALA P, 1990, INT J CLIN PHARM TH, V28, P211; HILL A, 1993, J SUBST ABUSE TREAT, V10, P449, DOI 10.1016/0740-5472(93)90005-M; HILLBOM M, 1989, ALCOHOL, V6, P223, DOI 10.1016/0741-8329(89)90022-0; HILLBOM ME, 1984, ACTA NEUROL SCAND, V69, P39, DOI 10.1111/j.1600-0404.1984.tb07778.x; HOBBS WR, 1996, GOODMAN GILMANS PHAR, P361; HOEY LL, 1994, PHARMACOTHERAPY, V14, P572; HOEY LL, 1994, PHARMACOTHERAPY, V14, P579; HORWITZ RI, 1989, ARCH INTERN MED, V149, P1089, DOI 10.1001/archinte.149.5.1089; HOSEIN IN, 1979, W INDIAN MED J, V28, P45; HOSEIN IN, 1978, CURR MED RES OPIN, V5, P632, DOI 10.1185/03007997809110199; HUEY L Y, 1975, Psychopharmacology Bulletin, V11, P24; JACOB MS, 1983, J CLIN PSYCHOPHARM, V3, P185; JAFFE JH, 1983, CLIN PHARMACOL THER, V34, P623, DOI 10.1038/clpt.1983.224; JANDA SM, 1990, DICP ANN PHARMAC, V24, P545, DOI 10.1177/106002809002400518; KAIM SC, 1969, AM J PSYCHIAT, V125, P1640, DOI 10.1176/ajp.125.12.1640; KASSER C, 1995, TOPICS ADDICT MED, V1, P1; KATTA BB, 1991, CAN J PSYCHIAT, V36, P155, DOI 10.1177/070674379103600232; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P359; KNOTT DH, 1981, POSTGRAD MED, V69, P65, DOI 10.1080/00325481.1981.11715753; KOPPI S, 1987, NEUROPSYCHOBIOLOGY, V17, P49, DOI 10.1159/000118340; KRAMP P, 1978, ACTA PSYCHIAT SCAND, V58, P174, DOI 10.1111/j.1600-0447.1978.tb06930.x; KRAMP P, 1979, PSYCHIAT RES, V1, P161, DOI 10.1016/0165-1781(79)90057-X; KRAUS ML, 1985, NEW ENGL J MED, V313, P905, DOI 10.1056/NEJM198510103131501; Kristensen C.B., 1986, NORD PSYKIATR TIDSSK, V40, P139; KUHR BM, 1979, J CLIN PSYCHIAT, V40, P198; LATIES VG, 1958, Q J STUD ALCOHOL, V19, P238; LECHTENBERG R, 1990, ARCH NEUROL-CHICAGO, V47, P535, DOI 10.1001/archneur.1990.00530050055012; LICHTIGFELD FJ, 1989, INT J NEUROSCI, V49, P71, DOI 10.3109/00207458909087040; LICHTIGFELD FJ, 1982, S AFR MED J, V61, P349; LICHTIGFELD FJ, 1989, ALCOHOL ALCOHOLISM, V24, P109, DOI 10.1093/oxfordjournals.alcalc.a044873; LINDHOUT D, 1994, EPILEPSIA, V35, pS19, DOI 10.1111/j.1528-1157.1994.tb05952.x; LINEAWEAVER WC, 1988, CRIT CARE MED, V16, P294, DOI 10.1097/00003246-198803000-00018; LISKOW BI, 1989, J STUD ALCOHOL, V50, P414, DOI 10.15288/jsa.1989.50.414; MALCOLM R, 1989, AM J PSYCHIAT, V146, P617; MANHEM P, 1985, ALCOHOL CLIN EXP RES, V9, P238, DOI 10.1111/j.1530-0277.1985.tb05743.x; MANIKANT S, 1993, INDIAN J MED RES-B, V98, P170; MARCUS R, 1996, GOODMAN GILMANS PHAR, P1550; MASSMAN JE, 1988, J PSYCHOACTIVE DRUGS, V20, P443, DOI 10.1080/02791072.1988.10472515; MAYOSMITH MF, 1995, ALCOHOL CLIN EXP RES, V19, P656, DOI 10.1111/j.1530-0277.1995.tb01563.x; MCLENDON DM, 1980, CURR THER RES CLIN E, V28, P447; *MED EC DAT INC, 1993, 1993 RED BOOK; MENDELS J, 1985, J CLIN PSYCHIAT, V46, P172; MENDELSON JH, 1969, ANN NY ACAD SCI, V162, P918, DOI 10.1111/j.1749-6632.1969.tb13021.x; MILLER WC, 1984, CLIN THER, V6, P364; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MOROZ R, 1964, PSYCHIAT QUART, V38, P619, DOI 10.1007/BF01573406; MORTON WA, 1994, AM J DRUG ALCOHOL AB, V20, P75, DOI 10.3109/00952999409084058; MOSKOWITZ G, 1983, ALCOHOL CLIN EXP RES, V7, P42, DOI 10.1111/j.1530-0277.1983.tb05409.x; MULLER DJ, 1969, SOUTHERN MED J, V62, P495, DOI 10.1097/00007611-196904000-00031; MURPHY DJ, 1983, ALCOHOL ALCOHOLISM, V18, P227; Myles M J, 1992, Nurs RSA, V7, P9; NARANJO CA, 1983, CLIN PHARMACOL THER, V34, P214, DOI 10.1038/clpt.1983.155; NOLOP KB, 1985, CRIT CARE MED, V13, P246, DOI 10.1097/00003246-198504000-00008; OBRIEN JE, 1983, CURR THER RES CLIN E, V34, P825; OJUTKANGAS R, 1994, INT J NEUROSCI, V76, P35, DOI 10.3109/00207459408985989; PALESTINE ML, 1976, CURR THER RES CLIN E, V20, P289; PALSSON A, 1986, ACTA PSYCHIAT SCAND, V73, P140, DOI 10.1111/j.1600-0447.1986.tb10551.x; PELLEGRINI CA, 1991, CURRENT SURGICAL DIA, P25; POL S, 1991, ANN INTERN MED, V114, P705, DOI 10.7326/0003-4819-114-8-705; POTTER JF, 1984, CLIN EXP HYPERTENS A, V6, P1147, DOI 10.3109/10641968409039587; POUTANEN P, 1979, BRIT J ADDICT, V74, P201; RADOUCOTHOMAS S, 1989, PROG NEURO-PSYCHOPH, V13, P55, DOI 10.1016/0278-5846(89)90004-3; RAGLAND G, 1990, Emergency Medicine Clinics of North America, V8, P761; REINISCH JM, 1995, JAMA-J AM MED ASSOC, V274, P1518, DOI 10.1001/jama.274.19.1518; RITOLA E, 1981, ACTA PSYCHIAT SCAND, V64, P254, DOI 10.1111/j.1600-0447.1981.tb00781.x; RITSON B, 1986, DRUG ALCOHOL DEPEN, V18, P329, DOI 10.1016/0376-8716(86)90095-5; ROBINSON BJ, 1989, ALCOHOL CLIN EXP RES, V13, P95, DOI 10.1111/j.1530-0277.1989.tb00290.x; ROCCATAGLIATA G, 1980, INT PHARMACOPSYCHIAT, V15, P105, DOI 10.1159/000468420; ROMACH MK, 1991, ANNU REV MED, V42, P323, DOI 10.1146/annurev.me.42.020191.001543; ROSENFELD J. E., 1961, QUART JOUR STUD ALCOHOL SUPPL, V1., P77; ROTHSTEIN E, 1973, AM J PSYCHIAT, V130, P1381, DOI 10.1176/ajp.130.12.1381; SAITZ R, 1995, J GEN INTERN MED, V10, P479, DOI 10.1007/BF02602395; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SALLOUM IM, 1995, PSYCHOPHARMACOL BULL, V31, P305; Schmitz RE, 1977, CURR ALCOHOL, V3, P575; SCHUCKIT MA, 1995, ADDICTION, V90, P1335, DOI 10.1046/j.1360-0443.1995.901013355.x; SELLERS EM, 1976, CLIN PHARMACOL THER, V20, P199; SELLERS EM, 1977, J STUD ALCOHOL, V38, P2096, DOI 10.15288/jsa.1977.38.2096; SELLERS EM, 1983, CLIN PHARMACOL THER, V34, P822, DOI 10.1038/clpt.1983.256; SERENY G, 1965, BRIT MED J, V1, P92, DOI 10.1136/bmj.1.5427.92; SHAW JM, 1981, J CLIN PSYCHOPHARM, V1, P382, DOI 10.1097/00004714-198111000-00006; SHUCKIT MA, 1994, HARRISONS PRINCIPLES, P2420; SILLANPAA M, 1979, J INT MED RES, V7, P168, DOI 10.1177/030006057900700302; SIMPSON R K, 1968, Journal of the American Osteopathic Association, V68, P123; SOLOMON J, 1983, CLIN THER, V6, P52; SONCK T, 1976, EXERPTA MED INT C SE, V38, P251; SPARADEO FR, 1982, J STUD ALCOHOL, V43, P1124, DOI 10.15288/jsa.1982.43.1124; SPENCER J, 1980, MED J AUSTRALIA, V2, P211, DOI 10.5694/j.1326-5377.1980.tb112199.x; STANLEY TH, 1986, SEMIN ANESTH PERIO M, V5, P273; STERNEBRING B, 1983, EUR J CLIN PHARMACOL, V24, P611, DOI 10.1007/BF00542209; STHAXHOLDT O, 1984, ANAESTHESIA, V39, P240; Stojek A, 1987, Psychiatr Pol, V21, P369; STOJEK A, 1986, Materia Medica Polona, V18, P249; STUPPAECK CH, 1994, ADDICTION, V89, P1287, DOI 10.1111/j.1360-0443.1994.tb03307.x; STUPPAECK CH, 1992, ALCOHOL ALCOHOLISM, V27, P153; SULLIVAN JT, 1991, J CLIN PSYCHOPHARM, V11, P291; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; THOMAS DW, 1964, JAMA-J AM MED ASSOC, V188, P244; TUBRIDY P, 1988, BRIT J ADDICT, V83, P581; WADSTEIN J, 1986, ACTA PSYCHIAT SCAND, V73, P144; WALINDER J, 1981, DRUG ALCOHOL DEPEN, V8, P345, DOI 10.1016/0376-8716(81)90043-0; WARTENBERG AA, 1990, ALCOHOL CLIN EXP RES, V14, P71, DOI 10.1111/j.1530-0277.1990.tb00449.x; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409; WILKINS AJ, 1983, PSYCHOPHARMACOLOGY, V81, P78, DOI 10.1007/BF00439278; WILSON A, 1984, ALCOHOL CLIN EXP RES, V8, P542, DOI 10.1111/j.1530-0277.1984.tb05726.x; WILSON A, 1985, ALCOHOL CLIN EXP RES, V9, P23, DOI 10.1111/j.1530-0277.1985.tb05043.x; Wolf K M, 1993, J Am Board Fam Pract, V6, P502; WORNER TM, 1994, AM J DRUG ALCOHOL AB, V20, P115, DOI 10.3109/00952999409084061; YAM PCI, 1992, BRIT J ANAESTH, V68, P106, DOI 10.1093/bja/68.1.106; YEH HS, 1992, J GEN INTERN MED, V7, P123, DOI 10.1007/BF02599121; YOUNG GP, 1987, ANN EMERG MED, V16, P847, DOI 10.1016/S0196-0644(87)80520-6; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZECHNICH RJ, 1982, LANCET, V1, P1071; ZILM DH, 1980, ALCOHOL CLIN EXP RES, V4, P400, DOI 10.1111/j.1530-0277.1980.tb04839.x; ZILM DH, 1975, ANN INTERN MED, V83, P234, DOI 10.7326/0003-4819-83-2-234	175	500	513	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					144	151		10.1001/jama.278.2.144	http://dx.doi.org/10.1001/jama.278.2.144			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214531				2022-12-28	WOS:A1997XH66700036
J	Burkhalter, H				Burkhalter, H			Landmines: Time for a ban	LANCET			English	Editorial Material											Burkhalter, H (corresponding author), PHYSICIANS HUMAN RIGHTS,WASHINGTON OFF,110 MARYLAND AVE,NE,SUITE 511,WASHINGTON,DC 20002, USA.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					63	63		10.1016/S0140-6736(96)30027-5	http://dx.doi.org/10.1016/S0140-6736(96)30027-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217729				2022-12-28	WOS:A1997XH86900053
J	Geltman, P				Geltman, P			Rwanda: Physician complicity and rebuilding the medical community	LANCET			English	Editorial Material											Geltman, P (corresponding author), BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON MED CTR,BOSTON,MA 02118, USA.			Geltman, Paul/0000-0002-9704-7782				Geltman P, 1997, JAMA-J AM MED ASSOC, V277, P289, DOI 10.1001/jama.277.4.289; HALL P, 1994, 1994 REPORT GENOCIDE	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					64	64		10.1016/S0140-6736(05)66266-6	http://dx.doi.org/10.1016/S0140-6736(05)66266-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217731	hybrid			2022-12-28	WOS:A1997XH86900055
J	Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P				Salvarani, C; Cantini, F; Olivieri, I; Barozzi, L; Macchioni, L; Niccoli, L; Padula, A; DeMatteis, M; Pavlica, P			Proximal bursitis in active polymyalgia rheumatica	ANNALS OF INTERNAL MEDICINE			English	Article							GIANT-CELL ARTERITIS; FOLLOW-UP; SYNOVITIS; JOINT; ARTHRITIS; SHOULDER; CRITERIA	Background: The cause of musculoskeletal symptoms in the proximal extremities of patients who have polymyalgia rheumatica is not completely understood. The diffuse and severe discomfort can only be partially explained by the mild joint synovitis that is observed in these patients. Objective: To determine the involvement of the synovial structures of the shoulder girdle of patients who have active symptoms of polymyalgia rheumatica. Design: Case-control study. Setting: 2 secondary referral centers of rheumatology. Patients: 13 case-patients who had active symptoms of polymyalgia rheumatica seen during a 6-month period, 9 control-patients who had early symptoms of elderly-onset rheumatoid arthritis, and 10 age-matched healthy controls. Measurements: Magnetic resonance imaging of the shoulder was done on the 13 case-patients, 9 control-patients, and 10 healthy controls. Results: The frequency of subacromial and subdeltoid bursitis was significantly higher in the case-patients (who had polymyalgia rheumatica) than in the control-patients (who had elderly-onset rheumatoid arthritis). The frequencies of synovitis of the joints and tenosynovitis of the biceps did not significantly differ between the 13 case-patients and the 9 control-patients. None of the healthy controls showed evidence of fluid accumulation in the joints, bursae, or sheaths of the long head of the biceps. Conclusions: Inflammation of subacromial and subdeltoid bursae in association with synovitis of the glenohumeral joints and tenosynovitis of the biceps may contribute to the diffuse discomfort in the shoulder girdle observed in patients with polymyalgia rheumatica.	AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA 2, UNITA REUMATOL, I-42100 REGGIO EMILIA, ITALY; OSPED PRATO, DIV MED INTERNA 2, UNITA REUMATOL, PRATO, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV REUMATOL, BOLOGNA, ITALY; AZIENDA OSPED S ORSOLA MALPIGHI, SERV RADIOL, BOLOGNA, ITALY	IRCCS Arcispedale S. Maria Nuova; Prato Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Salvarani, C (corresponding author), AZIENDA OSPED ARCISPEDALE S MARIA NUOVA, DIV MED INTERNA, UNITA REUMATOL 2, V UMBERTO 1 N50, I-42100 REGGIO EMILIA, ITALY.		Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Boiardi L, 1996, BRIT J RHEUMATOL, V35, P642; CHOU CT, 1984, ARTHRITIS RHEUM-US, V27, P1107, DOI 10.1002/art.1780271005; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; DOUGLAS WAC, 1983, ANN RHEUM DIS, V42, P311, DOI 10.1136/ard.42.3.311; HEALEY LA, 1984, SEMIN ARTHRITIS RHEU, V13, P322, DOI 10.1016/0049-0172(84)90012-X; KIEFT GJ, 1990, ANN RHEUM DIS, V49, P7, DOI 10.1136/ard.49.1.7; KOSKI JM, 1992, BRIT J RHEUMATOL, V31, P201; MCCARTY DJ, 1985, JAMA-J AM MED ASSOC, V254, P2763, DOI 10.1001/jama.254.19.2763; Meliconi R, 1996, ARTHRITIS RHEUM-US, V39, P1199, DOI 10.1002/art.1780390719; ODUFFY JD, 1976, MAYO CLIN PROC, V51, P519; OLIVIERI I, IN PRESS J CLIN EXP; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; SALVARANI C, 1992, J RHEUMATOL, V19, P1100; SALVARANI C, 1995, ARTHRITIS RHEUM, V38, P369, DOI 10.1002/art.1780380311; Salvarani C, 1996, ARTHRITIS RHEUM, V39, P73, DOI 10.1002/art.1780390110; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SALVARANI C, 1987, J RHEUMATOL, V14, P1209; SCHWEITZER ME, 1995, RADIOLOGY, V194, P821, DOI 10.1148/radiology.194.3.7862986	19	118	122	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					27	31		10.7326/0003-4819-127-1-199707010-00005	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214249				2022-12-28	WOS:A1997XG91400004
J	Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J				Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J			Safety of surfaces and equipment for children in playgrounds	LANCET			English	Article								Background The safety of playgrounds is important to protect children from injury, hut studies are mostly done mainly under laboratory conditions without epidemiological data. We investigated the safety of different playground surfaces, and types and heights of equipment in public playgrounds in the City of Cardiff, UK. Methods We did a correlational study of 330 children aged between 0 and 14 years. All children were hurt when playing in playgrounds in Cardiff and presented to the Accident and Emergency Department in Cardiff Royal Infirmary during summer (April to September) 1992 and 1993, and the whole of 1994. We studied the children's hospital records to establish the type of injury and interviewed their parents to find out the playground and type of equipment involved. The main outcome measures were the number of children injured whilst playing, and injury rates per observed number of children on different surfaces, types, and heights of equipment. Findings Children sustained significantly more injuries in playgrounds with concrete surfaces than in those with bark or rubberised surfaces (p<0.001). Playgrounds with rubber surfaces had the lowest rare of injury, with a risk half that of bark and a fifth of that of concrete. Bark surfaces were not significantly more protective against arm fractures than concrete. Most injuries were equipment related. Injury risk due to falls from monkey bars (suspended parallel bars or rings between which children swing) was twice that far climbing-frames and seven times that for swings or slides. The height of the equipment correlated significantly with the number of fractures (p=0.005) from falls. Interpretation Rubber or bath surfacing is associated with a low rate of injuries and we support their use in all public playgrounds. Bark alone is insufficient, however, to prevent all injuries, particularly arm fractures. Rubberised impact-absorbing surfaces are safer than bark. We believe that playing on monkey bars increases the risk of injury in playgrounds and that they should generally not he installed. Safety standards should be based on physical and epidemiological data. Our data suggest that the proposed raising of the maximum fall height from 2.5 m to 3.0 m in Europe is worrying.	UNIV WALES,COLL MED,ACAD CTR,LLANDOUGH HOSP,DEPT CHILD HLTH,PENARTH CF64 2XX,S GLAM,WALES; CARDIFF CTY COUNCIL,SPORTS & LEISURE DEPT,CARDIFF,S GLAM,WALES; CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF,S GLAM,WALES	Cardiff Royal Infirmary								Altman D.G., 1991, PRACTICAL STAT MED R; ATKEN M, 1989, STAT MODELLING GLIM; BALL DJ, 1991, J ROY SOC HEALTH, V111, P134, DOI 10.1177/146642409111100405; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; *CIT CARD LEIS AM, 1993, PLAYGR STRAT; HESELTINE P, 1989, PLAYGROUND MANAGEMEN; HESLETINE P, 1987, PLAYGROUNDS PLANNING, P20; HESLETINE P, 1989, PLAYGROUND MANAGEMEN; *HLTH PROM WAL, 1996, SAF AR YOUR PLAYGR P; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; MOTT A, 1974, ARCH DIS CHILD, V71, P328; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986	12	79	80	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1874	1876		10.1016/S0140-6736(96)10343-3	http://dx.doi.org/10.1016/S0140-6736(96)10343-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217759				2022-12-28	WOS:A1997XG41700010
J	Belfort, M; Weiner, A				Belfort, M; Weiner, A			Another bridge between kingdoms: tRNA splicing in archaea and eukaryotes	CELL			English	Review							TRANSFER-RNA; INTRON; ENDONUCLEASE; RECOGNITION; PHYLOGENY; VOLCANII		SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Yale University	Belfort, M (corresponding author), SUNY ALBANY,MOL GENET PROGRAM,WADSWORTH CTR,NEW YORK STATE DEPT HLTH,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618				BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BELFORT M, 1997, IN PRESS NUCLEIC ACI; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Condon C, 1996, P NATL ACAD SCI USA, V93, P6992, DOI 10.1073/pnas.93.14.6992; Curcio MJ, 1996, TRENDS GENET, V12, P436; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; GARRETT RA, 1994, SYST APPL MICROBIOL, V16, P680; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; NEGRI NED, 1997, CELL, V89, P859; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; PALMER JR, 1994, J BACTERIOL, V176, P3820, DOI 10.1128/JB.176.12.3820-3823.1994; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; Shub DA, 1991, CURR OPIN GENET DEV, V1, P478, DOI 10.1016/S0959-437X(05)80195-9; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Weber U, 1996, NUCLEIC ACIDS RES, V24, P2212, DOI 10.1093/nar/24.12.2212; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	21	54	60	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1003	1006		10.1016/S0092-8674(00)80287-1	http://dx.doi.org/10.1016/S0092-8674(00)80287-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215622	hybrid			2022-12-28	WOS:A1997XG83000004
J	Adams, JS; Lee, G				Adams, JS; Lee, G			Gains in bone mineral density with resolution of vitamin D intoxication	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN; OSTEOPOROSIS; PREVENTION; MILK	Background: Vitamin D intoxication is associated with the mobilization of skeletal calcium. Objective: To ascertain how the resolution of vitamin D intoxication affects bone density. Design: Case series. Setting: Referral service for metabolic bone disease in a tertiary care teaching hospital. Patients: Four patients with osteoporosis who were each using several nonprescription dietary supplements and were found to have fasting hypercalciuria. Intervention: Discontinuation of use of dietary supplements. Measurements: Serial measurement of serum levels of 25-hydroxyvitamin D, ratio of fasting urinary calcium to creatinine, and bone mineral density for 3 years. Results: Discontinuation of use of dietary supplements resulted in the normalization of serum levels of 25-hydroxyvitamin D, the normalization of the ratio of urinary calcium to creatinine, and a mean annual increase in bone mineral density (+/-SD) of 1.9% +/- 0.6%. Conclusions: Occult vitamin D intoxication was detected in patients who were using dietary supplements that contained an unadvertised high level of vitamin D. Resolution of vitamin D intoxication was associated with a rebound in bone mineral density.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), CEDARS SINAI MED CTR, B131, 8700 BEVERLY BLVD, LOS ANGELES, CA 94309 USA.		Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1956, BRIT MED J, V2, P149; BERTHJONES J, 1993, BRIT J DERMATOL, V129, P411, DOI 10.1111/j.1365-2133.1993.tb03168.x; CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; DIAMOND T, 1994, ANN INTERN MED, V120, P8, DOI 10.7326/0003-4819-120-1-199401010-00002; FRASER DR, 1995, LANCET, V345, P104, DOI 10.1016/S0140-6736(95)90067-5; HENNEY JE, 1993, NEW YORK STATE J MED, V93, P86; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; Parfitt AM, 1996, ANN INTERN MED, V125, P413, DOI 10.7326/0003-4819-125-5-199609010-00009; POUILLES JM, 1992, CLIN RHEUMATOL, V11, P492, DOI 10.1007/BF02283104; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; VANDERSCHUEREN D, 1991, CALCIFIED TISSUE INT, V49, P84, DOI 10.1007/BF02565126; ZERWEKH JE, 1992, OSTEOPOROSIS INT, V2, P128, DOI 10.1007/BF01623819	16	77	81	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					203	206		10.7326/0003-4819-127-3-199708010-00004	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245225				2022-12-28	WOS:A1997XN12900004
J	Meier, DE; Morrison, RS; Cassel, CK				Meier, DE; Morrison, RS; Cassel, CK			Improving palliative care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER PAIN MANAGEMENT; TERMINALLY ILL PATIENTS; PHYSICIAN ATTITUDES; MEDICAL-EDUCATION; ADVANCE DIRECTIVES; DYING PATIENT; UNITED-STATES; DEATH; HOSPICE; LIFE	Although most deaths in the United States occur in hospitals, data suggest that hospitals and physicians are not equipped to handle the medical and psychosocial problems of dying patients. In this article, we review the barriers to achieving a peaceful death, including inadequate medical professional education on palliative care, and public and professional uncertainty about the difference between forgoing life-sustaining treatment and active euthanasia, and health professionals' difficulty recognizing when patients are dying and the associated sense that death is a professional failure. Other barriers include fiscal constraints on the length of stay, the number of nurses available to care for dying patients, legal and regulatory constraints on obtaining opioid prescriptions, and a segregated system of hospice care that requires patients to be separated from familiar health care providers and settings in order to receive palliative care at the end of life. Identifying the opportunities that can improve the delivery of palliative care at the end of life is the first step toward developing corrective approaches. Strategies that enhance these opportunities are proposed.			Meier, DE (corresponding author), MT SINAI MED CTR, BOX 1070, NEW YORK, NY 10029 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AM MED ASS, 1993, ANN MED SCH QUEST 2; *AM SOC CLIN ONC A, 1992, J CLIN ONCOL, V10, P1976; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANGAROLO R, 1994, APS B, V4, P9; [Anonymous], 1994, AHCPR PUBL, V94-0592; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BLANK LL, 1995, WESTERN J MED, V163, P297; Byock I R, 1993, J Palliat Care, V9, P25; Byock I R, 1994, J Palliat Care, V10, P8; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL C, 1996, ACP OBSERVER     JUL, P2; CASSEL C, 1994, I MED WORKSH EX FEAS; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CHERNY NI, 1995, CANCER-AM CANCER SOC, V76, P2181, DOI 10.1002/1097-0142(19951201)76:11<2181::AID-CNCR2820761102>3.0.CO;2-F; CHERNY NI, 1994, P AMSLC CLIN ONCOL, V12, pA434; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, J GEN INTERN MED, V11, P422, DOI 10.1007/BF02600190; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIDICH J, 1989, CLEV CLIN J MED, V56, P762, DOI 10.3949/ccjm.56.8.762; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; FORD G, 1993, OXFORD TXB PALLIATIV, P43; GIANELLI D, 1996, AM MED NEWS     0916, P5; Gilligan T, 1996, ANN INTERN MED, V125, P137, DOI 10.7326/0003-4819-125-2-199607150-00010; GRAY D, 1987, J CHRON DIS, V40, P801, DOI 10.1016/0021-9681(87)90132-9; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; *HAST CTR, 1987, GUID TERM LIF SUST T; HERMAN TA, 1980, NEW YORK STATE J MED, V80, P200; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; JORANSON DE, 1994, J PAIN SYMPTOM MANAG, V9, P244, DOI 10.1016/0885-3924(94)90101-5; JORANSON DE, 1995, AM PAIN SOC B, V5, P1; KANE AC, 1986, OMEGA, V16, P11; Kane RS, 1996, J AM GERIATR SOC, V44, P321, DOI 10.1111/j.1532-5415.1996.tb00923.x; KIDDER D, 1992, HEALTH SERV RES, V27, P195; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lewin Tamar, 1996, N Y Times Web, pD20; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; LYNN J, 1995, WESTERN J MED, V163, P250; MacDonald N, 1993, J Cancer Educ, V8, P197; MACDONALD N, 1991, CANCER DETECT PREV, V15, P253; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MEIER DE, 1993, PHYSICIAN ASSISTED D; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MORRISON RS, 1994, GENERATIONS, V18, P48; NARKIEWICZ R, 1986, AM J HOSP CARE, P12; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; *NAT HOSP ORG, 1995, NAT HOSP ORG FACT SH; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT; OJIMCNAIR K, 1984, HLTH MARKETING Q, V2, P119; PERRONE C, 1995, 712901 NAT HOSP ORG; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; RAPPAPORT W, 1993, SURGERY, V113, P163; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT J, 1993, OXFORD TXB PALLIATIV; SCOTT RA, 1995, MILBANK Q, V73, P77, DOI 10.2307/3350314; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; The Joint Commission on Accreditation of Healthcare Organizations, 1996, COMPR ACCR MAN HOSP; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TULSKY JA, 1996, J GEN INTERN MED, V156, P1285; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P449, DOI 10.1001/jama.274.6.449; vonGunten CF, 1996, NEW ENGL J MED, V335, P1766; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALSH D, 1994, J PAIN SYMPTOM MANAG, V9, P109, DOI 10.1016/0885-3924(94)90163-5; WEISSMAN DE, 1993, J PAIN SYMPTOM MANAG, V8, P29, DOI 10.1016/0885-3924(93)90117-E; *WHO EXP COMM, 1990, TECHN REP SER WHO, V804; 1995, MED ETHICS ADVIS NOV, P143; 1996, UPDATE UPDATE CHOICE, P1	85	113	117	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					225	230		10.7326/0003-4819-127-3-199708010-00008	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245229				2022-12-28	WOS:A1997XN12900008
J	Wilson, TE; Grawunder, U; Lieber, MR				Wilson, TE; Grawunder, U; Lieber, MR			Yeast DNA ligase IV mediates non-homologous DNA end joining	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; GENE; REPAIR; CDC9	The discovery of homologues from the yeast Saccharomyces cerevisiae of the human Ku DNA-end-binding proteins (HDF1 and KU80) has established that this organism is capable of non-homologous double-strand end joining (NHET)(1-5), a form of DNA double-strand break repair (DSBR) active in mammalian V(D)J recombination(6-8). Identification of the DNA ligase that mediates NHEJ in yeast will help elucidate the function of the four mammalian DNA ligases in DSBR, V(D)J recombination and other reactions(9,10). Here we show that S. cerevisiae has two typical DNA ligases, the known DNA ligase I homologue CDC9 (refs 11-14) and the previously unknown DNA ligase IV homologue DNL4. dnl4 mutants are deficient in precise and end-processed NHEJ. DNL4 and HDF1 are epistatic in this regard, with the mutation of each having equivalent effects. dn14 mutants are complemented by overexpression of Dn14 but not of Cdc9, and deficiency of Dn14 alone does not impair either cell growth or the Cdc9-mediated responses to ionizing and ultraviolet radiation. Thus, S. cerevisiae has two distinct and separate Ligation pathways.	WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Lieber M, 1996, CURR BIOL, V6, P134, DOI 10.1016/S0960-9822(02)00443-8; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Lindahl T, 1995, J CELL SCI, P73; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MOORE CW, 1982, J BACTERIOL, V150, P1227, DOI 10.1128/JB.150.3.1227-1233.1982; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Siede W, 1996, GENETICS, V142, P91; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	24	335	335	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					495	498		10.1038/41365	http://dx.doi.org/10.1038/41365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242411	Bronze			2022-12-28	WOS:A1997XN55300054
J	Edwardson, JM; An, S; Jahn, R				Edwardson, JM; An, S; Jahn, R			The secretory granule protein syncollin binds to syntaxin in a Ca2+-sensitive manner	CELL			English	Article							PANCREATIC ZYMOGEN GRANULES; NEUROTRANSMITTER RELEASE; MEMBRANE-FUSION; PLASMA-MEMBRANES; VESICLE FUSION; REGULATED EXOCYTOSIS; VESICULAR TRANSPORT; CALCIUM-DEPENDENCE; EXOCRINE PANCREAS; AMYLASE RELEASE	The membrane proteins synaptobrevin, syntaxin, and SNAP-25 form the core of a ubiquitous fusion machine that interacts with the soluble proteins NSF and alpha-SNAP. During regulated exocytosis, membrane fusion is usually strictly controlled by Ca2+ ions. However, the mechanism by which Ca2+ regulates exocytosis is still unclear. Here we show that the membranes of exocrine secretory granules contain an 18-kDa protein, syncollin, that binds to syntaxin at tow Ca2+ concentrations and dissociates at concentrations known to stimulate exocytosis. Syncollin has a single hydrophobic domain at its N-terminus and shows no significant homology with any known protein. Recombinant syncollin inhibits fusion in vitro between zymogen granules and pancreatic plasma membranes, and its potency falls as Ca2+ concentration rises. We suggest that syncollin acts as a Ca2+-sensitive regulator of exocytosis in exocrine tissues.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University	Edwardson, JM (corresponding author), UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND.			Jahn, Reinhard/0000-0003-1542-3498				ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; IWATSUKI N, 1980, NATURE, V283, P492, DOI 10.1038/283492a0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LEE EG, 1994, BIOCHEM J, V298, P599, DOI 10.1042/bj2980599; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOM P, 1993, CELL, V74, P661; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	57	70	74	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					325	333		10.1016/S0092-8674(00)80340-2	http://dx.doi.org/10.1016/S0092-8674(00)80340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244306	hybrid			2022-12-28	WOS:A1997XN24900016
J	Schwartz, S; Thiel, E				Schwartz, S; Thiel, E			Palate destruction by aspergillus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Schwartz, S (corresponding author), FREE UNIV BERLIN,D-12200 BERLIN,GERMANY.			Schwartz, Stefan/0000-0001-8833-5793					0	8	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					241	241		10.1056/NEJM199707243370405	http://dx.doi.org/10.1056/NEJM199707243370405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227930				2022-12-28	WOS:A1997XL99400005
J	Stamos, JK; Shulman, S				Stamos, JK; Shulman, S			Abandoning empirical antibiotics for febrile children	LANCET			English	Editorial Material							OCCULT BACTEREMIA				Stamos, JK (corresponding author), NORTHWESTERN UNIV,SCH MED,CHILDRENS MEM HOSP,DEPT PEDIAT,CHICAGO,IL 60614, USA.							BARAFF LJ, 1993, PEDIATRICS, V82, P1; BASS JW, 1993, PEDIATR INFECT DIS J, V12, P466, DOI 10.1097/00006454-199306000-00003; Browne GJ, 1997, ARCH DIS CHILD, V76, P129, DOI 10.1136/adc.76.2.129; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; LONG SS, 1994, J PEDIATR-US, V124, P585, DOI 10.1016/S0022-3476(05)83137-3; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					84	84		10.1016/S0140-6736(05)61812-0	http://dx.doi.org/10.1016/S0140-6736(05)61812-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228958				2022-12-28	WOS:A1997XK11400006
J	Saitoh, S; Takahashi, K; Yanagida, M				Saitoh, S; Takahashi, K; Yanagida, M			Mis6, a fission yeast inner centromere protein, acts during G1/S and forms specialized chromatin required for equal segregation	CELL			English	Article							SPINDLE POLE BODY; DNA TOPOISOMERASE-II; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; S-POMBE; FUNCTIONAL-ANALYSIS; GENE DISRUPTION; CHROMOSOME; MITOSIS	Disorder in sister chromatid separation can lead to genome instability and cancer. A temperature-sensitive S. pombe mis6-302 frequently loses a minichromosome at 26 degrees C and abolishes equal segregation of regular chromosomes at 36 degrees C. The mis6(+) gene is essential for viability, and its deletion results in missegregation identical to mis6-302. Miss acts before or at the onset of S phase, and mitotic missegregation defects are produced only after the passage of G1/S at 36 degrees C. Mise locates at the centromeres throughout the cell cycle. In the mutant, positioning of the centromeres becomes abnormal, and specialized chromatin in the inner centromeres, which give the smear micrococcal nuclease pattern in wild type, is disrupted. The ability to establish correct biorientation of sister centromeres in metaphase cells requires the Mis6-containing chromatin and originates during the passage of G1/S.			Saitoh, S (corresponding author), KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.			Saitoh, Shigeaki/0000-0001-5408-296X				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MATSUMOTO T, 1990, CURR GENET, V18, P323, DOI 10.1007/BF00318213; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; NIWA O, 1986, MOL GEN GENET, V203, P397, DOI 10.1007/BF00422063; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SPENCER F, 1990, GENETICS, V124, P237; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P457; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UZAWA S, 1992, J CELL SCI, V101, P267; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WOODS A, 1989, J CELL SCI, V93, P491	62	196	199	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					131	143		10.1016/S0092-8674(00)80320-7	http://dx.doi.org/10.1016/S0092-8674(00)80320-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230309	Bronze			2022-12-28	WOS:A1997XL36200015
J	Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ				Springer, MS; Cleven, GC; Madsen, O; deJong, WW; Waddell, VG; Amrine, HM; Stanhope, MJ			Endemic African mammals shake the phylogenetic tree	NATURE			English	Article							SUBSTITUTIONS; EVOLUTION; DNA; RNA	The order Insectivora, including living taxa (lipotyphlans) and archaic fossil forms, is central to the question of higher-level relationships among placental mammals(1). Beginning with Huxley(2), it has been argued that insectivores retain many primitive features and are closer to the ancestral stock of mammals than are other living groups(3). Nevertheless, cladistic analysis suggests that living insectivores, at least, are united by derived anatomical features(4). Here we analyse DNA sequences from three mitochondrial genes and two nuclear genes to examine relationships of insectivores to other mammals. The representative insectivores are not monophyletic in any of our analyses. Rather, golden moles are included in a clade that contains hyraxes, manatees, elephants, elephant shrews and aardvarks. Members of this group are of presumed African origin(5,6). This implies that there was an extensive African radiation from a single common ancestor that gave rise to ecologically divergent adaptive types. 12S ribosomal RNA transversions suggest that the base of this radiation occurred during Africa's window of isolation in the Cretaceous period before land connections were developed with Europe in the early Cenozoic era.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,INST SYSTEMAT & POPULAT BIOL,NL-1090 GT AMSTERDAM,NETHERLANDS; QUEENS UNIV,BELFAST BT9 07BL,ANTRIM,NORTH IRELAND	Radboud University Nijmegen; University of Amsterdam; Queens University Belfast	Springer, MS (corresponding author), UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521, USA.		Klein, Richard G/B-5910-2009; Madsen, Ole/E-3730-2012	Madsen, Ole/0000-0001-8082-7881				Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cope E.D., 1884, AM NAT, V18, P790; COPE E. D., 1884, AM NAT, P892; DEJONG WW, 1981, NATURE, V292, P538, DOI 10.1038/292538a0; DERIJK P, 1994, NUCLEIC ACIDS RES, V22, P3495; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; Fischer MS, 1993, MAMMAL PHYLOGENY, P217; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GLOVER TD, 1973, J REPROD FERTIL, V35, P45, DOI 10.1530/jrf.0.0350045; HARTENBERGER JL, 1986, CR ACAD SCI II, V302, P247; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Huxley TH., 1880, P R SOC LOND, V43, P649, DOI DOI 10.1111/J.1469-7998.1869.TB07343.X; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Lavergne A, 1996, MOL PHYLOGENET EVOL, V6, P245, DOI 10.1006/mpev.1996.0074; Leunissen J. A. M., 1993, MAMMAL PHYLOGENY PLA, V2, P5; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Madsen O, 1997, MOL BIOL EVOL, V14, P363, DOI 10.1093/oxfordjournals.molbev.a025772; Matthew W.D., 1909, MEM AM MUS NAT HIST, V9, P291; Novacek M.J., 1982, P3; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Porter CA, 1996, MOL PHYLOGENET EVOL, V5, P89, DOI 10.1006/mpev.1996.0008; SIBLEY CG, 1988, SCI AM, V254, P82; Springer MS, 1996, J MOL EVOL, V43, P357; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P1138; Stanhope MJ, 1996, J MOL EVOL, V43, P83, DOI 10.1007/BF02337352; Swofford David L., 1996, P407; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; [No title captured]	31	266	282	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					61	64		10.1038/40386	http://dx.doi.org/10.1038/40386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214502	Bronze, Green Submitted			2022-12-28	WOS:A1997XJ14300049
J	Benoist, C; Mathis, D				Benoist, C; Mathis, D			Immunology - Selection for survival?	SCIENCE			English	Editorial Material											Benoist, C (corresponding author), ULP,INST GENET & BIOL MOL & CELLULAIRE,INSERM,CNRS,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,CU STRASBOURG,FRANCE.							MOLLER G, 1996, IMMUNOL REV, V150; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; ROOKE R, IN PRESS IMMUNITY; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1997, SCIENCE, V276, P2059; TOUGH DF, 1995, STEM CELLS, V13, P242, DOI 10.1002/stem.5530130305; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947	7	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2000	2001		10.1126/science.276.5321.2000	http://dx.doi.org/10.1126/science.276.5321.2000			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221508				2022-12-28	WOS:A1997XG74800049
J	Amir, J; Harel, L; Smetana, Z; Varsano, I				Amir, J; Harel, L; Smetana, Z; Varsano, I			Treatment of herpes simplex gingivostomatitis with aciclovir in children: A randomised double blind placebo controlled study	BRITISH MEDICAL JOURNAL			English	Article							VIRUS TYPE-1 INFECTION; ORAL ACYCLOVIR; GENITAL HERPES; CLOSED COMMUNITY; CONTROLLED TRIAL	Objectives: To examine the efficacy of aciclovir suspension for treating herpetic gingivostomatitis in young children. Design: Randomised double blind placebo controlled study. Setting: Day care unit of a tertiary paediatric hospital. Subjects: 72 children aged 1-6 years with clinical manifestations of gingivostomatitis lasting less than 72 hours; 61 children with cultures positive for herpes simplex virus finished the study. Main outcome measures: Duration of oral lesions, fever, eating and drinking difficulties, and viral shedding. Intervention: Aciclovir suspension 15 mg/kg five times a day for seven days, or placebo. Results: Children receiving aciclovir had oral lesions for a shorter period than children receiving placebo (median 4 v 10 days (difference 6 days, 95% confidence interval 4.0 to 8.0)) and earlier disappearance of the following signs and symptoms: fever (1 v 3 days (2 days, 0.8 to 3.2)); extraoral lesions (lesions around the mouth but outside the oral cavity) (0 v 5.5 days (5.5 days, 1.3 to 4.7)); eating difficulties (4 v 7 days (3 days, 1.31 to 4.69)); and drinking difficulties (3 v 6 days (3 days, 1.1 to 4.9)). Viral shedding was significantly shorter in the group treated with aciclovir (1 v 5 days (4 days, 2.9 to 5.1)). Conclusions: Oral aciclovir treatment for herpetic gingivostomatitis, started within the first three days of onset, shortens the duration of all clinical manifestations and the infectivity of affected children. Further studies are needed to evaluate the ideal dose and length of treatment.	HASHARON HOSP,GOLDA MED CTR,AMBULATORY CARE UNIT,PETAH TIQWA,ISRAEL; CHAIM SHEBA MED CTR,CENT VIROL LAB,IL-52621 TEL HASHOMER,ISRAEL	Rabin Medical Center; Chaim Sheba Medical Center	Amir, J (corresponding author), SCHNEIDER CHILDRENS MED CTR ISRAEL,DEPT PAEDIAT C,PETAH TIQWA,ISRAEL.							BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; Cataldo F, 1993, Pediatr Med Chir, V15, P193; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; DUCOULOMBIER H, 1988, ANN PEDIATR-PARIS, V35, P212; FIFE KH, 1994, J INFECT DIS, V169, P133; HALE BD, 1963, JAMA-J AM MED ASSOC, V183, P1068; JOHNSON FB, 1984, J CLIN MICROBIOL, V20, P120, DOI 10.1128/JCM.20.1.120-122.1984; KUZUSHIMA K, 1991, PEDIATRICS, V87, P152; KUZUSHIMA K, 1992, PEDIATRICS, V89, P379; LEVENTONKRISS S, 1976, ISRAEL J MED SCI, V12, P553; Mueller R, 1988, KINDERARZT, V19, P1189; RABORN GW, 1987, J AM DENT ASSOC, V115, P38, DOI 10.14219/jada.archive.1987.0211; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; SMETANA Z, 1994, ISRAEL J MED SCI, V30, P375; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; WHITLEY RJ, 1985, PEDIATR REV, V7, P119	16	66	69	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1800	1803		10.1136/bmj.314.7097.1800	http://dx.doi.org/10.1136/bmj.314.7097.1800			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224082	Green Published			2022-12-28	WOS:A1997XG16600023
J	Rosenbaum, M; Leibel, RL; Hirsch, J				Rosenbaum, M; Leibel, RL; Hirsch, J			Medical progress - Obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BODY-WEIGHT; ENERGY-EXPENDITURE; DIETARY OBESITY; NEUROPEPTIDE-Y; FOOD-INTAKE; MESSENGER-RNA; MOUSE MODEL; RISK FACTOR; FAT; BALANCE		ROCKEFELLER UNIV, HUMAN BEHAV & METAB LAB, NEW YORK, NY 10021 USA	Rockefeller University					NIDDK NIH HHS [DK26687, DK30583, DK52431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030583, R01DK052431, P30DK026687] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ANGEL A, 1996, PROGR OBESITY RES, V7; [Anonymous], EATING DISORDERS OBE; ARONNE LJ, 1995, AM J PHYSIOL-REG I, V269, pR222, DOI 10.1152/ajpregu.1995.269.1.R222; ASTRUP A, 1994, AM J PHYSIOL, V266, pE592, DOI 10.1152/ajpendo.1994.266.4.E592; BELANGER B, 1988, FRAMINGHAM PUBLICATI; BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; BIRCH LL, 1991, NEW ENGL J MED, V324, P232, DOI 10.1056/NEJM199101243240405; BLUNDELL J, 1991, TRENDS PHARMACOL SCI, V12, P147, DOI 10.1016/0165-6147(91)90532-W; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; BOUCHARD C, 1995, INT J OBESITY, V19, pS10; BOUCHARD C, 1996, REGULATION BODY WEIG, V7; Bouchard C, 1994, GENETICS OBESITY; BRAY GA, 1989, VITAM HORM, V45, P1; Bray GA, 1995, OBES RES, V3, pS569, DOI 10.1002/j.1550-8528.1995.tb00229.x; BUTERA PC, 1993, PHYSIOL BEHAV, V53, P1235, DOI 10.1016/0031-9384(93)90387-U; Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chagnon YC, 1997, OBES RES, V5, P115, DOI 10.1002/j.1550-8528.1997.tb00651.x; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CHUA SC, 1991, MOL BRAIN RES, V11, P291, DOI 10.1016/0169-328X(91)90038-Y; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; Chung WK, 1996, GENOME RES, V6, P431, DOI 10.1101/gr.6.5.431; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Considine RV, 1996, BIOCHEM BIOPH RES CO, V220, P735, DOI 10.1006/bbrc.1996.0473; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; CORBETT SW, 1982, AM J PHYSIOL, V242, pE273, DOI 10.1152/ajpendo.1982.242.4.E273; DANFORTH E, 1984, CLIN ENDOCRINOL META, V13, P581, DOI 10.1016/S0300-595X(84)80039-0; Duggirala R, 1996, AM J HUM GENET, V59, P694; EDHOLM OG, 1977, J HUM NUTR, V31, P413; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FELIG P, 1978, NEW ENGL J MED, V298, P1025, DOI 10.1056/NEJM197805042981813; Figlewicz DP, 1996, J LAB CLIN MED, V127, P328, DOI 10.1016/S0022-2143(96)90179-1; FLATT JP, 1993, ANN NY ACAD SCI, V683, P122; FLATT JP, 1995, AM J CLIN NUTR, V61, p952S, DOI 10.1093/ajcn/61.4.952S; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANK GC, 1978, AM J CLIN NUTR, V31, P328, DOI 10.1093/ajcn/31.2.328; FRANKISH HM, 1995, PEPTIDES, V16, P757, DOI 10.1016/0196-9781(94)00200-P; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRIEDMAN MI, 1986, BRAIN RES BULL, V17, P855, DOI 10.1016/0361-9230(86)90099-7; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; GEARY N, 1996, OBESITY ADV UNDERSTA; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; Havel PJ, 1996, J CLIN ENDOCR METAB, V81, P4406, DOI 10.1210/jc.81.12.4406; HILL JO, 1993, ANN INTERN MED, V119, P694, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00013; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Hirsch J, 1972, Adv Psychosom Med, V7, P229; Hirsch J, 1997, NATURE, V387, P27, DOI 10.1038/387027a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; JEBB SA, 1991, INT J OBESITY, V15, P367; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Kolaczynski JW, 1996, J CLIN ENDOCR METAB, V81, P4162, DOI 10.1210/jc.81.11.4162; KROTKIEWSKI M, 1990, AM J CLIN NUTR, V51, P321, DOI 10.1093/ajcn/51.3.321; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LANDSBERG L, 1984, CLIN ENDOCRINOL META, V13, P475, DOI 10.1016/S0300-595X(84)80034-1; LANTIGUA RA, 1980, NEW ENGL J MED, V303, P735, DOI 10.1056/NEJM198009253031305; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibel RL, 1997, NAT GENET, V16, P218, DOI 10.1038/ng0797-218; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBEL RL, 1995, NEW ENGL J MED, V333, P399; LEIBEL RL, 1991, AM J PHYSIOL, V260, pR785, DOI 10.1152/ajpregu.1991.260.4.R785; LEIBEL RL, 1984, METABOLISM, V33, P164, DOI 10.1016/0026-0495(84)90130-6; LEIBEL RL, 1992, AM J CLIN NUTR, V55, P350, DOI 10.1093/ajcn/55.2.350; LEIBEL RL, 1990, WORLD REV NUTR DIET, V63, P90; LEIBEL RL, 1996, PROGR OBESITY RES, V7, P263; Leibowitz SF, 1995, OBES RES, V3, pS573, DOI 10.1002/j.1550-8528.1995.tb00230.x; MADDISON S, 1977, PHYSIOL BEHAV, V19, P819, DOI 10.1016/0031-9384(77)90322-5; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; McGregor GP, 1996, ENDOCRINOLOGY, V137, P1501, DOI 10.1210/en.137.4.1501; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Nechad M., 1986, BROWN ADIPOSE TISSUE; NEEL JV, 1962, AM J HUM GENET, V14, P353; Newsholme E A, 1978, Biochem Soc Symp, P183; Norman RA, 1996, DIABETES, V45, P1229, DOI 10.2337/diabetes.45.9.1229; OLDENDORF WH, 1981, PEPTIDES, V2, P109, DOI 10.1016/0196-9781(81)90020-6; Ostlund RE, 1996, J CLIN ENDOCR METAB, V81, P3909, DOI 10.1210/jc.81.11.3909; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RAVUSSIN E, 1995, METABOLISM, V44, P12, DOI 10.1016/0026-0495(95)90312-7; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; REED DR, 1995, INT J OBESITY, V19, P599; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; ROHNERJEANRENAUD F, 1995, INT J OBESITY, V19, P517; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; Rosenbaum M, 1988, Adv Pediatr, V35, P73; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; ROSENBAUM M, IN PRESS J CLIN ENDO; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; SCHEMMEL R, 1970, J NUTR, V100, P1041; SCHWARTZ MW, 1993, ANN NY ACAD SCI, V692, P60; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; SMITH GP, 1985, AM J PHYSIOL, V249, pR638, DOI 10.1152/ajpregu.1985.249.5.R638; SOURS HE, 1981, AM J CLIN NUTR, V34, P453, DOI 10.1093/ajcn/34.4.453; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; STEFFENS AB, 1990, NEUROSCI BIOBEHAV R, V14, P305, DOI 10.1016/S0149-7634(05)80040-5; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMPSON DB, 1995, DIABETES, V44, P478, DOI 10.2337/diabetes.44.4.478; TREMBLAY A, 1994, METABOLISM, V43, P814, DOI 10.1016/0026-0495(94)90259-3; TREMBLAY A, 1995, INT J OBESITY, V19, P79; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WEIGLE DS, 1988, METABOLISM, V37, P930, DOI 10.1016/0026-0495(88)90149-7; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; WEST DB, 1994, J CLIN INVEST, V94, P1410, DOI 10.1172/JCI117477; WOLFE RR, 1992, ENERGY METABOLISM, P495; Woods SC, 1996, NEUROSCI BIOBEHAV R, V20, P139, DOI 10.1016/0149-7634(95)00044-F; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZukowskaGrojec Z, 1995, ANN NY ACAD SCI, V771, P219, DOI 10.1111/j.1749-6632.1995.tb44683.x; 1994, MMWR-MORBID MORTAL W, V43, P818	139	546	560	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					396	407		10.1056/NEJM199708073370606	http://dx.doi.org/10.1056/NEJM199708073370606			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241130				2022-12-28	WOS:A1997XP40700006
J	Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA				Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA			Cloning and characterization of a mammalian proton-coupled metal-ion transporter	NATURE			English	Article							RAT SMALL-INTESTINE; INTRACELLULAR PARASITES; NATURAL-RESISTANCE; XENOPUS-OOCYTES; MESSENGER-RNA; IRON; CELLS; COTRANSPORTER; INFECTION; REDUCTION	Metal ions are essential cofactors for a wealth of biological processes, including oxidative phosphorylation, gene regulation and free-radical homeostasis. Failure to maintain appropriate levels of metal ions in humans is a feature of hereditary haemoduomatosis(1), disorders of metal-ion deficiency, and certain neurodegenerative diseases(2). Despite their pivotal physiological roles, however, there is no molecular information on how metal ions are actively absorbed by mammalian cells. We have now identified a new metal-ion transporter in the rat, DCT1, which has an unusually broad substrate range that includes Fe2+ Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, and Pb2+. DCT1 mediates active transport that is proton-coupled and depends on the cell membrane potential, It is a 561-amino-acid protein with 12 putative membrane-spanning domains and is ubiquitously expressed, most notably in the proximal duodenum. DCT1 is upregulated by dietary iron deficiency, and may represent a key mediator of intestinal iron absorption. DCT1 is a member of the 'natural-resistance-associated macrophage protein' (Nramp) family(3-5) and thus its properties provide insight into how these proteins confer resistance to pathogens.	YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gunshin, H (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,77 AVE LOUIS PASTEUR,BOSTON,MA 02115, USA.		Boron, Walter/ABI-1564-2020	Nussberger, Stephan/0000-0003-3619-4452; Boron, Walter/0000-0003-4741-7287; Mackenzie, Bryan/0000-0002-9661-8838; Hediger, Matthias/0000-0003-1946-027X; Romero, Michael F/0000-0002-1555-7835	NIDDK NIH HHS [F32 DK009342, F32 DK009342-03, F32 DK009342-02, F32 DK009342-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Conrad ME, 1996, J CLIN INVEST, V98, P1449, DOI 10.1172/JCI118933; DOREY C, 1993, BRIT J NUTR, V70, P157, DOI 10.1079/BJN19930113; EIDE DJ, IN PRESS CURR OPIN C; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; GUNSHIN H, 1991, AGR BIOL CHEM TOKYO, V55, P2813, DOI 10.1080/00021369.1991.10857152; HAN O, 1995, J NUTR, V125, P1291; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HIRSCH EC, 1997, MOL NEUROL, V94, P135; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKENZIE B, UNPUB COUPLING STOIC; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; NICHOLS GM, 1989, AM J GASTROENTEROL, V84, P851; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J LEUKOCYTE BIOL, V58, P382, DOI 10.1002/jlb.58.4.382; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	30	2510	2612	10	185	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					482	488		10.1038/41343	http://dx.doi.org/10.1038/41343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242408				2022-12-28	WOS:A1997XN55300051
J	Baird, DT				Baird, DT			Amenorrhoea	LANCET			English	Article							POLYCYSTIC-OVARY-SYNDROME; HORMONE-RELEASING HORMONE; MALE PATTERN BALDNESS; HYPOTHALAMIC AMENORRHEA; CLOMIPHENE CITRATE; HYPERPROLACTINEMIC AMENORRHEA; WOMEN; OVULATION; INDUCTION; PREGNANCY				Baird, DT (corresponding author), UNIV EDINBURGH, CTR REPROD BIOL, DEPT OBSTET & GYNAECOL, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND.							ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; ADASHI EY, 1986, SEMIN REPROD ENDOCR, V4, P255, DOI 10.1055/s-2007-1022505; BAIRD DT, 1995, ENDOCRINOLOGY, P2059; BAIRD DT, 1991, OVARIAN ENDOCRINOLOG, P1; Baird DT, 1993, OVARY, P529; Bardin C W, 1973, Recent Prog Horm Res, V29, P65; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; BLACKWELL RE, 1992, ENDOCRIN METAB CLIN, V21, P105, DOI 10.1016/S0889-8529(18)30234-2; BOHNET HG, 1976, J CLIN ENDOCR METAB, V42, P132, DOI 10.1210/jcem-42-1-132; CAREY AH, 1993, CLIN ENDOCRINOL, V38, P653, DOI 10.1111/j.1365-2265.1993.tb02150.x; CAREY AH, 1994, HUM MOL GENET, V3, P1873, DOI 10.1093/hmg/3.10.1873; CLARKE IJ, 1987, OXFORD REV REPROD B, V9, P54; CORNER GW, 1951, LANCET, V260, P919; CROSIGNANI PG, 1990, BAILLIERE CLIN OB GY, V4, P441, DOI 10.1016/S0950-3552(05)80303-7; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; DUNAIF A, 1995, AM J MED, V98, pS33, DOI 10.1016/S0002-9343(99)80057-6; FAUSER BCJ, 1994, OVULATION INDUCTION, P145; FERIN M, 1993, MENSTRUAL CYCLE; FERRARI C, 1986, HUM REPROD, V1, P507, DOI 10.1093/oxfordjournals.humrep.a136464; FERRIMAN D, 1979, CLIN ENDOCRINOL, V11, P291, DOI 10.1111/j.1365-2265.1979.tb03077.x; FILICORI M, 1991, J CLIN ENDOCR METAB, V72, P965, DOI 10.1210/jcem-72-5-965; FORBES AP, 1954, J CLIN ENDOCR METAB, V14, P265, DOI 10.1210/jcem-14-3-265; FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; French F S, 1990, Recent Prog Horm Res, V46, P1; GEMZELL C, 1979, FERTIL STERIL, V31, P363; Gharani N, 1997, HUM MOL GENET, V6, P397, DOI 10.1093/hmg/6.3.397; GINDOFF PR, 1986, FERTIL STERIL, V46, P1156; GLASIER AF, 1990, BAILLIERE CLIN OB GY, V4, P491, DOI 10.1016/S0950-3552(05)80306-2; HAGUE WM, 1988, CLIN ENDOCRINOL, V29, P593, DOI 10.1111/j.1365-2265.1988.tb03707.x; HARRIS GW, 1970, BRIT MED BULL, V26, P3, DOI 10.1093/oxfordjournals.bmb.a070739; HOMBURG R, 1989, BRIT MED J, V298, P809, DOI 10.1136/bmj.298.6676.809; HOTCHKISS J, 1995, REPROD ENDOCRINOLOGY, P123; Huhtaniemi I, 1996, INT CONGR SER, V1106, P89; IMPERATOMCGINLE.J, 1995, REPROD ENDOCRINOLOGY, V1, P935; JONES GS, 1969, AM J OBSTET GYNECOL, V104, P597, DOI 10.1016/S0002-9378(16)34255-7; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KAZER RR, 1987, J CLIN ENDOCR METAB, V65, P233, DOI 10.1210/jcem-65-2-233; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; LACHELIN GCL, 1978, AM J OBSTET GYNECOL, V130, P825, DOI 10.1016/0002-9378(78)90017-0; LAWS ER, 1987, ENDOCRIN METAB CLIN, V16, P647, DOI 10.1016/S0889-8529(18)30467-5; Letterie GS, 1996, HUM REPROD, V11, P19; LEYENDECKER G, 1983, J REPROD FERTIL, V69, P397; Loumaye E, 1995, HUM REPROD UPDATE, V1, P188, DOI 10.1093/humupd/1.2.188; LUTJEN P, 1984, NATURE, V307, P174, DOI 10.1038/307174a0; MARCH CM, 1995, REPROD ENDOCRINOLOGY, V2, P1475; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; MULLER J, 1992, J CLIN ENDOCR METAB, V75, P331, DOI 10.1210/jc.75.1.331; POLSON DW, 1989, FERTIL STERIL, V51, P30; RABINOWE SL, 1989, FERTIL STERIL, V51, P450; ROCK JA, 1995, REPROD ENDOCRINOLOGY, P1445; Saenger P, 1996, NEW ENGL J MED, V335, P1749, DOI 10.1056/NEJM199612053352307; SCHENKER JG, 1982, FERTIL STERIL, V37, P593; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; Sheehan HL, 1939, Q J MED, V8, P277; SHORT RV, 1976, PROC R SOC SER B-BIO, V195, P3, DOI 10.1098/rspb.1976.0095; SOHVAL AR, 1965, AM J MED, V38, P615, DOI 10.1016/0002-9343(65)90137-3; STARUP J, 1971, ACTA ENDOCRINOL-COP, V66, P248, DOI 10.1530/acta.0.0660248; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; TAKEDA T, 1992, INTERNAL MED, V31, P394, DOI 10.2169/internalmedicine.31.394; TAYLOR AE, 1993, OVARY, P629; Troche V, 1986, Obstet Gynecol Surv, V41, P74, DOI 10.1097/00006254-198602000-00002; VANDERSPUY ZM, 1988, BRIT MED J, V296, P962, DOI 10.1136/bmj.296.6627.962; WARREN MP, 1993, ENDOCRINOLOGY, P2679; WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403; WENTZ AC, 1995, REPROD ENDOCRINOLOGY, V2, P1385; White DM, 1996, J CLIN ENDOCR METAB, V81, P3821, DOI 10.1210/jc.81.11.3821; WILDT L, 1987, J CLIN ENDOCR METAB, V64, P1334, DOI 10.1210/jcem-64-6-1334; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	72	15	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 26	1997	350	9073					275	279		10.1016/S0140-6736(97)06297-1	http://dx.doi.org/10.1016/S0140-6736(97)06297-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242812				2022-12-28	WOS:A1997XM86600041
J	Isaac, MT; Tome, MB				Isaac, MT; Tome, MB			Selective serotonin reuptake inhibitors plus pindolol	LANCET			English	Letter											Isaac, MT (corresponding author), LEWISHAM HOSP,SUITE 6,LONDON SE13 6LH,ENGLAND.							Berman RM, 1997, AM J PSYCHIAT, V154, P37; Perez V, 1997, LANCET, V349, P1594, DOI 10.1016/S0140-6736(96)08007-5; Tome MB, 1997, J AFFECT DISORDERS, V44, P101, DOI 10.1016/S0165-0327(97)00030-X; Tome MB, 1997, INT CLIN PSYCHOPHARM, V12, P81, DOI 10.1097/00004850-199703000-00003; TOME MB, IN PRESS INT J PSYCH	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					288	289		10.1016/S0140-6736(05)62250-7	http://dx.doi.org/10.1016/S0140-6736(05)62250-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242815				2022-12-28	WOS:A1997XM86600045
J	Killcross, S; Robbins, TW; Everitt, BJ				Killcross, S; Robbins, TW; Everitt, BJ			Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala	NATURE			English	Article							POTENTIATED STARTLE; MEMORY; ORGANIZATION; HIPPOCAMPUS; ANXIETY; EMOTION; LESIONS; SYSTEM; BRAIN	The amygdala has long been thought to be involved in emotional behaviour(1,2), and its role in anxiety and conditioned fear has been highlighted(3,4). Individual amygdaloid nuclei have been shown to project to various cortical and subcortical regions implicated in affective processing(5-7). Here we show that some of these nuclei have separate roles in distinct mechanisms underlying conditioned fear responses. Rats with lesions of the central nucleus exhibited reduction in the suppression of behaviour elicited by a conditioned fear stimulus, but were simultaneously able to direct their actions to avoid further presentations of this aversive stimulus. In contrast, animals with lesions of the basolateral amygdala were unable to avoid the conditioned aversive stimulus by their choice behaviour, but exhibited normal conditioned suppression to this stimulus. This double dissociation demonstrates that distinct neural systems involving separate amygdaloid nuclei mediate different types of conditioned fear behaviour. We suggest that theories of amygdala function should take into account the roles of discrete amygdala subsystems in controlling different components of integrated emotional responses.			Killcross, S (corresponding author), UNIV CAMBRIDGE, DEPT EXPT PSYCHOL, DOWNING ST, CAMBRIDGE CB2 3EB, ENGLAND.		Killcross, Simon/N-1426-2019; anand, amit/A-7222-2009; Robbins, Trevor W/A-7551-2008; Killcross, Simon/A-4113-2009	Killcross, Simon/0000-0002-5571-548X; Robbins, Trevor/0000-0003-0642-5977; Everitt, Barry/0000-0003-4431-6536				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AMARAL D G, 1992, P1; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO AR, 1994, DESCARTES ERROR; DAVIS M, 1987, PSYCHOL LEARN MOTIV, V21, P263; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EVERITT B J, 1992, P401; EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; GROENEWEGEN HJ, 1990, PROG BRAIN RES, V85, P95; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; MOWRER OH, 1954, AM J PSYCHOL, V67, P15, DOI 10.2307/1418068; PARENT MB, 1992, BEHAV NEUROSCI, V106, P789, DOI 10.1037/0735-7044.106.5.789; SANANES CB, 1992, BEHAV NEUROSCI, V106, P72, DOI 10.1037/0735-7044.106.1.72; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; Wan FJ, 1997, NEUROSCIENCE, V76, P715, DOI 10.1016/S0306-4522(96)00218-7; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	30	518	524	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					377	380		10.1038/41097	http://dx.doi.org/10.1038/41097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237754				2022-12-28	WOS:A1997XM52800050
J	Marcoux, S; Maheux, R; Berube, S; Langevin, M; Graves, G; Wrixon, W; OKeane, J; Mackay, G; Gagnon, S; Mechas, T; Fisch, P; Hamel, G; Blanchet, P; Laberge, P; Champoux, F; Dupont, P; Rioux, JE; Richard, R; Laganiere, L; Maheux, R; Bergeron, J; Villeneuve, M; Langevin, M; Lacroix, M; Gagnon, SR; Fleury, J; StPierre, L; Ainmelk, Y; Quintin, JM; Miron, P; StMichel, P; Faucher, G; Caron, MJ; Bernier, C; Lorrain, J; Chemaly, R; Sabbah, R; Perreault, D; Vincelli, L; Bissonnette, F; Girard, Y; Benoit, J; Sergerie, M; Falcone, T; Hemmings, R; Tulandi, T; Gagnon, M; Foley, C; Choquette, P; Barry, Y; Durocher, F; Piche, Y; Collin, M; Lefebvre, G; Reid, RL; Reid, J; Smith, J; Greenblatt, E; Gotlieb, L; Collins, J; Daya, S; Gunby, J; Johnston, RU; Farlinger, D; Yuzpe, A; Tummon, I; Slota, D; Vilos, GA; Vilos, E; Kredentser, J; Wall, E; Scott, JZ; Cheung, AP; Nordstrom, L; Racette, N; White, D; Fluker, M; White, D				Marcoux, S; Maheux, R; Berube, S; Langevin, M; Graves, G; Wrixon, W; OKeane, J; Mackay, G; Gagnon, S; Mechas, T; Fisch, P; Hamel, G; Blanchet, P; Laberge, P; Champoux, F; Dupont, P; Rioux, JE; Richard, R; Laganiere, L; Maheux, R; Bergeron, J; Villeneuve, M; Langevin, M; Lacroix, M; Gagnon, SR; Fleury, J; StPierre, L; Ainmelk, Y; Quintin, JM; Miron, P; StMichel, P; Faucher, G; Caron, MJ; Bernier, C; Lorrain, J; Chemaly, R; Sabbah, R; Perreault, D; Vincelli, L; Bissonnette, F; Girard, Y; Benoit, J; Sergerie, M; Falcone, T; Hemmings, R; Tulandi, T; Gagnon, M; Foley, C; Choquette, P; Barry, Y; Durocher, F; Piche, Y; Collin, M; Lefebvre, G; Reid, RL; Reid, J; Smith, J; Greenblatt, E; Gotlieb, L; Collins, J; Daya, S; Gunby, J; Johnston, RU; Farlinger, D; Yuzpe, A; Tummon, I; Slota, D; Vilos, GA; Vilos, E; Kredentser, J; Wall, E; Scott, JZ; Cheung, AP; Nordstrom, L; Racette, N; White, D; Fluker, M; White, D			Laparoscopic surgery in infertile, women with minimal or mild endometriosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PELVIC ENDOMETRIOSIS; SPONTANEOUS-ABORTION; MODALITIES	Background Minimal or mild endometriosis is frequently diagnosed in infertile women. It is often treated by resection or ablation of the lesions, but whether this improves fertility has not been established. We carried out a randomized, controlled trial to determine whether laparoscopic surgery enhanced fecundity in infertile women with minimal or mild endometriosis. Methods We studied 341 infertile women 20 to 39 years of age with minimal or mild endometriosis. During diagnostic laparoscopy the women were randomly assigned to undergo resection or ablation of visible endometriosis or diagnostic laparoscopy only. They were followed for 36 weeks after the laparoscopy or, for those who became pregnant during that interval, for up to 20 weeks of pregnancy. Results Among the 172 women who had resection or ablation of endometriosis, 50 became preg nant and had pregnancies that continued for 20 weeks or longer, as compared with 29 of the 169 women in the diagnostic-laparoscopy group (cumulative probabilities, 30.7 percent and 17.7 percent, respectively; P = 0.006 by the log-rank test). The corresponding rates of fecundity were 4.7 and 2.4 per 100 person-months (rate ratio, 1.9; 95 percent confidence interval, 1.2 to 3.1). Fetal losses occurred in 20.6 percent of all the recognized pregnancies in the laparoscopic-surgery group and in 21.6 percent of all those in the diagnostic-laparoscopy group (P = 0.91). Four minor operative complications (intestinal contusion, slight tear of the tubal serosa, difficult pneumoperitoneum, and vascular trauma) were reported (three in the surgery group and one in the control group). Conclusions Laparoscopic resection or ablation of minimal and mild endometriosis enhances fecundity in infertile women. (C)1997, Massachusetts Medical Society.	CTR HOSP UNIV QUEBEC, QUEBEC CITY, PQ G1L 3L5, CANADA; UNIV LAVAL, EPIDEMIOL RES GRP, QUEBEC CITY, PQ G1K 7P4, CANADA; GRACE MATERN HOSP, HALIFAX, NS, CANADA; VICTORIA GEN HOSP, HALIFAX, NS B3H 2Y9, CANADA; HOP CHICOUTIMI, CHICOUTIMI, PQ, CANADA; HOP ST SACREMENT, QUEBEC CITY, PQ, CANADA; CHU LAVAL, PAVILLON CTR HOSP, QUEBEC CITY, PQ G1V 4G2, CANADA; CTR HOSP REG AMIANTE, THETFORD MINES, PQ, CANADA; HOP HOTEL DIEU, ARTHABASKA, PQ, CANADA; CTR HOSP UNIV SHERBROOKE, SHERBROOKE, PQ, CANADA; HOP MAISON NEUVE ROSEMONT, MONTREAL, PQ H1T 2M4, CANADA; HOP SACRE COEUR, MONTREAL, PQ H4J 1C5, CANADA; HOP ST LUC, MONTREAL, PQ H2X 1P1, CANADA; ROYAL VICTORIA HOSP, MONTREAL, PQ H3A 1A1, CANADA; CITE SANTE, LAVAL, PQ, CANADA; OTTAWA CIVIC HOSP, OTTAWA, ON K1Y 4E9, CANADA; KINGSTON GEN HOSP, KINGSTON, JAMAICA; TORONTO GEN HOSP, TORONTO, ON, CANADA; CHEDOKE MCMASTER HOSP, HAMILTON, ON, CANADA; ORILLA SOLDIERS MEM HOSP, ORILLIA, ON, CANADA; ST JOSEPHS HOSP, LONDON, ON N6A 4V2, CANADA; LONDON UNIV HOSP, LONDON, ON, CANADA; HLTH SCI CTR, WINNIPEG, MB, CANADA; UNIV ALBERTA HOSP, EDMONTON, AB T6G 2B7, CANADA; FRASER BURRARD HOSP SOC, VANCOUVER, BC, CANADA; UNIV HOSP SHAUGHNESSY SITE, VANCOUVER, BC, CANADA	Laval University; Laval University; Dalhousie University; Dalhousie University; University of Victoria; Laval University; Laval University; University of Sherbrooke; University of Sherbrooke; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; Royal Victoria Hospital; Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; McMaster University; McGill University; Western University (University of Western Ontario); University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Alberta			Greenblatt, Ellen/C-1437-2016					*AM FERT SOC, 1985, FERTIL STERIL, V43, P351; [Anonymous], 1994, Hum Reprod, V9, P1158; CHONG AP, 1990, FERTIL STERIL, V53, P407; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1979, FERTIL STERIL, V32, P80; DAVIES JA, 1994, BRIT J OBSTET GYNAEC, V101, P267, DOI 10.1111/j.1471-0528.1994.tb13129.x; FAYEZ JA, 1988, AM J OBSTET GYNECOL, V159, P927, DOI 10.1016/S0002-9378(88)80173-X; GROLL M, 1984, FERTIL STERIL, V41, P933; HOUSTON DE, 1987, AM J EPIDEMIOL, V125, P959, DOI 10.1093/oxfordjournals.aje.a114634; HUGHES EG, 1993, FERTIL STERIL, V59, P963; HULL MGR, 1992, HUM REPROD, V7, P785, DOI 10.1093/oxfordjournals.humrep.a137738; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONINCKX PR, 1991, FERTIL STERIL, V55, P759; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Levinson CJ., 1989, P 2 WORLD C GYN END; MAHMOOD TA, 1991, HUM REPROD, V6, P544, DOI 10.1093/oxfordjournals.humrep.a137377; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MATORRAS R, 1995, FERTIL STERIL, V63, P34, DOI 10.1016/S0015-0282(16)57293-8; NAPLES JD, 1981, OBSTET GYNECOL, V57, P509; NOWROOZI K, 1987, INT J FERTIL, V32, P442; OLIVE DL, 1993, NEW ENGL J MED, V328, P1759, DOI 10.1056/NEJM199306173282407; PAULSON JD, 1991, J REPROD MED, V36, P151; SEILER JC, 1986, FERTIL STERIL, V46, P1098; THOMAS EJ, 1995, INT J GYNECOL OBSTET, V48, P149, DOI 10.1016/0020-7292(94)02277-6; VERCELLINI P, 1993, J REPROD MED, V38, P49; WHEELER JM, 1983, FERTIL STERIL, V39, P656	26	617	656	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					217	222		10.1056/NEJM199707243370401	http://dx.doi.org/10.1056/NEJM199707243370401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227926				2022-12-28	WOS:A1997XL99400001
J	Embil, JM; Kramer, M; Kinnear, S; Light, RB				Embil, JM; Kramer, M; Kinnear, S; Light, RB			A blinding headache	LANCET			English	Article							PITUITARY APOPLEXY		UNIV MANITOBA,DEPT MED,DIV INFECT DIS,WINNIPEG,MB,CANADA; UNIV MANITOBA,DIV GEN INTERNAL MED,WINNIPEG,MB,CANADA; UNIV MANITOBA,DIV CRIT CARE,WINNIPEG,MB,CANADA	University of Manitoba; University of Manitoba; University of Manitoba								CARDOSO ER, 1984, NEUROSURGERY, V14, P363, DOI 10.1227/00006123-198403000-00021; JEFFERSON M, 1959, LANCET, V1, P342; LINDHOLM PB, 1986, ACTA NEUROL SCAND, V74, P304; REID RL, 1985, ARCH NEUROL-CHICAGO, V42, P712, DOI 10.1001/archneur.1985.04060070106028; REUTENS DC, 1990, AUST NZ J MED, V20, P590, DOI 10.1111/j.1445-5994.1990.tb01321.x	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					182	182		10.1016/S0140-6736(97)05112-X	http://dx.doi.org/10.1016/S0140-6736(97)05112-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250187				2022-12-28	WOS:A1997XL72200014
J	Girbes, ARJ; Zijlstra, JG				Girbes, ARJ; Zijlstra, JG			Ibopamine and survival in severe congestive heart failure: PRIME II	LANCET			English	Letter									UNIV GRONINGEN HOSP,DEPT MED,ICU,NL-9700 RB GRONINGEN,NETHERLANDS	University of Groningen	Girbes, ARJ (corresponding author), UNIV GRONINGEN HOSP,DEPT SURG,ICU,POB 30001,NL-9700 RB GRONINGEN,NETHERLANDS.		zijlstra, jan g/E-6782-2011	zijlstra, jan g/0000-0001-9079-0795				GIRBES ARJ, 1993, EUR HEART J, V14, P279, DOI 10.1093/eurheartj/14.2.279; GIRBES ARJ, 1993, HEART FAILURE CONDUC, P199; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Niebauer J, 1997, LANCET, V349, P966, DOI 10.1016/S0140-6736(97)22014-3; SALVADEO A, 1988, INT J CLIN PHARM TH, V26, P98	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					147	148		10.1016/S0140-6736(05)61858-2	http://dx.doi.org/10.1016/S0140-6736(05)61858-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228993	Bronze			2022-12-28	WOS:A1997XK11400062
J	Cheng, SH; Chiang, TL				Cheng, SH; Chiang, TL			The effect of universal health insurance on health care utilization in Taiwan - Results from a natural experiment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL-CARE; AMBULATORY CARE; SERVICES; ACCESS; DEMAND	Context.-The government of Taiwan introduced universal health insurance to cover all citizens in 1995. This national health insurance program was proposed to assure the accessibility to health care at reasonable cost. Evaluation of the consequences, including health care utilization and expenditure, is crucial for policy adjustment. Objectives.-To evaluate the effect of Taiwan's national health insurance on health care utilization. Design.-Cohort survey conducted before and after the implementation of the national health insurance program. Participants.-A total of 1021 randomly selected Taiwanese adults. Main Outcome Measures.-Physician visits in the 2 weeks prior to the survey and hospital admissions and emergency department visits in the immediate past year. Results.-After the introduction of universal health insurance, the newly insured consumed more than twice the amount of outpatient physician visits (0.21 vs 0.48, P<.05) and hospital admissions (0.04 vs 0.11, P<.05) than before universal health insurance was implemented, bringing them to the same amount of health care contacts as the previously insured group. The newly insured also experienced an insignificant increase in emergency department visits. In contrast, the previously insured group had a small but statistically significant increase in outpatient visits (0.48 vs 0.59, P<.05) and insignificant changes in hospital admissions and emergency department visits. Conclusion. The universal health insurance removed some barriers to health care for those newly insured. The co-payment design in the insurance scheme seemed to have an insignificant effect on curbing medical care utilization, Taiwanese health policy analysts should seriously consider the growth of health care expenditures since the implementation of universal health insurance.	NATL TAIWAN UNIV,COLL PUBL HLTH,CTR HLTH POLICY RES,TAIPEI 100,TAIWAN	National Taiwan University	Cheng, SH (corresponding author), NATL TAIWAN UNIV,GRAD INST PUBL HLTH,ROOM 1515,NO 1,SECT 1,JEN AI RD,TAIPEI 100,TAIWAN.			CHIANG, TUNG-LIANG/0000-0002-7876-3943				Aday L A, 1974, Health Serv Res, V9, P208; *BUR LAB INS, 1995, STAT DAT TAIW FUK AR, P372; *CENTR TRUST CHIN, 1995, STAT DAT GOV EMPL IN, P474; CHIANG TL, 1995, 1994 TAIWAN HLTH INT; CUNNINGHAM PJ, 1995, SOC SCI MED, V40, P393, DOI 10.1016/0277-9536(94)E0072-Z; DAVIS K, 1991, MILBANK Q, V69, P253, DOI 10.2307/3350204; *DEP BUDG ACC STAT, 1995, REP SURV FAM INC EXP; *DEP HLTH, 1996, STAT COMM DIS TAIW A; *DEP HLTH, 1995, HLTH VIT STAT, V1, P48; *DEP HLTH, 1996, HLTH VIT STAT, V1, P44; *DEP HLTH, 1997, 1 2 YEARS EV REP NAT, P102; *DIR GEN BUDG ACC, 1996, SOC IND TAIW AR REP, P46; ENTERLINE PE, 1973, NEW ENGL J MED, V288, P1152, DOI 10.1056/NEJM197305312882204; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; FRANK RG, 1986, HEALTH SERV RES, V21, P241; FREEMAN HE, 1993, HEALTH SERV RES, V28, P531; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HANH B, 1994, MED CARE, V32, P227; MANNING WG, 1987, AM ECON REV, V77, P251; Moore W J, 1992, Health Care Financ Rev, V14, P133; MULLER C, 1986, HEALTH SERV RES, V21, P129; PEABODY JW, 1995, JAMA-J AM MED ASSOC, V273, P777, DOI 10.1001/jama.273.10.777; *SAS I, 1988, SAS LANG GUID PERS C, P92; SAVER BG, 1993, AM J PUBLIC HEALTH, V83, P1583, DOI 10.2105/AJPH.83.11.1583; STEWART WH, 1961, NEW ENGL J MED, V265, P1187, DOI 10.1056/NEJM196112142652405; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; WU KS, 1996, HLTH INSURANCE, P177	27	234	239	1	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					89	93		10.1001/jama.278.2.89	http://dx.doi.org/10.1001/jama.278.2.89			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214512				2022-12-28	WOS:A1997XH66700002
J	Sherwood, T				Sherwood, T			Lancet ombudsman's first report	LANCET			English	Editorial Material																		Chalmers I, 1996, LANCET, V348, P410, DOI 10.1016/S0140-6736(05)65033-7; Horton R, 1996, LANCET, V348, P6, DOI 10.1016/S0140-6736(05)64352-8; Sharp D, 1997, LANCET, V349, P374, DOI 10.1016/S0140-6736(97)80007-4; Smith GD, 1996, LANCET, V348, P411, DOI 10.1016/S0140-6736(05)65034-9	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					4	5		10.1016/S0140-6736(05)66235-6	http://dx.doi.org/10.1016/S0140-6736(05)66235-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217711				2022-12-28	WOS:A1997XH86900005
J	MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A				MaierDobersberger, T; Ferenci, P; Polli, C; Balac, P; Dienes, HP; Kaserer, K; Datz, C; Vogel, W; Gangl, A			Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction	ANNALS OF INTERNAL MEDICINE			English	Article						hepatolenticular degeneration; polymerase chain reaction; mutation; linkage (genetics); copper	HEPATIC-FAILURE; DIAGNOSIS; GENE	Background: Most known mutations in the gene associated with Wilson disease are rare. Only the His1069Gln mutation is found often in patients of Northern or Eastern European origin. Objective: To examine the frequency of the His1069Gln mutation in Austrian patients with Wilson disease and their families by using a new, rapid polymerase chain reaction (PCR) test. Design: Cross-sectional study. Setting: University medical center. Patients: 83 patients from 72 families and 98 relatives of 11 homozygous index patients. Measurements: Results of a semi-nested PCR-based assay to detect the His1069Gln mutation in Wilson disease, clinical symptoms, and liver histologic findings. Results: 20 patients, including 5 siblings, were homozygous for the His1069Gln mutation. Thirty-three patients, including 4 siblings, were compound heterozygotes. The mutation was not detected in 30 patients, including 2 siblings. Homozygotes were older at onset of symptoms (mean age, 24 +/- 6 years) than compound heterozygotes (17 +/- 6 years [95% CI, 3.3 to 10.7 years]; P = 0.0135) and patients with other mutations (18 +/- 8 years [CI, 1.8 to 10.2 years]; P = 0.117). Homozygotes were more often female (73.3%) than were compound heterozygotes (48% [CI, 0.94% to 2.46%]) and patients with other mutations (50% [CI, 0.91% to 2.37%]) (P = 0.05). Four of 98 asymptomatic relatives of 11 homozygous index patients were also homozygotes. Heterozygosity was confirmed in 46 relatives (19 parents, 11 children, and 16 distant relatives). Conclusion: The His1069Gln mutation was detected in 61% of Austrian patients with Wilson disease. Polymerase chain reaction may be useful for diagnosis and screening of family members of homozygous index patients, even if first-degree relatives are not available for examination.	UNIV VIENNA, DEPT CLIN PATHOL, A-1090 VIENNA, AUSTRIA; UNIV SHEFFIELD, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND; UNIV COLOGNE, DEPT PATHOL, D-50931 COLOGNE, GERMANY; LKH SALZBURG, DEPT MED 1, A-5020 SALZBURG, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Sheffield; University of Cologne; University of Innsbruck	MaierDobersberger, T (corresponding author), UNIV VIENNA, DEPT INTERNAL MED 4, WAEHRINGER GUERTEL 18, A-1090 VIENNA, AUSTRIA.							BERMAN DH, 1991, GASTROENTEROLOGY, V100, P1129, DOI 10.1016/0016-5085(91)90294-U; CZLONKOWSKA A, 1995, Z GASTROENTEROL, V33, P475; DANKS DM, 1990, BRIT MED J, V301, P331, DOI 10.1136/bmj.301.6747.331; FARRER LA, 1991, NEUROLOGY, V41, P992, DOI 10.1212/WNL.41.7.992; FASSMANN H, 1986, MIGRATIONSSTROME INN, P22; FIGUS A, 1995, AM J HUM GENET, V57, P1318; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; HOUWEN RHJ, 1995, J MED GENET, V32, P480, DOI 10.1136/jmg.32.6.480; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; KASAI N, 1992, LAB ANIM SCI, V42, P363; KINGSTON HM, 1986, ANAL CHEM, V58, P2534, DOI 10.1021/ac00125a038; MAIERDOBERSBERGER T, 1995, GASTROENTEROLOGY, V109, P2015, DOI 10.1016/0016-5085(95)90771-8; MCCULLOUGH AJ, 1983, GASTROENTEROLOGY, V84, P161; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PROPST A, 1995, GASTROENTEROLOGY, V108, P885, DOI 10.1016/0016-5085(95)90465-4; ROSS ME, 1985, ANN NEUROL, V17, P411, DOI 10.1002/ana.410170421; Scheinberg IH, 1984, MAJOR PROBLEMS INTER, VXXIII; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; SCHILSKY ML, 1994, HEPATOLOGY, V19, P583, DOI 10.1002/hep.1840190307; STERNLIEB I, 1990, HEPATOLOGY, V12, P1234, DOI 10.1002/hep.1840120526; STRICKLAND GT, 1972, CLIN SCI, V43, P617, DOI 10.1042/cs0430617; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; THOMAS GR, 1995, AM J HUM GENET, V56, P1315; 1995, Z GASTROENTEROL, V33, P472	24	87	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					21	+		10.7326/0003-4819-127-1-199707010-00004	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214248				2022-12-28	WOS:A1997XG91400003
J	Taliani, G; Badolato, MC; Pasquazzi, C				Taliani, G; Badolato, MC; Pasquazzi, C			Hepatitis C virus genotype, hepatitis C virus RNA titers, and response to interferon	ANNALS OF INTERNAL MEDICINE			English	Letter											Taliani, G (corresponding author), UNIV ROMA LA SAPIENZA, PIAZZALE ALDO MORO 5, ROME, ITALY.							Halfon P, 1996, J HEPATOL, V25, P307, DOI 10.1016/S0168-8278(96)80116-4; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002	3	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					89	89		10.7326/0003-4819-127-1-199707010-00021	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00021			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214263				2022-12-28	WOS:A1997XG91400020
J	Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B				Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B			Reduction of concentration of HIV-1, in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED DISEASES; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; INFECTION; MEN; ASSOCIATION; THERAPY; SPREAD; MALAWI	Background transmission of HIV-1 is predominantly by heterosexual contact in sub-Saharan Africa, where sexually transmitted diseases (STDs) are also common. Epidemiological studies suggest that STDs facilitate transmission of HIV-1, but the biological mechanism remains unclear, We investigated the hypothesis that STDs increase the likelihood of transmission of HIV-1 through increased concentration of the virus in semen. Methods HIV-1 RNA concentrations were measured in seminal and blood plasma from 135 HIV-1-seropositive men in Malawi; 86 had urethritis and 49 controls did not have urethritis. Men with urethritis received antibiotic treatment according to the guidelines of the Malawian STD Advisory Committee. Samples were analysed at baseline and at week 1 and week 2 after antibiotic therapy in urethritis patients, and at baseline and week 2 in the control group. Findings HIV-1-seropositive men with urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seropositive men without urethritis (12.4 vs 1.51x10(4) copies/mL, p=0.035), despite similar CD4 counts and concentrations of blood plasma viral RNA. Gonorrhoea was associated with the greatest concentration of HIV-1 in semen (15.8x10(4) copies/mL). After the urethritis patients received antimicrobial therapy directed against STDs, the concentration of HIV-1 RNA in semen decreased significantly (from 12.4x10(4) copies/mL to 8.91x10(4) copies/mL at 1 week [p=0.03] and 4.12x10(4) copies/mL at 2 weeks [p=0.0001]). Blood plasma viral RNA concentrations did not change. There was no significant change in seminal plasma HIV-1 RNA concentrations during the 2-week period in the control group (p=0.421). These results suggest that urethritis increases the infectiousness of men with HIV-1 infection. HIV-1-control programmes, which include detection and treatment of STDs in patients already infected with HIV-1, may help to curb the epidemic. Targeting of gonococcal urethritis may be a particularly effective strategy.	UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,AIDSCAP,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; LILONGWE CENT HOSP,LILONGWE,MALAWI; JOHN SNOW INC,MALAWI SUPPORT AIDS & FAMILY HLTH PROJECT,BOSTON,MA; KANTONSSPITAL,DEPT MED,ST GALLEN,SWITZERLAND	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Cohen, MS (corresponding author), UNIV N CAROLINA,DEPT MED,CB 7030,547 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Royce, Rachel A/A-7964-2012		PHS HHS [UO31496, R0149381] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atkins MC, 1996, BRIT MED J, V313, P341, DOI 10.1136/bmj.313.7053.341; BEHETS FMT, 1995, J INFECT DIS, V171, P451, DOI 10.1093/infdis/171.2.451; Busch MP, 1996, J INFECT DIS, V174, P26, DOI 10.1093/infdis/174.1.26; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eron JJ, 1996, JAMA-J AM MED ASSOC, V275, P36, DOI 10.1001/jama.275.1.36; ERON JJ, 1997, 4 C RETR OPP INF WAS; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GILLIAM BL, IN PRESS J ACQUIR IM; GOBBERS E, 1996, 11 INT C AIDS VANC J; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HAIZLIP J, 1995, SEX TRANSM DIS, V22, P145, DOI 10.1097/00007435-199505000-00002; HO JL, 1995, J EXP MED, V181, P1493, DOI 10.1084/jem.181.4.1493; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kissinger P, 1996, J GEN INTERN MED, V11, P750, DOI 10.1007/BF02598989; KIVIAT NB, 1990, HUM PATHOL, V21, P831, DOI 10.1016/0046-8177(90)90052-7; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LULE G, 1994, GENITOURIN MED, V70, P384; MERSON MH, 1993, SCIENCE, V260, P1266, DOI 10.1126/science.8493570; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMSEY KH, 1995, J INFECT DIS, V172, P186, DOI 10.1093/infdis/172.1.186; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; SPECK CE, 1996, 11 INT C AIDS VANC; VERNAZZA P, IN PRESS AIDS; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	34	687	703	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1868	1873		10.1016/S0140-6736(97)02190-9	http://dx.doi.org/10.1016/S0140-6736(97)02190-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217758				2022-12-28	WOS:A1997XG41700009
J	Dunlop, MG				Dunlop, MG			Science, medicine, and the future - Colorectal cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RISK		WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Dunlop, MG (corresponding author), UNIV EDINBURGH, DEPT SURG, COLON CANC GENET GRP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				Anker P, 1997, GASTROENTEROLOGY, V112, P1114, DOI 10.1016/S0016-5085(97)70121-5; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Caruso M, 1996, P NATL ACAD SCI USA, V93, P11302, DOI 10.1073/pnas.93.21.11302; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; DUNLOP MG, 1992, BRIT J SURG, V79, P488, DOI 10.1002/bjs.1800790606; DUNLOP MG, IN PRESS BMJ; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; Huber BE, 1995, ADV DRUG DELIVER REV, V17, P279, DOI 10.1016/0169-409X(95)00062-C; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leach FS, 1996, CANCER RES, V56, P235; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; Vasen HFA, 1996, LANCET, V348, P433, DOI 10.1016/S0140-6736(96)01340-2	21	25	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1882	1885		10.1136/bmj.314.7098.1882	http://dx.doi.org/10.1136/bmj.314.7098.1882			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224134	Green Published			2022-12-28	WOS:A1997XH73800031
J	Kimber, JR; Watson, L; Mathias, CJ				Kimber, JR; Watson, L; Mathias, CJ			Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine	LANCET			English	Article							SECRETION; SOMATOSTATIN	Background Idiopathic Parkinson's disease is a common neurodegenerative disease that is difficult to distinguish from other parkinsonian syndromes such as multiple-system atrophy (MSA). In MSA, autonomic dysfunction is common and is associated with either parkinsonian or cerebellar features, or both. Differentiation of idiopathic Parkinson's disease from MSA is important because prognosis, complications, and response to therapy vary according to disorder. Our aim was to find out whether clonidine/growth hormone (GH) testing distinguishes idiopathic Parkinson's disease from MSA. Methods Clonidine is a centrally active alpha(2)-adrenoceptor agonist that raises concentrations of GH in serum in healthy people and those with pure autonomic failure (with peripheral lesions), but not in those with MSA (with a central autonomic deficit). We investigated the effects of clonidine on 14 people with idiopathic Parkinson's disease (without autonomic deficits), 31 people with MSA of the three different clinical forms (parkinsonian, cerebellar, and mixed), 19 people with pure autonomic failure, and 27 healthy participants. In nine people with parkinsonian MSA (MSA-P),the GH response to levodopa was also assessed. Findings Clonidine raised serum GH concentrations in patients with idiopathic Parkinson's disease (median increase 8.98 [IQR 6.6-16.6] mU/L), normal participants (13.2 [7.0-18.6] mU/L), and patients with pure autonomic failure (12.5 [5.6-18.2] mU/L). In those with MSA who had central autonomic failure, GH concentrations were unchanged (MSA-P; 0.41 [-0.30 to 2.09] mU/L and cerebellar MSA [MSA-C] 1.67 [0-4.49] mU/L). The GH response to clonidine in idiopathic Parkinson's disease was significantly different from that in MSA-P (p<0.0002). In MSA-P, the dopamine precursor levodopa raised GH concentrations (from mean 2.7 [SE 1.0] mU/L to mean 18.2 [6.0] mU/L, p<0.05) and GH-releasing hormone (GHRH) concentrations (from mean 20.6 [3.25] ng/L to mean 68.0 [10.6] ng/L, p<0.05), excluding dysfunction of pituitary somatotrophs or GHRH neurons as a cause for the absent GH response to clonidine in MSA. Interpretation The GH responses to clonidine clearly differentiated idiopathic Parkinson's disease from MSA-C and MSA-P. Together with the levodopa studies they indicated a specific alpha(2)-adrenoceptor-hypothalamic deficit in MSA. The clonidine-GH test may provide further insight into central neurotransmitter and alpha(2)-adrenoceptor-hypothalamic abnormalities in MSA.	ST MARYS HOSP,IMPERIAL COLL,SCH MED,DEPT MED,NEUROVASC MED UNIT,LONDON W2 1NY,ENGLAND; UNIV LONDON,NATL HOSP NEUROL & NEUROSURG,INST NEUROL,DEPT CLIN NEUROL,AUTON UNIT,LONDON,ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust								ALDAMLUJI S, 1993, BAILLIERE CLIN ENDOC, V7, P355, DOI 10.1016/S0950-351X(05)80180-6; BANNISTER R, 1988, AUTONOMIC FAILURE TX, P281; BLUETPAJOT MT, 1993, J PEDIATR ENDOCRINOL, V6, P357; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; CHIHARA K, 1986, J CLIN ENDOCR METAB, V62, P466, DOI 10.1210/jcem-62-3-466; COLISIMO C, 1995, ARCH NEUROL-CHICAGO, V52, P294; DAVIE CA, 1995, ANN NEUROL, V37, P204, DOI 10.1002/ana.410370211; EARDLEY I, 1989, BRIT J UROL, V64, P360, DOI 10.1111/j.1464-410X.1989.tb06043.x; ENJALBERT A, 1986, PSYCHONEUROENDOCRINO, V11, P155, DOI 10.1016/0306-4530(86)90050-8; Frohman L A, 1986, Methods Enzymol, V124, P371; Fulham M J, 1991, Clin Auton Res, V1, P27, DOI 10.1007/BF01826055; GALEADEBONO A, 1977, J NEUROL NEUROSUR PS, V40, P162, DOI 10.1136/jnnp.40.2.162; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; LIGHTMAN SL, 1992, AUTONOMIC FAILURE TX, P378; Mathias Christopher J., 1996, P1953; MATHIAS CJ, 1990, Q J MED, V75, P617; Mathias CJ, 1992, AUTONOMIC FAILURE TX, P255; MATHIAS CJ, 1974, NEURODEGENEERATIVE D, P743; MULLER EE, 1987, PHYSIOL REV, V67, P962, DOI 10.1152/physrev.1987.67.3.962; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P334; RUDOLPH CD, 1980, NEUROENDOCRINOLOGY, V31, P121, DOI 10.1159/000123062; SCHOENBERG BS, 1987, MOVEMENT DISORD, V2, P17; SILER TM, 1974, J CLIN ENDOCR METAB, V38, P742, DOI 10.1210/jcem-38-5-742; SOPWITH AM, 1985, CLIN ENDOCRINOL, V22, P337, DOI 10.1111/j.1365-2265.1985.tb03245.x; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; SPOKES EGS, 1979, J NEUROL SCI, V19, P275; THORNIADES TN, 1992, LANCET, V340, P263; 1996, CLIN AUTOM RES, V6, P125	29	91	94	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1877	1881		10.1016/S0140-6736(96)10168-9	http://dx.doi.org/10.1016/S0140-6736(96)10168-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217760				2022-12-28	WOS:A1997XG41700011
J	Harris, J				Harris, J			The injustice of compensation for victims of medical accidents	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool	Harris, J (corresponding author), UNIV MANCHESTER,INST MED LAW & BIOETH,MANCHESTER M13 9PL,LANCS,ENGLAND.							*BMA WORK PART NO, 1987, REP; Brazier M., 1993, COMPENSATION DAMAGE, P51; BRAZIER M, 1993, COMPENSATION DAMAGE, P75; Brazier M., 1992, MED PATIENTS LAW; Harris J., 1996, J CONT HLTH LAW POLI, V1, P100; Jones M.A., 1996, MED NEGLIGENCE; *NZ LAW COMM, 1988, PERS INJ PREV REC; OLDERTZ C, 1986, MED J, V52, P43	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1821	1823		10.1136/bmj.314.7097.1821	http://dx.doi.org/10.1136/bmj.314.7097.1821			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224089	Green Published			2022-12-28	WOS:A1997XG16600031
J	Taylor, DH; Leese, B				Taylor, DH; Leese, B			Recruitment, retention, and time commitment change of general practitioners in England and Wales, 1990-4: A retrospective study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To describe the recruitment and retention of general practitioners and changes in their time commitment from 1 October 1990 to 1 October 1994. Design: Retrospective analysis of yearly data. Setting: England and Wales. Subjects: General practitioners in unrestricted practice. Main outcome measures: Numbers of general practitioners moving into and out of general practice; proportion of general practitioners practising less than full time; proportion of general practitioners having unchanged time commitment over the study period; and proportion of general practitioners leaving general practice in 1991 who were subsequently practising in 1994. Results: Numbers of general practitioners entering general practice (1565 in 1990, 1400 in 1994) fell over the study period as did the numbers leaving general practice (1488 in 1990, 1115 in 1994). The net effect was an increase in both the total and full time equivalent general practitioners practising from 1 October 1990 (26 757 full time equivalents) to 1 October 1994 (27 063 full time equivalents). Numbers of general practitioners practising full time were decreasing whereas part time practice was increasing women were more likely to practise part time. 35.5% (43/121) of women practising full time and 17.8% (24/135) of men practising full time who left practice in 1991 were practising again in 1994. Conclusion: Simply using total numbers of general practitioners or net increase to describe workforce trends masks much movement in and out of general practice and between differing time commitments. Recruitment and retention issues need to be separated if reasonable policies are to be developed to assure the necessary general practitioner workforce for a primary care led NHS.	UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester								ANAKOR M, 1996, DOCTOR          0613, P53; ANDALO D, 1996, GP NEWS         0621, P36; BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; *BMA HLTH POL EC R, 1996, Q B, V11, P8; BOWE, 1996, DOCTOR          0613, P50; BOWER H, 1996, DOCTOR          0125, P1; *DEP HLTH, 1995, STAT GEN MED PRACT E; *DEP HLTH, 1996, CM3512; *DEP HLTH, 1996, CM3390; HASTINGS A, 1993, BRIT J GEN PRACT, V43, P47; *HMSO, 1996, 25 HMSO; JOHNSON N, 1996, MANCHASTER METR 0209, P10; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; MASHTA O, 1996, GP NEWS         0621, P19; MIHILL C, 1996, GUARDIAN        0222, P9; ODOWD A, 1996, PULSE           0615, P10; Olsen NDL, 1996, BRIT MED J, V312, P525, DOI 10.1136/bmj.312.7030.525; TURNER P, 1996, PULSE           0608, P3; [No title captured]; 1996, PULSE           0615, P8; 1996, PULSE           0615, P7; 1996, PULSE           0615, P3; 1996, DOCTOR          0613, P22; 1996, GP NEWS         0719, P2; 1996, BRIT MED J, V312, P514	25	25	25	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1806	1810		10.1136/bmj.314.7097.1806	http://dx.doi.org/10.1136/bmj.314.7097.1806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224085	Green Published			2022-12-28	WOS:A1997XG16600026
J	Marmot, MG; Bosma, H; Hemingway, H; Brunner, E; Stansfeld, S				Marmot, MG; Bosma, H; Hemingway, H; Brunner, E; Stansfeld, S			Contribution of job control and other risk factors to social variations in coronary heart disease incidence	LANCET			English	Article							CARDIOVASCULAR-DISEASE; ARTERY DISEASE; WHITEHALL-II; STRAIN; INEQUALITIES; MORTALITY; HEALTH; QUESTIONNAIRE; PREVALENCE; POPULATION	Background The first Whitehall Study showed an inverse social gradient in mortality from coronary heart disease (CHD) among British civil servants-namely, that there were higher rates in men of lower employment grade. About a quarter of this gradient could be attributed to coronary risk factors. We analysed 5-year CHD incidence rates from the Whitehall II study to assess the contribution to the social gradient of psychosocial work environment, social support, coronary risk factors, and physical height. Methods Data were collected in the first three phases of examination of men and women in the Whitehall II study. 7372 people were contacted on all three occasions. Mean length of follow-up was 5.3 years. Characteristics from the baseline, phase 1, questionnaire, and examination were related to newly reported CHD in people without CHD at baseline. Three self-reported CHD outcomes were examined: angina and chest pain from the Rose questionnaire, and doctor-diagnosed ischaemia. The contribution of different factors to the socioeconomic differences in incident CHD was assessed by adjustment of odds ratios. Findings Compared with men in the highest grade (adminstrators), men in the lowest grade (clerical and office-support staff) had an age-adjusted odds ratio of developing any new CHD of 1.50. The largest difference was for doctor-diagnosed ischaemia (odds ratio for the lowest compared with the highest grade 2.27). For women, the odds ratio in the lowest grade was 1.47 for any CHD. Of factors examined, the largest contribution to the socioeconomic gradient in CHD frequency was from low control at work. Height and standard coronary risk factors made smaller contributions. Adjustment for all these factors reduced the odds ratios for newly reported CHD in the lowest-grade from 1.5 to 0.95 in men, and from 1.47 to 1.07 in women. Interpretation Much of the inverse social gradient in CHD incidence can be attributed to differences in psychosocial work environment. Additional contributions were made by coronary risk factors-mainly smoking-and from factors that act early in life, as represented by physical height.			Marmot, MG (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, INT CTR HLTH & SOC, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Bosma, Hans/A-6184-2013; Brunner, Eric/H-2114-2011; Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019; Blewett, Verna L/A-5270-2012	Brunner, Eric/0000-0002-0595-4474; Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419; 	AHRQ HHS [5 RO1 HS06516] Funding Source: Medline; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 RO1 HL36310] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BJORNTORP P, 1991, J INTERN MED, V230, P195; BLACK D, 1988, INEQUALITIES HLTH; BOBAK M, 1996, DETERMINANTS EPIDEMI; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; DREVER F, 1996, POPUL TRENDS, V86, P15; Gunnell DJ, 1996, PUBLIC HEALTH, V110, P85, DOI 10.1016/S0033-3506(96)80052-7; HLATKY MA, 1995, CIRCULATION, V92, P327, DOI 10.1161/01.CIR.92.3.327; JOHNSON JV, 1989, SCAND J WORK ENV HEA, V15, P271, DOI 10.5271/sjweh.1852; Karasek R., 1990, HLTH WORK STRESS PRO; MACINTYRE S, 1986, SOC SCI MED, V23, P393, DOI 10.1016/0277-9536(86)90082-1; MARMOT M, 1988, INT J HEALTH SERV, V18, P659, DOI 10.2190/KTC1-N5LK-J1PM-9GRQ; MARMOT M, 1995, SOC HLTH; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; North FM, 1996, AM J PUBLIC HEALTH, V86, P332, DOI 10.2105/AJPH.86.3.332; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; Power C, 1996, BRIT MED J, V313, P449; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; Rose G, 1982, CARDIOVASCULAR SURVE; SAPOLSKY RM, 1987, ENDOCRINOLOGY, V121, P1605, DOI 10.1210/endo-121-5-1605; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; STANSFELD S, 1992, SOC SCI MED, V35, P1027, DOI 10.1016/0277-9536(92)90242-I; SUADICANI P, 1993, ATHEROSCLEROSIS, V101, P165, DOI 10.1016/0021-9150(93)90113-9; *VAR SUBGR CHIEF M, 1996, VAR HLTH WHAT CAN DE; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WILCOSKY T, 1987, AM J EPIDEMIOL, V125, P400, DOI 10.1093/oxfordjournals.aje.a114546	33	812	818	2	56	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					235	239		10.1016/S0140-6736(97)04244-X	http://dx.doi.org/10.1016/S0140-6736(97)04244-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242799				2022-12-28	WOS:A1997XM86600009
J	Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S				Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S			Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis	SCIENCE			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; CELL-DEATH; NEURAL CELLS; MUTATIONS; GENE; DEGENERATION; DISEASE; MICE; SUPEROXIDE-DISMUTASE-1; OVEREXPRESSION	Mutations in the gene encoding copper/zinc superoxide dismutase enzyme produce an animal model of familial amyotrophic lateral sclerosis (FALS), a fatal disorder characterized by paralysis. Overexpression of the proto-oncogene bcl-2 delayed onset of motor neuron disease and prolonged survival in transgenic mice expressing the FALS-linked mutation in which glycine is substituted by alanine at position 93. it did not, however, alter the duration of the disease. Overexpression of bcl-2 also attenuated the magnitude of spinal cord motor neuron degeneration in the FALS-transgenic mice.	COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; HOP CANTONAL UNIV GENEVA,DIV NEUROPSYCHIAT,CH-1225 GENEVA,SWITZERLAND	Columbia University; University of Geneva					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001724] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01724] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; COSLULICH SC, 1996, CURR BIOL, V6, P997; deBilbao F, 1996, NEUROREPORT, V7, P3051, DOI 10.1097/00001756-199611250-00051; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P2459; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; GURNEY ME, UNPUB; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mena MA, 1997, J NEUROCHEM, V69, P21; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Miller Robert G., 1997, Neurology, V48, pS28; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1996, ANN NEUROL, V39, P158, DOI 10.1002/ana.410390204; Przedborski S, 1996, NEURODEGENERATION, V5, P57; Przedborski S, 1996, J NEUROCHEM, V67, P1383; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1995, ADV NEUROL, V68, P7; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, J NEUROSCI, V16, P5654; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; VIRGO L, 1995, BRAIN RES, V676, P196, DOI 10.1016/0006-8993(95)00052-R; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	46	390	397	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					559	562		10.1126/science.277.5325.559	http://dx.doi.org/10.1126/science.277.5325.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228005				2022-12-28	WOS:A1997XM86700050
J	Pan, DJ; Rubin, GM				Pan, DJ; Rubin, GM			Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis	CELL			English	Article							XENOPUS-EMBRYOS; GENE-EXPRESSION; CELL FATE; PROTEIN; MELANOGASTER; SPECIFICITY; DISINTEGRIN; PHENOTYPES; HOMOLOG; FUSION	Notch and the disintegrin metalloprotease encoded by the kuzbanian (kuz) gene are both required for a lateral inhibition process during Drosophila neurogenesis. We show that a mutant KUZ protein lacking protease activity acts as a dominant-negative form in Drosophila. Expression of such a dominant-negative KUZ protein can perturb lateral inhibition in Xenopus, leading to the overproduction of primary neurons. This suggests an evolutionarily conserved role for KUZ. The Notch family of receptors are known to be processed into smaller forms under normal physiological conditions. We provide genetic and biochemical evidence that Notch is an in vivo substrate for the KUZ protease, and that this cleavage may be part of the normal biosynthesis of functional Notch proteins.			Pan, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1994, MECH DEVELOP, V48, P35, DOI 10.1016/0925-4773(94)90004-3; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Karim FD, 1996, GENETICS, V143, P315; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wolff Tanya, 1993, P1277; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	36	434	452	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					271	280		10.1016/S0092-8674(00)80335-9	http://dx.doi.org/10.1016/S0092-8674(00)80335-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244301	Bronze			2022-12-28	WOS:A1997XN24900011
J	Netzer, WJ; Hartl, FU				Netzer, WJ; Hartl, FU			Recombination of protein domains facilitated by co-translational folding in eukaryotes	NATURE			English	Article							ESCHERICHIA-COLI; EXON THEORY; IN-VIVO; EXPRESSION; BINDING; CHAPERONIN; COMPLEX; CHAINS; GENES; GROEL	The evolution of complex genomes requires that new combinations of pre-existing protein domains successfully fold into modular polypeptides. During eukaryotic translation model two-domain polypeptides fold efficiently by sequential and co-translational folding of their domains. In contrast, folding of the same proteins in Escherichia coli is post-translational, and leads to intramolecular misfolding of concurrently folding domains. Sequential domain folding in eukaryotes may have been critical in the evolution of modular polypeptides, by increasing the probability that random gene-fusion events resulted in immediately foldable protein structures.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Max Planck Society			Hartl, F. Ulrich/Y-8206-2019					Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bremer H, 1996, ESCHERICHIA COLI SAL; CAMEAU DE, 1985, J BACTERIOL, V164, P578; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GESTELAND RF, 1966, J MOL BIOL, V18, P356, DOI 10.1016/S0022-2836(66)80253-X; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAWKINS AR, 1995, EUR J BIOCHEM, V232, P7, DOI 10.1111/j.1432-1033.1995.tb20775.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAVALLIE ER, 1995, CURR OPIN BIOTECH, V6, P501, DOI 10.1016/0958-1669(95)80083-2; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; SHARROCKS AD, 1994, GENE, V138, P105, DOI 10.1016/0378-1119(94)90789-7; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U	39	329	339	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					343	349		10.1038/41024	http://dx.doi.org/10.1038/41024			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237751	Bronze			2022-12-28	WOS:A1997XM52800040
J	Berlin, JA				Berlin, JA			Does blinding of readers affect the results of meta-analyses?	LANCET			English	Article									UNIV PENN,SCH MED,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	Berlin, JA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA 19104, USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007728] Funding Source: NIH RePORTER; AHRQ HHS [1-RO1-HS-07728] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERLIN JA, ONLINE J CURR CLIN T; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806	2	342	345	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					185	186		10.1016/S0140-6736(05)62352-5	http://dx.doi.org/10.1016/S0140-6736(05)62352-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250191	hybrid			2022-12-28	WOS:A1997XL72200018
J	Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ				Loftus, SK; Morris, JA; Carstea, ED; Gu, JZ; Cummings, C; Brown, A; Ellison, J; Ohno, K; Rosenfeld, MA; Tagle, DA; Pentchev, PG; Pavan, WJ			Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene	SCIENCE			English	Article							MOUSE; ACCUMULATION; LOCALIZATION; DEGRADATION; REDUCTASE; DOMAIN; MOTIF	An integrated human-mouse positional candidate approach was used to identify the gene responsible for the phenotypes observed in a mouse model of Niemann-Pick type C (NP-C) disease. The predicted murine NPC1 protein has sequence homology to the putative transmembrane domains of the Hedgehog signaling molecule Patched, to the cholesterol-sensing regions of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and SREBP cleavage-activating protein (SCAP), and to the NPC1 orthologs identified in human, the nematode Caenorhabditis elegans, and the yeast Saccharomyces cerevisiae. The mouse model may provide an important resource for studying the role of NPC1 in cholesterol homeostasis and neurodegeneration and for assessing the efficacy of new drugs for NP-C disease.	NIH, NATL HUMAN GENOME RES INST, LAB GENET DIS RES, BETHESDA, MD 20892 USA; NINCDS, NATL HUMAN GENOME RES INST, NIH, BETHESDA, MD 20892 USA; NINCDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; TOTTORI UNIV, FAC MED, SCH LIFE SCI, YONAGO, TOTTORI 683, JAPAN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Tottori University				Pavan, William/0000-0001-8281-5120; Loftus, Stacie/0000-0002-1958-4689				Akaboshi S, 1997, HUM GENET, V99, P350, DOI 10.1007/s004390050370; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; COXEY RA, 1993, J LIPID RES, V34, P1165; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Erickson RP, 1997, MAMM GENOME, V8, P355, DOI 10.1007/s003359900440; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; HEILEIN UAO, 1986, NUCLEIC ACIDS RES, V14, P6403; Herz J, 1997, NAT GENET, V15, P123, DOI 10.1038/ng0297-123; HIGASHI Y, 1991, INT CONGR SER, V962, P85; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; KELLY RG, 1994, GENOMICS, V24, P509, DOI 10.1006/geno.1994.1660; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYAWAKI S, 1982, J HERED, V73, P257, DOI 10.1093/oxfordjournals.jhered.a109635; MORRIS C, 1982, AM J PATHOL, V140, P140; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OGATA S, 1994, J BIOL CHEM, V269, P5210; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Pentchev Peter G., 1994, Trends in Cell Biology, V4, P365, DOI 10.1016/0962-8924(94)90086-8; PENTCHEV PG, 1977, BIOCHIM BIOPHYS ACTA, V488, P312, DOI 10.1016/0005-2760(77)90189-8; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SAKAI Y, 1991, BIOCHEM GENET, V29, P103, DOI 10.1007/BF00578243; Salen G, 1996, J LIPID RES, V37, P1169; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yamamoto Toshiharu, 1994, No To Hattatsu, V26, P318	41	672	706	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					232	235		10.1126/science.277.5323.232	http://dx.doi.org/10.1126/science.277.5323.232			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211850				2022-12-28	WOS:A1997XK41800043
J	Buchanan, JAG; Morris, A; Fortune, F				Buchanan, JAG; Morris, A; Fortune, F			A mechanic who coughed up blood for 15 months	LANCET			English	Article							BEHCETS		UNITED MED & DENT SCH,GUYS HOSP,UNIT MED RELAT ORAL DIS,LONDON SE1 9RT,ENGLAND; BUCKLAND HOSP,DOVER,KENT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								HAMURYNDAN V, 1994, BR J RHEUMATOL, V3, P48; Hasan A, 1996, LANCET, V347, P789, DOI 10.1016/S0140-6736(96)90868-5; International Study Group for Behcet's disease, 1990, LANCET, V335, pP1078; OZARMAGAN G, 1991, ACTA DERM-VENEREOL, V71, P75; RAZ I, 1989, CHEST, V95, P585, DOI 10.1378/chest.95.3.585	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					28	28		10.1016/S0140-6736(97)05077-0	http://dx.doi.org/10.1016/S0140-6736(97)05077-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217717				2022-12-28	WOS:A1997XH86900013
J	Everett, C				Everett, C			Incidence and outcome of bleeding before the 20th week of pregnancy: Prospective study from general practice	BRITISH MEDICAL JOURNAL			English	Article							SPONTANEOUS-ABORTION	Objective: To estimate the miscarriage rate in a cohort of pregnant women and the final outcome of pregnancy. Design: Two year prospective community study. Setting: Women registered with four semirural practices at one health centre. Subjects: 626 pregnant women from a population 21 448. 5140 of whom were women aged 15-44 years. Main outcome measures: Vaginal bleeding and outcome of pregnancy. Results: 76 of the 89 women with an unwanted pregnancy requested a termination. In the 550 ongoing pregnancies bleeding occurred before the 20th week in 117 (21%), and 67 (12%) ended in miscarriage. The risk of miscarriage was not significantly increased after a miscarriage in the previous pregnancy (11 (15%) women had miscarriage v 55 (12%) women who had not had miscarriage who had previously had a live birth). Of the 117 women with bleeding, 64 were not admitted to hospital by the general practitioner; 42 of these women had an ultrasound examination at the heatlh centre and 19 subsequently miscarried at home. In hospital 41 of 46 women who miscarried had evacuation of the uterus. Conclusions: Bleeding occurred in one fifth of recognised pregnancies before the 20th week and over half of these miscarried. Treatment of women with miscarriage at home means current statistics on miscarriage in Britain are missing many cases.	CHURCH COTTAGE,ALTON GU34 4HD,HANTS,ENGLAND		Everett, C (corresponding author), ALTON HLTH CTR,ALTON GU34 2QX,HANTS,ENGLAND.							COHENOVERBEEK TE, 1990, LANCET, V336, P27, DOI 10.1016/0140-6736(90)91528-I; *DEP HLTH, 1993, STAT PUBL HLTH; Everett CB, 1996, BRIT J GEN PRACT, V46, P7; EVERETT CB, 1988, BRIT MED J, V295, P583; FRENCH FE, 1962, PUBLIC HEALTH REP, V77, P835, DOI 10.2307/4591645; *HOSP EP STAT HES, 1994, HOSP EP STAT HES FIN; Huisjes H. J., 1984, SPONTANEOUS ABORTION, P6; James WH, 1996, HUM REPROD, V11, P2333; KNUDSEN UB, 1991, EUR J OBSTET GYN R B, V39, P31, DOI 10.1016/0028-2243(91)90138-B; NAYLOR AF, 1979, FERTIL STERIL, V31, P282; Oakley Ann, 1984, MISCARRIAGE; *OFF POP CENS SURV, 1995, POP TRENDS, P79; RAI R, 1994, DIPLOMATE, V1, P269; REGAN L, 1989, BRIT MED J, V299, P541, DOI 10.1136/bmj.299.6698.541; REGAN L, 1991, BMJ-BRIT MED J, V302, P543, DOI 10.1136/bmj.302.6776.543; Stabile I., 1992, SPONTANEOUS ABORTION; WEINBERG CR, 1994, ANN NY ACAD SCI, V709, P280, DOI 10.1111/j.1749-6632.1994.tb30416.x; WHITTAKER PG, 1983, LANCET, V1, P1126; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	19	217	226	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					32	34		10.1136/bmj.315.7099.32	http://dx.doi.org/10.1136/bmj.315.7099.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233324	Green Published			2022-12-28	WOS:A1997XJ94700027
J	Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A				Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A			Retinopathy of prematurity in middle-income countries	LANCET			English	Article							CHILDHOOD BLINDNESS; VISUAL IMPAIRMENT; CHILDREN; SCHOOL; EPIDEMIOLOGY; INDIA; BIRTH	Background In the 1940s and 1950s retinopathy of prematurity (ROP) was the single commonest cause of blindness in children in many industrialised countries; it now accounts for only 6-18% of blindness registrations. It is not known what proportion of blindness is due to ROP in countries that do not have blindness registers. Information on blindness in children in these countries can be obtained by examining children in schools for the blind. Methods Between 1991 and 1996, 4121 children in 23 countries with a visual acuity in the better eye of less than 6/60 were examined with a standard method. Findings The proportion of severe visual impairment or blindness due to ROP ranged from 0% in most African countries to 38.6% in Cuba. Interpretation These data suggest that ROP is becoming a major cause of potentially preventable blindness among children in middle-income countries that have introduced neonatal intensive-care services for preterm and low-birthweight babies.	INST CHILD HLTH,DEPT EPIDEMIOL,LONDON,ENGLAND; MOORFIELDS EYE HOSP,LONDON,ENGLAND	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Gilbert, C (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436; Rahi, Jugnoo/0000-0002-5718-9209				Adekeye M., 1996, THESIS I OPHTHALMOLO; BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; *CRYOTH RET PREM C, 1996, ARCH OPHTHALMOL-CHIC, V114, P417; CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2; Czeizel A, 1991, Acta Paediatr Hung, V31, P365; DARLOW BA, 1988, ARCH DIS CHILD, V63, P1083, DOI 10.1136/adc.63.9.1083; DOYLE LW, 1995, MED J AUSTRALIA, V163, P11, DOI 10.5694/j.1326-5377.1995.tb126079.x; ECKSTEIN MB, 1995, BRIT J OPHTHALMOL, V79, P633, DOI 10.1136/bjo.79.7.633; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Fielder AR, 1997, CLIN RISK, V3, P47; FLYNN JT, 1995, PEDIATRICS, V95, P755; GILBERT C, 1993, INT OPHTHALMOL, V17, P229, DOI 10.1007/BF01007745; GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485; GILBERT C, IN PRESS OPHTHAL EPI; Gilbert C E, 1995, Ophthalmic Epidemiol, V2, P77, DOI 10.3109/09286589509057086; GILBERT CE, 1993, EYE, V7, P184, DOI 10.1038/eye.1993.39; GILBERT CE, 1994, DEV MED CHILD NEUROL, V36, P334; GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425; HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MASOOD SS, 1995, THESIS I OPHTHALMOLO; NG YK, 1988, LANCET, V2, P1235; OSULLIVAN J, IN PRESS S AFR MED J; RAHI JS, 1995, EYE, V9, P545, DOI 10.1038/eye.1995.137; SAUNDERS RA, 1995, J PEDIATR OPHTHALMOL, V32, P302; Sorsby A., 1966, REPORTS PUBLIC HLTH, V114; TSUKAHARA S, 1985, JPN J OPHTHALMOL, V29, P315; *UK DEP HLTH, 1991, STAT B UK DEP HLTH, V3; VANDERPOL BAE, 1986, DOC OPHTHALMOL, V61, P223, DOI 10.1007/BF00142346	29	294	330	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					12	14		10.1016/S0140-6736(97)01107-0	http://dx.doi.org/10.1016/S0140-6736(97)01107-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217713				2022-12-28	WOS:A1997XH86900009
J	Salvarani, C; Macchioni, P; Boiardi, L				Salvarani, C; Macchioni, P; Boiardi, L			Polymyalgia rheumatica	LANCET			English	Article							GIANT-CELL ARTERITIS; ERYTHROCYTE SEDIMENTATION-RATE; C-REACTIVE PROTEIN; CORTICOSTEROID TREATMENT; TEMPORAL ARTERITIS; OLMSTED COUNTY; LONG; SYNOVITIS; DISEASE; EPIDEMIOLOGY				Salvarani, C (corresponding author), AZIENDA OSPEDALLERA,SERV REUMATOL,ARCISPEDALE S MARIA NUOVA,V UMBERTO 1 N50,I-42100 REGGIO EMILIA,ITALY.		Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133				AHMED T, 1978, ARTHRITIS RHEUM, V21, P221, DOI 10.1002/art.1780210207; ANDERSSON R, 1986, ACTA MED SCAND, V220, P465; ARNOLD MH, 1993, CLIN EXP RHEUMATOL, V11, P629; AYOUB WT, 1985, AM J MED, V79, P309, DOI 10.1016/0002-9343(85)90309-2; BAGRATUNI L, 1963, Br Med J, V1, P513; BARBER HS, 1957, ANN RHEUM DIS, V16, P230, DOI 10.1136/ard.16.2.230; BEHN AR, 1983, ANN RHEUM DIS, V42, P374, DOI 10.1136/ard.42.4.374; BIRD HA, 1979, ANN RHEUM DIS, V38, P434, DOI 10.1136/ard.38.5.434; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; Boiardi L, 1996, BRIT J RHEUMATOL, V35, P642; Bruce W, 1888, Br Med J, V2, P811; CHOU CT, 1984, ARTHRITIS RHEUM-US, V27, P1107, DOI 10.1002/art.1780271005; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; CIMMINO MA, 1993, CLIN EXP RHEUMATOL, V11, P309; DASGUPTA B, 1987, ANN RHEUM DIS, V46, P746, DOI 10.1136/ard.46.10.746; DOUGLAS WAC, 1983, ANN RHEUM DIS, V42, P311, DOI 10.1136/ard.42.3.311; Elling P, 1996, J RHEUMATOL, V23, P112; Ferraccioli G, 1996, J RHEUMATOL, V23, P624; FRANZEN P, 1992, J RHEUMATOL, V19, P273; GABRIEL SE, IN PRESS ARTHRITIS R; GonzalezGay MA, 1997, ARCH INTERN MED, V157, P317, DOI 10.1001/archinte.157.3.317; HAGA HJ, 1993, J RHEUMATOL, V20, P1335; Haworth S, 1996, BRIT J RHEUMATOL, V35, P632; HEALEY LA, 1984, SEMIN ARTHRITIS RHEU, V13, P322, DOI 10.1016/0049-0172(84)90012-X; Helfgott SM, 1996, ARTHRITIS RHEUM, V39, P304, DOI 10.1002/art.1780390220; HUNDER G G, 1978, Bulletin on the Rheumatic Diseases, V29, P980; Johansen M, 1995, CLIN EXP RHEUMATOL, V13, P745; KYLE V, 1989, ANN RHEUM DIS, V48, P667, DOI 10.1136/ard.48.8.667; KYLE V, 1990, BRIT MED J, V300, P344, DOI 10.1136/bmj.300.6721.344; LIANG GC, 1974, ARTHRITIS RHEUM, V17, P19, DOI 10.1002/art.1780170105; MACCHIONI P, 1994, J RHEUMATOL, V21, P1860; MCCARTY DJ, 1985, JAMA-J AM MED ASSOC, V254, P2763, DOI 10.1001/jama.254.19.2763; Meliconi R, 1997, CLIN EXP IMMUNOL, V107, P494, DOI 10.1046/j.1365-2249.1997.d01-946.x; Meliconi R, 1996, ARTHRITIS RHEUM-US, V39, P1199, DOI 10.1002/art.1780390719; NOLTORP S, 1991, CLIN EXP RHEUMATOL, V9, P351; ODUFFY JD, 1976, MAYO CLIN PROC, V51, P519; Olivieri I, 1997, J RHEUMATOL, V24, P249; OLIVIERI I, IN PRESS CLIN EXP RH; POUNTAIN GD, 1994, BRIT J RHEUMATOL, V33, P550; RICHARDSON JE, 1987, ARTHRITIS RHEUM, V30, P1293, DOI 10.1002/art.1780301113; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; SALVARANI C, 1994, ARTHRITIS RHEUM, V37, P1621, DOI 10.1002/art.1780371111; SALVARANI C, 1992, J RHEUMATOL, V19, P1100; SALVARANI C, 1995, ARTHRITIS RHEUM, V38, P369, DOI 10.1002/art.1780380311; Salvarani C, 1996, LANCET, V348, P550, DOI 10.1016/S0140-6736(05)64714-9; SALVARANI C, 1987, CLIN EXP RHEUMATOL, V5, P205; Salvarani C, 1996, ARTHRITIS RHEUM, V39, P73, DOI 10.1002/art.1780390110; SALVARANI C, 1994, J RHEUMATOL, V21, P1865; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SALVARANI C, 1995, ANN RHEUM DIS, V54, P640, DOI 10.1136/ard.54.8.640; SALVARANI C, IN PRESS ANN INTERN; SCHAUFELBERGER C, 1995, BRIT J RHEUMATOL, V34, P261; SCHWARTZBERG M, 1995, BRIT J RHEUMATOL, V34, P392; SILVA M, 1986, ANN RHEUM DIS, V45, P136; vanderVeen MJ, 1996, ANN RHEUM DIS, V55, P218, DOI 10.1136/ard.55.4.218; WAGNER AD, 1994, J CLIN INVEST, V94, P1134, DOI 10.1172/JCI117428; Weyand CM, 1996, J CLIN INVEST, V98, P1642, DOI 10.1172/JCI118959; WEYAND CM, 1994, ANN INTERN MED, V121, P484, DOI 10.7326/0003-4819-121-7-199410010-00003; WEYAND CM, 1995, RHEUM DIS CLIN N AM, V21, P1027	60	63	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					43	47		10.1016/S0140-6736(97)05001-0	http://dx.doi.org/10.1016/S0140-6736(97)05001-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217726				2022-12-28	WOS:A1997XH86900042
J	Shiff, SJ; Rigas, B				Shiff, SJ; Rigas, B			Colon adenomatous polyps - Do they grow inward?	LANCET			English	Editorial Material							CELL				Shiff, SJ (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; Itzkowitz SH, 1993, GASTROINTESTINAL DIS, P1402; LIGHTDALE C, 1982, CANCER RES, V42, P4280; LIPKIN M, 1992, J CELL BIOCHEM, P1; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	1997	349	9069					1853	1854		10.1016/S0140-6736(05)63870-6	http://dx.doi.org/10.1016/S0140-6736(05)63870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217752				2022-12-28	WOS:A1997XG41700003
J	Hebert, PR; Gaziano, JM; Chan, KS; Hennekens, CH				Hebert, PR; Gaziano, JM; Chan, KS; Hennekens, CH			Cholesterol lowering with statin drugs, risk of stroke, and total mortality - An overview of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; EXPANDED CLINICAL-EVALUATION; COA REDUCTASE INHIBITOR; SERUM-CHOLESTEROL; LOVASTATIN EXCEL; HEART-DISEASE; MODERATE HYPERCHOLESTEROLEMIA; CAROTID ATHEROSCLEROSIS; PATIENT CHARACTERISTICS; MYOCARDIAL-INFARCTION	Objective.-To examine whether cholesterol lowering with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin drugs) reduces the risks of stroke and total mortality. Data Sources.-We conducted a computerized literature search from 1985 through 1995 to identify all published trials testing statin drugs. The Cholesterol and Recurrent Events (CARE) data were added after the report was published in October 1996. Our search was limited to English-language articles and included published overviews containing relevant individual trials. Trial Selection.-Criteria for inclusion of randomized trials in the overview were (1) statin drugs alone used to reduce lipid levels rather than multifactorial interventions including another type of cholesterol-lowering drug and (2) inclusion of data on deaths and/or strokes. Data Extraction.-Data were extracted by 2 researchers, and only minor discrepancies, which were easily resolved by discussion, occurred. Principal investigators of the trials and their funding agencies were also contacted to secure any relevant data not included in the published reports. Data Synthesis.-A total of 16 individual trials including approximately 29 000 subjects treated and followed up an average of 3.3 years were included in the overview. The average reductions in total and low-density lipoprotein cholesterol achieved were large-22% and 30%, respectively. A total of 454 strokes (fatal plus nonfatal) and 1175 deaths occurred. Those assigned to statin drugs experienced significant reductions in risks of stroke of 29% (95% confidence interval [CI], 14%-41%) as well as total mortality of 22% (95% CI, 12%-31%), which was attributable to a significant reduction in cardiovascular disease (CVD) deaths of 28% (95% CI, 16%-37%), There was no evidence of any increased risk in non-CVD mortality (relative risk [RR], 0.93; 95% CI, 0.75-1.14), There was also no significant increase in risk of cancer (RR, 1.03; 95% CI, 0.90-1.17). Conclusion.-This overview of all published randomized trials of statin drugs demonstrates large reductions in cholesterol and clear evidence of benefit on stroke and total mortality. There was, as expected, a large and significant decrease in CVD mortality, but there was no significant evidence for any increases in either non-CVD deaths or cancer incidence.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, VET AFFAIRS MED CTR, DEPT MED, BROCKTON, MA 02401 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; [Anonymous], 1993, Am J Cardiol, V72, P1031; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADFORD RH, 1990, AM J CARDIOL, V66, pB44, DOI 10.1016/0002-9149(90)90440-C; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; CROUSE JR, 1992, CONTROL CLIN TRIALS, V13, P495, DOI 10.1016/0197-2456(92)90206-F; Dalen JE, 1996, JAMA-J AM MED ASSOC, V275, P67, DOI 10.1001/jama.275.1.67; DUMONT JM, 1993, CONTROL CLIN TRIALS, V14, P209, DOI 10.1016/0197-2456(93)90004-W; FURBERG CD, 1994, AM J CARDIOL, V73, P1133, DOI 10.1016/0002-9149(94)90297-6; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Gaziano JM, 1996, ANN INTERN MED, V124, P914, DOI 10.7326/0003-4819-124-10-199605150-00009; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HEBERT PR, 1995, ARCH INTERN MED, V155, P50, DOI 10.1001/archinte.155.1.50; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HOLME I, 1995, AM J CARDIOL, V76, pC10, DOI 10.1016/S0002-9149(99)80465-2; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JONES PH, 1991, CLIN CARDIOL, V14, P146, DOI 10.1002/clc.4960140211; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LORD I, 1992, J CLIN EPIDEMIOL, V45, P849, DOI 10.1016/0895-4356(92)90068-X; MAAS INV, 1994, LANCET, V344, P633; MANTEL N, 1959, J NATL CANCER I, V22, P719; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1985, CIRCULATION, V72, P451; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Qizilbash N, 1995, LANCET, V346, P1647; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; ROSSOUW JE, 1995, AM J CARDIOL, V76, pC86, DOI 10.1016/S0002-9149(99)80476-7; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SHEAR CL, 1992, CIRCULATION, V85, P1293, DOI 10.1161/01.CIR.85.4.1293; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; TONKIN A, 1995, AM J CARDIOL, V76, P474; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CONTROL CLIN TRIALS, V14, P45, DOI 10.1016/0197-2456(93)90049-J; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; Wolf P A, 1983, Neurol Clin, V1, P317; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1996, CONSUMER REP     MAR, P36	54	658	676	1	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					313	321		10.1001/jama.278.4.313	http://dx.doi.org/10.1001/jama.278.4.313			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228438				2022-12-28	WOS:A1997XL05900033
J	Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV				Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV			Nerve ingrowth into diseased intervertebral disc in chronic back pain	LANCET			English	Article							SUBSTANCE-P; INNERVATION; FIBERS; RAT	Background In the healthy back only the outer third of the annulus fibrosus of the intervertebral disc is innervated. Nerve ingrowth deeper into diseased intervertebral disc has been reported, but how common this feature is and whether it is associated with chronic pain are unknown. We examined nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain. Methods We collected 46 samples of intervertebral discs from 38 patients during spinal fusion for chronic back pain. 30 samples were from pain levels clinically established by discography and 16 samples were from adjacent vertebral levels with no pain. We obtained 34 control samples of intervertebral disc from previously healthy individuals with normal histology within 8 h of recorded death. We used standard immunohistochemical techniques to test for a general nerve marker, a nociceptive neurotransmitter (substance P), and a protein expressed during axonogenesis (growth-associated protein 43 [GAP43]). Findings We identified nerve fibres in the outer third of the annulus fibrosus in 48 (60%) of the 80 samples of intervertebral discs. Nerves were restricted to the outer or middle third of the annulus fibrosus in the 34 control samples. Among the patients with chronic low back pain, nerves extended into the inner third of the annulus fibrosus and into the nucleus pulposus in 21 (46%) and ten (22%) samples, respectively. Nerves usually accompanied blood vessels, but in 14 of the samples from back-pain patients, isolated nerve fibres were seen in the discal matrix. Both types of nerve fibres expressed substance P, but only non-vessel-associated fibres expressed GAP43, Deep nerve ingrowth into the inner third of the annulus fibrosus, the nucleus pulposus, or both was seen in four (25%) of 16 biopsy samples from non-pain levels and in 17 (57%) samples from pain levels. Of the 16 paired samples from both pain and non-pain levels, five pain-level samples and one non-pain-level sample showed deep nerve ingrowth. Interpretation Our finding of isolated nerve fibres that express substance P deep within diseased intervertebral discs and their association with pain suggests an important role for nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain.	UNIV MANCHESTER, DEPT PATHOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; CTR HOSP UNIV, TOURS, FRANCE; LONDON CLIN, LONDON, ENGLAND	University of Manchester; CHU Tours; University of London; University College London	Freemont, AJ (corresponding author), UNIV MANCHESTER, DEPT RHEUMATOL, MANCHESTER M13 9PT, LANCS, ENGLAND.		Freemont, Tony J/A-9000-2015; Hoyland, Judith A/P-5168-2014	Freemont, Tony J/0000-0002-9780-208X; Hoyland, Judith A/0000-0003-4876-5208				AHMED M, 1993, SPINE, V18, P268, DOI 10.1097/00007632-199302000-00016; AHMED M, 1991, NEURO ORTHOP, V12, P19; ASHTON IK, 1994, ACTA ORTHOP SCAND, V65, P635, DOI 10.3109/17453679408994620; ASHTON IK, 1994, J ORTHOP RES, V12, P186, DOI 10.1002/jor.1100120206; BOGDUK N, 1981, J ANAT, V132, P39; COLLINS DH, 1949, PATHOLOGY ARTICULAR, P256; COPPES MH, 1990, LANCET, V336, P189, DOI 10.1016/0140-6736(90)91723-N; DAVIS DV, 1967, GRAYS ANATOMY DESCRI, P498; FAIRBANK JCT, 1996, INT SOC BACK PAIN RE, P86; GARDNER DL, 1992, PATHOLOGICAL BASIS C, P126; GRONBLAD M, 1991, ACTA ORTHOP SCAND, V62, P614; GRONBLAD M, 1991, CLIN ORTHOP RELAT R, P291; GRONBLAD M, 1990, ACTA ORTHOP SCA S235, V61, P40; HENRY JL, 1982, CIBA F SYMP, V91, P206; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; JACKSON HC, 1966, J BONE JOINT SURG AM, VA 48, P1272, DOI 10.2106/00004623-196648070-00002; JESSELL TM, 1982, LANCET, V2, P1084; KANG JD, 1995, SPINE, V20, P2373, DOI 10.1097/00007632-199511001-00001; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KONTTINEN YT, 1990, SPINE, V15, P383, DOI 10.1097/00007632-199005000-00008; MALINSKY JII, 1959, ACTA ANAT, V38, P96; MCCARTHY PW, 1991, SPINE, V16, P653, DOI 10.1097/00007632-199106000-00010; Olmarker K, 1997, SPINE, V22, P471, DOI 10.1097/00007632-199703010-00001; Palmgren T, 1996, SPINE, V21, P1301, DOI 10.1097/00007632-199606010-00004; ROBERTS S, 1995, LUMBAR SPINE DISORDE, P73; TOLONEN J, 1995, SPINE, V20, P271, DOI 10.1097/00007632-199502000-00003; VERNONROBERTS B, 1992, LUMBAR SPINE BACK PA, P24; Virri J, 1994, Eur Spine J, V3, P336, DOI 10.1007/BF02200147; WEINSTEIN J, 1988, SPINE, V13, P1344, DOI 10.1097/00007632-198812000-00002	29	613	679	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					178	181		10.1016/S0140-6736(97)02135-1	http://dx.doi.org/10.1016/S0140-6736(97)02135-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250186				2022-12-28	WOS:A1997XL72200013
J	Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC				Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC			X-linked IAP is a direct inhibitor of cell-death proteases	NATURE			English	Article							APOPTOSIS	The inhibitor-of-apoptosis (IAP) family of genes has an evolutionarily conserved role in regulating programmed cell death in animals ranging from insects to humans(1-6). Ectopic expression of human IAP proteins can suppress cell death induced by a variety of stimuli, but the mechanism of this inhibition was previously unknown. Here we show that human X-chromosome-linked IAP directly inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. As the caspases are highly conserved throughout the animal kingdom and are the principal effectors of apoptosis(7), our findings suggest how IAPs might inhibit cell death, providing evidence for a mechanism of action for these mammalian cell-death suppressors.	BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH RES,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, IN PRESS BLOOD; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAMAKAWA T, 1995, J BIOL CHEM, V270, P25328; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	27	1637	1733	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					300	304		10.1038/40901	http://dx.doi.org/10.1038/40901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230442	Bronze, Green Submitted			2022-12-28	WOS:A1997XL12100057
J	Sundar, S; Agrawal, NK; Sinha, PR; Horwith, GS; Murray, HW				Sundar, S; Agrawal, NK; Sinha, PR; Horwith, GS; Murray, HW			Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony	ANNALS OF INTERNAL MEDICINE			English	Article							KALA-AZAR; AMBISOME; INDIA	Background: Visceral leishmaniasis (kala-azar) is a worldwide, disseminated intracellular protozoal infection for which prolonged, conventional therapy with pentavalent antimony has become increasingly less effective. Objective: To determine the efficacy and minimal effective dose of short-course therapy with amphotericin B lipid complex in visceral leishmaniasis. Design: A randomized, open-label study. Setting: Inpatient kala-azar treatment unit in the state of Bihar in northeast India, where visceral leishmaniasis is endemic. Patients: 60 patients with active infection who had not responded to or who had relapse after receiving conventional (>30 days) treatment with pentavalent antimony. Intervention: Intravenous amphotericin B lipid complex was given once daily for 5 consecutive days by 2-hour infusion. Patients were randomly assigned to receive 1, 2, or 3 mg/kg of body weight per day (total doses of 5, 10, or 15 mg/kg, respectively). Measurements: Clinical and parasitologic responses (the latter were measured by parasite density score of the splenic aspirate) were determined 14 days after treatment. Definitive responses were assessed 6 months after treatment according to clinical outcomes and findings on examination of bone marrow aspirate. Results: All 60 patients responded to 5 days of treatment. Fourteen days after therapy, all patients had parasite-free splenic aspirates and were considered to have an apparent clinical and parasitologic response. Six months after therapy, definitive responses were documented in 15 of 19 (84% [95% CI, 60% to 97%]), 18 of 20 (90% [CI, 68% to 99%]), and 21 of 21 (100% [CI, 84% to 100%]) patients who received total doses of 5, 10, and 15 mg/kg, respectively. Conclusion: Short-course therapy with low-dose amphotericin B lipid complex is effective for visceral leishmaniasis and is an important therapeutic alternative in the management of this serious intracellular protozoal infection.	BANARAS HINDU UNIV, INST MED SCI, DEPT MED, VARANASI 221005, UTTAR PRADESH, INDIA; LIPOSOME CO, CLIN RES, PRINCETON, NJ 08540 USA; CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA	Banaras Hindu University (BHU); Cornell University			Murray, Heather/GQY-8016-2022					ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; CHUNGE CN, 1990, T ROY SOC TROP MED H, V84, P221, DOI 10.1016/0035-9203(90)90263-E; Davidson RN, 1996, CLIN INFECT DIS, V22, P938, DOI 10.1093/clinids/22.6.938; DAVIDSON RN, 1994, Q J MED, V87, P75; DIETZE R, 1995, T ROY SOC TROP MED H, V89, P309, DOI 10.1016/0035-9203(95)90557-X; GRADONI L, 1995, B WORLD HEALTH ORGAN, V73, P191; Jha T K, 1994, J Assoc Physicians India, V42, P263; JHA TK, 1995, AM J TROP MED HYG, V52, P536, DOI 10.4269/ajtmh.1995.52.536; MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C; MURRAY HW, 1989, J CLIN INVEST, V83, P1253, DOI 10.1172/JCI114009; Murray HW, 1996, J INFECT DIS, V173, P1041, DOI 10.1093/infdis/173.4.1041; OLLIARO PL, 1993, PARASITOL TODAY, V9, P323, DOI 10.1016/0169-4758(93)90231-4; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; Ribera E, 1996, AM J MED, V100, P496, DOI 10.1016/S0002-9343(97)89503-4; Russo R, 1996, J INFECTION, V32, P133, DOI 10.1016/S0163-4453(96)91343-2; Seaman J, 1996, ANN INTERN MED, V124, P664, DOI 10.7326/0003-4819-124-7-199604010-00007; SEAMAN J, 1995, CLIN INFECT DIS, V21, P188, DOI 10.1093/clinids/21.1.188; Sundar S, 1996, J INFECT DIS, V173, P762, DOI 10.1093/infdis/173.3.762; SUNDAR S, 1994, J INFECT DIS, V170, P659, DOI 10.1093/infdis/170.3.659; Thakur CP, 1996, T ROY SOC TROP MED H, V90, P319, DOI 10.1016/S0035-9203(96)90271-0	20	82	83	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					133	137		10.7326/0003-4819-127-2-199707150-00007	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230003				2022-12-28	WOS:A1997XK15800009
J	vantVeer, P; Lobbezoo, IE; MartinMoreno, JM; Guallar, E; GomezAracena, J; Kardinaal, AFM; Kohlmeier, L; Martin, BC; Strain, JJ; Thamm, M; vanZoonen, P; Baumann, BA; Huttunen, JK; Kok, FJ				vantVeer, P; Lobbezoo, IE; MartinMoreno, JM; Guallar, E; GomezAracena, J; Kardinaal, AFM; Kohlmeier, L; Martin, BC; Strain, JJ; Thamm, M; vanZoonen, P; Baumann, BA; Huttunen, JK; Kok, FJ			DDT (dicophane) and postmenopausal breast cancer in Europe: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYCHLORINATED BIPHENYL RESIDUES; ORGANOCHLORINE PESTICIDES; ADIPOSE-TISSUE; HUMAN-MILK; WOMEN; PCBS; RISK	Objective: To examine any possible links between exposure to DDE (1,1-dichIoro-2,2-bis(p-chlorophenyl)ethylene), the persistent metabolite of the pesticide dicophane (DDT), and breast cancer. Design: Multicentre study of exposure to DDE by measurement of adipose tissue aspirated from the buttocks. Laboratory measurements were conducted in a single Laboratory. Additional data on risk factors for breast cancer were obtained by standard questionnaires. Setting: Centres in Germany, the Netherlands, Northern Ireland, Switzerland, and Spain. Subjects: 265 postmenopausal women with breast cancer and 341 controls matched for age and centre. Main outcome measure: Adipose DDE concentrations. Results: Women with breast cancer had adipose DDE concentrations 9.2% lower than control women. No increased risk of breast cancer was found at higher concentrations. The odds ratio of breast cancer, adjusted for age and centre, for the highest versus the lowest fourth of DDE distribution was 0.73 (95% confidence interval 0.44 to 1.21) and decreased to 0.48 (0.25 to 0.95; P for trend = 0.02) after adjustment for body mass index, age at first birth, and current alcohol drinking. Adjustment for other risk factors did not materially affect these estimates. Conclusions: The lower DDE concentrations observed among the women with breast cancer may be secondary to disease inception. This study does not support the hypothesis that DDE increases risk of breast cancer in postmenopausal women in Europe.	NATL SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, E-28029 MADRID, SPAIN; UNIV MALAGA, DEPT PREVENT MED, E-29071 MALAGA, SPAIN; TNO, NUTR & FOOD RES INST, DEPT EPIDEMIOL, NL-3700 AJ ZEIST, NETHERLANDS; UNIV N CAROLINA, DEPT EPIDEMIOL & NUTR, CHAPEL HILL, NC 27599 USA; UNIV ZURICH, INST SOCIAL & PREVENT MED, DIV EPIDEMIOL NON COMMUNICABLE DIS, CH-8006 ZURICH, SWITZERLAND; UNIV ULSTER, DEPT BIOL & BIOMED SCI, HUMAN NUTR RES GRP, COLERAINE BT52 1SA, LONDONDERRY, NORTH IRELAND; ROBERT KOCH INST, DEPT HLTH RISKS & PREVENT, D-12101 BERLIN, GERMANY; NATL INST PUBL HLTH & ENVIRONM PROTECT, PESTICIDE DEPT, LAB ORGAN & ANALYT CHEM, NL-3420 BA BILTHOVEN, NETHERLANDS; NATL PUBL HLTH INST, FIN-00300 HELSINKI, FINLAND	Universidad de Malaga; Netherlands Organization Applied Science Research; University of North Carolina; University of North Carolina Chapel Hill; University of Zurich; Ulster University; Robert Koch Institute; Netherlands National Institute for Public Health & the Environment; Finland National Institute for Health & Welfare	vantVeer, P (corresponding author), DEPT HUMAN NUTR & EPIDEMIOL, POB 8129, NL-6700 EV WAGENINGEN, NETHERLANDS.		Martin-Moreno, Jose M./S-7733-2016; Guallar, Eliseo/D-3807-2014	Martin-Moreno, Jose M./0000-0002-8648-5541; Guallar, Eliseo/0000-0002-4471-9565				Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; BEYNEN AC, 1985, AM J CLIN NUTR, V42, P317, DOI 10.1093/ajcn/42.2.317; BOUWMAN H, 1990, J TOXICOL ENV HEALTH, V31, P93, DOI 10.1080/15287399009531440; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; DEWAILLY E, 1994, LANCET, V344, P1707, DOI 10.1016/S0140-6736(94)90491-X; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; GREVE PA, 1990, INT J ENVIRON AN CH, V38, P265, DOI 10.1080/03067319008026932; GREVE PA, 1983, 628219001 NAT I PUBL, P1; HANSEN LG, 1994, SCIENCE, V266, P526, DOI 10.1126/science.7939693; HERNANDEZ LM, 1993, B ENVIRON CONTAM TOX, V50, P308, DOI 10.1007/BF00191738; HORN M, 1994, ZBL HYG UMWELTMED, V196, P95; *INT AG RES CANC, 1908, IARC MONOGR, V1, P186; KALOYANOVA FP, 1991, HUMAN TOXICOLOGY PES, P59; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; KUTZ FW, 1991, REV ENVIRON CONTAM T, V120, P1; LEVINE R, 1991, HDB PESTICIDE TOXICO, V1, P275; Liem A. K. D., 1995, ORGANOHALOGEN COMPOU, V26, P69; MUSSALORAUHAMAA H, 1990, CANCER, V66, P2124, DOI 10.1002/1097-0142(19901115)66:10<2124::AID-CNCR2820661014>3.0.CO;2-A; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; SAS, 1988, SAS STAT US GUID REL; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; STONE R, 1994, SCIENCE, V265, P308, DOI 10.1126/science.8023147; UNGER M, 1984, ENVIRON RES, V34, P24, DOI 10.1016/0013-9351(84)90072-0; vantVeer P, 1996, CANCER EPIDEM BIOMAR, V5, P441; WASSERMANN M, 1976, B ENVIRON CONTAM TOX, V15, P478, DOI 10.1007/BF01685076; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648	28	125	127	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	1997	315	7100					81	85		10.1136/bmj.315.7100.81	http://dx.doi.org/10.1136/bmj.315.7100.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240045	Green Published			2022-12-28	WOS:A1997XL25200018
J	Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP				Shi, YG; Hata, A; Lo, RS; Massague, J; Pavletich, NP			A structural basis for mutational inactivation of the tumour suppressor Smad4	NATURE			English	Article							PROTEIN	The Smad4/DPC4 tumour suppressor(1) is inactivated in nearly half of pancreatic carcinomas(2) and to a lesser extent in a variety of other cancers(2-4). Smad4/DPC4, and the related tumour suppressor Smad2, belong to the SMAD family of proteins that mediate signalling by the TGF-beta/activin/BMP-2/4 cytokine superfamily from receptor Ser/Thr protein kinases at the cell surface to the nucleus(5-7). SMAD proteins, which are phosphorylated by the activated receptor, propagate the signal, in part, through homo- and hetero-oligomeric interactions(8-13). Smad4/DPC4 plays a central role as it is the shared hetero-oligomerization partner of the other SMADs. The conserved carboxy-terminal domains of SMADs are sufficient for inducing most of the ligand-specific effects, and are the primary targets of tumorigenic inactivation. We now describe the crystal structure of the C-terminal domain (CTD) of the Smad4/DPC4 tumour suppressor, determined at 2.5 Angstrom resolution. The structure reveals that the Smad4/DPC4 CTD forms a crystallographic trimer through a conserved protein-protein interface, to which the majority of the tumour-derived missense mutations map. These mutations disrupt homooligomerization in vitro and in vivo indicating that the trimeric assembly of the Smad4/DPC4 CTD is critical for signalling and is disrupted by tumorigenic mutations.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Shi, Yigong/0000-0003-2030-168X; Massague, Joan/0000-0001-9324-8408				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IECHLEIDER RJ, 1996, J BIOL CHEM, V271, P17617; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SK, 1996, CANCER RES, V56, P2519; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nagatake M, 1996, CANCER RES, V56, P2718; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHELDRICK G, 1991, PATTERSON INTERPRETA; STURA EA, 1992, CRYSTALLIZATION NUCL, P99; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	369	393	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	1997	388	6637					87	93		10.1038/40431	http://dx.doi.org/10.1038/40431			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214508	Bronze			2022-12-28	WOS:A1997XJ14300056
J	Sheffield, JVL; Larson, EB				Sheffield, JVL; Larson, EB			Update in general internal medicine	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle								Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Alderman EL, 1996, NEW ENGL J MED, V335, P217; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Dargie HJ, 1996, J INTERN MED, V239, P309, DOI 10.1046/j.1365-2796.1996.461800000.x; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Espeland MA, 1996, J AM GERIATR SOC, V44, P1183, DOI 10.1111/j.1532-5415.1996.tb01367.x; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDERSEN TR, 1994, LANCET, V344, P1383; Perry G, 1997, NEW ENGL J MED, V336, P525; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907	21	3	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					43	51		10.7326/0003-4819-127-1-199707010-00008	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214252				2022-12-28	WOS:A1997XG91400007
J	Evans, M; Perera, PW; Donoghue, J				Evans, M; Perera, PW; Donoghue, J			Drug induced psychosis with doxazosin	BRITISH MEDICAL JOURNAL			English	Letter											Evans, M (corresponding author), WIRRAL HOSP,WIRRAL L63 4JY,MERSEYSIDE,ENGLAND.							*BMA ROYAL PHARM S, 1995, BRIT NAT FORM, P83; CHIN DKF, 1986, BRIT MED J, V293, P1347, DOI 10.1136/bmj.293.6558.1347; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1869	1869		10.1136/bmj.314.7098.1869	http://dx.doi.org/10.1136/bmj.314.7098.1869			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9235156	Green Published			2022-12-28	WOS:A1997XH73800024
J	Hale, AS				Hale, AS			ABC of mental health - Anxiety	BRITISH MEDICAL JOURNAL			English	Review							DISORDER	Although there is considerable overlap between the various anxiety disorders, it is important to make a diagnosis as they have different optimal treatments.			Hale, AS (corresponding author), UNIV SHEFFIELD,SHEFFIELD,S YORKSHIRE,ENGLAND.							CLARK DM, 1994, BRIT J PSYCHIAT, V164, P759, DOI 10.1192/bjp.164.6.759; HUNT C, 1991, International Review of Psychiatry, V3, P215, DOI 10.3109/09540269109110402; MURRAY M, 1995, PREVENTION ANXIETY D; National Medical Advisory Committee, 1994, MAN ANX INS; Nutt DJ, 1996, BRIT J HOSP MED, V55, P187; SHAPIRO F, 1989, J BEHAV THER EXP PSY, V20, P211, DOI 10.1016/0005-7916(89)90025-6	6	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1886	1889		10.1136/bmj.314.7098.1886	http://dx.doi.org/10.1136/bmj.314.7098.1886			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224135	Green Published			2022-12-28	WOS:A1997XH73800032
J	Williams, LA; Evans, SF; Newnham, JP				Williams, LA; Evans, SF; Newnham, JP			Prospective cohort study of factors influencing the relative weights of the placenta and the newborn infant	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL WEIGHT; MORTALITY; DEATH; CHILDHOOD; PREGNANCY; ENGLAND	Objectives: To determine the demographic, environmental, and medical factors that influence the relative weights of the newborn infant and the placenta and compare this ratio with other factors known to predispose to adult ill health. Design: Prospective cohort study. Setting: The tertiary referral centre for perinatal care in Perth, Western Australia. Subjects: 2507 pregnant women who delivered a single live infant at term. Main outcome measures: Placental weight, birth weight, and the ratio of placental weight to birth weight. Results: By multiple regression analysis the placental weight to birthweight ratio was significantly and positively associated with gestational age, female sex, Asian parentage, increasing maternal body mass index, increased maternal weight at booking, lower socioeconomic status, maternal anaemia, and increasing number of cigarettes smoked daily. There were no consistent relations between the placental weight to birthweight ratio and measures of newborn size. Conclusions: The ratio of placental weight to birth weight is not an accurate marker of fetal growth. In its role as a predictor of adult disease the ratio may be acting as a surrogate for other factors which are already known to influence health and may act before or after birth. Determining the role that relative growth rates of the fetus and placenta have in predisposing to adult disease requires prospective study to account for the many confounding variables which complicate this hypothesis.	UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP,WOMEN & INFANTS RES FDN,SUBIACO,WA 6008,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia			Study, Raine/K-4517-2013	Newnham, John/0000-0001-9983-7457				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Evans S, 1996, EARLY HUM DEV, V45, P203, DOI 10.1016/0378-3782(96)01728-8; Garn S.M., 1971, HUMAN RACES; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MCCRABB GJ, 1992, J AGR SCI, V118, P127, DOI 10.1017/S002185960006809X; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PERRY IJ, 1995, BMJ-BRIT MED J, V310, P436, DOI 10.1136/bmj.310.6977.436	16	149	149	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1864	1868		10.1136/bmj.314.7098.1864	http://dx.doi.org/10.1136/bmj.314.7098.1864			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224128	Green Published			2022-12-28	WOS:A1997XH73800022
J	Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL				Coleman, JL; Gebbia, JA; Piesman, J; Degen, JL; Bugge, TH; Benach, JL			Plasminogen is required for efficient dissemination of B-burgdorferi in ticks and for enhancement of spirochetemia in mice	CELL			English	Article							LYME-DISEASE SPIROCHETE; OUTER SURFACE-PROTEIN; BORRELIA-BURGDORFERI; IXODES-DAMMINI; HUMAN-PLASMA; ACTIVATOR; UROKINASE; BLOOD; TRANSMISSION; SYSTEM	The role of the host plasminogen activation system in transmission of and invasion by Borrelia burgdorferi, the tick-borne spirochetal agent of Lyme disease, was investigated using plasminogen (Plg)-knockout mice. PLG was not detected in spirochetes from unfed ticks, but binding occurred as ticks fed on the host's blood. Plasminogen activators were derived from the host blood meal. PLG was required for efficient dissemination of B. burgdorferi within the tick and for enhancement of spirochetemia in mice but was not critical for transmission and infection. These results provide evidence for a bacterium using a vertebrate protease to disseminate in an invertebrate vector and underscores the interplay among vector, pathogen, and host in promoting the life cycle and disease.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,STONY BROOK,NY 11794; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; CTR DIS CONTROL & PREVENT,FT COLLINS,CO 80522	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Centers for Disease Control & Prevention - USA	Coleman, JL (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,NEW YORK STATE DEPT HLTH,STONY BROOK,NY 11794, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47826] Funding Source: Medline; NIAID NIH HHS [AI 27044] Funding Source: Medline; NIAMS NIH HHS [AR 40445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; BENACH JL, 1988, J IMMUNOL, V140, P265; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1987, J INFECT DIS, V155, P1300, DOI 10.1093/infdis/155.6.1300; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURKOT TR, 1994, J INFECT DIS, V170, P883, DOI 10.1093/infdis/170.4.883; CASTELLINO FJ, 1973, BIOCHEM BIOPH RES CO, V53, P845, DOI 10.1016/0006-291X(73)90170-8; COLEMAN JL, 1995, INFECT IMMUN, V63, P2478, DOI 10.1128/IAI.63.7.2478-2484.1995; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FINGERLE V, 1995, J CLIN MICROBIOL, V33, P1867, DOI 10.1128/JCM.33.7.1867-1869.1995; FUCHS H, 1994, P NATL ACAD SCI USA, V91, P12594, DOI 10.1073/pnas.91.26.12594; Fuchs H, 1996, INFECT IMMUN, V64, P4307, DOI 10.1128/IAI.64.10.4307-4312.1996; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GARCIAMONCO JC, 1995, ANN NEUROL, V37, P691, DOI 10.1002/ana.410370602; Gebbia JA, 1995, EXP APPL ACAROL, V19, P593, DOI 10.1007/BF00048814; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; HU LT, 1995, INFECT IMMUN, V63, P3491, DOI 10.1128/IAI.63.9.3491-3496.1995; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KLEMPNER MS, 1995, J INFECT DIS, V171, P1258, DOI 10.1093/infdis/171.5.1258; KRUITHOF EKO, 1984, BLOOD, V64, P907; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; MCDONOUGH KA, 1993, J MED ENTOMOL, V30, P772, DOI 10.1093/jmedent/30.4.772; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; MUNDERLOH UG, 1995, ANNU REV ENTOMOL, V40, P221, DOI 10.1146/annurev.en.40.010195.001253; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; Perides G, 1996, BIOCHEM BIOPH RES CO, V219, P690, DOI 10.1006/bbrc.1996.0296; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1995, J MED ENTOMOL, V32, P519, DOI 10.1093/jmedent/32.4.519; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; PIESMAN J, 1993, J MED ENTOMOL, V30, P199, DOI 10.1093/jmedent/30.1.199; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827; SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989; Sonenshine DE., 1993, BIOL TICKS; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WHEELER CM, 1989, J INFECT DIS, V59, P265; YANG LM, 1994, INFECT IMMUN, V62, P492, DOI 10.1128/IAI.62.2.492-500.1994; ZUNG JL, 1989, CAN J ZOOL, V67, P1737, DOI 10.1139/z89-249	52	272	281	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1111	1119		10.1016/S0092-8674(00)80298-6	http://dx.doi.org/10.1016/S0092-8674(00)80298-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215633	Bronze			2022-12-28	WOS:A1997XG83000015
J	Lagasse, E; Weissman, IL				Lagasse, E; Weissman, IL			Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice	CELL			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; MONONUCLEAR PHAGOCYTE SYSTEM; OP OP MOUSE; GROWTH-FACTOR; FACTOR CSF-1; APOPTOSIS; LINEAGE; MURINE; DEATH	Osteopetrotic (op/op) mice lack functional M-CSF and have depressed levels of macrophages and osteoclasts. We prepared transgenic mice (hMRP8bcl-2) that express human Bcl-2 in monocytes. in vitro hMRP8bcl-2 monocytes do not undergo apoptosis in the absence of serum and M-CSF, while op/op and wild-type monocytes die. These Bcl-2-expressing monocytes spontaneously undergo macrophage differentiation. In vivo, the op/op hMRP8bcl-2 mice show significant replenishment of tissue macrophages. Their long bone osteopetrosis is largely reversed, and extensive medullary hematopoiesis appears in the bone marrow. We propose that M-CSF augments monocyte survival, permitting them to respond to internal and external cues for their differentiation.			Lagasse, E (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL & DEV BIOL, STANFORD, CA 94305 USA.							BALNER H, 1963, TRANSPLANTATION, V1, P217, DOI 10.1097/00007890-196301020-00009; BUTCHER EC, 1980, J IMMUNOL METHODS, V37, P109, DOI 10.1016/0022-1759(80)90196-9; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, P3; CURRY JL, 1967, SCIENCE, V236, P1229; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HATTERSLEY G, 1989, J CELL PHYSIOL, V140, P478, DOI 10.1002/jcp.1041400311; HUME DA, 1988, J IMMUNOL, V141, P3405; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; IWAI K, 1994, BLOOD, V84, P1201; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KOIKE K, 1986, BLOOD, V67, P859; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEE MY, 1992, BLOOD, V80, P1710; LIESCHKE GJ, 1994, BLOOD, V84, P27; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MCARTHUR GA, 1994, BLOOD, V83, P972; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1970, J CELL PHYSIOL, V76, P89, DOI 10.1002/jcp.1040760113; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Olweus J, 1996, BLOOD, V88, P3741, DOI 10.1182/blood.V88.10.3741.bloodjournal88103741; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1981, LYMPHOKINES, P102; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; VANFURTH R, 1988, J IMMUNOL METHODS, V108, P45, DOI 10.1016/0022-1759(88)90401-2; VANFURTH R, 1985, MONONUCLEAR PHAGOCYT, P201; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VOLKMAN A, 1965, BRIT J EXP PATHOL, V46, P62; WANG HG, 1994, ONCOGENE, V9, P2751; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; WIKTORJEDRZEJCZAK W, 1994, ENDOCRINOLOGY, V134, P1932, DOI 10.1210/en.134.4.1932; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	64	250	256	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1021	1031		10.1016/S0092-8674(00)80290-1	http://dx.doi.org/10.1016/S0092-8674(00)80290-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215625	Bronze			2022-12-28	WOS:A1997XG83000007
J	Cambridge, SB; Davis, RL; Minden, JS				Cambridge, SB; Davis, RL; Minden, JS			Drosophila mitotic domain boundaries as cell fate boundaries	SCIENCE			English	Article							EMBRYOS; EXPRESSION; GAL4; GENE; MELANOGASTER; PRODUCTS; YEAST	Fate determination in Drosophila embryos is evidenced by the appearance of mitotic domains. To identify fate or fates of cells, individual cells in mitotic domains 2, 8, and 15 were marked and monitored through development. Comparison of the different fates indicated that domain boundaries are cell fate boundaries. Cells were marked by expression of GAL4-dependent transgenes after photoactivation of a caged GAL4VP16 analog that had its DNA binding activity inhibited with a photolabile blocking reagent. Caged GAL4VP16 was also used to induce gene expression in Xenopus embryos. Thus, photoactivated gene expression is a versatile tool for spatiotemporal control of gene expression.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Carnegie Mellon University; Carnegie Mellon University; Harvard University; Harvard Medical School			Cambridge, Sidney/GYQ-5764-2022					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; AFANASEVA GB, 1974, CHEM HETEROCYCLIC CO, V10, P302; BOMZE HM, 1994, GENETICS, V136, P965; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; DAVIS I, 1995, DEV BIOL, V170, P726, DOI 10.1006/dbio.1995.1251; FOE VE, 1989, DEVELOPMENT, V107, P1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Marriott G, 1996, BIOCHEMISTRY-US, V35, P3170, DOI 10.1021/bi952207o; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; Minden JS, 1996, BIOTECHNIQUES, V20, P122; Namba R, 1997, DEVELOPMENT, V124, P1393; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309; TECHNAU G M, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P196, DOI 10.1007/BF00848247; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B	24	53	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					825	828		10.1126/science.277.5327.825	http://dx.doi.org/10.1126/science.277.5327.825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242613				2022-12-28	WOS:A1997XQ24700046
J	Weber, J				Weber, J			Distinguishing between response to HIV vaccine and response to HIV	LANCET			English	Editorial Material							VIRUS				Weber, J (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT COMMUNICABLE DIS & GENITOURINARY MED,PRAED ST,LONDON W2 1PG,ENGLAND.							Bloom BR, 1996, SCIENCE, V272, P1888, DOI 10.1126/science.272.5270.1888; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; *OFF PRES, 1997, COMM ADDR MORG STAT; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Weber J, 1996, J VIROL, V70, P7827, DOI 10.1128/JVI.70.11.7827-7832.1996; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7	7	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					230	231		10.1016/S0140-6736(97)22030-1	http://dx.doi.org/10.1016/S0140-6736(97)22030-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242794				2022-12-28	WOS:A1997XM86600002
J	Altaba, ARI				Altaba, ARI			Catching a Gli-mpse of Hedgehog	CELL			English	Review							ZINC-FINGER PROTEIN		NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	New York University	Altaba, ARI (corresponding author), NYU,MED CTR,SKIRBALL INST,DEV GENET PROGRAM,NEW YORK,NY 10016, USA.			Ruiz i Altaba, Ariel/0000-0003-2292-3933				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ARUGA J, 1994, J NEUROCHEM, V63, P1880; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Hepker J, 1997, DEVELOPMENT, V124, P549; Lee J, 1997, DEVELOPMENT, V124, P2537; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Mo R, 1997, DEVELOPMENT, V124, P113; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PLATT KA, 1997, DEVELOPMENT, V62, P121; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Struhl G, 1997, DEVELOPMENT, V124, P2143; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629	20	142	147	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					193	196		10.1016/S0092-8674(00)80325-6	http://dx.doi.org/10.1016/S0092-8674(00)80325-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244291	hybrid, Green Published			2022-12-28	WOS:A1997XN24900001
J	Benefit, BR; McCrossin, ML				Benefit, BR; McCrossin, ML			Earliest known Old World monkey skull	NATURE			English	Article							MABOKO ISLAND; FACIAL MORPHOLOGY; KENYA; VICTORIAPITHECUS; MIOCENE; AEGYPTOPITHECUS; PRIMATES; AGE	Similarities of the skull are commonly used to support hypotheses of ancestor-descendant relationships between fossil and living ape genera, especially between the late Miocene apes Sivapithecus and Dryopithecus from Eurasia and the living orang-utan (Pongo) from Borneo and Sumatra(1-4). Yet determining whether cranio-facial traits shared by extant and Miocene apes are primitive or derived is severely hampered by the rarity of well-preserved fossil crania, particularly of early members of their closest outgroup, the Old World monkeys (Cercopithecoidea). The discovery of a complete and undistorted skull of Victorispithecus at middle Miocene deposits from Maboko Island, Kenya, provides evidence of intact cranial-vault and basicranial morphology, brain size and craniofacial hafting for a primate from between 32 and 7 million years ago. Victoriapithecus represents a branch of Old World monkey that is intermediate between extant cercopithecids (Colobinae and Cercopithecinae) and the common ancestor they shared with apes (Hominoidea)(5-8). The skull preserves traits widely thought to be derived for extant and fossil members of a proposed Sivapithecus/Pongo clade, but which now appear to be primitive features of ancestral Old World higher primates in general.			Benefit, BR (corresponding author), SO ILLINOIS UNIV,DEPT ANTHROPOL,CARBONDALE,IL 62901, USA.		Klein, Richard G/B-5910-2009					ANDREWS P, 1981, J HUM EVOL, V10, P35, DOI 10.1016/S0047-2484(81)80024-3; BENEFIT BR, 1994, AM J PHYS ANTHROPOL, V95, P277, DOI 10.1002/ajpa.1330950304; BENEFIT BR, 1993, AM J PHYS ANTHROPOL, V92, P329, DOI 10.1002/ajpa.1330920307; BENEFIT BR, 1991, P NATL ACAD SCI USA, V88, P5267, DOI 10.1073/pnas.88.12.5267; BENEFIT BR, 1993, J HUM EVOL, V25, P83, DOI 10.1006/jhev.1993.1041; Brown B., 1988, P247; Delson E., 1975, P405; FEIBEL CS, 1991, J HUM EVOL, V21, P221, DOI 10.1016/0047-2484(91)90063-2; HARRISON T, 1989, J HUM EVOL, V18, P3, DOI 10.1016/0047-2484(89)90022-5; HARRISON T, 1987, J HUM EVOL, V16, P41, DOI 10.1016/0047-2484(87)90060-1; LEAKEY E, 1986, NATURE, V342, P143; LEAKEY MG, 1991, FOLIA PRIMATOL, V56, P65, DOI 10.1159/000156531; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Moya Sola Salvadoor, 1995, Journal of Human Evolution, V29, P101; MOYASOLA S, 1993, NATURE, V365, P543, DOI DOI 10.1038/365543A0; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; RADINSKY L, 1974, AM J PHYS ANTHROPOL, V41, P15, DOI 10.1002/ajpa.1330410104; SIMONS EL, 1987, J HUM EVOL, V16, P273, DOI 10.1016/0047-2484(87)90003-0; SIMONS EL, 1967, SCI AM, V218, P28; STRASSER E, 1987, J HUM EVOL, V16, P81, DOI 10.1016/0047-2484(87)90061-3; STROMER E, 1913, Z DTSCH GEOL GES, V65, P349; VOGEL C, 1966, BIBLIOTHECA PRIMATOL, V4, P1; Von Koenigswald G. H. R., 1969, FOSSIL VERTEBRATES A, P39	23	43	43	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					368	371		10.1038/41078	http://dx.doi.org/10.1038/41078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237753				2022-12-28	WOS:A1997XM52800047
J	Welch, KMA				Welch, KMA			A 27-year-old woman with migraine headaches	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUNG-ADULTS; ACTIVATION; PROPHYLAXIS; SUMATRIPTAN; ESTROGEN; DISORDER; THERAPY		HENRY FORD HOSP & HLTH SCI CTR, DEPT NEUROL, NMR RES CTR, DETROIT, MI USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; OAKLAND UNIV, ROCHESTER, MI 48063 USA; HENRY FORD HOSP & HLTH SCI CTR, DEPT NEUROL, HEADACHE RES CTR, DETROIT, MI USA	Henry Ford Health System; Case Western Reserve University; University of Michigan System; University of Michigan; Oakland University; Henry Ford Health System								BARKLEY GL, 1990, CEPHALALGIA, V10, P171, DOI 10.1046/j.1468-2982.1990.1004171.x; BRESLAU N, 1993, J PSYCHIAT RES, V27, P211, DOI 10.1016/0022-3956(93)90009-Q; COUCH JR, 1979, ARCH NEUROL-CHICAGO, V36, P695, DOI 10.1001/archneur.1979.00500470065013; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; GOADSBY PJ, 1991, CEPHALALGIA, V11, P3, DOI 10.1177/0333102491011S1102; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x; Herzog AG, 1997, NEUROLOGY, V48, P101, DOI 10.1212/WNL.48.1.101; LINET MS, 1989, JAMA-J AM MED ASSOC, V261, P2211, DOI 10.1001/jama.261.15.2211; LIPTON RB, 1993, NEUROLOGY, V43, P6; MacGregor EA, 1997, NEUROL CLIN, V15, P125, DOI 10.1016/S0733-8619(05)70299-1; Mathew NT, 1997, NEUROL CLIN, V15, P167, DOI 10.1016/S0733-8619(05)70302-9; MELLOR C, 1991, EUR NEUROL, V31, P306; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MOSKOWITZ MA, 1992, J NEUROL, V238, P518; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; OTTMAN R, 1993, NEUROLOGY, V43, P1954, DOI 10.1212/WNL.43.10.1954; Peikert A, 1996, CEPHALALGIA, V16, P257, DOI 10.1046/j.1468-2982.1996.1604257.x; RAPAPORT A, 1985, CEPHALALGIA S3, V5, P448; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; SAXENA PR, 1992, CEPHALALGIA, V12, P187, DOI 10.1046/j.1468-2982.1992.1204187.x; Schoenen J, 1997, NEUROLOGY, V48, P8005; Silberstein SD, 1997, NEUROL CLIN, V15, P209, DOI 10.1016/S0733-8619(05)70305-4; SOMERVILLE BW, 1975, NEUROLOGY, V25, P239, DOI 10.1212/WNL.25.3.239; SORBI M, 1989, HEADACHE, V29, P111, DOI 10.1111/j.1526-4610.1989.hed2902111.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Stewart WF, 1996, CEPHALALGIA, V16, P231, DOI 10.1046/j.1468-2982.1996.1604231.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Tfelt-Hansen Peer, 1993, P313; Tfelt-Hansen Peer, 1993, P353; TZOURIO C, 1993, BMJ-BRIT MED J, V307, P289, DOI 10.1136/bmj.307.6899.289; Visser WH, 1996, CEPHALALGIA, V16, P264, DOI 10.1046/j.1468-2982.1996.1604264.x; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658; WELCH K, 1984, CEPHALALGIA, V4, P227, DOI 10.1046/j.1468-2982.1984.0404227.x; WELCH KMA, 1993, NEW ENGL J MED, V329, P1476; WELCH KMA, 1990, NEUROL CLIN, V8, P817, DOI 10.1016/S0733-8619(18)30319-0; WELCH KMA, 1995, J NEUROL SCI, V134, P9, DOI 10.1016/0022-510X(95)00196-1; WELCH KMA, 1987, ARCH NEUROL-CHICAGO, V44, P323, DOI 10.1001/archneur.1987.00520150063024; Welch KMA, 1997, NEUROLOGY, V48, P8001; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505	44	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					322	328						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228439				2022-12-28	WOS:A1997XL05900034
J	Klein, R; Klein, BEK				Klein, R; Klein, BEK			Diabetic eye disease	LANCET			English	Article							NON-HISPANIC WHITES; COST-EFFECTIVENESS; RISK-FACTORS; MICROVASCULAR COMPLICATIONS; PROLIFERATIVE RETINOPATHY; CIGARETTE-SMOKING; BLOOD-PRESSURE; PARTIAL SIGHT; PIMA-INDIANS; PREVALENCE				Klein, R (corresponding author), UNIV WISCONSIN, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 610 N WALNUT ST, 460 WARF, MADISON, WI 53705 USA.				NEI NIH HHS [EY03083] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1994, DIABETES CARE, V17, P616; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; ARFKEN CL, 1994, ARCH INTERN MED, V154, P2597, DOI 10.1001/archinte.154.22.2597; BALLARD DJ, 1986, DIABETES CARE, V9, P334, DOI 10.2337/diacare.9.4.334; Bennett P H, 1976, Recent Prog Horm Res, V32, P333; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; CRUICKSHANKS KJ, 1993, OPHTHALMOLOGY, V100, P862; DANIELSEN R, 1982, ACTA MED SCAND, V212, P277; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; *DIAB CONTR COMPL, 1996, JAMA-J AM MED ASSOC, V276, P1406; *DIAB RET VITR STU, 1985, ARCH OPHTHALMOL-CHIC, V92, P492; Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647; DORF A, 1976, DIABETES, V25, P554, DOI 10.2337/diabetes.25.7.554; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EDERER F, 1981, AM J OPHTHALMOL, V91, P381, DOI 10.1016/0002-9394(81)90293-2; Ferris F, 1996, Trans Am Ophthalmol Soc, V94, P505; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; Ferris FL, 1996, DIABETES CARE, V19, P1291, DOI 10.2337/diacare.19.11.1291; Foulds W S, 1983, Health Bull (Edinb), V41, P318; FRANK RN, 1991, OPHTHALMOLOGY, V98, P586; FUJIMOTO W, 1967, DIABETES MELLITUS AS, P225; GIARDINO I, 1997, TXB DIABETES, V1, P1; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; GRIFFITH SP, 1993, J FAM PRACTICE, V37, P49; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; Henricsson M, 1996, ACTA OPHTHALMOL SCAN, V74, P533; HOUSTON A, 1982, ADV DIABETES EPIDEMI; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; Jerneld B, 1988, Acta Ophthalmol Suppl, V188, P3; KING H, 1983, AM J EPIDEMIOL, V117, P659, DOI 10.1093/oxfordjournals.aje.a113599; Klein B E, 1995, Ophthalmic Epidemiol, V2, P49, DOI 10.3109/09286589509071451; KLEIN BEK, 1990, DIABETES CARE, V13, P1034, DOI 10.2337/diacare.13.10.1034; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173; Klein R, 1996, DIABETES CARE, V19, P744, DOI 10.2337/diacare.19.7.744; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1985, DIABETES CARE, V8, P311, DOI 10.2337/diacare.8.4.311; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1993, OPHTHALMOLOGY, V100, P1140; Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427; KLEIN R, 1983, AM J EPIDEMIOL, V118, P228, DOI 10.1093/oxfordjournals.aje.a113630; KLEIN R, 1995, NIH PUBLICATION, P293; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; Kohner E, 1982, COMPLICATIONS DIABET; KOHNER EM, 1991, TXB DIABETES, P564; KOSTRABA JN, 1991, AM J EPIDEMIOL, V133, P381, DOI 10.1093/oxfordjournals.aje.a115892; KOSTRABA JN, 1989, DIABETES CARE, V12, P686, DOI 10.2337/diacare.12.10.686; Kraft SK, 1997, ARCH FAM MED, V6, P29, DOI 10.1001/archfami.6.1.29; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; LAIRSON DR, 1992, DIABETES CARE, V15, P1369, DOI 10.2337/diacare.15.10.1369; LEE ET, 1992, DIABETES CARE, V15, P1620, DOI 10.2337/diacare.15.11.1620; LEE ET, 1992, DIABETES, V41, P359, DOI 10.2337/diabetes.41.3.359; Lloyd CE, 1995, J DIABETES COMPLICAT, V9, P140, DOI 10.1016/1056-8727(94)00039-Q; MCLEOD BK, 1988, EYE, V2, P424, DOI 10.1038/eye.1988.77; MOGENSEN CE, 1994, RES METHODOLOGIES 1, V5; Moss S E, 1995, Arch Fam Med, V4, P529, DOI 10.1001/archfami.4.6.529; MOSS SE, 1991, DIABETES CARE, V14, P119, DOI 10.2337/diacare.14.2.119; MURPHY RP, 1990, ARCH OPHTHALMOL-CHIC, V108, P215, DOI 10.1001/archopht.1990.01070040067032; National Committee for Quality Assurance, 1996, HLTH PLAN EMPL DAT I; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; *NIH, 1990, NAT EY HLTH ED PROGR; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHORE AC, 1997, TXB DIABETES, V1, P1; SJOLIE AK, 1985, ACTA OPHTHALMOL, V63, P1; SJOLIE AK, 1995, P 32 NORD C OPHTH OD; SPRAFKA JM, 1990, ARCH INTERN MED, V150, P857, DOI 10.1001/archinte.150.4.857; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; The American Academy of Periodontology, 1989, P WORLD WORKSH CLIN, P1; THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P95, DOI 10.1136/bjo.73.2.95; *U GROUP DIAB PROG, 1982, DIABETES S31, V5, P1; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796	87	63	64	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					197	204		10.1016/S0140-6736(97)04195-0	http://dx.doi.org/10.1016/S0140-6736(97)04195-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250197				2022-12-28	WOS:A1997XL72200044
J	Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C				Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C			Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase	SCIENCE			English	Article							CHAIN-ELONGATION INTERMEDIATE; MACROLIDE BIOSYNTHESIS; INTACT INCORPORATION; GENE-CLUSTER; ANTIBIOTICS; NARGENICIN; ORGANIZATION; DIKETIDE; HOST; RING	A genetic block was introduced in the first condensation step of the polyketide biosynthetic pathway that leads to the formation of 6-deoxyerythronolide B (6-dEB), the macrocyclic precursor of erythromycin. Exogenous addition of designed synthetic molecules to small-scale cultures of this null mutant resulted in highly selective multimilligram production of unnatural polyketides, including aromatic and ring-expanded variants of 6-dEB. Unexpected incorporation patterns were observed, illustrating the catalytic versatility of modular polyketide synthases. Further processing of some of these scaffolds by postpolyketide enzymes of the erythromycin pathway resulted in the generation of novel antibacterials with in vitro potency comparable to that of their natural counterparts.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Brown University				Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031925, R01GM022172] Funding Source: NIH RePORTER; NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM31925, GM22172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abiko A, 1997, J AM CHEM SOC, V119, P2586, DOI 10.1021/ja963754f; ADACHI T, 1988, J ANTIBIOT, V41, P966, DOI 10.7164/antibiotics.41.966; BAKER WR, 1988, J ORG CHEM, V53, P2340, DOI 10.1021/jo00245a038; Bedford D, 1996, CHEM BIOL, V3, P827, DOI 10.1016/S1074-5521(96)90068-X; CANE DE, 1993, J AM CHEM SOC, V115, P527, DOI 10.1021/ja00055a024; CANE DE, 1995, J ANTIBIOT, V48, P647, DOI 10.7164/antibiotics.48.647; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1988, J AM CHEM SOC, V110, P4840, DOI 10.1021/ja00222a059; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CANE DE, 1995, J AM CHEM SOC, V117, P6633, DOI 10.1021/ja00129a044; CORNISH VW, 1994, CURR OPIN STRUC BIOL, V4, P601, DOI 10.1016/S0959-440X(94)90224-0; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DAUM SJ, 1979, ANNU REV MICROBIOL, V533, P241; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; DUTTON CJ, 1994, TETRAHEDRON LETT, V35, P327, DOI 10.1016/S0040-4039(00)76544-0; EVANS DA, 1981, J AM CHEM SOC, V103, P2127, DOI 10.1021/ja00398a058; Griesgraber G, 1996, J ANTIBIOT, V49, P465, DOI 10.7164/antibiotics.49.465; HAILES HC, 1994, TETRAHEDRON LETT, V35, P307, DOI 10.1016/S0040-4039(00)76539-7; HU ZH, 1994, MOL MICROBIOL, V14, P163, DOI 10.1111/j.1365-2958.1994.tb01276.x; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; McDaniel R, 1997, J AM CHEM SOC, V119, P4309, DOI 10.1021/ja9702531; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MORIMOTO S, 1990, J ANTIBIOT, V43, P286, DOI 10.7164/antibiotics.43.286; OHagan D., 1991, POLYKETIDE METABOLIT; OLIYNYK M, 1996, GENE, V183, P231; PATERSON I, 1985, TETRAHEDRON, V41, P3569, DOI 10.1016/S0040-4020(01)91380-8; PATZELT H, 1993, J CHEM SOC CHEM COMM, P1258, DOI 10.1039/c39930001258; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; Pieper R, 1996, BIOCHEMISTRY-US, V35, P2054, DOI 10.1021/bi952860b; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Seebach D., 1990, ORG SYNTH, VVII, P153; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; Vincent JG, 1944, P SOC EXP BIOL MED, V55, P162, DOI 10.3181/00379727-55-14502; WALKER MA, 1991, J ORG CHEM, V56, P5747, DOI 10.1021/jo00020a006; WEBER JM, 1985, J BACTERIOL, V164, P425, DOI 10.1128/JB.164.1.425-433.1985; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	49	252	270	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					367	369		10.1126/science.277.5324.367	http://dx.doi.org/10.1126/science.277.5324.367			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219693				2022-12-28	WOS:A1997XL35800045
J	Moreland, LW; Baumgartner, SW; Schiff, MH; Tindall, EA; Fleischmann, RM; Weaver, AL; Ettlinger, RE; Cohen, S; Koopman, WJ; Mohler, K; Widmer, MB; Blosch, CM				Moreland, LW; Baumgartner, SW; Schiff, MH; Tindall, EA; Fleischmann, RM; Weaver, AL; Ettlinger, RE; Cohen, S; Koopman, WJ; Mohler, K; Widmer, MB; Blosch, CM			Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INCREASED PLASMA-CONCENTRATIONS; CARTILAGE PANNUS JUNCTION; FACTOR SOLUBLE RECEPTORS; FACTOR-BINDING-PROTEIN; FACTOR-ALPHA CA2; FACTOR TNF; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; DISEASE SEVERITY; REVISED CRITERIA	Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease. This study evaluated the safety and efficacy of a novel TNF antagonist - a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1 (TNFR:Fc). Methods In this multicenter, double-blind trial, we randomly assigned 180 patients with refractory rheumatoid arthritis to receive subcutaneous injections of placebo or one of three doses of TNFR:Fc (0.25, 2, or 16 mg per square meter of body-surface area) twice weekly for three months. The clinical response was measured by changes in composite symptoms of arthritis defined according to American College of Rheumatology criteria. Results Treatment with TNFR:Fc led to significant reductions in disease activity, and the therapeutic effects of TNFR:Fc were dose-related. At th ree months, 75 percent of the patients in the group assigned to 16 mg of TNFR:Fc per square meter had improvement of 20 percent or more in symptoms, as com pared with 14 percent in the placebo group (P<0.001). In the group assigned to 16 mg per square meter, the mean percent reduction in the number of tender or swollen joints at three months was 61 percent, as compared with 25 percent in the placebo group (P<0.001). The most common adverse events were mild injection-site reactions and mild upper respiratory tract symptoms. There were no dose-limiting toxic effects, and no antibodies to TNFR:Fc were detected in serum samples. Conclusions In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis. (C)1997, Massachusetts Medical Society.	PHYSICIANS CLIN SPOKANE,SPOKANE,WA; PORTLAND MED ASSOC,PORTLAND,OR; METROPLEX CLIN RES CTR,DALLAS,TX; ARTHRIT CTR NEBRASKA,LINCOLN,NE; IMMUNEX CORP,SEATTLE,WA	Metroplex Clinical Research Center; Immunex Corporation	Moreland, LW (corresponding author), UNIV ALABAMA,DIV CLIN IMMUNOL & RHEUMATOL,ARTHRIT CLIN INTERVENT PROGRAM,1717 6TH AVE S,RM 068,BIRMINGHAM,AL 35294, USA.			Moreland, Larry/0000-0003-4483-0359				AHMADZADEH N, 1990, CLIN EXP RHEUMATOL, V8, P387; ANDUS T, 1992, HEPATOLOGY, V16, P749, DOI 10.1002/hep.1840160322; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; AUSTGULEN R, 1993, PEDIATR RES, V33, P82, DOI 10.1203/00006450-199301000-00017; BARRERA P, 1993, ARTHRITIS RHEUM-US, V36, P1070, DOI 10.1002/art.1780360807; BAUMANN P, 1993, AM J REPROD IMMUNOL, V30, P184, DOI 10.1111/j.1600-0897.1993.tb00619.x; BECKHAM JC, 1992, J CLIN IMMUNOL, V12, P353, DOI 10.1007/BF00920793; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BRENNAN FM, 1989, LANCET, V2, P244; BRENNAN FM, 1992, CURR OPIN IMMUNOL, V4, P754, DOI 10.1016/0952-7915(92)90057-L; BROCKHAUS M, 1992, KIDNEY INT, V42, P663, DOI 10.1038/ki.1992.332; CHIKANZA IC, 1993, CLIN EXP IMMUNOL, V92, P19; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; COPE AP, 1992, ARTHRITIS RHEUM, V35, P1160, DOI 10.1002/art.1780351008; DELEURAN BW, 1992, ARTHRITIS RHEUM, V35, P1170, DOI 10.1002/art.1780351009; DIGEL W, 1992, J CLIN INVEST, V89, P1690, DOI 10.1172/JCI115769; Eason JD, 1996, TRANSPLANTATION, V61, P224, DOI 10.1097/00007890-199601270-00011; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ELSASSERBEILE U, 1994, TUMOR BIOL, V15, P17, DOI 10.1159/000217869; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FRIES JF, 1982, J RHEUMATOL, V9, P789; FROON AHM, 1994, CRIT CARE MED, V22, P803, DOI 10.1097/00003246-199405000-00015; FURUKAWA S, 1994, J PEDIATR-US, V124, P721, DOI 10.1016/S0022-3476(05)81361-7; GIRARDIN E, 1992, IMMUNOLOGY, V76, P20; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; KERN P, 1992, J INFECT DIS, V166, P930, DOI 10.1093/infdis/166.4.930; KERN P, 1992, J INFECT DIS, V166, P1467; KRAUS T, 1992, TRANSPLANT P, V24, P2539; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MacNaul K L, 1992, Matrix Suppl, V1, P198; Maini R. N., 1995, Arthritis and Rheumatism, V38, pS186; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moreland LW, 1996, J RHEUMATOL, V23, P1849; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; NAM MH, 1993, CLIN RES, V41, pA249; NAWROTH PP, 1986, J EXP MED, V163, P1363, DOI 10.1084/jem.163.6.1363; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; Rankin ECC, 1996, CLIN IMMUNOTHER, V6, P143, DOI 10.1007/BF03259511; ROUXLOMBARD P, 1993, ARTHRITIS RHEUM-US, V36, P485, DOI 10.1002/art.1780360408; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SHINGU M, 1993, CLIN EXP IMMUNOL, V94, P145; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TSUKADA N, 1993, NEUROLOGY, V43, P2679, DOI 10.1212/WNL.43.12.2679; Ward R A, 1993, ASAIO J, V39, pM782; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WESTACOTT CI, 1994, J RHEUMATOL, V21, P1710; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; WOOLEY PH, 1993, J IMMUNOL, V151, P6602; ZANGERLE R, 1994, J ACQ IMMUN DEF SYND, V7, P79	57	1338	1429	1	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					141	147		10.1056/NEJM199707173370301	http://dx.doi.org/10.1056/NEJM199707173370301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219699	Bronze			2022-12-28	WOS:A1997XK81800001
J	Slee, PHTJ				Slee, PHTJ			Nail changes after chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Slee, PHTJ (corresponding author), ST ANTONIUS HOSP,NL-3430 EM NIEUWEGEIN,NETHERLANDS.								0	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					168	168		10.1056/NEJM199707173370305	http://dx.doi.org/10.1056/NEJM199707173370305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219703				2022-12-28	WOS:A1997XK81800005
J	Kostis, JB; Davis, BR; Cutler, J; Grimm, RH; Berge, KG; Cohen, JD; Lacy, CR; Perry, HM; Blaufox, MD; WassertheilSmoller, S; Black, HR; Schron, E; Berkson, DM; Curb, JD; Smith, WM; McDonald, R; Applegate, WB				Kostis, JB; Davis, BR; Cutler, J; Grimm, RH; Berge, KG; Cohen, JD; Lacy, CR; Perry, HM; Blaufox, MD; WassertheilSmoller, S; Black, HR; Schron, E; Berkson, DM; Curb, JD; Smith, WM; McDonald, R; Applegate, WB			Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DYSFUNCTION; UNITED-STATES; MORTALITY; MORBIDITY; TRIAL; PREVALENCE	Context.-Heart failure is often preceded by isolated systolic hypertension, but the effectiveness of antihypertensive treatment in preventing heart failure is not known. Objective.-To assess the effect of diuretic-based antihypertensive stepped-care treatment on the occurrence of heart failure in older persons with isolated systolic hypertension. Design.-Analysis of data from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Participants.-A total of 4736 persons aged 60 years and older with systolic blood pressure between 160 and 219 mm Hg and diastolic blood pressure below 90 mm Hg who participated in the Systolic Hypertension in the Elderly Program (SHEP). Intervention.-Stepped-care antihypertensive drug therapy, in which the step 1 drug is chlorthalidone (12.5-25 mg) or matching placebo, and the step 2 drug is atenolol (25-50 mg) or matching placebo. Main Outcome Measures.-Fatal and nonfatal heart failure. Results.-During an average of 4.5 years of follow-up, fatal or nonfatal heart failure occurred in 55 of 2365 patients randomized to active therapy and 105 of the 2371 patients randomized to placebo (relative risk [RR], 0.51; 95% confidence interval [CI], 0.37-0.71; P<.001; number needed to treat to prevent 1 event [NNT], 48). Among patients with a history of or electrocardiographic evidence of prior myocardial infarction (MI), the RR was 0.19 (95% CI, 0.06-0.53; P=.002; NNT, 15). Older patients, men, and those with higher systolic blood pressure or a history of or electrocardiographic evidence of MI at baseline had higher risk of developing heart failure. Conclusion.-In older persons with isolated systolic hypertension, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in preventing heart failure. Among patients with prior MI, an 80% risk reduction was observed.	UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; NHLBI, BETHESDA, MD 20892 USA; MINNEAPOLIS MED RES FDN INC, SHAPIRO CTR EVIDENCE BASED MED, MINNEAPOLIS, MN USA; UNIV MINNESOTA, MINNEAPOLIS, MN USA; MAYO CLIN & MAYO FDN, MAYO MED SCH, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA; ALBERT EINSTEIN COLL MED, DEPT NUCL MED, BRON, FRANCE; ALBERT EINSTEIN COLL MED, DEPT SOCIAL MED, BRON, FRANCE; ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL, BRON, FRANCE; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PREVENT MED, CHICAGO, IL 60612 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, CHICAGO, IL 60611 USA; IDA & NORMAN STONE MED CTR, CHICAGO, IL USA; UNIV HAWAII, JOHN A BURNS SCH MED, DEPT MED, HONOLULU, HI 96822 USA; PACIFIC HLTH RES INST, HONOLULU, HI USA; SRI INT, DIV HLTH SCI, MENLO PK, CA 94025 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA USA; UNIV TENNESSEE, DEPT PREVENT MED, MEMPHIS, TN USA	University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Rush University; Northwestern University; University of Hawaii System; Pacific Health Research & Education Institute; SRI International; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Health Science Center	Kostis, JB (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, NEW BRUNSWICK, NJ 08903 USA.		Blaufox, MDonald/AAF-6965-2020	Blaufox, MDonald/0000-0002-4148-6866				AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1980, LANCET, V1, P1261; BALL SG, 1993, LANCET, V342, P821; BORHANI NO, 1991, HYPERTENSION, V17, P2, DOI 10.1161/01.HYP.17.3_Suppl.II2; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; Kostis JB, 1995, AM J HYPERTENS, V8, P1147, DOI 10.1016/0895-7061(95)00363-0; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MOREAU T, 1986, BIOMETRIKA, V73, P513; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SCHOENFELD D, 1980, BIOMETRIKA, V67, P145; *US DEP HLTH HUM S, 1994, QUICK REF GUID CLIN, V11; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; 1994, MMWR-MORBID MORTAL W, V43, P77	25	431	445	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					212	216						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218667				2022-12-28	WOS:A1997XK10800026
J	vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK				vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK			Retrospective study of doctors' ''end of life decisions'' in caring for mentally handicapped people in institutions in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To gain insight into the reasons behind and the prevalence of doctors' decisions at the end of life that might hasten a patient's death (''end of life decisions'') in institutions caring for mentally handicapped people in the Netherlands, and to describe important aspects of the decisions making process. Design: Survey of random sample of doctors caring for mentally handicapped people by means of self completed questionnaires and structured interviews. Subjects: 89 of the 101 selected doctors completed the questionnaire. 67 doctors had taken an end of life decision and were interviewed about their most recent case. Main outcome measures: Prevalence of end of life decisions; types of decisions; characteristics of patients; reasons why the decision was taken; and the decision making process. Results: The 89 doctors reported 222 deaths for 1995, An end of life decision was taken in 97 cases (44%); in 75 the decision was to withdraw or withhold treatment, and in 22 it was to relieve pain or symptoms with opiates in dosages that may have shortened life. In the 67 most recent cases with an end of life decision the patients were mostly incompetent (63) and under 65 years old (51). Only two patients explicitly asked to die, but in 23 cases there had been some communication with the patient In 60 cases the doctors discussed the decision with nursing staff and in 46 with a colleague. Conclusions: End of life decisions are an important aspect of the institutionalised care of mentally handicapped people. The proportion of such decisions in the total number of deaths is similar to that in other specialties. However, the discussion of such decisions is less open in the care of mental handicap than in other specialties. Because of distinctive features of care in this specialty an open debate about end of life decisions should not be postponed.	HEEREN LOO LOZENOORD,ERMELO,NETHERLANDS		vanThiel, GJMW (corresponding author), UNIV UTRECHT,CTR BIOETH & HLTH LAW,POB 80105,NL-3508 TC UTRECHT,NETHERLANDS.		Van Thiel, Ghislaine/R-8977-2019	van Thiel, Ghislaine/0000-0003-1799-1894				DRANE JF, 1985, HASTINGS CENT REP, V15, P17, DOI 10.2307/3560639; Jonsen A. R., 1992, CLIN ETHICS; *MIN VOLSG WELZ SP, 1995, PERK BUIT MEERJ INT; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIA MED DECIS; *VER GEH NED, 1996, JB VERST GEH DIC LRZ; *VER GEH NED, 1996, LAND REG ZORG DIENST	8	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					88	91		10.1136/bmj.315.7100.88	http://dx.doi.org/10.1136/bmj.315.7100.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240047	Green Published			2022-12-28	WOS:A1997XL25200020
J	Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J				Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J			Pax6 controls progenitor cell identity and neuronal fate in response to graded shh signaling	CELL			English	Article							SONIC HEDGEHOG; FLOOR PLATE; MOTOR-NEURONS; EXPRESSION PATTERN; NERVOUS-SYSTEM; CHICK-EMBRYO; NEURAL-TUBE; GENE; DIFFERENTIATION; INDUCTION	Distinct classes of motor neurons and ventral interneurons are generated by the graded signaling activity of Sonic hedgehog (Shh). Shh controls neuronal fate by establishing different progenitor cell populations in the ventral neural tube that are defined by the expression of Pax6 and Nkx2.2. Pax6 establishes distinct ventral progenitor cell populations and controls the identity of motor neurons and ventral interneurons, mediating graded Shh signaling in the ventral spinal cord and hindbrain.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NAGOYA UNIV,DIV BIOL SCI,NAGOYA,AICHI 46401,JAPAN	Columbia University; Howard Hughes Medical Institute; University of Edinburgh; Nagoya University			VAN HEYNINGEN, Veronica/GYE-0531-2022; Kawakami, Atsushi/D-3785-2019; van Heyningen, Veronica/B-8039-2008; Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022	Kawakami, Atsushi/0000-0001-9461-6372; van Heyningen, Veronica/0000-0003-0359-0141; Schedl, Andreas/0000-0001-9380-7396; Briscoe, James/0000-0002-1020-5240; Ericson, Johan/0000-0002-8019-7127	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARTH KA, 1995, DEVELOPMENT, V121, P1755; CALLISTER RJ, 1987, J COMP NEUROL, V255, P369, DOI 10.1002/cne.902550305; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERICSON J, 1992, SCIENCE, V256, P1550; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; GOSHGARIAN HG, 1981, J COMP NEUROL, V201, P441, DOI 10.1002/cne.902010309; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KRAMMER EB, 1987, ADV ANAT EMBRYOL CEL, V103, P1; KURATANI S, 1990, ANAT EMBRYOL, V182, P435; KURATANI S, 1988, AM J ANAT, V182, P155, DOI 10.1002/aja.1001820206; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Liinamaa TL, 1997, J COMP NEUROL, V377, P298, DOI 10.1002/(SICI)1096-9861(19970113)377:2<298::AID-CNE10>3.0.CO;2-N; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; OSUMI N, 1997, IN PRESS DEVELOPMENT; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RYAN G, 1995, DEVELOPMENT, V121, P867; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; Stoykova A, 1996, DEVELOPMENT, V122, P3453; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Warren N, 1997, DEVELOPMENT, V124, P1573; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	51	808	823	5	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					169	180		10.1016/S0092-8674(00)80323-2	http://dx.doi.org/10.1016/S0092-8674(00)80323-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230312	hybrid			2022-12-28	WOS:A1997XL36200018
J	Moretta, A				Moretta, A			Molecular mechanisms in cell-mediated cytotoxicity	CELL			English	Review							NATURAL-KILLER-CELLS; CLASS-I MOLECULES; T-LYMPHOCYTES; FAS; RECEPTORS; BINDING; DEATH; ACTIVATION; TRANSPORT; ANTIGENS		UNIV GENOA,INST HISTOL,I-16132 GENOA,ITALY	University of Genoa	Moretta, A (corresponding author), UNIV BRESCIA,DEPT BIOMED SCI & BIOTECHNOL,I-25100 BRESCIA,ITALY.							Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOLHUIS RLH, 1996, IMMUNOPATHOL, V18, P211; BOTET ML, 1997, IMMUNOL REV, V155, P165; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; FAHNESTOCK ML, 1995, IMMUNITY, V3, P583, DOI 10.1016/1074-7613(95)90129-9; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Fruh K, 1997, J MOL MED-JMM, V75, P18, DOI 10.1007/s001090050082; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GROSS G, 1992, FASEB J, V6, P3370, DOI 10.1096/fasebj.6.15.1464371; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; JANS KDA, 1996, J BIOL CHEM, V271, P30781; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Karre K, 1997, NATURE, V386, P446, DOI 10.1038/386446a0; Lazetic S, 1996, J IMMUNOL, V157, P4741; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Munz C, 1997, J EXP MED, V185, P385, DOI 10.1084/jem.185.3.385; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pazmany L, 1996, SCIENCE, V274, P792, DOI 10.1126/science.274.5288.792; Pende D, 1997, EUR J IMMUNOL, V27, P1875, DOI 10.1002/eji.1830270809; PerezVillar JJ, 1997, J IMMUNOL, V158, P5736; Renard V, 1997, IMMUNOL REV, V155, P205, DOI 10.1111/j.1600-065X.1997.tb00953.x; Reyburn H, 1997, IMMUNOL REV, V155, P119, DOI 10.1111/j.1600-065X.1997.tb00944.x; Ropke M, 1996, P NATL ACAD SCI USA, V93, P14704, DOI 10.1073/pnas.93.25.14704; SARIN A, 1997, IMMUNITY, V6, P206; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; Sivori S, 1996, EUR J IMMUNOL, V26, P2487, DOI 10.1002/eji.1830261032; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; THALE R, 1995, J VIROL, V69, P6098; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Valiante NM, 1997, IMMUNOL REV, V155, P155, DOI 10.1111/j.1600-065X.1997.tb00948.x; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	49	65	68	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					13	18		10.1016/S0092-8674(00)80309-8	http://dx.doi.org/10.1016/S0092-8674(00)80309-8			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230298	Bronze			2022-12-28	WOS:A1997XL36200004
J	Shapiro, HT				Shapiro, HT			Ethical and policy issues of human cloning	SCIENCE			English	Article											Shapiro, HT (corresponding author), PRINCETON UNIV,PRINCETON,NJ 08544, USA.							Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	1	7	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					195	196		10.1126/science.277.5323.195	http://dx.doi.org/10.1126/science.277.5323.195			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235635				2022-12-28	WOS:A1997XK41800032
J	Zou, H; Rothstein, R				Zou, H; Rothstein, R			Holliday junctions accumulate in replication mutants via a RecA homolog-independent mechanism	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DNA-POLYMERASE-EPSILON; ESCHERICHIA-COLI; MEIOTIC RECOMBINATION; MISMATCH REPAIR; PRIMASE COMPLEX; RIBOSOMAL DNA; GENE-PRODUCT; PROTEIN; ALPHA	The Holliday junction recombination intermediate, an X-shaped DNA molecule (xDNA), was analyzed at rDNA in mitotically growing yeast. In wild-type cells, xDNA is only detected at S phase, suggesting that recombination is stimulated to repair replication-related lesions. A search for mutations that increase the level of xDNA uncovered a gene encoding a subunit of DNA polymerase alpha. Systematic examination of replication mutants revealed that defects in polymerase alpha and delta but not the epsilon complex stimulate the level of xDNA. These xDNAs are Holliday junctions and not replication intermediates. The level of Holliday junctions is greatly reduced in rad52 mutants, but surprisingly, not in mutants defective in the three known mitotically expressed yeast RecA homologs.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	Columbia University				Rothstein, Rodney/0000-0002-4107-9654	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050237, R01GM050237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1990, GENETICS, V124, P573; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CAO Y, 1995, GENETICS, V139, P1483; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FRIEDBERG EC, 1995, DNA REPAIR; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GERRING S L, 1991, P57; GNAGLOFF S, 1996, EMBO J, V15, P1715; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KADYK LC, 1992, GENETICS, V132, P387; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KUNZ BA, 1989, GENETICS, V122, P535; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LIANG C, 1994, MOL CELL BIOL, V14, P1520, DOI 10.1128/MCB.14.2.1520; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MCDONALD JP, 1994, GENETICS, V137, P393; MONTELONE BA, 1981, J BACTERIOL, V147, P517, DOI 10.1128/JB.147.2.517-525.1981; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PETES TD, 1991, MOL CELLULAR BIOL YE; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; RATTRAY AJ, 1995, GENETICS, V139, P45; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1980, NATURE, V284, P426, DOI 10.1038/284426a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YOUNG CSH, 1984, J VIROL, V51, P571, DOI 10.1128/JVI.51.3.571-577.1984; ZGAGA Z, 1991, CURR GENET, V19, P329, DOI 10.1007/BF00355064	68	227	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					87	96		10.1016/S0092-8674(00)80316-5	http://dx.doi.org/10.1016/S0092-8674(00)80316-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230305	hybrid			2022-12-28	WOS:A1997XL36200011
J	Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A				Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A			Properties of ideal composite knots	NATURE			English	Article							NUMBER	The shortest tube of constant diameter that can form a given knot represents the 'ideal' form of the knot(1,2). Ideal knots provide an irreducible representation of the knot, and they have some intriguing mathematical and physical features, including a direct correspondence with the time-averaged shapes of knotted DNA molecules in solution(1,2). Here we describe the properties of ideal forms of composite knots-knots obtained by the sequential tying of two or more independent knots (called factor knots) on the same string. We find that the writhe (related to the handedness of crossing points) of composite knots is the sum of that of the ideal forms of the factor knots. By comparing ideal composite knots with simulated configurations of knotted, thermally fluctuating DNA, we conclude that the additivity of writhe applies also to randomly distorted configurations of composite knots and their corresponding factor knots. We show that composite knots with several factor knots may possess distinct structural isomers that can be interconverted only by loosening the knot.	UNIV LAUSANNE,LAB ANAL ULTRASTRUCT,CH-1015 LAUSANNE,SWITZERLAND; INST MOL PHYS,PL-60159 POZNAN,POLAND; POZNAN TECH UNIV,INST PHYS,PL-60965 POZNAN,POLAND; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903	University of Lausanne; Poznan University of Technology; Rutgers State University New Brunswick			Katritch, Vsevolod/Q-8357-2016; Stasiak, Andrzej/E-5551-2010; Pieranski, Piotr/H-7805-2014; Katritch, Vsevolod/Y-2721-2019	Katritch, Vsevolod/0000-0003-3883-4505; Stasiak, Andrzej/0000-0002-0398-1989; 				Calugareanu G., 1959, REV MATH PURE APPL, V4, P5; FULLER FB, 1978, P NATL ACAD SCI USA, V75, P3557, DOI 10.1073/pnas.75.8.3557; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; Katritch V, 1996, NATURE, V384, P142, DOI 10.1038/384142a0; Pieranski P, 1996, PRODIALOG, V5, P111; Rolfsen D., 1976, MATH LECT SERIES, V7; Stasiak A, 1996, NATURE, V384, P122, DOI 10.1038/384122a0; VanRensburg EJJ, 1997, J KNOT THEOR RAMIF, V6, P31; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P	9	82	80	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					148	151		10.1038/40582	http://dx.doi.org/10.1038/40582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217153	Bronze			2022-12-28	WOS:A1997XK10900042
J	Eastman, RC; Keen, H				Eastman, RC; Keen, H			The impact of cardiovascular disease on people with diabetes: The potential for prevention	LANCET			English	Article							MORTALITY; PROTEINURIA; PREDICTOR; MELLITUS		GUYS HOSP,METAB MED UNIT,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Eastman, RC (corresponding author), NIDDKD,DIV DIABET & METAB DIS,BLDG 31,ROOM 9A16,31 CTR DR,MSC 2560,BETHESDA,MD 20892, USA.							Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; Anderson K, 1990, AM HEART J, V121, P293; ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; [Anonymous], 1995, DIABETES AM; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; COWIE CC, 1995, DIABETES AM, P117; *DCCT STUD GROUP, IN PRESS JAMA; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; Fuller JH, 1996, ANN MED, V28, P319, DOI 10.3109/07853899608999088; GEISS LA, 1995, DIABETES, V44, P456; Kenny S. J., 1995, DIABETES AM, P47; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KOCHANEK KD, 1994, MONTHLY VITAL STAT R, V43, P17; KULLER LH, 1995, DIABETES AM, P449; MARRE M, 1996, KIDNEY HYPERTENSION, P351; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MATTOCK MB, 1997, CARDIOVASCULAR DIS P, V3, P30; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PALUMBO PJ, 1995, DIABETES AM, P401; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; Pyorala K, 1996, LANCET, V348, pS26, DOI 10.1016/S0140-6736(96)98009-5; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; *UK PROSP DIAB STU, 1995, DIABETES, V44, P1249; United States Renal Data System, 1994, USRDS 1994 ANN DAT R; WINGARD DL, 1995, DIABETES AM, P429	29	20	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI29	SI32						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250281				2022-12-28	WOS:A1997XM26500008
J	Zimmet, PZ; Alberti, KGMM				Zimmet, PZ; Alberti, KGMM			The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: An epidemic in progress	LANCET			English	Article							CORONARY HEART-DISEASE; CAUSE-SPECIFIC MORTALITY; RISK-FACTORS; CARDIOVASCULAR MORTALITY; POPULATION; HYPERINSULINEMIA; PREVENTION; PREVALENCE; TANZANIA; NIDDM		INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MED SCH NEWCASTLE UPON TYNE,HUMAN DIABET & METAB RES CTR,SCH CLIN MED SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK			Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776				ALBERTI KGMM, 1993, DIABETOLOGIA, V36, P978, DOI 10.1007/BF02374487; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Eriksson J, 1997, DIABETOLOGIA, V40, P125; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HEAD J, 1990, DIABETOLOGIA, V33, P477, DOI 10.1007/BF00405109; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; JARRETT RJ, 1988, DIABETOLOGIA, V31, P71, DOI 10.1007/BF00395550; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; Lowe LP, 1997, DIABETES CARE, V20, P163, DOI 10.2337/diacare.20.2.163; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; Meigs JB, 1997, AM J MED, V102, P38, DOI 10.1016/S0002-9343(96)00383-X; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; NELSON RG, 1990, CIRCULATION, V81, P987, DOI 10.1161/01.CIR.81.3.987; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; SONGER TJ, 1992, DIABETES METAB REV, V8, P389, DOI 10.1002/dmr.5610080406; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; SWAI ABM, 1993, INT J EPIDEMIOL, V22, P651, DOI 10.1093/ije/22.4.651; TUOMILEHTO J, 1992, DIABETES METAB REV, V8, P339, DOI 10.1002/dmr.5610080403; *UKPDS GROUP, 1991, DIABETOLOGIA, V34, P877; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; *WHO, 1985, DIABETOLOGIA, V28, P615; World Health Organization, 1994, WHO TECHN REP SER, V844; ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203; ZIMMET P, 1991, DIABETES ANN, V6, P1; ZIMMET PZ, 1995, DIABETES CARE, V18, P1050, DOI 10.2337/diacare.18.7.1050; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232; Zimmet PZ, 1997, J DIABETES COMPLICAT, V11, P60, DOI 10.1016/S1056-8727(96)00090-6; ZIMMET PZ, 1993, DIABETES CARE, V16, P56, DOI 10.2337/diacare.16.3.56	37	28	29	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI1	SI4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250275				2022-12-28	WOS:A1997XM26500002
J	Fairfield, G; Hunter, DJ; Mechanic, D; Rosleff, F				Fairfield, G; Hunter, DJ; Mechanic, D; Rosleff, F			Managed care - Origins, principles, and evolution	BRITISH MEDICAL JOURNAL			English	Article							PLANS		UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND; RUTGERS STATE UNIV,NEW BRUNSWICK,NJ 08903; BURE MANAGED CARE,S-40229 GOTHENBURG,SWEDEN	University of Leeds; Rutgers State University New Brunswick								Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Fairfield G, 1996, BRIT MED J, V312, P1554, DOI 10.1136/bmj.312.7046.1554; GOLD M, 1995, SELECTED EXTERNAL RE, V3; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GROSS P, 1995, HLTH SERVICES J 0427, P20; *HEALTHC 2000, 1995, UK HLTH HEALTHC SERV; HURLEY R, 1996, SELECTED EXTERNAL RE, V6; INGLEHART JK, 1993, NEW ENGL J MED, V327, P742; INGLEHART JK, 1994, NEW ENGL J MED, V331, P1167; LUFT HS, 1987, HLTH MAINTENANCE ORG; MECHANIC D, 1994, INQUIRY-J HEALTH CAR, V31, P124; NEWMAN P, 1995, BRIT MED J, V310, P652; ROSLEFF F, 1995, EUROPEAN HEALTHCARE; Starr Paul, 1982, SOCIAL TRANSFORMATIO, P32; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; Zelman W. A., 1996, CHANGING HLTH CARE M	16	29	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1823	1826		10.1136/bmj.314.7097.1823	http://dx.doi.org/10.1136/bmj.314.7097.1823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224090	Green Published			2022-12-28	WOS:A1997XG16600032
J	Zino, S; Skeaff, M; Williams, S; Mann, J				Zino, S; Skeaff, M; Williams, S; Mann, J			Randomised controlled trial of effect of fruit and vegetable consumption on plasma concentrations of lipids and antioxidants	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-E CONSUMPTION; UNITED-STATES; BETA-CAROTENE; CANCER PREVENTION; CLINICAL-TRIAL; MEN; DISEASE; RISK; LIPOPROTEINS; ASSAY	Objectives: To determine the extent to which plasma antioxidant concentrations in people with habitual low intake of fruit and vegetables respond to increased intakes of these foods. To examine whether advice to increase fruit and vegetables will result in reduction of concentrations of total and low density lipoprotein cholesterol. Design: Randomised controlled trial in which intervention and control groups were followed up for eight weeks. The intervention group was asked to consume eight servings of fruit and vegetables a day. Setting: Dunedin, New Zealand. Subjects: Eighty seven subjects with normal lipid concentrations who ate three or fewer servings of fruit and vegetables daily. Main outcome measures: Plasma concentrations of vitamin C, retinol, alpha and beta carotene, alpha tocopherol, lipids, and lipoproteins. Dietary intake assessed with diet records over four days. Results: The mean plasma vitamin C, alpha carotene, and beta carotene concentrations increased in parallel with increased dietary intake of fruit and vegetables in the intervention group. Concentrations of retinol, alpha tocopherol, lipids, and lipoproteins remained unchanged despite some increase in dietary vitamin E and a small reduction in saturated fat intake. Conclusions: Following a recommendation to increase fruit and vegetable consumption produces change in plasma concentrations of vitamin C, alpha carotene, and beta carotene likely to reduce incidence of cancer. More specific dietary advice to modify fat intake may be necessary to reduce the risk of cardiovascular disease mediated by lipoprotein and vitamin E.	UNIV OTAGO, DEPT HUMAN NUTR, DUNEDIN, NEW ZEALAND; UNIV OTAGO, DEPT SOCIAL & PREVENT MED, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago			Skeaff, Clark/C-2713-2009					Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; COX C, 1995, BMJ-BRIT MED J, V311, P1260, DOI 10.1136/bmj.311.7015.1260; dePee S, 1996, EUR J CLIN NUTR, V50, pS38; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; JIALAL I, 1993, CLIN CARDIOL, V16, P6, DOI 10.1002/clc.4960161304; JOHNSON EJ, 1992, AM J CLIN NUTR, V56, P128, DOI 10.1093/ajcn/56.1.128; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; LEMARCHAND L, 1994, CANCER EPIDEM BIOMAR, V3, P245; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Mackerras D, 1996, J CLIN EPIDEMIOL, V49, P957, DOI 10.1016/0895-4356(96)00142-4; MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3; MURPHY SP, 1990, AM J CLIN NUTR, V52, P361, DOI 10.1093/ajcn/52.2.361; NOMURA AMY, 1985, CANCER RES, V45, P2369; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SMITH SA, 1995, CANCER CAUSE CONTROL, V6, P292, DOI 10.1007/BF00051404; STAHELIN HB, 1984, J NATL CANCER I, V73, P1463; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; THURNHAM DI, 1988, CLIN CHEM, V34, P377; VANPOPPEL G, 1995, AM J CLIN NUTR, V62, P1393, DOI 10.1093/ajcn/62.6.1393S; VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25	31	132	133	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	1997	314	7097					1787	1791		10.1136/bmj.314.7097.1787	http://dx.doi.org/10.1136/bmj.314.7097.1787			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224079	Green Published			2022-12-28	WOS:A1997XG16600020
J	Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA				Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA			A model for the microtubule-Ncd motor protein complex obtained by cryo-electron microscopy and image analysis	CELL			English	Article							KINESIN HEAVY-CHAIN; 3-DIMENSIONAL STRUCTURE; DROSOPHILA; RECONSTRUCTION; MICROGRAPHS; MOTILITY; MOVEMENT; TUBULIN; DOMAINS; INVITRO	Kinesin motors convert chemical energy from ATP hydrolysis into unidirectional movement. To understand how kinesin motors bind to and move along microtubules, we fit the atomic structure of the motor domain of Ncd (a kinesin motor involved in meiosis and mitosis) into three-dimensional density maps of Ncd-microtubule complexes calculated by cryo-electron microscopy and image analysis. The model reveals that Ncd shares an extensive interaction surface with the microtubule, and that a portion of the binding site involves loops that contain conserved residues. In the Ncd dimer, the microtubule-bound motor domain makes intimate contact with its partner head, which is dissociated from the microtubule. This head-head interaction may be important in positioning the dissociated head to take a step to the next binding site on the microtubule protofilament.	SCRIPPS RES INST, DEPT CELL BIOL MB25, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hoenger, Andreas/0000-0001-9176-6658	NIAMS NIH HHS [AR42895] Funding Source: Medline; NIGMS NIH HHS [GM52468] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052468, R37GM052468] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; AMOS LA, 1974, J CELL SCI, V14, P523; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Carragher B, 1996, J STRUCT BIOL, V116, P107, DOI 10.1006/jsbi.1996.0018; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hoenger A, 1996, J MOL BIOL, V263, P114, DOI 10.1006/jmbi.1996.0561; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORGAN D, 1993, BIOPHYS J, V64, pA243; RAY S, 1995, CELL MOTIL CYTOSKEL, V30, P146, DOI 10.1002/cm.970300206; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; Sosa H, 1997, J STRUCT BIOL, V118, P149, DOI 10.1006/jsbi.1997.3851; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Tucker C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Wade RH, 1995, PROTEINS, V23, P502, DOI 10.1002/prot.340230405; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	42	142	143	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					217	224		10.1016/S0092-8674(00)80330-X	http://dx.doi.org/10.1016/S0092-8674(00)80330-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244296	Bronze			2022-12-28	WOS:A1997XN24900006
J	Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH				Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH			The safety of newborn early discharge - The Washington State experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL DISCHARGE; MOTHERS; POPULATION; INFANTS	Context.-While early discharge of newborns following routine vaginal delivery has become common practice, its safety has not been firmly established. Objective.-To assess the risk for rehospitalization following newborn early discharge. Design.-Population-based, case-control study. Setting.-Washington State linked birth certificate and hospital discharge abstracts covering 310 578 live births from 1991 through 1994. Patients.-Case patients were 2029 newborns rehospitalized in the first month of life. Control subjects were 8657 randomly selected newborns not rehospitalized and frequency matched to case patients on year of birth. Cesarean deliveries, multiple births, and births at less than 36 weeks' gestation were not included. Main Outcome Measure.-Stratified analyses and logistic regression were performed to assess the risk for rehospitalization within a month of birth after early discharge (<30 hours after birth) compared with later discharge (30-78 hours after birth). Results.-Seventeen percent of newborns were discharged early. Newborns discharged early were more likely to be rehospitalized within 7 days (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.11-1.47), 14 days (OR, 1.16; 95% CI, 1.03-1.32), and 28 days (OR, 1.12; 95% CI, 1.00-1.25) of discharge than newborns sent home later. Subgroups at increased risk for rehospitalization following early discharge included newborns born to primigravidas (OR,1.25; 95% CI, 1.07-1.45), mothers younger than 18 years (OR, 1.22; 95% CI, 0.79-1.91), and mothers with premature rupture of membranes (OR, 1.41;95% CI, 0.85-2.36). Early discharge was also associated with an increased risk of readmission for jaundice, dehydration, and sepsis. Conclusion.-Newborns discharged home early (<30 hours after birth) are at increased risk for rehospitalization during the first month of life.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of North Carolina; University of North Carolina Chapel Hill			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Shay, David/0000-0001-9619-4820	BHP HRSA HHS [5-T32-PE10002] Funding Source: Medline	BHP HRSA HHS		ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRESLOW NE, 1980, STATISTICAL METHODS, P1; BRITTON JR, 1994, PEDIATRICS, V94, P291; CARTY EM, 1990, BIRTH-ISS PERINAT C, V17, P199, DOI 10.1111/j.1523-536X.1990.tb00021.x; CLARK G, 1996, AAP NEWS, V12, P1; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; Gauda EB, 1996, JAMA-J AM MED ASSOC, V275, P1823, DOI 10.1001/jama.275.23.1823; HELLMAN LM, 1962, LANCET, V1, P227; JANSSON P, 1985, AM J NURS, V85, P547, DOI 10.2307/3425241; KEMPER KJ, 1990, AM J DIS CHILD, V144, P238, DOI 10.1001/archpedi.1990.02150260118043; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; RHODES MK, 1994, MIL MED, V159, P227, DOI 10.1093/milmed/159.3.227; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCUPHOLME A, 1981, J NURSE-MIDWIFERY, V26, P19, DOI 10.1016/0091-2182(81)90171-3; SOLA A, 1996, SOC PED RES ANN M, V39, pA113; WALDENSTROM U, 1987, UPSALA J MED SCI, V92, P301, DOI 10.3109/03009738709178701; *WASH STAT DEP HLT, 1996, BIRA18M1 WASH STAT D; WELT SI, 1993, AM J PERINAT, V10, P384, DOI 10.1055/s-2007-994768; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1995, NY TIMES        1011, pC18; 1995, VITAL HLTH STAT, V13	29	129	134	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					293	298		10.1001/jama.278.4.293	http://dx.doi.org/10.1001/jama.278.4.293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228434				2022-12-28	WOS:A1997XL05900029
J	Bryan, CS				Bryan, CS			Mr Gates's summer vacation: A centennial remembrance	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	27th Annual Meeting of the American-Osler-Society	APR 03-04, 1997	WILLIAMSBURG, VA	Amer Osler Soc			OSLER	In 1897, Frederick T. Gates, a Baptist minister and adviser to John D. Rockefeller Sr., read the entire second edition of The Principles and Practice of Medicine by William Osler while on a summer vacation at Lake Liberty, New York. The book reinforced the low opinion Gates had of the efficacy of medicine but convinced him that medical science would be a wise investment for the Rockefeller fortune. The results of this investment included the Rockefeller Institute for Medical Research, the General Education Board, the Rockefeller Foundation, and the International Health Board. Gates sponsored Rockefeller funding of full-time clinical professorships, an idea that Osler opposed but that eventually became the prevailing model for medical departments at universities in the United States.			Bryan, CS (corresponding author), UNIV S CAROLINA, SCH MED, DEPT MED, 2 RICHLAND MED PK, SUITE 502, COLUMBIA, SC 29203 USA.							Abrahamson S, 1996, ACAD MED, V71, P343, DOI 10.1097/00001888-199604000-00008; BERLINER HS, 1985, SYSTEM SCI MED PHILA, P77; BERLINER HS, 1985, SYSTEM SCI MED PHILA, P168; BERLINER HS, 1985, SYSTEM SCI MED PHILA, P139; BERLINER HS, 1985, SYSTEM SCI MED PHILA, P53; BORDLEY J, 1976, 2 CENTURIES AM MED, P165; CHENEY AM, 1963, J HOPKINS HOSP J HOP, V3, P176; CORNER GW, 1964, HIST ROCKEFELLER I 1, P1; CUSHING H, 1920, COMMUNICATION   0504; CUSHING H, 1925, LIFE W OLSER, V1, P454; Elks ML, 1996, PERSPECT BIOL MED, V39, P601; Engel G. L, 1988, TASK MED DIALOGUE WI, P113; FELXNER S, 1993, WH WELCH HEROIC AGE, P297; FLEMING D, 1954, WH WELCH RISE MODERN, P171; FLEXNER A, 1940, I REMEMBER AUTOBIOGR, P176; Flexner A, 1910, CARNEGIE FDN ADV TEA, V4; FLEXNER S, 1993, WH WELCH HEROIC AGE, P269; FOSDICK RB, 1952, STORY ROCKEFELLER FD, P8; FOSDICK RB, 1952, STORY ROCKEFELLER FD, P1; FYE WB, 1989, NEW ENGL J MED, V320, P1425, DOI 10.1056/NEJM198905253202123; Gates Frederick Taylor, 1977, CHAPTERS MY LIFE, P161; GATES FT, 1904, COMMUNICATION   0413; GATES FT, 1977, CHAPTERS MY LIFE, P181; GATES FT, 1902, COMMUNICATION   0304; GATES FT, 1977, CHAPTERS MY LIFE, P232; GATES FT, 1977, CHAPTERS MY LIFE, P180; GATES FT, 1912, COMMUNICATION   0118; GATES FT, 1923, COMMUNICATION   0428; GOLDEN RL, 1992, ANN INTERN MED, V116, P255, DOI 10.7326/0003-4819-116-3-255; GOLDEN RL, 1995, SURGERY, V118, P504, DOI 10.1016/S0039-6060(05)80366-6; Harrell G T, 1973, Bull Hist Med, V47, P545; HARVEY AM, 1981, SCI BEDSIDE CLIN RES, P133; Hudson R P, 1972, Bull Hist Med, V46, P545; LENORE ME, 1982, DEATH CLIN REQUEIM R, P20; LUDMERER KM, 1985, LEARNING HEAL DEV AM, P207; LUDMERER KM, 1985, LEARNING HEAL DEV AM, P201; NEVINS A, 1953, STUDY POWER JD ROCKE, V2, P217; OSLER W, 1915, INT CLIN, V4, P1; ROCKEFELLER JD, 1929, COMMUNICATION   0515; ROCKEFELLER JD, 1911, COMMUNICATION   0802; WELCH WH, 1911, COMMUNICATION   0108; WHEATLEY SC, 1988, POLITICS PHILANTHROP, P27; WHEATLEY SC, 1988, POLITICS PHILANTHROP, P102	43	2	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					148	153		10.7326/0003-4819-127-2-199707150-00010	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XK158	9230006				2022-12-28	WOS:A1997XK15800012
J	Graef, IA; Crabtree, GR				Graef, IA; Crabtree, GR			The transcriptional paradox: Octamer factors and B and T cells	SCIENCE			English	Editorial Material							FUNCTIONAL-CHARACTERIZATION; CYCLOSPORINE-A; LYMPHOCYTES-T; COACTIVATOR; ENHANCER; PROTEIN; BINDING; GENE; DOWNSTREAM; ACTIVATION				Graef, IA (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	19	11	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					193	194		10.1126/science.277.5323.193	http://dx.doi.org/10.1126/science.277.5323.193			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235633				2022-12-28	WOS:A1997XK41800030
J	Jacobson, MA				Jacobson, MA			Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNE-DEFICIENCY-SYNDROME; VIRUS RETINITIS; INTRAVITREAL GANCICLOVIR; SUSTAINED-RELEASE; ORAL GANCICLOVIR; AIDS PATIENTS; MAINTENANCE THERAPY; REPLICATION INVITRO; PROGRESSION RATES; FOSCARNET THERAPY		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	Jacobson, MA (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,WARD 84,995 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.				NIAID NIH HHS [AI27663, AI27763] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, U01AI027663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADUMA P, 1995, MOL PHARMACOL, V47, P816; *AIDS CLIN TRIAL G, IN PRESS J INFECT DI; ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; ANDERSON RD, 1995, CLIN THER, V17, P425, DOI 10.1016/0149-2918(95)80107-3; AREVALO JF, 1995, J INFECT DIS, V172, P951, DOI 10.1093/infdis/172.4.951; Baldanti F, 1996, J VIROL, V70, P1390, DOI 10.1128/JVI.70.3.1390-1395.1996; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BIRON KK, 1996, 36 INT C ANT AG CHEM, P168; BLOOM JN, 1988, ANN INTERN MED, V109, P963, DOI 10.7326/0003-4819-109-12-963; BROWN F, 1997, 4 C RETR OPP INF WAS, P209; CANTRILL HL, 1989, OPHTHALMOLOGY, V96, P367, DOI 10.1016/S0161-6420(89)32900-9; Cherrington JM, 1996, J INFECT DIS, V173, P987, DOI 10.1093/infdis/173.4.987; CHERRINGTON JM, 1997, 4 CRETR OPP INF WASH, P120; CHOU SW, 1995, J INFECT DIS, V172, P239, DOI 10.1093/infdis/172.1.239; COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; *COLL DHPG TREATM, 1986, NEW ENGL J MED, V314, P801; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; CUNDY KC, 1995, ANTIMICROB AGENTS CH, V39, P1247, DOI 10.1128/AAC.39.6.1247; DEARMOND B, 1991, J ACQ IMMUN DEF SYND, V4, pS53; DIAZLLOPIS M, 1994, BRIT J OPHTHALMOL, V78, P120, DOI 10.1136/bjo.78.2.120; DIETERICH D, 1996, 36 INT C ANT AG CHEM, P8; Drew W L, 1993, Clin Diagn Virol, V1, P179; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DUNKLE LM, 1996, 11 INT C AIDS VANC J, P20; DUNN JP, 1995, AM J OPHTHALMOL, V119, P587, DOI 10.1016/S0002-9394(14)70217-X; ENGSTROM RE, 1995, AM J OPHTHALMOL, V120, P376, DOI 10.1016/S0002-9394(14)72168-3; FREEMAN WR, 1993, AM J OPHTHALMOL, V116, P713, DOI 10.1016/S0002-9394(14)73471-3; FREITAS VR, 1989, ANTIVIR RES, V12, P205, DOI 10.1016/0166-3542(89)90030-2; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GROSSNIKLAUS HE, 1987, OPHTHALMOLOGY, V94, P1601; HENRY K, 1987, AM J OPHTHALMOL, V103, P17, DOI 10.1016/S0002-9394(14)74163-7; HO HT, 1992, MOL PHARMACOL, V41, P197; HOLLAND GN, 1992, ARCH OPHTHALMOL-CHIC, V110, P1435, DOI 10.1001/archopht.1992.01080220097029; HOLLAND GN, 1989, ARCH OPHTHALMOL-CHIC, V107, P1759, DOI 10.1001/archopht.1989.01070020841024; HOLLAND GN, 1982, AM J OPHTHALMOL, V93, P393, DOI 10.1016/0002-9394(82)90127-1; HOLLAND GN, 1995, AM J OPHTHALMOL, V119, P576, DOI 10.1016/S0002-9394(14)70215-6; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; HUTCHERSON SL, 1995, 35 INT C ANT AG CHEM, P204; JABS D A, 1986, Archives of Ophthalmology, V104, P1436; Jabs D A, 1995, Trans Am Ophthalmol Soc, V93, P623; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1992, AIDS, V6, P515, DOI 10.1097/00002030-199205000-00015; JACOBSON MA, 1993, J INFECT DIS, V168, P444, DOI 10.1093/infdis/168.2.444; JACOBSON MA, 1991, J INFECT DIS, V163, P1348, DOI 10.1093/infdis/163.6.1348; JACOBSON MA, 1994, ANTIMICROB AGENTS CH, V38, P1190, DOI 10.1128/AAC.38.5.1190; JACOBSON MA, 1987, ANTIMICROB AGENTS CH, V31, P1251, DOI 10.1128/AAC.31.8.1251; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; JACOBSON MA, 1994, AIDS, V8, P451, DOI 10.1097/00002030-199404000-00006; JACOBSON MA, 1988, J MED VIROL, V25, P339, DOI 10.1002/jmv.1890250311; JACOBSON MA, 1991, J CLIN ENDOCR METAB, V72, P1130, DOI 10.1210/jcem-72-5-1130; JACOBSON MA, 1992, J ACQUIR IMMUNE D S1, V5, pS1; KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; LALEZARI JP, 1995, J INFECT DIS, V171, P788, DOI 10.1093/infdis/171.4.788; LALEZARI JP, 1996, 11TH INT C AIDS VANC, V2, P226; LASKIN OL, 1987, AM J MED, V83, P201, DOI 10.1016/0002-9343(87)90685-1; Lea AP, 1996, DRUGS, V52, P225, DOI 10.2165/00003495-199652020-00006; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; MANISCHEWITZ JF, 1990, ANTIMICROB AGENTS CH, V34, P373, DOI 10.1128/AAC.34.2.373; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Marx JL, 1996, ARCH OPHTHALMOL-CHIC, V114, P815, DOI 10.1001/archopht.1996.01100140029003; MATHERON S, 1996, 11 INT C AIDS VANC J, V1, P296; Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203; *OR GANC EUR AUSTR, 1995, AIDS, V9, P471; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PEARSON PA, 1993, AM J OPHTHALMOL, V115, P686, DOI 10.1016/S0002-9394(14)71487-4; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; POLIS MA, 1995, ANTIMICROB AGENTS CH, V39, P882, DOI 10.1128/AAC.39.4.882; Rahhal FM, 1996, ANN INTERN MED, V125, P98, DOI 10.7326/0003-4819-125-2-199607150-00003; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SARAN BR, 1994, RETINA-J RET VIT DIS, V14, P248, DOI 10.1097/00006982-199414030-00010; SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839; SNOECK R, 1992, EUR J CLIN MICROBIOL, V11, P1144, DOI 10.1007/BF01961133; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; SQUIRES KE, 1993, 1 NAT C HUM RETR WAS, P154; *STUD OC COMPL AID, 1994, OPHTHALMOLOGY, V101, P1250; *STUD OC COMPL AID, 1997, ANN INTERN MED, V126, P264; *STUD OC COMPL AID, 1996, ARCH OPHTHALMOL-CHIC, V114, P23; *STUD OC COMPL AID, 1992, NEW ENGL J MED, V326, P213; *STUD OC COMPL AID, 1992, NEW ENGL J MED, V326, P1172; SULLIVAN V, 1993, NATURE, V366, P756, DOI 10.1038/366756a0; SULLIVAN V, 1992, NATURE, V359, P85, DOI 10.1038/359085a0; SULLIVAN V, 1992, NATURE, V358, P162, DOI 10.1038/358162a0; TABURET AM, 1992, ANTIMICROB AGENTS CH, V36, P1821, DOI 10.1128/AAC.36.9.1821; TATAROWICZ WA, 1992, J INFECT DIS, V166, P904, DOI 10.1093/infdis/166.4.904; TOLPIN M, 1993, 9 INT C AIDS 4 STD W, P54; USSERY FM, 1988, OPHTHALMOLOGY, V95, P640; WAGSTAFF AJ, 1994, DRUGS, V48, P199, DOI 10.2165/00003495-199448020-00007; WANG LH, 1996, 36 INT C ANT AG CHEM, P168; Wilhelmus KR., 1996, OCULAR INFECT IMMUNI, P1088; XIONG XF, 1996, 36 INT C ANT AG CHEM, P168	96	107	118	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					105	114		10.1056/NEJM199707103370207	http://dx.doi.org/10.1056/NEJM199707103370207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211681				2022-12-28	WOS:A1997XJ82200007
J	Dippel, E; Schrag, H; Goerdt, S; Orfanos, CE				Dippel, E; Schrag, H; Goerdt, S; Orfanos, CE			Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma	LANCET			English	Article									FREE UNIV BERLIN,UNIV MED CTR BENJAMIN FRANKLIN,DEPT DERMATOL,D-12200 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ARMUS S, 1990, J AM ACAD DERMATOL, V23, P898, DOI 10.1016/0190-9622(90)70312-6; BUNN PA, 1986, CANCER, V57, P1689, DOI 10.1002/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; LORINCZ AL, 1996, LANCET, V347, P781; ZIC J, 1992, J AM ACAD DERMATOL, V27, P729, DOI 10.1016/0190-9622(92)70246-C	5	77	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					32	33		10.1016/S0140-6736(05)66242-3	http://dx.doi.org/10.1016/S0140-6736(05)66242-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217723				2022-12-28	WOS:A1997XH86900019
J	McCartney, P; Macdowall, W; Thorogood, M				McCartney, P; Macdowall, W; Thorogood, M			A randomised controlled trial of feedback to general practitioners of their prophylactic aspirin prescribing	BRITISH MEDICAL JOURNAL			English	Article											McCartney, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND.			Macdowall, Wendy/0000-0001-5868-8336				KING R, 1995, BMJ-BRIT MED J, V311, P1504, DOI 10.1136/bmj.311.7018.1504; MCCORMICKK A, 1995, MORBIDITY STAT GEN P, V5; *NHS CTR REV DISS, 1995, EFFECTIVENESS MATTER, P1; 1994, DRUG THER B, V32, P1	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					35	36		10.1136/bmj.315.7099.35	http://dx.doi.org/10.1136/bmj.315.7099.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233326	Green Published			2022-12-28	WOS:A1997XJ94700029
J	Setchell, KDR; ZimmerNechemias, L; Cai, JN; Heubi, JE				Setchell, KDR; ZimmerNechemias, L; Cai, JN; Heubi, JE			Exposure of infants to phyto-oestrogens from soy-based infant formula	LANCET			English	Article							CANCER RISK; HUMAN-URINE; GENISTEIN; IDENTIFICATION; ISOFLAVONES; ESTROGENS; PHYTOESTROGENS; JAPANESE; DISEASE; DIETS	Background The isoflavones genistein, daidzein, and their glycosides, found in high concentrations in soybeans and soy-protein foods, may have beneficial effects in the prevention or treatment of many hormone-dependent diseases. Because these bioactive phyto-oestrogens possess a wide range of hormonal and non-hormonal activities, it has been suggested that adverse effects may occur in infants fed soy-based formulas. Methods To evaluate the extent of infant exposure to phyto-oestrogens from soy formula, the isoflavone composition of 25 randomly selected samples from five major brands of commercially available soy-based infant formulas were analysed, and the plasma concentrations of genistein and daidzein, and the intestinally derived metabolite, equol, were compared in 4-month-old infants fed exclusively soy-based infant formula (n=7), cow-milk formula (n=7), or human breast-milk (n=7). Findings All of the soy formulas contained mainly glycosides of genistein and daidzein, and the total isoflavone content was similar among the five formulas analysed and was related to the proportion of soy isolate used in their manufacture. From the concentrations of isoflavones in these formulas (means 32-47 mu g/mL), the typical daily volume of milk consumed, and average bodyweight, a 1-month-old infant fed soy formula would be exposed to 28-47 per day, or about 4.5-8.0 mg/kg bodyweight per day, of total isoflavones. Mean (SD) plasma concentrations of genistein and daidzein in the seven infants fed soy-based formulas were 684 (443) ng/mL and 295 (60) ng/mL, respectively, which was significantly greater (p<0.05) than in the infants fed either cow-milk formulas (3.2 [0.7] and 2.1 [0.3] ng/mL), or human breast-milk (2.8 [0.7] and 1.4 [0.1] ng/mL), and an order of magnitude higher per bodyweight than typical plasma concentrations of adults consuming soy foods. Interpretation The daily exposure of infants to isoflavones in soy infant-formulas is 6-11 fold higher on a bodyweight basis than the dose that has hormonal effects in adults consuming soy foods. Circulating concentrations of isoflavones in the seven infants fed soy-based formula were 13000-22000 times higher than plasma oestradiol concentrations in early life, and may be sufficient to exert biological effects, whereas the contribution of isoflavones from breast-milk and cow-milk is negligible.	CHILDRENS HOSP MED CTR, DIV GASTROENTEROL & NUTR, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Setchell, KDR (corresponding author), CHILDRENS HOSP MED CTR, CLIN MASS SPECTROMETRY CTR, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-08084] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AXELSON M, 1982, BIOCHEM J, V201, P353, DOI 10.1042/bj2010353; BANNWART C, 1988, BIOMED ENVIRON MASS, V17, P1, DOI 10.1002/bms.1200170104; BARNES S, 1995, P SOC EXP BIOL MED, V208, P103; Bennetts H. W., 1946, AUSTRALIAN VET JOUR, V22, P2, DOI 10.1111/j.1751-0813.1946.tb15473.x; CASSIDY A, 1994, AM J CLIN NUTR, V60, P333, DOI 10.1093/ajcn/60.3.333; Coward L, 1996, CLIN CHIM ACTA, V247, P121, DOI 10.1016/0009-8981(95)06242-4; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; CRUZ MLA, 1994, PEDIATR RES, V35, P135, DOI 10.1203/00006450-199402000-00001; ELDRIDGE AC, 1982, J AGR FOOD CHEM, V30, P353, DOI 10.1021/jf00110a035; Franke AA, 1996, CLIN CHEM, V42, P955; FRANKE AA, 1995, P SOC EXP BIOL MED, V208, P18, DOI 10.3181/00379727-208-43826; HADFIELD P, 1995, NEW SCI         0902, P5; IRVINE C, 1995, NZ MED J, V108, P218; JOANNOU GE, 1995, J STEROID BIOCHEM, V54, P167, DOI 10.1016/0960-0760(95)00131-I; KIRKMAN LM, 1995, NUTR CANCER, V24, P1, DOI 10.1080/01635589509514388; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; Martin L, 1980, ESTROGENS ENV, P103; MESSINA M, 1995, AM J CLIN NUTR, V62, P645, DOI 10.1093/ajcn/62.3.645; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MORTON MS, 1994, J ENDOCRINOL, V142, P251, DOI 10.1677/joe.0.1420251; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225, DOI 10.1016/0016-5085(87)91006-7; SETCHELL KDR, 1984, AM J CLIN NUTR, V40, P569, DOI 10.1093/ajcn/40.3.569; SETCHELL KDR, 1987, J CHROMATOGR, V386, P315, DOI 10.1016/S0021-9673(01)94608-4; Setchell KDR, 1995, P NUT SOC N, V20, P1; SETCHELL KDR, 1985, ESTROGENS ENV INFLUE, P73; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; SETCHELL KDR, IN PRESS AM J CLIN N; Slavin JL, 1996, CLIN CHEM, V42, P841; *UK DEP HLTH, 1996, 96244 UK DEP HLTH; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679, DOI 10.1210/jcem-42-4-679	34	575	595	0	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	1997	350	9070					23	27		10.1016/S0140-6736(96)09480-9	http://dx.doi.org/10.1016/S0140-6736(96)09480-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217716				2022-12-28	WOS:A1997XH86900012
J	Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K				Kenyon, TA; Ridzon, R; LuskinHawk, R; Schultz, C; Paul, WS; Valway, SE; Onorato, IM; Castro, K			A nosocomial outbreak of multidrug-resistant tuberculosis	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTED PATIENTS; LENGTH-POLYMORPHISM ANALYSIS; HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; UNIT	Background: An outbreak of seven cases (in six patients and one health care worker, all of whom had AIDS) of multidrug-resistant tuberculosis occurred in a hospital in Chicago. The hospital had a respirator-fit testing program but no acid-fast bacilli isolation rooms. Objective: To identify risk factors for transmission of Mycobacterium tuberculosis. Design: Retrospective cohort study. Setting: Private hospital. Participants: Patients and health care workers exposed to M. tuberculosis. Measurements: Analysis of M. tuberculosis isolates, tuberculin skin testing, assessment of exposure, and assessment of participant characteristics. Results: All seven M. tuberculosis isolates had matching DNA fingerprints. Of patients exposed to M. tuberculosis, those who developed tuberculosis had lower CD4(+) T-lymphocyte counts (P = 0.02) and were more likely to be ambulatory (P = 0.03) than those who did not. Of 74 exposed health care workers, the 11 (15%)who had conversion on tuberculin skin testing were no more likely than those who did not have conversion to report that they always wore a respirator with a high-efficiency particulate air filter. Conclusions: Transmission of M. tuberculosis occurred in a hospital that did not have recommended isolation rooms. A respirator-fit testing program did not protect health care workers in this setting.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; ST JOSEPH HOSP, CHICAGO, IL USA; CHICAGO DEPT PUBL HLTH, CHICAGO, IL USA	Centers for Disease Control & Prevention - USA; Chicago Department of Public Health			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dean A.G., 1994, EPI INFO VERSION 6 W; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1993, J INFECT DIS, V168, P1219, DOI 10.1093/infdis/168.5.1219; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7	18	63	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					32	36		10.7326/0003-4819-127-1-199707010-00006	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214250				2022-12-28	WOS:A1997XG91400005
J	Arruda, WO; Rosa, JFT				Arruda, WO; Rosa, JFT			A 44-year-old woman with diarrhoea and double vision	LANCET			English	Article									UNIV FED PARANA,DEPT CIIRURG TORACICA,BR-80060150 CURITIBA,PARANA,BRAZIL	Universidade Federal do Parana	Arruda, WO (corresponding author), UNIV FED PARANA,DEPT CLIN MED NEUROL,RUA GEN CAMEIRO 181,BR-80060150 CURITIBA,PARANA,BRAZIL.		Arruda, Walter Oleschko/AAJ-8256-2020					AMANN ST, 1994, SOUTHERN MED J, V87, P855, DOI 10.1097/00007611-199408000-00024; Krejs GJ, 1992, CECIL TXB MED, P680; REIMUND JM, 1992, DIGEST DIS SCI, V37, P1922, DOI 10.1007/BF01308090	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1882	1882		10.1016/S0140-6736(97)04392-4	http://dx.doi.org/10.1016/S0140-6736(97)04392-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217761				2022-12-28	WOS:A1997XG41700012
J	Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H				Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H			Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REED-STERNBERG CELLS; GENE REARRANGEMENTS; SOMATIC MUTATIONS; CHAIN; NEOPLASMS; LYMPHOMAS; SUBTYPE; LINEAGE; MARKER; PCR	Background The atypical cells of nodular lymphocyte-predominant Hodgkin's disease, designated lymphocytic and histiocytic (L&H) cells, have a B-cell phenotype. To clarify the clonality of these cells, we studied rearranged immunoglobulin genes for the variable region of the heavy chain (V-H genes) in individual L&H cells from 11 patients with nodular lymphocyte-predominant Hodgkin's disease. We also studied the expression of immunoglobulin light chains by those cells in six of the same patients. Methods Single CD20+ L&H cells were isolated from frozen sections by a technique of micromanipulation. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction (PCR), sequenced, and compared with germ-line V-H genes. Immunoglobulin light-chain messenger RNA (mRNA) was detected by in situ hybridization. Results Of 615 L&H cells isolated from all the frozen sections, 160 yielded PCR products. In each of the 11 patients, the L&H cells that could be evaluated had identically rearranged V-H genes, whether they were isolated from the same nodule, different nodules, or different blocks of tissue. All the V-H sequences derived from the L&H cells were highly mutated (7.5 to 27.2 percent). in two cases the coding capacity of the V-H genes was completely or partially disrupted by mutations. Intraclonal diversity was found in six cases, and monotypic immunoglobulin light-chain mRNA was found in six. Conclusions The L&H cells of nodular lymphocyte-predominant Hodgkin's disease represent a monoclonal expansion of B cells. The high load of V-H gene mutations and signs of intraclonal diversity suggest a relation between L&H cells and germinal-center B cells at the centroblastic stage of differentiation. (C) 1997, Massachusetts Medical Society.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; CONSULTAT & REFERENCE CTR LYMPH NODE PATHOL & HAE, BERLIN, GERMANY; UNIV PERUGIA, INST HEMATOL, I-06100 PERUGIA, ITALY; CHU PURPAN, HOP TOULOUSE, LAB CENT ANAT PATHOL, TOULOUSE, FRANCE; UCL, SCH MED, DEPT HISTOPATHOL, LONDON, ENGLAND; UNIV BOLOGNA, SEZ EMOLINFOPATOL, SERV ANAT PATOL 2, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Perugia; CHU de Toulouse; University of London; University College London; UCL Medical School; University of Bologna			Pileri, Stefano/AAP-6337-2020; Marafioti, Teresa/B-4493-2009; Marafioti, Teresa/AAA-4652-2019	Marafioti, Teresa/0000-0003-1223-6275; Marafioti, Teresa/0000-0003-1223-6275; FALINI, Brunangelo/0000-0002-7198-5965				ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; COLBY TV, 1982, CANCER, V49, P1848, DOI 10.1002/1097-0142(19820501)49:9<1848::AID-CNCR2820490918>3.0.CO;2-Y; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DELABIE J, 1994, BLOOD, V84, P3291; Falini B, 1996, BLOOD, V87, P465, DOI 10.1182/blood.V87.2.465.bloodjournal872465; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HANSMANN ML, 1990, AM J CLIN PATHOL, V93, P219, DOI 10.1093/ajcp/93.2.219; HARRIS NL, 1994, BLOOD, V84, P1361; Hell K, 1995, HISTOPATHOLOGY, V27, P491, DOI 10.1111/j.1365-2559.1995.tb00319.x; HUMMEL M, 1995, NEW ENGL J MED, V333, P901, DOI 10.1056/NEJM199510053331403; HUMMEL M, 1994, BLOOD, V84, P403; Jackson H, 1944, NEW ENGL J MED, V230, P1, DOI 10.1056/NEJM194401062300101; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; KORKOLOPOULOU P, 1994, HISTOPATHOLOGY, V24, P511; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; LUKES RJ, 1966, CANCER RES, V26, P1063; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; PINKUS GS, 1988, AM J PATHOL, V133, P211; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; REE HJ, 1989, CANCER, V63, P2030, DOI 10.1002/1097-0142(19890515)63:10<2030::AID-CNCR2820631027>3.0.CO;2-P; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; SCHMID C, 1991, AM J PATHOL, V139, P1281; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; SUNDEEN JT, 1988, AM J SURG PATHOL, V12, P599; TAMARU J, 1994, BLOOD, V84, P708; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312	34	240	246	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					453	458		10.1056/NEJM199708143370703	http://dx.doi.org/10.1056/NEJM199708143370703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250847				2022-12-28	WOS:A1997XQ49900003
J	Shadmehr, R; Holcomb, HH				Shadmehr, R; Holcomb, HH			Neural correlates of motor memory consolidation	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; INITIATED HAND MOVEMENTS; PREMOTOR CORTEX; FUNCTIONAL-ANATOMY; NEURONAL-ACTIVITY; ELBOW MOVEMENTS; BLOOD-FLOW; CEREBELLUM; MONKEY; MODEL	Computational studies suggest that acquisition of a motor skill involves learning an internal model of the dynamics of the task, which enables the brain to predict and compensate for mechanical behavior. During the hours that follow completion of practice, representation of the internal model gradually changes, becoming less fragile with respect to behavioral interference. Here, functional imaging of the brain demonstrates that within 6 hours after completion of practice, while performance remains unchanged, the brain engages new regions to perform the task; there is a shift from prefrontal regions of the cortex to the premotor, posterior parietal, and cerebellar cortex structures. This shift is specific to recall of an established motor skill and suggests that with the passage of time, there is a change in the neural representation of the internal model and that this change may underlie its increased functional stability.	UNIV MARYLAND,MARYLAND PSYCHIAT RES CTR,BALTIMORE,MD 21228; JOHNS HOPKINS UNIV,DEPT RADIOL,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Shadmehr, R (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,720 RUTLAND AVE,419 TRAYLOR,BALTIMORE,MD 21205, USA.							AIZAWA H, 1991, EXP BRAIN RES, V84, P668; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; [Anonymous], 1993, BRAIN ACTIVATION; Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492, DOI 10.1152/jn.1996.76.1.492; BOUSSAOUD D, 1993, EXP BRAIN RES, V95, P28; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; Brindley, 1964, INT BRAIN RES ORG B, V3, P80; Carelli RM, 1997, J NEUROSCI, V17, P1804; CHEN YC, 1995, EXP BRAIN RES, V102, P461; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; CONRAD B, 1974, BRAIN RES, V71, P507, DOI 10.1016/0006-8993(74)90994-9; DETTMERS C, 1995, J NEUROPHYSIOL, V74, P802, DOI 10.1152/jn.1995.74.2.802; Flanagan JR, 1997, J NEUROSCI, V17, P1519; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1993, P ROY SOC B-BIOL SCI, V254, P47, DOI 10.1098/rspb.1993.0125; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Fuster JM, 1995, MEMORY CEREBRAL CORT; GERMAIN L, 1993, BRAIN RES, V611, P175, DOI 10.1016/0006-8993(93)91792-Q; GHEZ C, 1995, CAN J PHYSIOL PHARM, V73, P273, DOI 10.1139/y95-038; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Goodkin H. P., 1993, Canadian Journal of Neurological Sciences, V20, pS93; GORDON AM, 1993, J NEUROPHYSIOL, V69, P1789, DOI 10.1152/jn.1993.69.6.1789; GOTTLIEB GL, 1994, EXP BRAIN RES, V97, P545; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HALSBAND U, 1990, BRAIN, V113, P207, DOI 10.1093/brain/113.1.207; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; HRELJAC A, 1993, BIOL CYBERN, V68, P375, DOI 10.1007/BF00201862; ITO M, 1972, BRAIN RES, V40, P80; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1313, DOI 10.1152/jn.1997.77.3.1313; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; KARNI A, 1995, NATURE, V377, P155; KAWASHIMA R, 1995, CEREB CORTEX, V5, P111, DOI 10.1093/cercor/5.2.111; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KAWATO M, 1988, BIOL CYBERN, V59, P161, DOI 10.1007/BF00318008; KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195; Kleim JA, 1997, J NEUROSCI, V17, P717; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MILNER TE, 1993, EXP BRAIN RES, V94, P522; MITZ AR, 1991, J NEUROSCI, V11, P1855; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; PASSINGHAM RE, 1988, EXP BRAIN RES, V70, P590; PASSINGHAM RE, 1989, BRAIN BEHAV EVOLUT, V33, P189, DOI 10.1159/000115927; PAVLIDES C, 1993, J NEUROPHYSIOL, V70, P733, DOI 10.1152/jn.1993.70.2.733; POIZNER H, 1995, BRAIN, V118, P227, DOI 10.1093/brain/118.1.227; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; RAICHLE ME, 1983, J NUCL MED, V24, P790; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; SASAKI K, 1982, EXP BRAIN RES, V48, P429; SASAKI K, 1986, BRAIN RES, V374, P278, DOI 10.1016/0006-8993(86)90422-1; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SEITZ RJ, 1994, NEUROREPORT, V5, P2541, DOI 10.1097/00001756-199412000-00034; SEITZ RJ, 1992, EUR J NEUROSCI, V4, P154, DOI 10.1111/j.1460-9568.1992.tb00862.x; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, J NEUROSCI, V17, P409, DOI 10.1523/JNEUROSCI.17-01-00409.1997; SHADMEHR R, IN PRESS NEUROMECHAN; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; SHINDY WW, 1994, CEREB CORTEX, V4, P443, DOI 10.1093/cercor/4.4.443; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Tanne J, 1995, NEUROREPORT, V7, P267, DOI 10.1097/00001756-199512000-00064; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; VILIS T, 1980, J NEUROPHYSIOL, V43, P279, DOI 10.1152/jn.1980.43.2.279; Wise SP, 1996, ACQUISITION OF MOTOR BEHAVIOR IN VERTEBRATES, P261; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOODS RP, 1992, J COMPUT ASSIST TOMO, V115, P665; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	78	730	738	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					821	825		10.1126/science.277.5327.821	http://dx.doi.org/10.1126/science.277.5327.821			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242612				2022-12-28	WOS:A1997XQ24700045
J	Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR				Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR			A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-This large outbreak of foodborne disease highlights the challenge of investigating outbreaks caused by intentional contamination and demonstrates the vulnerability of self-service foods to intentional contamination. Objective.-To investigate a large community outbreak of Salmonella Typhimurium infections. Design.-Epidemiologic investigation of patients with Salmonella gastroenteritis and possible exposures in The Dalles, Oregon. Cohort and case-control investigations were conducted among groups of restaurant patrons and employees to identify exposures associated with illness. Setting.-A community in Oregon. Outbreak period was September and October 1984. Patients.-A total of 751 persons with Salmonella gastroenteritis associated with eating or working at area restaurants. Most patients were identified through passive surveillance; active surveillance was conducted for selected groups. A case was defined either by clinical criteria or by a stool culture yielding S Typhimurium. Results.-The outbreak occurred in 2 waves, September 9 through 18 and September 19 through October 10. Most cases were associated with 10 restaurants, and epidemiologic studies of customers at 4 restaurants and of employees at all 10 restaurants implicated eating from salad bars as the major risk factor for infection. Eight (80%) of 10 affected restaurants compared with only 3 (11%) of the 28 other restaurants in The Dalles operated salad bars (relative risk, 7.5; 95% confidence interval, 2.4-22.7; P<.001). The implicated food items on the salad bars differed from one restaurant to another. The investigation did not identify any water supply, food item, supplier, or distributor common to all affected restaurants, nor were employees exposed to any single common source. In some instances, infected employees may have contributed to the spread of illness by inadvertently contaminating foods. However, no evidence was found linking ill employees to initiation of the outbreak. Errors in food rotation and inadequate refrigeration on ice-chilled salad bars may have facilitated growth of the S Typhimurium but could not have caused the outbreak. A subsequent criminal investigation revealed that members of a religious commune had deliberately contaminated the salad bars. An S Typhimurium strain found in a laboratory at the commune was indistinguishable from the outbreak strain. Conclusions.-This outbreak of salmonellosis was caused by intentional contamination of restaurant salad bars by members of a religious commune.	CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; OREGON HLTH DIV,PORTLAND,OR	Centers for Disease Control & Prevention - USA; Oregon Health & Science University	Torok, TJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,MAILSTOP G-17,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASER MJ, 1981, AM J EPIDEMIOL, V114, P663, DOI 10.1093/oxfordjournals.aje.a113237; BUCHWALD DS, 1984, REV INFECT DIS, V6, P345; CALLISTER S, 1985, OREGONIAN       1230, pB1; CALLISTER S, 1985, OREGONIAN          S, P36; DEAN A, 1995, EPI INFO VERSION 6 W; FITZGERALD F, 1986, CITIES HILL; JOSEPH PR, 1965, NEW ENGL J MED, V273, P188, DOI 10.1056/NEJM196507222730403; Kaplan David E., 1996, CULT END WORLD; LAATZ J, 1986, OREGONIAN       0320, pE6; LAATZ J, 1986, OREGONIAN       0320, pA1; LAATZ J, 1986, OREGONIAN       0723, pB2; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MARTIN WJ, 1980, MANUAL CLIN MICROBIO, P207; PETHER JVS, 1982, J INFECTION, V5, P81, DOI 10.1016/S0163-4453(82)93365-5; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; ROBERTS D, 1982, J HYG-CAMBRIDGE, V89, P491, DOI 10.1017/S0022172400071059; RUBENSTEIN AD, 1953, NEW ENGL J MED, V248, P527, DOI 10.1056/NEJM195303262481301	20	369	384	2	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					389	395		10.1001/jama.278.5.389	http://dx.doi.org/10.1001/jama.278.5.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244330				2022-12-28	WOS:A1997XN51800030
J	Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T				Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T			The agents of biological warfare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Vogel, P (corresponding author), USA,MIL RES INST INFECT DIS,DIV PATHOL,1425 PORTER ST,FT DETRICK,MD 21702, USA.		Vogel, Peter/N-2490-2018	Vogel, Peter/0000-0002-7535-0545					0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					438	439		10.1001/jama.278.5.438	http://dx.doi.org/10.1001/jama.278.5.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244340				2022-12-28	WOS:A1997XN51800040
J	Saunders, M; Dische, S; Barrett, A; Harvey, A; Gibson, D; Parmar, M				Saunders, M; Dische, S; Barrett, A; Harvey, A; Gibson, D; Parmar, M			Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial	LANCET			English	Article							THERAPY-ONCOLOGY-GROUP; PHASE-III TRIAL; RADIATION-THERAPY; CARCINOMA; BRONCHUS	Background Human tumour cells can proliferate rapidly, and giving radiotherapy in many small fractions may reduce long-term normal-tissue morbidity. In response to these observations, we developed the CHART (continuous hyperfractionated accelerated radiotherapy) regimen, which uses thirty-six small fractions of 1.5 Gy given three times per day, to give 54 Gy in only 12 consecutive days. We report the long-term follow-up of a trial of CHART versus conventional radiotherapy in patients with locally advanced non-small-cell lung cancer (NSCLC). Methods 563 patients were entered by thirteen centres between April, 1990, and March, 1995. We included patients with NSCLC localised to the chest with a performance status of 0 or 1 in whom radical radiotherapy was chosen as the definitive management. Patients were randomly allocated in a 3:2 ratio to CHART or conventional radiotherapy. The latter was thirty fractions of 2 Gy to a total dose of 60 Gy in 6 weeks. Results The groups were well matched for possible prognostic factors, Overall there was a 24% reduction in the relative risk of death, which is equivalent to an absolute improvement in 2-year survival of 9% from 20% to 29% (p=0.004, 95% CI 0.63-0.92). Subgroup analyses (predefined) suggest that the largest benefit occurred in patients with squamous cell carcinomas (82% of the cases) 1 in whom there was a 34% reduction in the relative risk of death (an absolute improvement at 2 years of 14% from 19% to 33%), During the first 3 months, severe dysphagia occurred more often in the CHART group than in the group on conventional radiotherapy (19 vs 3%). Otherwise, there were no important differences in short-term or long-term morbidity. Interpretation CHART compared with conventional radiotherapy gave a significant improvement in survival of patients with NSCLC. Further improvement may be achieved with dose escalation in conformal radiotherapy, by the addition of cytotoxic chemotherapy, and by hypoxic cell radiosensitisation.	MRC, CANC TRIALS OFF, CAMBRIDGE CB2 2BW, ENGLAND; MT VERNON HOSP, MARIE CURIE RES WING, NORTHWOOD HA6 2RN, MIDDX, ENGLAND; UNIV GLASGOW, WESTERN INFIRM, BEATSON ONCOL CTR, GLASGOW G11 6NT, LANARK, SCOTLAND	Beatson Oncology Centre; University of Glasgow								AIRD EGA, 1995, RADIOTHER ONCOL, V36, P235, DOI 10.1016/0167-8140(95)01598-B; ALBERTI W, 1995, BRIT MED J, V311, P899; COX JD, 1991, INT J RADIAT ONCOL, V20, P1375, DOI 10.1016/0360-3016(91)90252-Y; DILLMAN RO, 1993, P AN M AM SOC CLIN, V12, P329; DISCHE S, IN PRESS RADIOTHER O; DRUMMOND MF, IN PRESS CLIN ONCOL; FOWLER JF, 1989, BRIT J RADIOL, V62, P679, DOI 10.1259/0007-1285-62-740-679; GREEN MR, 1994, LUNG CANCER-J IASLC, V11, pS11, DOI 10.1016/0169-5002(94)91859-7; *INT COMM RAD UN M, 1978, 29 DEP HLTH INT COMM; JONES A, 1964, BRIT J RADIOL, V37, P727, DOI 10.1259/0007-1285-37-442-727; MORTON RF, 1991, ANN INTERN MED, V115, P681, DOI 10.7326/0003-4819-115-9-681; NOORDIJK EM, 1988, RADIOTHER ONCOL, V13, P83, DOI 10.1016/0167-8140(88)90029-1; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PARMAR MKB, 1994, STAT MED, V13, P1297, DOI 10.1002/sim.4780131304; PAYNE DG, 1988, J CLIN ONCOL, V6, P552, DOI 10.1200/JCO.1988.6.3.552; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; ROSWIT B, 1968, RADIOLOGY, V90, P688, DOI 10.1148/90.4.688; Saunders M I, 1991, Clin Oncol (R Coll Radiol), V3, P185; Saunders MI, 1996, BRIT J CANCER, V73, P1455, DOI 10.1038/bjc.1996.276; SAUNDERS MI, 1984, INT J RADIAT ONCOL, V10, P499, DOI 10.1016/0360-3016(84)90029-4; SAUNDERS MI, 1990, INT J RADIAT ONCOL, V19, P1211, DOI 10.1016/0360-3016(90)90231-8; SAUSE WT, 1995, J NATL CANCER I, V87, P198, DOI 10.1093/jnci/87.3.198; *STAND MED ADV COM, 1994, MAN LUNG CANC CURR C, P18; WILSON GD, 1988, BRIT J CANCER, V58, P423, DOI 10.1038/bjc.1988.234	25	452	470	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					161	165		10.1016/S0140-6736(97)06305-8	http://dx.doi.org/10.1016/S0140-6736(97)06305-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250182				2022-12-28	WOS:A1997XL72200009
J	Mesecar, AD; Stoddard, BL; Koshland, DE				Mesecar, AD; Stoddard, BL; Koshland, DE			Orbital steering in the catalytic power of enzymes: Small structural changes with large catalytic consequences	SCIENCE			English	Article							DEPENDENT ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; LIVER DIHYDROFOLATE-REDUCTASE; HYDRIDE-DONATION REACTION; TRANSITION-STATE; PIG-HEART; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; GLUTATHIONE-REDUCTASE; STO-3G CALCULATIONS	Small structural perturbations in the enzyme isocitrate dehydrogenase (IDH) were made in order to evaluate the contribution of precise substrate alignment to the catalytic power of an enzyme. The reaction trajectory of IDH was modified (i) after the adenine moiety of nicotinamide adenine dinucleotide phosphate was changed to hypoxanthine (the 6-amino was changed to 6-hydroxyl), and (ii) by replacing Mg2+, which has six coordinating ligands, with Ca2+, which has eight coordinating ligands. Both changes make large (10(-3) to 10(-5)) changes in the reaction velocity but only small changes in the orientation of the substrates (both distance and angle) as revealed by cryocrystallographic trapping of active IDH complexes. The results provide evidence that orbital overlap produced by optimal orientation of reacting orbitals plays a major quantitative role in the catalytic power of enzymes.	LAWRENCE BERKELEY NATL LAB,CTR ADV MAT,BERKELEY,CA; FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,SEATTLE,WA 98104	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Fred Hutchinson Cancer Center	Mesecar, AD (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Mesecar, Andrew/0000-0002-1241-2577	NIGMS NIH HHS [GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BARTUNIK HD, 1992, PHILOS T ROY SOC A, V340, P209, DOI 10.1098/rsta.1992.0061; Bodor N., 1990, THEOCHEM, V65, P315, DOI 10.1016/0166-1280(90)85146-E; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN KA, 1992, FARADAY DISCUSS, V93, P217, DOI 10.1039/fd9929300217; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; BRUNGER AT, 1992, X PLOR VERSION 3 1; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; COLMAN RF, 1972, J BIOL CHEM, V247, P215; CUMMINS PL, 1990, J COMPUT CHEM, V11, P791, DOI 10.1002/jcc.540110703; DAFFORN A, 1971, P NATL ACAD SCI USA, V68, P2463, DOI 10.1073/pnas.68.10.2463; DEAN AM, 1993, BIOCHEMISTRY-US, V32, P9302, DOI 10.1021/bi00087a007; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6549, DOI 10.1021/ja00412a002; DONKERSLOOT MCA, 1981, J AM CHEM SOC, V103, P6554, DOI 10.1021/ja00412a003; EHRLICH RS, 1989, BIOCHEMISTRY-US, V28, P2058, DOI 10.1021/bi00431a014; EHRLICH RS, 1995, BBA-PROTEIN STRUCT M, V1246, P135, DOI 10.1016/0167-4838(94)00192-J; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GROS P, 1992, PROTEINS, V12, P63, DOI 10.1002/prot.340120108; Hackney D. D., 1990, ENZYMES, P1; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HUHTA DW, 1992, ACTA CHEM SCAND, P778; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KATI WM, 1992, BIOCHEMISTRY-US, V31, P7356, DOI 10.1021/bi00147a021; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; KOSHLAND DE, 1962, J THEOR BIOL, V2, P75, DOI 10.1016/0022-5193(62)90037-1; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; MCTIGUE MA, 1993, BIOCHEMISTRY-US, V32, P6855, DOI 10.1021/bi00078a008; MENGER FM, 1985, ACCOUNTS CHEM RES, V18, P128, DOI 10.1021/ar00113a001; MENGER FM, 1993, ACCOUNTS CHEM RES, V26, P206, DOI 10.1021/ar00028a011; NAVEZA J, 1994, ACTA CRYSTALLOGR A, V50, P157; NORTHROP DB, 1974, J BIOL CHEM, V249, P2928; OTWINOWSKI Z, P CCP4 STUD WEEK DAT; PAGE MI, 1972, J AM CHEM SOC, V94, P8828, DOI 10.1021/ja00780a031; Perutz M. F., 1990, MECH COOPERATIVITY; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHREINER S, 1976, J AM CHEM SOC, V98, P4770; SHERROD MJ, 1989, J AM CHEM SOC, V111, P2611, DOI 10.1021/ja00189a040; SHERROD MJ, 1990, TETRAHEDRON LETT, V31, P459, DOI 10.1016/0040-4039(90)87007-M; Stoddard BL, 1996, NAT STRUCT BIOL, V3, P590, DOI 10.1038/nsb0796-590; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; Stryer L., 1988, BIOCHEMISTRY-US, P375; SUSTMANN R, 1989, ANGEW CHEM INT EDIT, V28, P1023, DOI 10.1002/anie.198910231; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Warshel A, 1991, COMPUTER MODELING CH; WILLIAMS IH, 1990, J AM CHEM SOC, V112, P530, DOI 10.1021/ja00158a009; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; WU YD, 1987, J AM CHEM SOC, V109, P2226, DOI 10.1021/ja00241a074	61	198	205	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					202	206		10.1126/science.277.5323.202	http://dx.doi.org/10.1126/science.277.5323.202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211842				2022-12-28	WOS:A1997XK41800034
J	Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J				Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J			Distinct cortical areas associated with native and second languages	NATURE			English	Article							BRAIN; SPEECH; REPRESENTATION; ORGANIZATION	The ability to acquire and use several languages selectively is a unique and essential human capacity. Here we investigate the fundamental question of how multiple languages are represented in a human brain. We applied functional magnetic resonance imaging (fMRI) to determine the spatial relationship between native and second languages in the human cortex, and show that within the frontal-lobe language-sensitive regions (Broca's area)(1-3), second languages acquired in adulthood ('late' bilingual subjects) are spatially separated from native languages. However, when acquired during the early language acquisition stage of development ('early' bilingual subjects), native and second languages tend to be represented in common frontal cortical areas. In both late and early bilingual subjects, the temporal-lobe language-sensitive regions (Wernicke's area)(1-3) also show effectively little or no separation of activity based on the age of language acquisition. This discovery of language-specific regions in Broca's area advances our understanding of the cortical representation that underlies multiple language functions.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Lee, Kyoung Min/J-2775-2012	Hirsch, Joy/0000-0002-1418-6489				BLACK PM, 1987, NEUROSURGERY, V20, P914, DOI 10.1227/00006123-198706000-00016; Damasio H, 1989, LESION ANAL NEUROPSY; DAMASIO H, 1995, HUMAN BRAIN ANATOMY; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; GESCHWIND N, 1970, SCIENCE, V170, P640; GOMEZTORTOSA E, 1995, BRAIN LANG, V48, P320, DOI 10.1006/brln.1995.1014; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HIRSCH J, 1994, P SOC MAG RES, V2, P637; KLEIN D, 1995, P NATL ACAD SCI USA, V92, P2899, DOI 10.1073/pnas.92.7.2899; KRETSCHMANN HJ, 1992, CRANIAL NEUROIMAGING; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Meyer KL, 1996, MAGNET RESON MED, V36, P606, DOI 10.1002/mrm.1910360416; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PETSCHE H, 1993, ELECTROEN CLIN NEURO, V86, P385, DOI 10.1016/0013-4694(93)90134-H; SCHWARTZ MS, 1994, J NEUROL NEUROSUR PS, V57, P121, DOI 10.1136/jnnp.57.1.121; STEINMETZ H, 1991, NEUROPSYCHOLOGIA, V29, P1149, DOI 10.1016/0028-3932(91)90030-C; Talairach J., 1988, COPLANAR STEREOTAXIC; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZATORRE RJ, 1989, BRAIN LANG, V36, P127, DOI 10.1016/0093-934X(89)90056-4; Zatorre RJ, 1996, CEREB CORTEX, V6, P21, DOI 10.1093/cercor/6.1.21	24	642	667	5	158	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					171	174		10.1038/40623	http://dx.doi.org/10.1038/40623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217156	Bronze			2022-12-28	WOS:A1997XK10900049
J	Huijbregts, P; Feskens, E; Rasanen, L; Fidanza, F; Nissinen, A; Menotti, A; Kromhout, D				Huijbregts, P; Feskens, E; Rasanen, L; Fidanza, F; Nissinen, A; Menotti, A; Kromhout, D			Dietary pattern and 20 year mortality in elderly men in Finland, Italy, and the Netherlands: Longitudinal cohort study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FOLLOW-UP; SUBSEQUENT MORTALITY; 20-YEAR MORTALITY; POPULATION GROUPS; 7 COUNTRIES; ZUTPHEN; SURVIVAL; HEALTH	Objective: To investigate the association of dietary pattern and mortality in international data. Design: Cohort study with 20 years' follow up of mortality. Setting: Five cohorts in Finland, the Netherlands, and Italy. Subjects: Population based random sample of 3045 men aged 50-70 years in 1970. Main outcome measures: Food intake was estimated using a cross check dietary history. In this dietary survey method, the usual food consumption pattern in the 6-12 months is estimated. A healthy diet indicator was calculated for the dietary pattern, using the World Health Organisation's guidelines for the prevention of chronic diseases. Vital status was verified after 20 years of follow up, and death rates were calculated. Results: Dietary intake varied greatly in 1970 between the three countries. In Finland and the Netherlands the intake of saturated fatty acids and cholesterol was high and the intake of alcohol was low; in Italy the opposite was observed. In total 1796 men (59%) died during 20 years of follow up. The healthy diet indicator was inversely associated with mortality (P for trend < 0.05). After adjustment for age, smoking, and alcohol consumption, the relative risk in the group with the healthiest diet indicator compared with the group with the least healthy was 0.87 (95% confidence interval 0.77 to 0.98). Estimated relative risks were essentially similar within each country. Conclusions: Dietary intake of men aged 50-70 is associated with a 20 year, all cause mortality in different cultures. The healthy diet indicator is useful in evaluating the relation of mortality to dietary patterns.	UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,NL-3720 BA BILTHOVEN,NETHERLANDS; UNIV HELSINKI,DEPT APPL CHEM & MICROBIOL,DIV NUTR,FIN-00014 HELSINKI,FINLAND; UNIV PERUGIA,INST FOOD SCI & NUTR,I-00610 PERUGIA,ITALY; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,FIN-70211 KUOPIO,FINLAND	University of Minnesota System; University of Minnesota Twin Cities; Netherlands National Institute for Public Health & the Environment; University of Helsinki; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); University of Perugia; University of Eastern Finland			Kromhout, Daan/A-8566-2014; Feskens, Edith/ABI-1446-2020; Feskens, Edith JM/A-3757-2012	Feskens, Edith/0000-0001-5819-2488; 				ALBERTIFIDANZA A, 1994, EUR J CLIN NUTR, V48, P85; BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; Burke Bertha S., 1947, JOUR AMER DIETETIC ASSOC, V23, P1041; DOLECEK TA, 1991, WORLD REV NUTR DIET, V66, P205; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FARCHI G, 1989, AM J CLIN NUTR, V50, P1095, DOI 10.1093/ajcn/50.5.1095; FARCHI G, 1995, EUR J CLIN NUTR, V49, P408; Fidanza A. A., 1988, International Journal for Vitamin and Nutrition Research, V58, P442; FIDANZA F, 1991, P NUTR SOC, V50, P519, DOI 10.1079/PNS19910065; GORDON T, 1984, AM J CLIN NUTR, V39, P152, DOI 10.1093/ajcn/39.1.152; HARTOG CD, 1965, VOEDING, V26, P184; HUIJBREGTS PPCW, 1995, EUR J CLIN NUTR, V49, P852; HUIJBREGTS PPCW, 1995, INT J EPIDEMIOL, V24, P313, DOI 10.1093/ije/24.2.313; KANT AK, 1993, AM J CLIN NUTR, V57, P434, DOI 10.1093/ajcn/57.3.434; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P287, DOI 10.1093/ajcn/37.2.287; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KROMHOUT D, 1988, AM J CLIN NUTR, V47, P668, DOI 10.1093/ajcn/47.4.668; KROMHOUT D, 1982, LANCET, V2, P519; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; NUBE M, 1987, J AM DIET ASSOC, V87, P171; PEKKARINEN M, 1981, CURRENT TOPICS NUTR, V5; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; World Health Organization (WHO), 1990, WHO TECHN REP SER, V797; [No title captured]	28	285	291	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					13	17		10.1136/bmj.315.7099.13	http://dx.doi.org/10.1136/bmj.315.7099.13			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233319	Green Published, Green Accepted			2022-12-28	WOS:A1997XJ94700020
J	Hornblow, A				Hornblow, A			New Zealand's health reforms: A clash of cultures	BRITISH MEDICAL JOURNAL			English	Article							ACCULTURATION; ORGANIZATIONS; CARE				Hornblow, A (corresponding author), UNIV OTAGO,CHRISTCHURCH SCH MED,POB 4345,CHRISTCHURCH,NEW ZEALAND.							BLACK D, 1995, J ROY COLL PHYS LOND, V29, P442; BORREN P, 1993, 103 CTR HLTH EC HLTH; DAYAN CM, 1993, J ROY COLL PHYS LOND, V27, P238; EASTON B, 1994, POLIT SCI, V46, P215, DOI 10.1177/003231879404600205; ELSASS PM, 1994, HUM RELAT, V47, P431, DOI 10.1177/001872679404700404; HOOD JN, 1994, HUM RELAT, V47, P159, DOI 10.1177/001872679404700202; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Kerr D, 1996, NEW ZEAL MED J, V109, P334; LEUNG K, 1990, APPL CROSS CULTURAL, P209; *MIN HLTH, 1991, YOUR HLTH PUBL HLTH; Richards T, 1996, BRIT MED J, V312, P1622, DOI 10.1136/bmj.312.7047.1622; Strebel P, 1996, HARVARD BUSINESS MAY, P86; 1996, PRESS           0809, P9; 1996, BRIT MED J, V312, P1664	15	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1892	1894		10.1136/bmj.314.7098.1892	http://dx.doi.org/10.1136/bmj.314.7098.1892			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224137	Green Published			2022-12-28	WOS:A1997XH73800034
J	Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS				Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS			A G protein-coupled receptor phosphatase required for rhodopsin function	SCIENCE			English	Article							ROD OUTER SEGMENTS; RETINAL-DEGENERATION; IN-VIVO; 48-KDA PROTEIN; PHOSPHODIESTERASE ACTIVATION; DROSOPHILA-MELANOGASTER; PHOTOEXCITED RHODOPSIN; ADRENERGIC-RECEPTOR; VISUAL TRANSDUCTION; PHOTORECEPTOR CELL	Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors are phosphorylated by kinases that mediate agonist-dependent receptor deactivation. Although many receptor kinases have been isolated, the corresponding phosphatases, necessary for restoring the ground state of the receptor, have not been identified. Drosophila RDGC (retinal degeneration C) is a phosphatase required for rhodopsin dephosphorylation in vivo. Loss of RDGC caused severe defects in the termination of the light response as well as extensive light-dependent retinal degeneration. These phenotypes resulted from the hyperphosphorylation of rhodopsin because expression of a truncated rhodopsin lacking the phosphorylation sites restored normal photoreceptor function. These results suggest the existence of a family of receptor phosphatases involved in the regulation of G protein-coupled signaling cascades.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Britt, Steven/GVT-1340-2022	Jalink, Kees/0000-0001-7019-3440; Britt, Steven/0000-0001-7656-7984				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Fong TM, 1996, CELL SIGNAL, V8, P217; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hurley James B., 1994, Current Opinion in Neurobiology, V4, P481, DOI 10.1016/0959-4388(94)90047-7; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; KING AJ, 1994, EUR J BIOCHEM, V225, P383, DOI 10.1111/j.1432-1033.1994.00383.x; KUNH H, 1972, FEBS LETT, V20, P1; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kutuzov MA, 1996, EUR J BIOCHEM, V238, P613, DOI 10.1111/j.1432-1033.1996.0613w.x; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN RS, UNPUB; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH WC, 1994, J BIOL CHEM, V269, P15407; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; VINOS J, UNPUB; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; YANG SD, 1988, J BIOL CHEM, V263, P8856; YANG SD, 1991, BIOCHEM BIOPH RES CO, V178, P1306, DOI 10.1016/0006-291X(91)91036-C; ZHAO XY, 1995, BIOPHYS CHEM, V56, P183, DOI 10.1016/0301-4622(95)00031-R; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	54	100	102	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					687	690		10.1126/science.277.5326.687	http://dx.doi.org/10.1126/science.277.5326.687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235891				2022-12-28	WOS:A1997XN90700041
J	Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA				Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA			HIV-1 disease progression and AIDS-defining disorders in rural Uganda	LANCET			English	Article							SUB-SAHARAN AFRICA; STAGING SYSTEM; NATURAL-HISTORY; HOMOSEXUAL MEN; SLIM DISEASE; DRUG-USERS; INFECTION; COHORT; MORTALITY; WOMEN	Background The majority of people infected with HIV-1 live in Africa, yet little is known about the natural history of the disease in that continent. We studied survival times, disease progression, and AIDS-defining disorders, according to the proposed WHO staging system, in a population-based, rural cohort in Uganda. Methods In 1990 we recruited a random sample of people already infected with HIV-1 (as prevalent cases) detected during the initial survey round of a general-population study to form a natural-history cohort. Individuals from the general-population cohort who seroconverted between 1990 and 1995 (incident cases) were also invited to enrol. Participants were seen routinely every 3 months and when they were ill. Findings By the end of 1995, 93 prevalent cases and 86 incident cases had been enrolled. Four patients in the prevalent group were in stage 4 (AIDS) at the initial visit. During the next 5 years, 37 prevalent cases progressed to AIDS. Seven incident cases progressed to AIDS and the cumulative progression to AIDS at 1, 3, and 5 years after seroconversion was 2%, 6%, and 22%, respectively. The cumulative probability of AIDS at 4 years from entering stages 1, 2, and 3 was 11%, 33%, and 58%, respectively. There were 47 deaths among prevalent cases and seven among incident cases during follow-up. The cumulative mortality 4 years after patients entered stages 1, 2, 3, and 4 was 9%, 33%, 56%, and 86%, respectively. The median survival after the onset of AIDS was 9.3 months. Interpretation Our results are important for the setting of priorities and rationalisation of treatment availability in countries with poor resources. We found that progression rates to AIDS are similar to those in developed countries for homosexual cohorts and greater than for cohorts infected by other modes of transmission. However, we have found that the rates of all-cause mortality are much higher and the progression times to death are shorter than in developed countries.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Morgan, D (corresponding author), UGANDA VIRUS RES INST,MED RES COUNCIL PROGRAMME AIDS,POB 49,ENTEBBE,UGANDA.							ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; Brettle RP, 1996, AIDS, V10, P419, DOI 10.1097/00002030-199604000-00011; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; COLEBUNDERS RL, 1991, AIDS, V5, pS103; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DelAmo J, 1996, INT J STD AIDS, V7, P44, DOI 10.1258/0956462961917041; FLEGG PJ, 1994, J INFECTION, V29, P311, DOI 10.1016/S0163-4453(94)91266-1; Hendriks JCM, 1996, AIDS, V10, P649, DOI 10.1097/00002030-199606000-00011; *HIV AIDS SURV REP, 1996, STD AIDS CONTR PROGR; HU DJ, 1995, J ACQ IMMUN DEF SYND, V10, P374; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V269, P2694; Kitayaporn D, 1996, J ACQ IMMUN DEF SYND, V11, P77, DOI 10.1097/00042560-199601010-00010; Kumarasamy N, 1995, INT J STD AIDS, V6, P447, DOI 10.1177/095646249500600615; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; LIFSON AR, 1995, ANN INTERN MED, V122, P262, DOI 10.7326/0003-4819-122-4-199502150-00004; Low N, 1996, GENITOURIN MED, V72, P12; LUCAS S, 1989, AIDS, V3, P47, DOI 10.1097/00002030-198903010-00012; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; Morgan D, 1997, AIDS, V11, P633, DOI 10.1097/00002030-199705000-00011; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; OFARRELL N, 1995, GENITOURIN MED, V71, P358; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; *WHO, 1994, WHOGPATCOSEP944; 1996, AIDS CARE, V8, P249	38	105	106	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					245	250		10.1016/S0140-6736(97)01474-8	http://dx.doi.org/10.1016/S0140-6736(97)01474-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242801				2022-12-28	WOS:A1997XM86600011
J	Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT				Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT			A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues	LANCET			English	Article							POLYCHLORINATED-BIPHENYLS; CANCER MORTALITY; DIETARY FACTORS; WORKERS; CONSUMPTION; EXPOSURE	Background The steady worldwide increase in the incidence of non-Hodgkin lymphoma during the past few decades remains mostly unexplained. Several studies suggest that there may be an association between the agricultural use of the organochlorine 1,1,1-trichloro-2,2'bis(p-chlorophenyl)ethane (DDT) and increased. risk of non-Hodgkin lymphoma. We have investigated the association between risk of non-Hodgkin lymphoma and body burden of selected organochlorines in the general population in a nested case-control study. Methods We measured prediagnostic serum concentrations of DDT, its metabolites, and other organochlorines, including polychlorinated biphenyls (PCBs), in 74 cases of non-Hodgkin lymphoma and 147 matched controls identified from a prospective cohort of 25 802 adults, established in 1974 in Washington County, Maryland, USA. We report results for total lipid-corrected serum concentrations of DDT and total PCBs. Findings There was a strong dose-response relation between quartiles of total lipid-corrected serum PCB concentrations and risk of non-Hodgkin lymphoma overall (odds ratios by quartile: 1.0; 1.3 [95% CI 0.5-3.3]; 2-8 [1.1-7.6]); and 4.5 [1.7-12.0]; p for trend=0.0008) and separately in men and in women. There was also evidence suggesting that seropositivity for the Epstein-Barr virus early antigen potentiated the effects of serum PCBs. By contrast, total lipid-corrected serum concentrations of DDT were not associated with risk of non-Hodgkin lymphoma. Interpretation These results should be regarded as hypothesis-generating. Before causal inferences can be made about exposure to PCBs and increased risk of non-Hodgkin lymphoma, our findings require replication and the biological plausibility of the association needs further investigation.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,ATLANTA,GA; GEORGETOWN UNIV,SCH MED,WASHINGTON,DC	Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Georgetown University	Rothman, N (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892, USA.		Zahm, Shelia H/B-5025-2015; Needham, Larry/E-4930-2011		NCI NIH HHS [CA60754] Funding Source: Medline; NHLBI NIH HHS [HL21670] Funding Source: Medline; NIEHS NIH HHS [ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERTAZZI PA, 1987, AM J IND MED, V11, P165, DOI 10.1002/ajim.4700110206; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; BROWN DP, 1987, ARCH ENVIRON HEALTH, V42, P333, DOI 10.1080/00039896.1987.9934355; BUSH DM, 1995, THESIS J HOPKINS U S; CANTOR KP, 1992, CANCER RES, V52, P2447; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Chiu BCH, 1996, JAMA-J AM MED ASSOC, V275, P1315, DOI 10.1001/jama.275.17.1315; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DEVESA SS, 1992, CANCER RES, V52, pS5432; Dewailly E, 1996, AM J PUBLIC HEALTH, V86, P1241, DOI 10.2105/AJPH.86.9.1241; DUGGAN RE, 1983, PESTICIDE RESIDUE LE; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; Hardell L, 1996, INT J ONCOL, V9, P603; HARTGE P, 1992, CANCER RES, V52, pS5566; HOOVER RN, 1992, CANCER RES, V52, pS5477; International Agency for Research on Cancer, 1987, IARC MON EV CARC R S, V7; KREISS K, 1985, ENVIRON HEALTH PERSP, V60, P193, DOI 10.2307/3429961; LUKA J, 1984, J IMMUNOL METHODS, V67, P145, DOI 10.1016/0022-1759(84)90093-0; MUELLER NE, 1992, CANCER RES, V52, pS5479; Nanni O, 1996, OCCUP ENVIRON MED, V53, P652, DOI 10.1136/oem.53.10.652; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; SILBERHORN EM, 1990, CRIT REV TOXICOL, V20, P439, DOI 10.3109/10408449009029331; SINKS T, 1992, AM J EPIDEMIOL, V136, P389, DOI 10.1093/oxfordjournals.aje.a116511; SVENSSON BG, 1994, INT ARCH OCC ENV HEA, V65, P351, DOI 10.1007/BF00383243; SVENSSON BG, 1995, SCAND J WORK ENV HEA, V21, P106, DOI 10.5271/sjweh.17; TRYPHONAS H, 1994, EXP CLIN IMMUNOGENET, V11, P149; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; WOODS JS, 1987, J NATL CANCER I, V78, P899; YASSI A, 1994, AM J IND MED, V25, P425, DOI 10.1002/ajim.4700250310; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725; [No title captured]	32	145	151	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					240	244		10.1016/S0140-6736(97)02088-6	http://dx.doi.org/10.1016/S0140-6736(97)02088-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242800	hybrid			2022-12-28	WOS:A1997XM86600010
J	Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV				Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV			Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; B-CELL ACTIVATION; CLASS-I MOLECULES; FC-GAMMA-RIIB; LYMPHOCYTES-B; IMMUNOGLOBULIN-SUPERFAMILY; CYTOPLASMIC DOMAIN; NEGATIVE SELECTION; SELF-TOLERANCE; CROSS-LINKING	Two signaling molecules have been implicated in the modulation of immune receptor activation by inhibitory coreceptors: an inositol polyphosphate 5'-phosphatase, SHIP, and a tyrosine phosphatase, SHP-1. To address the necessity, interaction, or redundancy of these signaling molecules, we have generated SHP-1-or SHIP-deficient B cell lines and determined their ability to mediate inhibitory signaling. Two distinct classes of inhibitory responses are defined, mediated by the selective recruitment of SHP-1 or SHIP. The Fc gamma RIIB class of inhibitory signaling is dependent on SHIP and not SHP-1; conversely, the KIR class requires SHP-1 and not SHIP. The consequence of this selective recruitment by inhibitory receptor engagement is seen in BCR-triggered apoptosis. SHP-1-mediated inhibitory signaling blocks apoptosis, while SHIP recruitment attenuates a proapoptotic signal initiated by Fc gamma RIIB.	KANSAI MED UNIV,INST LIVER RES,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN	Kansai Medical University; Kobe University	Ono, M (corresponding author), ROCKEFELLER UNIV,LAB MOL GENET & IMMUNOL,1230 YORK AVE,NEW YORK,NY 10021, USA.		okada, hidetaka/C-6990-2011; Kurosaki, Tomohiro/D-1306-2009; Ravetch, Jeffrey/Z-1596-2019; Okada, Hidetaka/AAP-7775-2020	Kurosaki, Tomohiro/0000-0002-6352-304X; Ravetch, Jeffrey/0000-0003-2024-9041; 				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Ashman RF, 1996, J IMMUNOL, V157, P5; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PHILLIPS JH, 1995, SCIENCE, V268, P1173; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VITALE M, 1995, P NATL ACAD SCI USA, V92, P3536, DOI 10.1073/pnas.92.8.3536; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Yamashita Y, 1996, J EXP MED, V184, P113, DOI 10.1084/jem.184.1.113; YI TL, 1992, GENOMICS, V14, P793, DOI 10.1016/S0888-7543(05)80189-2	59	422	440	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					293	301		10.1016/S0092-8674(00)80337-2	http://dx.doi.org/10.1016/S0092-8674(00)80337-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244303	Bronze			2022-12-28	WOS:A1997XN24900013
J	Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE				Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE			Plasma homocysteine levels and mortality in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; PYRIDOXAL-PHOSPHATE; RISK FACTOR; HOMOCYST(E)INE; ATHEROSCLEROSIS; MECHANISMS; STROKE; FOLATE	Background Elevated plasma homocysteine levels are a risk factor for coronary heart disease, but the prognostic value of homocysteine levels in patients with established coronary artery disease has not been defined. Methods We prospectively investigated the relation between plasma total homocysteine levels and mortality among 587 patients with angiographically confirmed coronary artery disease. At the time of angiography in 1991 or 1992, risk factors for coronary disease, including homocysteine levels, were evaluated. The majority of the patients subsequently underwent coronary-artery bypass grafting (318 patients) or percutaneous transluminal coronary angioplasty (120 patients); the remaining 149 were treated medically. Results After a median follow-up of 4.6 years, 64 patients (10.9 percent) had died. We found a strong, graded relation between plasma homocysteine levels and overall mortality. After four years, 3.8 percent of patients with homocysteine levels below 9 mu mol per liter had died, as compared with 24.7 percent of those with homocysteine levels of 15 mu mol per liter or higher. Homocysteine levels were only weakly related to the extent of coronary artery disease but were strongly related to the history with respect to myocardial infarction, the left ventricular ejection fraction, and the serum creatinine level. The relation of homocysteine levels to mortality remained strong after adjustment for these and other potential confounders. In an analysis in which the patients with homocysteine levels below 9 mu mol per liter were used as the reference group, the mortality ratios were 1.9 for patients with homocysteine levels of 9.0 to 14.9 mu mol per liter, 2.8 for those with levels of 15.0 to 19.9 mu mol per liter, and 4.5 for those with levels of 20.0 mu mol per liter or higher (P for trend = 0.02). When death due to cardiovascular disease (which occurred in 50 patients) was used as the end point in the analysis, the relation between homocysteine levels and mortality was slightly strengthened. Conclusions Plasma total homocysteine levels are a strong predictor of mortality in patients with angiographically confirmed coronary artery disease. (C)1997, Massachusetts Medical Society.	UNIV BERGEN, DEPT PUBL HLTH & PRIMARY HLTH CARE, DIV MED STAT, BERGEN, NORWAY; UNIV BERGEN, DEPT PHARMACOL, BERGEN, NORWAY; UNIV BERGEN, DEPT BIOL CLIN, DIV BIOCHEM, BERGEN, NORWAY	University of Bergen; University of Bergen; University of Bergen	Nygard, O (corresponding author), HAUKELAND UNIV HOSP, DEPT HEART DIS, N-5021 BERGEN, NORWAY.		Refsum, Helga/A-4073-2010; Ueland, Per M/C-7340-2013	Ueland, Per Magne/0000-0002-1903-0571				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM AG, IN PRESS KIDNEY INT; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DIXON WJ, 1992, BMDP STATISTICAL SOF; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1995, CIRCULATION, V91, P256; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; Hastie T. J., 1990, GEN ADDITIVE MODELS, V43; Malinow MR, 1996, J NUTR, V126, pS1238, DOI 10.1093/jn/126.suppl_4.1238S; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1985, AM J HUM GENET, V37, P1; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PEDERSEN TR, 1994, LANCET, V344, P1383; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SCHIMKE RN, 1965, J AMER MED ASSOC, V193, P711, DOI 10.1001/jama.1965.03090090017003; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Stamler JS, 1996, NUTR REV, V54, P1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; *STAT SCI, 1995, S PLUS US MAN VERS 3; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VERHOEF P, 1995, NUTR REV, V53, P283, DOI 10.1111/j.1753-4887.1995.tb01478.x; 1995, CIRCULATION, V92, P3172	41	1426	1510	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					230	236		10.1056/NEJM199707243370403	http://dx.doi.org/10.1056/NEJM199707243370403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227928				2022-12-28	WOS:A1997XL99400003
J	Chowdhury, AMR; Chowdhury, S; Islam, MN; Islam, A; Vaughan, JP				Chowdhury, AMR; Chowdhury, S; Islam, MN; Islam, A; Vaughan, JP			Control of tuberculosis by community health workers in Bangladesh	LANCET			English	Article							DIRECTLY OBSERVED THERAPY	Background Tuberculosis remains a major public-health problem in Bangladesh, despite national efforts to improve case identification and treatment compliance. In 1984, BRAC (formerly the Bangladesh Rural Advancement Committee), a national, non-governmental organisation, began an experimental tuberculosis-control programme in one thana (subdistrict). Community health workers screened villagers for chronic cough and collected sputum samples for acid-fast bacillus (AFB) microscopy (phase one). Positive patients received 12 months of directly observed therapy. Phase two (1992-94) included another nine thanas and, in phase three (1995), eight more thanas were included. From 1995, the treatment was an 8-month oral regimen. Methods In 1995-96, we analysed all programme data from 1992 to 1995. First we analysed phases two (12-month therapy) and three (8-month therapy) separately for proportion cured, died, treatment failed, defaulted, migrated, and referred. Second, we did a cross-sectional survey of tuberculosis cases in more than 9000 randomly selected households in two phase-two thanas and one non-programme thana, and analysed the follow-up of all patients treated in the programme thanas. Findings In the phase-two analysis, 3497 (90%) of 3886 cases identified had accepted 12-month treatment. In phase three, all of 1741 identified cases accepted the 8-month regimen. 2833 (81.0%) and 1496 (85.9%) in phases two and three, respectively, were cured; 336 (9.6%) and 133 (7.6%) died. The relapse rate 2 or more years after treatment was discontinued was higher than the early relapse rate. The dropout rate was 3.1%. In the cross-sectional survey, the prevalence of tuberculosis in the two programme thanes was half of that in the comparison thana, where only government services were available (0.07 vs 0.15 per 1000). Interpretation The BRAC tuberculosis-control programme has successfully achieved high rates of case detection and treatment compliance, with a cure rate of at least 85% and a dropout rate of 3.1%. The prevalence survey suggested that at least half of all existing cases had been detected by the programme.	LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND; INT CTR DIARRHOEAL DIS RES,DHAKA 1000,BANGLADESH	University of London; London School of Hygiene & Tropical Medicine; International Centre for Diarrhoeal Disease Research (ICDDR)	Chowdhury, AMR (corresponding author), BRAC,75 MOHAKHALI,DHAKA 1212,BANGLADESH.			Islam, Professor Dr. Md. Nazrul/0000-0003-1023-847X				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Chowdhury A. M. R., 1991, Small Enterprise Development, V2, P4; Chowdhury A.M.R., 1996, SIMPLE SOLUTION TEAC; CHOWDHURY AMR, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90788-5; CHOWDHURY AMR, 1991, IUATLD NEWSLETTER, P1; CONNOLLY MA, 1996, ASSESSMENT TUBERCULO; *DIR GEN HLTH SERV, 1989, REP NAT PREV SURV TU; *GOV BANGL, 1996, NAT GUID TUB CONTR; ISLAM MS, 1986, P WORLD C IUAT; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICH M, 1994, HLTH POLICY PLANN, V89, P130; VEEN J, 1990, NATL TUBERCULOSIS PR; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; *WHO, 1997, REP TUB EP 1997; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; Wilkinson D, 1997, LANCET, V349, P882, DOI 10.1016/S0140-6736(05)61791-6; Wise R, 1996, LANCET, V348, P282, DOI 10.1016/S0140-6736(05)64470-4	18	104	106	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					169	172		10.1016/S0140-6736(96)11311-8	http://dx.doi.org/10.1016/S0140-6736(96)11311-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250184				2022-12-28	WOS:A1997XL72200011
J	Grange, JM; Zumla, A				Grange, JM; Zumla, A			Making DOTS succeed	LANCET			English	Editorial Material									UCL, SCH MED, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	Grange, JM (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, SCH MED, DOVEHOUSE ST, LONDON W1P 6DB, ENGLAND.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				Brown P, 1997, NEW SCI, P4; Fox R, 1997, J ROY SOC MED, V90, P242, DOI 10.1177/014107689709000502; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; Volmink J, 1997, LANCET, V349, P1399, DOI 10.1016/S0140-6736(05)63244-8	4	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					157	157		10.1016/S0140-6736(05)62344-6	http://dx.doi.org/10.1016/S0140-6736(05)62344-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250177				2022-12-28	WOS:A1997XL72200003
J	Moy, E; Mazzaschi, AJ; Levin, RJ; Blake, DA; Griner, PF				Moy, E; Mazzaschi, AJ; Levin, RJ; Blake, DA; Griner, PF			Relationship between National Institutes of Health research awards to US medical schools and managed care market penetration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Medical research conducted in academic medical centers is often dependent on support from clinical revenues generated in these institutions. Anecdotal evidence suggests that managed care has the potential to affect research conducted in academic medical centers by challenging these clinical revenues. Objective.-To examine whether empirical evidence supports a relationship between managed care and the ability of US medical schools to sustain biomedical research. Design.-Data on annual extramural research grants awarded to US medical schools by the National Institutes of Health (NIH) from fiscal years 1986 to 1995 were obtained, and each medical school was matched to a market for which information about health maintenance organization (HMO) penetration in 1995 was available. Main Outcome Measures.-Growth in total NIH awards, traditional research project (R01) awards, R01 awards to clinical and basic science departments, and changes in institutional ranking by NIH awards were compared among schools located in markets with low, medium, and high managed care penetration. Results.-Medical schools in all markets had comparable rates of growth in NIH awards from 1986 to 1990. Thereafter, medical schools in markets with high managed care penetration had slower growth in the dollar amounts and numbers of NIH awards compared with schools in markets with low or medium managed care penetration. This slower growth for schools in high managed care markets was associated with loss of share of NIH awards, equal to $98 million in 1995, and lower institutional ranking by NIH awards. Much of this revenue loss can be explained by the slower growth of R01 awards to clinical departments in medical schools in high managed care markets. Conclusions.-These findings provide evidence of an inverse relationship between growth in NIH awards during the past decade and managed care penetration among US medical schools. Whether this association is causal remains to be determined.	ASSOC AMER MED COLL, DIV BIOMED RES, WASHINGTON, DC 20037 USA	Association of American Medical Colleges	Moy, E (corresponding author), ASSOC AMER MED COLL, CTR ASSESSMENT & MANAGEMENT CHANGE ACAD MED, 2450 N ST NW, WASHINGTON, DC 20037 USA.							*AD HOC GROUP MED, 1996, NIH RES GUID; *ASS AC HLTH CTR, 1996, END ER CROSS SUBS RE; BERMAN JJ, 1995, SOUTHERN MED J, V88, P295, DOI 10.1097/00007611-199503000-00009; BILLI JE, 1995, NEW ENGL J MED, V333, P979, DOI 10.1056/NEJM199510123331507; Blake DA, 1996, ACAD MED, V71, P818, DOI 10.1097/00001888-199608000-00007; Blumenthal D, 1996, HEALTH AFFAIR, V15, P200, DOI 10.1377/hlthaff.15.2.200; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; Bray GA, 1999, DIABETES CARE, V22, P623; Burnett DA, 1996, HEALTH AFFAIR, V15, P90, DOI 10.1377/hlthaff.15.3.90; Carey RM, 1996, ACAD MED, V71, P839, DOI 10.1097/00001888-199608000-00011; *COMM CRIT FED SUP, 1995, ALL FED FUNDS SCI TE; GEIGER R, 1995, J HIGH EDUC, V66, P336, DOI 10.2307/2943895; Gold MR, 1996, ACAD MED, V71, P828, DOI 10.1097/00001888-199608000-00010; INGLEHART JK, 1995, NEW ENGL J MED, V332, P407; Jones RF, 1996, ACAD MED, V71, P300, DOI 10.1097/00001888-199603000-00027; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; LASALANDRA M, 1997, BOSTON HLTH     0105, P17; Mechanic RE, 1996, HEALTH AFFAIR, V15, P72, DOI 10.1377/hlthaff.15.3.72; Miller RH, 1996, HEALTH AFFAIR, V15, P107, DOI 10.1377/hlthaff.15.2.107; Neilson EG, 1995, J INVEST MED, V43, P534; *NIH, 1996, NIH EXTR TRENDS FISC; PERRY DR, 1981, NEW ENGL J MED, V305, P320, DOI 10.1056/NEJM198108063050605; PHAM A, 1996, BOSTON GLOBE    0713, P65; RICH S, 1996, PITTSBURGH POST 0902, pA6; RICH S, 1996, WASHINGTON POST 0818, pA6; STEIN MD, 1993, JAMA-J AM MED ASSOC, V269, P781, DOI 10.1001/jama.269.6.781; WALKER PV, 1996, CHRON HIGHER ED 1213, pA30; 1996, SCI GOVT REP    1101, P6; 1996, INTERSTUDY COMPETITI; 1996, US MED           DEC, P1	30	96	96	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					217	221		10.1001/jama.278.3.217	http://dx.doi.org/10.1001/jama.278.3.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218668				2022-12-28	WOS:A1997XK10800027
J	Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G				Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G			Case-control study of oestrogen replacement therapy and risk of cervical cancer	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUSES; ORAL-CONTRACEPTIVES; ONCOGENIC TRANSFORMATION; GENITAL-TRACT; PROGESTERONE; NEOPLASIA; ESTROGEN; TYPE-16; WOMEN	Objective : To examine the relation between use of oestrogen replacement therapy and risk of cervical cancer. Design : Case-control study. Setting : Northern Italy. Subjects : 645 women aged 40-75 years with cervical cancer admitted between 1981 and 1993 to university and general hospitals. The control group consisted of 749 women aged 40-75 years admitted to the same hospitals with acute conditions judged to be unrelated to any of the known or suspected risk factors for cervical cancer. Main outcome measures : Use of oestrogen replacement therapy and risk of cervical cancer. Results : 40 cases versus 86 controls had ever used oestrogens, and the corresponding multivariate odds ratio was 0.5 (95% confidence interval 0.3 to 0.8). The odds ratios of cervical cancer decreased with duration of use, being 0.6 (0.4 to 1.1) for less than 12 months' use and 0.5 (0.2 to 1.0) for use for 12 months or more compared with never users. The protection tended to be somewhat stronger for women reporting first oestrogen use before age 50. The odds ratio was 0.9 (0.5 to 1.7) for women who had taken oestrogens within the past 10 years and 0.4 (0.2 to 0.7) for those who had taken them 10 or more years ago. Conclusion :These findings suggest that exogenous oestrogens do not increase the risk of cervical cancer and may decrease the risk.	MARIO NEGRI INST PHARMACOL RES,UNIT EPIDEMIOL METHODOL,I-20157 MILAN,ITALY; UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; CTR RIFERIMENTO ONCOL,DIV EPIDEMIOL,I-33081 AVIANO,PN,ITALY; UNIV MILAN,IST CLIN OSTETR GINECOL,I-20129 MILAN,ITALY; IST NAZL TUMORI,DIV GYNECOL ONCOL,I-20133 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; IRCCS Aviano (CRO); University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Parazzini, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,ANALYT EPIDEMIOL UNIT,VIA ERITREA 62,I-20157 MILAN,ITALY.		Chatenoud, Liliane/AAA-6377-2020; franceschi, silvia/M-2452-2014; Negri, Eva/B-7244-2013; Negri, Eva Vanna Lorenza/AAC-5698-2019	Chatenoud, Liliane/0000-0001-9599-8229; franceschi, silvia/0000-0003-4181-8071; Negri, Eva/0000-0001-9712-8526; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; parazzini, fabio/0000-0001-5624-4854; Bolis, Giorgio/0000-0001-8216-0080; La Vecchia, Carlo/0000-0003-1441-897X				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; BAKER RJ, 1978, GLIM SYSTEM; BERRY G, 1993, INT J CANCER, V55, P228; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; HILDESHEIM A, 1990, INT J CANCER, V45, P860, DOI 10.1002/ijc.2910450513; LAVECCHIA C, 1986, BRIT J CANCER, V54, P311, DOI 10.1038/bjc.1986.178; MANTEL N, 1959, J NATL CANCER I, V22, P719; MONSONEGO J, 1991, INT J CANCER, V48, P533, DOI 10.1002/ijc.2910480410; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PARAZZINI F, 1993, REV EPIDEMIOL SANTE, V41, P53; PARAZZINI F, 1991, GYNECOL ONCOL, V41, P1, DOI 10.1016/0090-8258(91)90246-2; PARAZZINI F, 1989, BRIT J CANCER, V59, P805, DOI 10.1038/bjc.1989.168; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; PATER A, 1990, AM J OBSTET GYNECOL, V162, P1099, DOI 10.1016/0002-9378(90)91323-5; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212; SERRA GB, 1992, TERAPIA ORMONALE NEL	19	42	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					85	88		10.1136/bmj.315.7100.85	http://dx.doi.org/10.1136/bmj.315.7100.85			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240046	Green Published			2022-12-28	WOS:A1997XL25200019
J	Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD				Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD			Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ANEMIA TYPE-II; N-ACETYLGLUCOSAMINYLTRANSFERASE-II; BROAD-SPECIFICITY ALPHA-1->2; RAT-LIVER; ERYTHROCYTE-MEMBRANE; STRUCTURAL DETERMINANTS; CONCANAVALIN-A; SWAINSONINE; HEMPAS	Alpha-mannosidase-II (alpha M-II) catalyzes the first committed step in the biosynthesis of complex asparagine-linked (N-linked) oligosaccharides (N-glycans). Genetic deficiency of alpha M-II should abolish complex N-glycan production as reportedly does inhibition of alpha M-II by swainsonine. We find that mice lacking a functional alpha M-II gene develop a dyserythropoietic anemia concurrent with loss of erythrocyte complex N-glycans. Unexpectedly, nonerythroid cell types continued to produce complex N-glycans by an alternate pathway comprising a distinct alpha-mannosidase. These studies reveal cell-type-specific variations in N-linked oligosaccharide biosynthesis and an essential role for alpha M-II in the formation of erythroid complex N-glycans. alpha M-II deficiency elicits a phenotype in mice that correlates with human congenital dyserythropoietic anemia type II.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; BURNHAM INST, LA JOLLA, CA 92037 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University System of Georgia; University of Georgia			Moremen, Kelley/AAD-4661-2019; Liao, Yung-Feng/A-9761-2011	Freeze, Hudson/0000-0001-6316-0501	NCI NIH HHS [CA71932] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline; NIGMS NIH HHS [GM32485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1991, ARCH BIOCHEM BIOPHYS, V291, P76, DOI 10.1016/0003-9861(91)90107-T; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAINES AJ, 1982, BRIT J HAEMATOL, V50, P563, DOI 10.1111/j.1365-2141.1982.tb01956.x; BEUTLER E, 1995, WILLIAMS HEMATOLOGY, P467; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; CAMPBELL RM, 1995, GLYCOBIOLOGY, V5, P535, DOI 10.1093/glycob/5.5.535; CHARUK JHM, 1995, EUR J BIOCHEM, V230, P797; COLEGATE SM, 1979, AUST J CHEM, V32, P2257, DOI 10.1071/CH9792257; CROOKSTON JH, 1969, BRIT J HAEMATOL, V17, P11, DOI 10.1111/j.1365-2141.1969.tb05660.x; DORLING PR, 1978, NEUROPATH APPL NEURO, V4, P285, DOI 10.1111/j.1365-2990.1978.tb00547.x; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1981, P NATL ACAD SCI-BIOL, V78, P7393, DOI 10.1073/pnas.78.12.7393; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA MN, 1992, BRIT J HAEMATOL, V82, P745, DOI 10.1111/j.1365-2141.1992.tb06953.x; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; FUKUDA MN, 1989, BLOOD, V73, P1331; HAKOMORI S, 1981, SEMIN HEMATOL, V82, P745; HARPAZ N, 1980, J BIOL CHEM, V255, P4894; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HUGHES RC, 1986, EUR J BIOCHEM, V158, P227, DOI 10.1111/j.1432-1033.1986.tb09742.x; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MERKLE RK, 1997, IN PRESS BIOCH BIOPH; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; PALEK J, 1995, WILLIAMS HEMATOLOGY, P406; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCARTEZZINI P, 1982, BRIT J HAEMATOL, V51, P569, DOI 10.1111/j.1365-2141.1982.tb02820.x; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; Tan J, 1996, AM J HUM GENET, V59, P810; TULSIANI DRP, 1988, ARCH BIOCHEM BIOPHYS, V264, P607, DOI 10.1016/0003-9861(88)90327-X; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; TULSIANI DRP, 1984, ARCH BIOCHEM BIOPHYS, V232, P76, DOI 10.1016/0003-9861(84)90522-8; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753	56	156	167	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	1997	90	1					157	167		10.1016/S0092-8674(00)80322-0	http://dx.doi.org/10.1016/S0092-8674(00)80322-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230311	Bronze			2022-12-28	WOS:A1997XL36200017
J	Hurme, R; Berndt, KD; Normark, SJ; Rhen, M				Hurme, R; Berndt, KD; Normark, SJ; Rhen, M			A proteinaceous gene regulatory thermometer in Salmonella	CELL			English	Article							HELICAL COILED-COILS; SHOCK TRANSCRIPTION FACTOR-1; SMOOTH-MUSCLE TROPOMYOSIN; HEAT-SHOCK; ESCHERICHIA-COLI; DNA-BINDING; ENVIRONMENTAL-REGULATION; TEMPERATURE REGULATION; PATHOGENIC BACTERIA; SHIGELLA-FLEXNERI	Novel utilization of the coiled-coil motif is presented that enables TlpA, an autoregulatory repressor protein in Salmonella, to sense temperature shifts directly and thereby to modulate the extent of transcription repression. Salmonella cells shifted to higher temperatures, such as those encountered at host entry, showed derepressed tlpA activity. tlpA::lacZ fusions indicated that the promoter itself is insensitive to thermal shifts and that transcription control was exerted by the autorepressor TlpA only. In vitro studies with highly purified TlpA showed concentration and temperature dependence for both fully folded conformation and function, indicating that the thermosensing in TlpA is based on monomer-to-coiled-coil equilibrium.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAIRD GD, 1985, J GEN MICROBIOL, V131, P1815; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORNELIS GR, 1991, MOL MICROBIOL, V5, P1023, DOI 10.1111/j.1365-2958.1991.tb01875.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DORMAN CJ, 1991, INFECT IMMUN, V59, P745, DOI 10.1128/IAI.59.3.745-749.1991; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Groisman EA, 1996, TRENDS MICROBIOL, V4, P127, DOI 10.1016/0966-842X(96)30013-9; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; HURME R, 1994, J BIOL CHEM, V269, P10675; Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAURELLI AT, 1989, MICROB PATHOGENESIS, V7, P1, DOI 10.1016/0882-4010(89)90106-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MIKULSKIS AV, 1994, MOL MICROBIOL, V11, P77, DOI 10.1111/j.1365-2958.1994.tb00291.x; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1989, SCIENCE, V243, P536; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; QI SY, 1995, MOL MICROBIOL, V17, P523, DOI 10.1111/j.1365-2958.1995.mmi_17030523.x; RHEN M, 1993, MOL MICROBIOL, V10, P45, DOI 10.1111/j.1365-2958.1993.tb00902.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; TOBE T, 1993, J BACTERIOL, V175, P6142, DOI 10.1128/JB.175.19.6142-6149.1993; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	63	104	122	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					55	64		10.1016/S0092-8674(00)80313-X	http://dx.doi.org/10.1016/S0092-8674(00)80313-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230302	Bronze			2022-12-28	WOS:A1997XL36200008
J	KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S				KaneiIshii, C; Tanikawa, J; Nakai, A; Morimoto, RI; Ishii, S			Activation of heat shock transcription factor 3 by c-Myb in the absence of cellular stress	SCIENCE			English	Article							HSP70 GENE-TRANSCRIPTION; DNA-BINDING ABILITY; COILED-COIL; MOLECULAR-CLONING; LEUCINE-ZIPPER; OLIGOMERIZATION; EXPRESSION; HSF1; TRANSACTIVATION; TRIMERIZATION	In vertebrates, the presence of multiple heat shock transcription factors (HSFs) indicates that these factors may be regulated by distinct stress signals. HSF3 was specifically activated in unstressed proliferating cells by direct binding to the c-myb proto-oncogene product (c-Myb). These factors formed a complex through their DNA binding domains that stimulated the nuclear entry and formation of the transcriptionally active trimer of HSF3. Because c-Myb participates in cellular proliferation, this regulatory pathway may provide a link between cellular proliferation and the stress response.	RIKEN, TSUKUBA LIFE SCI CTR, MOL GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, DEPT CELL BIOL, CHEST DIS RES INST, KYOTO 606, JAPAN; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, RICE INST BIOMED RES, EVANSTON, IL 60208 USA; OSAKA UNIV, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN	RIKEN; Kyoto University; Northwestern University; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KARISEDER J, 1996, BICOH BIOPHYS RES CO, V220, P153; KIMURA Y, IN PRESS GENES DEV; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOROMOTO RI, 1994, BIOL HEAT SHOCK PROT, P417; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NAIR SC, IN PRESS CELL STRESS; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	34	58	58	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					246	248		10.1126/science.277.5323.246	http://dx.doi.org/10.1126/science.277.5323.246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211854				2022-12-28	WOS:A1997XK41800047
J	Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C				Lindahl, P; Johansson, BR; Leveen, P; Betsholtz, C			Pericyte loss and microaneurysm formation in PDGF-B-deficient mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; ENDOTHELIAL-CELLS; BETA-RECEPTOR; EXPRESSION; INHIBITION; EMBRYO; TEK	Platelet-derived growth factor (pDGF)-B-deficient mouse embryos were found to lack microvascular pericytes, which normally form part of the capillary wall, and they developed numerous capillary microaneurysms that ruptured at late gestation. Endothelial cells of the sprouting capillaries in the mutant mice appeared to be unable to attract pDGF-R beta-positive pericyte progenitor cells. Pericytes may contribute to the mechanical stability of the capillary wall, Comparisons made between PDGF null mouse phenotypes suggest a general role for PDGFs in the development of myofibroblasts.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT ANAT & CELL BIOL,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								BERNSTEIN LR, 1982, J CELL SCI, V56, P71; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BUZNEY SM, 1977, INVEST OPHTH VIS SCI, V16, P392; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fujimoto K, 1995, ANAT RECORD, V242, P562, DOI 10.1002/ar.1092420412; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hogan B, 1994, MANIPULATING MOUSE E; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LINDAHL P, UNPUB; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; OSTERBY R, 1974, ACTA MED SCAND, V574, P1; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WESTERMARK B, 1993, BIOL PLATELET DERIVE	33	1587	1644	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					242	245		10.1126/science.277.5323.242	http://dx.doi.org/10.1126/science.277.5323.242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211853				2022-12-28	WOS:A1997XK41800046
J	Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T				Zwilling, S; Dieckmann, A; Pfisterer, P; Angel, P; Wirth, T			Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells	SCIENCE			English	Article							BINDING TRANSCRIPTION FACTORS; FUNCTIONAL-CHARACTERIZATION; IMMUNOGLOBULIN PROMOTERS; OCT2 TRANSACTIVATION; ACTIVATION; SITES	BOB.1/OBF.1 is a transcriptional coactivator that is constitutively expressed in B cells and interacts with the Oct1 and Oct2 transcription factors. Upon activation of Jurkat T cells and primary murine thymocytes with phorbol esters and ionomycin, BOB.1/OBF.1 expression and transactivation function were induced. BOB.1/OBF.1 was phosphorylated at Ser(184) both in vivo and in vitro, and this modification was required for inducible activation. Mutation of Ser(184) also diminished transactivation function in B cells, suggesting that the activating phosphorylation that is inducible in T cells is constitutively present in B cells. Thus, BOB.1/OBF.1 is a transcriptional coactivator that is critically regulated by posttranslational modifications to mediate cell type-specific gene expression.	UNIV WURZBURG, INST MED STRAHLENKUNDE & ZELLFORSCH, D-97078 WURZBURG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT SIGNALTRANSDUKT & WACHSTUMSKONTROLLE, D-69120 HEIDELBERG, GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1	23	76	77	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					221	225		10.1126/science.277.5323.221	http://dx.doi.org/10.1126/science.277.5323.221			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211847				2022-12-28	WOS:A1997XK41800040
J	Castillo, PE; Malenka, RC; Nicoll, RA				Castillo, PE; Malenka, RC; Nicoll, RA			Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons	NATURE			English	Article							GLUTAMATE-RECEPTOR; AMPA RECEPTORS; BINDING-SITES; SUBUNITS; LOCALIZATION; RESPONSES; DESENSITIZATION; DEPOLARIZATIONS; ANTAGONIST; CLONING	Glutamate, the neurotransmitter at most excitatory synapses in the brain, activates a variety of receptor subtypes that can broadly be divided into ionotropic (ligand-gated ion channels) and metabotropic (G-protein-coupled) receptors. Ionotropic receptors mediate fast excitatory synaptic transmission, and based on pharmacological and molecular biological studies are divided into NMDA and non-NMDA subtypes. The non-NMDA receptor group is further divided into AMPA and kainate subtypes(1). Virtually all fast excitatory postsynaptic currents studied so far in the central nervous system are mediated by the AMPA and NMDA subtypes of receptors. Surprisingly, despite extensive analysis of their structural biophysical properties and anatomical distribution, a synaptic role for kainate receptors in the brain has not been found(2). Here we report that repetitive activation of the hippocampal messy fibre pathway, which is associated with high-affinity kainate binding(3) and many of the kainate receptor subtypes(4-8), generates a slow excitatory synaptic current with all of the properties expected of a kainate receptor. This activity-dependent synaptic current greatly augments the excitatory drive of CA3 pyramidal cells.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL & PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Burnashev N, 1996, J PHYSIOL-LONDON, V496, P165, DOI 10.1113/jphysiol.1996.sp021674; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FOSTER AC, 1981, NATURE, V289, P73, DOI 10.1038/289073a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; REPRESA A, 1987, NEUROSCIENCE, V20, P739, DOI 10.1016/0306-4522(87)90237-5; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SAWADA S, 1988, EXP BRAIN RES, V72, P135, DOI 10.1007/BF00248508; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SCANZIANI JH, 1997, NATURE, V385, P630; SIEGEL SJ, 1995, J NEUROSCI, V15, P2707; Swanson GT, 1996, J PHYSIOL-LONDON, V492, P129, DOI 10.1113/jphysiol.1996.sp021295; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	31	416	422	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					182	186		10.1038/40645	http://dx.doi.org/10.1038/40645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217159	Bronze			2022-12-28	WOS:A1997XK10900052
J	Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH				Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH			Representation of motion boundaries in retinotopic human visual cortical areas	NATURE			English	Article							SENSORY STIMULATION; MACAQUE MONKEY; HUMAN BRAIN; MT; NEURONS; CORTEX; SEGREGATION; PERCEPTION; LESIONS; FMRI	Edges are important in the interpretation of the retinal image. Although luminance edges have been studied extensively, much less is known about how or where the primate visual system detects boundaries defined by differences in surface properties such as texture, motion or binocular disparity. Here we use functional magnetic resonance imaging (fMRI) to localize human visual cortical activity related to the processing of one such higher-order edge type: motion boundaries. We describe a robust fMRI signal that is selective for motion segmentation. This boundary-specific signal is present, and retinotopically organized, within early visual areas, beginning in the primary visual cortex (area V1). Surprisingly, it is largely absent from the motion-selective area MT/V5 and far extrastriate visual areas. Changes in the surface velocity defining the motion boundaries affect the strength of the fMRI signal. In parallel psychophysical experiments, the perceptual salience of the boundaries shows a similar dependence on surface velocity. These results demonstrate that information for segmenting scenes by relative motion is represented as early as V1.	MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,CHARLESTOWN,MA 02129; MIT,DEPT BRAIN & COGNIT SCI,PERCEPTUAL SCI GRP,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,DEPT COGNIT SCI,LA JOLLA,CA 92093	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Reppas, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829				BANTON T, 1993, PERCEPTION, V22, P1195, DOI 10.1068/p221195; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DICK M, 1987, SCIENCE, V237, P400, DOI 10.1126/science.3603025; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; MARCAR VL, 1995, J NEUROPHYSIOL, V74, P1258, DOI 10.1152/jn.1995.74.3.1258; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2436; MURAKAMI I, 1995, VISION RES, V35, P1835, DOI 10.1016/0042-6989(94)00269-R; NAKAYAMA K, 1974, PERCEPTION, V3, P63, DOI 10.1068/p030063; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; ORBAN GA, 1995, P NATL ACAD SCI USA, V92, P993, DOI 10.1073/pnas.92.4.993; PATZWAHL DR, 1994, VISUAL NEUROSCI, V11, P1135, DOI 10.1017/S0952523800006945; REGAN D, 1992, J NEUROSCI, V12, P2198; REPPAS JB, 1996, RECHERCHE, V289, P52; SACHTLER WL, 1995, VISION RES, V35, P807, DOI 10.1016/0042-6989(94)00160-N; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAINA LM, 1994, NEUROREPORT, V5, P2289, DOI 10.1097/00001756-199411000-00021; VANDOORN AJ, 1982, EXP BRAIN RES, V45, P189, DOI 10.1007/BF00235778	30	97	97	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					175	179		10.1038/40633	http://dx.doi.org/10.1038/40633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217157	Bronze			2022-12-28	WOS:A1997XK10900050
J	Hale, AS				Hale, AS			ABC of mental health - Depression	BRITISH MEDICAL JOURNAL			English	Review																		Bridges PK, 1995, BRIT J HOSP MED, V54, P501; *CLIN RES AUD GROU, 1995, DEPR ILN CRIT REV CU; Craig TKJ, 1996, INT REV PSYCHIATR, V8, P341, DOI 10.3109/09540269609051549; Kendrick T, 1996, BRIT MED J, V313, P829; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; WILLIAMS R, 1994, SUICIDE PREVENTION C	6	36	37	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					43	46		10.1136/bmj.315.7099.43	http://dx.doi.org/10.1136/bmj.315.7099.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233328	Green Published			2022-12-28	WOS:A1997XJ94700034
J	Mason, D; Birmingham, L; Grubin, D				Mason, D; Birmingham, L; Grubin, D			Substance use in remand prisoners: A consecutive case study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To determine the prevalence of drug and alcohol use among newly remanded prisoners, assess the effectiveness of prison reception screening, and examine the clinical management of substance misusers among remand prisoners. Design: A consecutive case study of remand prisoners screened at reception for substance misuse and treatment needs and comparison of findings with those of prison reception screening and treatment provision. Setting: A large adult male remand prison (Durham). Subjects: 548 men aged 21 and over awaiting trial. Main outcome measures: Prevalence of substance misuse; treatment needs of substance misusers; effectiveness of prison reception screening for substance misuse; provision of detoxification programmes. Results: Before remand 312 (57%) men were using illicit drugs and 181 (33%) met DSM-IV drug misuse or dependence criteria: 177 (32%) men met misuse or dependence criteria for alcohol. 391 (71%) men were judged to require help directed at their drug or alcohol use and 197 (36%) were judged to require a detoxification programme. The prison reception screen identified recent illicit drug use in 131 (24%) of 536 men and problem drinking in 103 (19%). Drug use was more likely to be identified by prison screening if an inmate was using multiple substances. using opiates, or had a diagnosis of abuse or dependence. 47 (9%) of 536 inmates were prescribed treatment to ease the symptoms of substance withdrawal. Conclusions: The prevalence of substance misuse in newly remanded prisoners is high. Prison reception health screening consistently underestimates drug and alcohol use. In many cases in which substance use is identified the quantities and numbers of different substances being used are underestimated. Initial management of inmates identified by prison screening as having problems with dependence producing substances is poor. Few receive a detoxification programme, so that many are left with the option of continuing to use drugs in prison or facing untreated withdrawal.	UNIV NEWCASTLE UPON TYNE,ST NICHOLAS HOSP,DEPT FORENS PSYCHIAT,NEWCASTLE TYNE NE3 3XT,TYNE & WEAR,ENGLAND	Newcastle University - UK								Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; Gore SM, 1996, LANCET, V348, P1124, DOI 10.1016/S0140-6736(96)06318-0; Joyce L, 1996, PRISON SER J, V107, P16; MAXWELL AE, 1977, BRIT J PSYCHIAT, V130, P79, DOI 10.1192/bjp.130.1.79; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P121; PHILLIPS GT, 1987, BRIT J ADDICT, V82, P691; ROSS M, 1994, BRIT MED J, V308, P1092, DOI 10.1136/bmj.308.6936.1092; SMITH R, 1992, BRIT MED J, V304, P134, DOI 10.1136/bmj.304.6820.134	10	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					18	21		10.1136/bmj.315.7099.18	http://dx.doi.org/10.1136/bmj.315.7099.18			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233320	Green Published			2022-12-28	WOS:A1997XJ94700021
J	Campbell, RWF				Campbell, RWF			Whither digitalis?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; SURVIVAL; DIGOXIN				Campbell, RWF (corresponding author), FREEMAN RD HOSP,ACAD DEPT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.							Banerjee AK, 1996, INT J CARDIOL, V55, P9, DOI 10.1016/0167-5273(96)02580-6; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; LEOR J, 1995, CARDIOVASC DRUG THER, V9, P723, DOI 10.1007/BF00878556; PUGH SE, 1989, BRIT HEART J, V61, P529; RYAN TJ, 1983, CIRCULATION, V67, P735, DOI 10.1161/01.CIR.67.4.735; Saunders KB, 1997, LANCET, V349, P833, DOI 10.1016/S0140-6736(96)09057-5	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1854	1855		10.1016/S0140-6736(05)63871-8	http://dx.doi.org/10.1016/S0140-6736(05)63871-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217753				2022-12-28	WOS:A1997XG41700004
J	Shale, DJ				Shale, DJ			Could diuretics in hypoxic states be bad for the pulmonary circulation?	LANCET			English	Editorial Material							DISEASE				Shale, DJ (corresponding author), LLANDOUGH HOSP,ACAD CTR,DEPT MED,CARDIFF CF64 2XX,S GLAM,WALES.							FARBER MO, 1982, ARCH INTERN MED, V142, P1326, DOI 10.1001/archinte.142.7.1326; FISHMAN AP, 1976, CIRC RES, V38, P221, DOI 10.1161/01.RES.38.4.221; KEILY DG, 1997, BR J CLIN PHARM, V43, P309; KLINGER JR, 1991, CHEST, V99, P715, DOI 10.1378/chest.99.3.715; LIPWORTH BJ, 1994, CHEST, V105, P1360, DOI 10.1378/chest.105.5.1360	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1856	1856		10.1016/S0140-6736(05)63873-1	http://dx.doi.org/10.1016/S0140-6736(05)63873-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217755				2022-12-28	WOS:A1997XG41700006
J	Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A				Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A			Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors	SCIENCE			English	Article							TNF RECEPTOR; DEATH	TRAIL (also called Apo2L) belongs to the tumor necrosis factor family, activates rapid apoptosis in tumor cells, and binds to the death-signaling receptor DR4. Two additional TRAIL receptors were identified. The receptor designated death receptor 5 (DR5) contained a cytoplasmic death domain and induced apoptosis much like DR4. The receptor designated decoy receptor 1 (DcR1) displayed properties of a glycophospholipid-anchored cell surface protein. DcR1 acted as a decoy receptor that inhibited TRAIL signaling. Thus, a cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				[Anonymous], UNPUB; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Ashkenazi Avi, 1995, Methods (Orlando), V8, P104, DOI 10.1006/meth.1995.9996; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MARSTERS SA, UNPUB; MORAN P, 1991, J BIOL CHEM, V266, P1250; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PITTI RM, 1996, J BIOL CHEM, V271, P12697; PITTI RM, UNPUB; SHERIDAN JB, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	29	1503	1662	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					818	821		10.1126/science.277.5327.818	http://dx.doi.org/10.1126/science.277.5327.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242611				2022-12-28	WOS:A1997XQ24700044
J	Johnson, JL; Craig, EA				Johnson, JL; Craig, EA			Protein folding in vivo: Unraveling complex pathways	CELL			English	Review							CHAPERONES				Johnson, JL (corresponding author), UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706, USA.							BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fenton WA, 1997, PROTEIN SCI, V6, P743; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Ziegelhoffer T, 1996, CURR BIOL, V6, P272, DOI 10.1016/S0960-9822(02)00476-1	19	146	150	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					201	204		10.1016/S0092-8674(00)80327-X	http://dx.doi.org/10.1016/S0092-8674(00)80327-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244293	Bronze			2022-12-28	WOS:A1997XN24900003
J	Tronchere, H; Wang, JW; Fu, XD				Tronchere, H; Wang, JW; Fu, XD			A protein related to splicing factor U2AF(35) that interacts with U2AF(65) and SR proteins in splicing of pre-mRNA	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; BIOCHEMICAL-CHARACTERIZATION; INTRACELLULAR-LOCALIZATION; SERINE-RICH; SNRNP; PURIFICATION; RECOGNITION; CLONING; GENE	Recognition of a functional 3' splice site in pre-mRNA splicing requires a heterodimer of the proteins U2AF(65)/U2AF(35). U2AF(65) binds to RNA at the polypyrimidine tract(1,2), whereas U2AF(35) is thought to interact through its arginine/serine-rich (RS) domain with other RS-domain-containing factors;bound at the 5' splice site, assembled in splicing enhancer complexes, or associated with the U4/U6 . U5 small nuclear ribonucleoprotein complex(3-7). It is unclear, however, how such network interactions can all be established through the small RS domain in U2AF(35). Here we describe the function of a U2AF(35)-related protein (Urp), which is the human homologue of a mouse imprinted gene. Nuclear extracts depleted of Urp are defective in splicing, but activity can be restored by addition of recombinant Urp. U2AF(35) could not replace Urp in complementation, indicating that their functions do not overlap. Co-immunodepletion showed that Urp is associated with the U2AF(65)/U2AF(35) heterodimer, Binding studies revealed that Urp specifically interacts with U2AF(65) through a U2AF(35)-homologous region and with SR proteins (a large family of RS-domain-containing proteins) through its RS domain. Therefore, Urp and U2AF(35) may independently position RS-domain-containing factors within spliceosomes.	UNIV CALIF SAN DIEGO, DEPT MED, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			TRONCHERE, Helene/M-5631-2014					Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Fetzer S, 1997, RNA, V3, P344; FU XD, 1995, RNA, V1, P663; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; KITAGAWA K, 1995, GENOMICS, V30, P257, DOI 10.1006/geno.1995.9879; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; ROSCIGNO RF, 1995, RNA, V1, P692; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YAMAOKA T, 1995, GENOMICS, V27, P337, DOI 10.1006/geno.1995.1051; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	23	85	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					397	400		10.1038/41137	http://dx.doi.org/10.1038/41137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237760	Bronze			2022-12-28	WOS:A1997XM52800056
J	Greengold, NL				Greengold, NL			Ambivalence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					268	268						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228419				2022-12-28	WOS:A1997XL05900001
J	Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L				Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L			Water on the sun: Line assignments based on variational calculations	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; GROUND-STATE; (H2O)-O-16; CM-1; SPECTROSCOPY; MOLECULES; STRENGTHS; H2O-16; BANDS	The infrared spectrum of hot water observed in a sunspot has been assigned. The high temperature of the sunspot, (3200 K) gave rise to a highly congested pure rotational spectrum in the 10-micrometer region that involved energy levels at least halfway to dissociation, Traditional spectroscopy, based on perturbation theory, is inadequate for this problem. Instead, accurate variational solutions of the vibration-rotation Schrodinger equation were used to make assignments, revealing unexpected features, including rotational difference bands and fewer degeneracies than anticipated. These results indicate that a shift away from perturbation theory to first. principles calculations is necessary in order to assign spectra of hot polyatomic molecules such as water.	UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT OBSERV, TUCSON, AZ 85732 USA; RUSSIAN ACAD SCI, INST APPL PHYS, NIZHNII NOVGOROD 603600, RUSSIA	University of London; University College London; University of Waterloo; University of Arizona; National Optical Astronomy Observatory; Russian Academy of Sciences; Institute of Applied Physics of the Russian Academy of Sciences			Tennyson, Jonathan/I-2222-2012; Nikolay, Zobov/U-1709-2019; Bernath, Peter F/B-6567-2012	Tennyson, Jonathan/0000-0002-4994-5238; Bernath, Peter F/0000-0002-1255-396X				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; BACIC Z, 1989, ANNU REV PHYS CHEM, V40, P469, DOI 10.1146/annurev.pc.40.100189.002345; CAMYPEYRET C, 1980, J PHYS LETT-PARIS, V41, pL23, DOI 10.1051/jphyslet:0198000410202300; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; FLAUD JM, 1974, J MOL SPECTROSC, V51, P142, DOI 10.1016/0022-2852(74)90177-5; FLAUD JM, 1977, J MOL SPECTROSC, V65, P219, DOI 10.1016/0022-2852(77)90189-8; FLAUD JM, 1981, WATER VAPOUR LINE PA; GABRIEL W, 1993, J CHEM PHYS, V99, P897, DOI 10.1063/1.465354; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JENSEN P, 1997, ADV SERIES PHYSICAL, V9; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; Partridge H, 1997, J CHEM PHYS, V106, P4618, DOI 10.1063/1.473987; Polyansky OL, 1996, J CHEM PHYS, V105, P6490, DOI 10.1063/1.472501; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; Polyansky OL, 1997, J MOL SPECTROSC, V184, P35, DOI 10.1006/jmsp.1997.7307; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; Polyansky OL, 1997, J MOL SPECTROSC, V186, P213, DOI 10.1006/jmsp.1997.7443; *PROP EN PAN WORK, 1993, 287 NATO AGARD PROP; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; Schwenke D. W., COMMUNICATION; TENNYSON J, 1995, REP PROG PHYS, V58, P421, DOI 10.1088/0034-4885/58/4/002; TENNYSON J, 1995, COMPUT PHYS COMMUN, V86, P175, DOI 10.1016/0010-4655(94)00139-S; TENNYSON J, 1994, PHYS REV A, V50, P314, DOI 10.1103/PhysRevA.50.314; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TOTH RA, 1993, J OPT SOC AM B, V10, P1526, DOI 10.1364/JOSAB.10.001526; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; ULENIKOV ON, 1986, J MOL SPECTROSC, V117, P195, DOI 10.1016/0022-2852(86)90149-9; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; WALLACE L, 1994, 199401 NATL SOL OBS; Worden H, 1997, J GEOPHYS RES-ATMOS, V102, P1287, DOI 10.1029/96JD02982; Zobov NF, 1996, CHEM PHYS LETT, V260, P381, DOI 10.1016/0009-2614(96)00872-X	35	123	124	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					346	348		10.1126/science.277.5324.346	http://dx.doi.org/10.1126/science.277.5324.346			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219686				2022-12-28	WOS:A1997XL35800038
J	VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M				VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M			Differential effects of early hippocampal pathology on episodic and semantic memory	SCIENCE			English	Article							RHESUS-MONKEYS; ASSOCIATION; IMPAIRMENT; EPILEPSY; AMNESIA; CORTEX	Global anterograde amnesia is described in three patients with brain injuries that occurred in one case at birth, in another by age 4, and in the third at age 9. Magnetic resonance techniques revealed bilateral hippocampal pathology in ail three cases. Remarkably, despite their pronounced amnesia For the episodes of everyday life, all three patients attended mainstream schools and attained levels of speech and language competence, literacy, and factual knowledge that are within the low average to average range. The findings provide support for the view that the episodic and semantic components of cognitive memory are partly dissociable, with only the episodic component being fully dependent an the hippocampus.	UCL, SCH MED, INST CHILD HLTH, RADIOL & PHYS UNIT, LONDON WC1N 1EH, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND; NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	University of London; University College London; UCL Medical School; University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	VarghaKhadem, F (corresponding author), UCL, SCH MED,WOLFSON CTR,INST CHILD HLTH, COGNIT NEUROSCI UNIT, MECKLENBURGH SQ, LONDON WC1N 2AP, ENGLAND.		Gadian, David G/C-4961-2008; Vargha-Khadem, Faraneh/C-2558-2008; Van Paesschen, Wim/A-4540-2010; Fahimifar, Sepideh/M-5303-2019; Watkins, Kate E/A-6559-2012; Connelly, Alan/A-9065-2013	Van Paesschen, Wim/0000-0002-8535-1699; Watkins, Kate E/0000-0002-2621-482X; Connelly, Alan/0000-0001-7159-8079; vargha-khadem, faraneh/0000-0003-4890-8379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CONNELLY A, 1994, NEUROLOGY, V44, P1411, DOI 10.1212/WNL.44.8.1411; Cross JH, 1996, ANN NEUROL, V39, P107, DOI 10.1002/ana.410390116; Gadian DG, 1996, NEUROLOGY, V46, P974, DOI 10.1212/WNL.46.4.974; Goulet S., 1995, Society for Neuroscience Abstracts, V21, P1446; ISAACS EB, 1989, BRIT J DEV PSYCHOL, V7, P377, DOI 10.1111/j.2044-835X.1989.tb00814.x; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1993, NEUROLOGY, V43, P1793, DOI 10.1212/WNL.43.9.1793; LANG C, 1981, J NEUROL NEUROSUR PS, V44, P626, DOI 10.1136/jnnp.44.7.626; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Murray E. A., 1996, Society for Neuroscience Abstracts, V22, P281; Murray E. A., 1993, Society for Neuroscience Abstracts, V19, P438; MURRAY EA, 1993, J NEUROSCI, V13, P4549; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NATHAN PW, 1950, J NEUROL NEUROSUR PS, V13, P191, DOI 10.1136/jnnp.13.3.191; OSTERGAARD AL, 1987, NEUROPSYCHOLOGIA, V25, P341, DOI 10.1016/0028-3932(87)90023-6; Osterrieth P, 1944, ARCH PSYCHOL, V30, P306; PARKINSON JK, 1988, J NEUROSCI, V8, P4159; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Rempel-Clower N. L., 1994, Society for Neuroscience Abstracts, V20, P1075; Rust J, 1993, WECHSLER OBJECTIVE R; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SPIEGLER BJ, 1981, BEHAV BRAIN RES, V3, P303, DOI 10.1016/0166-4328(81)90002-4; SPIEGLER BJ, 1979, SOC NEUR ABSTR, V5, P323; Squire Larry R., 1995, P825; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; Talley JL, 1993, CAVLT 2 CHILDRENS AU; Tulving Endel, 1995, P839; VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wilson B, 1985, RIVERMEAD BEHAVIOURA; Wood F., 1982, HUMAN MEMORY AMNESIA, P167; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	1179	1197	4	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					376	380		10.1126/science.277.5324.376	http://dx.doi.org/10.1126/science.277.5324.376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219696				2022-12-28	WOS:A1997XL35800048
J	Brown, NJ; Snowden, M; Griffin, MR				Brown, NJ; Snowden, M; Griffin, MR			Recurrent angiotensin-converting enzyme inhibitor-associated angioedema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known. Objective.-To test the hypothesis that the association between ACE inhibitor use and angioedema may not be recognized and to determine characteristics of angioedema associated with continued use of ACE inhibitors. Design.-Retrospective cohort study. Setting.-Tennessee Medicaid program. Patients.-Medicaid enrollees aged 15 years or older who used an ACE inhibitor and had a first documented episode of angioedema between 1986 and 1992 were followed up for recurrent episodes through June 1993. Measurements and Main Results.-We previously identified 82 patients with a first confirmed diagnosis of angioedema during 51 752 person-years of ACE inhibitor use in this population (1.6 per 1000 person-years). Among these 82 patients, there were 16 outpatient recurrences of angioedema among 13 patients during 189 patient-years of follow-up (8.5 per 100 patient-years). The rate of angioedema was much higher in users of ACE inhibitors with continued exposure (18.7 per 100 patient-years) than in those whose use of the drug was discontinued (1.8 per 100 patient-years) (P=.001). Review of the medical records for patients taking ACE inhibitors who had recurrent angioedema revealed that physicians attributed angioedema to a number of causes not related to ACE inhibitor use, even after multiple recurrences. Conclusion.-Continuing use of ACE inhibitors in spite of angioedema results in a markedly increased rate of angioedema recurrence with serious morbidity.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PREVENT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	Brown, NJ (corresponding author), VANDERBILT UNIV,DEPT MED,560 MED RES BLDG 1,NASHVILLE,TN 37232, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00095-533] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; *PHS US DEP HLTH H, 1988, INT CLASS DIS 9 REV; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153	4	117	121	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					232	233		10.1001/jama.278.3.232	http://dx.doi.org/10.1001/jama.278.3.232			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218671				2022-12-28	WOS:A1997XK10800030
J	Moirand, R; Adams, PC; Bicheler, V; Brissot, P; Deugnier, Y				Moirand, R; Adams, PC; Bicheler, V; Brissot, P; Deugnier, Y			Clinical features of genetic hemochromatosis in women compared with men	ANNALS OF INTERNAL MEDICINE			English	Article						hemochromatosis; hereditary diseases; sex factors; iron; ferritin	HEREDITARY HEMOCHROMATOSIS; BLOOD-DONORS; IRON; PREVALENCE; EXPRESSION; DIAGNOSIS; FIBROSIS; SIBLINGS	Background: The clinical expression of hemochromatosis is presumed to be less frequent and less severe in women than in men because of the iron loss associated with menses and pregnancy, but this hypothesis has not been validated. Objective: To compare the clinical features of women who have genetic hemochromatosis with those of men who have the disease. Design: Cross-sectional study. Setting: Tertiary referral centers for hemochromatosis in France and Canada. Patients: 176 women and 176 men with hemochromatosis, matched for year of birth. Measurements: Age at presentation, clinical symptoms, transferrin saturation, serum ferritin level, hepatic iron concentration, and hepatic iron index. Results: Hepatic iron concentration and hepatic iron index were similar in men and women. Women had lower serum ferritin levels than men did (911 mu g/L compared with 1911 mu g/L; mean difference, 1000 mu g/L [95% CI, 669 mu g/L to 1331 mu g/L]) and less iron removed by venesections (5.5 g and 8.6 g; mean difference, 3.1 g [CI, 1.5 g to 4.8 gl). Compared with women, men had a higher incidence of cirrhosis (25.6% and 13.8%; mean difference, 11.8 percentage points [CI, 3.2 to 20.4 percentage points]) and diabetes (15.9% and 7.4%; mean difference, 8.5 percentage points [CI, 1.9 to 5.2 percentage points]). Compared with men, women had a higher incidence of fatigue (64.8% and 42%; mean difference, -22.8 percentage points [CI, -32.3 to -12.5 percentage points]) and pigmentation (48% and 44.9%; mean difference, -13.1 percentage points [CI, -23.4 to 2.7 percentage points]). Hepatic iron concentration and hepatic iron index were greater in women in whom menstruation had stopped before 50 years of age. Serum ferritin levels and transferrin saturation were normal in 6.2% of women and 0% of men. Conclusions: Women with genetic hemochromatosis can have full phenotypic expression of the disease, including cirrhosis. Recognizing the nonspecific nature of presenting symptoms in women is essential for early diagnosis and treatment.	HOP PONTCHAILLOU, CLIN MALAD FOIE, F-35033 RENNES, FRANCE; HOP PONTCHAILLOU, INSERM, U49, RENNES, FRANCE; UNIV WESTERN ONTARIO, HLTH SCI CTR, LONDON, ON N6A 5C1, CANADA	CHU Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); London Health Sciences Centre; University of Manitoba; Children's Hospital Research Institute of Manitoba; Western University (University of Western Ontario)			Adams, Paul/G-2868-2011	Moirand, Romain/0000-0002-5346-5755				Adams P. C., 1996, Hepatology, V24, p198A; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, AM J MED, V90, P445; ADAMS PC, 1992, HEPATOLOGY, V15, P263, DOI 10.1002/hep.1840150215; Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130; ADAMS PC, 1992, DIGEST DIS SCI, V37, P361, DOI 10.1007/BF01307728; ASSY N, IN PRESS DIG DIS SCI; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; CRAWFORD DHG, 1993, HEPATOLOGY, V17, P833, DOI 10.1016/0270-9139(93)90160-O; DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050, DOI 10.1016/0016-5085(92)90331-R; EDWARDS CQ, 1984, ANN INTERN MED, V101, P707, DOI 10.7326/0003-4819-101-5-707; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LOREAL O, 1992, J HEPATOL, V16, P122, DOI 10.1016/S0168-8278(05)80104-7; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; SHELDON JH, 1935, HAEMOCHROMATOSIS, P164; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103	24	118	120	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					105	+		10.7326/0003-4819-127-2-199707150-00002	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9229998				2022-12-28	WOS:A1997XK15800004
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - Traditional Chinese medicine: One country, two systems	BRITISH MEDICAL JOURNAL			English	Article								China is the only country in the world where Western medicine and traditional medicine are practised alongside each ether at every level of the healthcare system, Traditional Chinese medicine has a unique theoretical and practical approach to the treatment of disease, which has developed over thousands of years. Traditional treatments include herbal remedies, acupuncture, acupressure and massage, and moxibustion. They account for around 40% of all health care delivered in China, The current government policy of expansion of traditional facilities and manpower is being questioned because many hospitals using traditional Chinese medicine are already underutilised and depend on government subsidies for survival, Research priorities include randomised controlled trials of common treatments and analysis of the active agents in herbal remedies, As more studies show the clinical effectiveness of traditional Chinese medicine, an integrated approach to disease using a combination of Western medicine and traditional approaches becomes a possibility for the future.	HLTH UNLIMITED,LONDON SE1 9NT,ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH,LONDON WC1 N1EH,ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				Chen R, 1966, CHINA REV, V3, P24; HESKETH T, 1994, BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441; HIEN TT, 1993, LANCET, V341, P603; Kaptchuk T, 1983, WEB HAS NO WEAVER; World Bank, 1992, CHIN LONG TERM ISS O; ZHENG X, 1995, SOC SCI MED, V41, P1057, DOI 10.1016/0277-9536(94)00431-R; 1992, CHINA DAILY     1104	7	147	155	5	52	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					115	117		10.1136/bmj.315.7100.115	http://dx.doi.org/10.1136/bmj.315.7100.115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240055	Green Published			2022-12-28	WOS:A1997XL25200033
J	Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G				Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G			A small, stable RNA induced by oxidative stress: Role as a pleiotropic regulator and antimutator	CELL			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSCRIPTIONAL ACTIVATOR; FORMATE HYDROGENLYASE; GENETIC-REGULATION; POSITIVE CONTROL; OPERON FUSIONS; ANTISENSE RNA; OMPF PROTEIN	Exposure of E. coli to hydrogen peroxide induces the transcription of a small RNA denoted oxyS. The oxyS RNA is stable, abundant, and does not encode a protein. oxyS activates and represses the expression of numerous genes in E. coli, and eight targets, including genes encoding the transcriptional regulators FhlA and sigma(s), were identified. oxyS expression also leads to a reduction in spontaneous and chemically-induced mutagenesis. Our results suggest that the oxyS RNA acts as a regulator that integrates adaptation to hydrogen peroxide with other cellular stress responses and helps to protect cells against oxidative damage.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL GENET & BIOTECHNOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Altuvia, S (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892, USA.			Storz, Gisela/0000-0001-6698-1241				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ALTUVIA S, 1991, J MOL BIOL, V218, P723, DOI 10.1016/0022-2836(91)90261-4; ANDERSEN J, 1989, J BIOL CHEM, V264, P17961; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWNLEE GG, 1971, NATURE-NEW BIOL, V229, P147, DOI 10.1038/newbio229147a0; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; ELASCO JG, 1993, CONTROL MESSENGER RN, P3; GILMAN MZ, 1983, CELL, V35, P285, DOI 10.1016/0092-8674(83)90231-3; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GUSTAFSSON C, 1992, J BACTERIOL, V174, P7878, DOI 10.1128/JB.174.23.7878-7879.1992; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; IVANOVA A, 1994, MOL MICROBIOL, V12, P571, DOI 10.1111/j.1365-2958.1994.tb01043.x; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; McKenney K, 1981, Gene Amplif Anal, V2, P383; Miller J.H., 1972, EXPT MOL GENETICS; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SALSER W, 1967, NATURE, V215, P588, DOI 10.1038/215588a0; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; Silhavy T. J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Springer AL, 1996, J BACTERIOL, V178, P2154, DOI 10.1128/jb.178.7.2154-2157.1996; STORZ G, 1994, METHOD ENZYMOL, V234, P217; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; Turlin E, 1996, BIOCHIMIE, V78, P822, DOI 10.1016/S0300-9084(97)84334-9; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	51	367	374	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					43	53		10.1016/S0092-8674(00)80312-8	http://dx.doi.org/10.1016/S0092-8674(00)80312-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230301	hybrid			2022-12-28	WOS:A1997XL36200007
J	Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA				Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA			Muscle force is generated by myosin heads stereospecifically attached to actin	NATURE			English	Article							X-RAY-DIFFRACTION; SKELETAL-MUSCLE; CROSS-BRIDGES; CONTRACTING MUSCLE; STRUCTURAL-CHANGES; STRIATED-MUSCLE; FIBERS; REFLECTIONS; MOVEMENTS; STATES	Muscle force is generated by myosin crossbridges interacting with actin. As estimated from stiffness(1,2) and equatorial X-ray diffraction(3) of muscle and muscle fibres, most myosin cross-bridges are attached to actin during isometric contraction, but a much smaller fraction is bound stereospecifically(4-7). To determine the fraction of crossbridges contributing to tension and the structural changes that attached crossbridges undergo when generating force, we monitored the X-ray diffraction pattern during temperature-induced tension rise in fully activated permeabilized frog muscle fibres. Temperature jumps(8) from 5-6 degrees C to 16-19 degrees C initiated a 1.7-fold increase in tension without significantly changing fibre stiffness or the intensities of the (1,1) equatorial and (14.5 nm)(-1) meridional X-ray reflections. However, tension rise was accompanied by a 20% decrease in the intensity of the (1,0) equatorial reflection and an increase in the intensity of the first actin layer line by similar to 13% of that in rigor. Our results show that muscle force is associated with a transition of the crossbridges from a state in which they are nonspecifically attached to actin to one in which stereospecifically bound myosin crossbridges label the actin helix.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; RUSSIAN ACAD SCI,INST PHYSIOL,URALS BRANCH,EKATERINBURG 620219,RUSSIA; MOSCOW MV LOMONOSOV STATE UNIV,INST MECH,MOSCOW 119899,RUSSIA	MRC National Institute for Medical Research; Russian Academy of Sciences; Lomonosov Moscow State University			Tsaturyan, Andrey K/B-1037-2014; Bershitsky, Sergey/S-4829-2016; Bershitsky, Sergey/AAE-6814-2019; Tsaturyan, Andrey/GXF-8722-2022; Ferenczi, Michael/F-9510-2015	Tsaturyan, Andrey K/0000-0002-0447-7725; Bershitsky, Sergey/0000-0001-5342-1739; Ferenczi, Michael/0000-0002-0349-331X				AMEMIYA Y, 1987, SCIENCE, V237, P164, DOI 10.1126/science.3496662; Bershitsky S, 1996, BIOPHYS J, V71, P1462, DOI 10.1016/S0006-3495(96)79347-5; BERSHITSKY SY, 1995, BIOPHYS J, V69, P1011, DOI 10.1016/S0006-3495(95)79976-3; BORDOGNA G, 1991, INFORM PROCESS MANAG, V27, P15, DOI 10.1016/0306-4573(91)90028-K; BRENNER B, 1993, P NATL ACAD SCI USA, V90, P5252, DOI 10.1073/pnas.90.11.5252; COOKE R, 1984, CONTRACTILE MECHANIS, P413; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HASELGROVE JC, 1973, J MOL BIOL, V77, P549, DOI 10.1016/0022-2836(73)90222-2; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIROSE K, 1993, BIOPHYS J, V65, P397, DOI 10.1016/S0006-3495(93)81061-0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MARTINFERNANDEZ ML, 1994, J MUSCLE RES CELL M, V15, P319; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PIAZZESI G, 1995, BIOPHYS J, V68, pS92; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; VAINSHTEIN BK, 1963, DIFFRACTION XRAYS CH; Yagi N, 1991, Adv Biophys, V27, P35, DOI 10.1016/0065-227X(91)90006-Y	29	82	84	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					186	190		10.1038/40651	http://dx.doi.org/10.1038/40651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217160	Bronze			2022-12-28	WOS:A1997XK10900053
J	Musch, DC; Martin, DF; Gordon, JF; Davis, MD; Kuppermann, BD; Heinemann, MH; Campbell, S; Boddice, S; Duker, JS; Naughton, K; McGeary, J; Chong, LP; Walonker, F; Levin, L; Lopez, K; Gomes, A; Davis, JL; Simmons, T; Vandenbrook, R; Fish, RH; Hutchison, C; Ai, E; Luckie, A; Tashayyod, D; Anand, R; Chuang, EL; Lawrence, B; Robinson, MR; Champagne, K; Cantrill, HL; Brallier, A; Freeman, WR; Jarman, C; Wieland, MR; Coverstone, V; Ligh, JK; Hutt, R; Norman, BC; Cristiano, J; Neger, R; Crawford, K; Weinberg, DV; Munana, A; Murphy, FP; Pace, B; Duh, YJ; Gordon, JE; Johnson, PJ; Lee, JA; Pang, CF; Safyan, E; Seidl, NL; Stoecker, JF; Ashton, P; Smith, TJ; Armstrong, J; Brothers, R; Hubbard, L; Dieterich, DT; Frost, KR; Maguire, MG; Nussenblatt, RB; Sanborn, GE				Musch, DC; Martin, DF; Gordon, JF; Davis, MD; Kuppermann, BD; Heinemann, MH; Campbell, S; Boddice, S; Duker, JS; Naughton, K; McGeary, J; Chong, LP; Walonker, F; Levin, L; Lopez, K; Gomes, A; Davis, JL; Simmons, T; Vandenbrook, R; Fish, RH; Hutchison, C; Ai, E; Luckie, A; Tashayyod, D; Anand, R; Chuang, EL; Lawrence, B; Robinson, MR; Champagne, K; Cantrill, HL; Brallier, A; Freeman, WR; Jarman, C; Wieland, MR; Coverstone, V; Ligh, JK; Hutt, R; Norman, BC; Cristiano, J; Neger, R; Crawford, K; Weinberg, DV; Munana, A; Murphy, FP; Pace, B; Duh, YJ; Gordon, JE; Johnson, PJ; Lee, JA; Pang, CF; Safyan, E; Seidl, NL; Stoecker, JF; Ashton, P; Smith, TJ; Armstrong, J; Brothers, R; Hubbard, L; Dieterich, DT; Frost, KR; Maguire, MG; Nussenblatt, RB; Sanborn, GE			Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RHEGMATOGENOUS RETINAL-DETACHMENT; DIHYDROXY PROPOXYMETHYL GUANINE; VIRUS RETINITIS; INTRAVITREAL GANCICLOVIR; AIDS; THERAPY; FOSCARNET; RETINOPATHY	Background Sustained-release, intraocular implants that deliver ganciclovir are an alternative method for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS). Methods We conducted a randomized study of 188 patients with AIDS and newly diagnosed cytomegalovirus retinitis. The patients were randomly assigned to treatment with an implant delivering 1 mu g of ganciclovir per hour, an implant delivering 2 mu g of ganciclovir per hour, or intravenous ganciclovir. The primary outcome we studied was progression of cytomegalovirus retinitis. Results The median time to progression of retinitis was 221 days with the 1-mu g-per-hour implant (75 eyes), 191 days with the 2-mu g-per-hour implant (71 eyes), and 71 days with ganciclovir administered intravenously (76 eyes; P<0.001). The risk of progression of retinitis was almost three times as great among patients treated with intravenous ganciclovir as among those treated with a ganciclovir implant (risk ratio, 2.8; P<0.001). However, the risk of disease in the initially uninvolved eye was lower with Intravenous ganciclovir than with a ganciclovir implant (risk ratio, 0.5; P=0.19). Patients treated with intravenous ganciclovir were also less likely to have extraocular cytomegalovirus infections (0, vs. 10.3 percent in the two implant groups; P=0.04). Conclusions For the treatment of cytomegalovirus retinitis, the sustained-release ganciclovir implant is more effective than intravenous ganciclovir, but patients treated with a ganciclovir implant alone remain at greater risk for the development of cytomegalovirus disease outside of the treated eye. (C) 1997, Massachusetts Medical Society.	CHIRON VIS INC,IRVINE,CA 92718; UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI; UNIV MICHIGAN,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; EMORY UNIV,DEPT OPHTHALMOL,ATLANTA,GA 30322; CHIRON VIS INC,RES & DEV,CLAREMONT,CA; UNIV WISCONSIN,DEPT OPHTHALMOL,MADISON,WI; UNIV CALIF IRVINE,DEPT OPHTHALMOL,IRVINE,CA 92717; CONTROLLED DELIVERY SYST,WATERTOWN,MA; UNIV WISCONSIN,PUNDUS PHOTOGRAPH READING CTR,MADISON,WI; NEW YORK UNIV MED,NEW YORK,NY; AMER FDN AIDS RES,ROCKVILLE,MD; UNIV PENN,PHILADELPHIA,PA 19104; NEI,BETHESDA,MD 20892; UNIV VIRGINIA,RICHMOND,VA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Emory University; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine; University of Wisconsin System; University of Wisconsin Madison; New York University; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Virginia			Davis, Janet L/GPC-8037-2022	Davis, Janet L/0000-0001-6395-5881; Musch, David/0000-0002-4164-3841				ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; AREVALO JF, 1995, J INFECT DIS, V172, P951, DOI 10.1093/infdis/172.4.951; CANTRILL HL, 1989, OPHTHALMOLOGY, V96, P367, DOI 10.1016/S0161-6420(89)32900-9; COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; *COLL DHPG TREATM, 1986, NEW ENGL J MED, V314, P801; COX DR, 1972, J R STAT SOC B, V34, P187; Drew W L, 1993, Clin Diagn Virol, V1, P179; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; ENGSTROM RE, 1995, AM J OPHTHALMOL, V120, P376, DOI 10.1016/S0002-9394(14)72168-3; FANNING MM, 1990, J ACQ IMMUN DEF SYND, V3, P472; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FREEMAN WR, 1993, AM J OPHTHALMOL, V116, P713, DOI 10.1016/S0002-9394(14)73471-3; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; FREEMAN WR, 1987, AM J OPHTHALMOL, V103, P527, DOI 10.1016/S0002-9394(14)74276-X; FRIEDBERG DN, 1995, ARCH OPHTHALMOL-CHIC, V113, P1354, DOI 10.1001/archopht.1995.01100110014003; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GROSS JG, 1990, OPHTHALMOLOGY, V97, P681; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425; HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316; HENRY K, 1987, AM J OPHTHALMOL, V103, P17, DOI 10.1016/S0002-9394(14)74163-7; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; HOLLAND GN, 1986, ARCH OPHTHALMOL-CHIC, V104, P1794, DOI 10.1001/archopht.1986.01050240068042; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOLLAND GN, 1987, OPHTHALMOLOGY, V94, P815; IRVINE AR, 1995, ARCH OPHTHALMOL-CHIC, V113, P25, DOI 10.1001/archopht.1995.01100010027016; JABS DA, 1991, ARCH OPHTHALMOL-CHIC, V109, P794, DOI 10.1001/archopht.1991.01080060058024; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; KUPPERMANN BD, 1993, J INFECT DIS, V168, P1506, DOI 10.1093/infdis/168.6.1506; LALEZARI JP, 1994, ANN INTERN MED, V101, P1250; LEHOANG P, 1989, OPHTHALMOLOGY, V96, P865; MAR EC, 1983, ANTIMICROB AGENTS CH, V24, P518, DOI 10.1128/AAC.24.4.518; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; MORLET N, 1994, ARCH OPHTHALMOL-CHIC, V112, P1404, DOI 10.1001/archopht.1994.01090230014002; ORELLANA J, 1991, OPHTHALMOLOGY, V98, P939; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PERTEL P, 1992, J ACQ IMMUN DEF SYND, V5, P1069; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; POLIS MA, 1995, JAMA-J AM MED ASSOC, V273, P1457, DOI 10.1001/jama.273.18.1457; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SANDY CJ, 1995, EYE, V9, P277, DOI 10.1038/eye.1995.54; SIDIKARO Y, 1991, OPHTHALMOLOGY, V98, P129; SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; *STUD OC COMPL AID, 1995, ARCH INTERN MED, V155, P65; *STUD OC COMPL AID, 1997, ANN INTERN MED, V126, P264; *STUD OC COMPL AID, 1996, ARCH OPHTHALMOL-CHIC, V114, P23; *STUD OC COMPL AID, 1992, NEW ENGL J MED, V326, P213; *STUD OC COMPL AID, 1992, NEW ENGL J MED, V326, P1172; THERNEAU TM, 1996, 58 MAYO FDN DEP HLTH; USSERY FM, 1988, OPHTHALMOLOGY, V95, P640; WALMSLEY SL, 1988, J INFECT DIS, V157, P569, DOI 10.1093/infdis/157.3.569; 1994, ARCH OPHTHALMOL-CHIC, V112, P19	60	196	206	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					83	90		10.1056/NEJM199707103370203	http://dx.doi.org/10.1056/NEJM199707103370203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ822	9211677				2022-12-28	WOS:A1997XJ82200003
J	vanderHeijden, GJMG; vanderWindt, DAWM; deWinter, AF				vanderHeijden, GJMG; vanderWindt, DAWM; deWinter, AF			Physiotherapy for patients with soft tissue shoulder disorders: A systematic review of randomised clinical trials	BRITISH MEDICAL JOURNAL			English	Article							ROTATOR CUFF TENDINITIS; DOUBLE-BLIND; GENERAL-PRACTICE; QUALITY; THERAPY	Objective: To assess the effectiveness of physiotherapy for patients with soft tissue shoulder disorders. Design: A systematic computerised literature search of Medline and Embase, supplemented with citation tracking, for relevant trials with random allocation published before 1996. Subjects: Patients treated with physiotherapy for disorders of soft tissue of the shoulder. Main outcome measures: Success rates, mobility, pain, functional status. Results: Six of the 20 assessed trials satisfied at least five of eight validity criteria. Assessment of methods was often hampered by insufficient information on various validity criteria, and trials were often flawed by lack of blinding, high proportions of withdrawals from treatment and high proportions of missing values. Trial sizes were small: only six trials included intervention groups of more than 25 patients. Ultrasound therapy, evaluated in six trials, was not shown to be effective. Four other trials favoured physiotherapy (laser therapy or manipulation), but the validity of their methods was unsatisfactory. Conclusions: There is evidence that ultrasound therapy is ineffective in the treatment of soft tissue shoulder disorders. Due to small trial sizes and unsatisfactory methods, evidence for the effectiveness of other methods of physiotherapy is inconclusive. For all methods of treatment, trials were too heterogeneous with respect to included patients, index and reference treatments, and follow up to merit valid statistical pooling. Future studies should show whether physiotherapy is superior to treatment with drugs, steroid injections, or a wait and see policy.	VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	vanderHeijden, GJMG (corresponding author), INST REHABIL RES,POB 192,NL-6430 AD HOENSBROEK,NETHERLANDS.							Altman DG, 1996, BRIT MED J, V313, P570; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; [Anonymous], 1994, REUMA ONDERZOEK MEER; BERRY H, 1980, CURR MED RES OPIN, V7, P121, DOI 10.1185/03007998009112038; BINDER A, 1984, LANCET, V1, P695; Biswas A K, 1979, J Indian Med Assoc, V72, P276; BROX JI, 1993, BMJ-BRIT MED J, V307, P899, DOI 10.1136/bmj.307.6909.899; BULGEN DY, 1984, ANN RHEUM DIS, V43, P353, DOI 10.1136/ard.43.3.353; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHARD MD, 1988, J ORTHOP RHEUMATOL, V1, P33; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; CROFT P, 1993, EPIDEMIOLOGY RHEUMAT, P375; DACRE JE, 1989, ANN RHEUM DIS, V48, P322, DOI 10.1136/ard.48.4.322; DEKKER J, 1993, PHYS THER, V73, P577; Delacerda F G, 1982, J Orthop Sports Phys Ther, V4, P51; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DOWNING DS, 1986, PHYS THER, V66, P194, DOI 10.1093/ptj/66.2.194; EDERER F, 1975, AM J MED, V58, P295, DOI 10.1016/0002-9343(75)90594-X; ENGLAND S, 1989, SCAND J RHEUMATOL, V18, P427, DOI 10.3109/03009748909102106; EYSENCK HJ, 1994, BRIT MED J, V309, P789, DOI 10.1136/bmj.309.6957.789; FERNANDES L, 1980, LANCET, V1, P208; GENTLE PH, 1994, BR J GEN PRACT, V34, P371; GRUNDMEIJER HG, 1988, HUISARTS PRAKT, V12, P44; Gudmundsen JVJ, 1987, NOR TIDSSKR IDRETTSM, V2, P6; Hartvig P, 1989, Tidsskr Nor Laegeforen, V109, P2184; Herrera-Lasso I., 1993, PHYSIOTHERAPY, V79, P251, DOI [10.1016/S0031-9406(10)60708-0, DOI 10.1016/S0031-9406(10)60708-0]; Knorre BV, 1990, Z PHYSIOTHERAPIE, V42, P221; Knusel O., 1984, Z PHYSIKAISHE MED BI, V13, P337; LAMBERTS H, 1991, REASON ENCOUNTER E 1; LECLAIRE R, 1991, ARCH PHYS MED REHAB, V72, P284; LEE PN, 1974, ANN RHEUM DIS, V33, P116, DOI 10.1136/ard.33.2.116; LEE PN, 1973, PHYSIOTHERAPY, V9, P312; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; NITZ AJ, 1986, PHYS THER, V66, P1912, DOI 10.1093/ptj/66.12.1912; NYKANEN M, 1995, SCAND J REHABIL MED, V27, P105; PETERS D, 1994, BRIT J GEN PRACT, V44, P25; REY B, 1991, PHYSIOTHERAPY CONTRO, P91; Saunders L, 1995, CLIN REHABIL, V9, P126, DOI DOI 10.1177/026921559500900207; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; *STAND REP TRIALS, 1994, JAMA-J AM MED ASSOC, V272, P1926; *STAND REP TRIALS, 1995, JAMA-J AM MED ASSOC, V273, P776; THOMAS D, 1980, RHEUMATOL REHABIL, V19, P173, DOI 10.1093/rheumatology/19.3.173; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; VANDERWINDT DAWM, 1995, J CLIN EPIDEMIOL, V48, P691, DOI 10.1016/0895-4356(94)00170-U; VECCHIO P, 1993, BRIT J RHEUMATOL, V32, P740	46	126	126	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					25	30		10.1136/bmj.315.7099.25	http://dx.doi.org/10.1136/bmj.315.7099.25			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233322	Green Published			2022-12-28	WOS:A1997XJ94700023
J	Magee, PT				Magee, PT			Which came first, the hypha or the yeast?	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; STE12 HOMOLOG				Magee, PT (corresponding author), UNIV MINNESOTA, DEPT GENET & CELL BIOL, ST PAUL, MN 55108 USA.							Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; Ishii N, 1997, MICROBIOL-SGM, V143, P429, DOI 10.1099/00221287-143-2-429; JOHNSTON M, 1993, BIOL YEAST SACCHAROM, V2, P193; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; SINGH P, 1994, BIOCHEM BIOPH RES CO, V205, P1079, DOI 10.1006/bbrc.1994.2776; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; WAHI M, 1995, GENETICS, V140, P79	7	21	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					52	53		10.1126/science.277.5322.52	http://dx.doi.org/10.1126/science.277.5322.52			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9229773				2022-12-28	WOS:A1997XJ41800032
J	Eghbali, M; Curmi, JP; Birnir, B; Gage, PW				Eghbali, M; Curmi, JP; Birnir, B; Gage, PW			Hippocampal GABA(A) channel conductance increased ky diazepam	NATURE			English	Article							OPEN-STATE SUBSTRUCTURE; PIG HEART-CELLS; CHLORIDE CHANNELS; POTASSIUM CHANNELS; RECEPTOR CHANNELS; AMINO-ACIDS; NEURONS; CULTURE; BENZODIAZEPINE; CLAMP	Benzodiazepines, which are widely used clinically for relief of anxiety and for sedation(1), are thought to enhance synaptic inhibition in the central nervous system by increasing the open probability of chloride channels activated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)(2,3). Here we show that the benzodiazepine diazepam tan also increase the conductance of GABA(A) channels activated by low concentrations of GABA (0.5 or 5 mu M) in rat cultured hippocampal neurons. Before exposure to diazepam, chloride channels activated by GABA had conductances of 8 to 53 pS. Diazepam caused a concentration-dependent and reversible increase in the conductance of these channels towards a maximum conductance of 70-80 pS and the effect was as great as 7-fold in channels of lowest initial conductance. Increasing the conductance of GABA(A) channels tonically activated by low ambient concentrations of GABA in the extracellular environment(4) maybe an important way in which these drugs depress excitation in the central nervous system. That any drug has such a large effect on single channel conductance has not been reported previously and has implications for models of channel structure and conductance.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research				Birnir, Bryndis/0000-0002-1763-0266				BIRNIR B, 1994, J MEMBRANE BIOL, V142, P93; CURMI JP, 1993, J MEMBRANE BIOL, V136, P2673; FATIMASHAD K, 1992, P ROY SOC B-BIOL SCI, V250, P99, DOI 10.1098/rspb.1992.0136; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LUDEWIG W, 1996, NATURE, V383, P340; MATHERS DA, 1991, CAN J PHYSIOL PHARM, V69, P1057, DOI 10.1139/y91-157; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Otis TS, 1992, P NATL ACAD SCI USA, V78, P7180; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V241, P153, DOI 10.1098/rspb.1990.0079; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; SEGAL M, 1984, J NEUROPHYSIOL, V52, P469, DOI 10.1152/jn.1984.52.3.469; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; TWYMAN RE, 1989, ANN NEUROL, V25, P213, DOI 10.1002/ana.410250302; VICINI S, 1987, J PHARMACOL EXP THER, V243, P1195	23	132	135	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					71	75		10.1038/40404	http://dx.doi.org/10.1038/40404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214504	Bronze			2022-12-28	WOS:A1997XJ14300052
J	Linzer, M; Yang, EH; Estes, NAM; Wang, P; Vorperian, VR; Kapoor, WN				Linzer, M; Yang, EH; Estes, NAM; Wang, P; Vorperian, VR; Kapoor, WN			Diagnosing syncope .2. Unexplained syncope	ANNALS OF INTERNAL MEDICINE			English	Review							HEAD-UP TILT; NEURALLY-MEDIATED SYNCOPE; CAROTID-SINUS MASSAGE; INTRACARDIAC ELECTROPHYSIOLOGIC TECHNIQUES; SIGNAL-AVERAGED ELECTROCARDIOGRAM; BUNDLE-BRANCH BLOCK; UNKNOWN ORIGIN; RECURRENT SYNCOPE; UPRIGHT TILT; VASOVAGAL SYNCOPE	Purpose: To review the literature on diagnostic testing in syncope that remains unexplained after initial clinical assessment. Data Sources: MEDLINE search. Study Selection: Published papers were selected if they addressed diagnostic testing in syncope, near syncope, or dizziness. Data Extraction: Studies were identified as population studies, referral studies, or case series. Data Synthesis: After a thorough history, physical examination, and electrocardiography, the cause of syncope remains undiagnosed in 50% of patients. In such patients, information may be derived from the results of carefully selected diagnostic tests, especially 1) electrophysiologic studies in patients with organic heart disease, 2) Holter monitoring or telemetry in patients known to have or suspected of having heart disease, 3) loop monitoring in patients with frequent events and normal hearts, 4) psychiatric evaluation in patients with frequent events and no injury, and 5) tilt-table testing in patients who have infrequent events or in whom vasovagal syncope is suspected. Hospitalization is indicated for high-risk patients, especially those with known heart disease and elderly patients. Conclusions: A flexible, focused approach is required to diagnose syncope. Features of the initial history and physical examination help guide diagnostic testing.	UNIV WISCONSIN, SCH MED, DEPT MED, CLIN SCI CTR H6375, MADISON, WI 53792 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV CARDIOL, BOSTON, MA 02111 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15261 USA	University of Wisconsin System; University of Wisconsin Madison; Tufts Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Linzer, M (corresponding author), UNIV WISCONSIN, SCH MED, DEPT MED, CLIN SCI CTR J5210, 600 HIGHLAND AVE, MADISON, WI 53792 USA.							ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BACHINSKY WB, 1992, AM J CARDIOL, V69, P1044, DOI 10.1016/0002-9149(92)90861-R; BASS EB, 1990, ARCH INTERN MED, V150, P1073, DOI 10.1001/archinte.150.5.1073; BASS EB, 1988, AM J CARDIOL, V62, P1186, DOI 10.1016/0002-9149(88)90257-3; BOUDOULAS H, 1983, J ELECTROCARDIOL, V16, P91, DOI 10.1016/S0022-0736(83)80164-2; BOUDOULAS H, 1979, J ELECTROCARDIOL, V12, P103, DOI 10.1016/S0022-0736(79)80052-7; BRIGNOLE M, 1991, AM J CARDIOL, V68, P1032, DOI 10.1016/0002-9149(91)90491-3; BRIGNOLE M, 1991, AM HEART J, V122, P1644, DOI 10.1016/0002-8703(91)90282-M; BROWN AP, 1987, BRIT HEART J, V58, P251; CALKINS H, 1991, AM J CARDIOL, V67, P207, DOI 10.1016/0002-9149(91)90447-S; CHEN MY, 1989, AM J CARDIOL, V63, P66, DOI 10.1016/0002-9149(89)91077-1; CLARK PI, 1980, CHEST, V77, P722, DOI 10.1378/chest.77.6.722; CLICK RL, 1987, AM J CARDIOL, V59, P817, DOI 10.1016/0002-9149(87)91098-8; CROZIER IG, 1988, NEW ZEAL MED J, V101, P106; CUMBEE SR, 1990, SOUTHERN MED J, V83, P39, DOI 10.1097/00007611-199001000-00013; DAVIDSON E, 1991, CLIN CARDIOL, V14, P141, DOI 10.1002/clc.4960140210; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DENES P, 1988, ARCH INTERN MED, V148, P1922, DOI 10.1001/archinte.148.9.1922; DENES P, 1985, PACE, V8, P424, DOI 10.1111/j.1540-8159.1985.tb05782.x; DENNISS AR, 1992, INT J CARDIOL, V35, P211; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; DOHERTY JU, 1985, AM J CARDIOL, V55, P703, DOI 10.1016/0002-9149(85)90140-7; EAGLE KA, 1985, AM J MED, V79, P455, DOI 10.1016/0002-9343(85)90032-4; ENGEL GL, 1978, ANN INTERN MED, V89, P403, DOI 10.7326/0003-4819-89-3-403; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; FUJIMURA O, 1989, NEW ENGL J MED, V321, P1703, DOI 10.1056/NEJM198912213212503; GANG ES, 1986, AM J CARDIOL, V58, P1014, DOI 10.1016/S0002-9149(86)80030-3; GEORGESON S, 1992, J GEN INTERN MED, V7, P379, DOI 10.1007/BF02599151; GIBSON TC, 1984, AM J CARDIOL, V53, P1013, DOI 10.1016/0002-9149(84)90628-3; GRAFF L, 1988, ANN EMERG MED, V17, P943, DOI 10.1016/S0196-0644(88)80677-2; GRUBB BP, 1993, MED SCI SPORT EXER, V25, P24, DOI 10.1249/00005768-199301000-00005; GRUBB BP, 1992, PACE, V15, P742, DOI 10.1111/j.1540-8159.1992.tb06840.x; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GRUBB BP, 1991, CIRCULATION, V84, P1157, DOI 10.1161/01.CIR.84.3.1157; GRUBB BP, 1992, AM J CARDIOL, V69, P904, DOI 10.1016/0002-9149(92)90790-6; GRUBB BP, 1992, CLIN CARDIOL, V15, P839, DOI 10.1002/clc.4960151109; GULAMHUSEIN S, 1982, AM J MED, V73, P700, DOI 10.1016/0002-9343(82)90413-2; HACKEL A, 1991, J AM GERIATR SOC, V39, P663, DOI 10.1111/j.1532-5415.1991.tb03619.x; HESS DS, 1982, AM J CARDIOL, V50, P1309, DOI 10.1016/0002-9149(82)90468-4; HOEFNAGELS WAJ, 1991, J NEUROL NEUROSUR PS, V54, P953, DOI 10.1136/jnnp.54.11.953; HOROWITZ LN, 1987, J AM COLL CARDIOL, V9, P1261, DOI 10.1016/S0735-1097(87)80465-5; JONAS S, 1977, ANN NEUROL, V1, P470, DOI 10.1002/ana.410010511; KADISH A, 1990, J AM COLL CARDIOL, V16, P1415, DOI 10.1016/0735-1097(90)90385-3; KALA R, 1982, ACTA MED SCAND, P13; KAPOOR W, 1986, AM J MED, V80, P419, DOI 10.1016/0002-9343(86)90716-3; KAPOOR WN, 1987, AM J MED, V82, P20, DOI 10.1016/0002-9343(87)90372-X; KAPOOR WN, 1982, JAMA-J AM MED ASSOC, V247, P2687, DOI 10.1001/jama.247.19.2687; KAPOOR WN, 1995, AM J MED, V99, P505, DOI 10.1016/S0002-9343(99)80227-7; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KAUL U, 1986, INT J CARDIOL, V10, P23, DOI 10.1016/0167-5273(86)90162-2; KENNY RA, 1991, AGE AGEING, V20, P449, DOI 10.1093/ageing/20.6.449; KENNY RA, 1986, LANCET, V1, P1352; KOENIG D, 1992, J INTERN MED, V232, P169, DOI 10.1111/j.1365-2796.1992.tb00567.x; KRAHN AD, 1995, CIRCULATION, V92, P1819, DOI 10.1161/01.CIR.92.7.1819; KROL RB, 1987, J AM COLL CARDIOL, V10, P358, DOI 10.1016/S0735-1097(87)80019-0; KRUMHOLZ HM, 1994, J AM COLL CARDIOL, V24, P125, DOI 10.1016/0735-1097(94)90552-5; KUCHAR DL, 1986, AM J CARDIOL, V58, P949, DOI 10.1016/S0002-9149(86)80017-0; LACROIX D, 1991, AM HEART J, V122, P1346, DOI 10.1016/0002-8703(91)90576-4; LERMANSAGIE T, 1991, J PEDIATR-US, V118, P676, DOI 10.1016/S0022-3476(05)80025-3; LINZER M, 1991, J CLIN EPIDEMIOL, V44, P1037, DOI 10.1016/0895-4356(91)90005-T; LINZER M, 1990, PSYCHOSOMATICS, V31, P181, DOI 10.1016/S0033-3182(90)72192-5; LINZER M, 1990, AM J CARDIOL, V66, P214, DOI 10.1016/0002-9149(90)90591-N; LINZER M, 1991, J GEN INTERN MED, V6, P113, DOI 10.1007/BF02598305; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; LINZER M, 1994, J GEN INTERN MED, V9, P181, DOI 10.1007/BF02600121; LIPSITZ LA, 1985, Q J MED, V55, P45; LIPSITZ LA, 1986, AM J CARDIOL, V58, P810, DOI 10.1016/0002-9149(86)90359-0; LIPSITZ LA, 1983, ANN INTERN MED, V99, P92, DOI 10.7326/0003-4819-99-1-92; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LIPSITZ LA, 1989, ARCH INTERN MED, V149, P2709, DOI 10.1001/archinte.149.12.2709; LURIE KG, 1993, AM J CARDIOL, V72, P1286, DOI 10.1016/0002-9149(93)90298-Q; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; MCINTOSH SJ, 1993, AM J MED, V95, P203, DOI 10.1016/0002-9343(93)90261-M; MOAZEZ F, 1991, AM HEART J, V121, P81, DOI 10.1016/0002-8703(91)90959-L; MORADY F, 1984, AM J CARDIOL, V54, P587, DOI 10.1016/0002-9149(84)90254-6; MORILLO CA, 1995, AM HEART J, V129, P901, DOI 10.1016/0002-8703(95)90110-8; MULLER T, 1991, EUR HEART J, V12, P139, DOI 10.1093/oxfordjournals.eurheartj.a059859; MUNRO NC, 1994, J AM GERIATR SOC, V42, P1248, DOI 10.1111/j.1532-5415.1994.tb06505.x; OVADIA M, 1994, CIRCULATION, V89, P228, DOI 10.1161/01.CIR.89.1.228; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; RAVIELE A, 1994, AM HEART J, V127, P103, DOI 10.1016/0002-8703(94)90515-0; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; Recchia D, 1995, J GEN INTERN MED, V10, P649, DOI 10.1007/BF02602755; REIFFEL JA, 1985, AM HEART J, V110, P1146, DOI 10.1016/0002-8703(85)90004-3; SAKAGUCHI S, 1995, AM J CARDIOL, V75, P476, DOI 10.1016/S0002-9149(99)80584-0; SHELDON R, 1992, J AM COLL CARDIOL, V19, P773, DOI 10.1016/0735-1097(92)90517-Q; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; STEINBERG JS, 1994, J AM COLL CARDIOL, V23, P99, DOI 10.1016/0735-1097(94)90507-X; STRASBERG B, 1989, AM HEART J, V118, P923, DOI 10.1016/0002-8703(89)90225-1; SUGRUE DD, 1987, J AM GERIATR SOC, V35, P1079, DOI 10.1111/j.1532-5415.1987.tb04924.x; TEICHMAN SL, 1985, AM HEART J, V110, P469, DOI 10.1016/0002-8703(85)90171-1; THILENIUS OG, 1991, PEDIATRICS, V87, P334; TONNESSEN GE, 1994, ARCH INTERN MED, V154, P1613, DOI 10.1001/archinte.154.14.1613; TWIDALE N, 1987, AUST NZ J MED, V17, P512, DOI 10.1111/j.1445-5994.1987.tb00112.x; VAITKEVICIUS PV, 1991, ANN INTERN MED, V115, P865, DOI 10.7326/0003-4819-115-11-865; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; WENNBERG JE, 1984, NEW ENGL J MED, V311, P295, DOI 10.1056/NEJM198408023110505; WESTVEER DC, 1984, CARDIOVASC REV REP, V5, P770; WINTERS SL, 1987, J AM COLL CARDIOL, V10, P775, DOI 10.1016/S0735-1097(87)80269-3; XIAO CC, 1992, AM J CARDIOL, V69, P755; ZELDIS SM, 1980, CHEST, V78, P456, DOI 10.1378/chest.78.3.456; ZIPES DP, 1995, CIRCULATION, V92, P673	110	245	256	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					76	86		10.7326/0003-4819-127-1-199707010-00014	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00014			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214258				2022-12-28	WOS:A1997XG91400013
J	Solomon, DH; Bates, DW; Panush, RS; Katz, JN				Solomon, DH; Bates, DW; Panush, RS; Katz, JN			Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: A critical review of the literature and proposed methodologic standards	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-BACK-PAIN; PRIMARY-CARE PRACTITIONERS; MANAGEMENT; OSTEOARTHRITIS; PHYSICIANS; CHIROPRACTORS; GENERALIST; SPECIALIST; ARTHRITIS; HIP	Purpose: To compare the outcomes of care provided by generalists with that provided by specialists for patients with musculoskeletal and rheumatic conditions. Data Sources: English-language studies published between 1966 and April 1996 were identified through a MEDLINE search. Study Selection: Studies that compared generalists' and specialists' treatment preferences, appropriateness of care, or outcomes with regard to musculoskeletal and rheumatic conditions were examined. Data Extraction: Studies were reviewed for methodologic rigor and outcomes. Data Synthesis: Low back pain is treated by many types of providers, without consistent differences in outcomes across provider types. In one study, however, patients were more satisfied with chiropractic care than with care provided by primary care physicians, although the former cost twice as much as the latter. For osteoarthritis of the hip, rheumatologists and primary care providers reported using different therapeutic regimens. For acute mono- and oligoarthritis, rheumatologists performed arthrocentesis more appropriately than nonrheumatologists and produced shorter durations of hospitalization. In the management of gout, rheumatologists used colchicine during the introduction of urate-lowering therapy more appropriately than other providers. In two population-based cohorts of patients with rheumatoid arthritis, patients cared for by rheumatologists were prescribed significantly more disease-modifying agents and had less disability than patients cared for by generalists. Conclusions: Although empirical data are scant, there seem to be differences between generalists and specialists for a range of outcomes in various musculoskeletal and rheumatic conditions. Studies to date have important methodologic limitations that need to be addressed in future research.	BRIGHAM & WOMENS HOSP, RB BRIGHAM MULTIPURP ARTHRIT & MUSCULOSK DIS CTR, DIV RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, LIVINGSTON, NJ 07039 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02138 USA; UNIV MED & DENT NEW JERSEY, ST BARNABAS MED CTR, LIVINGSTON, NJ 07039 USA	Harvard University; Brigham & Women's Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center					NIAMS NIH HHS [AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BELLAMY N, 1988, J RHEUMATOL, V15, P1841; BERGEMANN BW, 1980, J MANIP PHYSIOL THER, V3, P143; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CHERKIN DC, 1989, WESTERN J MED, V150, P351; DEYO RA, 1989, SPINE, V14, P501, DOI 10.1097/00007632-198905000-00005; Evans TI, 1996, J RHEUMATOL, V23, P143; Fairbank J C, 1980, Physiotherapy, V66, P271; FREUND DA, 1989, J ALLERGY CLIN IMMUN, V84, P401, DOI 10.1016/0091-6749(89)90428-4; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; JACKSON CG, 1993, ARTHRITIS RHEUM, V36, pS143; JOHNSON MR, 1989, J MANIP PHYSIOL THER, V12, P335; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; Klashman David, 1994, Arthritis and Rheumatism, V37, pS356; LIANG MH, 1978, ANN INTERN MED, V88, P666, DOI 10.7326/0003-4819-88-5-666; MAZZUCA SA, 1993, J RHEUMATOL, V20, P80; MAZZUCA SA, 1991, J RHEUMATOL, V18, P1593; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; Panush R S, 1995, J Clin Rheumatol, V1, P74, DOI 10.1097/00124743-199504000-00003; Parisek R., 1994, Arthritis and Rheumatism, V37, pS356; PRASHKER M, 1995, ARTHRITIS RHEUM, V38, P1383; ROBERTS WN, 1987, JAMA-J AM MED ASSOC, V257, P1920, DOI 10.1001/jama.257.14.1920; ROMANO PS, 1994, J CLIN EPIDEMIOL, V47, P249, DOI 10.1016/0895-4356(94)90006-X; SHEKELLE PG, 1995, SPINE, V20, P221, DOI 10.1097/00007632-199501150-00018; Stano M, 1996, MED CARE, V34, P191, DOI 10.1097/00005650-199603000-00001; STUART RA, 1991, N Z MED J, V104, P116; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; WALKER DJ, 1995, J ROY COLL PHYS LOND, V29, P101; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; Yelin Edward, 1995, Arthritis and Rheumatism, V38, pS187	35	102	103	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					52	60		10.7326/0003-4819-127-1-199707010-00009	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214253				2022-12-28	WOS:A1997XG91400008
J	Malcolm, L				Malcolm, L			GP budget holding in New Zealand: Lessons for Britain and elsewhere?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH				Malcolm, L (corresponding author), AOTEAROA HLTH,RD 1,LYTTELTON,NEW ZEALAND.							BERWICK D, 1995, BRIT MED J, V310, P1349, DOI 10.1136/bmj.310.6991.1349; KERR D, 1996, NZ MED J, V109, P354; Malcolm L, 1996, NEW ZEAL MED J, V109, P184; Malcolm L, 1996, NEW ZEAL MED J, V109, P356; Malcolm L, 1995, Health Serv Manage Res, V8, P121; MALCOLM L, 1994, HEALTH POLICY, V29, P85, DOI 10.1016/0168-8510(94)90008-6; MALCOLM L, 1995, MANAGED CARE PRINCIP, P199; *MIN HLTH, 1996, HLTH POL AGREE; *MIN HLTH, 1996, PURCH YOUR HLTH 1994; *MIN HLTH, 1996, HLTH NZ BRIEF PAP MI; Pringle M, 1996, BRIT MED J, V313, P1026; Williams C, 1996, BRIT MED J, V313, P901; 1996, ECONOMIST       1019, P17	13	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1890	1892		10.1136/bmj.314.7098.1890	http://dx.doi.org/10.1136/bmj.314.7098.1890			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224136	Green Published			2022-12-28	WOS:A1997XH73800033
J	Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P				Kallipolitis, BH; NorregaardMadsen, M; ValentinHansen, P			Protein-protein communication: Structural model of the repression complex formed by CytR and the global regulator CRP	CELL			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; CLONING VECTORS; ACTIVATOR COMPLEX; CRYSTAL-STRUCTURE; DEOP2 PROMOTER; DNA; BINDING; PROGRAM; GENE	The cAMP receptor protein (CRP) and the Lad-related CytR antiactivator bind cooperatively to adjacent DNA sites at or near promoters, an interaction that involves direct protein contacts. Here, we identify a collection of amino acid substitutions in CytR that reestablish protein-protein communication to mutant CRP proteins specifically defective in cooperative binding with wild-type CytR. To assess the location and spatial arrangement of these substitutions, we built a three-dimensional model of CytR based on the recent X-ray structure of the highly homologous PurR repressor bound to DNA. This approach enables us to specify the patch on CytR's surface that contacts CRP. Furthermore, our results permit the construction of a three-dimensional structure of the higher order nucleoprotein complex formed by CytR and CRP.			Kallipolitis, BH (corresponding author), ODENSE UNIV, DEPT MOL BIOL, CAMPUSVEJ 55, DK-5230 ODENSE M, DENMARK.			Kallipolitis, Birgitte H./0000-0003-1233-9776				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GREER J, 1991, METHOD ENZYMOL, V202, P239; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leung DW, 1989, TECHNIQUE, V1, P11; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T, 1989, MOL CLONING; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; Pedersen H, 1997, EMBO J, V16, P2108, DOI 10.1093/emboj/16.8.2108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	35	35	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1101	1109		10.1016/S0092-8674(00)80297-4	http://dx.doi.org/10.1016/S0092-8674(00)80297-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215632	Bronze			2022-12-28	WOS:A1997XG83000014
J	Hedtke, B; Borner, T; Weihe, A				Hedtke, B; Borner, T; Weihe, A			Mitochondrial and chloroplast phage-type RNA polymerases in Arabidopsis	SCIENCE			English	Article							PROTEIN-TRANSPORT; BACTERIOPHAGE-T7; SUBUNIT	In addition to the RNA polymerases (RNAPs) transcribing the nuclear genes, eukaryotic cells also require RNAPs to transcribe the genes of the mitochondrial genome and, in plants, of the chloroplast genome, The plant Arabidopsis thaliana was found to contain two nuclear genes similar to genes encoding the mitochondrial RNAP from yeast and RNAPs of bacteriophages T7, T3, and SP6. The putative transit peptides of the two polymerases were capable of targeting fusion proteins to mitochondria and chloroplasts, respectively, in vitro. The results indicate that the mitochondrial RNAP in plants is a bacteriophage-type enzyme. A gene duplication event may have generated the second RNAP, which along with the plastid-encoded eubacteria-like RNAP could transcribe the chloroplast genome.	HUMBOLDT UNIV BERLIN,INST BIOL,D-10115 BERLIN,GERMANY	Humboldt University of Berlin				Borner, Thomas/0000-0001-9548-3348				Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BOGORAD L, 1990, MOL BIOL PLASTIDS, P93; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; Ems SC, 1995, PLANT MOL BIOL, V29, P721, DOI 10.1007/BF00041163; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KELLY JL, 1986, J BIOL CHEM, V261, P348; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weihe A, 1997, NUCLEIC ACIDS RES, V25, P2319, DOI 10.1093/nar/25.12.2319	21	303	321	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					809	811		10.1126/science.277.5327.809	http://dx.doi.org/10.1126/science.277.5327.809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242608				2022-12-28	WOS:A1997XQ24700041
J	Ferguson, JR				Ferguson, JR			Biological weapons and US law	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								During the past 8 years, the US Congress has developed a comprehensive legal framework to prevent the illegitimate use of toxins and infectious agents. As part of this framework, Congress has defined as a federal crime virtually every step in the process of developing or acquiring a biological agent for use as a weapon. At the same time, Congress has vested federal law enforcement agencies with broad civil and investigative powers to enable the government to intervene before such weapons are used or even developed. Finally, Congress has directed the Centers for Disease Control and Prevention to establish a regulatory regime to monitor the location and transfer of hazardous biological agents and to insure that any use of such agents complies with appropriate biosafety requirements.	NORTHWESTERN UNIV,SCH LAW,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University; Northwestern University	Ferguson, JR (corresponding author), SONNENSCHEIN NATH & ROSENTHAL,8000 SEARS TOWER,CHICAGO,IL 60606, USA.							[Anonymous], 1991, TECHN TERR FED EFF; Cole Leonard A., 1997, 11 PLAGUE POLITICS B; *OFF TECHN ASS, 1995, PROL WEAP MASS DESTR; *OFF TECHN ASS, 1992, TECHN TERR STRUCT SE; SOPKO J, 1996, FOREIGN POLICY, V105, P6; *US DEP HHS CDC, 1996, FED REG         1024, V61, P55190	6	23	23	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					357	360						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244312				2022-12-28	WOS:A1997XN51800002
J	Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S				Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S			An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD GEL-ELECTROPHORESIS; SONNEI	Context.-Shigella dysenteriae type 2 is rare in the United States, and outbreaks associated with this pathogen are uncommon. Objective.-To determine the magnitude and source of an outbreak of S dysenteriae type 2. Design.-Retrospective cohort. Setting.-Laboratory of a large medical center. Patients.-Case patients were identified as laboratory workers who had diarrhea on or after October 28 and a positive stool culture or temperature greater than 37.8 degrees C. Laboratory workers with diarrhea only were probable case patients. Main Outcome Measures.-We interviewed laboratory staff and performed identification, serotyping, and pulsed-field gel electrophoresis on isolates from case patients, implicated food, and laboratory stock culture. Results.-From October 29 through November 1, a total of 12 (27%) of 45 laboratory staff developed severe, acute diarrheal illness; 8 had S dysenteriae isolated from stool and 4 were hospitalized. All case patients reported having eaten muffins or doughnuts placed in the staff break room on October 29. Pulsed-field gel electrophoresis showed stool isolates from 9 case patients were indistinguishable from S dysenteriae type 2 recovered from an uneaten muffin and from the laboratory's stock strain, a portion of which was missing. Conclusions.-The source of the outbreak was most likely the laboratory's stock culture, which was used to contaminate the pastries. Results of this investigation underscore the need for adequate precautions to prevent inadvertent or intentional contamination from highly pathogenic laboratory specimens.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; TEXAS DEPT HLTH,BUR LABS,AUSTIN,TX 78756; TEXAS DEPT HLTH,BUR CHRON DIS PREVENT & CONTROL,AUSTIN,TX 78756; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,STATE BRANCH,ATLANTA,GA 30333; DALLAS CTY HLTH & HUMAN SERV,DALLAS,TX	Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services; Centers for Disease Control & Prevention - USA								[Anonymous], 1995, CONTROL COMMUNICABLE; *ASS OFF AN CHEM, 1992, BACT AN MAN; BLASER MJ, 1983, J INFECT DIS, V147, P771, DOI 10.1093/infdis/147.4.771; BRIAN MJ, 1993, J CLIN MICROBIOL, V31, P2152, DOI 10.1128/JCM.31.8.2152-2156.1993; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P250; Dean A.G., 1994, EPI INFO VERSION 6 W; Evans AC, 1938, LANCET, V2, P187; LIU PYF, 1995, J CLIN MICROBIOL, V33, P1779, DOI 10.1128/JCM.33.7.1779-1783.1995; NASTASI A, 1991, MICROBIOLOGICA, V14, P219; *OR HLTH DIV, 1984, COMM DIS SUMM, V33, P1; PARKER MT, 1983, TOPLEY WILSONS PRINC, V3, P434; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; ROWE B, 1983, TOPLEY WILSONS PRINC, V2, P320; SCHMITZ K. E. F., 1917, Zeitschrift fur Hygiene und Infektionskrankheiten, V84, P449, DOI 10.1007/BF02284440; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; 1966, SCIENCE J, V2, P11; 1988, UPI             1214	18	110	115	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					396	398		10.1001/jama.278.5.396	http://dx.doi.org/10.1001/jama.278.5.396			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244331				2022-12-28	WOS:A1997XN51800031
J	Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR				Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR			Simplification of DNA topology below equilibrium values by type II topoisomerases	SCIENCE			English	Article							ESCHERICHIA-COLI; PURIFICATION; MECHANISM; TRANSPORT; ENZYME; HELIX; IV	Type II DNA topoisomerases catalyze the interconversion of DNA topoisomers by transporting one DNA segment through another. The steady-state fraction of knotted or catenated DNA molecules produced by prokaryotic and eukaryotic type II topoisomerases was found to be as much as 80 times lower than at thermodynamic equilibrium. These enzymes also yielded a tighter distribution of linking number topoisomers than at equilibrium. Thus, topoisomerases do not merely catalyze passage of randomly juxtaposed DNA segments but control a global property of DNA, its topology. The results imply that type II topoisomerases use the energy of adenosine triphosphate hydrolysis to preferentially remove the topological links that provide barriers to DNA segregation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; NYU,DEPT CHEM,NEW YORK,NY 10003	University of California System; University of California Berkeley; New York University			Vologodskii, Alexander V/A-6994-2009; Vologodskii, Alexander V/I-6201-2013		NIGMS NIH HHS [GM31657, GM54215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054215, R01GM031657, R37GM031657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES AD, 1993, DNA TOPOLOGY; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; KATO J, 1992, J BIOL CHEM, V267, P25676; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, J BIOL CHEM, V268, P24481; POHL WF, 1978, J MATH BIOL, V6, P383, DOI 10.1007/BF02463003; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, J MOL BIOL, V267, P312, DOI 10.1006/jmbi.1996.0877; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; WANG JC, 1966, J MOL BIOL, V15, P111, DOI 10.1016/S0022-2836(66)80213-9; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	25	230	231	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					690	693		10.1126/science.277.5326.690	http://dx.doi.org/10.1126/science.277.5326.690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235892				2022-12-28	WOS:A1997XN90700042
J	Gillum, RF; Mussolino, ME; Madans, JH				Gillum, RF; Mussolino, ME; Madans, JH			Coronary heart disease incidence and survival in African-American women and men - The NHANES I epidemiologic follow-up study	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; blacks; follow-up studies; myocardial infarction; sex factors	RISK-FACTORS; UNITED-STATES; MYOCARDIAL-INFARCTION; BLACK POPULATIONS; CIGARETTE-SMOKING; EVANS COUNTY; WHITE MEN; MORTALITY; INFORMATION; CHOLESTEROL	Background: Relatively few data are available on risk for or survival with cor Objective: To determine whether incidence of coronary heart disease, rate of survival with the disease. and rate of coronary surgery differ between ethnic groups. Design: Prospective cohort study. Setting: United States. Participants: Persons who responded to the National Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study. Included in this analysis were 11 406 white persons and African-American persons aged 25 to 74 years who had no history of coronary heart disease. Average follow-up for survivors was 19 years (maximum, 22 years). Measurements: Incident coronary heart disease. Results: Compared with that in white persons, the age-adjusted risk for coronary heart disease was higher in African-American women aged 25 to 54 years (relative risk. 1.76 [95% CI, 1.36 to 2.29]) but was lower in African-American men within each age subgroup. The age-adjusted risk was lower in African-American men for all ages combined (25 to 74 years) (relative risk, 0.78 [CI, 0.65 to 0.93] for coronary heart disease and 0.62 [CI, 0.42 to 0.92] for acute myocardial infarction). The higher rate in African-American women aged 25 to 54 years could be explained statistically by the higher risk factor levels iri these women. Ethnic groups did not significantly differ in survival after the first hospitalization for coronary heart disease. However, the incidence of coronary procedures after hospitalization for coronary heart disease was markedly lower in African-American persons than in white persons (age- and sex-adjusted relative risk, 0.40 [CI, 0.16 to 0.991). Conclusions: Total incidence of coronary heart disease is higher in African-American women aged 25 to 54 years than in white women of the same ages and is lower in African-American men aged 25 to 74 years than in white men of the same ages.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF CTR DIRECTOR, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Gillum, RF (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF ANAL EPIDEMIOL & HLTH PROMOT, 6525 BELCREST RD, HYATTSVILLE, MD 20782 USA.							Cohen B B, 1987, Vital Health Stat 1, P1; COOPER R, 1991, CARDIOVASCULAR DISEA, P205; Cooper R S, 1992, Ann Epidemiol, V2, P637; Cox C S, 1992, Vital Health Stat 1, P1; Engel A, 1978, Vital Health Stat 1, P1; Finucane F F, 1990, Vital Health Stat 1, P1; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1987, AM HEART J, V113, P804, DOI 10.1016/0002-8703(87)90723-X; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GILLUM RF, 1984, AM HEART J, V108, P727, DOI 10.1016/0002-8703(84)90664-1; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; INGRAM DD, 1989, STAT MED, V8, P525, DOI 10.1002/sim.4780080502; INGRAM DD, 1994, SERIES VITAL HLTH ST, V2, P1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KEIL JE, 1995, ARCH INTERN MED, V155, P1521, DOI 10.1001/archinte.155.14.1521; KEIL JE, 1984, AM HEART J, V108, P779, DOI 10.1016/0002-8703(84)90671-9; KLAG MJ, 1989, CIRCULATION S1, V80, P300; Kumanyika S, 1996, NEW ENGL J MED, V335, P738, DOI 10.1056/NEJM199609053351011; LEAVERTON PE, 1990, HLTH STATUS WELL BEI, P53; Lee Marshall H., 1990, Annals of Epidemiology, V1, P1; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P465; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HERBERT S., 1978, PLAN OPERATION HLTH, P1; *NAT CTR HLTH STAT, 1979, HANES 1 HEM CLIN CHE; National Heart Lung and Blood Institute, 1994, REP WORK GROUP RES C, P1; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Popkin BM, 1996, NEW ENGL J MED, V335, P716, DOI 10.1056/NEJM199609053351006; *RES TRIANGL I, 1992, SOFTW SURV DES AN SU; *SAS I INC, 1991, P217 SAS I INC, P1; *SAS I INC, 1985, SAS US GUID STAT, P529; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Traven ND, 1996, ANN EPIDEMIOL, V6, P130, DOI 10.1016/1047-2797(95)00131-X; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WATKINS LO, 1986, AM J CARDIOL, V57, P538, DOI 10.1016/0002-9149(86)90831-3; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0	45	124	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					111	+		10.7326/0003-4819-127-2-199707150-00003	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9229999				2022-12-28	WOS:A1997XK15800005
J	Graziano, MSA; Hu, XT; Gross, CG				Graziano, MSA; Hu, XT; Gross, CG			Coding the locations of objects in the dark	SCIENCE			English	Article							FUNCTIONAL-ORGANIZATION; VISUAL RESPONSES; INFERIOR AREA-6; MACAQUE MONKEY; MOVEMENTS; NEURONS; CORTEX	The ventral premotor cortex in primates is thought to be involved in sensory-motor integration. Many of its neurons respond to visual stimuli in the space near the arms or face. In this study on the ventral premotor cortex of monkeys, an object was presented within the visual receptive fields of individual neurons, then the lights were turned off and the object was silently removed. A subset of the neurons continued to respond in the dark as if the object were still present and visible. Such cells exhibit ''object permanence,'' encoding the presence of an object that is no longer visible. These cells may underlie the ability to reach toward or avoid objects that are no longer directly visible.			Graziano, MSA (corresponding author), PRINCETON UNIV,DEPT PSYCHOL,PRINCETON,NJ 08544, USA.				NATIONAL EYE INSTITUTE [R01EY011347] Funding Source: NIH RePORTER; NEI NIH HHS [EY11347] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; Graziano Michael S. A., 1995, P1021; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; GRAZIANO MSA, IN PRESS J NEUROPHYS; Gross C.G., 1995, NEUROSCIENTIST, V1, P43, DOI [10.1177/107385849500100107, DOI 10.1177/107385849500100107]; Piaget J., 1952, ORIGINS INTELLIGENCE; Proteau L., 1992, VISION MOTOR CONTROL; RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	12	122	125	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 11	1997	277	5323					239	241		10.1126/science.277.5323.239	http://dx.doi.org/10.1126/science.277.5323.239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211852				2022-12-28	WOS:A1997XK41800045
J	Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S				Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S			Harm reduction measures and injecting inside prison versus mandatory drugs testing: Results of a cross sectional anonymous questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							HIV SURVEILLANCE	Objectives: (a) To determine both the frequency of injecting inside prison and use of sterilising tablets to clean needles in the previous four weeks; (b) to assess the efficiency of random mandatory drugs testing at detecting prisoners who inject heroin inside prison; (c) to determine the percentage of prisoners who had been offered vaccination against hepatitis B. Design: Cross sectional willing anonymous salivary HIV surveillance linked to a self completion risk factor questionnaire. Setting: Lowmoss prison, Glasgow, and Aberdeen prison on 11 and 30 October 1996. Subjects: 293 (94%) of all 312 inmates at Lowmoss and 146 (93%) of all 157 at Aberdeen, resulting in 286 and 143 valid questionnaires. Main outcome measures: Frequency of injecting inside prison in the precious four weeks by injector inmates who had been in prison for at least four weeks. Results: 116 (41%) Lowmoss and 53 (37%) Aberdeen prisoners had a history of injecting drug use but only 4% of inmates (17/395; 95% confidence interval 2% to 6%) had ever been offered vaccination against hepatitis B. 42 Lowmoss prisoners (estimated 207 injections and 258 uses of sterilising tablets) and 31 Aberdeen prisoners (229 injections, 221 uses) had injected inside prison in the previous four weeks. The prisons together held 112 injector inmates who had been in prison for more than four weeks, of whom 57 (51%; 42% to 60%) had injected in prison in the past four weeks; their estimated mean number of injections was 6.0 (SD 5.7). Prisoners injecting heroin six times in four weeks will test positive in random mandatory drugs testing on at most 18 days out of 28. Conclusions: Sterilising tablets and hepatitis B vaccination should be offered to all prisoners. Random mandatory drugs testing seriously underestimates injector inmates' harm reduction needs.	REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND; CHURCHILL HOSP,OXFORD OX3 7LJ,ENGLAND; MRC BIAS,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND	MRC Biostatistics Unit; University of Oxford								Acheson D, 1997, BRIT MED J, V314, P302; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1996, HERALD          0122, P12; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; FREEMAN J, 1996, HERALD          1012, P4; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; GORE SM, 1995, BRIT MED J, V310, P595, DOI 10.1136/bmj.310.6979.595; GORE SM, IN PRESS INT J STD A; GORE SM, 1995, ANSWER, V39, P1; Her Majesty's Inspectorate of Prisons, 1996, PAT PRIS NEW STRAT H; *HM PRIS SERV, 1995, DRUG MIS PRIS POL ST, P7; JURGENS R, 1996, HIV AIDS PRISONS; MANGTANI P, 1995, BRIT MED J, V311, P1500, DOI 10.1136/bmj.311.7018.1500; Nelles J., 1995, DRUG HIV PREVENTION; PAYNEJAMES JJ, 1994, J ROY SOC MED, V87, P13; *TASK FORC REV SER, 1996, IND REV DRUG TREATM; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; *WHO, 1993, GLOB PROGR AIDS WHO; WOODS J, 1997, SCOTSMAN        0114, P13	21	55	55	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					21	24		10.1136/bmj.315.7099.21	http://dx.doi.org/10.1136/bmj.315.7099.21			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233321	Green Published			2022-12-28	WOS:A1997XJ94700022
J	Hofmann, JC; Wenger, NS; Davis, RB; Teno, J; Connors, AF; Desbiens, N; Lynn, J; Phillips, RS				Hofmann, JC; Wenger, NS; Davis, RB; Teno, J; Connors, AF; Desbiens, N; Lynn, J; Phillips, RS			Patient preferences for communication with physicians about end-of-life decisions	ANNALS OF INTERNAL MEDICINE			English	Article						decision making; cardiopulmonary resuscitation; respiration, artificial	ILL HOSPITALIZED ADULTS; NOT-RESUSCITATE ORDERS; SUPPORT PROGNOSTIC MODEL; MEDICAL INTENSIVE-CARE; NURSING-HOME RESIDENTS; ADVANCE DIRECTIVES; HEALTH-CARE; SUSTAINING TREATMENT; CARDIOPULMONARY-RESUSCITATION; PROMOTING COMPLETION	Background: Physicians are frequently unaware of patient preferences for end-of-life care. Identifying and exploring barriers to patient-physician communication about end-of-life issues may help guide physicians and their patients toward more effective discussions. Objective: To examine correlates and associated outcomes of patient communication and patient preferences for communication with physicians about cardiopulmonary resuscitation and prolonged mechanical ventilation. Design: Prospective cohort study. Setting: Five tertiary care hospitals. Patients: 1832 (85%) of 2162 eligible patients completed interviews. Measurements: Surveys of patient characteristics and preferences for end-of-life care; perceptions of prognosis, decision making, and quality of life; and patient preferences for communication with physicians about end-of-life decisions. Results: Fewer than one fourth (23%) of seriously ill patients had discussed preferences for cardiopulmonary resuscitation with their physicians. Of patients who had not discussed their preferences for resuscitation, 58% were not interested in doing so. Of patients who had not discussed and did not want to discuss their preferences, 25% did not want resuscitation. In multivariable analyses, patient factors independently associated with not wanting to discuss preferences for cardiopulmonary resuscitation included being of an ethnicity other than black (adjusted odds ratio [OR]I 1.48 [95% CI, 1.10 to 1.99), not having an advance directive (OR, 1.35 [CI, 1.04 to 1.76]), estimating an excellent prognosis (OR, 1.72 [Cl, 1.32 to 2.59]), reporting fair to excellent quality of life (OR, 1.36 [CI, 1.05 to 1.76]), and not desiring active involvement in medical decisions (OR, 1.33 [Ci, 1.07 to 1.65]). Factors independently associated with wanting to discuss preferences for resuscitation but not doing so included being black (OR, 1.53 [CI, 1.11 to 2.11]) and being younger (OR, 1.14 per 10-year interval younger [CI, 1.04 to 1.25]). Conclusions: Among seriously ill hospitalized adults, communication about preferences for cardiopulmonary resuscitation is uncommon. A majority of patients who have not discussed preferences for end-of-life care do not want to do so. For patients who do not want to discuss their preferences, as well as patients with an unmet need for such discussions, failure to discuss preferences for cardiopulmonary resuscitation and mechanical ventilation may result in unwanted interventions.	BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, WASHINGTON, DC 20037 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; DUKE UNIV, MED CTR, DURHAM, NC 27706 USA; MARSHFIELD CLIN FDN MED RES & EDUC, MARSHFIELD, WI 54449 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; George Washington University; Case Western Reserve University; University of Virginia; Duke University; Marshfield Clinic				Connors, Alfred F./0000-0001-7123-3360	BHP HRSA HHS [5T32PE11001] Funding Source: Medline	BHP HRSA HHS		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BROWN D, 1994, GYNECOL ONCOL, V55, P355, DOI 10.1006/gyno.1994.1306; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; COULTON CJ, 1990, J CLIN EPIDEMIOL, V43, pS51, DOI 10.1016/0895-4356(90)90219-F; CUGLIARI AM, 1995, ARCH INTERN MED, V155, P1893, DOI 10.1001/archinte.155.17.1893; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; ELPERN EH, 1992, CRIT CARE MED, V20, P43, DOI 10.1097/00003246-199201000-00014; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; Layde P M, 1995, Arch Fam Med, V4, P518, DOI 10.1001/archfami.4.6.518; LEVY MR, 1984, WESTERN J MED, V140, P111; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MIRVIS DM, 1994, J AM COLL CARDIOL, V24, P1297, DOI 10.1016/0735-1097(94)90112-0; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS15; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SOLOMON MZ, 1995, COMMUNICATING EFFECT, P8; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; Terry M, 1994, Arch Fam Med, V3, P141, DOI 10.1001/archfami.3.2.141; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; UHLMANN RF, 1989, WESTERN J MED, V150, P705; UHLMANN RF, 1984, WESTERN J MED, V140, P114; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351	71	351	353	0	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					1	+		10.7326/0003-4819-127-1-199707010-00001	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214246				2022-12-28	WOS:A1997XG91400001
J	Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW				Bullitt, E; Rout, MP; Kilmartin, JV; Akey, CW			The yeast spindle pole body is assembled around a central crystal of Spc42p	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; TILT SERIES; HALF-BRIDGE; CELL-CYCLE; PROTEIN; RECONSTRUCTION; PLAQUES; DUPLICATION; CENTROSOMES	The spindle pole body (SPB) is the microtubule organizing center (MTOC) in the yeast Saccharomyces that plays a pivotal role in such diverse processes as mitosis, budding, and mating. We have used cryoelectron microscopy and image processing to study the structure of isolated diploid SPBs. We show that SPBs are present in two lateral-size classes, sharing a similar vertical architecture comprised of six major layers. Tomographic reconstructions of heparin-stripped SPBs reveal a central hexagonally packed layer. Overexpression of Spc42p results in the growth of a similar layer, forming a crystal that encircles the SPB. Hence, the SPB is an MTOC that utilizes crystallographic packing of subunits in its construction.	ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Rockefeller University; MRC Laboratory Molecular Biology	Bullitt, E (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118, USA.		Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X; Akey, Christopher/0000-0002-3059-3121				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AKEY CW, 1992, NUCLEAR TRAFFICKING, P31; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BYERS B, 1978, J CELL SCI, V30, P331; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1974, COLD SPRING HARB SYM, V38, P123; Byers B, 1981, MOL BIOL YEAST SACCH, P59; DENGLER J, 1989, ULTRAMICROSCOPY, V30, P337, DOI 10.1016/0304-3991(89)90063-6; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERRABOLU R, 1994, J CELL SCI, V107, P9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GUCKENBERGER R, 1982, ULTRAMICROSCOPY, V9, P167, DOI 10.1016/0304-3991(82)90239-X; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Kilmartin JV, 1996, EMBO J, V15, P4592, DOI 10.1002/j.1460-2075.1996.tb00837.x; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; KING SM, 1982, J CELL BIOL, V94, P341, DOI 10.1083/jcb.94.2.341; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LIU Y, 1995, ULTRAMICROSCOPY, V58, P393, DOI 10.1016/0304-3991(95)00006-M; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; Owen CH, 1996, ULTRAMICROSCOPY, V63, P27, DOI 10.1016/0304-3991(95)00154-9; PETERSON JB, 1972, J CELL BIOL, V53, P837, DOI 10.1083/jcb.53.3.837; PETERSON JB, 1976, J CELL SCI, V22, P219; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROUT MP, 1991, COLD SH Q B, V56, P687; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Spang A, 1996, J CELL BIOL, V134, P429, DOI 10.1083/jcb.134.2.429; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STALLMEYER MJB, 1989, J MOL BIOL, V205, P519, DOI 10.1016/0022-2836(89)90223-4; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	43	154	154	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1077	1086		10.1016/S0092-8674(00)80295-0	http://dx.doi.org/10.1016/S0092-8674(00)80295-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215630	hybrid			2022-12-28	WOS:A1997XG83000012
J	Brown, JP; Wei, WY; Sedivy, JM				Brown, JP; Wei, WY; Sedivy, JM			Bypass of senescence after disruption of p21(CIP1/WAF1) gene in normal diploid human fibroblasts	SCIENCE			English	Article							REPLICATIVE SENESCENCE; TELOMERASE ACTIVITY; IMMORTAL CELLS; P53; EXPRESSION; MECHANISMS; P16(INK4); DIVISION; CULTURE; CANCER	Most somatic cells die after a finite number of cell divisions, a phenomenon described as senescence. The p21(CIP1/WAF1) gene encodes an inhibitor of cyclin-dependent kinases. Inactivation: of p21 by two sequential rounds of targeted homologous recombination was sufficient to bypass senescence in normal diploid human fibroblasts. At the checkpoint between the prereplicative phase of growth and the phase of chromosome replication, cells lacking p21 failed to arrest the cell cycle in response to DNA damage, but their apoptotic response and genomic stability were unaltered. These results establish the feasibility of using gene targeting for genetic studies of normal human cells.			Brown, JP (corresponding author), BROWN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, PROVIDENCE, RI 02912 USA.				NIGMS NIH HHS [GM41690] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bond J, 1996, ONCOGENE, V13, P2097; BROWN JP, UNPUYB; Campisi Judith, 1996, P121; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENE AE, 1973, TISSUE CULTURE METHO, P69; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TAHARA H, 1995, ONCOGENE, V10, P835; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VARIZI H, 1996, EXP GERONTOL, V31, P295; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WEI W, UNPUB; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9	36	660	686	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					831	834		10.1126/science.277.5327.831	http://dx.doi.org/10.1126/science.277.5327.831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242615				2022-12-28	WOS:A1997XQ24700048
J	Annas, GJ				Annas, GJ			'Reefer Madness' - The Federal response to California's medical-marijuana law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas George J, 1989, Villanova Law Rev, V34, P771; ANNAS GJ, 1991, NEW ENGL J MED, V325, P362, DOI 10.1056/NEJM199108013250519; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; GOLDEN T, 1997, NY TIMES        0417, pA14; Golden Tim, 1997, N Y Times Web, P7; GOODMAN E, 1997, BOSTON GLOBE    0202, pC7; GOULD SJ, 1993, TIMES           0504; Grinspoon L, 1995, MARIHUANA FORBIDDEN; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; LEARY WE, 1997, NY TIMES        0221, pA27; Sidney S, 1997, AM J PUBLIC HEALTH, V87, P585, DOI 10.2105/AJPH.87.4.585; STAPLETON S, 1997, AM MED NEWS     0317, P1; STAPLETON S, 1997, AM MED NEWS     0317, P33; WREN C, 1997, NY TIMES        0420, pE4	14	37	37	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					435	439		10.1056/NEJM199708073370621	http://dx.doi.org/10.1056/NEJM199708073370621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241134	Green Published			2022-12-28	WOS:A1997XP40700029
J	Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT				Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT			Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; HEMOLYTIC UREMIC SYNDROME; OUTBREAK; EPIDEMIOLOGY	Background Escherichia coli O157:H7 is a leading cause of diarrhea and the hemolytic-uremic syndrome. Current public health surveillance for E. coli O157:H7 requires considerable resources; traditional methods lack the sensitivity and specificity to detect outbreaks effectively. Methods During 1994 and 1995, the Minnesota Department of Health requested that all clinical isolates of E. coli O157:H7 be submitted to our laboratory. Isolates were subtyped by pulsed-field gel electrophoresis (PFGE), and patients were interviewed about potential sources of infection. Results In 1994 and 1995, 344 cases of E. coli O157:H7 infection were reported to the Minnesota Department of Health; 317 (92 percent) were subtyped by PFGE, and 143 distinct PFGE patterns were identified. Ten outbreaks of E. coli O157:H7 were identified; these accounted for 56 (18 percent) of the 317 subtyped cases, Four outbreaks were detected solely as a result of subtype-specific surveillance. In 11 two-week periods, the number of reported cases of E. coli O157:H7 doubled from the previous two weeks. In eight of these instances, the patterns identified were dissimilar and there were no outbreaks. Two of the remaining three increases resulted from multiple simultaneous outbreaks. Conclusions Subtype-specific surveillance for E. coli O157:H7 can identify outbreaks that are not detected by traditional methods and can ascertain whether sudden increases in reported cases are due to sporadic isolated cases or to one or more outbreaks. (C) 1997, Massachusetts Medical Society.	MINNESOTA DEPT HLTH,DIV PUBL HLTH LABS,MINNEAPOLIS,MN 55440	Minnesota Department of Health (MHD)	Bender, JB (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440, USA.			Bender, Jeffrey/0000-0003-4645-9936	PHS HHS [U50/CCU511190] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banatvala N, 1996, J INFECT DIS, V173, P480, DOI 10.1093/infdis/173.2.480; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Krause U, 1996, J CLIN MICROBIOL, V34, P959, DOI 10.1128/JCM.34.4.959-961.1996; *MN DEP HLTH, 1996, MINN HLTH STAT 1994; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; RODRIGUE DC, 1995, J INFECT DIS, V172, P1122, DOI 10.1093/infdis/172.4.1122; Shefer AM, 1996, WESTERN J MED, V165, P15; SWAMINATHAN B, 1995, DIAGNOSTIC MOL MICRO, P26; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; 1996, MMWR-MORBID MORTAL W, V45, P437; 1995, MMWR-MORBID MORTAL W, V44, P417; 1995, MMWR-MORBID MORTAL W, V44, P157	17	118	126	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					388	394		10.1056/NEJM199708073370604	http://dx.doi.org/10.1056/NEJM199708073370604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241128				2022-12-28	WOS:A1997XP40700004
J	Bartlett, JG				Bartlett, JG			Update in infectious diseases	ANNALS OF INTERNAL MEDICINE			English	Article											Bartlett, JG (corresponding author), JOHNS HOPKINS UNIV, SCH MED, ROSS RES BLDG, ROOM 1159, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.							Bartlett JG, 1997, ANN INTERN MED, V126, P48, DOI 10.7326/0003-4819-126-1-199701010-00007; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; FARR BM, 1987, ANTIMICROB AGENTS CH, V31, P1183, DOI 10.1128/AAC.31.8.1183; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1224; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; 1996, MMWR-MORBID MORTAL W, V45, P853; 1996, MMWR-MORBID MORTAL W, V45, P549; 1997, MED LETT DRUGS THER, V39, P9; 1996, MMWR-MORBID MORTAL W, V45, P611; 1996, MMWR-MORBID MORTAL W, V45, P468	15	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					217	224		10.7326/0003-4819-127-3-199708010-00007	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245228				2022-12-28	WOS:A1997XN12900007
J	Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R				Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R			Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article						interleukin-6; lymphoma, large-cell, diffuse; outcome assessment (health care); disease-free survival; survival rate	NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; MONOCLONAL-ANTIBODY; LEVELS CORRELATE; B CELLS; DISEASE; EXPRESSION; CANCER; PARAMETERS; SURVIVAL	Background: Interleukin-6 has important lymphoid bioregulatory effects, and serum levels of interleukin-6 are often elevated in patients with lymphoma. Objective: To determine the relation between serum levels of interleukin-6 before treatment and outcome in patients with diffuse large-cell lymphoma. Design: Retrospective cohort analysis with multivariate analysis. Setting: Tertiary referral center. Participants: 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemotherapy protocols and 45 healthy controls. Measurements: Serum levels of interleukin-6 were measured by using a sensitive enzyme-linked immunosorbent assay. Levels below the upper limit of the range for controls were considered normal. Outcomes were complete response, failure-free survival, and overall survival. Results: Serum levels of interleukin-6 were higher in patients with lymphoma (median, 4.6 pg/mL [range, undetectable to 224 pg/mL]) than in controls (median, undetectable [range, undetectable to 4.3 pg/mL]) (P = 0.009). The complete response rate was 95% for persons with normal interleukin-6 levels and 66% for persons with high interleukin-6 levels (P = 0.001). Patients with high interleukin-6 levels had inferior failure-free and overall survival rates (P < 0.001 for both comparisons). The actuarial 4-year failure-free and overall survival rates were 72% and 85%, respectively, for persons with normal interleukin-6 levels and 37% and 46%, respectively, for persons with high interleukin-6 levels. In multivariate analysis, interleukin-6 was selected as the most significant predictor of complete response and failure-free survival. Failure-free and overall survival of patients stratified according to International Prognostic Index score could be further stratified by interleukin-6 level (P less than or equal to 0.03 for all comparisons). Conclusion: In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an independent prognostic factor for complete response and failure-free survival.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOIMMUNOTHERAPY, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Royal Melbourne Hospital			Kurzrock, Razelle/AAU-9782-2020; Seymour, John/K-7326-2019	Seymour, John/0000-0003-2188-6835; Cabanillas, Fernando/0000-0001-9234-7893; Talpaz, Moshe/0000-0003-3361-3981				Altman DG, 1991, PRACTICAL STAT MED R; BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C; BLAY JY, 1992, CANCER RES, V52, P3317; CABANILLAS F, 1990, SEMIN ONCOL, V17, P28; COX DR, 1972, J R STAT SOC B, V34, P187; EMILIE D, 1994, BLOOD, V84, P2472; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; FREEMAN GJ, 1989, J CLIN INVEST, V83, P1512, DOI 10.1172/JCI114046; GAUSE A, 1991, HEMATOL ONCOL, V9, P307; GROGAN TM, 1988, BLOOD, V71, P1157; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HONG C, 1992, LEUKEMIA LYMPHOMA, V8, P97, DOI 10.3109/10428199209049823; HORST E, 1990, LEUKEMIA, V4, P595; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KURZROCK R, 1993, CANCER RES, V53, P2118; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LU ZY, 1995, BLOOD, V86, P3123; LUDWIG H, 1991, BLOOD, V77, P2794; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NACHBAUR DM, 1991, ANN HEMATOL, V62, P54, DOI 10.1007/BF01714900; PLUDA JM, 1993, J CLIN ONCOL, V11, P1099, DOI 10.1200/JCO.1993.11.6.1099; ROSENBERG SA, 1982, CANCER, V49, P2112; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; Seymour JF, 1997, AM J MED, V102, P21; SEYMOUR JF, 1995, J CLIN ONCOL, V13, P575, DOI 10.1200/JCO.1995.13.3.575; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1994, BLOOD, V83, P1165; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; TOSATO G, 1993, J CLIN INVEST, V91, P2806, DOI 10.1172/JCI116523; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; UCHIYAMA H, 1993, BLOOD, V82, P3712; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VELASQUEZ WS, 1989, BLOOD, V74, P551; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YEE C, 1989, BLOOD, V74, P798; YOSHIZAKI K, 1989, BLOOD, V74, P1360	40	93	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					186	+		10.7326/0003-4819-127-3-199708010-00002	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245223				2022-12-28	WOS:A1997XN12900002
J	Levine, RL; Wayne, MA; Miller, CC				Levine, RL; Wayne, MA; Miller, CC			End-tidal carbon dioxide and outcome of out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE COMPRESSION-DECOMPRESSION; CARDIOPULMONARY-RESUSCITATION; PROGNOSTIC INDICATOR; SURVIVAL; PRESSURE; EPINEPHRINE; PREDICTION; EMERGENCY; INDEX; PCO2	Background Survival after cardiac arrest occurring outside the hospital averages less than 3 percent, Unfortunately, the outcome of prolonged resuscitative attempts cannot be predicted. End-tidal carbon dioxide levels reflect cardiac output during cardiopulmonary resuscitation. We prospectively determined whether death could be predicted by monitoring end-tidal carbon dioxide during resuscitation after cardiac arrest. Methods We performed a prospective observational study in 150 consecutive victims of cardiac arrest outside the hospital who had electrical activity but no pulse. The patients were intubated and evaluated by mainstream end-tidal carbon dioxide monitoring. Our hypothesis was that an end-tidal carbon dioxide level of 10 mm Hg or less after 20 minutes of standard advanced cardiac life support would predict death. Results There was no difference in the mean age or initial end-tidal carbon dioxide level between patients who survived to hospital admission (survivors) and those who did not (nonsurvivors). After 20 minutes of advanced cardiac life support, end-tidal carbon dioxide (+/-SD) averaged 4.4+/-2.9 mm Hg in nonsurvivors and 32.8+/-7.4 mm Hg in survivors (P<0.001). A 20-minute end-tidal carbon dioxide value of 10 mm Hg or less successfully discriminated between the 35 patients who survived to hospital admission and the 115 nonsurvivors. When a 20-minute end-tidal carbon dioxide value of 10 mm Hg or less was used as a screening test to predict death, the sensitivity, specificity, positive predictive value, and negative predictive value were all 100 percent. Conclusions An end-tidal carbon dioxide level of 10 mm Hg or less measured 20 minutes after the initiation of advanced cardiac life support accurately predicts death in patients with cardiac arrest associated with electrical activity but no pulse. Cardiopulmonary resuscitation may reasonably be terminated in such patients. (C) 1997, Massachusetts Medical Society.	CITY BELLINGHAM EMERGENCY MED SERV,BELLINGHAM,WA 98225; BAYLOR COLL MED,DEPT MED,DIV PULM CRIT CARE,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,DIV EMERGENCY MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT SURG,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								ASPLIN BR, 1995, ANN EMERG MED, V25, P756, DOI 10.1016/S0196-0644(95)70203-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Bhende MS, 1995, PEDIATR EMERG CARE, V11, P365, DOI 10.1097/00006565-199512000-00008; CALLAHAM M, 1992, CRIT CARE MED, V20, P337, DOI 10.1097/00003246-199203000-00008; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; Cantineau JP, 1996, CRIT CARE MED, V24, P791, DOI 10.1097/00003246-199605000-00011; CANTINEAU JP, 1994, AM J EMERG MED, V12, P267, DOI 10.1016/0735-6757(94)90136-8; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; CUMMINS RO, 1994, TXB ADV CARDIAC LIFE; DOHI S, 1987, CRIT CARE MED, V15, P944, DOI 10.1097/00003246-198710000-00010; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRAY WA, 1993, JAMA-J AM MED ASSOC, V270, P1471, DOI 10.1001/jama.270.12.1471; GULY UM, 1995, BRIT HEART J, V73, P372; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P333; IDRIS AH, 1994, ANN EMERG MED, V23, P568, DOI 10.1016/S0196-0644(94)70080-X; ISSERLES SA, 1991, ANESTH ANALG, V73, P808; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KERN KB, 1992, ARCH INTERN MED, V152, P145, DOI 10.1001/archinte.152.1.145; KERN KB, 1989, J AM COLL CARDIOL, V13, P1184, DOI 10.1016/0735-1097(89)90282-9; LAMBERT Y, 1992, ANESTHESIOLOGY S, V77, pA1081; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MARWICK TH, 1991, RESUSCITATION, V22, P129, DOI 10.1016/0300-9572(91)90003-H; ORNATO JP, 1988, CRIT CARE MED, V16, P241, DOI 10.1097/00003246-198803000-00007; PANTRIDG.JF, 1967, LANCET, V2, P271; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; SAS Institute, 1988, SAS STAT US GUID VER; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHIBUTANI K, 1994, ANESTH ANALG, V79, P829; VARON AJ, 1991, J CLIN MONITOR, V7, P289, DOI 10.1007/BF01619347; WAYNE MA, 1995, ANN EMERG MED, V25, P762, DOI 10.1016/S0196-0644(95)70204-0; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; WEST JB, 1977, AM REV RESPIR DIS, V116, P919; WRIGHT D, 1990, BRIT MED J, V301, P600, DOI 10.1136/bmj.301.6752.600	39	277	283	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					301	306		10.1056/NEJM199707313370503	http://dx.doi.org/10.1056/NEJM199707313370503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233867				2022-12-28	WOS:A1997XN11900003
J	Wirth, FA				Wirth, FA			Secondary syphilis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Wirth, FA (corresponding author), UNIV MARYLAND,SCH MED,BALTIMORE,MD 21201, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					321	321		10.1056/NEJM199707313370506	http://dx.doi.org/10.1056/NEJM199707313370506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233869				2022-12-28	WOS:A1997XN11900006
J	Horton, R				Horton, R			Will the UK cope?	LANCET			English	Editorial Material																		ABBOTT A, 1997, NATURE, V387, P750; Farthing MJG, 1997, GUT, V41, P1; HORTON R, 1995, LANCET, V346, P1610, DOI 10.1016/S0140-6736(95)91935-X; LOCK S, 1995, BRIT MED J, V310, P1547, DOI 10.1136/bmj.310.6994.1547; LOCK S, 1996, FRAUD MISCONDUCT MED; Marshall E, 1996, SCIENCE, V274, P908, DOI 10.1126/science.274.5289.908; Smith R, 1996, BRIT MED J, V312, P789; 1996, LANCET, V347, P843; 1997, NATURE, V388, P112	9	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					234	234		10.1016/S0140-6736(05)62223-4	http://dx.doi.org/10.1016/S0140-6736(05)62223-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242798				2022-12-28	WOS:A1997XM86600007
J	Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M				Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M			Cooperation of BMP7 and SHH in the induction of forebrain ventral midline cells by prechordal mesoderm	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-7; FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; SPINAL-CORD; EXPRESSION; SIGNALS; BRAIN; EYE	Ventral midline cells at different rostrocaudal levels of the central nervous system exhibit distinct properties but share the ability to pattern the dorsoventral axis of the neural tube. We show here that ventral midline cells acquire distinct identities in response to the different signaling activities of underlying mesoderm. Signals from prechordal mesoderm control the differentiation of rostral diencephalic ventral midline cells, whereas notochord induces floor plate cells caudally. Sonic hedgehog (SHH) is expressed throughout axial mesoderm and is required for the induction of both rostral diencephalic ventral midline cells and floor plate. However, prechordal mesoderm also expresses BMP7 whose function is required coordinately with SHH to induce rostral diencephalic ventral midline eels. BMP7 acts directly on neural cells, modifying their response to SHH so that they differentiate into rostral diencephalic Ventral midline cells rather than floor prate cells. Our results suggest a model whereby axial mesoderm both induces the differentiation of overlying neural cells and controls the rostrocaudal character of the ventral midline of the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; COLUMBIA UNIV,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; CREAT BIOMOL,HOPKINTON,MA 01748	MRC National Institute for Medical Research; Columbia University; Columbia University			Vesque, Christine/L-9839-2017; Dale, Kim J/A-4480-2016; Lints, Thierry/K-4408-2012; Furley, Andrew J. W./D-4798-2013; Vesque, Christine/Q-8461-2019; Furley, Andrew JW/B-7316-2012; Placzek, Marysia/E-6172-2010	Dale, Kim J/0000-0002-9294-947X; Furley, Andrew JW/0000-0001-5549-8668; Placzek, Marysia/0000-0002-4106-9229; Vesque, Christine/0000-0001-7983-4953	NINDS NIH HHS [NS 30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Adelmann H. B., 1922, American Journal of Anatomy, V31, P55, DOI 10.1002/aja.1000310104; Adelmann HB, 1932, J MORPHOL, V54, P1, DOI 10.1002/jmor.1050540102; Adelmann HB, 1930, J EXP ZOOL, V57, P223, DOI 10.1002/jez.1400570204; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HARLAND RM, 1997, IN PRESS NEURONAL DE; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEATH MJS, 1995, J PHYSIOL-LONDON, V486, P139, DOI 10.1113/jphysiol.1995.sp020798; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SEIFERT R, 1993, J ANAT, V183, P75; Solursh M, 1996, BIOCHEM BIOPH RES CO, V218, P438, DOI 10.1006/bbrc.1996.0078; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; ZECCA M, 1995, DEVELOPMENT, V121, P2265	49	245	251	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					257	269		10.1016/S0092-8674(00)80334-7	http://dx.doi.org/10.1016/S0092-8674(00)80334-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244300	hybrid			2022-12-28	WOS:A1997XN24900010
J	Hua, W; Young, EC; Fleming, ML; Gelles, J				Hua, W; Young, EC; Fleming, ML; Gelles, J			Coupling of kinesin steps to ATP hydrolysis	NATURE			English	Article							MICROTUBULE MOVEMENT; HEAVY-CHAIN; DERIVATIVES; MOLECULES	A key goal in the study of the function of ATP-driven motor enzymes is to quantify the movement produced from consumption of one ATP molecule(1-3). Discrete displacements of the processive motor kinesin along a microtubule have been reported as 5 and/or 8 mn (refs 4, 5). However, analysis of nanometre-scale movements is hindered by superimposed brownian motion, Moreover, because kinesin is processive and turns over stochastically, some observed displacements must arise from summation of smaller movements that are too closely spaced in time to be resolved, To address both of these problems, we used light microscopy instrumentation(6) with low positional drift (<39 pm s(-1)) to observe single molecules of a kinesin derivative moving slowly (similar to 2.5 nm s(-1)) at very low (150 nM) ATP concentration, so that ATP-induced displacements were widely spaced in time, This allowed increased time-averaging to suppress brownian noise (without application of external force(4,5)), permitting objective measurement of the distribution of all observed displacement sizes, The distribution was analysed with a statistics-based method which explicitly takes into account the occurrence of unresolved movements, and determines both the underlying step size and the coupling of steps to ATP hydrolytic events, Our data support a fundamental enzymatic cycle for kinesin in which hydrolysis of a single ATP molecule is coupled to a step distance of the microtubule protofilament lattice spacing of 8.12 nm (ref. 7). Step distances other than 8 nm are excluded, as is the coupling of each step to two or more consecutive ATP hydrolysis reactions with similar rates, or the coupling of two 8-nm steps to a single hydrolysis. The measured ratio of ATP consumption rate to stepping rate is invariant over a wide range of ATP concentration, suggesting that the 1 ATP to 8 nm coupling inferred from behaviour at low ATP can be generalized to high ATP.	BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS & STRUCT BIOL GRAD PROGRAM,WALTHAM,MA 02254	Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X				Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1995, THESIS BRANDEIS U WA; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; GALLAGHER NC, 1981, IEEE T ACOUST SPEECH, V29, P1136, DOI 10.1109/TASSP.1981.1163708; GELLES J, 1995, BIOPHYS J, V68, pS276; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Segel I.H., 1975, ENZYME KINETICS; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	29	270	274	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					390	393		10.1038/41118	http://dx.doi.org/10.1038/41118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237758				2022-12-28	WOS:A1997XM52800054
J	Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD				Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD			In vitro propagation of the prion-like state of yeast Sup35 protein	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BIOLOGY; GENE; DISEASES; URE3	The yeast cytoplasmically inherited genetic determinant [PSI+] is presumed to be a manifestation of the prion-like properties of the Sup35 protein (Sup35p). Here, cell-free conversion of Sup35p from [psi(-)] cells (Sup35(psi-)) to the prion-like [PSI+]-specific form (Sup35p(PSI+)) was observed. The conversion reaction could be repeated for several consecutive cycles, thus modeling in vitro continuous [PSI+] propagation. Size fractionation of lysates of [PSI+] cells demonstrated that the converting activity was associated solely with Sup35p(PSI+) aggregates, which agrees with the nucleation model for [PSI+] propagation. Sup35p(PSI+) was purified and showed high conversion activity, thus confirming the prion hypothesis for Sup35p.	CARDIOL RES CTR,INST EXPT CARDIOL,MOSCOW 121552,RUSSIA	National Medical Research Center of Cardiology			Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Frolova L, 1996, RNA, V2, P334; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, MOL CELL BIOL, V17, P2798, DOI 10.1128/MCB.17.5.2798; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PAUSHKIN SV, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1987, FEBS LETT, V225, P205, DOI 10.1016/0014-5793(87)81158-4; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	22	196	201	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					381	383		10.1126/science.277.5324.381	http://dx.doi.org/10.1126/science.277.5324.381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219697				2022-12-28	WOS:A1997XL35800049
J	McGee, G				McGee, G			Subject to payment?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Ethics Committee of the American Fertility Society, 1994, FERTIL STERIL S1, V62, p1S; McGee G., 1997, PERFECT BABY PRAGMAT	2	38	39	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					199	200		10.1001/jama.278.3.199	http://dx.doi.org/10.1001/jama.278.3.199			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218656				2022-12-28	WOS:A1997XK10800012
J	MacMillan, HL; Fleming, JE; Troome, N; Boyle, MH; Wong, M; Racine, YA; Beardslee, WR; Offord, DR				MacMillan, HL; Fleming, JE; Troome, N; Boyle, MH; Wong, M; Racine, YA; Beardslee, WR; Offord, DR			Prevalence of child physical and sexual abuse in the community - Results from the Ontario health supplement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIOLENCE; NEGLECT; PSYCHOPATHOLOGY; DISORDERS	Context.-Although child maltreatment is considered common, few community surveys have examined the prevalence of more than 1 type of maltreatment among both males and females. Objective.-To determine the prevalence of a history of physical and sexual abuse during childhood among the general population. Design.-General population survey. Setting.-Household dwellings in the province of Ontario, Canada. Participants.-A random sample (N=9953) of residents aged 15 years and older participated in the Ontario Health Supplement. Main Outcome Measure.-Self-administered questionnaire about a history of physical and sexual abuse in childhood. Results.-A history of child physical abuse was reported more often by males (31.2%) than females (21.1%), while sexual abuse during childhood was more commonly reported by females (12.8%) than males (4.3%). Severe physical abuse was reported by similar proportions of males (10.7%) and females (9.2%), A greater percentage of females reported a history of severe sexual abuse (11.1%) compared with males (3.9%). Age of the respondent was not significantly associated with childhood abuse within any category for males. However, for females, the reported prevalence in childhood of sexual abuse, co-occurrence of physical and sexual abuse, and both categories of severe abuse decreased with increasing age of the respondent. Conclusions.-A history of childhood maltreatment among Ontario residents is common. Child abuse may be more prevalent in younger women compared with older women, or there may be a greater willingness among younger women to report abuse.	MCMASTER UNIV, FAC HLTH SCI, CTR STUDIES CHILDREN RISK, HAMILTON, NEW ZEALAND; UNIV TORONTO, FAC SOCIAL WORK, TORONTO, ON M5S 1A1, CANADA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02115 USA	University of Toronto; Harvard University; Harvard Medical School	MacMillan, HL (corresponding author), HAMILTON HLTH SCI CORP, CTR STUDIES CHILDREN RISK, PATTERSON BLDG, CHEDOKE DIV, BOX 2000, HAMILTON, ON L8N 3Z5, CANADA.		MacMillan, Harriet/B-4530-2016	MacMillan, Harriet/0000-0002-1223-706X				[Anonymous], 1994, REDUCING RISKS MENTA; BADGLEY RF, 1984, JE501984E DEP SUPPL; BAGLEY C, 1989, CAN J PUBLIC HEALTH, V80, P295; Bagley C., 1988, CHILD SEXUAL ABUSE C; Besharov D. J., 1981, CHILD ABUSE NEGLECT, V5, P383, DOI DOI 10.1016/0145-2134(81)90048-X; Boyle MH, 1996, CAN J PSYCHIAT, V41, P549, DOI 10.1177/070674379604100903; BREWIN CR, 1993, PSYCHOL BULL, V113, P82, DOI 10.1037/0033-2909.113.1.82; CICCHETTI D, 1995, J AM ACAD CHILD PSY, V34, P541, DOI 10.1097/00004583-199505000-00008; Femina D, 1990, CHILD ABUSE NEGLECT, V14, P227, DOI DOI 10.1016/0145-2134(90)90033-P; FINKELHOR D, 1994, CHILD ABUSE NEGLECT, V18, P409, DOI 10.1016/0145-2134(94)90026-4; FINKELHOR D, 1994, PEDIATRICS, V94, P413; Finkelhor D, 1994, Future Child, V4, P31, DOI 10.2307/1602522; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KUFELDT K, 1987, CHILD ABUSE NEGLECT, V11, P531, DOI 10.1016/0145-2134(87)90079-2; OFFORD DR, 1996, BANF INT BEHAV SER, V3, P329; Robins LN, 1991, PSYCHIAT DISORDERS A, P328; SARIOLA H, 1992, CHILD ABUSE NEGLECT, V16, P823, DOI 10.1016/0145-2134(92)90084-5; *STAT CAN, 1993, 89533 MIN IND SCI TE; *STAT CAN, 1993, 93339 MIN IND SCI TE; Straus M.A., 1990, PHYS VIOLENCE AM FAM, P49; WIDOM CS, 1988, AM J ORTHOPSYCHIAT, V58, P260, DOI 10.1111/j.1939-0025.1988.tb01587.x; WILLIAMS LM, 1994, J CONSULT CLIN PSYCH, V62, P1167, DOI 10.1037//0022-006X.63.3.343; WINDLE M, 1995, AM J PSYCHIAT, V152, P1322; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107; WOLFNER GD, 1993, CHILD ABUSE NEGLECT, V17, P197, DOI 10.1016/0145-2134(93)90040-C; Zigler E., 1989, CHILD MALTREATMENT T, P38	27	337	343	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					131	135		10.1001/jama.278.2.131	http://dx.doi.org/10.1001/jama.278.2.131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214528				2022-12-28	WOS:A1997XH66700033
J	Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q				Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q			Prevalence of HIV and injecting drug use in men entering Liverpool prison	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND; LIVERPOOL PUBL HLTH LAB,COMMUNICABLE DIS SURVEILLANCE CTR NW,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	Liverpool School of Tropical Medicine	Bellis, MA (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,SEXUAL HLTH & ENVIRONM EPIDEMIOL UNIT,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND.		Bellis, Mark A./HGA-2019-2022; Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				Curtis SP, 1995, INT J STD AIDS, V6, P387, DOI 10.1177/095646249500600602; FORD BT, 1992, AIDS, V6, P623; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MORRISON CL, 1995, POSTGRAD MED J, V71, P593, DOI 10.1136/pgmj.71.840.593; Yirrell DI, 1997, BRIT MED J, V314, P1446, DOI 10.1136/bmj.314.7092.1446	5	37	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					30	31		10.1136/bmj.315.7099.30	http://dx.doi.org/10.1136/bmj.315.7099.30			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233323	Green Published			2022-12-28	WOS:A1997XJ94700024
J	Solomon, T				Solomon, T			Hong Kong, 1894: The role of James A Lowson in the controversial discovery of the plague bacillus	LANCET			English	Article									CHO QUAN HOSP, WELLCOME TRUST CLIN RES UNIT, CTR TROP DIS, HO CHI MINH CITY, VIETNAM					Solomon, Tom/0000-0001-7266-6547				ANONYMOUS, 1894, LANCET, Vii, P391; BIBEL DJ, 1976, BACTERIOL REV, V40, P633, DOI 10.1128/MMBR.40.3.633-651.1976; BRENAN B, 1894, COMMUNICATION   0704; Butler T, 1983, PLAGUE OTHER YERSINI; Cantlie Stewart Jean, 1983, QUALITY MERCY LIVES; CHOA GH, 1981, LIFE TIMES KH KAI; Howard-Jones N, 1975, Clio Med, V10, P23; HOWARDJONES N, 1973, PERSPEC MICROBIOL ME, V16, P293; KITASATO, 1994, HONG KONG WEEKL 0710; KITASATO S, 1901, PHILA MED J, V7, P94; Kitasato S., 1894, LANCET, V2, P428; KITASATO S, 1898, 20 CENTURY PRACT, V15, P325; LAGRANGE E, 1926, J TROP MED HYG, V29, P199; LOWSON J, 1895, EPIDEMIC BUBONIC PLA; LOWSON JA, 1894, PLAGUE ARCH, V5; LOWSON JA, 1897, BRIT MED J, V1, P237; LOWSON JA, 1935, BRIT MED J, V2, P880; LOWSON JA, 1894, COMMUNICATION   0516; MIZUNOE K, 1977, COLLECTED PAPERS SHI; MOLLARET H, 1985, A YERSIN VAINQUER PE, P320; NOTTER L, 1896, BRIT MED J, V2, P1831; SEVERN AGM, 1927, J TROP MED HYG, P208; Sinn E., 1989, POWER CHARITY EARLY; SOLOMON T, 1995, J TROP MED HYG, V98, P209; VAN LOGHEM J J, 1944, Antonie Van Leeuwenhoek, V10, P15; Yersin Alexandre, 1894, ANN I PASTEUR PARIS, V8, P662; Yule WL, 1995, SCOT MED J, V40, P184, DOI 10.1177/003693309504000609; 1896, BRIT MED J, V2, P1760; 1894, LANCET, V1, P1581; 1894, LANCET, V2, P269; 1894, CHINA MAIL      0620; 1894, LANCET, V2, P325; 1894, BRIT MED J, V2, P201; 1994, HONG KONG TELEG 0510; 1931, BRIT MED J, V1, P1141; 1894, BRIT MED J, V2, P369	36	15	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	1997	350	9070					59	62		10.1016/S0140-6736(97)01438-4	http://dx.doi.org/10.1016/S0140-6736(97)01438-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217728				2022-12-28	WOS:A1997XH86900052
J	Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ				Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ			Sensitization to morphine induced by viral-mediated gene transfer	SCIENCE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; VENTRAL TEGMENTAL AREA; TYROSINE-HYDROXYLASE; BEHAVIORAL SENSITIZATION; INDIVIDUAL-DIFFERENCES; AMPHETAMINE; COCAINE; NEURONS; RATS; EXPRESSION	Repeated administration of morphine sensitizes animals to the stimulant and rewarding properties of the drug. It also selectively increases expression of GluR1 (an AMPA glutamate receptor subunit) in the ventral tegmental area, a midbrain region implicated in morphine action, By viral-mediated gene transfer, a causal relation is shown between these behavioral and biochemical adaptations: Morphine's stimulant and rewarding properties are intensified after microinjections of a viral vector expressing GluR1 into the ventral tegmental area, These results confirm the importance of AMPA receptors in morphine action and demonstrate specific locomotor and motivational adaptations resulting from altered expression of a single localized gene product.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, NEW HAVEN, CT 06508 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA; HARVARD UNIV, MCLEAN HOSP, SCH MED, DEPT GENET, BELMONT, MA 02178 USA	Yale University; Yale University; Yale University; Harvard University; McLean Hospital				Haile, Colin/0000-0001-8293-7291; /0000-0002-4162-3947				Berhow MT, 1996, J NEUROSCI, V16, P4707; Berhow MT, 1996, J NEUROSCI, V16, P8019; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; CARLEZON WA, UNPUB; DEROCHE V, 1993, BRAIN RES, V623, P341, DOI 10.1016/0006-8993(93)91451-W; DURING MJ, 1994, SCIENCE, V266, P1399, DOI 10.1126/science.266.5189.1399; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; HENRY DJ, 1995, J NEUROSCI, V15, P6287; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; ISACSON O, 1995, SCIENCE, V269, P856, DOI 10.1126/science.7638605; JAKOWEC MW, 1995, NEUROSCIENCE, V67, P909, DOI 10.1016/0306-4522(95)00094-Y; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KARIER R, 1991, BRAIN RES, V552, P295; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; LI Y, IN PRESS PSYCHOPHARM; Lim F, 1996, BIOTECHNIQUES, V20, P460; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Neve RL, 1996, CLIN NEUROSCI, V3, P262; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; PRUSS RM, 1991, NEURON, V7, P509, DOI 10.1016/0896-6273(91)90302-G; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SEGAL DS, 1992, BRAIN RES, V577, P351, DOI 10.1016/0006-8993(92)90297-M; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VEZINA P, 1989, BRAIN RES, V499, P108, DOI 10.1016/0006-8993(89)91140-2; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WISE RA, 1989, NEUROPHARMACOLOGICAL; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	36	233	239	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					812	814		10.1126/science.277.5327.812	http://dx.doi.org/10.1126/science.277.5327.812			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242609				2022-12-28	WOS:A1997XQ24700042
J	Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR				Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR			Distance-dependent electron transfer in DNA hairpins	SCIENCE			English	Article							OLIGONUCLEOTIDES; FLUORESCENCE; DYNAMICS	The distance dependence of photoinduced electron transfer in duplex DNA was determined for a family of synthetic DNA hairpins in which a stilbene dicarboxamide forms a bridge connecting two oligonucleotide arms. Investigation of the fluorescence and transient absorption spectra of these hairpins established that no photoinduced electron transfer occurs for a hairpin that has six deoxyadenosine-deoxythymidine base pairs. However, the introduction of a single deoxyguanosine-deoxycytidine base pair resulted in distance-dependent fluorescence quenching and the formation of the stilbene anion radical. Kinetic analysis suggests that duplex DNA is somewhat more effective than proteins as a medium for electron transfer but that it does not function as a molecular wire.	ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439	United States Department of Energy (DOE); Argonne National Laboratory	Lewis, FD (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.		Greenfield, Scott/GOE-6006-2022					[Anonymous], 1988, ELECT ABSORPTION SPE; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P128; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; GREENFIELD SR, 1995, OPT LETT, V20, P1394, DOI 10.1364/OL.20.001394; Greenfield SR, 1996, J AM CHEM SOC, V118, P6767, DOI 10.1021/ja9600789; Guckian KM, 1996, J AM CHEM SOC, V118, P8182, DOI 10.1021/ja961733f; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; LETSINGER RL, 1995, J AM CHEM SOC, V117, P7323, DOI 10.1021/ja00133a005; LEWIS FD, 1995, J AM CHEM SOC, V117, P8785, DOI 10.1021/ja00139a011; Lincoln P, 1997, J AM CHEM SOC, V119, P1454, DOI 10.1021/ja9631965; MATAGA N, 1990, J PHYS CHEM-US, V94, P1443, DOI 10.1021/j100367a045; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; Olson EJC, 1997, J PHYS CHEM B, V101, P299, DOI 10.1021/jp963109v; Priyadarshy S, 1996, J PHYS CHEM-US, V100, P17678, DOI 10.1021/jp961731h; REHM D, 1970, ISRAEL J CHEM, V8, P259; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Taubes G, 1997, SCIENCE, V275, P1420, DOI 10.1126/science.275.5305.1420; WALDECK DH, 1991, CHEM REV, V91, P415, DOI 10.1021/cr00003a007; WILSON EK, 1997, CHEM ENG NEWS, P33	23	553	566	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					673	676		10.1126/science.277.5326.673	http://dx.doi.org/10.1126/science.277.5326.673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235887				2022-12-28	WOS:A1997XN90700037
J	Moll, S; Ortel, TL				Moll, S; Ortel, TL			Monitoring warfarin therapy in patients with lupus anticoagulants	ANNALS OF INTERNAL MEDICINE			English	Article						warfarin; lupus coagulation inhibitor; anticoagulants; prothrombin time; thromboembolism	DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PROTHROMBIN TIME; ANTIBODIES; THROMBOPLASTIN; ERYTHEMATOSUS; POPULATION; INHIBITION; DIAGNOSIS; PLASMA	Background: Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy. Objectives: To determine the validity of the INR as a monitor for warfarin therapy in patients with lupus anticoagulants and to investigate alternate approaches to monitoring warfarin therapy in these patients. Design: Prospective case series. Setting: Tertiary care hospital. Patients: 34 patients with lupus anticoagulants. Measurements: Prothrombin times were determined by using several thromboplastins, and INRs were calculated for the patients receiving warfarin. Factor II levels, chromogenic factor X levels, and prothrombin-proconvertin times were determined for patients receiving warfarin. Results: For patients with lupus anticoagulants who were not receiving warfarin, prothrombin times were often elevated and varied significantly with different thromboplastins. individual thromboplastins differed in sensitivity to the presence of a lupus anticoagulant. For patients receiving warfarin, INRs obtained by using different thromboplastins greatly varied and often overestimated the extent of anticoagulation. Chromogenic factor X levels and prothrombin-proconvertin times correlated well with each other and with established therapeutic ranges. Conclusions: Lupus anticoagulants can influence prothrombin times and lead to INRs that do not accurately reflect the true level of anticoagulation. Use of the INR to standardize prothrombin times is invalid for some patients with lupus anticoagulants. To prevent supratherapeutic or subtherapeutic anticoagulation, these patients must be individually monitored with a test that is insensitive to lupus anticoagulants.	DUKE UNIV, DEPT MED, DIV HEMATOL, MED CTR, DURHAM, NC 27710 USA; FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, FRANZ VOLHARD KLIN, D-13122 BERLIN, GERMANY	Duke University; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin					NCRR NIH HHS [MO1-RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BAJAJ SP, 1983, BLOOD, V61, P684; BICK RL, 1994, MED CLIN N AM, V78, P667, DOI 10.1016/S0025-7125(16)30152-3; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; BRANDT JT, 1991, THROMB HAEMOSTASIS, V66, P453; CIAVARELLA N, 1980, THROMB RES, V19, P493, DOI 10.1016/0049-3848(80)90022-5; COON WW, 1973, CIRCULATION, V48, P839, DOI 10.1161/01.CIR.48.4.839; EGBERG N, 1982, THROMB RES, V25, P437, DOI 10.1016/0049-3848(82)90134-7; FLECK RA, 1988, BLOOD, V72, P512; GALLI M, 1989, BRIT J HAEMATOL, V72, P549, DOI 10.1111/j.1365-2141.1989.tb04322.x; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBERG JS, 1993, BLOOD, V81, P2958; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HORELLOU MH, 1987, J MED, V18, P199; Khamashta MA, 1996, LUPUS, V5, P463, DOI 10.1177/096120339600500527; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KHAMASHTA MA, 1995, NEW ENGL J MED, V333, P666; KOVACS MJ, 1994, THROMB HAEMOSTASIS, V71, P727; LE DT, 1994, ANN INTERN MED, V120, P552, DOI 10.7326/0003-4819-120-7-199404010-00004; Lind SE, 1997, BLOOD COAGUL FIBRIN, V8, P48, DOI 10.1097/00001721-199701000-00008; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MANNUCCI PM, 1979, SCAND J HAEMATOL, V22, P423; NASR SZ, 1995, NEW ENGL J MED, V333, P666; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; OWREN PA, 1951, SCAND J CLIN LAB INV, V3, P201, DOI 10.3109/00365515109060600; RAPAPORT SI, 1995, NEW ENGL J MED, V333, P665; RAPAPORT SI, 1960, BLOOD, V15, P212, DOI 10.1182/blood.V15.2.212.212; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; ROUBEY RAS, 1994, BLOOD, V84, P2854; Shapiro SS, 1996, ANNU REV MED, V47, P533; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P187; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; SLIVKA A, 1995, NEW ENGL J MED, V333, P665; The Committee of Stratigraphy of China, 1996, CPMPBWP21496, P1; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; VANDENBESSELAAR AMHP, 1993, THROMB HAEMOSTASIS, V69, P85	38	157	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					177	+		10.7326/0003-4819-127-3-199708010-00001	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245222				2022-12-28	WOS:A1997XN12900001
J	Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT				Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT			Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B	SCIENCE			English	Article							C-AKT; V-AKT	Protein kinase B (PKB) is a proto-oncogene that is activated in signaling pathways initiated by phosphoinositide 3-kinase. Chromatographic separation of brain cytosol revealed a kinase activity that phosphorylated and activated PKB only in the presence of phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P-3]. Phosphorylation occurred exclusively on threonine-308, a residue implicated in activation of PKB in vivo. PtdIns(3,4,5)P-3 was determined to have a dual role: its binding to the pleckstrin homology domain of PKB was required to allow phosphorylation by the upstream kinase and it directly activated the upstream kinase.	ONYX PHARMACEUT,RICHMOND,CA 94806; BABRAHAM INST,CAMBRIDGE CB2 4AT,ENGLAND; NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV LONDON KINGS COLL,DEPT CHEM,LONDON WC2R 2LS,ENGLAND; UNIV CAMBRIDGE,DEPT CHEM,CAMBRIDGE CB2 3RA,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of London; King's College London; University of Cambridge				Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKOE D, UNPUB	23	1031	1078	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					567	570		10.1126/science.277.5325.567	http://dx.doi.org/10.1126/science.277.5325.567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228007				2022-12-28	WOS:A1997XM86700052
J	Shine, KI				Shine, KI			Some imperatives for clinical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Shine, KI (corresponding author), NATL ACAD SCI,INST MED,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							*ASS AM MED COLL, 1996, FIN MED SCH REP AAMC, P34; JONES RF, 1995, ACAD MED, V71, P300; Shine KI, 1997, FASEB J, V11, P398, DOI 10.1096/fasebj.11.6.9194520; Shine KI, 1997, SCIENCE, V275, P9, DOI 10.1126/science.275.5296.9; [No title captured]	5	31	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					245	246		10.1001/jama.278.3.245	http://dx.doi.org/10.1001/jama.278.3.245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218674				2022-12-28	WOS:A1997XK10800033
J	Massel, D				Massel, D			Ibopamine and survival in severe congestive heart failure: PRIME II	LANCET			English	Letter											Massel, D (corresponding author), UNIV WESTERN ONTARIO,DIV CARDIOL,VICTORIA CAMPUS,LONDON,ON N6A 4G5,CANADA.							Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Lan KKG, 1982, COMMUN STATIST C, V1, P207, DOI DOI 10.1080/07474948208836014	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					147	147		10.1016/S0140-6736(05)61857-0	http://dx.doi.org/10.1016/S0140-6736(05)61857-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228992	Bronze			2022-12-28	WOS:A1997XK11400061
J	Ross, DA; Cutts, FT				Ross, DA; Cutts, FT			Vindication of policy of vitamin A with measles vaccination	LANCET			English	Editorial Material							CHILDHOOD MORTALITY; RURAL BANGLADESH				Ross, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT COMMUNICABLE & TROP DIS EPIDEMIOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BEATON G, 1993, 13 ACC SCN; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; *EXP PROGR IMM GLO, 1989, WKLY EPIDEMIOL REC, V64, P5; Jamison D.T., 1993, DIS CONTROL PRIORITI; JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; ROSS D, 1995, LANCET, V345, P1317, DOI 10.1016/S0140-6736(95)92531-7; SEMBA RD, 1995, LANCET, V345, P1330; *WHO, 1996, WHOGPV9601; WHO, 1995, WHONUT953, P3; *WHO, 1982, WHO TECH REP SER, V672; *WHO UNICEF IVACG, 1988, VIT A SUPPL GUID THE	12	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					81	82		10.1016/S0140-6736(05)61809-0	http://dx.doi.org/10.1016/S0140-6736(05)61809-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228955				2022-12-28	WOS:A1997XK11400003
J	Syvanne, M; Taskinen, MR				Syvanne, M; Taskinen, MR			Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus	LANCET			English	Article							HEART-DISEASE MORTALITY; POSTPRANDIAL LIPEMIA; GLUCOSE-TOLERANCE; ARTERY DISEASE; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; METABOLISM; PLASMA; MEN		UNIV HELSINKI,CENT HOSP,DEPT MED,DIV ENDOCRINOL & DIABET,FIN-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital	Syvanne, M (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT MED,DIV CARDIOL,FIN-00290 HELSINKI,FINLAND.		Taskinen, Marja-Riitta/AAN-5432-2020	Taskinen, Marja-Riitta/0000-0002-6229-3588				AUSTIN MA, 1992, ANN MED, V24, P477, DOI 10.3109/07853899209166999; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CHEN YDI, 1993, J CLIN ENDOCR METAB, V76, P172, DOI 10.1210/jc.76.1.172; FONTBONNE A, 1991, DIABETES METAB REV, V7, P179, DOI 10.1002/dmr.5610070307; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; Frayn Keith N., 1993, Current Opinion in Lipidology, V4, P197, DOI 10.1097/00041433-199306000-00004; FRUCHART JC, 1994, ATHEROSCLEROSIS, V110, pS35, DOI 10.1016/0021-9150(94)05374-R; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GRUNDY SM, 1992, ARCH INTERN MED, V152, P28, DOI 10.1001/archinte.152.1.28; HAFFNER SM, 1993, DIABETES CARE, V16, P835, DOI 10.2337/diacare.16.5.835; Hanefeld M, 1996, DIABETOLOGIA, V39, P1577, DOI 10.1007/s001250050617; Havel Richard J., 1994, Current Opinion in Lipidology, V5, P102, DOI 10.1097/00041433-199404000-00006; HOWARD BV, 1987, J LIPID RES, V28, P613; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; LEWIS GF, 1991, J CLIN ENDOCR METAB, V72, P934, DOI 10.1210/jcem-72-4-934; LOPESVIRELLA MF, 1996, DIABETES S3, V45, P40; LYONS TJ, 1992, DIABETES, V41, P67, DOI 10.2337/diab.41.2.S67; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MALMSTROM R, IN PRESS ARTERIOSCLE; Miesenbock G, 1992, CURRENT OPINION LIPI, V3, P196; SCHNEEMAN BO, 1993, P NATL ACAD SCI USA, V90, P2069, DOI 10.1073/pnas.90.5.2069; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Steiner G, 1996, DIABETOLOGIA, V39, P1655, DOI 10.1007/s001250050630; SYVANNE M, 1995, CIRCULATION, V92, P364, DOI 10.1161/01.CIR.92.3.364; SYVANNE M, 1994, J LIPID RES, V35, P15; Syvanne M, 1996, ATHEROSCLEROSIS, V127, P245, DOI 10.1016/S0021-9150(96)05962-X; SYVANNE M, 1993, ARTERIOSCLER THROMB, V13, P286, DOI 10.1161/01.ATV.13.2.286; TASKINEN M-R, 1987, Diabetes Metabolism Reviews, V3, P551; TASKINEN MR, 1990, BAILLIERE CLIN ENDOC, V4, P743, DOI 10.1016/S0950-351X(05)80078-3; Taskinen MR, 1996, ANN MED, V28, P335, DOI 10.3109/07853899608999090; WALDEN CE, 1984, NEW ENGL J MED, V311, P953, DOI 10.1056/NEJM198410113111505; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	34	105	112	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI20	SI23						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250279				2022-12-28	WOS:A1997XM26500006
J	Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M				Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M			Reliability of health information for the public on the world wide web: Systematic survey of advice on managing fever in children at home	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECTAL TEMPERATURE; PARENTS; INFANTS	Objective: To assess the reliability of healthcare information on the world wide web and therefore how it may help lay people cope with common health problems. Methods: Systematic search by means of two search engines, Yahoo and Excite, of parent oriented web pages relating to home management of feverish children. Reliability of information on the web sites was checked by comparison with published guidelines. Main outcome measures: Minimum temperature of child that should be considered as fever, optimal sites for measuring temperature, pharmacological and physical treatment of fever, conditions that may warrant a doctor's visit. Results: 41 web pages were retrieved and considered. 28 web pages gave a temperature above which a child is feverish; 26 pages indicated the optimal site for taking temperature, most recommending rectal measurement; 31 of the 34 pages that mentioned drug treatment recommended paracetamol as an antipyretic; 38 pages recommended non-drug measures, most commonly tepid sponging, dressing lightly, and increasing fluid intake; and 36 pages gave some indication of when a doctor should be called. Only four web pages adhered closely to the main recommendations in the guidelines. The largest deviations were in sponging procedures and how to take a child's temperature, whereas there was a general agreement in the use of paracetamol. Conclusions: Only a few web sites provided complete and accurate information for this common and widely discussed condition. This suggests an urgent need to check public oriented healthcare information on the internet for accuracy, completeness, and consistency.	MARIO NEGRI INST PHARMACOL RES, LAB MOTHER & CHILD HLTH, I-20157 MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Bonati, Maurizio/K-8980-2016; Pandolfini, Chiara/K-5693-2016	Bonati, Maurizio/0000-0003-3997-3726; Pandolfini, Chiara/0000-0001-9809-2991				ADAM D, 1994, EUR J PEDIATR, V153, P394; CASEY R, 1984, PEDIATRICS, V73, P600; Coeira E., 1996, BRIT MED J, V312, P3; DEAN AG, 1994, EPI INFO VERSION 6; ELRADHI AS, 1994, FEVER PAEDIAT PRACTI, P229; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Impicciatore P, 1997, BRIT MED J, V314, P373, DOI 10.1136/bmj.314.7077.373a; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; KLUGER MJ, 1992, PEDIATRICS, V90, P846; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; KRAMER MS, 1985, PEDIATRICS, V75, P1110; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; LaPorte RE, 1996, ANN EPIDEMIOL, V6, P162, DOI 10.1016/1047-2797(95)00133-6; LESKO SM, 1995, JAMA-J AM MED ASSOC, V273, P929, DOI 10.1001/jama.273.12.929; McIntyre J, 1996, ARCH DIS CHILD, V74, P164, DOI 10.1136/adc.74.2.164; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MOSS MH, 1970, PEDIATRICS, V46, P445; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; PENNA A, 1991, BRIT J CLIN PHARMACO, V32, P143, DOI 10.1111/j.1365-2125.1991.tb03873.x; ROBINSON JS, 1989, AM J DIS CHILD, V143, P698, DOI 10.1001/archpedi.1989.02150180076024; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Spooner SA, 1996, PEDIATRICS, V98, P1185; TARLOW M, 1986, BRIT MED J, V292, P1543, DOI 10.1136/bmj.292.6535.1543; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1991, LANCET, V338, P1049	33	414	421	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1875	1879		10.1136/bmj.314.7098.1875	http://dx.doi.org/10.1136/bmj.314.7098.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224132	Green Published			2022-12-28	WOS:A1997XH73800028
J	Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P				Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P			Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes	LANCET			English	Article							GAMMA-PROBE; LYMPHADENECTOMY; MELANOMA	Background Axillary lymph-node dissection is an important staging procedure in the surgical treatment of breast cancer. However, early diagnosis has led to increasing numbers of dissections in which axillary nodes are free of disease. This raises questions about the need for the procedure. We carried out a study to assess, first, whether a single axillary lymph node (sentinel node) initially receives malignant cells from a breast carcinoma and, second, whether a clear sentinel node reliably forecasts a disease-free axilla. Methods In a consecutive series of 163 women with operable breast carcinoma, we injected microcolloidal human serum albumin labelled with technetium-99m. This tracer was injected subdermally, close to the tumour site, on the day before surgery, and scintigraphic images of the axilla and breast were taken 10 min, 30 min, and 3 h later. A mark was placed on the skin over the site of the radioactive node (sentinel node). During breast surgery, a hand-held gamma-ray detector probe was used to locate the sentinel node, and make possible its separate removal via a small axillary incision. Complete axillary lymphadenectomy was then done. The sentinel node was tagged separately from other nodes. Permanent sections of all removed nodes were prepared for pathological examination. Findings From the sentinel node, we could accurately predict axillary lymph-node status in 156 (97.5%) of the 160 patients in whom a sentinel node was identified, and in all cases (45 patients) with tumours less than 1.5 cm in diameter. In 32 (38%) of the 85 cases with metastatic axillary nodes, the only positive node was the sentinel node. Interpretation in the large majority of patients with breast cancer, lymphoscintigraphy and gamma-probe-guided surgery can be used to locate the sentinel node in the axilla, and thereby provide important information about the status of axillary nodes. Patients without clinical involvement of the axilla should undergo sentinel-node biopsy routinely, and may be spared complete axillary dissection when the sentinel node is disease-free.	EUROPEAN INST ONCOL,DIV NUCL MED,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT PATHOL,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT ANAESTHESIOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO)	Veronesi, U (corresponding author), EUROPEAN INST ONCOL,DIV SURG,VIA RIPAMONTI 435,I-20141 MILAN,ITALY.		Luini, Alberto/AAS-4322-2020; VERONESI, PAOLO/AAS-4132-2020; GALIMBERTI, Viviana Enrica/AAS-3963-2020; Viale, Giuseppe/AAE-8921-2019; paganelli, giovanni/AAC-5267-2022	VERONESI, PAOLO/0000-0001-8926-4106; GALIMBERTI, Viviana Enrica/0000-0002-5036-7439; Paganelli, Giovanni/0000-0002-2631-4652				Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; [Anonymous], 1992, SURG ONCOLOGY CLIN; CHILOSI M, 1994, BIOTECH HISTOCHEM, V69, P235, DOI 10.3109/10520299409106292; *CONS C, 1985, JAMA-J AM MED ASSOC, V254, P461; Doglioni C, 1996, AM J SURG PATHOL, V20, P1037, DOI 10.1097/00000478-199609000-00001; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FISHER B, 1981, SURG GYNECOL OBSTET, V152, P765; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Greco M, 1996, ANTICANCER RES, V16, P3913; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; MOFFAT FL, 1992, J SURG ONCOL, V51, P8, DOI 10.1002/jso.2930510105; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Rosen PP, 1993, TUMORS MAMMARY GLAND; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; VERONESI U, 1987, CANCER, V59, P682, DOI 10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z; *WHO, 1981, 2 WHO INT HIST CLASS	20	1541	1595	1	85	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1864	1867		10.1016/S0140-6736(97)01004-0	http://dx.doi.org/10.1016/S0140-6736(97)01004-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217757				2022-12-28	WOS:A1997XG41700008
J	Roberts, RL; Mosch, HU; Fink, GR				Roberts, RL; Mosch, HU; Fink, GR			14-3-3 proteins are essential for RAS/MAPK cascade signaling during pseudohyphal development in S-cerevisiae	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; YEAST; KINASE; 14-3-3-PROTEINS; ACTIVATION; RAS; PATHWAY; RAF-1; IDENTIFICATION	14-3-3 proteins are highly conserved ubiquitous proteins whose explicit functions have remained elusive. Here, we show that the S. cerevisiae 14-3-3 homologs BMH1 and BMH2 are not essential for viability or mating MAPK cascade signaling, but they are essential for pseudohyphal-development MAPK cascade signaling and other processes. Activated alleles of RAS2 and CDC42 induce pseudohyphal development and FG(TyA)-lacZ signaling in Bmh(+) strains but not in ste20 (p65(PAK)) Or bmh1 bmh2 mutant strains. Moreover, Bmh1p and Bmh2p associate with Ste20p in vivo. Three alleles of BMH1 encode proteins defective for FG(TyA)-lacZ signaling and association with Ste20p, yet these alleles complement other 14-3-3 functions. Therefore, the 14-3-3 proteins are specifically required for RAS/MAPK cascade signaling during pseudohyphal development in S. cerevisiae.	UNIV GOTTINGEN, INST MICROBIOL, D-37077 GOTTINGEN, GERMANY	University of Gottingen	Roberts, RL (corresponding author), MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07348] Funding Source: Medline; NIGMS NIH HHS [GM40266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Cherry J, 1997, SACCHAROMYCES GENOME; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Sherman F., 1986, METHODS YEAST GENETI; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; SUEN KL, 1995, ONCOGENE, V11, P825; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; vanHeusden GPH, 1996, FEBS LETT, V391, P252, DOI 10.1016/0014-5793(96)00746-6; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	43	186	187	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	1997	89	7					1055	1065		10.1016/S0092-8674(00)80293-7	http://dx.doi.org/10.1016/S0092-8674(00)80293-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215628	Bronze			2022-12-28	WOS:A1997XG83000010
J	Harris, TB; Launer, LJ; Madans, J; Feldman, JJ				Harris, TB; Launer, LJ; Madans, J; Feldman, JJ			Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITION EXAMINATION SURVEY; BODY-WEIGHT; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; OBESITY; MORTALITY; HAZARDS; CHOLESTEROL; PROGRAM	Objective: To evaluate risk of late life coronary heart disease associated with being overweight in late middle or old age and to assess whether weight change modifies this risk. Design: Longitudinal study of subjects in the epidemiological follow up study of the national health and nutrition examination survey I. Setting: United States. Subjects: 621 men and 960 women free of coronary heart disease in 1982-84 (mean age 77 years). Main outcome measure: Incidence of coronary heart disease. Results: Body mass index of 27 or more in late middle age nas associated with increased risk of coronary heart disease in late life (relative risk = 1.7 (95% confidence interval 1.3 to 2.1)) while body mass index of 27 or more in old age was not (1.1 (0.8 to 1.5)). This difference in risk was due largely to weight loss between middle and old age. Exclusion of those with weight loss of 10% or more increased risk associated with heavier weight in old age (1.4 (1.0 to 1.9)). Thinner older people who lost weight and heavier people who had gained weight showed increased risk of coronary heart disease compared with thinner people with stable weight. Conclusions: Heavier weight in late middle age was a risk factor for coronary heart disease in late life. Heavier weight in old age was associated with an increased risk once those with substantial weight loss were excluded. The contribution of weight to risk of coronary heart disease in older people may be underestimated if weight history is neglected.	NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT CHRON DIS & ENVIRONM EPIDEMIOL, BILTHOVEN, NETHERLANDS; NATL CTR HLTH STAT, HYATTSVILLE, MD 20782 USA	Netherlands National Institute for Public Health & the Environment; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Harris, TB (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA.							ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BURACK RC, 1985, J CHRON DIS, V38, P865, DOI 10.1016/0021-9681(85)90111-0; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; INGRAM DD, 1994, VITAL HLTH STAT, V1, P121; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LEAN MEJ, 1990, DIABETIC MED, V44, P133; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; *NAT CTR HLTH STAT, 1983, VIT HLTH STAT, V11, P230; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; SHINTON R, 1995, J EPIDEMIOL COMMUN H, V49, P259, DOI 10.1136/jech.49.3.259; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1987, VITAL HLTH STAT, V1, P22; 1979, VITAL HLTH STAT, V1, pA10	28	87	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	1997	314	7097					1791	1794		10.1136/bmj.314.7097.1791	http://dx.doi.org/10.1136/bmj.314.7097.1791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224080	Green Published			2022-12-28	WOS:A1997XG16600021
J	Parkhouse, J				Parkhouse, J			There is urgent need to raise recruitment - Even to stand still - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material																		*BRIT MED ASS, 1995, COR VAL MED PROF 21; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; MARDELL L, 1997, OVERSEAS DOCTORS ASS, V4, P9	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1810	1810		10.1136/bmj.314.7097.1810	http://dx.doi.org/10.1136/bmj.314.7097.1810			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224086	Green Published			2022-12-28	WOS:A1997XG16600027
J	Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL				Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL			Botulism surveillance and emergency response - A public health strategy for a global challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Shapiro, RL (corresponding author), CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							Aureli P, 1996, LANCET, V348, P1594, DOI 10.1016/S0140-6736(05)66220-4; CARDELLA MA, 1964, PHS PUBLICATION; COLE LA, 1996, SCI AM           DEC, P60; DANZIG R, 1996, STRATEGIC FORUM  JAN; FRANZ DR, 1997, JAMA-J AM MED ASSOC, V278, P3990; MCNALLY RE, 1994, EFFECTIVENESS MED DE; Siegel LS, 1993, CLOSTRIDIUM BOTULINU, P323; Smith L. D. S., 1988, BOTULISM ORGANISM IT; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; WANNEMACHER RW, 9120 US ARM BIOM RES; WEBER JT, 1993, J INFECT DIS, V167, P451, DOI 10.1093/infdis/167.2.451	11	65	72	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					433	435		10.1001/jama.278.5.433	http://dx.doi.org/10.1001/jama.278.5.433			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244338				2022-12-28	WOS:A1997XN51800038
J	Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B				Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B			A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes	CELL			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; T-CELLS; RHEUMATOID-ARTHRITIS; NUCLEOTIDE-SEQUENCE; CLONAL DELETION; B RETROVIRUS; STIMULATION; TRANSCRIPTION	Microbial superantigens (SAGs) have been implicated in the pathogenesis of human autoimmune diseases. Preferential expansion of the V beta 7 T cell receptor positive T cell subset in patients suffering from acute-onset type I diabetes has indicated the presence of a surface membrane-bound SAG. Here, we have isolated a novel mouse mammary tumor virus-related human endogenous retrovirus. We further show that the N-terminal moiety of the envelope gene encodes an MHC class II-dependent SAG. We propose that expression of this SAG, induced in extrapancreatic and professional antigen-presenting cells, leads to beta-cell destruction via the systemic activation of autoreactive T cells. The SAG encoded by this novel retrovirus thus constitutes a candidate autoimmune gene in type I diabetes.	UNIV ZURICH,SWISS NATL CTR RETROVIRUSES,CH-8028 ZURICH,SWITZERLAND; UNIV TURIN,SCH MED,DEPT INTERNAL MED,I-10126 TURIN,ITALY	University of Zurich; University of Turin	Conrad, B (corresponding author), UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.		Boeni, Juerg/B-8386-2015; Schüpbach, Jörg/G-4209-2016	Schüpbach, Jörg/0000-0002-8074-5891				ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; Badenhoop K, 1996, HUM IMMUNOL, V50, P103, DOI 10.1016/0198-8859(96)00146-2; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BRUNO G, 1993, DIABETES CARE, V16, P133, DOI 10.2337/diacare.16.1.133; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; *INT UN BIOCH NOM, 1985, EUR J BIOCHEM, V150, P1; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Roizman B, 1996, FIELDS VIROLOGY, P2221; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Stegall MD, 1996, TRANSPLANTATION, V61, P1272, DOI 10.1097/00007890-199604270-00027; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; TASSABEHJI M, 1994, NUCLEIC ACIDS RES, V22, P5211, DOI 10.1093/nar/22.24.5211; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V1, P261; Tyden G, 1996, NEW ENGL J MED, V335, P860, DOI 10.1056/NEJM199609193351205; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WainHobson S, 1996, TRENDS MICROBIOL, V4, P135, DOI 10.1016/0966-842X(96)10023-8; Weissmahr RN, 1997, J VIROL, V71, P3005, DOI 10.1128/JVI.71.4.3005-3012.1997; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992	52	346	356	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					303	313		10.1016/S0092-8674(00)80338-4	http://dx.doi.org/10.1016/S0092-8674(00)80338-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244304	Green Accepted, Bronze			2022-12-28	WOS:A1997XN24900014
J	McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI				McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI			A minK-HERG complex regulates the cardiac potassium current I-Kr	NATURE			English	Article							RECTIFIER K+ CURRENT; XENOPUS-OOCYTES; CHANNEL; EXPRESSION; PROTEIN; CELLS; LOCALIZATION; ARRHYTHMIA; MUTATIONS; MEMBRANE	MinK is a widely expressed protein of relative molecular mass similar to 15K that forms potassium channels by aggregation with other membrane proteins(1-3) MinK: governs :ion channel activiation(4) regulation by second messengers(5,6), and the function and structure of the ion conduction pathway(7,8). Association of minK with a channel protein known as KvLQT1 produces a voltage-gated outward K+ current (I-sK) resembling the slow cardiac repolarization current (I-Ks)(9,10). HERG, a human homologue of the ether-a-go-go gene of the fruitfly Drosophila melanogaster, encodes a protein that produces the rapidly activating cardiac delayed rectifier (I-Kr)(11,12). These two potassium currents, I-Kc, and I-Kr, provide the principal repolarizing currents in cardiac myocytes for the termination of action potentials(13,14). Although heterologously expressed HERG channels are largely indistinguishable from native cardiac I-Kr, a role for minK in this current is suggested by the diminished I-Kr in an atrial tumour line subjected to minK antisense suppression(15). Here we show that HERG and minK form a stable complex, and that this heteromultimerization regulates I-Kr activity. MinK, through the formation of heteromeric channel complexes, is thus central to the control of the heart rate and rhythm.	YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT PEDIAT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University	McDonald, TV (corresponding author), ALBERT EINSTEIN COLL MED,SECT MOL CARDIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		; Goldstein, Steven A./E-9817-2015	Fishman, Glenn/0000-0002-2366-8527; Goldstein, Steven A./0000-0001-5207-5061				ATTALI B, 1992, J BIOL CHEM, V267, P8650; BARHANIN J, 1996, NATURE, V384, P80; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; Brahmajothi MV, 1996, CIRC RES, V78, P1083, DOI 10.1161/01.RES.78.6.1083; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; CHOY AMJ, 1996, CIRCULATION, V94, P164; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MARGIOTTA JF, 1987, P NATL ACAD SCI USA, V84, P8155, DOI 10.1073/pnas.84.22.8155; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; POND AL, UNPUB CIRC RES; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANG W, 1996, NEURON, V16, P571; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246	30	296	306	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					289	292		10.1038/40882	http://dx.doi.org/10.1038/40882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230439	Green Submitted			2022-12-28	WOS:A1997XL12100054
J	Troncy, E; Collet, JP; Shapiro, S; Guimond, JG; Blair, L; Charbonneau, M; Blaise, G				Troncy, E; Collet, JP; Shapiro, S; Guimond, JG; Blair, L; Charbonneau, M; Blaise, G			Should we treat acute respiratory distress syndrome with inhaled nitric oxide?	LANCET			English	Article									MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH HOSP,CTR CLIN EPIDEMIOL & COMMUNITY STUDIES,MONTREAL,PQ,CANADA; UNIV MONTREAL,CTR HOSP,DEPT MED,MONTREAL,PQ,CANADA	McGill University; Universite de Montreal	Troncy, E (corresponding author), UNIV MONTREAL,CTR HOSP,ANAESTHESIA LAB,PAVILLON NOTRE DAME,MONTREAL,PQ H2L 4M1,CANADA.		Troncy, Eric/J-6650-2013	Troncy, Eric/0000-0003-0209-5261				BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; GERLACH H, 1993, INTENS CARE MED, V19, P443, DOI 10.1007/BF01711084; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605	4	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					111	112		10.1016/S0140-6736(97)24028-6	http://dx.doi.org/10.1016/S0140-6736(97)24028-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228965				2022-12-28	WOS:A1997XK11400013
J	Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V				Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V			The space around us	SCIENCE			English	Editorial Material							INFERIOR AREA-6; MACAQUE MONKEY; FUNCTIONAL-ORGANIZATION; VISUAL RESPONSES; PROJECTIONS; NEURONS; MOVEMENTS; AFFERENT; CORTEX				Rizzolatti, G (corresponding author), UNIV PARMA, IST FISIOL UMANA, VIA GRAMSCI 14, I-43100 PARMA, ITALY.		Gallese, Vittorio/ABD-5097-2021; Fadiga, Luciano/AAC-7404-2022; Galantucci, Bruno/E-5770-2010; FOGASSI, Leonardo/K-3541-2018	Gallese, Vittorio/0000-0003-4815-3607; fadiga, luciano/0000-0001-5691-5080; FOGASSI, Leonardo/0000-0003-3348-039X				Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [DOI 10.1016/J.JPHYSPARIS.2008.03.001, 10.1002/cphy.cp010233]; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Fogassi L, 1996, NATO ADV SCI I D-BEH, V85, P99; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; Gross C.G., 1995, NEUROSCIENTIST, V1, P43, DOI [10.1177/107385849500100107, DOI 10.1177/107385849500100107]; HE SQ, 1993, J NEUROSCI, V13, P952; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; LEINONEN L, 1979, EXP BRAIN RES, V34, P299; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M, 1994, SOC NEUR ABSTR, V20; Merleau-Ponty M., 1962, PHENOMENOLOGY PERCEP; MURATA A, IN PRESS J NEUROPHYS; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X	23	472	472	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					190	191		10.1126/science.277.5323.190	http://dx.doi.org/10.1126/science.277.5323.190			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235632				2022-12-28	WOS:A1997XK41800028
J	Rudd, PM; Guile, GR; Kuster, B; Harvey, DJ; Opdenakker, G; Dwek, RA				Rudd, PM; Guile, GR; Kuster, B; Harvey, DJ; Opdenakker, G; Dwek, RA			Oligosaccharide sequencing technology	NATURE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ANIONIC OLIGOSACCHARIDES; SACCHARIDES; ELECTROPHORESIS; GELATINASE; GLYCANS; SYSTEM		CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM	KU Leuven	Rudd, PM (corresponding author), UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Harvey, David/A-5579-2013; Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Kuster, Bernhard/Q-6031-2016	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Kuster, Bernhard/0000-0002-9094-1677; Harvey, David/0000-0003-0544-771X				ALPERT AJ, 1994, J CHROMATOGR A, V676, P191, DOI 10.1016/0021-9673(94)00467-6; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; EDGE CJ, 1992, P NATL ACAD SCI USA, V89, P6388; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HASE S, 1994, METHOD ENZYMOL, V230, P225; HERMENTIN P, 1994, ANAL BIOCHEM, V221, P29, DOI 10.1006/abio.1994.1374; Iourin O, 1996, GLYCOCONJUGATE J, V13, P1031, DOI 10.1007/BF01053199; JACKSON P, 1991, ANAL BIOCHEM, V196, P238, DOI 10.1016/0003-2697(91)90460-B; Kakehi K, 1996, J CHROMATOGR A, V720, P377, DOI 10.1016/0021-9673(95)00264-2; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; LENNARZ WJ, 1994, METH ENZYM GUIDE TEC, V230, P1; LINDEN JC, 1975, J CHROMATOGR, V105, P125, DOI 10.1016/S0021-9673(01)81096-7; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Mehta A, 1997, P NATL ACAD SCI USA, V94, P1822, DOI 10.1073/pnas.94.5.1822; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; OPDENAKKER G, 1991, FEBS LETT, V284, P73, DOI 10.1016/0014-5793(91)80765-U; PALMER JK, 1975, ANAL LETT, V8, P215, DOI 10.1080/00032717508058200; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; RUDD PM, 1997, CURR OPIN BIOTECHNOL, V8; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; WING DR, 1992, GLYCOCONJUGATE J, V9, P293, DOI 10.1007/BF00731089; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472	27	123	131	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					205	207		10.1038/40677	http://dx.doi.org/10.1038/40677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217165				2022-12-28	WOS:A1997XK10900058
J	Bero, LA; Jadad, AR				Bero, LA; Jadad, AR			How consumers and policymakers can use systematic reviews for decision making	ANNALS OF INTERNAL MEDICINE			English	Article							RESEARCH-AND-DEVELOPMENT; PASSIVE SMOKING; HEART-DISEASE; CLINICAL-PRACTICE; HEALTH-CARE; NHS; PERSPECTIVES; PREGNANCY; SCIENCE; TRIALS	Systematic reviews can be a very useful decision-making tool because they objectively summarize large amounts of information, identify gaps in medical research, and identify beneficial or harmful interventions. Consumers can use systematic reviews to help them make health care decisions. Policymakers can use systematic reviews to help them make decisions about what types of health care to provide. Despite the potential value of systematic reviews, little evidence of their direct impact on the decisions made by consumers and policymakers is available. We discuss strategies for optimizing the use of systematic reviews by increasing the awareness and identification of reviews, learning to critically evaluate the findings of reviews, and overcoming barriers to the incorporation of reviews into the decision-making process. In addition, the participation of consumers and policymakers in the design, conduct, and reporting of systematic reviews can help to produce reviews that are relevant and understandable to target audiences. Because decisions that involve health care policies and issues are complex processes in which information (such as that provided by systematic reviews) plays only a part, strategies for increasing the use of systematic reviews should be evaluated for their usefulness in the decisionmaking process.	MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HLTH INFORMAT RES UNIT, HAMILTON, ON L8N 3Z5, CANADA	McMaster University	Bero, LA (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							BARNES D, 1996, QUALITY REV ARTICLES; BASTIAN H, 1994, J CONSUMER HLTH FORU, V32, P15; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; BERO L, 1996, REPORT EURASSESS SUB; BUCHER HC, 1993, BMJ-BRIT MED J, V307, P13, DOI 10.1136/bmj.307.6895.13; CAPLAN N, 1980, NEW DIRECTIONS PROGR; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; *COCHR COLL, 1996, COCHR LIB DAT DISK C; COCHRAN W. G., 1937, J. Roy. Statist. Soc. 1937., (Suppl.), V4, P102; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; DIAMOND GA, 1993, ANN INTERN MED, V118, P455, DOI 10.7326/0003-4819-118-6-199303150-00010; DIXON AS, 1990, MED CARE, V28, P201, DOI 10.1097/00005650-199003000-00002; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; FREEMANTLE N, 1995, SOC SCI MED, V40, P1365, DOI 10.1016/0277-9536(94)00272-U; GILES W, 1993, FETAL DIAGN THER, V8, P247, DOI 10.1159/000263835; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GOEL V, 1994, DISSEMINATING RES CH, V6, P166; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; HADORN D, 1994, JOINT COMM J QUAL IM, V20, P547, DOI 10.1016/S1070-3241(16)30100-6; Haynes R B, 1996, ACP J Club, V125, pA14; Jadad AR, 1996, LANCET, V347, P274, DOI 10.1016/S0140-6736(96)90456-0; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; JADAD AR, 1996, SUPPORT CARE CANCER, V3, P245; JONES R, 1995, BRIT MED J, V311, P1076, DOI 10.1136/bmj.311.7012.1076; KENNEDY G, 1996, EXTEND ACCURACY NEWS; Light R.J., 1984, SUMMING SCI REV RES; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; NEILSON J, 1996, PREGNANCY CHILDBIRTH, V2; NHS Executive, 1996, PROM CLIN EFF FRAM A; NISBETT R, 1980, HUMAN INFERENCE STRA, P273; Oliver S, 1996, BMJ-BRIT MED J, V313, P1251, DOI 10.1136/bmj.313.7067.1251a; OLIVER SR, 1995, BRIT MED J, V310, P1318, DOI 10.1136/bmj.310.6990.1318; PEARSON V, 1994, 26 U BRIS HLTH CAR E; Phillips KA, 1996, INT J QUAL HEALTH C, V8, P21, DOI 10.1093/intqhc/8.1.21; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; Rogers EM., 1983, DIFFUSION INNOVATION; SACKS HS, 1992, MED USES STATISTICS, P427; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; Scott Robert A., 1979, WHY SOCIOLOGY DOES N; SISK JE, 1993, MILBANK Q, V71, P477, DOI 10.2307/3350411; SOLARI ME, 1966, CLIN TRIALS J, V3, P537; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; SULLUM J, 1995, NATL REV, V47, P48; Weiss C.H., 1983, ETHICS SOCIAL SCI PO, P213; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; Yates F, 1938, J AGR SCI, V28, P556, DOI 10.1017/S0021859600050978	51	120	124	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1997	127	1					37	42		10.7326/0003-4819-127-1-199707010-00007	http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG914	9214251				2022-12-28	WOS:A1997XG91400006
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Units of analysis	BRITISH MEDICAL JOURNAL			English	Article							CALCULATING CORRELATION-COEFFICIENTS		ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	Altman, DG (corresponding author), INST HLTH SCI,CTR STAT MED,IMPERIAL CANC RES FUND,MED STAT GRP,OXFORD,ENGLAND.							Andersen B, 1990, METHODOLOGICAL ERROR; Bland J.M., 1996, BMJ-BRIT MED J, V312, p572a; BLAND JM, 1994, BRIT MED J, V308, P896, DOI 10.1136/bmj.308.6933.896; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BLAND JM, 1995, BRIT MED J, V310, P633, DOI 10.1136/bmj.310.6980.633; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230	8	168	168	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1874	1874		10.1136/bmj.314.7098.1874	http://dx.doi.org/10.1136/bmj.314.7098.1874			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224131	Bronze, Green Published			2022-12-28	WOS:A1997XH73800027
J	Wyatt, JC				Wyatt, JC			Measuring quality and impact of the world wide web - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							RECOMMENDATIONS				Wyatt, JC (corresponding author), INST HLTH SCI,IMPERIAL CANC RES FUND,CTR STAT MED,POB 777,OXFORD OX3 7LF,ENGLAND.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BOWER H, 1996, BRIT MED J, V13, P381; Friedman C.P., 1997, EVALUATION METHODS M, P41; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JONES RG, 1992, LANCET, V339, P248, DOI 10.1016/0140-6736(92)90053-6; OPPENHEIM AN, 1991, QUESTIONNAIRE DESIGN; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; SACKETT DL, 1986, ARCH INTERN MED, V146, P464; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; TUFTE ER, 1997, VISUAL EXPLORATIONS; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; Wyatt JC, 1996, BRIT MED J, V313, P1380, DOI 10.1136/bmj.313.7069.1380	13	193	196	1	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1879	1881		10.1136/bmj.314.7098.1879	http://dx.doi.org/10.1136/bmj.314.7098.1879			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224133	Green Published			2022-12-28	WOS:A1997XH73800029
J	Schonhofer, PS; Werner, B; Troger, U				Schonhofer, PS; Werner, B; Troger, U			Ocular damage associated with proton pump inhibitors	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP, INST CLIN PHARMACOL, D-39120 MAGDEBURG, GERMANY; Otto von Guericke Universitat, Inst Clin Pharmacol, D-39120 Magdeburg, GERMANY	University Hospital Magdeburg; Otto von Guericke University	Schonhofer, PS (corresponding author), INST CLIN PHARMACOL, D-28205 BREMEN, GERMANY.	uwe.troeger@medizin.uni-magdeburg.de						Aalkjaer C, 1988, Prog Biochem Pharmacol, V23, P150; ASSOUAD M, 1994, LANCET, V344, P549, DOI 10.1016/S0140-6736(94)91945-3; MCCABE RD, 1992, AM J PHYSIOL, V262, pH1955, DOI 10.1152/ajpheart.1992.262.6.H1955; RODRIGUEZ LAG, 1995, LANCET, V345, P1059, DOI 10.1016/S0140-6736(95)90805-6; 1995, ARZNEI TELEGRAMM, V7, P79	5	25	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	1997	314	7097					1805	1805		10.1136/bmj.314.7097.1805	http://dx.doi.org/10.1136/bmj.314.7097.1805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224084	Green Published			2022-12-28	WOS:A1997XG16600025
J	Lovestone, S; Graham, N; Howard, R				Lovestone, S; Graham, N; Howard, R			Guidelines on drug treatments for Alzheimer's disease	LANCET			English	Editorial Material									ROYAL FREE HOSP,DEPT OLD AGE PSYCHIAT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lovestone, S (corresponding author), INST PSYCHIAT,OLD AGE PSYCHIAT SECT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Lovestone, Simon/E-8725-2010	Lovestone, Simon/0000-0003-0473-4565; Howard, Robert/0000-0002-3071-2338; Livingston, Gill/0000-0001-6741-5516				FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kelly CA, 1997, BRIT MED J, V314, P693, DOI 10.1136/bmj.314.7082.693; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939	3	59	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					232	233		10.1016/S0140-6736(05)62221-0	http://dx.doi.org/10.1016/S0140-6736(05)62221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242796				2022-12-28	WOS:A1997XM86600005
J	Syme, SL; Balfour, JL				Syme, SL; Balfour, JL			Explaining inequalities in coronary heart disease	LANCET			English	Editorial Material											Syme, SL (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT EPIDEMIOL,BERKELEY,CA 94720, USA.							ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; BERRUETACLEMENT J, 1984, CHANGED LIVES EFFECT; BOSMAH, 1997, BRIT MED J, V314, P558; HAAN MN, 1989, PATHWAYS HLTH; Karasek R., 1990, HLTH WORK STRESS PRO; Syme S.L., 1989, STRESS PERSONAL CONT	6	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					231	232		10.1016/S0140-6736(05)62220-9	http://dx.doi.org/10.1016/S0140-6736(05)62220-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242795				2022-12-28	WOS:A1997XM86600004
J	Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M				Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M			Identification and characterization of an I kappa B kinase	CELL			English	Article							TUMOR-NECROSIS-FACTOR; DEATH DOMAIN; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; FACTOR-ALPHA; ACTIVATION; PROTEIN; INTERACTS; FAMILY; CD40	Activation of the transcription factor NF-kappa B by tumor necrosis factor (TNF) and interleukin-1 (IL-1) requires the NF-kappa B-inducing kinase (NIK). In a yeast two-hybrid screen for NIK-interacting proteins, we have identified a protein kinase previously known as CHUK. Overexpression of CHUK activates a NF-kappa B-dependent reporter gene. A catalytically inactive mutant of CHUK is a dominant-negative inhibitor of TNF-, IL-1-, TRAF-, and NIK-induced NF-kappa B activation. CHUK associates with the NF-kappa B inhibitory protein, I kappa B-alpha, in mammalian cells. CHUK specifically phosphorylates I kappa B-alpha on both serine 32 and serine 36, modifications that are required for targeted degradation of I kappa B-alpha via the ubiquitin-proteasome pathway. This phosphorylation of I kappa B-alpha is greatly enhanced by NIK costimulation. Thus, CHUK is a NIK-activated I kappa B-alpha kinase that links TNF- and IL-1-induced kinase cascades to NF-kappa B activation.	TULARIK INC, San Francisco, CA 94080 USA					Regnier, Catherine/0000-0002-4386-1324				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHOI KY, 1994, CELL, V78, P499; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Orth R, 1997, J BIOL CHEM, V272, P8841; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1997, IN PRESS P NATL ACAD; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	56	1071	1123	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					373	383		10.1016/S0092-8674(00)80344-X	http://dx.doi.org/10.1016/S0092-8674(00)80344-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244310	Bronze			2022-12-28	WOS:A1997XN24900020
J	Medzhitov, R; PrestonHurlburt, P; Janeway, CA				Medzhitov, R; PrestonHurlburt, P; Janeway, CA			A human homologue of the Drosophila Toll protein signals activation of adaptive immunity	NATURE			English	Article							IL-1 RECEPTOR; LEUCINE; DORSAL; EMBRYO; IMMUNOLOGY	Induction of the adaptive immune response depends on the expression of co-stimulatory molecules and cytokines by antigen-presenting cells. The mechanisms that control the initial induction of these signals upon infection are poorly understood. It has been proposed that their expression is controlled by the non-clonal, or innate, component of immunity that preceded in evolution the development of an adaptive immune system in vertebrates(1). We report here the cloning and characterization of a human homologue of the Drosophila toll protein (Toll) which has been shown to induce the innate immune response in adult Drosophila(2-4). Like Drosophila Toll, human Toll is a type I transmembrane protein with an extracellular domain consisting of a leucine-rich repeat (LRR) domain, and a cytoplasmic domain homologous to the cytoplasmic domain of the human interleukin (IL)-1 receptor. Both Drosophila Toll and the IL-1 receptor are known to signal through the NF-kappa B pathway(5-7). We show that a constitutively active mutant of human Toll transfected into human cell lines can induce the activation of NF-kappa B and the expression of NF-kappa B-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8, as well as the expression of the co-stimulatory molecule B7.1, which is required for the activation of naive T cells.	HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University								ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; INNIS MA, 1992, PCR PROTOCOLS GUIDE; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Medzhitov R, 1996, RES IMMUNOL, V147, P208, DOI 10.1016/0923-2494(96)87222-1; MIYAKE K, 1995, J IMMUNOL, V154, P3333; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	21	3912	4386	11	345	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					394	397		10.1038/41131	http://dx.doi.org/10.1038/41131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237759	Bronze			2022-12-28	WOS:A1997XM52800055
J	Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH				Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH			Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians	LANCET			English	Article							FORMULA-FED INFANTS; 1ST YEAR; BREAST; MILK; LIFE	Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance status was obtained from a 75 g oral glucose-tolerance test. A standard questionnaire given to mothers was used to classify infant-feeding practices for the first 2 months of life into three groups; exclusively breastfed, some breastfeeding, or exclusively bottlefed. The association between the three infant-feeding groups and NIDDM was analysed by multiple logistic regression. Findings Data were available for 720 Pima Indians aged between 10 and 39 years. 325 people who were Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance exclusively bottlefed had significantly higher age-adjusted and sex-adjusted mean relative weights (146%) than 144 people who were exclusively breastfed (140%) or 251 people who had some breastfeeding (139%) (p=0.019), People who were exclusively breastfed had significantly lower rates of NIDDM than those who were exclusively bottlefed in ail age-groups (age 10-19, 0 of 56 vs 6 [3.6%] of 165; age 20-29, 5 [8.6%] of 58 vs 17 [14.7%] of 116]; age 30-39, 6 [20.0%] of 30 vs 13 [29.6%] of 44). The odds ratio for NIDDM in exclusively breastfed people, compared with those exclusively bottlefed, was 0.41 (95% CI 0.18-0.93) adjusted for age, sex, birthdate, parental diabetes, and birthweight. Interpretation Exclusive breastfeeding for the first 2 months of life is associated with a significantly lower rate of NIDDM in Pima Indians. The increase in prevalence of diabetes in some populations may be due to the concomitant decrease in breastfeeding.	NIDDK,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ 85014; NATL CANC INST,CANC PREVENT STUDIES BRANCH,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pettitt, DJ (corresponding author), NIDDK,DIABET & ARTHRIT EPIDEMIOL SECT,PHOENIX,AZ 85014, USA.		Bennett, Peter/AAH-9605-2021; Hanson, Robert L/O-3238-2015	Hanson, Robert L/0000-0002-4252-7068				AYNSLEYGREEN A, 1989, BAILLIERE CLIN ENDOC, V3, P837, DOI 10.1016/S0950-351X(89)80056-4; BENNETT PH, 1971, LANCET, V2, P125; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; BROOK CGD, 1972, LANCET, V2, P624; Cavallo MG, 1996, LANCET, V348, P926, DOI 10.1016/S0140-6736(95)12065-3; DEWEY KG, 1992, PEDIATRICS, V89, P1035; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; EVANS HE, 1979, PEDIATR ANN, V8, P110; FORMAN MR, 1984, AM J EPIDEMIOL, V119, P335, DOI 10.1093/oxfordjournals.aje.a113752; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; FORMAN MR, 1982, AM J CLIN NUTR, V35, P1477, DOI 10.1093/ajcn/35.6.1477; Frederick I B, 1984, Obstet Gynecol Annu, V13, P131; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GrummerStrawn LM, 1996, INT J EPIDEMIOL, V25, P94, DOI 10.1093/ije/25.1.94; HALL B, 1975, LANCET, V1, P779; HAMOSH M, 1988, J PEDIATR GASTR NUTR, V7, P10, DOI 10.1097/00005176-198801000-00004; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFFE DB, 1966, ASSESSMENT NUTRITION; KARGES W, 1995, MOL MECH MOL ASPECTS, P79; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KNOWLER WC, 1979, DIABETOLOGIA, V17, P161, DOI 10.1007/BF01219743; KOVAR MG, 1984, PEDIATRICS, V74, P615; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1979, LANCET, V2, P57; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; *NAT RES COUNC, 1964, NAT AC SCI PUBL, V1146, P4; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; SALMENPERA L, 1988, J PEDIATR GASTR NUTR, V7, P651, DOI 10.1097/00005176-198809000-00005; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; Thorogood M, 1979, J R Coll Gen Pract, V29, P427; *WHO STUD GROUP PR, 1994, WHO TECHN REP SER, V844; Wright P, 1981, Health Bull (Edinb), V39, P197	34	191	195	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					166	168		10.1016/S0140-6736(96)12103-6	http://dx.doi.org/10.1016/S0140-6736(96)12103-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250183				2022-12-28	WOS:A1997XL72200010
J	Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A				Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A			Epidemics of syphilis in the Russian Federation: Trends, origins, and priorities for control	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; INFECTION	After continuous decline throughout the 1980s, surveillance-defined estimates of the incidence of syphilis in Russia have shown a rapid and substantial increase during the 1990s. The reasons for this epidemic are unclear, but must be sought among changes both in sexual behaviour and in the patterns of provision, use, and effectiveness of diagnostic, treatment, and contact tracing services. High incidence of sexually transmitted disease causes correspondingly high levels of morbidity and suffering as well as significant health-care and other economic costs. Our current understanding suggests that the transmissibility of HIV is increased by infection with sexually transmitted disease. The syphilis epidemic together with changes in sexual behaviour, increased travel and migration, and rapid increases in injecting drug use may create the conditions for an epidemic of sexually acquired HIV infection in Russia that substantially outstrips those encountered in most Western European countries.	MINIST HLTH RUSSIAN FEDERAT,MOSCOW,RUSSIA; RUSSIAN ASSOC AGAINST STD,SANAM,MOSCOW,RUSSIA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT EPIDEMIOL & COMMUNITY HLTH,LONDON,ENGLAND; UNIV INSTELLING ANTWERP,DEPT EPIDEMIOL & COMMUNITY HLTH,ANTWERP,BELGIUM; WHO,REG OFF EUROPE,DK-2100 COPENHAGEN,DENMARK	Ministry of Health of the Russian Federation; Imperial College London; University of Antwerp; World Health Organization			Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036				AKOVBIAN BA, 1995, SEX TRANSM DIS, V4, P15; *EC INT UN, 1995, COUNTR REP; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GASPARD M, 1993, NATO EC C EC DEV COO; GIMPELSON V, 1993, NATO EC C EC DEV COO; GROMYKO A, 1996, WHO M EP SEX TRANSM; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; Hethcote H., 1984, LECT NOTES BIOMATH, V56, P18; INGRAM M, 1995, BRIT MED J, V311, P528, DOI 10.1136/bmj.311.7004.528b; KREISS J, 1988, GENITOURIN MED, V64, P1; LINGLOF T, 1995, SEX TRANSM DIS, V22, P160, DOI 10.1097/00007435-199505000-00005; *MIN HLTH RUSS FED, 1993, 286 MIN HLTH RUSS FE; *MIN HLTH RUSS FED, 1993, TREATM PREV SYPH REC; *MIN HLTH USSR, 1986, 1570 MIN HLTH USSR; *MIN HLTH USSR, 1985, 1161 MIN HLTH USSR; *NAT AIDS PREV CON, 1994, RUSS FED ASS NAT PRO; PLUMMER FA, 1991, AIDS, V5, pS169; RENTON AM, 1994, SOC SCI MED, V38, P1153, DOI 10.1016/0277-9536(94)90230-5; TICHONOVA L, 1995, ANN M ALL RUSS ASS V; TICHONOVA LI, 1995, SEX TRANSM DIS, V4, P15	21	147	153	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					210	213		10.1016/S0140-6736(97)01382-2	http://dx.doi.org/10.1016/S0140-6736(97)01382-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250199				2022-12-28	WOS:A1997XL72200046
J	Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC				Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC			Inhibition of Bax channel-forming activity by Bcl-2	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; PROTEIN	Proteins of the Bcl-2 family are intracellular membrane-associated proteins that regulate programmed cell death (apoptosis) either positively or negatively by as yet unknown mechanisms. Bax, a pro-apoptotic member of the Bcl-2 family, was shown to form channels in lipid membranes. Bax triggered the release of liposome-encapsulated carboxyfluorescein at both neutral and acidic pH. AS physiological pH, release could be blocked by Bcl-2, Bcl-2, in contrast, triggered carboxyfluorescein release at acidic pH only. In planar lipid bilayers, Bax formed pH- and voltage-dependent ion-conducting channels. Thus, the pro-apoptotic effects of Bax may be elicited through an intrinsic pore-forming activity that can be antagonized by Bcl-2.	IST CIBERNET & BIOFIS, I-16149 GENOA, ITALY		Antonsson, B (corresponding author), GLAXO WELLCOME RES & DEV SA, GENEVA BIOMED RES INST, CH-1288 GENEVA, SWITZERLAND.			martinou, Jean-claude/0000-0002-9847-2051; SADOUL, Remy/0000-0002-4763-0320				BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Conti F., UNPUB; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HALDAR S, 1994, ARCH BIOCHEM BIOPHYS, V315, P483, DOI 10.1006/abbi.1994.1529; HENNET T, 1993, CANCER RES, V53, P1456; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Montal M, 1974, Methods Enzymol, V32, P545; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113	16	901	927	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					370	372		10.1126/science.277.5324.370	http://dx.doi.org/10.1126/science.277.5324.370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219694				2022-12-28	WOS:A1997XL35800046
J	Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE				Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE			The ionosphere of Europa from Galileo radio occultations	SCIENCE			English	Article							ATMOSPHERE; JUPITER	The Galileo spacecraft performed six radio occultation observations of Jupiter's Galilean satellite Europa during its tour of the jovian system, In five of the six instances, these occultations revealed the presence of a tenuous ionosphere on Europa, with an average maximum electron density of nearly 10(4) per cubic centimeter near the surface and a plasma scale height of about 240 +/- 40 kilometers from the surface to 300 kilometers and of 440 +/- 60 kilometers above 300 kilometers. Such an ionosphere could be produced by solar photoionization and jovian magnetospheric particle impact in an atmosphere having a surface density of about 10(8) electrons per cubic centimeter. If this atmosphere is composed primarily of O-2, then the principal ion is O-2(+) and the neutral atmosphere temperature implied by the 240-kilometer scale height is about 600 kelvin. If it is composed of H2O, the principal ion is H3O+ and the neutral temperature is about 340 kelvin. In either case, these temperatures are much higher than those observed on Europa's surface, and an external heating source from the jovian magnetosphere is required.	STANFORD UNIV,CTR RADAR ASTRON,STANFORD,CA 94305; NASA,GODDARD SPACE FLIGHT CTR,EXTRATERR PHYS LAB,GREENBELT,MD 20771; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045	Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; University of Kansas	Kliore, AJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Flasar, F Michael/C-8509-2012	Hinson, David/0000-0002-1620-4011				BARTH CA, COMMUNICATION; BARTH CA, IN PRESS GEOPHYS RES; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; FJELDBO G, 1971, ASTRON J, V76, P123, DOI 10.1086/111096; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOWARD HT, 1992, SPACE SCI REV, V60, P565, DOI 10.1007/BF00216868; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; KLIORE A, 1974, SCIENCE, V183, P323, DOI 10.1126/science.183.4122.323; KLIORE AJ, 1972, X62150 NASA TM AM RE; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; SCHREIER R, 1993, J GEOPHYS RES-SPACE, V98, P21231, DOI 10.1029/93JA02585; TORR MR, 1985, J GEOPHYS RES-SPACE, V90, P6675, DOI 10.1029/JA090iA07p06675; WU FM, 1978, ASTROPHYS J, V325, P325; [No title captured]	16	95	95	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					355	358		10.1126/science.277.5324.355	http://dx.doi.org/10.1126/science.277.5324.355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219689				2022-12-28	WOS:A1997XL35800041
J	Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A				Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A			The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants	SCIENCE			English	Article							C-TERMINAL DOMAIN; TYPE-1 NF1 GENE; NEUROFIBROMATOSIS TYPE-1; TRIPHOSPHATE CONFORMATION; 3-DIMENSIONAL STRUCTURES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; BINDING DOMAIN; PROTEIN GAP; MECHANISM	The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120(GAP) (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms, The structure shows the partly hydrophilic and partly hydrophobic nature of the communication between the two molecules, which explains the sensitivity of the interaction toward both sails and lipids, An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Pas to neutralize developing charges in the transition state, The switch II region of Pas is stabilized by GAP-334, thus allowing glutamine-61 of Pas, mutation of which activates the oncogenic potential, to participate in catalysis, The structural arrangement in the active site is consistent with a mostly associative mechanism of phosphoryl transfer and provides an explanation for the activation of Pas by glycine-12 and glutamine-61 mutations, Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Pas, and even its mutation to alanine would disturb the arrangements of residues in the transition state.	MAX PLANCK INST MOL PHYSIOL, ABT STRUKT BIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; AHMADIAN MR, IN PRESS NATURE STRU; AHMADIAN MR, UNPUB; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRUNGER AT, 1996, X PLOR VERSION 3 8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Morcos P, 1996, MOL CELL BIOL, V16, P2496; MORI S, 1995, J BIOL CHEM, V270, P28834, DOI 10.1074/jbc.270.48.28834; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHEFFZEK K, UNPUB; SCHLICTING I, IN PRESS BIOCHEMISTR; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; 1997, PROTEIN-STRUCT FUNCT, V27, P315	77	1161	1206	2	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	1997	277	5324					333	338		10.1126/science.277.5324.333	http://dx.doi.org/10.1126/science.277.5324.333			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219684				2022-12-28	WOS:A1997XL35800036
J	Holleman, F; Hoekstra, JBL				Holleman, F; Hoekstra, JBL			Drug therapy - Insulin lispro	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SOLUBLE HUMAN INSULIN; DEPENDENT DIABETES-MELLITUS; GROWTH-FACTOR-I; RECEPTOR-BINDING; HYPOGLYCEMIA UNAWARENESS; PRO(B29)>-HUMAN INSULIN; SUBCUTANEOUS INJECTION; IDDM PATIENTS; ANALOG; PHARMACOKINETICS				Holleman, F (corresponding author), DIAKONESSEN HOSP,DEPT INTERNAL MED,BOSBOOMSTR 1,NL-3582 KE UTRECHT,NETHERLANDS.			Holleman, Frits/0000-0001-5858-5089				ANDERSON J, 1994, DIABETES, V43, pA61; Anderson JH, 1997, DIABETES, V46, P265, DOI 10.2337/diabetes.46.2.265; ANDERSON JH, 1994, DIABETOLOGIA, V37, pA169; ANTSIFEROV M, 1995, DIABETOLOGIA, V38, pA190; BASTYR EJ, 1996, DIABETES S2, V45, pA56; BERGER M, 1982, DIABETES CARE, V5, P77, DOI 10.2337/diacare.5.2.77; BINDER C, 1984, DIABETES CARE, V7, P188, DOI 10.2337/diacare.7.2.188; BINDER C, 1983, ARTIFICIAL SYSTEMS I, V6, P53; BORNFELDT KE, 1991, DIABETOLOGIA, V34, P307, DOI 10.1007/BF00405001; BRAIMON J, 1996, DIABETES S2, V45, pA185; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BREMS DN, 1992, PROTEIN ENG, V5, P527, DOI 10.1093/protein/5.6.527; BRUNELLE RL, 1995, DIABETOLOGIA S1, V38, pA33; BUELKESAM J, 1994, J AM COLL TOXICOL, V13, P247, DOI 10.3109/10915819409140597; COATES PA, 1995, DIABETES, V44, pA130; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DeFelippis M.R., 1996, DIABETES S2, V45, p74A; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DESMET M, 1994, DIABETES, V43, pA167; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; DIMARCHI RD, 1994, HORM RES, V41, P93, DOI 10.1159/000183967; DIMITRIADIS GD, 1983, DIABETES CARE, V6, P374, DOI 10.2337/diacare.6.4.374; DREJER K, 1992, DIABETES METAB REV, V8, P259, DOI 10.1002/dmr.5610080305; Fineberg NS, 1996, DIABETES, V45, P1750, DOI 10.2337/diabetes.45.12.1750; FINEBERG SE, 1995, DIABETOLOGIA, V38, pA4; FRANK BH, 1991, DIABETES S1, V40, pA423; Garg SK, 1996, DIABETIC MED, V13, P47, DOI 10.1002/(SICI)1096-9136(199601)13:1<47::AID-DIA999>3.0.CO;2-M; GERICH JE, 1992, BRIT MED J, V305, P324, DOI 10.1136/bmj.305.6849.324; Heinemann L, 1996, DIABETIC MED, V13, P625, DOI 10.1002/(SICI)1096-9136(199607)13:7<625::AID-DIA134>3.3.CO;2-U; Helton DR, 1996, ARZNEIMITTELFORSCH, V46, P91; Henrichs HR, 1996, LANCET, V348, P1248, DOI 10.1016/S0140-6736(05)65529-8; Holleman F, 1996, DIABETES CARE, V19, P1426, DOI 10.2337/diacare.19.12.1426; HOME PD, 1981, METABOLISM, V30, P439, DOI 10.1016/0026-0495(81)90177-3; HOWEY DC, 1995, CLIN PHARMACOL THER, V58, P459, DOI 10.1016/0009-9236(95)90060-8; HOWEY DC, 1994, DIABETES, V43, P396, DOI 10.2337/diabetes.43.3.396; JACOBS MAJ, 1994, HORM METAB RES S, V26, pA34; JORGENSEN L N, 1990, Diabetologia, V33, pA116; JORGENSEN LN, 1992, DIABETOLOGIA, V35, pA3; KANG S, 1991, DIABETES CARE, V14, P571, DOI 10.2337/diacare.14.7.571; KANG S, 1991, DIABETES CARE, V14, P942, DOI 10.2337/diacare.14.11.942; Karsidag K., 1996, Diabetologia, V39, pA222; Lahtela JT, 1997, DIABETES CARE, V20, P71, DOI 10.2337/diacare.20.1.71; LEAN MEJ, 1985, BRIT MED J, V290, P105, DOI 10.1136/bmj.290.6462.105; LONG HB, 1992, PEPTIDES CHEM BIOL, P88; LOUGHEED WD, 1996, DIABETES S1, V45, pA198; MARAN A, 1993, BMJ-BRIT MED J, V306, P167, DOI 10.1136/bmj.306.6871.167; Markussen J, 1996, DIABETOLOGIA, V39, P281; MARTIN JM, 1994, DIABETIC MED, V11, pS35; MYERS S, 1995, DIABETOLOGIA, V38, pA4; NIELSEN FS, 1995, DIABETOLOGIA, V38, P592, DOI 10.1007/BF00400729; PAMPANELLI S, 1995, DIABETES CARE, V18, P1452, DOI 10.2337/diacare.18.11.1452; Pein M., 1996, Diabetologia, V39, pA223; Pfutzner A, 1996, EXP CLIN ENDOCR DIAB, V104, P25; PFUTZNER A, 1996, DIABETOLOGIA S1, V39, pA222; PIEBER TR, 1995, DIABETOLOGIA, V38, pA3; POYRY K, 1995, DIABETES, V44, pA106; RADZIUK J, 1992, DIABETOLOGIA, V35, pA3; Radziuk J., 1996, DIABETES S2, V45, p218A; Radziuk J. R., 1996, Diabetologia, V39, pA224; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; Roach P, 1996, DIABETES S2, V45, p261A; ROWE R, 1996, DIABETES S2, V45, pA71; Schmitt H., 1996, Diabetologia, V39, pA221; SHAW WN, 1991, DIABETES S1, V40, pA464; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SLIEKER LJ, 1991, DIABETES S1, V40, pA168; SLIEKER LJ, 1994, ADV EXPT MED BIOL, V343, P25; terBraak EW, 1996, DIABETES CARE, V19, P1437, DOI 10.2337/diacare.19.12.1437; TORLONE E, 1994, DIABETOLOGIA, V37, P713, DOI 10.1007/s001250050169; Torlone E, 1996, DIABETES CARE, V19, P945, DOI 10.2337/diacare.19.9.945; TORRI M, 1995, DIABETES, V44, pA130; Tsui E., 1996, Diabetologia, V39, pA223; TUOMINEN JA, 1995, DIABETOLOGIA, V38, P106, DOI 10.1007/BF02369359; VENEMAN TF, 1994, EUR J CLIN INVEST, V24, P785, DOI 10.1111/j.1365-2362.1994.tb02020.x; VIGNATI L, 1995, DIABETOLOGIA, V38, pA191; VIGNATI L, 1994, DIABETOLOGIA, V37, pA78; VOLUND A, 1991, DIABETIC MED, V8, P839, DOI 10.1111/j.1464-5491.1991.tb02122.x; VORA JP, 1988, BRIT MED J, V297, P1236, DOI 10.1136/bmj.297.6658.1236; WOODWORTH J, 1993, DIABETES, V42, pA54; ZIMMERMANN J, 1994, DIABETES, V43, pA166; ZINMAN B, 1993, DIABETES CARE, V16, P24, DOI 10.2337/diacare.16.3.24; Zinman B, 1997, DIABETES, V46, P440, DOI 10.2337/diabetes.46.3.440; ZWICKL CM, 1995, ARZNEIMITTEL-FORSCH, V45-1, P524	83	161	169	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					176	183		10.1056/NEJM199707173370307	http://dx.doi.org/10.1056/NEJM199707173370307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219705				2022-12-28	WOS:A1997XK81800007
J	Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV				Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV			A high deuterium abundance at redshift z=0.7	NATURE			English	Article							NUCLEOSYNTHESIS	Of the light elements, the primordial abundance of deuterium relative to hydrogen, (D/H)(p), provides the most sensitive diagnostic(1) for the cosmological mass density parameter, Omega(B). Recent high-redshift D/H measurements are highly discrepant(2-6), although this may reflect observational uncertainties(7,8). The larger primordial D/H values imply a low Omega(B) (requiring the Universe to be. dominated by non-baryonic matter), and cause problems for galactic chemical evolution models, which have difficulty in reproducing the steep decline in D/H to the present-day values, Conversely, the lower D/H values measured at high redshift imply an Omega(B) greater than that derived from Li-7 and He-4 abundance measurements, and may require a deuterium-abundance evolution that is too low to easily explain. Here we report the first measurement of D/H at intermediate redshift (z = 0.7010), in a gas cloud selected to minimize observational uncertainties, Our analysis yields a value of D/H ((2.0 +/- 0.5) x 10(-4)) which is at the upper end of the range of values measured at high redshifts. This finding, together with other independent observations, suggests that there may be inhomogeneity in (D/H)(p) of at least a factor of ten.	SUNY STONY BROOK,DEPT PHYS & ASTRON,STONY BROOK,NY 11794; UNIV SUSSEX,CTR ASTRON,BRIGHTON BN1 9QH,E SUSSEX,ENGLAND; INST ASTRON,CAMBRIDGE CB3 0HA,ENGLAND; INST ASTROPHYS,F-75014 PARIS,FRANCE; UNIV CHICAGO,ENRICO FERMI INST,DEPT ASTRON & ASTROPHYS,CHICAGO,IL 60637; ROYAL OBSERV,EDINBURGH EH9 3HJ,MIDLOTHIAN,SCOTLAND; UNIV NEW S WALES,SCH PHYS,SYDNEY,NSW 2052,AUSTRALIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Sussex; University of Cambridge; UDICE-French Research Universities; Sorbonne Universite; University of Chicago; University of Edinburgh; University of New South Wales Sydney			Lemoine, Martin/AAE-6416-2019; Webb, John/J-9122-2018	Lemoine, Martin/0000-0002-2395-7812; Webb, John/0000-0002-0004-9360				BURLES S, UNPUB SCIENCE; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; Copi C.J., ASTROPH9606156; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; Hata N, 1997, PHYS REV D, V55, P540, DOI 10.1103/PhysRevD.55.540; HOGAN CJ, ASTROPH9609138; JEDAMZIK K, 1995, ASTROPHYS J, V452, P33, DOI 10.1086/176278; JEDAMZIK K, ASTROPH9609103; LANZETTA KM, 1993, ASTROPHYS J SUPPL S, V84, P109, DOI 10.1086/191749; Pagel B.E.J., 1997, NUCLEOSYNTHESIS CHEM; Rugers M, 1996, ASTRON J, V111, P2135, DOI 10.1086/117949; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; Schramm DN, 1996, NATURE, V381, P193, DOI 10.1038/381193a0; Songaila A, 1997, NATURE, V385, P137, DOI 10.1038/385137a0; Tytler D, 1996, NATURE, V381, P207, DOI 10.1038/381207a0; TYTLER D, ASTROPH9612121; VANGIONIFLAM E, 1995, ASTROPHYS J, V441, P471, DOI 10.1086/175373; VIDALMADJAR A, ASTROPH9612020; Wampler EJ, 1996, NATURE, V383, P308, DOI 10.1038/383308a0; WEBB JK, 1991, MON NOT R ASTRON SOC, V250, P657, DOI 10.1093/mnras/250.4.657; WEBB JK, 1987, THESIS CAMBRIDGE U; White M, 1996, MON NOT R ASTRON SOC, V283, P107, DOI 10.1093/mnras/283.1.107; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0	24	141	141	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					250	252		10.1038/40814	http://dx.doi.org/10.1038/40814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230433				2022-12-28	WOS:A1997XL12100042
J	Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF				Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF			Emergency department use of aspirin in patients with possible acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							UNSTABLE ANGINA; TRIAL	Background: Efforts have been made to improve the suboptimal use of aspirin af Objective: To assess the frequency and timing of aspirin administration in emergency department patients with possible myocardial infarction. Design: Retrospective record review. Setting: Emergency departments of four hospitals affiliated with the same university. Patients: All patients who were admitted to the four hospitals in 1994 for evaluation and treatment of suspected acute myocardial infarction. Measurements: The frequency and timing of aspirin administration and the definitive diagnosis established before discharge from the hospital. Results: Aspirin was not given to 253 of 463 emergency department patients (55%) who had a definitive diagnosis of acute myocardial infarction. Seventy-eight pet-cent of patients who did receive aspirin received it more than 30 minutes after arrival in the emergency department. Conclusion: Aspirin therapy is underutilized as the first intervention in patients who are admitted with suspected myocardial infarction.	MIRIAM HOSP, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02906 USA; MEM HOSP, DEPT MED, DIV CARDIOL, PAWTUCKET, RI 02860 USA; VET AFFAIRS MED CTR, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02908 USA; ROGER WILLIAMS CANC MED CTR, PROVIDENCE, RI USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Lifespan Health Rhode Island; Miriam Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Roger Williams Medical Center; Brown University			Tilkemeier, Peter/AAW-4936-2020; Garber, Carol/ABD-4375-2021	Garber, Carol/0000-0002-1268-576X				[Anonymous], 1988, LANCET, V2, P349; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Gunnar R M, 1990, Circulation, V82, P664; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	13	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					126	129		10.7326/0003-4819-127-2-199707150-00005	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230001				2022-12-28	WOS:A1997XK15800007
J	Halligan, PW; Marshall, JC				Halligan, PW; Marshall, JC			The art of visual neglect	LANCET			English	Editorial Material							VISUOSPATIAL NEGLECT				Halligan, PW (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,NEUROPSYCHOL UNIT,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				Halligan P.W., 1991, NEUROPSYCHOL REHABIL, V1, P5, DOI https://doi.org/10.1080/09602019108401377; HALLIGAN PW, 1993, INT J NEUROSCI, V70, P149, DOI 10.3109/00207459309000571; Jung R., 1974, PSYCHOPATHOLOGIE MUS, P27; MARSH GG, 1987, CORTEX, V23, P149, DOI 10.1016/S0010-9452(87)80027-8; MARSHALL JC, 1993, J NEUROL, V240, P37, DOI 10.1007/BF00838444; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; SCHNIDER A, 1993, NEUROPSY NEUROPSY BE, V6, P249; VIGOUROUX RA, 1990, REV NEUROL, V146, P665	8	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					139	140		10.1016/S0140-6736(97)03165-6	http://dx.doi.org/10.1016/S0140-6736(97)03165-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228978				2022-12-28	WOS:A1997XK11400046
J	James, JA; Laing, GJ; Logan, S; Rossdale, M				James, JA; Laing, GJ; Logan, S; Rossdale, M			Feasibility of screening toddlers for iron deficiency anaemia in general practice	BRITISH MEDICAL JOURNAL			English	Article									DEPT CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	James, JA (corresponding author), MONTPELIER HLTH CTR,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL D, 1996, HLTH CHILDREN; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; JAMES JA, 1995, BRIT MED J, V311, P230, DOI 10.1136/bmj.311.6999.230	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					102	103		10.1136/bmj.315.7100.102	http://dx.doi.org/10.1136/bmj.315.7100.102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240051	Green Published			2022-12-28	WOS:A1997XL25200026
J	Liao, SR; Lin, JL; Do, H; Johnson, AE				Liao, SR; Lin, JL; Do, H; Johnson, AE			Both lumenal and cytosolic gating of the aqueous ER translocon pore are regulated from inside the ribosome during membrane protein integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CONDUCTING CHANNEL; MESSENGER-RNA; TRANSLATION; GLYCOPROTEIN; ENVIRONMENT; BIOGENESIS; SEQUENCES; SEGMENTS; SIGNAL	Portions of the nascent chain are exposed to the lumen, the cytosol, or neither at different stages during the cotranslational integration of a protein into the ER membrane, as shown by compartment-specific collisional quenching of fluorophores incorporated into the polypeptide. The opening or closing of each end of the aqueous translocon pore is tightly controlled and occurs in a sequence that does not compromise the membrane's permeability barrier. Surprisingly, these structural changes at the membrane are effected by the transmembrane segment in the nascent protein from inside the ribosome. Thus, the ribosome, not the translocon, first recognizes the transmembrane segment and triggers long-range structural changes at the translocon that may be involved in shifting its function from translocation to integration.	TEXAS A&M UNIV,HLTH SCI CTR,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,HLTH SCI CTR,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liao, SR (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [F32 GM017828-02, F32 GM017828-01, F32 GM17828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HEDGE RS, 1996, CELL, V85, P217; Johnson AE, 1995, COLD SPRING HARB SYM, V60, P71, DOI 10.1101/SQB.1995.060.01.010; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SPIESS M, 1989, J BIOL CHEM, V264, P19117; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988; WALTEWR P, 1994, ANN REV CELL BIOL, V140, P87; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519	30	211	212	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					31	41		10.1016/S0092-8674(00)80311-6	http://dx.doi.org/10.1016/S0092-8674(00)80311-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230300	Bronze			2022-12-28	WOS:A1997XL36200006
J	Quake, SR; Babcock, H; Chu, S				Quake, SR; Babcock, H; Chu, S			The dynamics of partially extended single molecules of DNA	NATURE			English	Article							STRETCHED POLYMER-CHAINS; TRANSIENT ELECTRIC BIREFRINGENCE; DIELECTRIC-RELAXATION; SCATTERING; FRAGMENTS; MODES	The behaviour of an isolated polymer floating in a solvent forms the basis of our understanding of polymer dynamics(1,2). Classical theories describe the motion of a polymer with linear equations of motion, which yield a set of 'normal modes', analogous to the fundamental frequency and the harmonics of a vibrating violin string. But hydrodynamic interactions make polymer dynamics inherently nonlinear, and the linearizing approximations required for the normal-mode picture have therefore been questioned(1). Here we test the normal-mode theory by measuring the fluctuations of single molecules of DNA held in a partially extended state with optical tweezers. We find that the motion of the DNA can be described by linearly independent normal modes, and we have experimentally determined the eigenstates of the system. Furthermore, we show that the spectrum of relaxation times obeys a power law.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University				Babcock, Hazen/0000-0003-4835-3692				ADAM M, 1977, MACROMOLECULES, V10, P1229, DOI 10.1021/ma60060a014; AMELAR S, 1991, MACROMOLECULES, V24, P3505, DOI 10.1021/ma00012a007; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; De Gennes P.-G., 1979, SCALING CONCEPTS POL; Doi M., 1988, THEORY POLYM DYNAMIC; HONG MK, 1992, PHYS REV LETT, V68, P1430, DOI 10.1103/PhysRevLett.68.1430; Johnson R.M., 1970, POLYM JPN, V1, P742, DOI [10.1295/polymj.1.742, DOI 10.1295/POLYMJ.1.742]; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; LEWIS RJ, 1986, MACROMOLECULES, V19, P134, DOI 10.1021/ma00155a021; MARCIANO Y, 1995, MACROMOLECULES, V28, P985, DOI 10.1021/ma00108a028; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PINCUS P, 1977, MACROMOLECULES, V10, P210, DOI 10.1021/ma60055a042; PINCUS P, 1976, MACROMOLECULES, V9, P386, DOI 10.1021/ma60051a002; Press W.H., 1994, NUMERICAL RECIPES; SAHOUANI H, 1992, MACROMOLECULES, V25, P5632, DOI 10.1021/ma00047a012; SAMMLER RL, 1990, MACROMOLECULES, V23, P2388, DOI 10.1021/ma00210a042; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; WATANABE H, 1995, MACROMOLECULES, V28, P6443, DOI 10.1021/ma00123a009; Watanabe H, 1996, MACROMOLECULES, V29, P97, DOI 10.1021/ma9510348; WATANABE H, 1993, MACROMOLECULES, V26, P5073, DOI 10.1021/ma00071a015; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1956, J CHEM PHYS, V24, P279, DOI 10.1063/1.1742463	25	233	241	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					151	154		10.1038/40588	http://dx.doi.org/10.1038/40588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217154				2022-12-28	WOS:A1997XK10900043
J	Retchin, SM; Brown, RS; Yeh, SCJ; Chu, D; Moreno, L				Retchin, SM; Brown, RS; Yeh, SCJ; Chu, D; Moreno, L			Outcomes of stroke patients in Medicare fee for service and managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE-ORGANIZATIONS; ELDERLY PATIENTS; QUALITY	Context.-Increasing numbers of Medicare beneficiaries have been enrolling in health maintenance organizations (HMOs) because HMO participation reduces out-of-pocket expenses, and the federal government views HMOs as a way to contain Medicare costs. However, results comparing outcomes and quality of care in HMOs vs fee for service (FFS) have been mixed, and outcomes after stroke have not been adequately assessed. Objective.-To compare discharge destinations and survival rates following stroke in Medicare HMOs with similar FFS settings. Design.-An observational study for 2 groups evaluating stroke patients' discharge destinations and survival times from the date of hospital admission. Setting.-A total of 19 HMOs were selected from 12 states. The FFS sample was drawn from the same geographic areas. Patients.-The sample included 402 HMO patients from 71 hospitals and 408 FFS patients from 60 hospitals. Process and Outcome Measures.-Data were abstracted from medical records on demographics, clinical characteristics of stroke, comorbid illnesses, and discharge destinations following hospitalization. Data on survival were obtained from Medicare files and included 25 to 37 months of follow-up (median, 30.4 months, HMO; 31.1 months, FFS) from the date of hospital admission. Results.-There were 109 patients who died during the hospitalization (49 HMO, 12.2%; 60 FFS, 14.7%), and a total of 410 patients had died by the end of follow-up (191 HMO, 47.5%; 219 FFS, 53.7%). Approximately one fourth of both groups had do-not-resuscitate orders (HMO, 25.4%; FFS, 27.9%; P=.68). After controlling for age, marital status, and characteristics of dependency at discharge, HMO patients were more likely than FFS patients to be sent to nursing homes (HMO, 41.8%; FFS, 27.9%; P=.001) and less likely to be discharged to rehabilitation hospitals or units (HMO, 16.2%; FFS, 23.4%; P=.03). At follow-up, no significant differences in relative risk of dying were found between HMO and I-FS groups (relative risk, 0.96; 95% confidence interval, 0.73-1.26; P=.77). Conclusions.-Patients in Medicare HMOs who experience strokes are more likely to be discharged to nursing homes and less likely to go to rehabilitation facilities following the acute event, However, they have similar survival patterns compared with comparable patients in FFS settings after adjusting for other factors.	VIRGINIA COMMONWEALTH UNIV,SCH MED,DEPT INTERNAL MED,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV,SCH ALLIED HLTH,DEPT HLTH ADM,RICHMOND,VA; MATH POLICY RES INC,PRINCETON,NJ	Virginia Commonwealth University; Virginia Commonwealth University; Mathematica								ALTER M, 1986, Neuroepidemiology, V5, P148, DOI 10.1159/000110824; BROWN RS, 1994, HMOS AND THE ELDERLY, P13; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; Caronna J J, 1983, Neurol Clin, V1, P103; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; COX DR, 1972, J R STAT SOC B, V34, P187; Hill JW, 1990, BIASED SELECTION TEF; IGLEHART J, 1982, NEW ENGL J MED, V308, P451; KAHN KL, 1992, PUBLICATION RAND; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; Lichtenstein R, 1991, Med Care, V29, P318, DOI 10.1097/00005650-199104000-00002; Maddala G.S., 1986, LTD DEPENDENT QUALIT; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Nelson L, 1997, HEALTH AFFAIR, V16, P148, DOI 10.1377/hlthaff.16.2.148; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; PRESTON JA, 1991, J AM GERIATR SOC, V39, P683, DOI 10.1111/j.1532-5415.1991.tb03622.x; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1995, AM J MED, V98, P529; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; RETCHIN SM, 1994, HMOS AND THE ELDERLY, P167; RETCHIN SM, 1991, ARCH INTERN MED, V151, P2244, DOI 10.1001/archinte.151.11.2244; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RETCHIN SM, 1991, AM J MED, V90, P236; RETCHIN SM, IN PRESS ARCH INTERN; RILEY G, 1991, HLTH SERV RES, V26, P13; RUBENSTEIN LV, 1988, PUBLICATION RAND; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P187; *STATA CORP, 1997, STATA STAT SOFTW COM; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Yelin EH, 1996, JAMA-J AM MED ASSOC, V276, P1048, DOI 10.1001/jama.276.13.1048	33	77	77	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	1997	278	2					119	124						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH667	9214526				2022-12-28	WOS:A1997XH66700031
J	Hunter, DJ; Fairfield, G				Hunter, DJ; Fairfield, G			Managed care - Disease management	BRITISH MEDICAL JOURNAL			English	Article											Hunter, DJ (corresponding author), UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							DELLBY V, 1996, INT J HLTH CARE QUAL, V9, P4; FAIRFIELD G, 1997, BMJ, V314; HOLLAMBY R, 1995, EUROPEAN HOSP MANAGE, V2, P20; HUNTER D, 1996, HLTH SERVICES J S7, V106, P11; *IBM PHARM CONS SH, 1995, DIS MAN NHS GUID POT; Lawrence M, 1996, BMJ-BRIT MED J, V313, P125, DOI 10.1136/bmj.313.7050.125; *NHS EX, 1994, COMM APPR NHS REG DI; *NHS EX, 1996, PART IND DIS MAN GEN; ROSLEFF F, 1995, EUROPEAN HEALTHCARE; *WILK GROUP, 1995, INT HLTH CAR PHARM C	10	96	100	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					50	53		10.1136/bmj.315.7099.50	http://dx.doi.org/10.1136/bmj.315.7099.50			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233330	Green Published			2022-12-28	WOS:A1997XJ94700038
J	Edgell, DR; Doolittle, WF				Edgell, DR; Doolittle, WF			Archaea and the origin(s) of DNA replication proteins	CELL			English	Review							POLYMERASES; EUKARYOTES; EVOLUTION; HOMOLOGY; GENES				Edgell, DR (corresponding author), DALHOUSIE UNIV,DEPT BIOCHEM,CANADIAN INST ADV RES,HALIFAX,NS B3H 4H7,CANADA.		Edgell, David/AAJ-1971-2020	Doolittle, W. Ford/0000-0002-4675-8832				Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; BULT CJ, 1996, SCIENCE, V273, P1066; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DIFFLEY JF, 1996, GENE DEV, V10, P2819; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DOOLITTLE RF, 1995, PHILOS T R SOC B, V349, P235, DOI 10.1098/rstb.1995.0107; Doolittle WF, 1996, P NATL ACAD SCI USA, V93, P8797, DOI 10.1073/pnas.93.17.8797; Forterre P., 1993, BIOCH ARCHAEA, P325; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kornberg A., 1992, DNA REPLICATION; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; NOLLING J, 1992, NUCLEIC ACIDS RES, V20, P6501, DOI 10.1093/nar/20.24.6501; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Prasartkaew S, 1996, NUCLEIC ACIDS RES, V24, P3934, DOI 10.1093/nar/24.20.3934; REECK GR, 1987, CELL, V50, P667, DOI 10.1016/0092-8674(87)90322-9; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X	27	224	230	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					995	998		10.1016/S0092-8674(00)80285-8	http://dx.doi.org/10.1016/S0092-8674(00)80285-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215620	Bronze			2022-12-28	WOS:A1997XG83000002
J	Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D				Yang, XL; KhosraviFar, R; Chang, HY; Baltimore, D			Daxx, a novel Fas-binding protein that activates JNK and apoptosis	CELL			English	Article							C-JUN; TNF RECEPTOR; DEATH DOMAIN; CELL-DEATH; ANTIGEN; INTERACTS; KINASE	The Fas cell surface receptor induces apoptosis upon receptor oligomerization. We have identified a novel signaling protein, termed Daxx, that binds specifically to the Fas death domain. Overexpression of Daxx enhances Fas-mediated apoptosis and activates the Jun N-terminal kinase (JMK) pathway. A C-terminal portion of Daxx interacts with the Fas death domain, while a different region activates both JNK and apoptosis. The Fas-binding domain of Daxx is a dominant-negative inhibitor of both Fas-induced apoptosis and JMK activation, while the FADD death domain partially inhibits death but not JNK activation. The Daxx apoptotic pathway is sensitive to both Bcl-2 and dominant-negative JNK pathway components and acts cooperatively with the FADD pathway. Thus, Daxx and FADD define two distinct apoptotic pathways downstream of Fas.			Yang, XL (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Khosravi-Far, Roya/C-3789-2008		NCI NIH HHS [R01 CA051462-17, CA51462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN PH, 1994, ONCOGENE, V9, P791; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HSU H, 1996, CELL, V84, P290; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; JOHNSON NL, 1996, J BIOL CHEM, V271, P3299; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	44	804	857	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1067	1076		10.1016/S0092-8674(00)80294-9	http://dx.doi.org/10.1016/S0092-8674(00)80294-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215629	Green Accepted, Bronze			2022-12-28	WOS:A1997XG83000011
J	Osborne, KA; Robichon, A; Burgess, E; Butland, S; Shaw, RA; Coulthard, A; Pereira, HS; Greenspan, RJ; Sokolowski, MB				Osborne, KA; Robichon, A; Burgess, E; Butland, S; Shaw, RA; Coulthard, A; Pereira, HS; Greenspan, RJ; Sokolowski, MB			Natural behavior polymorphism due to a cGMP-dependent protein kinase of Drosophila	SCIENCE			English	Article							LONG-TERM-MEMORY; FORAGING STRATEGIES; GENE-EXPRESSION; LEARNING MUTANT; MELANOGASTER; BINDING; MICE; ELEMENTS; MUTATION; CYCLASE	Naturally occuring polymorphisms in behavior are difficult to map genetically and thus are refractory to molecular characterization. An exception is the foraging gene (for), a gene that has two naturally occurring variants in Drosophila melanogaster food-search behavior: rover and sitter. Molecular mapping placed for mutations in the dg2 gene, which encodes a cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG). Revers had higher PKG activity than sitters, and transgenic sitters expressing a dg2 complementary DNA from rover showed transformation of behavior to rover. Thus, PKG levels affected food-search behavior, and natural variation in PKG activity accounted for a behavioral polymorphism.	YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA; NYU, DEPT BIOL, NEW YORK, NY 10003 USA; NYU, CTR NEURAL SCI, NEW YORK, NY 10003 USA	York University - Canada; New York University; New York University			Coulthard, Alan/C-3649-2011	Coulthard, Alan/0000-0003-1110-9207; Butland, Stefanie/0000-0002-5427-8951; robichon, alain/0000-0003-1075-9646; Pereira, H. Sofia/0000-0002-7933-6097; Sokolowski, Marla/0000-0002-7462-8007				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHOI KW, 1991, J BIOL CHEM, V266, P15999; COMWELL TL, 1989, J BIOL CHEM, V264, P1146; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DEBELLE JS, 1987, HEREDITY, V59, P73, DOI 10.1038/hdy.1987.98; DEBELLE JS, 1989, GENETICS, V123, P157; DEBELLE JS, 1993, GENOME, V36, P94, DOI 10.1139/g93-013; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; FICUS RR, 1988, METHOD ENZYMOL, V159, P150; GOODWIN SF, 1993, J NEUROGENET, V8, P232; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; Hall, 1994, FLEXIBILITY CONSTRAI, P15; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Kane NS, 1997, NEURON, V18, P307, DOI 10.1016/S0896-6273(00)80270-6; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MCGINNIS W, 1983, CELL, V34, P75, DOI 10.1016/0092-8674(83)90137-X; PAUPARDINTRITSC.D, 1986, NATURE, V323, P814; PEREIRA HS, 1993, P NATL ACAD SCI USA, V90, P5044, DOI 10.1073/pnas.90.11.5044; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook T, 1989, MOL CLONING LAB MANU; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Sokolowski MB, 1997, P NATL ACAD SCI USA, V94, P7373, DOI 10.1073/pnas.94.14.7373; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; WOODY CD, 1986, BRAIN RES, V386, P379, DOI 10.1016/0006-8993(86)90175-7; WYATT TA, 1993, AM J PHYSIOL, V265, pC201, DOI 10.1152/ajpcell.1993.265.1.C201; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	38	438	453	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					834	836		10.1126/science.277.5327.834	http://dx.doi.org/10.1126/science.277.5327.834			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242616				2022-12-28	WOS:A1997XQ24700049
J	Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F				Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F			Evidence for interacting gas flows and an extended volatile source distribution in the coma of comet C/1996 B2 (Hyakutake)	SCIENCE			English	Article							PHYSICO-CHEMICAL PHENOMENA; P/HALLEY; NUCLEUS; WEST	Images of comet C/1996 B2 (Hyakutake) taken during its close approach to Earth show differences in the distribution of gas and dust in the inner coma and reveal two are-shaped molecular resonant emission features. The morphology of these features, as well as the apparent decoupling gas from dust in the inner coma, suggest that an extended region of icy grains surrounds the nucleus of Hyakutake and contributes substantially to the production of volatiles. Model simulations suggest the same conclusion and indicate that the brighter are is explainable by the presence of a trailing condensation of ice-bearing granules with a rate of volatile production approximately 23 percent of that of the nucleus.	UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; INDIANA UNIV,DEPT ASTRON,BLOOMINGTON,IN 47405; NATL OPT ASTRON OBSERV,TUCSON,AZ 85719; UNIV WISCONSIN,DEPT PHYS,MADISON,WI 53706	University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington; National Optical Astronomy Observatory; University of Wisconsin System; University of Wisconsin Madison	Harris, WM (corresponding author), UNIV WISCONSIN,SPACE ASTRON LAB,1150 UNIV AVE,MADISON,WI 53706, USA.		Combi, Michael/J-1697-2012	Combi, Michael/0000-0002-9805-0078				AHEARN MF, 1980, MOON PLANETS, V23, P41; AHEARN MF, 1977, ASTRON J, V82, P518, DOI 10.1086/112085; AHEARN MF, IN PRESS P 1996 AST; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; COMBI MR, 1980, ASTROPHYS J, V237, P1026; DELSEMME AH, 1970, PLANET SPACE SCI, V18, P709, DOI 10.1016/0032-0633(70)90052-8; DELSEMME AH, 1971, PLANET SPACE SCI, V19, P1259, DOI 10.1016/0032-0633(71)90181-4; FEHRENBACH C, 1973, CR ACAD SCI B PHYS, V277, P569; HAFFNER LM, COMMUNICATION; HANNER MS, 1981, ICARUS, V47, P342, DOI 10.1016/0019-1035(81)90182-2; Harmon J.K., 1996, BAAS, V28, P1195; HARRIS WM, 1996, B AM ASTRON SOC, V28, P1088; HUGGINS W, 1981, CR HEBD ACAD SCI, V10, P26; JEWITT DC, 1987, ASTROPHYS J, V317, P992, DOI 10.1086/165347; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; KITAMURA Y, 1986, ICARUS, V66, P241, DOI 10.1016/0019-1035(86)90155-7; KOROSMEZEY A, 1990, ICARUS, V84, P118, DOI 10.1016/0019-1035(90)90162-3; LAFFONT C, 1996, B AM ASTRON SOC, V28, P926; LARSON S, 1987, ASTRON ASTROPHYS, V187, P639; MAZETS EP, 1987, ASTRON ASTROPHYS, V187, P699; Mukai T., 1985, Advances in Space Research, V5, P339, DOI 10.1016/0273-1177(85)90107-3; NEWBURN RL, 1981, ASTRON J, V86, P469, DOI 10.1086/112906; SAITO K, 1981, ICARUS, V41, P351; SCHLEICHER DG, 1996, B AM ASTRON SOC, V28, P1089; TOZZI GP, COMMUNICATION; TOZZI GP, 1996, B AM ASTRON SOC, V28, P1089	26	39	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					676	681		10.1126/science.277.5326.676	http://dx.doi.org/10.1126/science.277.5326.676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235888				2022-12-28	WOS:A1997XN90700038
J	Rolfs, RT; Joesoef, R; Hendershot, EF; Rompalo, AM; Augenbraun, MH; Chiu, M; Bolan, G; Johnson, SC; French, P; Steen, E; Radolf, JD; Larsen, S				Rolfs, RT; Joesoef, R; Hendershot, EF; Rompalo, AM; Augenbraun, MH; Chiu, M; Bolan, G; Johnson, SC; French, P; Steen, E; Radolf, JD; Larsen, S			A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TREPONEMA-PALLIDUM; CEREBROSPINAL-FLUID; HIV-INFECTION; SECONDARY SYPHILIS; MEMBRANE IMMUNOGEN; PENICILLIN LEVELS; LATENT SYPHILIS; NEUROSYPHILIS; AIDS	Background Reports of neurosyphilis and invasion of cerebrospinal fluid by Treponema pallidum in patients with human immunodeficiency virus (HIV) infection have led to doubts about the adequacy of the recommended penicillin G benzathine therapy for early syphilis. Methods In a multicenter, randomized, double-blind trial, we assessed two treatments for early syphilis: 2.4 million units of penicillin G benzathine and that therapy enhanced with a 10-day course of amoxicillin and probenecid. The serologic and clinical responses of patients with and without HIV infection were studied during one year of follow-up. Results From 1991 through 1994, 541 patients were enrolled, including 101 patients (19 percent) who had HIV infection but differed little from the uninfected patients in their clinical presentations. The rates at which chancres and rashes resolved did not differ significantly according to treatment assignment or HIV status. Serologically defined treatment failures were more common among the HIV-infected patients. The single clinically defined treatment failure was in an HIV-infected patient. Rates of serologically defined treatment failure did not differ according to treatment group (18 percent at six months with usual therapy; 17 percent with enhanced therapy). T. pallidum was found at enrollment in the cerebrospinal fluid of 32 of 131 patients (24 percent) and after therapy in 7 of 35 patients tested. None had clinically evident neurosyphilis, and the rate of detection of T. pallidum did not differ according to HIV status. Conclusions After treatment for primary or secondary syphilis, the HIV-infected patients responded less well serologically than the patients without HIV infection, but clinically defined failure was uncommon in both groups. Enhanced treatment with amoxicillin and probenecid did not improve the outcomes. Although T. pallidum was detected in cerebrospinal fluid before therapy in a quarter of the patients tested, such a finding did not predict treatment failure. The current recommendations for treating early syphilis appear adequate for most patients, whether or not they have HIV infection. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, DIV STD LAB RES, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; BALTIMORE HLTH DEPT, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, MED CTR, BALTIMORE, MD 21218 USA; SUNY HLTH SCI CTR, BROOKLYN, NY 11203 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX USA; SAN FRANCISCO DEPT PUBL HLTH, SAN FRANCISCO, CA USA; WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA; NATL NAVAL MED CTR, PULM DIS SECT, BETHESDA, MD 20889 USA; MED COLL PENN & HAHNEMANN UNIV, PHILADELPHIA, PA USA; PHILADELPHIA DEPT PUBL HLTH, PHILADELPHIA, PA USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; San Francisco Department of Public Health; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Walter Reed National Military Medical Center; Drexel University	Rolfs, RT (corresponding author), CTR DIS CONTROL & PREVENT, COMMUN OFF, DIV STD PREVENT, NATL CTR HIV STD & TB PREVENT, MAILSTOP E-06, ATLANTA, GA 30333 USA.							AKINS DR, 1993, INFECT IMMUN, V61, P1202, DOI 10.1128/IAI.61.4.1202-1210.1993; Altman D.G., 1991, PRACTICAL STAT MED R; [Anonymous], 1993, MMWR MORB MORTAL WKL, V42, pRR; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; BYRNE TN, 1991, J NEUROL SCI, V103, P48, DOI 10.1016/0022-510X(91)90282-C; CHEMOUILLI P, 1989, REV MED INTERNE, V10, P503; DOWELL ME, 1992, AM J MED, V93, P481, DOI 10.1016/0002-9343(92)90574-U; DUCAS J, 1981, JAMA-J AM MED ASSOC, V246, P2583, DOI 10.1001/jama.246.22.2583; FABER WR, 1983, SEX TRANSM DIS, V10, P148, DOI 10.1097/00007435-198307000-00011; FERARU ER, 1990, NEUROLOGY, V40, P541, DOI 10.1212/WNL.40.3_Part_1.541; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P92, DOI 10.1097/00007435-197707000-00004; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; GOODMAN SN, 1995, ANN INTERN MED, V122, P4781; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; GRAMAN PS, 1987, SEX TRANSM DIS, V14, P205, DOI 10.1097/00007435-198710000-00005; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P359, DOI 10.1001/jama.257.3.359; HIRA SK, 1987, INT J DERMATOL, V26, P103, DOI 10.1111/j.1365-4362.1987.tb00532.x; HOOK EW, 1992, AM J MED, V93, P477, DOI 10.1016/0002-9343(92)90573-T; HSU PL, 1989, INFECT IMMUN, V57, P196, DOI 10.1128/IAI.57.1.196-203.1989; HUTCHINSON CM, 1994, ANN INTERN MED, V121, P94, DOI 10.7326/0003-4819-121-2-199407150-00003; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KASE CS, 1988, ARCH NEUROL-CHICAGO, V45, P832, DOI 10.1001/archneur.1988.00520320018007; KIDD PG, 1989, CLIN IMMUNOL IMMUNOP, V52, P3, DOI 10.1016/0090-1229(89)90187-6; LANDAY AL, 1989, CLIN IMMUNOL IMMUNOP, V52, P48, DOI 10.1016/0090-1229(89)90192-X; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN S, 1990, MANUAL TESTS SYPHILI; LITTELL R. C., 1996, SAS SYSTEM MIXED MOD, P87; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MOHR JA, 1976, JAMA-J AM MED ASSOC, V236, P2208, DOI 10.1001/jama.236.19.2208; MORRISON RE, 1985, GENITOURIN MED, V61, P359; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; MUSHER DM, 1988, ANN INTERN MED, V109, P849, DOI 10.7326/0003-4819-109-11-849; POLNIKORN N, 1980, BRIT J VENER DIS, V56, P363; Radolf Justin D., 1993, P224; ROLFS RT, 1995, CLIN INFECT DIS, V20, pS23, DOI 10.1093/clinids/20.Supplement_1.S23; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; TELZAK EE, 1991, AIDS, V5, P591, DOI 10.1097/00002030-199105000-00020; TRAMONT EC, 1976, JAMA-J AM MED ASSOC, V236, P2206, DOI 10.1001/jama.236.19.2206; TRAMONT EC, 1987, NEW ENGL J MED, V316, P1600, DOI 10.1056/NEJM198706183162510; WEIGEL LM, 1992, INFECT IMMUN, V60, P1568, DOI 10.1128/IAI.60.4.1568-1576.1992; Yinnon AM, 1996, ARCH INTERN MED, V156, P321, DOI 10.1001/archinte.156.3.321; YODER FW, 1975, JAMA-J AM MED ASSOC, V232, P270, DOI 10.1001/jama.232.3.270; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZENKER PN, 1990, REV INFECT DIS, V12, pS590; 1988, MMWR-MORBID MORTAL W, V36, P833; 1988, MMWR-MORBID MORTAL W, V37, P600; 1988, MMWR-MORBID MORTAL W, V37, P607; 1988, MMWR-MORBID MORTAL W, V33, P845; 1992, MMWR MORB MORTAL WLD, V41, P1	55	335	353	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					307	314		10.1056/NEJM199707313370504	http://dx.doi.org/10.1056/NEJM199707313370504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9235493	Bronze			2022-12-28	WOS:A1997XN11900004
J	Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM				Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM			The regulation of anoikis: MEKK-1 activation requires cleavage by caspases	CELL			English	Article							EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; KINASE; EXPRESSION; PROTEINASE; CELLS; RAF-1; ICE	Certain cell types undergo apoptosis when they lose integrin-mediated contacts with the extracellular matrix (''anoikis''). The Jun N-terminal kinase (JNK) pathway is activated in and promotes anoikis. This activation requires caspase activity. We presently report that a DEVD motif-specific caspase that cleaves MEKK-1 specifically is activated when cells lose matrix contact. This cleavage is required for the activation of the kinase activity. When overexpressed, the MEKK-1 cleavage product stimulates apoptosis; the wild-type, full-length MEKK-1 sensitizes cells to anoikis; and a cleavage-resistant mutant of MEKK-1 partially protects cells against anoikis. The cleavage-resistant or kinase-inactive mutants also prevent caspase-7 from being activated completely. Thus, caspases can induce apoptosis by activating MEKK-1, which in turn activates more caspase activity, comprising a positive feedback loop.	BURNHAM INST,LA JOLLA,CA 92037; UNIV COLORADO,SCH MED,DIV BASIC SCI,NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	Sanford Burnham Prebys Medical Discovery Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN A, 1997, SCIENCE, V275, P1081; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gilmore TD, 1996, ONCOGENE, V13, P1367; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAGATA S, 1997, J BIOL CHEM, V274, P20977; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIDMANN C, 1997, UNPUB SCIENCE; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	34	459	468	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					315	323		10.1016/S0092-8674(00)80339-6	http://dx.doi.org/10.1016/S0092-8674(00)80339-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244305	Bronze			2022-12-28	WOS:A1997XN24900015
J	Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J				Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J			Structural adaptations in the specialized bacteriophage T4 co-chaperonin Gp31 expand the size of the Anfinsen cage	CELL			English	Article							BYPASS 31 MUTATIONS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-PRODUCTS; PROTEIN; GROEL; BACTERIAL; LAMBDA; HEAD; MORPHOGENESIS	The Gp31 protein from bacteriophage T4 functionally substitutes for the bacterial co-chaperonin GroES in assisted protein folding reactions both in vitro and in vivo. But Gp31 is required for the folding and/or assembly of the T4 major capsid protein Gp23, and this requirement cannot be satisfied by GroES. The 2.3 Angstrom crystal structure of Gp31 shows that its tertiary and quaternary structures are similar to those of GroES despite the existence of only 14% sequence identity between the two proteins. However, Gp31 shows a series of structural adaptations which will increase the size and the hydrophilicity of the ''Anfinsen cage,'' the enclosed cavity within the GroEL/GroES complex that is the location of the chaperonin-assisted protein folding reaction.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva	Hunt, JF (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DOERMANN AH, 1984, J VIROL, V51, P315, DOI 10.1128/JVI.51.2.315-320.1984; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1996, CHAPERONINS; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SIMON LD, 1984, J VIROL, V51, P321, DOI 10.1128/JVI.51.2.321-328.1984; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZeilstraRyalls J, 1996, FASEB J, V10, P148, DOI 10.1096/fasebj.10.1.8566535; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	71	87	90	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					361	371		10.1016/S0092-8674(00)80343-8	http://dx.doi.org/10.1016/S0092-8674(00)80343-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244309	Bronze			2022-12-28	WOS:A1997XN24900019
J	Festing, MFW				Festing, MFW			Fat rats and carcinogenesis screening	NATURE			English	Editorial Material							LABORATORY RODENTS; BODY-WEIGHT; PATHOLOGY; SURVIVAL; MICE				Festing, MFW (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,POB 138,LEICESTER LE1 9HN,LEICS,ENGLAND.							ABELSON PH, 1992, SCIENCE, V255, P141, DOI 10.1126/science.1553536; ARCOS JC, 1968, CHEM INDUCTION CANC; BRONSON RT, 1993, AGING-CLIN EXP RES, V5, P253, DOI 10.1007/BF03324169; FELTON RP, 1989, J TOXICOL ENV HEALTH, V26, P399, DOI 10.1080/15287398909531264; FESTING MFW, 1990, TOXICOL APPL PHARM, V102, P197, DOI 10.1016/0041-008X(90)90020-U; FESTING MFW, 1993, AGING-CLIN EXP RES, V5, P309, DOI 10.1007/BF03324180; FESTING MFW, 1995, ENVIRON HEALTH PERSP, V103, P44, DOI 10.2307/3432255; HASEMAN JK, 1979, J TOXICOL ENV HEALTH, V5, P89, DOI 10.1080/15287397909529728; HASEMAN JK, 1992, FUND APPL TOXICOL, V19, P207, DOI 10.1016/0272-0590(92)90153-9; MCAUSLANE JAN, 1991, HUM EXP TOXICOL, V10, P205, DOI 10.1177/096032719101000310; NOHYNEK GJ, 1993, HUM EXP TOXICOL, V12, P87, DOI 10.1177/096032719301200201; Nomura T., 1991, ILAR J, V33, P42; Popper Karl R., 1972, OBJECTIVE KNOWLEDGE; RAO GN, 1989, LAB ANIM SCI, V39, P389; ROE FJC, 1994, LAB ANIM, V28, P148, DOI 10.1258/002367794780745236; SHELLABARGER CJ, 1978, JNCI-J NATL CANCER I, V61, P1505; SPROTT RL, 1993, AGING-CLIN EXP RES, V5, P249, DOI 10.1007/BF03324168; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0	18	9	9	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					321	322		10.1038/40964	http://dx.doi.org/10.1038/40964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237745				2022-12-28	WOS:A1997XM52800020
J	Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP				Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP			Mating type switching in yeast controlled by asymmetric localization of ASH1 mRNA	SCIENCE			English	Article							CLASS-V MYOSIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MUTATIONAL ANALYSIS; GENE; IDENTIFICATION; TROPOMYOSIN; REQUIREMENT; TRANSPORT; MYO2	Cell divisions that produce progeny differing in their patterns of gene expression are key to the development of multicellular organisms. In the budding yeast Saccharomyces cerevisiae, mother cells but not daughter cells can switch mating type because they selectively express the HO endonuclease gene. This asymmetry is due to the preferential accumulation of an unstable transcriptional repressor protein, Ash1p, in daughter cell nuclei. Here it is shown that ASH1 messenger RNA (mRNA) preferentially accumulates in daughter cells by a process that is dependent on actin and myosin. A cis-acting element in the 3'-untranslated region of ASH1 mRNA is sufficient to localize a chimeric RNA to daughter cells. These results suggest that localization of mRNA may have been an early property of the eukaryotic lineage.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Long, RM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Calatrava, Isidro González/S-4410-2018	Calatrava, Isidro González/0000-0003-4784-2582; Nasmyth, Kim/0000-0001-7030-4403	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008088] Funding Source: NIH RePORTER; NICHD NIH HHS [7 F32 HD08088-02] Funding Source: Medline; NIGMS NIH HHS [GM54887] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1996, ANNU REV CELL DEV BI, V12, P129, DOI 10.1146/annurev.cellbio.12.1.129; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BOGUCKAGLOTZER J, 1996, SEMIN CELL DEV BIOL, V7, P357; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; Long RM, 1995, RNA, V1, P1071; Long Roy M., 1996, Molecular Biology of the Cell, V7, p104A; Manseau L, 1996, DEVELOPMENT, V122, P2109; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; Politz JC, 1995, NUCLEIC ACIDS RES, V23, P4946, DOI 10.1093/nar/23.24.4946; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; Sherman F, 1986, LAB COURSE MANUAL ME; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; St. Johnston D., 1995, CELL, V81, P161, DOI DOI 10.1016/0092-8674(95)90324-0; STEWARD O, 1997, MRNA METABOLISM POST; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; WERTMAN KF, 1992, GENETICS, V132, P337	39	391	396	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					383	387		10.1126/science.277.5324.383	http://dx.doi.org/10.1126/science.277.5324.383			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219698				2022-12-28	WOS:A1997XL35800050
J	Williams, GH; Wara, DW; Carbone, P				Williams, GH; Wara, DW; Carbone, P			Funding for patient-oriented research - Critical strain on a fundamental linchpin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL INVESTIGATOR; PHYSICIAN-SCIENTIST	Context.-Interest in clinical investigative careers has declined over the past 2 decades. While several factors are likely involved in this decline, one is the perceived difficulty in obtaining support for investigator-initiated clinical research projects. Objective.-To analyze the priority scores and funding rates of patient-oriented research (POR) compared with laboratory-oriented research (LOR) when grant applications to the National Institutes of Health (NIH) are reviewed by study sections of the NIH Division of Research Grants. Design.-Research grant applications submitted to NIH were classified by the applicant as involving human subjects or not (LOR). Those classified as involving human subjects were divided into clinical (POR) and nonclinical research. The association of priority score and POR or LOR status was evaluated using chi(2) statistical techniques. Setting and Participants.-Twelve thousand investigator-initiated grant applications (R01s) in 2 of the 1994 NIH review cycles. Main Outcome Measures.-Grant application priority scores and funding rates. Results.-On the basis of the following 3 criteria, POR applications fare less well than LOR applications: (1) POR status and ranking in the total application pool; (2) percentage of POR vs LOR applications in the top 20th percentile; and (3) funding rates of POR applications. Furthermore, the fate of a POR application depended on which study section reviewed the application. Those applications that were reviewed in study sections that primarily reviewed POR applications fared equivalently to LOR applications; in contrast, POR applications reviewed in study sections that primarily reviewed LOR applications encountered a less favorable fate. Conclusions.-These objective data provide strong support to the clinical research community's concern that investigator-initiated POR applications are not reviewed equitably at the NIH. By restructuring the review process, fairness is likely to be restored. Without restructuring, the POR component of the medical research community may be critically damaged.	HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA USA; UNIV WISCONSIN, SCH MED, MADISON, WI USA	Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	Williams, GH (corresponding author), BRIGHAM & WOMENS HOSP, DIV ENDOCRINE HYPERTENS, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.							Ahrens Jr. E. H., 1992, CRISIS CLIN RES; COLE S, 1992, MAKING SCI NATURE SO, P82; DIBONA GF, 1979, CLIN RES, V27, P253; GILL GN, 1984, AM SCHOLAR, V53, P353; GLICKMAN RM, 1985, J CLIN INVEST, V76, P1293, DOI 10.1172/JCI112102; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; Horton R, 1996, LANCET, V348, P1255, DOI 10.1016/S0140-6736(05)65751-0; Institute of Medicine, 1994, CAR CLIN RES OBST OP; KELLEY WN, 1985, CLIN RES, V33, P100; THIER SO, 1980, CLIN RES, V28, P85; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; WYNGAARDEN JB, 1986, CLIN RES, V33, P95	13	58	58	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					227	231		10.1001/jama.278.3.227	http://dx.doi.org/10.1001/jama.278.3.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218670				2022-12-28	WOS:A1997XK10800029
J	Lecuit, T; Cohen, SM				Lecuit, T; Cohen, SM			Proximal-distal axis formation in the Drosophila leg	NATURE			English	Article							PROTEIN-KINASE-A; LIMB DEVELOPMENT; IMAGINAL DISKS; SIGNAL-TRANSDUCTION; MORPHOGEN GRADIENT; WING DEVELOPMENT; VENTRAL CELLS; FEEDBACK LOOP; HEDGEHOG; GENE	Limb development requires the formation of a proximal-distal axis perpendicular to the main anterior-posterior and dorsal-ventral body axes. The secreted signalling proteins Decapentaplegic and Wingless act in a concentration-dependent manner to organize the proximal-distal axis. Discrete domains of proximal-distal gene expression are defined by different thresholds of Decapentaplegic and Wingless activities. Subsequent modulation of the relative sires of these domains by growth of the leg is required to form the mature pattern.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; BROOK WJ, 1996, SCIENCE, V273, P1371; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MARDON G, 1994, DEVELOPMENT, V120, P3473; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Singer MA, 1997, DEVELOPMENT, V124, P79; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Theisen H, 1996, DEVELOPMENT, V122, P3939; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	46	308	311	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					139	145		10.1038/40563	http://dx.doi.org/10.1038/40563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217152	Bronze			2022-12-28	WOS:A1997XK10900040
J	Malini, PL; Strocchi, E; Zanardi, M; Milani, M; Ambrosioni, E				Malini, PL; Strocchi, E; Zanardi, M; Milani, M; Ambrosioni, E			Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor	LANCET			English	Article							DOUBLE-BLIND; RECEPTOR ANTAGONIST; HUMAN-PLATELETS; GUINEA-PIGS; CROSS-OVER; PICOTAMIDE; PROSTAGLANDINS; BRADYKININ; BRONCHOCONSTRICTION; INDOMETHACIN	Background The increased prostaglandin synthesis that might follow stimulation of the arachidonic acid cascade by angiotensin-converting-enzyme inhibition (ACE-I) has been suggested to underlie the appearance of cough on ACE-I treatment. We investigated whether the prostanoid thromboxane was involved. Methods Nine patients with essential hypertension who had cough after enalapril 20 mg once a day (coughers) were treated, while continuing the enalapril, in a double-blind crossover study with placebo or picotamide, 600 mg twice daily. Picotamide is a platelet antiaggregant that acts through both inhibition of thromboxane synthase and thromboxane-receptor antagonism. Thirteen hypertensive patients with no history of ACE-I-induced cough were also treated with enalapril and served as controls. Cough frequency was measured by a visual analogue scale and by a daily cough diary. 24 h urinary recovery of 11-dehydrathromboxane-B-2 and 6-keto-PGF(1 alpha) were measured to assess any changes in endoperoxide metabolism during the study periods. Findings 11-dehydro-thromboxane-B-2 (TXB2) recovery was significantly reduced by picotamide, which led disappearance of cough in eight patients within Picotamide urinary recovery data suggested incomplete absorption in the non-responder. At baseline and after rechallenge with enalapril, 11-dehydro-TXB2 excretion was in the same range in the controls and in the coughers, but the latter showed significantly lower excretion of 6-keto-PGF(1 alpha) and their ratio of 11-dehydroTXB(2) to 6-keto-PGF(1 alpha) was twice that of the controls (1.40 [95% CI 0.86-1.95] vs 0.61 [0.37-0.84]). Interpretation A thromboxane antagonist is effective in ACE-I-induced cough. An imbalance between thromboxane and prostacyclin may represent a marker of patients susceptible to ACE-I-induced cough.			Malini, PL (corresponding author), S ORSOLA UNIV HOSP, MED CLIN 3, I-40138 BOLOGNA, ITALY.		Milani, Massimo/H-3205-2013	Milani, Massimo/0000-0001-7559-1202				BALSANO F, 1993, CIRCULATION, V87, P1563, DOI 10.1161/01.CIR.87.5.1563; BERRETTINI M, 1990, EUR J CLIN PHARMACOL, V39, P495, DOI 10.1007/BF00280943; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; FOGARI R, 1992, J CARDIOVASC PHARM, V19, P670; FOSSATI T, 1992, J CHROMATOGR-BIOMED, V577, P382, DOI 10.1016/0378-4347(92)80264-Q; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GILCHRIST NL, 1989, J HUM HYPERTENS, V3, P451; GRESELE P, 1989, THROMB HAEMOSTASIS, V61, P479; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; IGIC R, 1972, CIRC RES, V31, pII51; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; KIM RB, 1986, CLIN INVEST MED, V9, P192; KOHROGI H, 1988, J CLIN INVEST, V82, P2063, DOI 10.1172/JCI113827; LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387; MINUZ P, 1990, BRIT J CLIN PHARMACO, V30, P519, DOI 10.1111/j.1365-2125.1990.tb03809.x; MODESTI PA, 1994, BRIT J PHARMACOL, V112, P81, DOI 10.1111/j.1476-5381.1994.tb13033.x; MOLIMARD M, 1995, EUR J PHARMACOL, V278, P49, DOI 10.1016/0014-2999(95)00103-R; Patrono C, 1990, CIRCULATION S1, V8, pI12; ROSSONI G, 1980, PROSTAGLANDINS, V20, P547, DOI 10.1016/0090-6980(80)90042-8; STROCCHI E, 1992, DRUG INVEST, V4, P69, DOI 10.1007/BF03258383; SWARTZ SL, 1982, AM J CARDIOL, V49, P1405, DOI 10.1016/0002-9149(82)90351-4; Tomaki M, 1996, THORAX, V51, P199, DOI 10.1136/thx.51.2.199; WASLEN TA, 1989, CLIN INVEST MED, V12, P77	23	33	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	1997	350	9070					15	18		10.1016/S0140-6736(96)12045-6	http://dx.doi.org/10.1016/S0140-6736(96)12045-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217714				2022-12-28	WOS:A1997XH86900010
J	Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G				Kondo, H; Rabouille, C; Newman, R; Levine, TP; Pappin, D; Freemont, P; Warren, G			p47 is a cofactor for p97-mediated membrane fusion	NATURE			English	Article							MITOTIC GOLGI FRAGMENTS; VESICLE FUSION; CELL-CYCLE; YEAST; IDENTIFICATION; PROTEINS; HOMOLOGY; ATPASE; STACKS; FAMILY	At least two distinct ATPases, NSF and p97, are known to be involved in the heterotypic fusion of transport vesicles with their target membranes and the homotypic fusion of membrane compartments(1). The NSF-mediated fusion pathway is the best characterized, many of the components having been identified and their functions analysed(2-7). In contrast, none of the accessory proteins for the p97-mediated fusion pathway has been identified(8-10). Now we have identified the first such component, a protein of relative molecular mass 47,000 (p47), which forms a tight, stoichiometric complex with cytosolic p97 (one trimer of p47 per hexamer of p97). It is essential for the p97-mediated regrowth of Golgi cisternae from mitotic Golgi fragments, a process restricted to animal cells(11). As a homologue of p47 exists in budding yeast, this indicates that it might also be involved in other membrane fusion reactions catalysed by p97, such as karyogamy(10).	IMPERIAL CANC RES FUND,CELL BIOL LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT STRUCT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT SEQUENCING LAB,LONDON WC2A 3PX,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Cancer Research UK; Cancer Research UK; Cancer Research UK; MRC Laboratory Molecular Biology				Pappin, Darryl/0000-0002-8981-8401; Levine, Timothy/0000-0002-7231-0775				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; Schiavo Giampietro, 1994, Seminars in Cell Biology, V5, P221, DOI 10.1006/scel.1994.1028; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; Tu JL, 1996, MOL CELL BIOL, V16, P4199; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	24	351	361	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					75	78		10.1038/40411	http://dx.doi.org/10.1038/40411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214505	Bronze			2022-12-28	WOS:A1997XJ14300053
J	Sibon, OCM; Stevenson, VA; Theurkauf, WE				Sibon, OCM; Stevenson, VA; Theurkauf, WE			DNA-replication checkpoint control at the Drosophila midblastula transition	NATURE			English	Article							CELL-CYCLE CONTROL; MITOTIC-CYCLES; EMBRYOS; XENOPUS; EMBRYOGENESIS; BLASTODERM; BEHAVIOR; NUCLEAR	Embryogenesis is typically initiated by a series of rapid mitotic divisions that are under maternal genetic control(1). The switch to zygotic control of embryogenesis at the midblastula transition is accompanied by significant increases in cell-cycle length and gene transcription, and changes in embryo morphology(2,3). Here we show that mutations in the grapes (grp) checkpoint 1 kinase homologue(4) in Drosophila block the morphological and biochemical changes that accompany the midblastula transition, lead to a continuation of the maternal cell-cycle programme, and disrupt DNA-replication checkpoint control of cell-cycle progression. The timing of the midblastula transition is controlled by the ratio of nuclei to cytoplasm (the nucleocytoplasmic ratio), suggesting that this developmental transition is triggered by titration of a maternal factor by the increasing mass of nuclear material that accumulates during the rapid embryonic mitoses(5-9). Our observations support a model for cell-cycle control at the midblastula transition in which titration of a maternal component of the DNA-replication machinery slows DNA synthesis and induces a checkpoint-dependent delay in cell-cycle progression(10). This delay may allow both completion of S phase and transcription of genes that initiate the switch to zygotic control of embryogenesis.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,INST CELL & DEV BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Sibon, Ody/0000-0002-6836-6063; Theurkauf, William/0000-0001-7342-1912				BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CLUTE P, 1995, DEV BIOL, V171, P273, DOI 10.1006/dbio.1995.1280; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOE VE, 1983, J CELL SCI, V61, P31; Foe Victoria E., 1993, P149; FOGARTY P, 1994, DEVELOPMENT, V120, P2131; FOGARTY P, IN PRESS CURR BIOL; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; GILBERT SF, 1991, DEV BIOL, P75; KANE DA, 1993, DEVELOPMENT, V119, P447; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KLINGLER M, 1993, MECH DEVELOP, V43, P3, DOI 10.1016/0925-4773(93)90019-T; MATTHIES HJ, 1996, J CELL BIOL, V341, P455; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Pritchard DK, 1996, GENE DEV, V10, P1131, DOI 10.1101/gad.10.9.1131; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Theurkauf William E., 1994, V44, P489; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	29	225	226	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 3	1997	388	6637					93	97		10.1038/40439	http://dx.doi.org/10.1038/40439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ143	9214509	Bronze			2022-12-28	WOS:A1997XJ14300057
J	Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K				Avantaggiati, ML; Ogryzko, V; Gardner, K; Giordano, A; Levine, AS; Kelly, K			Recruitment of p300/CBP in p53-dependent signal pathways	CELL			English	Article							CELL-PROLIFERATION; P53; TRANSFORMATION; ACTIVATION; MUTANT; BCL-2; CYCLE; GENE	The products of the p53 and CBP/p300 genes have been individually implicated in control of cell growth and regulation of transcription. p53 is known to act as a positive and negative regulator of gene expression. Here we show that p53, in both wild-type and mutant conformation, forms a specific protein complex with p300. However, in its wild-type but not mutant conformation, p53 inhibits a promoter containing the DNA-binding sequences for the transcription factor AP1, in a p300-dependent manner. p300 stimulates the transcriptional activity of p53 on p53-regulated promoters, and it enhances the responsiveness to a physiological upstream modulator of p53 function, ionizing radiation. A dominant negative form of p300 prevents transcriptional activation by p53, and it counteracts p53-mediated G1 arrest and apoptosis. The data implicate p300 as an important component of p53-signaling, thus providing new insight into the mechanisms of cellular proliferation.	NCI,PATHOL LAB,BETHESDA,MD 20892; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Jefferson University			Giordano, Antonio/F-1927-2010; Ogryzko, Vasily/M-6665-2015	Giordano, Antonio/0000-0002-5959-016X; Ogryzko, Vasily/0000-0002-8548-1389				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; CHEN KV, 1992, SCIENCE, V255, P459; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FAN SJ, 1995, CANCER RES, V55, P1649; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Muraoka M, 1996, ONCOGENE, V12, P1565; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PURI L, 1997, EMBO J, V16, P369; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	35	593	607	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1175	1184		10.1016/S0092-8674(00)80304-9	http://dx.doi.org/10.1016/S0092-8674(00)80304-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215639	Bronze			2022-12-28	WOS:A1997XG83000021
J	AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB				AzaBlanc, P; RamirezWeber, FA; Laget, MP; Schwartz, C; Kornberg, TB			Proteolysis that is inhibited by Hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor	CELL			English	Article							DROSOPHILA IMAGINAL DISKS; SIGNAL-TRANSDUCTION; KINASE-A; GENE-EXPRESSION; FUSED GENE; POLARITY; COMPARTMENTS; MELANOGASTER; PATTERN; ENCODES	Cell-cell communication at anterior/posterior compartment borders in Drosophila involves Hedgehog (Hh), a protein secreted by posterior cells, and Cubitus interruptus (Ci), a protein in the Hh response pathway in anterior cells. Although Ci is thought to have roles as a transcription factor repressing hh expression and activating target genes, it localizes in the cytoplasm of anterior cells. We report here the identification of a domain that tethers Ci in the cytoplasm and show that in some anterior cells, Ci is cleaved to generate a form that lacks the tethering domain. This form translocates to the nucleus where it represses hh and other target genes. Hh inhibits proteolysis of Ci, and we suggest that this inhibition leads to the observed patterns of expression of key target genes at the compartment border.			AzaBlanc, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELSENFELD AL, 1995, DEVELOPMENT, V121, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANG G, 1997, NAT GENET, V15, P266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHAM A, 1995, GENETICS, V140, P587; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; ROBBINS DJ, 1997, IN PRESS CELL; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SANICOLA M, 1995, GENETICS, V139, P754; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1626; SISSON JC, 1997, IN PRESS CELL; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	53	538	555	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 27	1997	89	7					1043	1053		10.1016/S0092-8674(00)80292-5	http://dx.doi.org/10.1016/S0092-8674(00)80292-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XG830	9215627	Bronze			2022-12-28	WOS:A1997XG83000009
J	Christopher, GW; Cieslak, TJ; Pavlin, JA; Eitzen, EM				Christopher, GW; Cieslak, TJ; Pavlin, JA; Eitzen, EM			Biological warfare - A historical perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KOREAN-WAR; ALLEGATIONS; OUTBREAK; ANTHRAX	The deliberate use of microorganisms and toxins as weapons has been attempted throughout history. Biological warfare has evolved from the crude use of cadavers to contaminate water supplies to the development of specialized munitions for battlefield and covert use. The modern development of biological agents as weapons has paralleled advances in basic and applied microbiology. These include the identification of virulent pathogens suitable for aerosol delivery and industrial-scale fermentation processes to produce large quantities of pathogens and toxins. The history of biological warfare is difficult to assess because of a number of confounding factors. These include difficulties in verification of alleged or attempted biological attacks, the use of allegations of biological attacks for propaganda purposes, the paucity of pertinent microbiological or epidemiologic data, and the incidence of naturally occurring endemic or epidemic diseases during hostilities. Biological warfare has been renounced by 140 nations, primarily for strategic and other pragmatic reasons. International diplomatic efforts, including the 1972 Biological Weapons Convention, have not been entirely effective in preventing the enhancement and proliferation of offensive biological warfare programs. The threats posed by biological weapons are likely to continue into the future.			Christopher, GW (corresponding author), USA, MED RES INST INFECT DIS,OPERAT MED DIV,MCMR,UIZ, T LTC CHRISTOPHER, 1425 PORTER ST, FT DETRICK, MD 21702 USA.			Christopher, George/0000-0001-7471-4610				ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; BECKET B, 1983, WEAPONS TOMORROW; BERDAL B P, 1990, Tidsskrift for den Norske Laegeforening, V110, P736; *CHEM BIOL ARMS CO, 1997, UNPUB 4 REV C BIOL T; DAPLAN DE, 1996, CULT END WORLD; DERBES VJ, 1966, J AMER MED ASSOC, V196, P59, DOI 10.1001/jama.196.1.59; FARMER JJ, 1977, LANCET, V2, P459; Geissler E, 1986, BIOL TOXIN WEAPONS T; GOLDSTEIN L, 1996, WASHINGTON POST 1011, pA24; GRAHAM B, 1996, WASHINGTON POST 1002, pA1; HARRIS R, 1982, HIGHER FORM KILLING; HARRIS S, 1992, ANN NY ACAD SCI, V666, P21, DOI 10.1111/j.1749-6632.1992.tb38021.x; HARRIS SH, 1994, FACTORIES DEATH; HUGHJONES M, 1992, INTELL NATL SECUR, V7, P379; Jezek Z, 1988, HUMAN MONKEYPOX; King P. Z., 1943, CHIN MED J, V61, P259; LAZOWSKI ES, 1977, ASM NEWS, V43, P300; LEITENBERG M, 1993, BIOLOGICALS, V21, P187, DOI 10.1006/biol.1993.1074; LIVINGSTONE NC, 1984, CBW POOR MANS ATOM B; LON J, 1990, OREGONIAN       0120, pA1; MANCHEE RJ, 1988, CHEM BRIT, V24, P690; MCCALL S, 1995, P US NAVAL I, V121, P40; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Mitscherlich A, 1983, MED OHNE MENSCHLICHK; MOON JEV, 1992, ANN NY ACAD SCI, V666, P53, DOI 10.1111/j.1749-6632.1992.tb38022.x; *OR HLTH DIV, 1984, COMMUN DIS SUMM, V33, P20; PARKMAN F, 1901, CONSPIRACY PONTIAC I, P2; RICH V, 1992, LANCET, V339, P419; ROBERTSON AG, 1995, MIL MED, V160, P369, DOI 10.1093/milmed/160.8.369; ROLICKA M, 1995, MIL MED, V160, P97, DOI 10.1093/milmed/160.3.97; SCHAAP B, 1982, COVERT ACTION, V17, P28; SEELEY TD, 1985, SCI AM, V253, P128, DOI 10.1038/scientificamerican0985-128; SIMS NA, 1983, DIPLOMACY BIOL DISAR; Sipe C. Hale, 1929, INDIAN WARS PENNSYLV; SMITH RJ, 1992, WASHINGTON POST 0616, pA1; SMITH RJ, 1995, WASHINGTON POST 1101, pA8; Stearn E. W., 1945, EFFECT SMALLPOX DEST; *STOCKH INT PEAC R, 1971, RIS CB WEAP PROBL CH, P1; STUBBS M, 1962, NATOS 15 NATIONS, V7, P94; TOMLIN VV, 1985, VOEN MED ZH, V8, P26; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; *UN, 1996, PUBL BWCONF; *US DEP ARM, 1977, PUBL DTIC, P2; WHEAT RP, 1951, ARCH INTERN MED, V88, P461, DOI 10.1001/archinte.1951.03810100045004; WHO Group of Consultants, 1970, HLTH ASP CHEM BIOL W; Williams Peter, 1989, UNIT 731 JAPANS SECR; Witcover Jules, 1989, SABOTAGE BLACK TOM I; YU VL, 1979, NEW ENGL J MED, V300, P887, DOI 10.1056/NEJM197904193001604; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418; 1964, PRAVDA          0711, P3; 1951, NY TIMES        0413, P6; 1961, NY TIMES        0823, P7; 1976, WASHINGTON POST 1222	53	387	398	2	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					412	417		10.1001/jama.278.5.412	http://dx.doi.org/10.1001/jama.278.5.412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244333				2022-12-28	WOS:A1997XN51800033
J	Gordin, FM; Matts, JP; Miller, C; Brown, LS; Hafner, R; John, SL; Klein, M; Vaughn, A; Besch, CL; Perez, G; Szabo, S; ElSadr, W				Gordin, FM; Matts, JP; Miller, C; Brown, LS; Hafner, R; John, SL; Klein, M; Vaughn, A; Besch, CL; Perez, G; Szabo, S; ElSadr, W			A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; ACTIVE TUBERCULOSIS; DRUG-USERS; HIV; EPIDEMIOLOGY; PROGRESSION; OUTBREAK	Background Patients with human immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the development of active tuberculosis. As a public health measure, prophylactic treatment with isoniazid has been suggested for HIV-infected persons who have anergy and are in groups with a high prevalence of tuberculosis. Methods We conducted a multicenter, randomized, double-blind, placebo-controlled trial of six months of prophylactic isoniazid treatment in HIV-infected patients with anergy who have risk factors for tuberculosis infection. The primary end point was culture-confirmed tuberculosis. Results The study was conducted from November 1991 through June 1996. Over 90 percent of the patients had two or more risk factors for tuberculosis infection, and nearly 75 percent of patients were from greater New York City. After a mean follow-up of 33 months, tuberculosis was diagnosed in only 6 of 257 patients in the placebo group and 3 of 260 patients in the isoniazid group (risk ratio, 0.48; 95 percent confidence interval, 0.12 to 1.91; P=0.30). There were no significant differences between the two groups with regard to death, the progression of HIV disease or death, or adverse events. Conclusions Even in HIV-infected patients with anergy and multiple risk factors for latent tuberculosis infection, the rate of development of active tuberculosis is low. This finding does not support the use of isoniazid prophylaxis in high-risk patients with HIV infection and anergy unless they have been exposed to active tuberculosis. (C) 1997, Massachusetts Medical Society.	GEORGETOWN UNIV, WASHINGTON, DC USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, COMMUNITY PROGRAMS CLIN RES AIDS STAT CTR, MINNEAPOLIS, MN 55455 USA; ADDICT RES TREATMENT CORP, NEW YORK, NY USA; COLUMBIA UNIV, NEW YORK, NY USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; COLUMBIA UNIV COLL PHYS & SURG, HARLEM HOSP CTR, DIV INFECT DIS, NEW YORK, NY 10032 USA; CLIN DIRECTORS NETWORK REG 2 INC, NEW YORK, NY USA; TULANE UNIV, MED CTR, NEW ORLEANS, LA USA; NEW JERSEY COMMUNITY RES INITIAT, NEWARK, NJ USA; DELAWARE COMMUNITY PROGRAM CLIN RES AIDS, WILMINGTON, DE USA	Georgetown University; University of Minnesota System; University of Minnesota Twin Cities; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University; Tulane University	Gordin, FM (corresponding author), VET AFFAIRS MED CTR, INFECT DIS SECT 151B, MED SERV, 50 IRVING ST NW, WASHINGTON, DC 20422 USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1987, MMWR-MORBID MORTAL W, V36, p1S; ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chin DP, 1996, AM J RESP CRIT CARE, V153, P1982, DOI 10.1164/ajrccm.153.6.8665065; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GUCLAR A, 1993, AIDS, V7, P1345; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; Murray J F, 1991, Bull Int Union Tuberc Lung Dis, V66, P21; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P3434; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; WEBSTER CT, 1995, AM J RESP CRIT CARE, V151, P805, DOI 10.1164/ajrccm/151.3_Pt_1.805; WHALEN C, 1997, 4 C RETR OPP INF WAS; 1991, MMWR-MORBID MORTAL W, V40, P27; 1992, MMWR-MORBID MORTAL W, V41, P61; 1995, CLIN INFECT DIS   S1, V21, pS32	29	141	144	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					315	320		10.1056/NEJM199707313370505	http://dx.doi.org/10.1056/NEJM199707313370505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233868	Green Published			2022-12-28	WOS:A1997XN11900005
J	Steyer, JA; Horstmann, H; Almers, W				Steyer, JA; Horstmann, H; Almers, W			Transport, docking and exocytosis of single secretory granules in live chromaffin cells	NATURE			English	Article							NEUROTRANSMITTER RELEASE; VESICLE; ACTIN; SYNAPTOBREVIN; MICROSCOPY; CULTURE; QUANTA; POOL	Neurons maintain a limited pool of synaptic vesicles which are docked at active zones and are awaiting exocytosis(1-4). By contrast, endocrine cells releasing large, dense-core secretory granules have no active zones, and there is disagreement about the size(5) and even the existence(6) of the docked pool. It is not known how, and how rapidly, secretory vesicles are replaced at exocytic sites in either neurons or endocrine cells. By using electron microscopy, we have now been able to identify a pool of docked granules in chromaffin cells that is selectively depleted when cells secrete. With evanescent-wave fluorescence microscopy(7), we observed single granules undergoing exocytosis and leaving behind patches of bare plasmalemma. Fresh granules travelled to the plasmalemma at a top speed of 114 nm s(-1), taking an average of 6 min to arrive. On arrival, their motility diminished 4-food, probably as a result of docking. Some granules detached and returned to the cytosol. We conclude that a large pool of docked granules turns over slowly, that granules move actively to their docking sites, that docking is reversible, and that the 'rapidly releasable pool' measured electrophysiologically represents a small subset of docked granules.	MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY	Max Planck Society								BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; Chow Robert H., 1995, P245; EVANS LL, 1995, P NATL ACAD SCI USA, V92, P10954, DOI 10.1073/pnas.92.24.10954; GHOSH RN, 1994, BIOPHYS J, V66, P1301, DOI 10.1016/S0006-3495(94)80939-7; GILLIS KD, IN PRESS SEM CELL DE; GINGELL D, 1979, BIOPHYS J, V26, P507, DOI 10.1016/S0006-3495(79)85268-6; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; Moser T, 1997, J NEUROSCI, V17, P2314; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; SCHROEDER TJ, 1994, J BIOL CHEM, V269, P17215; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; TERAKAWA S, 1991, NEUROSCI LETT, V123, P82, DOI 10.1016/0304-3940(91)90163-N; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	24	349	354	2	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					474	478		10.1038/41329	http://dx.doi.org/10.1038/41329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242406	Green Submitted, Bronze			2022-12-28	WOS:A1997XN55300049
J	Stager, CL; Werker, JF				Stager, CL; Werker, JF			Infants listen for more phonetic detail in speech perception than in word-learning tasks	NATURE			English	Article								Infants aged 4-6 months discriminate the fine phonetic differences that distinguish syllables in both their native and unfamiliar languages(1-3), but by 10-12 months their perceptual sensitivities are reorganized so that they discriminate only the phonetic variations that are used to distinguish meaning in their native language(12). It would seem, then, that infants apply their well honed phonetic sensitivities as they advance and begin to associate words with objects, but the question of how speech perception sensitivities are used in early word learning has not yet been answered. Here we use a recently developed technique to show that when they are required to pair words with objects, infants of 14 months fail to use the fine phonetic detail they detect in syllable discrimination tasks. In contrast, infants of 8 months-who are not yet readily learning words-successfully discriminate phonetic detail in the same task in which infants aged 14 months fail. Taken together, these results suggest a second reorganization in infants's use of phonetic detail as they move from listening to syllables to learning words.			Stager, CL (corresponding author), UNIV BRITISH COLUMBIA,DEPT PSYCHOL,2136 W MALL,VANCOUVER,BC V6T 1Z4,CANADA.			Werker, Janet F./0000-0002-1168-9013				Barton D., 1978, DEV COMMUNICATION, P255; BENEDICT H, 1979, J CHILD LANG, V6, P183, DOI 10.1017/S0305000900002245; CharlesLuce J, 1995, J CHILD LANG, V22, P727, DOI 10.1017/S0305000900010023; JUSCZYK PW, 1995, HDB PERCEPTION COGNI, V11, P263; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; OVIATT SL, 1980, CHILD DEV, V51, P97, DOI 10.1111/j.1467-8624.1980.tb02514.x; SPELKE ES, 1994, COGNITIVE NEUROSCIEN, P165; TURKEWITZ G, 1982, DEV PSYCHOBIOL, V15, P357, DOI 10.1002/dev.420150408; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WERKER JF, 1995, INVITATION COGNITIVE, P87; WOODWARD A, 1993, 24 ANN CHILD LANGUAG, P35; [No title captured]	12	479	483	4	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					381	382		10.1038/41102	http://dx.doi.org/10.1038/41102			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237755	Bronze			2022-12-28	WOS:A1997XM52800051
J	Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL				Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL			Multistability of cognitive maps in the hippocampus of old rats	NATURE			English	Article							MEMORY DYSFUNCTION; PLACE CELLS; WATER MAZE; PERFORMANCE; STABILITY	Hippocampal neurons provide a population code for location(1). In young rats, environments are reliably 'mapped' by groups of neurons that have firing locations ('place fields'(2)) that can be stable for several months(3). Old animals exhibit deficits in spatial memory, raising the question of whether the quality or stability of their hippocampal 'cognitive maps'(4) is altered. By recording from large groups of neurons, we observed the hippocampal spatial code to be multistable. In young rats, the place field maps were reliable both within and between episodes in a familiar environment. In old rats, place field maps were accurate and stable during an episode, but frequently exhibited complete rearrangements between episodes. In a spatial memory task, both young and old rats exhibited bimodal performance, consistent with map multistability early in training. However, the performance of young rats became almost unimodal with further training, whereas that of old rats remained markedly bimodal. The multistability of the hippocampal map provides an insight into the dynamics of neural coding in high-level cortical structures and their changes during ageing, and may provide an explanation for the frequent failure of place recognition in elderly humans.	UNIV ARIZONA,DEPT NEUROL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,ARIZONA RES LABS,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona	Barnes, CA (corresponding author), UNIV ARIZONA,DEPT PSYCHOL,LIFE SCI N BLDG,ROOM 384,TUCSON,AZ 85724, USA.							BARNES CA, 1983, NEUROBIOL AGING, V4, P113, DOI 10.1016/0197-4580(83)90034-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; GOTHARD M, 1996, J NEUROSCI, V16, P8027; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LANDFIELD PW, 1988, NEUROBIOL AGING, V9, P571, DOI 10.1016/S0197-4580(88)80116-7; MARKUS EJ, 1994, HIPPOCAMPUS, V4, P410, DOI 10.1002/hipo.450040404; McNaughton BL, 1996, J EXP BIOL, V199, P173; MCNAUGHTON BL, 1989, PSYCHOBIOLOGY, V17, P230; Mizumori SJY, 1996, BEHAV NEUROSCI, V110, P1006; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Nadel L., 1985, CONTEXT LEARNING, P385; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; QUIRK GJ, 1990, J NEUROSCI, V10, P2008; Rapp P. R., 1995, Society for Neuroscience Abstracts, V21, P1710; Samsonovich A. V., 1997, THESIS U ARIZONA; SHAPIRO ML, 1993, BEHAV NEUROSCI, V107, P34, DOI 10.1037/0735-7044.107.1.34; SHEN J, 1996, THESIS U ARIZONA; Skaggs W., 1993, ADV NEURAL INFORM PR, V5, P1030; SPENCER RL, 1995, BEHAV BRAIN RES, V68, P139, DOI 10.1016/0166-4328(94)00167-E; THOMPSON LT, 1990, BRAIN RES, V509, P299, DOI 10.1016/0006-8993(90)90555-P; Tsodyks M, 1995, INT J NEURAL SYS S, V6, P81; UTTL B, 1993, PSYCHOL AGING, V8, P257, DOI 10.1037/0882-7974.8.2.257; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	30	267	273	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					272	275		10.1038/40859	http://dx.doi.org/10.1038/40859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230435				2022-12-28	WOS:A1997XL12100050
J	Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS				Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS			A multivalent PDZ-domain protein assembles signalling complexes in a g-protein-coupled cascade	NATURE			English	Article							SIGNALING PROTEINS; PTB DOMAIN; DROSOPHILA; TRANSDUCTION; JUNCTIONS; HOMOLOG; SEPTATE; KINASES; MODULE; GENE	How are signalling molecules organized into different pathways within the same cell? In Drosophila, the inaD gene encodes a protein consisting of five PDZ domains which serves as a scaffold to assemble different components of the phototransduction cascade, including the principal fight-activated ion channels, the effector phospholipase C-beta and protein kinase C, Null inaD mutants have a dramatically reorganized subcellular distribution of signalling molecules, and a total loss of transduction complexes. Also, mutants defective in a single PDZ domain produce signalling complexes that lack the target protein and display corresponding defects in their physiology. A picture emerges of a highly organized unit of signalling, a 'transducisome', with PDZ domains functioning as key elements in the organization of transduction complexes in vivo.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV TOKYO,INST MED SCI,TOKYO,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Tokyo			Sierralta, Jimena Alejandra/AAG-8877-2021; Sierralta, Jimena/A-7591-2008	Sierralta, Jimena/0000-0002-0257-146X; Socolich, Michael/0000-0002-0702-1061; Suzuki, Emiko/0000-0002-4005-0542				BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI KY, 1994, CELL, V78, P499; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HUALING D, 1997, NATURE, V386, P279; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINKE B, 1994, COMMENTS THEOR BIOL, V3, P229; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 1975, MUTANTS AFFECTING VI; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PRINTEN JA, 1994, GENETICS, V138, P309; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YEANDLE S, 1957, THESIS J HOPKINS U	50	538	549	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					243	249		10.1038/40805	http://dx.doi.org/10.1038/40805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230432	Bronze			2022-12-28	WOS:A1997XL12100041
J	Campbell, EG; Weissman, JS; Blumenthal, D				Campbell, EG; Weissman, JS; Blumenthal, D			Relationship between market competition and the activities and attitudes of medical school faculty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-Growth in health care market competition and the concomitant increasing dependence of academic health centers on clinical revenues may require medical school faculty to increase patient care activity, perhaps at the expense of research and teaching. However, the relationship between health care market competitiveness and the activities and attitudes of medical school faculty has not been established. Objective.-To examine the relationship between market competitiveness and the activities and attitudes of medical school faculty members. Design.-Mailed survey of 3394 life-science faculty in the 50 universities that received the most funding from the National Institutes of Health in 1993. Setting.-Medical schools in research-intensive universities. Participants.-A total of 2167 faculty responded to the survey (response rate, 64%). We analyzed the responses of 1671 medical school research faculty located in markets of differing health care competitiveness, ranging from least competitive (stage 1) to most competitive (stage 4) markets. Main Outcome Measures.-The number of publications in refereed journals in the last 3 years, the average number of hours per week of teaching contact, whether faculty in clinical departments had patient care responsibilities, and measures of departmental community, cooperation, and conflict. Results.-Clinical researchers in stage 1 and 2 markets published more scientific articles than those in stage 3 markets (14.5 vs 12.6, P=.04) or in stage 4 markets (14.5 vs 12.0, P=.03). Among 96 young faculty (professional age less than or equal to 10 years) in clinical departments, 11 (44%) of those in stage 1 and 2 markets had patient care duties compared with 32 (56.1%) of young faculty members in stage 3 markets (P=.04) and 12 (85.7%) of those in stage 4 markets (P=.01). The percentage of senior faculty in clinical departments (n=691) with patient care responsibilities did not differ significantly by market stage. Compared with faculty in less competitive markets, faculty in stage 4 markets perceived lower levels of departmental cooperation and higher levels of conflict. Conclusions.-Increased competitiveness of health care markets seems to hinder the capacity of academic health centers to conduct clinical research and to foster the careers of young clinical faculty.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Campbell, EG (corresponding author), MASSACHUSETTS GEN HOSP,HLTH POLICY RES & DEV UNIT,DIV GEN INTERNAL MED,50 STANIFORD ST,9TH FLOOR,BOSTON,MA 02114, USA.				NHGRI NIH HHS [HG00724-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000724, R55HG000724] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHRENS E, 1992, CRISIS CLIN RES OVER, P51; ANDERSON MS, 1994, J HIGH EDUC, V65, P332; Andrews F. M., 1979, SCI PRODUCTIVITY EFF; BERMAN JJ, 1995, SOUTHERN MED J, V88, P295, DOI 10.1097/00007611-199503000-00009; Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; Blumenthal D, 1996, HEALTH AFFAIR, V15, P200, DOI 10.1377/hlthaff.15.2.200; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; Blumenthal D, 1997, NAT GENET, V16, P104, DOI 10.1038/ng0597-104; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BOURNE S, 1996, 1996 MARKET CLASSIFI; COLTON T, 1970, STATISTICS MED; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; Gold MR, 1996, ACAD MED, V71, P828, DOI 10.1097/00001888-199608000-00010; INGLEHART JK, 1995, NEW ENGL J MED, V332, P401; INGLEHART JK, 1994, NEW ENGL J MED, V331, P1391; Institute of Medicine, 1994, CAR CLIN RES OBST OP; MOY E, 1996, ACAD MED, V71, P1369; Pelz Donald C., 1966, SCI ORG PRODUCTIVE C; STEIN MD, 1993, JAMA-J AM MED ASSOC, V269, P781, DOI 10.1001/jama.269.6.781; 1994, PETERSONS GUIDE GRAD	20	83	83	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					222	226		10.1001/jama.278.3.222	http://dx.doi.org/10.1001/jama.278.3.222			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218669				2022-12-28	WOS:A1997XK10800028
J	Froom, J; Culpepper, L; Jacobs, M; DeMelker, RA; Green, LA; vanBuchem, L; Grob, P; Heeren, T				Froom, J; Culpepper, L; Jacobs, M; DeMelker, RA; Green, LA; vanBuchem, L; Grob, P; Heeren, T			Antimicrobials for acute otitis media? A review from the international primary care network	BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; PLACEBO-CONTROLLED TRIAL; MIDDLE-EAR DISEASE; ANTIBIOTIC-TREATMENT; BACTERIAL-MENINGITIS; GENERAL-PRACTICE; CHILDREN; PENICILLIN; DIAGNOSIS; INFECTION		BOSTON UNIV,DEPT FAMILY MED,BOSTON,MA 02118; SUNY STONY BROOK,STONY BROOK,NY 11794; UNIV UTRECHT,NL-3584 CG UTRECHT,NETHERLANDS; UNIV COLORADO,DENVER,CO 80220; ST ELIZABETH HOSP,NL-500 LC TILBURG,NETHERLANDS; UNIV SURREY,GUILDFORD GU2 5YG,SURREY,ENGLAND	Boston University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Utrecht University; University of Colorado System; University of Colorado Denver; University of Surrey				Heeren, Timothy/0000-0001-5643-3559; Culpepper, Larry/0000-0002-7655-0477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007035] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS07035-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AARASON VA, 1996, BRIT MED J, V313, P387; ALHO OP, 1995, ARCH OTOLARYNGOL, V121, P839; ALHO OP, 1994, ARCH OTOLARYNGOL, V120, P807; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; APPELMAN CLM, 1990, GUIDELINE DUTCH COLL; BARRY B, 1994, SCAND J INFECT DIS, V26, P446, DOI 10.3109/00365549409008618; BLAKLEY BW, 1995, OTOLARYNG HEAD NECK, V112, P441; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P45; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; CLAESSEN JQPJ, 1994, CLIN OTOLARYNGOL, V19, P35; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DEMELKER RA, 1991, BRIT J GEN PRACT, V41, P504; DENEELING AJ, 1993, 253601001 RIJKS VOLK; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; EAVEY RD, 1985, J PEDIATR-US, V106, P402, DOI 10.1016/S0022-3476(85)80664-8; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FORD KL, 1991, J PEDIATR-US, V119, P941, DOI 10.1016/S0022-3476(05)83050-1; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FROOM J, 1991, J FAM PRACTICE, V32, P289; Froom J, 1993, Arch Fam Med, V2, P841, DOI 10.1001/archfami.2.8.841; GWALTNEY JM, 1982, AM J EPIDEMIOL, V116, P828, DOI 10.1093/oxfordjournals.aje.a113473; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HARDY AM, 1993, AM J PUBLIC HEALTH, V83, P1321, DOI 10.2105/AJPH.83.9.1321; HARRISON CJ, 1985, PEDIATR INFECT DIS J, V4, P641, DOI 10.1097/00006454-198511000-00009; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P17; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; Johnson AP, 1996, BRIT MED J, V312, P1454, DOI 10.1136/bmj.312.7044.1454; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; Lederberg J., 1992, I MED US COMMITTEE; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; LEE CJ, 1994, CRIT REV MICROBIOL, V20, P1, DOI 10.3109/10408419409113544; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; LUNDGREN K, 1979, INT J PEDIATR OTORHI, V1, P93, DOI 10.1016/0165-5876(79)90033-8; MACHKA K, 1988, EUR J CLIN MICROBIOL, V7, P14, DOI 10.1007/BF01962165; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; NEU HC, 1992, SCIENCE, V257, P1036; NIEMELA M, 1995, PEDIATRICS, V96, P884; RASMUSSEN F, 1994, J EPIDEMIOL COMMUN H, V48, P33, DOI 10.1136/jech.48.1.33; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; ROSS AK, 1988, J ROY COLL GEN PRACT, V38, P70; SASSEN ML, 1994, AM J OTOLARYNG, V15, P351, DOI 10.1016/0196-0709(94)90134-1; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; STENSTROM R, 1993, INT J PEDIATR OTORHI, V27, P127, DOI 10.1016/0165-5876(93)90128-P; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; van Klingeren B, 1992, Ned Tijdschr Geneeskd, V136, P860; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	58	133	134	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					98	102		10.1136/bmj.315.7100.98	http://dx.doi.org/10.1136/bmj.315.7100.98			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240050	Green Published			2022-12-28	WOS:A1997XL25200025
J	Light, DW				Light, DW			The real ethics of rationing	BRITISH MEDICAL JOURNAL			English	Article											Light, DW (corresponding author), UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND.							*ASS INT MUT, 1994, AIMS MISS; *AUD COMM, 1995, DOCT TAL WORK HOSP D; *AUD COMM, 1996, DOCT TAL CONT; Dixon J, 1997, BRIT MED J, V314, P58, DOI 10.1136/bmj.314.7073.58; Dixon J, 1997, BMJ-BRIT MED J, V314, P216, DOI 10.1136/bmj.314.7075.216a; DOBSON F, 1977, COMMUNICATION   0625; GRAY JAM, 1997, EVIDENCE BASED HEALT; HANCOCK C, 1997, HLTH SERV J      JUN, P26; Harrison A, 1997, BRIT MED J, V314, P139, DOI 10.1136/bmj.314.7074.139; *LAING BUISS, 1996, LAINGS REV PRIV HEAL, pA116; Light D, 1990, Health Serv J, V100, P1604; Light D, 1990, Health Serv J, V100, P1552; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; LIGHT DW, IN PRESS BIOETHICS S; LIGHT DW, 1992, NEEDS BASED PURCHASI; LIGHT DW, 1997, HLTH SERV J, V100, P1548; *NEW B RAT AG GROU, 1996, RAT AG NHS; ROBERTS CJ, 1995, HLTH SERV J      JAN, P15; Smith R, 1996, BRIT MED J, V312, P1553, DOI 10.1136/bmj.312.7046.1553; YATES DIM, 1995, PRIVATE EYE HEART HE	20	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					112	115		10.1136/bmj.315.7100.112	http://dx.doi.org/10.1136/bmj.315.7100.112			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240054	Green Published			2022-12-28	WOS:A1997XL25200032
J	Schwartz, L; Blew, B; Bui, S				Schwartz, L; Blew, B; Bui, S			Intracoronary-stent placement for coronary artery disease	LANCET			English	Article											Schwartz, L (corresponding author), UNIV TORONTO,DEPT MED,TORONTO,ON M5G 2C4,CANADA.							Detre KM, 1996, J AM COLL CARDIOL, V28, P609, DOI 10.1016/0735-1097(96)00216-1; George C. J., 1997, Journal of the American College of Cardiology, V29, p495A; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; TILLI FV, 1996, CIRCULATION S1, V94, P332	5	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					113	114		10.1016/S0140-6736(05)61815-6	http://dx.doi.org/10.1016/S0140-6736(05)61815-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228968				2022-12-28	WOS:A1997XK11400016
J	Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR				Ralph, J; MacKay, JJ; Hatfield, RD; OMalley, DM; Whetten, RW; Sederoff, RR			Abnormal lignin in a loblolly pine mutant	SCIENCE			English	Article							CINNAMYL-ALCOHOL-DEHYDROGENASE; BROWN-MIDRIB MUTANT; COMPRESSION WOOD; BM3 MUTATION; CROSS-LINKS; MAIZE; CONIFERYL; GRASSES; GENE; NMR	Novel lignin is formed in a mutant loblolly pine (Pinus taeda L.) severely depleted in cinnamyl alcohol dehydrogenase (E.C. 1.1.1.195), which converts coniferaldehyde to coniferyl alcohol, the primary lignin precursor in pines. Dihydrocbniferyl alcohol, a monomer not normally associated with the lignin biosynthetic pathway, is the major component of the mutant's lignin, accounting for similar to 30 percent (versus similar to 3 percent in normal pine) of the units. The level of aldehydes, including new 2-methoxybenzaldehydes, is also increased. The mutant pines grew normally indicating that, even within a species, extensive variations in lignin composition need not disrupt the essential functions of lignin.	UNIV WISCONSIN, DEPT FORESTRY, MADISON, WI 53706 USA; N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; N CAROLINA STATE UNIV, DEPT FORESTRY, RALEIGH, NC 27695 USA	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Ralph, J (corresponding author), USDA ARS, US DAIRY FORAGE RES CTR, 1925 LINDEN DR W, MADISON, WI 53706 USA.		MacKay, John/M-6978-2014; Whetten, Ross W/A-9734-2013; Ralph, John/C-3161-2009	MacKay, John/0000-0002-4883-195X; Ralph, John/0000-0002-6093-4521	NIGMS NIH HHS [GM45344-07] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER E, 1948, ACTA CHEM SCAND, V2, P839, DOI 10.3891/acta.chem.scand.02-0839; ADLER E, 1948, ACTA CHEM SCAND, V2, P93, DOI 10.3891/acta.chem.scand.02-0093; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BJORKMAN A, 1954, NATURE, V174, P1057, DOI 10.1038/1741057a0; BUCHOLTZ DL, 1980, J AGR FOOD CHEM, V28, P1239, DOI 10.1021/jf60232a045; Campbell MM, 1996, PLANT PHYSIOL, V110, P3, DOI 10.1104/pp.110.1.3; CHABBERT B, 1994, J SCI FOOD AGR, V64, P349, DOI 10.1002/jsfa.2740640317; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; CHERNEY JH, 1991, ADV AGRON, V46, P157; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; FUKUSHIMA K, 1991, WOOD SCI TECHNOL, V25, P371, DOI 10.1007/BF00226177; GRAND C, 1985, PHYSIOL VEG, V23, P905; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; Harkin J.M., 1967, OXIDATIVE COUPLING P, P243; HARKIN JM, 1973, CHEMISTRY BIOCHEMIST, V1, P323; HATFIELD RD, 1994, J SCI FOOD AGR, V65, P51, DOI 10.1002/jsfa.2740650109; HIBINO T, 1995, BIOSCI BIOTECH BIOCH, V59, P929, DOI 10.1271/bbb.59.929; HIGUCHI T, 1994, J BIOTECHNOL, V37, P151, DOI 10.1016/0168-1656(94)90006-X; KAMISAKA S, 1983, PLANT CELL PHYSIOL, V24, P369; KARHUNEN P, 1995, TETRAHEDRON LETT, V36, P169, DOI 10.1016/0040-4039(94)02203-N; KUC J, 1964, ARCH BIOCHEM BIOPHYS, V105, P103, DOI 10.1016/0003-9861(64)90240-1; LAPIERRE C, 1988, CR ACAD SCI III-VIE, V307, P723; LAPIERRE C, 1993, FORAGE CELL WALL STRUCTURE AND DIGESTIBILITY, P133; LAPIERRE C, 1988, HOLZFORSCHUNG, V42, P409, DOI 10.1515/hfsg.1988.42.6.409; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LU F, IN PRESS J AGR FOOD; Ludley FH, 1996, J AGR FOOD CHEM, V44, P2942, DOI 10.1021/jf9604908; MACKAY JJ, 1997, THESIS N CAROLINA ST; MACKAY JJ, IN PRESS P NATL ACAD; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; MONTIES B, 1995, ANN P PHYTOCHEM SOC, V5, P161; NAKAMURA M, 1978, MOL CELL ENDOCRINOL, V12, P209; NAKAMURA Y, 1976, HOLZFORSCHUNG, V30, P187, DOI 10.1515/hfsg.1976.30.6.187; Nakamura Y, 1978, CELL CHEM TECHNOL, V12, P199; NIMZ HH, 1981, HOLZFORSCHUNG, V35, P16, DOI 10.1515/hfsg.1981.35.1.16; OMALLEY DM, 1992, PLANT PHYSIOL, V98, P1364, DOI 10.1104/pp.98.4.1364; PILLONEL C, 1991, PLANTA, V185, P538, DOI 10.1007/BF00202964; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; RALPH J, 1992, J CHEM SOC PERK T 1, P2961, DOI 10.1039/p19920002961; Ralph J, 1996, J NAT PROD, V59, P341, DOI 10.1021/np960143s; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; RALPH J, 1995, CARBOHYD RES, V275, P167, DOI 10.1016/0008-6215(95)00237-N; RALPH J, IN PRESS LIGNIN LIGN; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; SARKANEN KV, 1967, TAPPI, V50, P587; SARKANEN KV, 1971, LIGNINS; SAVIDGE RA, 1987, PHYTOCHEMISTRY, V26, P93, DOI 10.1016/S0031-9422(00)81488-0; Timell T.E., 1986, COMPRESSION WOOD GYM; VIGNOLS F, 1995, PLANT CELL, V7, P407, DOI 10.1105/tpc.7.4.407	50	248	269	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					235	239		10.1126/science.277.5323.235	http://dx.doi.org/10.1126/science.277.5323.235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9211851				2022-12-28	WOS:A1997XK41800044
J	RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P				RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P			Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7	CELL			English	Article							RETINOIC ACID RECEPTOR; PROTEIN-KINASE; CELL-CYCLE; RESPONSE ELEMENT; IMMUNODETECTION	The activity of the N-terminal activation function AF-1 of RAR alpha 1 is abrogated upon mutation of a phosphorylatable serine residue (Ser-77). Recombinant RAR alpha was phosphorylated by a variety of proline-directed protein kinases in vitro. However, only the coexpression of cdk7 stimulated Ser-77 phosphorylation in vivo and enhanced transactivation by RAR alpha, but not by a S77A RAR mutant. Both free CAK (cdk7, cyclin H, MAT1) and the CAK-containing general transcription factor TFIIH phosphorylated Ser-77 in vitro. Furthermore RAR alpha bound free CAK and purified TFIIH in vitro, and RAR alpha-TFIIH complexes could be isolated from HeLa nuclear extracts. These findings represent the first example of activation of a transactivator through binding to and phosphorylation by a general transcription factor.			RochetteEgly, C (corresponding author), UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,BP 163,F-67404 ILLKIRCH GRAFFENS,FRANCE.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DRAPKIN R, 1996, P NATL ACAD SCI UYS, V93, P6468; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRONEMEYER H, 1995, TRANSCRIPTION FACTOR, V3; HOELJMAKERS JHJ, 1996, CURR OPIN GENE DEV, V6, P26; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; READON JT, 1996, P NATL ACAD SCI USA, V93, P6482; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638	44	255	267	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					97	107		10.1016/S0092-8674(00)80317-7	http://dx.doi.org/10.1016/S0092-8674(00)80317-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230306	Bronze			2022-12-28	WOS:A1997XL36200012
J	Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH				Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH			FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation	CELL			English	Article							DNA-BINDING PROTEIN; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; EXPRESSION; GENE; ASSOCIATION; NF-E2; MICE; LINEAGES; CLONING	The hematopoietic transcription factor GATA-1 is essential for development of the erythroid and megakaryocytic lineages. Using the conserved zinc finger DNA-binding domain of GATA-1 in the yeast two-hybrid system, we have identified a novel, multitype zinc finger protein, friend of GATA-1 (FOG), which binds GATA-1 but not a functionally inactive mutant lacking the amino (N) finger. FOG is coexpressed with GATA-1 during embryonic development and in erythroid and megakaryocytic cells. Furthermore, FOG and GATA-1 synergistically activate transcription from a hematopoietic-specific regulatory region and cooperate during both erythroid and megakaryocytic cell differentiation. These findings indicate that FOG acts as a cofactor for GATA-1 and provide a paradigm for the regulation of cell type-specific gene expression by GATA transcription factors.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Weiss, Mitchell J/A-1245-2013; Crossley, Merlin/D-7888-2011; Weiss, Mitchell J/W-9814-2018	Crossley, Merlin/0000-0003-2057-3642; Weiss, Mitchell J/0000-0003-2460-3036; Yu, Channing/0000-0002-3231-2565	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07753-18, T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVDASANI RA, 1997, IN PRESS EMBO J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TING KCN, 1996, NATURE, V384, P474; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	51	588	604	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					109	119		10.1016/S0092-8674(00)80318-9	http://dx.doi.org/10.1016/S0092-8674(00)80318-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230307	Bronze			2022-12-28	WOS:A1997XL36200013
J	Rapin, I				Rapin, I			Autism	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UTAH EPIDEMIOLOGIC SURVEY; PERVASIVE DEVELOPMENTAL DISORDERS; CHILDREN; MODEL		YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, ROSE F KENNEDY CTR RES MENTAL RETARDAT & HUMAN DE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rapin, I (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, SAUL R KOREY DEPT NEUROL, 1410 PELHAM PKY S, BRONX, NY 10461 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020489, P50NS020489] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 20489] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anderson G. M., 1994, NEUROBIOLOGY AUTISM, P227; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BallabanGil K, 1996, PEDIATR NEUROL, V15, P217, DOI 10.1016/S0887-8994(96)00219-6; BAUMAN M. L., 1992, MOVEMENT DISORDERS N, V1, P658; Beaumanoir A, 1995, CONTINUOUS SPIKES WA; BRYSON SE, 1988, J CHILD PSYCHOL PSYC, V29, P433, DOI 10.1111/j.1469-7610.1988.tb00735.x; CHAMBERLAIN RS, 1990, BIOL PSYCHIAT, V28, P773, DOI 10.1016/0006-3223(90)90513-2; Chugani HT, 1996, ANN NEUROL, V39, P643, DOI 10.1002/ana.410390514; COHEN DJ, 1997, AUTISM PERVASIVE DEV; COMINGS DE, 1991, AM J MED GENET, V39, P180, DOI 10.1002/ajmg.1320390213; Cook EH, 1997, MOL PSYCHIATR, V2, P247; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; DELONG GR, 1992, NEUROSCI BIOBEHAV R, V16, P63, DOI 10.1016/S0149-7634(05)80052-1; DELONG R, 1994, DEV MED CHILD NEUROL, V36, P674; DUNN M, 1997, BEHAV BELONGS BRAIN, P97; FILIPEK PA, 1995, CURR OPIN NEUROL, V8, P134, DOI 10.1097/00019052-199504000-00009; Frith U., 1991, AUTISM ASPERGER SYND; Gillberg C, 1996, DEV MED CHILD NEUROL, V38, P191; GILLBERG G, 1992, BIOL AUTISTIC SYNDRO; Grandin T., 1995, THINKING PICTURES OT; HORWITZ B, 1994, NEUROBIOLOGY AUTISM, P102; Kemper TL., 1994, NEUROBIOLOGY AUTISM; Kinsbourne M., 1991, PEDIAT NEUROLOGY BEH, P18; Klein SK, 1995, BRAIN LANG, V51, P383, DOI 10.1006/brln.1995.1067; KLIN A, 1995, J CHILD PSYCHOL PSYC, V36, P1127, DOI 10.1111/j.1469-7610.1995.tb01361.x; KLIN A, 1993, J AUTISM DEV DISORD, V23, P15, DOI 10.1007/BF01066416; KONSTANTAREAS MM, 1996, LANGUAGE LEARNING BE, P178; KRUG BA, **NON-TRADITIONAL**; KURITA H, 1992, J AUTISM DEV DISORD, V22, P175, DOI 10.1007/BF01058149; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; MESIBOV GB, 1994, CURR I AUT, P195; Minshew N.J., 1994, NEUROBIOLOGY AUTISM, P66; Mundy P., 2000, UNDERSTANDING OTHER, V2nd Edn, P181; NELSON KB, 1991, PEDIATRICS, V87, P761; Obler L. K., 1988, EXCEPTIONAL BRAIN NE; OLSSON I, 1988, ARCH NEUROL-CHICAGO, V45, P666, DOI 10.1001/archneur.1988.00520300086024; PIVEN J, 1995, AM J PSYCHIAT, V152, P1145; RAPI I, 1996, CLIN DEV MED, V139; RITVO ER, 1990, AM J PSYCHIAT, V147, P1614; RITVO ER, 1989, AM J PSYCHIAT, V146, P194; RITVO ER, 1989, AM J PSYCHIAT, V146, P1032; ROGERS SJ, 1989, J AM ACAD CHILD PSY, V28, P207, DOI 10.1097/00004583-198903000-00010; RUTTER M, 1994, J CHILD PSYCHOL PSYC, V35, P311, DOI 10.1111/j.1469-7610.1994.tb01164.x; Schopler E., 1986, CHILDHOOD AUTISM RAT; SPIKER D, 1994, AM J MED GENET, V54, P27, DOI 10.1002/ajmg.1320540107; SUGIYAMA T, 1992, INT CONGR SER, V965, P181; TAGERFLUSBERG H, 1994, CONSTRAINTS LANGUAGE; TREFFERT D, 1989, EXTRAORDINARY PEOPLE; Tuchman RF, 1997, PEDIATRICS, V99, P560, DOI 10.1542/peds.99.4.560; TUCHMAN RF, 1991, PEDIATRICS, V88, P1211; Venter A., 1992, HIGH FUNCTIONING IND, P187; VOLKMAR FR, 1989, J CHILD PSYCHOL PSYC, V30, P717, DOI 10.1111/j.1469-7610.1989.tb00784.x; VOLKMAR FR, 1990, J AM ACAD CHILD PSY, V29, P127, DOI 10.1097/00004583-199001000-00020; Wahlstrom, 1993, RETT SYNDROME CLIN B; WANGWRIGHT L, 1996, CLIN DEV MED, V139, P173; Waterhouse L, 1996, PSYCHOL REV, V103, P457, DOI 10.1037/0033-295X.103.3.457; Waterhouse L, 1996, J AUTISM DEV DISORD, V26, P59, DOI 10.1007/BF02276235; Woodhouse W, 1996, J CHILD PSYCHOL PSYC, V37, P665, DOI 10.1111/j.1469-7610.1996.tb01458.x; World Health Organisation, 1993, MENT DIS GLOSS GUID; [No title captured]	62	304	307	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	1997	337	2					97	104		10.1056/NEJM199707103370206	http://dx.doi.org/10.1056/NEJM199707103370206			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ822	9211680				2022-12-28	WOS:A1997XJ82200006
J	Lehmann, ED; Riley, WA; Clarkson, P; Gosling, RG				Lehmann, ED; Riley, WA; Clarkson, P; Gosling, RG			Non-invasive assessment of cardiovascular disease in diabetes mellitus	LANCET			English	Article							INTIMA-MEDIA THICKNESS; ENDOTHELIUM-DEPENDENT DILATION; CAROTID-ARTERY; NITRIC-OXIDE; NONINVASIVE DETECTION; SYSTEMIC ARTERIES; FASTING GLUCOSE; CORONARY-ARTERY; WAVE VELOCITY; IDDM PATIENTS		ROYAL HOSP NHS TRUST, DEPT DIAGNOST IMAGING, LONDON, ENGLAND; ROYAL BROMPTON HOSP, NATL HEART & LUNG INST, DEPT IMAGING, LONDON, ENGLAND; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROL, WINSTON SALEM, NC 27103 USA; UCL HOSP, MIDDLESEX HOSP, DEPT CARDIOL, LONDON, ENGLAND; S BANK UNIV, SCH APPL SCI, LONDON SE1 0AA, ENGLAND	University of London; Queen Mary University London; Imperial College London; Royal Brompton Hospital; Wake Forest University; Wake Forest Baptist Medical Center; University College London Hospitals NHS Foundation Trust; University of London; University College London; London South Bank University								ADAMS MR, 1995, CIRCULATION, V92, P2127, DOI 10.1161/01.CIR.92.8.2127; AGEWALL S, 1995, J HYPERTENS, V13, P463; AGEWALL S, 1995, STROKE, V26, P956, DOI 10.1161/01.STR.26.6.956; AHLGREN AR, 1995, DIABETOLOGIA, V38, P1082, DOI 10.1007/s001250050395; AIRAKSINEN KEJ, 1993, CARDIOVASC RES, V27, P942, DOI 10.1093/cvr/27.6.942; AMAR J, 1995, AM J HYPERTENS, V8, P426, DOI 10.1016/0895-7061(94)00186-F; ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P1468, DOI 10.1016/0735-1097(94)90141-4; Chappey O, 1997, EUR J CLIN INVEST, V27, P97, DOI 10.1046/j.1365-2362.1997.710624.x; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; DAHAN M, 1990, EUR HEART J, V11, P39, DOI 10.1093/eurheartj/11.suppl_G.39; ELLIOTT TG, 1993, CLIN SCI, V85, P687, DOI 10.1042/cs0850687; Espeland MA, 1996, STROKE, V27, P480, DOI 10.1161/01.STR.27.3.480; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FURBERG CD, 1993, CIRCULATION, V87, P82; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Goodfellow J, 1996, BRIT MED J, V312, P744; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Hopkins KD, 1996, DIABETES CARE, V19, P501, DOI 10.2337/diacare.19.5.501; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; Howard G, 1996, CIRCULATION, V93, P1809, DOI 10.1161/01.CIR.93.10.1809; HUIJBERTS MSP, 1993, J CLIN INVEST, V92, P1407, DOI 10.1172/JCI116716; JensenUrstad KJ, 1996, DIABETES, V45, P1253, DOI 10.2337/diabetes.45.9.1253; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; KARAMANOGLU M, 1993, EUR HEART J, V14, P160, DOI 10.1093/eurheartj/14.2.160; KAWAMORI R, 1992, DIABETES CARE, V15, P1290, DOI 10.2337/diacare.15.10.1290; Kelly R, 1989, J VASC MED BIOL, V3, P142; Lambert J, 1996, ARTERIOSCL THROM VAS, V16, P705, DOI 10.1161/01.ATV.16.5.705; LANNE T, 1992, ULTRASOUND MED BIOL, V18, P451, DOI 10.1016/0301-5629(92)90084-N; Lehmann ED, 1996, LANCET, V348, P1587, DOI 10.1016/S0140-6736(05)66202-2; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; Lehmann ED, 1996, LANCET, V348, P744, DOI 10.1016/S0140-6736(05)65619-X; Lehmann ED, 1996, DIABETOLOGIA, V39, P870, DOI 10.1007/s001250050526; Luscher TF, 1996, J HYPERTENS, V14, pS111; MILLER JA, 1995, AM J PHYSIOL-REG I, V269, pR380, DOI 10.1152/ajpregu.1995.269.2.R380; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; OXLUND H, 1989, DIABETOLOGIA, V32, P748, DOI 10.1007/BF00274536; RILEY WA, 1986, ARTERIOSCLEROSIS, V6, P378, DOI 10.1161/01.ATV.6.4.378; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432; SALONEN R, 1991, ULTRASOUND MED BIOL, V17, P225, DOI 10.1016/0301-5629(91)90043-V; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Tooke JE, 1996, DIABETOLOGIA, V39, P745; WADA T, 1994, ARTERIOSCLER THROMB, V14, P479, DOI 10.1161/01.ATV.14.3.479; Wagenknecht LE, 1997, STROKE, V28, P999, DOI 10.1161/01.STR.28.5.999; WAHLQVIST ML, 1988, DIABETES CARE, V11, P787, DOI 10.2337/diacare.11.10.787; WATANABE H, 1992, CARDIOVASC RES, V26, P1212, DOI 10.1093/cvr/26.12.1212; WILLEY KA, 1995, DIABETES CARE, V18, P1502, DOI 10.2337/diacare.18.11.1502; WRIGHT JS, 1991, THESIS U LONDON; YAMASAKI Y, 1994, DIABETES, V43, P634, DOI 10.2337/diabetes.43.5.634; ZENERE BM, 1995, DIABETES CARE, V18, P975, DOI 10.2337/diacare.18.7.975; Zinman B, 1996, DIABETES, V45, P692	60	55	56	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL	1997	350			1			SI14	SI19						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM265	9250278				2022-12-28	WOS:A1997XM26500005
J	Navis, G; deZeeuw, D; deJong, PE				Navis, G; deZeeuw, D; deJong, PE			ACE-inhibitors: Panacea for progressive renal disease?	LANCET			English	Editorial Material											Navis, G (corresponding author), UNIV GRONINGEN HOSP,DIV NEPHROL,POB 30001,NL-9700 RB GRONINGEN,NETHERLANDS.		de Zeeuw, Dick/E-9080-2014	de Zeeuw, Dick/0000-0003-3434-7777				APPERLOO AJ, 1994, KIDNEY INT, V45, pS174; Ellis A, 1942, LANCET, V1, P72; GANSEVOORT RT, 1993, AM J KIDNEY DIS, V2, P202; Giatras I., 1996, Journal of the American Society of Nephrology, V7, P1318; GIATRAS I, IN PRESS ANN INTERN; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Parving HH, 1996, BRIT MED J, V313, P591; Van Essen Gabe G., 1996, Journal of the American Society of Nephrology, V7, P1400; vanEssen GG, 1996, LANCET, V347, P94, DOI 10.1016/S0140-6736(96)90213-5; VANESSEN GG, IN PRESS KIDNEY IN S	12	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1852	1853		10.1016/S0140-6736(97)22026-X	http://dx.doi.org/10.1016/S0140-6736(97)22026-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217751				2022-12-28	WOS:A1997XG41700002
J	deGennes, PG				deGennes, PG			Polymer physics - Molecular individualism	SCIENCE			English	Editorial Material											deGennes, PG (corresponding author), ECOLE SUPER PHYS & CHIM IND VILLE PARIS,10 RUE VAUQUELIN,F-75231 PARIS 05,FRANCE.							BrochardWyart F, 1997, MRS BULL, V22, P48, DOI 10.1557/S0883769400032346; Ferry J.D., 1980, VISCOELASTIC PROPERT; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; STOCKMAYER WH, 1976, MOL FLUIDS, P107; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	6	97	98	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					1999	1999		10.1126/science.276.5321.1999	http://dx.doi.org/10.1126/science.276.5321.1999			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221507				2022-12-28	WOS:A1997XG74800048
J	Magnus, P; Jaakkola, JJK				Magnus, P; Jaakkola, JJK			Secular trend in the occurrence of asthma among children and young adults: Critical appraisal of repeated cross sectional surveys	BRITISH MEDICAL JOURNAL			English	Article							ALLERGIC RHINITIS; CHILDHOOD ASTHMA; RESPIRATORY SYMPTOMS; SCHOOL-CHILDREN; PREVALENCE; SCHOOLCHILDREN; SEVERITY; ADOLESCENTS; POPULATION; TIME	Objectives: To review repeated surveys of the rising prevalence of obstructive lung disease among children and young adults and determine whether systematic biases may explain the observed trends. Design: Review of published reports of repeated cross sectional surveys of asthma and wheezing among children and young adults. The repeated surveys used the same sampling frame, the same definition of outcome variables, and equivalent data collection methods. Setting Repeated surveys conducted anywhere in the world. Subjects: All repeated surveys whose last set of results were published in 1983 or later. Main outcome measures: Lifetime and current prevalences of asthma and current prevalence of wheezing. The absolute increase (yearly percentage) in the prevalences of asthma and wheezing was calculated and compared between studies. Results: 16 repeated surveys fulfilled the inclusion criteria. 12 reported increases in the current prevalence of asthma (from 0.09% to 0.97% a year) and eight reported increases in the current prevalence of wheezing (from 0.14% to 1.24% a year). Changes in labelling are likely to have occurred for the reporting of asthma, and information biases may have occurred for the reporting of wheezing. Only one study reported an increase in an objective measurement Conclusions: The evidence for increased prevalences of asthma and wheezing is weak because the measures used are susceptible to systematic errors. Until repeated surveys incorporating more objective data are available no firm conclusions about increases in obstructive lung disease among children and young adults can be drawn.	UNIV HELSINKI,DEPT PUBL HLTH,ENVIRONM EPIDEMIOL UNIT,HELSINKI,FINLAND	University of Helsinki	Magnus, P (corresponding author), NATL INST PUBL HLTH,DEPT POPULAT HLTH SCI,EPIDEMIOL SECT,POB 4404,N-0403 OSLO,NORWAY.		Jaakkola, Jouni J.K./G-4314-2012	Jaakkola, Jouni/0000-0003-4168-4683				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; BRUCE IN, 1993, Q J MED, V86, P425; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; LAOR A, 1993, BRIT MED J, V307, P841, DOI 10.1136/bmj.307.6908.841; MITCHELL EA, 1994, J PAEDIATR CHILD H, V30, P398, DOI 10.1111/j.1440-1754.1994.tb00687.x; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; NYSTAD W, IN PRESS EUR RESP J; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60, DOI 10.1177/140349489502300111; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; SACHER Y, 1994, ISRAEL J MED SCI, V30, P564; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SKJONSBERG OH, 1995, ALLERGY, V50, P806; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; 1992, EUR RESPIR J, V5, P601	30	223	225	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 21	1997	314	7097					1795	1799		10.1136/bmj.314.7097.1795	http://dx.doi.org/10.1136/bmj.314.7097.1795			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224081	Green Published			2022-12-28	WOS:A1997XG16600022
J	Nightingale, SL				Nightingale, SL			Workshop on thalidomide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-28	WOS:A1997XN51800011
J	Nightingale, SL				Nightingale, SL			Health advisory on concomitant fenfluramine and phentermine use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-28	WOS:A1997XN51800008
